Physical O
mapping O
220 O
kb O
centromeric O
of O
the O
human B
MHC I
and O
DNA O
sequence O
analysis O
of O
the O
43 O
- O
kb O
segment O
including O
the O
RING1 B
, O
HKE6 B
, O
and O
HKE4 B
genes I
. O

Physical O
mapping O
220 O
kb O
centromeric O
of O
the O
human B
MHC I
and O
DNA O
sequence O
analysis O
of O
the O
43 O
- O
kb O
segment O
including O
the O
RING1 B
, O
HKE6 B
, O
and O
HKE4 B
genes I
. O

DNA O
elements O
recognizing O
NF B
- I
Y I
and O
Sp1 B
regulate O
the O
human B
multidrug I
- I
resistance I
gene I
promoter I
. O

As O
tat B
itself O
dramatically O
increases O
HIV O
- O
1 O
gene O
expression O
, O
it O
too O
is O
presumably O
regulated O
in O
the O
latent O
state O
, O
and O
may O
also O
be O
activated O
by O
mitogenic O
stimulation O
. O

A O
GT O
- O
rich O
sequence O
binding O
the O
transcription B
factor I
Sp1 I
is O
crucial O
for O
high O
expression O
of O
the O
human B
type I
VII I
collagen I
gene I
( O
COL7A1 B
) O
in O
fibroblasts O
and O
keratinocytes O
. O

It O
was O
found O
that O
Nopp140 B
binds O
primarily O
to O
the O
CK2 B
regulatory I
subunit I
, I
beta I
. O

Like O
other O
IAPs B
, O
ch B
- I
IAP1 I
contains O
the O
N B
- I
terminal I
baculovirus I
IAP I
repeats I
and O
C O
- O
terminal O
RING O
finger O
motifs O
. O

Interestingly O
, O
basal O
MAPK B
, O
but O
not O
Raf B
- I
1 I
, O
activity O
was O
constitutively O
enhanced O
in O
Jak1 B
- O
deficient O
HeLa O
cells O
. O

Interestingly O
, O
basal O
MAPK B
, O
but O
not O
Raf B
- I
1 I
, O
activity O
was O
constitutively O
enhanced O
in O
Jak1 B
- O
deficient O
HeLa O
cells O
. O

Thus O
, O
primate O
vs O
. O
rodent O
promoter O
selectivity O
mediated O
by O
the O
TBP B
- O
TAFI B
complex O
is O
likely O
to O
be O
the O
result O
of O
cumulative O
subtle O
differences O
between O
individual O
subunits O
that O
lead O
to O
species O
- O
specific O
properties O
of O
RNA B
polymerase I
I I
transcription O
. O

Thus O
, O
primate O
vs O
. O
rodent O
promoter O
selectivity O
mediated O
by O
the O
TBP B
- O
TAFI B
complex O
is O
likely O
to O
be O
the O
result O
of O
cumulative O
subtle O
differences O
between O
individual O
subunits O
that O
lead O
to O
species O
- O
specific O
properties O
of O
RNA B
polymerase I
I I
transcription O
. O

The O
cDNA O
clones O
encode O
a O
polypeptide O
of O
657 O
amino O
acids O
with O
a O
bHLH O
( O
basic O
- O
helix O
- O
loop O
- O
helix O
) O
domain O
, O
characteristic O
of O
a O
large O
family O
of O
transcription O
factors O
, O
and O
a O
PAS B
( O
Per B
- O
Arnt B
- O
Sim B
) O
domain O
in O
the O
amino O
- O
terminal O
half O
region O
. O

The O
cDNA O
clones O
encode O
a O
polypeptide O
of O
657 O
amino O
acids O
with O
a O
bHLH O
( O
basic O
- O
helix O
- O
loop O
- O
helix O
) O
domain O
, O
characteristic O
of O
a O
large O
family O
of O
transcription O
factors O
, O
and O
a O
PAS B
( O
Per B
- O
Arnt B
- O
Sim B
) O
domain O
in O
the O
amino O
- O
terminal O
half O
region O
. O

The O
cDNA O
clones O
encode O
a O
polypeptide O
of O
657 O
amino O
acids O
with O
a O
bHLH O
( O
basic O
- O
helix O
- O
loop O
- O
helix O
) O
domain O
, O
characteristic O
of O
a O
large O
family O
of O
transcription O
factors O
, O
and O
a O
PAS B
( O
Per B
- O
Arnt B
- O
Sim B
) O
domain O
in O
the O
amino O
- O
terminal O
half O
region O
. O

The O
cDNA O
clones O
encode O
a O
polypeptide O
of O
657 O
amino O
acids O
with O
a O
bHLH O
( O
basic O
- O
helix O
- O
loop O
- O
helix O
) O
domain O
, O
characteristic O
of O
a O
large O
family O
of O
transcription O
factors O
, O
and O
a O
PAS B
( O
Per B
- O
Arnt B
- O
Sim B
) O
domain O
in O
the O
amino O
- O
terminal O
half O
region O
. O

Furthermore O
, O
ERK B
phosphorylation O
was O
substantially O
prolonged O
in O
LC O
/ O
BRY O
- O
treated O
cells O
compared O
to O
those O
exposed O
to O
BRY O
alone O
, O
and O
pretreatment O
with O
the O
highly O
specific O
MEK B
inhibitors O
, O
PD98059 O
, O
U0126 O
, O
and O
SL327 O
, O
opposed O
ERK B
activation O
while O
protecting O
cells O
from O
LC O
/ O
BRY O
- O
induced O
lethality O
. O

Furthermore O
, O
ERK B
phosphorylation O
was O
substantially O
prolonged O
in O
LC O
/ O
BRY O
- O
treated O
cells O
compared O
to O
those O
exposed O
to O
BRY O
alone O
, O
and O
pretreatment O
with O
the O
highly O
specific O
MEK B
inhibitors O
, O
PD98059 O
, O
U0126 O
, O
and O
SL327 O
, O
opposed O
ERK B
activation O
while O
protecting O
cells O
from O
LC O
/ O
BRY O
- O
induced O
lethality O
. O

Furthermore O
, O
ERK B
phosphorylation O
was O
substantially O
prolonged O
in O
LC O
/ O
BRY O
- O
treated O
cells O
compared O
to O
those O
exposed O
to O
BRY O
alone O
, O
and O
pretreatment O
with O
the O
highly O
specific O
MEK B
inhibitors O
, O
PD98059 O
, O
U0126 O
, O
and O
SL327 O
, O
opposed O
ERK B
activation O
while O
protecting O
cells O
from O
LC O
/ O
BRY O
- O
induced O
lethality O
. O

The O
cholesterol B
7alpha I
- I
hydroxylase I
gene I
( O
CYP7A B
) O
is O
transcriptionally O
regulated O
by O
a O
number O
of O
factors O
, O
including O
hormones O
, O
bile O
acids O
, O
and O
diurnal O
rhythm O
. O

The O
S B
. I
typhimurium I
aspartyl I
/ I
asparaginyl I
beta I
- I
hydroxylase I
homologue I
( O
designated O
lpxO B
) O
was O
cloned O
into O
pBluescriptSK O
and O
expressed O
in O
Escherichia O
coli O
K O
- O
12 O
, O
which O
does O
not O
contain O
lpxO B
. O

The O
S B
. I
typhimurium I
aspartyl I
/ I
asparaginyl I
beta I
- I
hydroxylase I
homologue I
( O
designated O
lpxO B
) O
was O
cloned O
into O
pBluescriptSK O
and O
expressed O
in O
Escherichia O
coli O
K O
- O
12 O
, O
which O
does O
not O
contain O
lpxO B
. O

The O
highest O
TTX B
content O
is O
10 O
. O
0 O
microg O
/ O
g O
in O
N O
. O
livescens O
. O

Here O
, O
we O
describe O
the O
nucleotide O
( O
nt O
) O
sequence O
and O
genomic O
organization O
of O
ipiB B
and O
ipiO B
. O

Here O
, O
we O
describe O
the O
nucleotide O
( O
nt O
) O
sequence O
and O
genomic O
organization O
of O
ipiB B
and O
ipiO B
. O

Soluble O
fibrin B
monomer O
complexes O
in O
thromboembolism O

EMT B
was O
localized O
to O
chromosome O
5q31 O
- O
32 O
, O
a O
region O
that O
contains O
the O
genes O
for O
several O
growth O
factors O
and O
receptors O
as O
well O
as O
early O
activation O
genes O
, O
particularly O
those O
involved O
in O
the O
hematopoietic O
system O
. O

Tbx6 B
maps O
to O
chromosome O
7 O
and O
does O
not O
appear O
to O
be O
linked O
to O
any O
known O
mutation O
. O

The O
encoded O
protein O
contains O
an O
amino O
terminal O
PDZ B
domain O
, O
followed O
by O
a O
predicted O
coiled O
- O
coil O
region O
, O
a O
PEST O
domain O
, O
and O
a O
carboxy O
- O
terminal O
SAM O
domain O
. O

Several O
studies O
have O
demonstrated O
that O
the O
corticotropin B
- I
releasing I
factor I
test O
( O
CRF B
) O
is O
useful O
for O
the O
aetiological O
diagnosis O
of O
Cushing O
' O
s O
syndrome O
: O
in O
Cushing O
' O
s O
disease O
, O
as O
opposed O
to O
ectopic O
ACTH B
secretion O
syndrome O
, O
the O
hypothalamus O
- O
pituitary O
- O
adrenal O
( O
HPA O
) O
axis O
can O
still O
be O
stimulated O
by O
CRF B
. O

Several O
studies O
have O
demonstrated O
that O
the O
corticotropin B
- I
releasing I
factor I
test O
( O
CRF B
) O
is O
useful O
for O
the O
aetiological O
diagnosis O
of O
Cushing O
' O
s O
syndrome O
: O
in O
Cushing O
' O
s O
disease O
, O
as O
opposed O
to O
ectopic O
ACTH B
secretion O
syndrome O
, O
the O
hypothalamus O
- O
pituitary O
- O
adrenal O
( O
HPA O
) O
axis O
can O
still O
be O
stimulated O
by O
CRF B
. O

Several O
studies O
have O
demonstrated O
that O
the O
corticotropin B
- I
releasing I
factor I
test O
( O
CRF B
) O
is O
useful O
for O
the O
aetiological O
diagnosis O
of O
Cushing O
' O
s O
syndrome O
: O
in O
Cushing O
' O
s O
disease O
, O
as O
opposed O
to O
ectopic O
ACTH B
secretion O
syndrome O
, O
the O
hypothalamus O
- O
pituitary O
- O
adrenal O
( O
HPA O
) O
axis O
can O
still O
be O
stimulated O
by O
CRF B
. O

The O
results O
of O
the O
transient O
- O
transfection O
assay O
showed O
that O
the O
Sp1 B
binding I
element I
located O
in O
the O
core O
region O
( O
positions O
- O
- O
64 O
to O
+ O
1 O
) O
of O
the O
alpha2 B
- I
integrin I
promoter I
plays O
an O
essential O
role O
in O
the O
alpha2 B
- I
integrin I
promoter I
activity O
and O
its O
downregulation O
by O
Erb B
- O
B2 B
. O

The O
results O
of O
the O
transient O
- O
transfection O
assay O
showed O
that O
the O
Sp1 B
binding I
element I
located O
in O
the O
core O
region O
( O
positions O
- O
- O
64 O
to O
+ O
1 O
) O
of O
the O
alpha2 B
- I
integrin I
promoter I
plays O
an O
essential O
role O
in O
the O
alpha2 B
- I
integrin I
promoter I
activity O
and O
its O
downregulation O
by O
Erb B
- O
B2 B
. O

Expression O
of O
FNCAT B
increased O
on O
serum O
treatment O
indicating O
that O
the O
region O
of O
the O
FN B
gene I
between O
positions O
+ O
69 O
and O
- O
510 O
bp O
mediated O
serum O
responsiveness O
. O

To O
test O
this O
hypothesis O
, O
we O
developed O
a O
system O
of O
transient O
transfection O
of O
rat O
adipocytes O
with O
constructs O
containing O
glyceraldehyde B
- I
3 I
- I
phosphate I
dehydrogenase I
( O
GAPDH B
) O
and O
fatty B
acid I
synthetase I
( O
FAS B
) O
promoters O
fused O
to O
gene B
reporter I
CAT I
. O

To O
test O
this O
hypothesis O
, O
we O
developed O
a O
system O
of O
transient O
transfection O
of O
rat O
adipocytes O
with O
constructs O
containing O
glyceraldehyde B
- I
3 I
- I
phosphate I
dehydrogenase I
( O
GAPDH B
) O
and O
fatty B
acid I
synthetase I
( O
FAS B
) O
promoters O
fused O
to O
gene B
reporter I
CAT I
. O

SHBG B
concentrations O
in O
women O
were O
also O
significantly O
higher O
at O
T O
- O
2 O
and O
T O
- O
3 O
when O
compared O
to O
T O
- O
1 O
values O
. O

The O
more O
severe O
the O
CRF O
, O
the O
more O
likely O
that O
total O
HDL B
and O
HDL2 B
cholesterol I
will O
be O
low O
. O

This O
is O
consistent O
with O
the O
need O
for O
a O
nuclear O
retinoid B
receptor I
function O
in O
RA O
- O
induced O
ERK2 B
activation O
. O

In O
the O
virus O
- O
infected O
cells O
, O
translation O
of O
the O
M1 B
protein I
was O
reduced O
to O
10 O
to O
20 O
% O
of O
that O
of O
the O
wild O
- O
type O
virus O
; O
however O
, O
the O
translation O
of O
neither O
the O
nucleoprotein O
nor O
NS1 B
was O
significantly O
interfered O
with O
, O
indicating O
the O
important O
role O
of O
NS1 B
in O
translational O
stimulation O
of O
the O
M1 B
protein I
. O

In O
the O
virus O
- O
infected O
cells O
, O
translation O
of O
the O
M1 B
protein I
was O
reduced O
to O
10 O
to O
20 O
% O
of O
that O
of O
the O
wild O
- O
type O
virus O
; O
however O
, O
the O
translation O
of O
neither O
the O
nucleoprotein O
nor O
NS1 B
was O
significantly O
interfered O
with O
, O
indicating O
the O
important O
role O
of O
NS1 B
in O
translational O
stimulation O
of O
the O
M1 B
protein I
. O

Interactions O
were O
also O
detected O
between O
full O
- O
length O
HSF1 B
and O
the O
small O
subunit O
( O
gamma O
) O
of O
TFIIA B
. O

Interactions O
were O
also O
detected O
between O
full O
- O
length O
HSF1 B
and O
the O
small O
subunit O
( O
gamma O
) O
of O
TFIIA B
. O

We O
report O
that O
Nim1 B
possesses O
intrinsic O
serine B
- I
kinase I
, O
threonine B
- I
kinase I
and O
tyrosine B
- I
kinase I
activities O
. O

In O
conclusion O
, O
ORCA3 B
regulates O
jasmonate O
- O
responsive O
expression O
of O
the O
Str B
gene I
via O
direct O
interaction O
with O
the O
JERE O
. O

ORF3 O
encodes O
a O
putative O
periplasmic B
c I
- I
type I
cytochrome I
with O
a O
molecular O
mass O
of O
94 O
, O
000 O
Da O
and O
contains O
seven O
c O
- O
heme O
- O
binding O
motifs O
but O
shows O
no O
sequence O
homology O
to O
occ B
or O
ORF1 O
. O

BACKGROUND O
- O
- O
Platelet B
activating I
factor I
( O
PAF B
) O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
airway O
hyperresponsiveness O
in O
asthma O
. O

TFEC B
RNA I
is O
found O
in O
many O
tissues O
of O
adult O
rats O
, O
but O
the O
relative O
concentrations O
of O
TFEC B
and O
TFE3 B
RNAs I
vary O
considerably O
in O
these O
different O
tissues O
. O

Our O
results O
show O
that O
unlike O
the O
case O
for O
sos1 B
, O
sos2 B
gene I
function O
is O
dispensable O
for O
normal O
mouse O
development O
, O
growth O
, O
and O
fertility O
. O

Studies O
of O
HS2 B
- I
gamma I
gene I
reporter I
constructs I
carrying O
CACCC O
box O
deletions O
revealed O
that O
the O
CACCC O
box O
sequence O
of O
the O
gamma O
gene O
promoter O
mediates O
the O
activation O
of O
the O
gamma O
gene O
by O
FKLF B
. O

This O
inhibition O
was O
due O
to O
competition O
from O
the O
EMC O
virus O
IRES O
present O
in O
pEP B
- I
2A I
transcripts I
, O
as O
well O
as O
the O
expression O
of O
proteolytically O
active O
2Apro B
. O

Some O
may O
affect O
the O
folding O
pathway O
or O
the O
affinity O
for O
chaperonins B
. O

The O
effect O
on O
FIV B
LTR I
promoter I
activity O
of O
progressively O
deleting O
these O
nuclear O
factor O
binding O
sites O
was O
examined O
by O
linking O
LTR O
deletion O
mutants O
to O
the O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
gene O
. O

A O
series O
of O
sequence O
fragments O
were O
placed O
5 O
' O
to O
the O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
reporter O
gene O
and O
ability O
to O
mediate O
transcription O
of O
CAT B
in O
response O
to O
IFN B
gamma I
or O
LPS O
treatment O
was O
studied O
following O
transient O
transfection O
in O
the O
macrophage O
- O
like O
cell O
line O
RAW O
264 O
. O
7 O
. O

A O
series O
of O
sequence O
fragments O
were O
placed O
5 O
' O
to O
the O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
reporter O
gene O
and O
ability O
to O
mediate O
transcription O
of O
CAT B
in O
response O
to O
IFN B
gamma I
or O
LPS O
treatment O
was O
studied O
following O
transient O
transfection O
in O
the O
macrophage O
- O
like O
cell O
line O
RAW O
264 O
. O
7 O
. O

Module O
2 O
of O
RifA B
lacks O
a O
beta B
- I
ketoacyl I
: I
acyl I
carrier I
protein I
reductase I
( O
KR B
) O
domain O
and O
the O
one O
in O
module O
3 O
has O
an O
apparently O
inactive O
NADPH B
binding I
motif I
, O
similar O
to O
one O
found O
in O
the O
Er B
PKS I
, O
while O
the O
other O
eight O
KR B
domains I
of O
the O
Rf B
PKS I
should O
be O
functional O
. O

Module O
2 O
of O
RifA B
lacks O
a O
beta B
- I
ketoacyl I
: I
acyl I
carrier I
protein I
reductase I
( O
KR B
) O
domain O
and O
the O
one O
in O
module O
3 O
has O
an O
apparently O
inactive O
NADPH B
binding I
motif I
, O
similar O
to O
one O
found O
in O
the O
Er B
PKS I
, O
while O
the O
other O
eight O
KR B
domains I
of O
the O
Rf B
PKS I
should O
be O
functional O
. O

In O
murine O
cells O
, O
FPGS B
expression O
is O
controlled O
by O
two O
promoters O
that O
, O
as O
we O
show O
here O
, O
vary O
substantially O
in O
their O
efficiency O
, O
at O
least O
in O
the O
context O
of O
a O
reporter O
gene O
assay O
. O

Should O
we O
use O
thiazide O
diuretics O
in O
hypertensive O
patients O
with O
non O
- O
insulin B
- O
dependent O
diabetes O
mellitus O
? O

The O
GST B
- O
CBL B
- O
LZIP B
fusion O
protein O
contains O
a O
binding O
site O
for O
the O
SH2 B
domain I
of O
the O
p85 B
subunit I
of O
phosphatidylinositol B
3 I
- I
kinase I
, O
which O
mapped O
to O
Tyr731 O
, O
which O
is O
present O
in O
the O
sequence O
YEAM O
. O

The O
GST B
- O
CBL B
- O
LZIP B
fusion O
protein O
contains O
a O
binding O
site O
for O
the O
SH2 B
domain I
of O
the O
p85 B
subunit I
of O
phosphatidylinositol B
3 I
- I
kinase I
, O
which O
mapped O
to O
Tyr731 O
, O
which O
is O
present O
in O
the O
sequence O
YEAM O
. O

The O
GST B
- O
CBL B
- O
LZIP B
fusion O
protein O
contains O
a O
binding O
site O
for O
the O
SH2 B
domain I
of O
the O
p85 B
subunit I
of O
phosphatidylinositol B
3 I
- I
kinase I
, O
which O
mapped O
to O
Tyr731 O
, O
which O
is O
present O
in O
the O
sequence O
YEAM O
. O

We O
now O
show O
that O
the O
FRAP B
Ser2035 O
- O
- O
> O
Ala O
mutant O
displays O
similar O
binding O
affinity O
when O
compared O
with O
the O
wild O
- O
type O
protein O
, O
whereas O
all O
other O
mutations O
at O
this O
site O
, O
including O
mimics O
of O
phosphoserine O
, O
abolish O
binding O
, O
presumably O
due O
to O
either O
unfavorable O
steric O
interactions O
or O
induced O
conformational O
changes O
. O

Differential O
decay O
of O
a O
polycistronic O
Escherichia O
coli O
transcript O
is O
initiated O
by O
RNaseE B
- O
dependent O
endonucleolytic O
processing O
. O

Defects O
in O
RT6 B
expression O
coincide O
with O
increased O
susceptibility O
in O
animal O
models O
for O
insulin B
- O
dependent O
diabetes O
mellitus O
and O
other O
autoimmune O
diseases O
. O

Defects O
in O
RT6 B
expression O
coincide O
with O
increased O
susceptibility O
in O
animal O
models O
for O
insulin B
- O
dependent O
diabetes O
mellitus O
and O
other O
autoimmune O
diseases O
. O

SYC1 B
( O
suppressor B
of I
yeast I
cbf5 I
- I
1 I
) O
was O
identified O
as O
a O
multicopy O
suppressor O
of O
cbf5 B
- I
1 I
and O
subsequently O
was O
found O
to O
be O
identical O
to O
RRN3 B
, O
an O
RNA B
polymerase I
I I
transcription I
factor I
. O

SYC1 B
( O
suppressor B
of I
yeast I
cbf5 I
- I
1 I
) O
was O
identified O
as O
a O
multicopy O
suppressor O
of O
cbf5 B
- I
1 I
and O
subsequently O
was O
found O
to O
be O
identical O
to O
RRN3 B
, O
an O
RNA B
polymerase I
I I
transcription I
factor I
. O

Both O
sequence O
analysis O
and O
restriction O
fragment O
length O
polymorphism O
analysis O
revealed O
a O
high O
degree O
of O
sequence O
( O
97 O
% O
homology O
) O
and O
structural O
similarity O
among O
members O
of O
the O
ART B
- O
CH B
family O
, O
indicating O
their O
common O
origin O
and O
recent O
penetration O
into O
chicken O
DNA O
. O

Both O
sequence O
analysis O
and O
restriction O
fragment O
length O
polymorphism O
analysis O
revealed O
a O
high O
degree O
of O
sequence O
( O
97 O
% O
homology O
) O
and O
structural O
similarity O
among O
members O
of O
the O
ART B
- O
CH B
family O
, O
indicating O
their O
common O
origin O
and O
recent O
penetration O
into O
chicken O
DNA O
. O

RESULTS O
: O
BMK B
- I
1 I
and O
other O
19 O
contents O
significantly O
decreased O
depolarization O
parameters O
Vmax O
, O
APA O
, O
OS O
, O
and O
MDP O
, O
which O
was O
similar O
to O
that O
of O
TTX B
and O
different O
from O
that O
of O
Nim O
and O
BaCl2 O
. O

Previous O
work O
has O
shown O
that O
glucose O
repression O
of O
PRB1 B
transcription O
is O
not O
mediated O
by O
HXK2 B
or O
by O
the O
SNF1 B
, O
SNF4 B
, O
and O
SNF6 B
genes I
( O
C O
. O

Previous O
work O
has O
shown O
that O
glucose O
repression O
of O
PRB1 B
transcription O
is O
not O
mediated O
by O
HXK2 B
or O
by O
the O
SNF1 B
, O
SNF4 B
, O
and O
SNF6 B
genes I
( O
C O
. O

Previous O
work O
has O
shown O
that O
glucose O
repression O
of O
PRB1 B
transcription O
is O
not O
mediated O
by O
HXK2 B
or O
by O
the O
SNF1 B
, O
SNF4 B
, O
and O
SNF6 B
genes I
( O
C O
. O

Previous O
work O
has O
shown O
that O
glucose O
repression O
of O
PRB1 B
transcription O
is O
not O
mediated O
by O
HXK2 B
or O
by O
the O
SNF1 B
, O
SNF4 B
, O
and O
SNF6 B
genes I
( O
C O
. O

The O
pyridostigmine O
inhibited O
AChE B
recovered O
only O
in O
the O
100 O
mumol O
kg O
- O
1 O
kg O
oxime O
groups O
at O
the O
end O
of O
the O
experiment O
. O

Mutation O
of O
this O
threonine O
to O
isoleucine O
had O
no O
observable O
effect O
on O
either O
nuclear O
localization O
of O
E1 B
or O
DNA O
replication O
of O
the O
intact O
viral O
genome O
. O

This O
enzyme O
is O
distinct O
from O
other O
known O
E3s B
, O
including O
E3 B
alpha I
/ O
UBR1 B
, O
E3 B
beta I
, O
and O
E6 B
- I
AP I
. O

This O
enzyme O
is O
distinct O
from O
other O
known O
E3s B
, O
including O
E3 B
alpha I
/ O
UBR1 B
, O
E3 B
beta I
, O
and O
E6 B
- I
AP I
. O

This O
evidence O
, O
together O
with O
the O
ability O
of O
a O
carboxyl O
- O
terminal O
coding O
sequence O
starting O
from O
the O
BamHI B
site I
to O
complement O
a O
shy1 B
mutant I
, O
suggests O
that O
the O
Shy1p B
contains O
two O
domains O
that O
can O
be O
separately O
expressed O
to O
form O
a O
functional O
protein O
. O

The O
zinc B
finger I
protein I
A20 I
is O
a O
tumor B
necrosis I
factor I
( O
TNF B
) O
- O
and O
interleukin B
1 I
( O
IL B
- I
1 I
) O
- O
inducible O
protein O
that O
negatively O
regulates O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappaB I
) O
- O
dependent O
gene O
expression O
. O

Mutant O
beta2 B
- I
adrenergic I
receptors I
with O
a O
Tyr O
- O
to O
- O
Phe O
substitution O
at O
Tyr O
- O
350 O
do O
not O
display O
agonist O
- O
induced O
desensitization O
, O
Src B
recruitment O
, O
or O
Src B
activation O
. O

Mutant O
beta2 B
- I
adrenergic I
receptors I
with O
a O
Tyr O
- O
to O
- O
Phe O
substitution O
at O
Tyr O
- O
350 O
do O
not O
display O
agonist O
- O
induced O
desensitization O
, O
Src B
recruitment O
, O
or O
Src B
activation O
. O

These O
data O
may O
indicate O
redundancy O
between O
members O
of O
the O
NGFI B
- I
B I
/ O
Nurr1 B
/ O
Nor1 B
subfamily O
and O
could O
explain O
why O
no O
phenotypic O
disturbances O
have O
yet O
been O
found O
in O
mice O
in O
which O
the O
NGFI B
- I
B I
gene I
has O
been O
inactivated O
. O

These O
data O
may O
indicate O
redundancy O
between O
members O
of O
the O
NGFI B
- I
B I
/ O
Nurr1 B
/ O
Nor1 B
subfamily O
and O
could O
explain O
why O
no O
phenotypic O
disturbances O
have O
yet O
been O
found O
in O
mice O
in O
which O
the O
NGFI B
- I
B I
gene I
has O
been O
inactivated O
. O

To O
directly O
address O
this O
issue O
, O
we O
used O
a O
tetracycline O
- O
regulated O
system O
in O
human O
U2OS O
osteosarcoma O
cells O
and O
thus O
found O
that O
BCL6 B
mediates O
growth O
suppression O
associated O
with O
impaired O
S O
phase O
progression O
and O
apoptosis O
. O

Stability O
of O
125 O
I O
- O
labeled O
insulin B
used O
in O
radioimmunoassay O
of O
insulin B
. O

Stability O
of O
125 O
I O
- O
labeled O
insulin B
used O
in O
radioimmunoassay O
of O
insulin B
. O

Paclitaxel O
caused O
a O
rapid O
and O
transient O
increase O
in O
c B
- I
Jun I
NH2 I
- I
terminal I
kinase I
( O
JNK B
) O
activity O
, O
a O
proposed O
mediator O
of O
stress O
activation O
pathways O
. O

We O
show O
here O
that O
Spb1p B
is O
able O
to O
bind O
[ O
( O
3 O
) O
H O
] O
AdoMet O
in O
vitro O
, O
suggesting O
that O
it O
is O
a O
novel O
methylase O
, O
whose O
possible O
substrates O
will O
be O
discussed O
. O

However O
, O
additional O
studies O
on O
cell O
lines O
and O
whole O
animals O
are O
required O
to O
understand O
GnRH B
signaling O
in O
the O
context O
of O
other O
hormones O
during O
the O
reproductive O
cycle O
of O
mouse O
and O
human O
. O

This O
duplicated O
genomic O
region O
is O
also O
linked O
tightly O
to O
D1Z2 B
, O
a O
genetic O
marker O
containing O
a O
highly O
polymorphic O
VNTR O
( O
variable O
number O
tandem O
repeat O
) O
consisting O
of O
an O
unusual O
40 O
- O
bp O
reiterated O
sequence O
. O

ATF6 B
, O
a O
basic B
- I
leucine I
zipper I
protein I
, O
was O
isolated O
by O
binding O
to O
SRF B
and O
in O
particular O
to O
its O
transcriptional O
activation O
domain O
. O

ATF6 B
, O
a O
basic B
- I
leucine I
zipper I
protein I
, O
was O
isolated O
by O
binding O
to O
SRF B
and O
in O
particular O
to O
its O
transcriptional O
activation O
domain O
. O

Cetn1 B
possesses O
the O
sequence O
features O
of O
an O
expressed O
retroposon O
: O
the O
gene O
lacks O
introns O
, O
the O
open O
reading O
frame O
is O
not O
interrupted O
by O
stop O
codons O
, O
and O
the O
coding O
region O
is O
flanked O
by O
a O
pair O
of O
direct O
repeats O
. O

The O
largest O
one O
probably O
corresponds O
to O
the O
precursor O
form O
of O
PS2 B
in O
E O
. O
coli O
. O

VAV B
and O
SOCS1 B
form O
a O
protein O
complex O
through O
interactions O
between O
the O
VAV B
NH I
( I
2 I
) I
- I
terminal I
regulatory I
region I
and O
the O
SH2 B
domain I
of O
SOCS1 B
in O
a O
phosphotyrosine O
- O
independent O
manner O
. O

VAV B
and O
SOCS1 B
form O
a O
protein O
complex O
through O
interactions O
between O
the O
VAV B
NH I
( I
2 I
) I
- I
terminal I
regulatory I
region I
and O
the O
SH2 B
domain I
of O
SOCS1 B
in O
a O
phosphotyrosine O
- O
independent O
manner O
. O

VAV B
and O
SOCS1 B
form O
a O
protein O
complex O
through O
interactions O
between O
the O
VAV B
NH I
( I
2 I
) I
- I
terminal I
regulatory I
region I
and O
the O
SH2 B
domain I
of O
SOCS1 B
in O
a O
phosphotyrosine O
- O
independent O
manner O
. O

Northern O
blot O
analysis O
with O
GPR37 B
probes O
revealed O
a O
main O
3 O
. O
8 O
- O
kb O
mRNA O
and O
a O
less O
abundant O
8 O
- O
kb O
mRNA O
, O
both O
expressed O
in O
human O
brain O
tissues O
, O
particularly O
in O
corpus O
callosum O
, O
medulla O
, O
putamen O
, O
and O
caudate O
nucleus O
. O

Our O
studies O
indicate O
no O
single O
trans O
- O
acting O
factor O
is O
absolutely O
essential O
for O
enhancer O
activity O
, O
and O
that O
the O
enhancer O
activity O
of O
MerI B
is O
mediated O
via O
a O
combinatorial O
and O
additive O
mechanism O
. O

Furthermore O
, O
disruption O
of O
pcr1 B
reduced O
expression O
of O
fbp1 B
, O
a O
glucose O
- O
repressible O
gene O
negatively O
regulated O
by O
PKA B
. O

Furthermore O
, O
disruption O
of O
pcr1 B
reduced O
expression O
of O
fbp1 B
, O
a O
glucose O
- O
repressible O
gene O
negatively O
regulated O
by O
PKA B
. O

Furthermore O
, O
disruption O
of O
pcr1 B
reduced O
expression O
of O
fbp1 B
, O
a O
glucose O
- O
repressible O
gene O
negatively O
regulated O
by O
PKA B
. O

In O
solution O
, O
[ O
( O
125 O
) O
I O
] O
- O
labeled O
ankyrin B
was O
found O
by O
ND O
- O
PAGE3 O
to O
enhance O
the O
affinity O
of O
spectrin B
self O
- O
association O
by O
10 O
- O
fold O
. O

In O
solution O
, O
[ O
( O
125 O
) O
I O
] O
- O
labeled O
ankyrin B
was O
found O
by O
ND O
- O
PAGE3 O
to O
enhance O
the O
affinity O
of O
spectrin B
self O
- O
association O
by O
10 O
- O
fold O
. O

In O
this O
study O
, O
the O
subcellular O
location O
, O
domain O
structure O
, O
and O
biochemical O
function O
of O
metaxin B
were O
investigated O
. O

Flux O
of O
the O
paramyxovirus O
hemagglutinin B
- O
neuraminidase B
glycoprotein O
through O
the O
endoplasmic O
reticulum O
activates O
transcription O
of O
the O
GRP78 B
- O
BiP B
gene O
. O

Flux O
of O
the O
paramyxovirus O
hemagglutinin B
- O
neuraminidase B
glycoprotein O
through O
the O
endoplasmic O
reticulum O
activates O
transcription O
of O
the O
GRP78 B
- O
BiP B
gene O
. O

Flux O
of O
the O
paramyxovirus O
hemagglutinin B
- O
neuraminidase B
glycoprotein O
through O
the O
endoplasmic O
reticulum O
activates O
transcription O
of O
the O
GRP78 B
- O
BiP B
gene O
. O

Flux O
of O
the O
paramyxovirus O
hemagglutinin B
- O
neuraminidase B
glycoprotein O
through O
the O
endoplasmic O
reticulum O
activates O
transcription O
of O
the O
GRP78 B
- O
BiP B
gene O
. O

Soggy B
, O
a O
spermatocyte O
- O
specific O
gene O
, O
lies O
3 O
. O
8 O
kb O
upstream O
of O
and O
antipodal O
to O
TEAD B
- I
2 I
, O
a O
transcription O
factor O
expressed O
at O
the O
beginning O
of O
mouse O
development O
. O

The O
goals O
of O
these O
experiments O
were O
to O
determine O
whether O
lactational O
anestrus O
would O
be O
prolonged O
by O
a O
48 O
- O
h O
fast O
at O
days O
13 O
and O
14 O
postpartum O
( O
pp O
) O
and O
, O
if O
so O
, O
to O
determine O
whether O
this O
effect O
could O
be O
reversed O
by O
treatment O
with O
the O
Ob B
protein I
leptin B
. O

Complete O
activation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
requires O
phosphorylation O
at O
both O
Y701 O
and O
a O
conserved O
PMS O
( O
727 O
) O
P O
sequence O
. O

The O
Ras B
GTPase I
- I
activating I
- I
protein I
- I
related I
human I
protein I
IQGAP2 B
harbors O
a O
potential O
actin B
binding I
domain I
and O
interacts O
with O
calmodulin B
and O
Rho B
family I
GTPases I
. O

The O
Ras B
GTPase I
- I
activating I
- I
protein I
- I
related I
human I
protein I
IQGAP2 B
harbors O
a O
potential O
actin B
binding I
domain I
and O
interacts O
with O
calmodulin B
and O
Rho B
family I
GTPases I
. O

Moreover O
, O
a O
hybrid O
protein O
composed O
of O
a O
PvALF B
activation I
domain I
and O
the O
DNA O
binding O
and O
dimerization O
domain O
of O
ROM2 B
activated O
gene O
expression O
, O
indicating O
that O
ROM2 B
recognizes O
the O
DLEC2 B
enhancer I
in O
vivo O
; O
consequently O
, O
ROM2 B
functions O
as O
a O
DNA O
binding O
site O
- O
dependent O
repressor O
. O

Moreover O
, O
a O
hybrid O
protein O
composed O
of O
a O
PvALF B
activation I
domain I
and O
the O
DNA O
binding O
and O
dimerization O
domain O
of O
ROM2 B
activated O
gene O
expression O
, O
indicating O
that O
ROM2 B
recognizes O
the O
DLEC2 B
enhancer I
in O
vivo O
; O
consequently O
, O
ROM2 B
functions O
as O
a O
DNA O
binding O
site O
- O
dependent O
repressor O
. O

Moreover O
, O
a O
hybrid O
protein O
composed O
of O
a O
PvALF B
activation I
domain I
and O
the O
DNA O
binding O
and O
dimerization O
domain O
of O
ROM2 B
activated O
gene O
expression O
, O
indicating O
that O
ROM2 B
recognizes O
the O
DLEC2 B
enhancer I
in O
vivo O
; O
consequently O
, O
ROM2 B
functions O
as O
a O
DNA O
binding O
site O
- O
dependent O
repressor O
. O

On O
the O
other O
hand O
, O
NE O
transport O
and O
antagonist O
( O
[ O
125I O
] O
RTI O
- O
55 O
) O
binding O
assays O
on O
whole O
LLC O
- O
NET O
cells O
treated O
with O
tunicamycin O
reveal O
a O
pronounced O
reduction O
in O
NE O
transport O
activity O
and O
hNET B
membrane O
density O
paralleled O
by O
an O
inability O
of O
NET B
proteins I
to O
replenish O
the O
higher O
M O
( O
r O
) O
hNET B
pool O
. O

On O
the O
other O
hand O
, O
NE O
transport O
and O
antagonist O
( O
[ O
125I O
] O
RTI O
- O
55 O
) O
binding O
assays O
on O
whole O
LLC O
- O
NET O
cells O
treated O
with O
tunicamycin O
reveal O
a O
pronounced O
reduction O
in O
NE O
transport O
activity O
and O
hNET B
membrane O
density O
paralleled O
by O
an O
inability O
of O
NET B
proteins I
to O
replenish O
the O
higher O
M O
( O
r O
) O
hNET B
pool O
. O

Plasmid O
pSP64E6E7 O
which O
contains O
the O
reading O
frames O
of O
both O
E6 B
and O
E7 B
was O
constructed O
in O
order O
to O
study O
the O
expression O
of O
both O
proteins O
in O
a O
coupled O
transcription O
/ O
rabbit O
reticulocyte O
translation O
system O
. O

Plasmid O
pSP64E6E7 O
which O
contains O
the O
reading O
frames O
of O
both O
E6 B
and O
E7 B
was O
constructed O
in O
order O
to O
study O
the O
expression O
of O
both O
proteins O
in O
a O
coupled O
transcription O
/ O
rabbit O
reticulocyte O
translation O
system O
. O

The O
derepressed O
expression O
of O
fixN B
was O
not O
observed O
in O
a O
purH B
mutant I
. O

Both O
viruses O
express O
the O
mil B
/ O
raf B
oncogene O
product O
as O
a O
gag B
- I
fusion I
polyprotein O
, O
while O
the O
myc B
oncogene O
of O
MH2 O
is O
expressed O
via O
a O
subgenomic O
mRNA O
. O

Both O
viruses O
express O
the O
mil B
/ O
raf B
oncogene O
product O
as O
a O
gag B
- I
fusion I
polyprotein O
, O
while O
the O
myc B
oncogene O
of O
MH2 O
is O
expressed O
via O
a O
subgenomic O
mRNA O
. O

Both O
viruses O
express O
the O
mil B
/ O
raf B
oncogene O
product O
as O
a O
gag B
- I
fusion I
polyprotein O
, O
while O
the O
myc B
oncogene O
of O
MH2 O
is O
expressed O
via O
a O
subgenomic O
mRNA O
. O

Recombinant O
protein O
encoded O
by O
ESX B
( O
for O
epithelial B
- I
restricted I
with I
serine I
box I
) O
exhibits O
Ets B
- I
like I
DNA O
binding O
specificity O
in O
electrophoretic O
mobility O
shift O
assays O
and O
, O
in O
transient O
transfection O
assays O
, O
transactivates O
Ets B
- I
responsive I
promoter I
elements I
including O
that O
found O
in O
the O
HER2 B
/ O
neu B
oncogene O
. O

Recombinant O
protein O
encoded O
by O
ESX B
( O
for O
epithelial B
- I
restricted I
with I
serine I
box I
) O
exhibits O
Ets B
- I
like I
DNA O
binding O
specificity O
in O
electrophoretic O
mobility O
shift O
assays O
and O
, O
in O
transient O
transfection O
assays O
, O
transactivates O
Ets B
- I
responsive I
promoter I
elements I
including O
that O
found O
in O
the O
HER2 B
/ O
neu B
oncogene O
. O

Recombinant O
protein O
encoded O
by O
ESX B
( O
for O
epithelial B
- I
restricted I
with I
serine I
box I
) O
exhibits O
Ets B
- I
like I
DNA O
binding O
specificity O
in O
electrophoretic O
mobility O
shift O
assays O
and O
, O
in O
transient O
transfection O
assays O
, O
transactivates O
Ets B
- I
responsive I
promoter I
elements I
including O
that O
found O
in O
the O
HER2 B
/ O
neu B
oncogene O
. O

The O
temporal O
changes O
in O
the O
plasma O
concentration O
of O
immunoreactive B
atrial I
natriuretic I
factor I
( O
iANF B
) O
were O
studied O
in O
six O
conscious O
dogs O
with O
an O
arteriovenous O
( O
AV O
) O
fistula O
, O
a O
model O
of O
chronic O
high O
- O
output O
heart O
failure O
. O

Two O
closely O
related O
groups O
of O
transcripts O
, O
Sagrp1 B
and O
Sagrp2 B
, O
controlled O
by O
a O
circadian O
rhythm O
have O
been O
isolated O
. O

Two O
closely O
related O
groups O
of O
transcripts O
, O
Sagrp1 B
and O
Sagrp2 B
, O
controlled O
by O
a O
circadian O
rhythm O
have O
been O
isolated O
. O

Of O
921 O
specimens O
, O
95 O
yielded O
non O
- O
albicans O
species O
, O
mainly O
from O
patients O
with O
low O
CD4 B
lymphocyte O
counts O
and O
extensive O
previous O
azole O
exposure O
. O

These O
findings O
suggest O
that O
eIF5 B
- O
eIF2beta B
interaction O
plays O
an O
essential O
role O
in O
eIF5 B
function O
in O
eukaryotic O
cells O
. O

These O
findings O
suggest O
that O
eIF5 B
- O
eIF2beta B
interaction O
plays O
an O
essential O
role O
in O
eIF5 B
function O
in O
eukaryotic O
cells O
. O

These O
findings O
suggest O
that O
eIF5 B
- O
eIF2beta B
interaction O
plays O
an O
essential O
role O
in O
eIF5 B
function O
in O
eukaryotic O
cells O
. O

Development O
of O
P O
carinii O
pneumonia O
was O
associated O
with O
the O
stage O
of O
Kaposi O
' O
s O
sarcoma O
, O
B O
subtype O
disease O
, O
and O
the O
presence O
of O
0 O
. O
20 O
X O
10 O
( O
9 O
) O
/ O
L O
( O
200 O
/ O
mm3 O
) O
or O
fewer O
CD4 B
cells O
at O
study O
entry O
. O

The O
melanoma B
growth I
stimulatory I
activity I
/ I
growth I
- I
regulated I
protein I
, O
CXCL1 B
, O
is O
constitutively O
expressed O
at O
high O
levels O
during O
inflammation O
and O
progression O
of O
melanocytes O
into O
malignant O
melanoma O
. O

Genetic O
analysis O
places O
CWH43 B
upstream O
of O
the O
BCK2 B
branch O
of O
the O
PKC1 B
signalling O
pathway O
, O
since O
cwh43 B
mutations O
were O
synthetic O
lethal O
with O
pkc1 B
deletion O
, O
whereas O
the O
cwh43 B
defects O
could O
be O
rescued O
by O
overexpression O
of O
BCK2 B
and O
not O
by O
high O
- O
copy O
- O
number O
expression O
of O
genes O
encoding O
downstream O
proteins O
of O
the O
PKC1 B
pathway O
However O
, O
unlike O
BCK2 B
, O
whose O
disruption O
in O
a O
cln3 B
mutant I
resulted O
in O
growth O
arrest O
in O
G O
( O
1 O
) O
, O
no O
growth O
defect O
was O
observed O
in O
a O
double O
cwh43 B
cln3 B
mutants I
. O

Genetic O
analysis O
places O
CWH43 B
upstream O
of O
the O
BCK2 B
branch O
of O
the O
PKC1 B
signalling O
pathway O
, O
since O
cwh43 B
mutations O
were O
synthetic O
lethal O
with O
pkc1 B
deletion O
, O
whereas O
the O
cwh43 B
defects O
could O
be O
rescued O
by O
overexpression O
of O
BCK2 B
and O
not O
by O
high O
- O
copy O
- O
number O
expression O
of O
genes O
encoding O
downstream O
proteins O
of O
the O
PKC1 B
pathway O
However O
, O
unlike O
BCK2 B
, O
whose O
disruption O
in O
a O
cln3 B
mutant I
resulted O
in O
growth O
arrest O
in O
G O
( O
1 O
) O
, O
no O
growth O
defect O
was O
observed O
in O
a O
double O
cwh43 B
cln3 B
mutants I
. O

Genetic O
analysis O
places O
CWH43 B
upstream O
of O
the O
BCK2 B
branch O
of O
the O
PKC1 B
signalling O
pathway O
, O
since O
cwh43 B
mutations O
were O
synthetic O
lethal O
with O
pkc1 B
deletion O
, O
whereas O
the O
cwh43 B
defects O
could O
be O
rescued O
by O
overexpression O
of O
BCK2 B
and O
not O
by O
high O
- O
copy O
- O
number O
expression O
of O
genes O
encoding O
downstream O
proteins O
of O
the O
PKC1 B
pathway O
However O
, O
unlike O
BCK2 B
, O
whose O
disruption O
in O
a O
cln3 B
mutant I
resulted O
in O
growth O
arrest O
in O
G O
( O
1 O
) O
, O
no O
growth O
defect O
was O
observed O
in O
a O
double O
cwh43 B
cln3 B
mutants I
. O

Genetic O
analysis O
places O
CWH43 B
upstream O
of O
the O
BCK2 B
branch O
of O
the O
PKC1 B
signalling O
pathway O
, O
since O
cwh43 B
mutations O
were O
synthetic O
lethal O
with O
pkc1 B
deletion O
, O
whereas O
the O
cwh43 B
defects O
could O
be O
rescued O
by O
overexpression O
of O
BCK2 B
and O
not O
by O
high O
- O
copy O
- O
number O
expression O
of O
genes O
encoding O
downstream O
proteins O
of O
the O
PKC1 B
pathway O
However O
, O
unlike O
BCK2 B
, O
whose O
disruption O
in O
a O
cln3 B
mutant I
resulted O
in O
growth O
arrest O
in O
G O
( O
1 O
) O
, O
no O
growth O
defect O
was O
observed O
in O
a O
double O
cwh43 B
cln3 B
mutants I
. O

Genetic O
analysis O
places O
CWH43 B
upstream O
of O
the O
BCK2 B
branch O
of O
the O
PKC1 B
signalling O
pathway O
, O
since O
cwh43 B
mutations O
were O
synthetic O
lethal O
with O
pkc1 B
deletion O
, O
whereas O
the O
cwh43 B
defects O
could O
be O
rescued O
by O
overexpression O
of O
BCK2 B
and O
not O
by O
high O
- O
copy O
- O
number O
expression O
of O
genes O
encoding O
downstream O
proteins O
of O
the O
PKC1 B
pathway O
However O
, O
unlike O
BCK2 B
, O
whose O
disruption O
in O
a O
cln3 B
mutant I
resulted O
in O
growth O
arrest O
in O
G O
( O
1 O
) O
, O
no O
growth O
defect O
was O
observed O
in O
a O
double O
cwh43 B
cln3 B
mutants I
. O

Genetic O
analysis O
places O
CWH43 B
upstream O
of O
the O
BCK2 B
branch O
of O
the O
PKC1 B
signalling O
pathway O
, O
since O
cwh43 B
mutations O
were O
synthetic O
lethal O
with O
pkc1 B
deletion O
, O
whereas O
the O
cwh43 B
defects O
could O
be O
rescued O
by O
overexpression O
of O
BCK2 B
and O
not O
by O
high O
- O
copy O
- O
number O
expression O
of O
genes O
encoding O
downstream O
proteins O
of O
the O
PKC1 B
pathway O
However O
, O
unlike O
BCK2 B
, O
whose O
disruption O
in O
a O
cln3 B
mutant I
resulted O
in O
growth O
arrest O
in O
G O
( O
1 O
) O
, O
no O
growth O
defect O
was O
observed O
in O
a O
double O
cwh43 B
cln3 B
mutants I
. O

Genetic O
analysis O
places O
CWH43 B
upstream O
of O
the O
BCK2 B
branch O
of O
the O
PKC1 B
signalling O
pathway O
, O
since O
cwh43 B
mutations O
were O
synthetic O
lethal O
with O
pkc1 B
deletion O
, O
whereas O
the O
cwh43 B
defects O
could O
be O
rescued O
by O
overexpression O
of O
BCK2 B
and O
not O
by O
high O
- O
copy O
- O
number O
expression O
of O
genes O
encoding O
downstream O
proteins O
of O
the O
PKC1 B
pathway O
However O
, O
unlike O
BCK2 B
, O
whose O
disruption O
in O
a O
cln3 B
mutant I
resulted O
in O
growth O
arrest O
in O
G O
( O
1 O
) O
, O
no O
growth O
defect O
was O
observed O
in O
a O
double O
cwh43 B
cln3 B
mutants I
. O

Genetic O
analysis O
places O
CWH43 B
upstream O
of O
the O
BCK2 B
branch O
of O
the O
PKC1 B
signalling O
pathway O
, O
since O
cwh43 B
mutations O
were O
synthetic O
lethal O
with O
pkc1 B
deletion O
, O
whereas O
the O
cwh43 B
defects O
could O
be O
rescued O
by O
overexpression O
of O
BCK2 B
and O
not O
by O
high O
- O
copy O
- O
number O
expression O
of O
genes O
encoding O
downstream O
proteins O
of O
the O
PKC1 B
pathway O
However O
, O
unlike O
BCK2 B
, O
whose O
disruption O
in O
a O
cln3 B
mutant I
resulted O
in O
growth O
arrest O
in O
G O
( O
1 O
) O
, O
no O
growth O
defect O
was O
observed O
in O
a O
double O
cwh43 B
cln3 B
mutants I
. O

Genetic O
analysis O
places O
CWH43 B
upstream O
of O
the O
BCK2 B
branch O
of O
the O
PKC1 B
signalling O
pathway O
, O
since O
cwh43 B
mutations O
were O
synthetic O
lethal O
with O
pkc1 B
deletion O
, O
whereas O
the O
cwh43 B
defects O
could O
be O
rescued O
by O
overexpression O
of O
BCK2 B
and O
not O
by O
high O
- O
copy O
- O
number O
expression O
of O
genes O
encoding O
downstream O
proteins O
of O
the O
PKC1 B
pathway O
However O
, O
unlike O
BCK2 B
, O
whose O
disruption O
in O
a O
cln3 B
mutant I
resulted O
in O
growth O
arrest O
in O
G O
( O
1 O
) O
, O
no O
growth O
defect O
was O
observed O
in O
a O
double O
cwh43 B
cln3 B
mutants I
. O

Genetic O
analysis O
places O
CWH43 B
upstream O
of O
the O
BCK2 B
branch O
of O
the O
PKC1 B
signalling O
pathway O
, O
since O
cwh43 B
mutations O
were O
synthetic O
lethal O
with O
pkc1 B
deletion O
, O
whereas O
the O
cwh43 B
defects O
could O
be O
rescued O
by O
overexpression O
of O
BCK2 B
and O
not O
by O
high O
- O
copy O
- O
number O
expression O
of O
genes O
encoding O
downstream O
proteins O
of O
the O
PKC1 B
pathway O
However O
, O
unlike O
BCK2 B
, O
whose O
disruption O
in O
a O
cln3 B
mutant I
resulted O
in O
growth O
arrest O
in O
G O
( O
1 O
) O
, O
no O
growth O
defect O
was O
observed O
in O
a O
double O
cwh43 B
cln3 B
mutants I
. O

Therefore O
, O
a O
structural O
interaction O
between O
PsaL B
and O
PsaI B
may O
stabilize O
the O
association O
of O
PsaL B
with O
the O
photosystem B
I I
core I
. O

Therefore O
, O
a O
structural O
interaction O
between O
PsaL B
and O
PsaI B
may O
stabilize O
the O
association O
of O
PsaL B
with O
the O
photosystem B
I I
core I
. O

Therefore O
, O
a O
structural O
interaction O
between O
PsaL B
and O
PsaI B
may O
stabilize O
the O
association O
of O
PsaL B
with O
the O
photosystem B
I I
core I
. O

Expression O
of O
CBP B
/ O
p300 B
potentiated O
HS2 O
- O
mediated O
transactivation O
. O

Expression O
of O
CBP B
/ O
p300 B
potentiated O
HS2 O
- O
mediated O
transactivation O
. O

We O
next O
developed O
a O
rapid O
purification O
method O
for O
bacterial B
recombinant I
MyoD I
- I
bHLH I
domain I
by O
affinity O
chromatography O
using O
a O
calmodulin B
- O
Sepharose O
column O
and O
investigated O
the O
phosphorylation O
of O
that O
peptide O
by O
PKC B
and O
its O
interactions O
with O
calmodulin B
and O
S100a B
. O

We O
next O
developed O
a O
rapid O
purification O
method O
for O
bacterial B
recombinant I
MyoD I
- I
bHLH I
domain I
by O
affinity O
chromatography O
using O
a O
calmodulin B
- O
Sepharose O
column O
and O
investigated O
the O
phosphorylation O
of O
that O
peptide O
by O
PKC B
and O
its O
interactions O
with O
calmodulin B
and O
S100a B
. O

We O
next O
developed O
a O
rapid O
purification O
method O
for O
bacterial B
recombinant I
MyoD I
- I
bHLH I
domain I
by O
affinity O
chromatography O
using O
a O
calmodulin B
- O
Sepharose O
column O
and O
investigated O
the O
phosphorylation O
of O
that O
peptide O
by O
PKC B
and O
its O
interactions O
with O
calmodulin B
and O
S100a B
. O

We O
next O
developed O
a O
rapid O
purification O
method O
for O
bacterial B
recombinant I
MyoD I
- I
bHLH I
domain I
by O
affinity O
chromatography O
using O
a O
calmodulin B
- O
Sepharose O
column O
and O
investigated O
the O
phosphorylation O
of O
that O
peptide O
by O
PKC B
and O
its O
interactions O
with O
calmodulin B
and O
S100a B
. O

HL B
is O
hypothesized O
to O
directly O
couple O
HDL B
lipid O
metabolism O
to O
tissue O
/ O
cellular O
lipid O
metabolism O
. O

HL B
is O
hypothesized O
to O
directly O
couple O
HDL B
lipid O
metabolism O
to O
tissue O
/ O
cellular O
lipid O
metabolism O
. O

We O
constructed O
a O
stable O
, O
doubly O
transfected O
cell O
line O
( O
TIS O
- O
10 O
) O
carrying O
a O
chromosomally O
integrated O
ptetO7 B
- I
CMV I
- I
L I
reporter O
construct O
and O
expressing O
the O
TetR B
- O
KRAB B
protein O
. O

We O
constructed O
a O
stable O
, O
doubly O
transfected O
cell O
line O
( O
TIS O
- O
10 O
) O
carrying O
a O
chromosomally O
integrated O
ptetO7 B
- I
CMV I
- I
L I
reporter O
construct O
and O
expressing O
the O
TetR B
- O
KRAB B
protein O
. O

We O
suggest O
that O
electrical O
stimulation O
of O
the O
NTS O
in O
rats O
undergoing O
such O
surgical O
preparation O
to O
observe O
the O
pressor O
response O
and O
/ O
or O
increase O
in O
pVP O
, O
represents O
a O
rapid O
approach O
for O
screening O
the O
neurosecretory O
function O
of O
the O
central O
neural O
integration O
to O
release O
vasopressin B
. O

Both O
DMP2 B
and O
DMP3 B
are O
closely O
localized O
on O
mouse O
chromosome O
5q21 O
, O
corresponding O
to O
human O
chromosome O
4q21 O
. O

Both O
DMP2 B
and O
DMP3 B
are O
closely O
localized O
on O
mouse O
chromosome O
5q21 O
, O
corresponding O
to O
human O
chromosome O
4q21 O
. O

A O
novel O
alternative O
spliced O
variant O
of O
the O
transcription O
factor O
AP2alpha B
is O
expressed O
in O
the O
murine O
ocular O
lens O
. O

Fig1p B
and O
Fig2p B
are O
likely O
to O
act O
at O
the O
cell O
surface O
as O
Fig1 B
: O
: O
beta B
- I
gal I
and O
Fig2 B
: O
: O
beta B
- I
gal I
fusion I
proteins I
localize O
to O
the O
periphery O
of O
mating O
cells O
. O

Fig1p B
and O
Fig2p B
are O
likely O
to O
act O
at O
the O
cell O
surface O
as O
Fig1 B
: O
: O
beta B
- I
gal I
and O
Fig2 B
: O
: O
beta B
- I
gal I
fusion I
proteins I
localize O
to O
the O
periphery O
of O
mating O
cells O
. O

Fig1p B
and O
Fig2p B
are O
likely O
to O
act O
at O
the O
cell O
surface O
as O
Fig1 B
: O
: O
beta B
- I
gal I
and O
Fig2 B
: O
: O
beta B
- I
gal I
fusion I
proteins I
localize O
to O
the O
periphery O
of O
mating O
cells O
. O

Fig1p B
and O
Fig2p B
are O
likely O
to O
act O
at O
the O
cell O
surface O
as O
Fig1 B
: O
: O
beta B
- I
gal I
and O
Fig2 B
: O
: O
beta B
- I
gal I
fusion I
proteins I
localize O
to O
the O
periphery O
of O
mating O
cells O
. O

Crystals O
of O
the O
triple O
mutant O
A42D B
/ O
D47P B
/ O
A63L B
, O
which O
are O
stable O
for O
days O
in O
its O
oxidized O
form O
, O
were O
grown O
from O
ammonium O
sulfate O
, O
with O
the O
cell O
constants O
a O
= O
b O
= O
34 O
. O
3 O
A O
and O
c O
= O
111 O
. O
8 O
A O
belonging O
to O
space O
group O
P3 O
( O
2 O
) O
21 O
. O

Crystals O
of O
the O
triple O
mutant O
A42D B
/ O
D47P B
/ O
A63L B
, O
which O
are O
stable O
for O
days O
in O
its O
oxidized O
form O
, O
were O
grown O
from O
ammonium O
sulfate O
, O
with O
the O
cell O
constants O
a O
= O
b O
= O
34 O
. O
3 O
A O
and O
c O
= O
111 O
. O
8 O
A O
belonging O
to O
space O
group O
P3 O
( O
2 O
) O
21 O
. O

Crystals O
of O
the O
triple O
mutant O
A42D B
/ O
D47P B
/ O
A63L B
, O
which O
are O
stable O
for O
days O
in O
its O
oxidized O
form O
, O
were O
grown O
from O
ammonium O
sulfate O
, O
with O
the O
cell O
constants O
a O
= O
b O
= O
34 O
. O
3 O
A O
and O
c O
= O
111 O
. O
8 O
A O
belonging O
to O
space O
group O
P3 O
( O
2 O
) O
21 O
. O

Our O
data O
suggest O
that O
association O
of O
TBP B
with O
the O
TATA O
box O
may O
be O
regulated O
, O
directly O
or O
indirectly O
, O
by O
a O
substrate O
of O
Snf1 B
. O

Our O
data O
suggest O
that O
association O
of O
TBP B
with O
the O
TATA O
box O
may O
be O
regulated O
, O
directly O
or O
indirectly O
, O
by O
a O
substrate O
of O
Snf1 B
. O

It O
was O
previously O
shown O
that O
Vi B
antigen I
expression O
was O
regulated O
by O
a O
system O
similar O
to O
the O
rcs B
regulatory O
system O
involved O
in O
colanic O
acid O
synthesis O
in O
Escherichia O
coli O
. O

In O
the O
absence O
of O
Mg2 O
+ O
, O
the O
extent O
of O
destabilization O
of O
tRNAPhe B
is O
greater O
but O
appears O
to O
be O
confined O
to O
internal O
regions O
of O
the O
acceptor O
and O
T O
psi O
C O
helices O
, O
as O
evidenced O
by O
the O
selectively O
enhanced O
exchange O
rates O
for O
imino O
protons O
associated O
with O
these O
base O
pairs O
. O

Serum B
alpha I
- I
amylase I
, O
trypsin B
, O
trypsin B
inhibitor I
, O
lipase B
and O
total O
protease O
activity O
in O
the O
pancreatic O
tissue O
was O
studied O
as O
indicator O
of O
the O
treatment O
efficacy O
with O
5 O
- O
fluorouracil O
electro O
- O
cumulation O
. O

Serum B
alpha I
- I
amylase I
, O
trypsin B
, O
trypsin B
inhibitor I
, O
lipase B
and O
total O
protease O
activity O
in O
the O
pancreatic O
tissue O
was O
studied O
as O
indicator O
of O
the O
treatment O
efficacy O
with O
5 O
- O
fluorouracil O
electro O
- O
cumulation O
. O

Consistent O
with O
the O
large O
pocket O
of O
Rb B
binding O
to O
TAF B
( I
II I
) I
250 I
, O
the O
large O
pocket O
domains O
of O
both O
p107 B
and O
p130 B
are O
able O
to O
bind O
to O
TAF B
( I
II I
) I
250 I
in O
vivo O
. O

Consistent O
with O
the O
large O
pocket O
of O
Rb B
binding O
to O
TAF B
( I
II I
) I
250 I
, O
the O
large O
pocket O
domains O
of O
both O
p107 B
and O
p130 B
are O
able O
to O
bind O
to O
TAF B
( I
II I
) I
250 I
in O
vivo O
. O

Consistent O
with O
the O
large O
pocket O
of O
Rb B
binding O
to O
TAF B
( I
II I
) I
250 I
, O
the O
large O
pocket O
domains O
of O
both O
p107 B
and O
p130 B
are O
able O
to O
bind O
to O
TAF B
( I
II I
) I
250 I
in O
vivo O
. O

Activation O
of O
the O
receptor O
induces O
Ret B
phosphorylation O
that O
leads O
the O
survival O
- O
promoting O
effects O
. O

DSS4 B
- I
1 I
is O
a O
dominant O
suppressor O
of O
sec4 B
- I
8 I
that O
encodes O
a O
nucleotide O
exchange O
protein O
that O
aids O
Sec4p B
function O
. O

Although O
mutant B
pex5delta I
cells O
expressing O
a O
yeast B
/ I
tobacco I
Pex5p I
chimaera I
failed O
to O
import O
a O
GFP B
- O
Eci1p B
reporter O
protein O
, O
they O
were O
able O
to O
grow O
on O
oleic O
acid O
. O

Although O
mutant B
pex5delta I
cells O
expressing O
a O
yeast B
/ I
tobacco I
Pex5p I
chimaera I
failed O
to O
import O
a O
GFP B
- O
Eci1p B
reporter O
protein O
, O
they O
were O
able O
to O
grow O
on O
oleic O
acid O
. O

Consistent O
with O
this O
observation O
, O
introduction O
of O
Smad B
sites I
into O
a O
TGFbeta B
- O
insensitive O
LEF1 B
/ O
TCF B
target O
gene O
confers O
cooperative O
TGFbeta B
and O
Wnt B
responsiveness O
to O
the O
promoter O
. O

Consistent O
with O
this O
observation O
, O
introduction O
of O
Smad B
sites I
into O
a O
TGFbeta B
- O
insensitive O
LEF1 B
/ O
TCF B
target O
gene O
confers O
cooperative O
TGFbeta B
and O
Wnt B
responsiveness O
to O
the O
promoter O
. O

Consistent O
with O
this O
observation O
, O
introduction O
of O
Smad B
sites I
into O
a O
TGFbeta B
- O
insensitive O
LEF1 B
/ O
TCF B
target O
gene O
confers O
cooperative O
TGFbeta B
and O
Wnt B
responsiveness O
to O
the O
promoter O
. O

Consistent O
with O
this O
observation O
, O
introduction O
of O
Smad B
sites I
into O
a O
TGFbeta B
- O
insensitive O
LEF1 B
/ O
TCF B
target O
gene O
confers O
cooperative O
TGFbeta B
and O
Wnt B
responsiveness O
to O
the O
promoter O
. O

Consistent O
with O
this O
observation O
, O
introduction O
of O
Smad B
sites I
into O
a O
TGFbeta B
- O
insensitive O
LEF1 B
/ O
TCF B
target O
gene O
confers O
cooperative O
TGFbeta B
and O
Wnt B
responsiveness O
to O
the O
promoter O
. O

Vk8 B
/ O
Jk2 B
and O
Vk1 B
/ O
Jk5 B
rearrangements O
encoded O
the O
respective O
L B
chain I
V I
- I
regions I
. O

Vk8 B
/ O
Jk2 B
and O
Vk1 B
/ O
Jk5 B
rearrangements O
encoded O
the O
respective O
L B
chain I
V I
- I
regions I
. O

Vk8 B
/ O
Jk2 B
and O
Vk1 B
/ O
Jk5 B
rearrangements O
encoded O
the O
respective O
L B
chain I
V I
- I
regions I
. O

Vk8 B
/ O
Jk2 B
and O
Vk1 B
/ O
Jk5 B
rearrangements O
encoded O
the O
respective O
L B
chain I
V I
- I
regions I
. O

The O
matrix O
of O
the O
CBs O
contains O
the O
diagnostic O
protein O
p80 B
- O
coilin B
, O
which O
is O
colocalized O
with O
the O
U7 B
small I
nuclear I
ribonucleoprotein I
( O
snRNP O
) O
, O
whereas O
the O
attached O
and O
embedded O
B O
- O
snurposomes O
contain O
splicing O
snRNPs O
. O

The O
matrix O
of O
the O
CBs O
contains O
the O
diagnostic O
protein O
p80 B
- O
coilin B
, O
which O
is O
colocalized O
with O
the O
U7 B
small I
nuclear I
ribonucleoprotein I
( O
snRNP O
) O
, O
whereas O
the O
attached O
and O
embedded O
B O
- O
snurposomes O
contain O
splicing O
snRNPs O
. O

PATIENTS O
: O
33 O
HIV O
- O
infected O
, O
zidovudine O
- O
experienced O
patients O
with O
serum O
HIV O
RNA O
levels O
of O
at O
least O
20 O
, O
000 O
copies O
/ O
mL O
and O
CD4 B
counts O
ranging O
from O
50 O
to O
400 O
cells O
/ O
mm3 O
. O

These O
data O
, O
taken O
together O
, O
suggest O
that O
CRF B
produces O
its O
behavioral O
activating O
and O
anxiogenic O
effects O
, O
at O
least O
in O
part O
, O
by O
increasing O
the O
activity O
of O
LC O
noradrenergic O
neurons O
. O

The O
sequence O
of O
Vac1p B
contains O
two O
putative O
zinc O
- O
binding O
RING O
motifs O
, O
a O
zinc O
finger O
motif O
, O
and O
a O
coiled O
- O
coil O
motif O
. O

The O
first O
operon O
, O
orf1 O
- O
tolQRA B
, O
is O
iron O
regulated O
throughout O
growth O
, O
but O
iron O
- O
regulated O
expression O
of O
tolB B
and O
oprL B
fusions I
occurs O
only O
in O
late O
log O
phase O
. O

The O
first O
operon O
, O
orf1 O
- O
tolQRA B
, O
is O
iron O
regulated O
throughout O
growth O
, O
but O
iron O
- O
regulated O
expression O
of O
tolB B
and O
oprL B
fusions I
occurs O
only O
in O
late O
log O
phase O
. O

Using O
green B
fluorescent I
protein I
fusions O
we O
demonstrate O
that O
the O
SYT B
, O
SSX B
and O
the O
SYT B
- O
SSX B
proteins O
are O
nuclear O
proteins O
. O

Using O
green B
fluorescent I
protein I
fusions O
we O
demonstrate O
that O
the O
SYT B
, O
SSX B
and O
the O
SYT B
- O
SSX B
proteins O
are O
nuclear O
proteins O
. O

Using O
green B
fluorescent I
protein I
fusions O
we O
demonstrate O
that O
the O
SYT B
, O
SSX B
and O
the O
SYT B
- O
SSX B
proteins O
are O
nuclear O
proteins O
. O

Using O
green B
fluorescent I
protein I
fusions O
we O
demonstrate O
that O
the O
SYT B
, O
SSX B
and O
the O
SYT B
- O
SSX B
proteins O
are O
nuclear O
proteins O
. O

These O
data O
suggested O
that O
mutant B
PS1 I
may O
cause O
disease O
as O
a O
result O
of O
reduction O
in O
PS1 B
function O
. O

The O
analysis O
of O
the O
organization O
of O
the O
sequence O
of O
the O
human O
ABP B
/ O
DAO B
gene O
reveals O
that O
the O
2 O
. O
4 O
- O
kilobase O
messenger O
RNA O
is O
transcribed O
from O
two O
close O
origins O
identifying O
the O
proximal O
promoter O
. O

The O
analysis O
of O
the O
organization O
of O
the O
sequence O
of O
the O
human O
ABP B
/ O
DAO B
gene O
reveals O
that O
the O
2 O
. O
4 O
- O
kilobase O
messenger O
RNA O
is O
transcribed O
from O
two O
close O
origins O
identifying O
the O
proximal O
promoter O
. O

To O
investigate O
the O
step O
of O
spliceosome O
assembly O
at O
which O
Snu17p B
acts O
, O
we O
have O
used O
nondenaturing O
gel O
electrophoresis O
. O

Mammalian O
ribonucleotide B
reductase I
shows O
S O
- O
phase O
specific O
expression O
and O
consists O
of O
two O
non O
- O
identical O
subunits O
, O
proteins B
R1 I
( O
large O
subunit O
) O
and O
R2 B
( O
small O
subunit O
) O
. O

Recombinant B
MsERK1 I
( O
rMsERK1 B
) O
, O
when O
overexpressed O
in O
Escherichia O
coli O
, O
is O
recognized O
by O
antibodies O
raised O
against O
MAP B
kinases I
from I
rat I
, I
Xenopus I
, I
and I
sea I
star I
and O
by O
anti B
- I
phosphotyrosine I
antibodies I
. O

The O
identification O
of O
SRP54sc B
and O
SRP54sp B
provides O
the O
first O
evidence O
for O
SRP B
related O
proteins O
in O
yeast O
. O

The O
identification O
of O
SRP54sc B
and O
SRP54sp B
provides O
the O
first O
evidence O
for O
SRP B
related O
proteins O
in O
yeast O
. O

The O
identification O
of O
SRP54sc B
and O
SRP54sp B
provides O
the O
first O
evidence O
for O
SRP B
related O
proteins O
in O
yeast O
. O

We O
previously O
demonstrated O
that O
AKT2 B
, O
a O
member O
of O
protein B
kinase I
B I
family I
, O
is O
activated O
by O
a O
number O
of O
growth O
factors O
via O
Ras B
and O
PI B
3 I
- I
kinase I
signaling O
pathways O
. O

We O
previously O
demonstrated O
that O
AKT2 B
, O
a O
member O
of O
protein B
kinase I
B I
family I
, O
is O
activated O
by O
a O
number O
of O
growth O
factors O
via O
Ras B
and O
PI B
3 I
- I
kinase I
signaling O
pathways O
. O

The O
expected O
products O
of O
the O
cloned O
bph B
genes I
, O
except O
bphA3 B
, O
were O
observed O
in O
E O
. O
coli O
in O
an O
in O
vitro O
transcription O
- O
translation O
system O
. O

A O
positive O
correlation O
was O
also O
established O
between O
the O
level O
of O
FP9C B
binding O
and O
the O
degree O
of O
cell O
differentiation O
in O
vitro O
. O

Unlike O
CSK B
, O
the O
SH3 B
domain I
of O
HYL B
was O
unique O
since O
the O
ALYDY O
motif O
was O
absent O
. O

Unlike O
CSK B
, O
the O
SH3 B
domain I
of O
HYL B
was O
unique O
since O
the O
ALYDY O
motif O
was O
absent O
. O

Fus3p B
and O
Kss1p B
together O
increase O
the O
expression O
of O
CLN3 B
and O
PCL2 B
genes I
that O
promote O
budding O
, O
and O
Kss1p B
inhibits O
the O
MAP B
kinase I
cascade O
. O

Fus3p B
and O
Kss1p B
together O
increase O
the O
expression O
of O
CLN3 B
and O
PCL2 B
genes I
that O
promote O
budding O
, O
and O
Kss1p B
inhibits O
the O
MAP B
kinase I
cascade O
. O

Fus3p B
and O
Kss1p B
together O
increase O
the O
expression O
of O
CLN3 B
and O
PCL2 B
genes I
that O
promote O
budding O
, O
and O
Kss1p B
inhibits O
the O
MAP B
kinase I
cascade O
. O

Fus3p B
and O
Kss1p B
together O
increase O
the O
expression O
of O
CLN3 B
and O
PCL2 B
genes I
that O
promote O
budding O
, O
and O
Kss1p B
inhibits O
the O
MAP B
kinase I
cascade O
. O

Human B
epidermal I
growth I
factor I
( O
EGF B
) O
, O
a O
naturally O
occurring O
protein O
, O
has O
been O
implicated O
in O
the O
protection O
of O
gastrointestinal O
mucosal O
integrity O
. O

A O
minimal O
pheromone O
induction O
domain O
, O
delineated O
as O
residues O
301 O
to O
335 O
of O
Ste12p B
, O
is O
dependent O
on O
the O
pheromone O
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinase I
pathway O
for O
induction O
activity O
. O

The O
library O
will O
thus O
be O
useful O
for O
the O
selection O
of O
cosmid O
clones O
which O
carry O
CDC B
genes I
from I
yeast I
by O
complementing O
first O
, O
with O
the O
vectorial O
yeast B
gene I
URA1 I
, O
the O
pyrimidine O
auxotrophy O
of O
most O
cdc B
- O
strains O
and O
then O
, O
with O
the O
respective O
CDC B
wild I
- I
type I
genes I
, O
of O
the O
temperature O
- O
sensitive O
mutant O
alleles O
. O

In O
addition O
, O
both O
activated O
Ral B
- I
GDS I
- I
like I
factor O
and O
Raf B
stimulate O
cyclin B
D I
( I
1 I
) I
transcription O
and O
E2F B
activity O
and O
act O
in O
synergy O
with O
PI B
3 I
- I
kinase I
. O

In O
addition O
, O
both O
activated O
Ral B
- I
GDS I
- I
like I
factor O
and O
Raf B
stimulate O
cyclin B
D I
( I
1 I
) I
transcription O
and O
E2F B
activity O
and O
act O
in O
synergy O
with O
PI B
3 I
- I
kinase I
. O

From O
the O
present O
results O
a O
concept O
of O
hormone O
- O
dependent O
AR B
activation O
is O
proposed O
, O
which O
requires O
a O
functional O
, O
direct O
or O
indirect O
intramolecular O
interaction O
between O
the O
TAD O
and O
the O
LBD O
. O

Like O
the O
DMA B
, O
but O
unlike O
all O
other O
mammalian B
class I
II I
A I
genes I
, O
the O
zebrafish O
gene O
codes O
for O
two O
cysteine O
residues O
which O
might O
potentially O
be O
involved O
in O
the O
formation O
of O
a O
disulfide O
bond O
in O
the O
alpha O
1 O
domain O
. O

Secretogranin B
II I
( O
SgII B
) O
is O
a O
secretory O
polypeptide O
stored O
in O
large O
dense O
core O
vesicles O
of O
neuroendocrine O
and O
neuronal O
cells O
. O

BK B
- O
induced O
translocation O
and O
overexpression O
of O
PKC B
isoforms I
as O
well O
as O
coexpression O
of O
inactive O
or O
constitutively O
active O
mutants O
of O
different O
PKC B
isozymes I
provided O
evidence O
for O
a O
role O
of O
the O
diacylglycerol O
- O
sensitive O
PKCs B
alpha I
and I
epsilon I
in O
BK B
signaling O
toward O
MAPK B
. O

BK B
- O
induced O
translocation O
and O
overexpression O
of O
PKC B
isoforms I
as O
well O
as O
coexpression O
of O
inactive O
or O
constitutively O
active O
mutants O
of O
different O
PKC B
isozymes I
provided O
evidence O
for O
a O
role O
of O
the O
diacylglycerol O
- O
sensitive O
PKCs B
alpha I
and I
epsilon I
in O
BK B
signaling O
toward O
MAPK B
. O

BK B
- O
induced O
translocation O
and O
overexpression O
of O
PKC B
isoforms I
as O
well O
as O
coexpression O
of O
inactive O
or O
constitutively O
active O
mutants O
of O
different O
PKC B
isozymes I
provided O
evidence O
for O
a O
role O
of O
the O
diacylglycerol O
- O
sensitive O
PKCs B
alpha I
and I
epsilon I
in O
BK B
signaling O
toward O
MAPK B
. O

Here O
we O
describe O
the O
characterization O
of O
cDNAs O
encoding O
two O
unusual O
E2Fs B
, O
E2F B
- I
4 I
and O
E2F B
- I
5 I
, O
each O
identified O
by O
the O
ability O
of O
their O
gene O
product O
to O
interact O
with O
p130 B
in O
a O
yeast O
two O
- O
hybrid O
system O
. O

Here O
we O
describe O
the O
characterization O
of O
cDNAs O
encoding O
two O
unusual O
E2Fs B
, O
E2F B
- I
4 I
and O
E2F B
- I
5 I
, O
each O
identified O
by O
the O
ability O
of O
their O
gene O
product O
to O
interact O
with O
p130 B
in O
a O
yeast O
two O
- O
hybrid O
system O
. O

Interestingly O
, O
unlike O
PAK65 B
, O
HPK1 B
does O
not O
contain O
the O
small B
GTPase I
Rac1 B
/ O
Cdc42 B
- O
binding O
domain O
and O
does O
not O
bind O
to O
either O
Rac1 B
or O
Cdc42 B
, O
suggesting O
that O
HPK1 B
. O
activation O
is O
Rac1 B
/ O
Cdc42 B
- O
independent O
. O

Interestingly O
, O
unlike O
PAK65 B
, O
HPK1 B
does O
not O
contain O
the O
small B
GTPase I
Rac1 B
/ O
Cdc42 B
- O
binding O
domain O
and O
does O
not O
bind O
to O
either O
Rac1 B
or O
Cdc42 B
, O
suggesting O
that O
HPK1 B
. O
activation O
is O
Rac1 B
/ O
Cdc42 B
- O
independent O
. O

Interestingly O
, O
unlike O
PAK65 B
, O
HPK1 B
does O
not O
contain O
the O
small B
GTPase I
Rac1 B
/ O
Cdc42 B
- O
binding O
domain O
and O
does O
not O
bind O
to O
either O
Rac1 B
or O
Cdc42 B
, O
suggesting O
that O
HPK1 B
. O
activation O
is O
Rac1 B
/ O
Cdc42 B
- O
independent O
. O

Interestingly O
, O
unlike O
PAK65 B
, O
HPK1 B
does O
not O
contain O
the O
small B
GTPase I
Rac1 B
/ O
Cdc42 B
- O
binding O
domain O
and O
does O
not O
bind O
to O
either O
Rac1 B
or O
Cdc42 B
, O
suggesting O
that O
HPK1 B
. O
activation O
is O
Rac1 B
/ O
Cdc42 B
- O
independent O
. O

Interestingly O
, O
unlike O
PAK65 B
, O
HPK1 B
does O
not O
contain O
the O
small B
GTPase I
Rac1 B
/ O
Cdc42 B
- O
binding O
domain O
and O
does O
not O
bind O
to O
either O
Rac1 B
or O
Cdc42 B
, O
suggesting O
that O
HPK1 B
. O
activation O
is O
Rac1 B
/ O
Cdc42 B
- O
independent O
. O

Interestingly O
, O
unlike O
PAK65 B
, O
HPK1 B
does O
not O
contain O
the O
small B
GTPase I
Rac1 B
/ O
Cdc42 B
- O
binding O
domain O
and O
does O
not O
bind O
to O
either O
Rac1 B
or O
Cdc42 B
, O
suggesting O
that O
HPK1 B
. O
activation O
is O
Rac1 B
/ O
Cdc42 B
- O
independent O
. O

Interestingly O
, O
unlike O
PAK65 B
, O
HPK1 B
does O
not O
contain O
the O
small B
GTPase I
Rac1 B
/ O
Cdc42 B
- O
binding O
domain O
and O
does O
not O
bind O
to O
either O
Rac1 B
or O
Cdc42 B
, O
suggesting O
that O
HPK1 B
. O
activation O
is O
Rac1 B
/ O
Cdc42 B
- O
independent O
. O

Interestingly O
, O
unlike O
PAK65 B
, O
HPK1 B
does O
not O
contain O
the O
small B
GTPase I
Rac1 B
/ O
Cdc42 B
- O
binding O
domain O
and O
does O
not O
bind O
to O
either O
Rac1 B
or O
Cdc42 B
, O
suggesting O
that O
HPK1 B
. O
activation O
is O
Rac1 B
/ O
Cdc42 B
- O
independent O
. O

Interestingly O
, O
unlike O
PAK65 B
, O
HPK1 B
does O
not O
contain O
the O
small B
GTPase I
Rac1 B
/ O
Cdc42 B
- O
binding O
domain O
and O
does O
not O
bind O
to O
either O
Rac1 B
or O
Cdc42 B
, O
suggesting O
that O
HPK1 B
. O
activation O
is O
Rac1 B
/ O
Cdc42 B
- O
independent O
. O

All O
such O
polypeptides O
containing O
263 O
or O
more O
residues O
derived O
from O
the O
C O
- O
terminus O
of O
P130gag B
- O
fps B
( O
i O
. O
e O
. O
residues O
920 O
- O
1182 O
) O
were O
enzymatically O
active O
as O
tyrosine B
kinases I
. O

All O
such O
polypeptides O
containing O
263 O
or O
more O
residues O
derived O
from O
the O
C O
- O
terminus O
of O
P130gag B
- O
fps B
( O
i O
. O
e O
. O
residues O
920 O
- O
1182 O
) O
were O
enzymatically O
active O
as O
tyrosine B
kinases I
. O

A O
structural O
model O
for O
Vpu B
is O
proposed O
in O
which O
the O
membrane O
anchor O
precedes O
a O
region O
comprising O
two O
amphipathic O
alpha O
- O
helices O
of O
opposed O
polarity O
, O
joined O
by O
a O
strongly O
acidic O
turn O
that O
protrudes O
into O
the O
cytoplasm O
and O
contains O
the O
CK B
- I
2 I
phosphorylation I
sites I
. O

The O
recombinant O
containing O
the O
full O
- O
length O
polyhedrin B
leader O
sequence O
gave O
levels O
of O
N B
mRNA I
comparable O
to O
those O
of O
AcNPV B
polyhedrin I
mRNA I
. O

Thus O
, O
CARP B
is O
a O
YB B
- I
1 I
associated I
factor I
and O
represents O
the O
first O
identified O
cardiac O
- O
restricted O
downstream O
regulatory O
gene O
in O
the O
homeobox O
gene O
Nkx2 B
- I
5 I
pathway O
and O
may O
serve O
as O
a O
negative O
regulator O
of O
HF B
- I
1 I
- O
dependent O
pathways O
for O
ventricular O
muscle O
gene O
expression O
. O

A O
model O
for O
the O
SMase B
- O
sphingomyelin O
complex O
structure O
was O
built O
to O
investigate O
how O
the O
SMase B
specifically O
recognizes O
its O
substrate O
. O

A O
model O
for O
the O
SMase B
- O
sphingomyelin O
complex O
structure O
was O
built O
to O
investigate O
how O
the O
SMase B
specifically O
recognizes O
its O
substrate O
. O

Transforming B
growth I
factor I
- I
beta I
( O
TGF B
- I
beta I
) O
inhibits O
cell O
cycle O
progression O
, O
in O
part O
through O
up O
- O
regulation O
of O
gene O
expression O
of O
the O
p21 B
( O
WAF1 B
/ O
Cip1 B
) O
( O
p21 B
) O
cell O
cycle O
inhibitor O
. O

Transforming B
growth I
factor I
- I
beta I
( O
TGF B
- I
beta I
) O
inhibits O
cell O
cycle O
progression O
, O
in O
part O
through O
up O
- O
regulation O
of O
gene O
expression O
of O
the O
p21 B
( O
WAF1 B
/ O
Cip1 B
) O
( O
p21 B
) O
cell O
cycle O
inhibitor O
. O

Transforming B
growth I
factor I
- I
beta I
( O
TGF B
- I
beta I
) O
inhibits O
cell O
cycle O
progression O
, O
in O
part O
through O
up O
- O
regulation O
of O
gene O
expression O
of O
the O
p21 B
( O
WAF1 B
/ O
Cip1 B
) O
( O
p21 B
) O
cell O
cycle O
inhibitor O
. O

Transforming B
growth I
factor I
- I
beta I
( O
TGF B
- I
beta I
) O
inhibits O
cell O
cycle O
progression O
, O
in O
part O
through O
up O
- O
regulation O
of O
gene O
expression O
of O
the O
p21 B
( O
WAF1 B
/ O
Cip1 B
) O
( O
p21 B
) O
cell O
cycle O
inhibitor O
. O

7 O
- O
Nitroindazole O
( O
7NI O
) O
, O
a O
relatively O
selective O
neuronal O
nitric B
oxide I
synthase I
( O
nNOS B
) O
inhibitor O
. O
was O
intraperitoneally O
administered O
to O
the O
guinea O
pigs O
30 O
minutes O
before O
the O
onset O
of O
local O
anoxia O
. O

An O
evaluation O
of O
a O
positive O
control O
for O
platelet O
neutralization O
procedure O
testing O
with O
seven O
commercial O
activated O
partial O
thromboplastin B
time O
reagents O
. O

A O
single O
clone O
, O
which O
was O
conserved O
and O
had O
near O
- O
perfect O
homology O
to O
eight O
human O
/ O
rodent O
expressed O
sequence O
tags O
, O
was O
used O
as O
template O
for O
5 O
' O
and O
3 O
' O
rapid O
amplification O
of O
cDNA O
ends O
and O
SPICE O
( O
system O
for O
polymerase O
chain O
reaction O
amplification O
of O
cDNA O
ends O
) O
reactions O
to O
obtain O
the O
3 O
. O
6 O
- O
kb O
cDNA O
, O
LGL2 B
( O
Genbank B
, I
AF I
110195 I
) O
encoding O
a O
deduced O
polypeptide O
( O
lgl2 B
) O
of O
963 O
amino O
acids O
. O

A O
single O
clone O
, O
which O
was O
conserved O
and O
had O
near O
- O
perfect O
homology O
to O
eight O
human O
/ O
rodent O
expressed O
sequence O
tags O
, O
was O
used O
as O
template O
for O
5 O
' O
and O
3 O
' O
rapid O
amplification O
of O
cDNA O
ends O
and O
SPICE O
( O
system O
for O
polymerase O
chain O
reaction O
amplification O
of O
cDNA O
ends O
) O
reactions O
to O
obtain O
the O
3 O
. O
6 O
- O
kb O
cDNA O
, O
LGL2 B
( O
Genbank B
, I
AF I
110195 I
) O
encoding O
a O
deduced O
polypeptide O
( O
lgl2 B
) O
of O
963 O
amino O
acids O
. O

Five O
girls O
with O
Turner O
' O
s O
syndrome O
aged O
12 O
to O
17 O
years O
showed O
LH B
values O
( O
5 O
. O
0 O
- O
14 O
. O
5 O
IU O
/ O
12 O
h O
) O
at O
the O
upper O
end O
of O
or O
slightly O
above O
the O
normal O
range O
and O
pathologically O
high O
values O
( O
22 O
. O
2 O
- O
43 O
. O
5 O
IU O
/ O
12 O
h O
) O
for O
FSH B
. O

Five O
girls O
with O
Turner O
' O
s O
syndrome O
aged O
12 O
to O
17 O
years O
showed O
LH B
values O
( O
5 O
. O
0 O
- O
14 O
. O
5 O
IU O
/ O
12 O
h O
) O
at O
the O
upper O
end O
of O
or O
slightly O
above O
the O
normal O
range O
and O
pathologically O
high O
values O
( O
22 O
. O
2 O
- O
43 O
. O
5 O
IU O
/ O
12 O
h O
) O
for O
FSH B
. O

In O
vitro O
death O
assays O
with O
transient O
overexpression O
of O
deletion O
constructs O
of O
both O
isoforms O
using O
beta B
- I
galactosidase I
as O
a O
reporter O
gene O
in O
MCF7 O
cells O
suggest O
the O
following O
: O
1 O
) O
the O
nucleotide O
binding O
domain O
may O
act O
as O
a O
negative O
regulator O
of O
the O
killing O
activity O
of O
DEFCAP B
; O
2 O
) O
the O
LRR B
/ O
CARD B
represents O
a O
putative O
constitutively O
active O
inducer O
of O
apoptosis O
; O
3 O
) O
the O
killing O
activity O
of O
LRR B
/ O
CARD B
is O
inhibitable O
by O
benzyloxycarbonyl O
- O
Val O
- O
Ala O
- O

In O
vitro O
death O
assays O
with O
transient O
overexpression O
of O
deletion O
constructs O
of O
both O
isoforms O
using O
beta B
- I
galactosidase I
as O
a O
reporter O
gene O
in O
MCF7 O
cells O
suggest O
the O
following O
: O
1 O
) O
the O
nucleotide O
binding O
domain O
may O
act O
as O
a O
negative O
regulator O
of O
the O
killing O
activity O
of O
DEFCAP B
; O
2 O
) O
the O
LRR B
/ O
CARD B
represents O
a O
putative O
constitutively O
active O
inducer O
of O
apoptosis O
; O
3 O
) O
the O
killing O
activity O
of O
LRR B
/ O
CARD B
is O
inhibitable O
by O
benzyloxycarbonyl O
- O
Val O
- O
Ala O
- O

In O
vitro O
death O
assays O
with O
transient O
overexpression O
of O
deletion O
constructs O
of O
both O
isoforms O
using O
beta B
- I
galactosidase I
as O
a O
reporter O
gene O
in O
MCF7 O
cells O
suggest O
the O
following O
: O
1 O
) O
the O
nucleotide O
binding O
domain O
may O
act O
as O
a O
negative O
regulator O
of O
the O
killing O
activity O
of O
DEFCAP B
; O
2 O
) O
the O
LRR B
/ O
CARD B
represents O
a O
putative O
constitutively O
active O
inducer O
of O
apoptosis O
; O
3 O
) O
the O
killing O
activity O
of O
LRR B
/ O
CARD B
is O
inhibitable O
by O
benzyloxycarbonyl O
- O
Val O
- O
Ala O
- O

In O
vitro O
death O
assays O
with O
transient O
overexpression O
of O
deletion O
constructs O
of O
both O
isoforms O
using O
beta B
- I
galactosidase I
as O
a O
reporter O
gene O
in O
MCF7 O
cells O
suggest O
the O
following O
: O
1 O
) O
the O
nucleotide O
binding O
domain O
may O
act O
as O
a O
negative O
regulator O
of O
the O
killing O
activity O
of O
DEFCAP B
; O
2 O
) O
the O
LRR B
/ O
CARD B
represents O
a O
putative O
constitutively O
active O
inducer O
of O
apoptosis O
; O
3 O
) O
the O
killing O
activity O
of O
LRR B
/ O
CARD B
is O
inhibitable O
by O
benzyloxycarbonyl O
- O
Val O
- O
Ala O
- O

In O
vitro O
death O
assays O
with O
transient O
overexpression O
of O
deletion O
constructs O
of O
both O
isoforms O
using O
beta B
- I
galactosidase I
as O
a O
reporter O
gene O
in O
MCF7 O
cells O
suggest O
the O
following O
: O
1 O
) O
the O
nucleotide O
binding O
domain O
may O
act O
as O
a O
negative O
regulator O
of O
the O
killing O
activity O
of O
DEFCAP B
; O
2 O
) O
the O
LRR B
/ O
CARD B
represents O
a O
putative O
constitutively O
active O
inducer O
of O
apoptosis O
; O
3 O
) O
the O
killing O
activity O
of O
LRR B
/ O
CARD B
is O
inhibitable O
by O
benzyloxycarbonyl O
- O
Val O
- O
Ala O
- O

Asp O
( O
OMe O
) O
- O
fluoromethyl O
ketone O
and O
to O
a O
lesser O
extent O
by O
Asp O
- O
Glu O
- O
Val O
- O
Asp O
( O
OMe O
) O
- O
fluoromethyl O
ketone O
; O
and O
4 O
) O
the O
CARD B
is O
critical O
for O
killing O
activity O
of O
DEFCAP B
. O

Asp O
( O
OMe O
) O
- O
fluoromethyl O
ketone O
and O
to O
a O
lesser O
extent O
by O
Asp O
- O
Glu O
- O
Val O
- O
Asp O
( O
OMe O
) O
- O
fluoromethyl O
ketone O
; O
and O
4 O
) O
the O
CARD B
is O
critical O
for O
killing O
activity O
of O
DEFCAP B
. O

The O
association O
of O
I B
- I
92 I
with O
p92 B
, O
p84 B
, O
p75 B
, O
p73 B
, O
p69 B
, O
and O
p57 B
was O
completely O
reversible O
after O
treatment O
with O
the O
detergent O
deoxycholate O
( O
DOC O
) O
. O

The O
association O
of O
I B
- I
92 I
with O
p92 B
, O
p84 B
, O
p75 B
, O
p73 B
, O
p69 B
, O
and O
p57 B
was O
completely O
reversible O
after O
treatment O
with O
the O
detergent O
deoxycholate O
( O
DOC O
) O
. O

The O
association O
of O
I B
- I
92 I
with O
p92 B
, O
p84 B
, O
p75 B
, O
p73 B
, O
p69 B
, O
and O
p57 B
was O
completely O
reversible O
after O
treatment O
with O
the O
detergent O
deoxycholate O
( O
DOC O
) O
. O

The O
association O
of O
I B
- I
92 I
with O
p92 B
, O
p84 B
, O
p75 B
, O
p73 B
, O
p69 B
, O
and O
p57 B
was O
completely O
reversible O
after O
treatment O
with O
the O
detergent O
deoxycholate O
( O
DOC O
) O
. O

The O
association O
of O
I B
- I
92 I
with O
p92 B
, O
p84 B
, O
p75 B
, O
p73 B
, O
p69 B
, O
and O
p57 B
was O
completely O
reversible O
after O
treatment O
with O
the O
detergent O
deoxycholate O
( O
DOC O
) O
. O

The O
association O
of O
I B
- I
92 I
with O
p92 B
, O
p84 B
, O
p75 B
, O
p73 B
, O
p69 B
, O
and O
p57 B
was O
completely O
reversible O
after O
treatment O
with O
the O
detergent O
deoxycholate O
( O
DOC O
) O
. O

Human B
parvovirus I
B19 I
gene I
expression O
from O
the O
viral B
p6 I
promoter I
( O
B19p6 B
) O
is O
restricted O
to O
primary O
human O
hematopoietic O
cells O
undergoing O
erythroid O
differentiation O
. O

Hetero O
- O
oligomerization O
of O
Smad4 B
with O
the O
pathway O
- O
restricted O
SMAD B
proteins I
is O
essential O
for O
Smad4 B
- O
mediated O
transcription O
. O

Hetero O
- O
oligomerization O
of O
Smad4 B
with O
the O
pathway O
- O
restricted O
SMAD B
proteins I
is O
essential O
for O
Smad4 B
- O
mediated O
transcription O
. O

This O
fragment O
contains O
two O
complete O
endo B
- I
beta I
- I
1 I
, I
4 I
- I
glucanase I
- I
encoding I
genes I
, O
designated O
celCCC B
and O
celCCG B
. O

This O
fragment O
contains O
two O
complete O
endo B
- I
beta I
- I
1 I
, I
4 I
- I
glucanase I
- I
encoding I
genes I
, O
designated O
celCCC B
and O
celCCG B
. O

Strains O
lacking O
a O
functional B
RPL16A I
gene I
grow O
as O
rapidly O
as O
wild O
type O
, O
whereas O
those O
containing O
a O
null O
allele O
of O
RPL16B B
grow O
more O
slowly O
than O
wild O
type O
. O

After O
Northern O
blot O
hybridization O
, O
two O
Cx31 B
transcripts I
of I
2 I
. I
2 I
and I
1 I
. I
8 I
kb I
were O
detected O
in O
total O
RNA O
of O
the O
human O
keratinocyte O
cell O
line O
HaCaT O
and O
two O
transcripts O
of O
2 O
. O
2 O
and O
1 O
. O
9 O
kb O
in O
total O
RNA O
of O
E6 B
/ O
E7 B
transfected O
human O
keratinocytes O
( O
HEK O
cells O
) O
. O

After O
Northern O
blot O
hybridization O
, O
two O
Cx31 B
transcripts I
of I
2 I
. I
2 I
and I
1 I
. I
8 I
kb I
were O
detected O
in O
total O
RNA O
of O
the O
human O
keratinocyte O
cell O
line O
HaCaT O
and O
two O
transcripts O
of O
2 O
. O
2 O
and O
1 O
. O
9 O
kb O
in O
total O
RNA O
of O
E6 B
/ O
E7 B
transfected O
human O
keratinocytes O
( O
HEK O
cells O
) O
. O

In O
summary O
, O
FGFR3 B
signaling O
pathway O
utilizes O
two O
GRB2 B
- I
containing I
complexes I
; O
Shc B
. O
GRB2 B
. O
Sos B
and O
80K B
- I
H I
. O
pp66 B
. O
GRB2 B
. O
Sos B
; O
these O
two O
complexes O
may O
alternatively O
link O
FGFG3 B
to O
mitogen B
- I
activated I
protein I
kinase I
. O

In O
summary O
, O
FGFR3 B
signaling O
pathway O
utilizes O
two O
GRB2 B
- I
containing I
complexes I
; O
Shc B
. O
GRB2 B
. O
Sos B
and O
80K B
- I
H I
. O
pp66 B
. O
GRB2 B
. O
Sos B
; O
these O
two O
complexes O
may O
alternatively O
link O
FGFG3 B
to O
mitogen B
- I
activated I
protein I
kinase I
. O

In O
summary O
, O
FGFR3 B
signaling O
pathway O
utilizes O
two O
GRB2 B
- I
containing I
complexes I
; O
Shc B
. O
GRB2 B
. O
Sos B
and O
80K B
- I
H I
. O
pp66 B
. O
GRB2 B
. O
Sos B
; O
these O
two O
complexes O
may O
alternatively O
link O
FGFG3 B
to O
mitogen B
- I
activated I
protein I
kinase I
. O

In O
summary O
, O
FGFR3 B
signaling O
pathway O
utilizes O
two O
GRB2 B
- I
containing I
complexes I
; O
Shc B
. O
GRB2 B
. O
Sos B
and O
80K B
- I
H I
. O
pp66 B
. O
GRB2 B
. O
Sos B
; O
these O
two O
complexes O
may O
alternatively O
link O
FGFG3 B
to O
mitogen B
- I
activated I
protein I
kinase I
. O

In O
summary O
, O
FGFR3 B
signaling O
pathway O
utilizes O
two O
GRB2 B
- I
containing I
complexes I
; O
Shc B
. O
GRB2 B
. O
Sos B
and O
80K B
- I
H I
. O
pp66 B
. O
GRB2 B
. O
Sos B
; O
these O
two O
complexes O
may O
alternatively O
link O
FGFG3 B
to O
mitogen B
- I
activated I
protein I
kinase I
. O

In O
summary O
, O
FGFR3 B
signaling O
pathway O
utilizes O
two O
GRB2 B
- I
containing I
complexes I
; O
Shc B
. O
GRB2 B
. O
Sos B
and O
80K B
- I
H I
. O
pp66 B
. O
GRB2 B
. O
Sos B
; O
these O
two O
complexes O
may O
alternatively O
link O
FGFG3 B
to O
mitogen B
- I
activated I
protein I
kinase I
. O

In O
summary O
, O
FGFR3 B
signaling O
pathway O
utilizes O
two O
GRB2 B
- I
containing I
complexes I
; O
Shc B
. O
GRB2 B
. O
Sos B
and O
80K B
- I
H I
. O
pp66 B
. O
GRB2 B
. O
Sos B
; O
these O
two O
complexes O
may O
alternatively O
link O
FGFG3 B
to O
mitogen B
- I
activated I
protein I
kinase I
. O

In O
summary O
, O
FGFR3 B
signaling O
pathway O
utilizes O
two O
GRB2 B
- I
containing I
complexes I
; O
Shc B
. O
GRB2 B
. O
Sos B
and O
80K B
- I
H I
. O
pp66 B
. O
GRB2 B
. O
Sos B
; O
these O
two O
complexes O
may O
alternatively O
link O
FGFG3 B
to O
mitogen B
- I
activated I
protein I
kinase I
. O

Four O
families O
of O
homing B
endonucleases I
have O
been O
identified O
, O
including O
the O
LAGLIDADG B
, O
the O
His B
- I
Cys I
box I
, O
the O
GIY B
- I
YIG I
and O
the O
H B
- I
N I
- I
H I
endonucleases I
. O

The O
GvpE B
protein I
involved O
in O
the O
regulation O
of O
gas O
vesicles O
synthesis O
in O
halophilic O
archaea O
has O
been O
identified O
as O
the O
transcriptional O
activator O
for O
the O
promoter O
located O
upstream O
of O
the O
gvpA B
gene I
encoding O
the O
major O
gas O
vesicle O
structural O
protein O
GvpA B
. O

Cloning O
and O
nucleotide O
sequence O
analysis O
reveals O
that O
BUR6 B
encodes O
a O
homolog O
of O
DRAP1 B
( O
also O
called O
NC2alpha B
) O
, O
a O
mammalian O
repressor O
of O
basal O
transcription O
. O

Cloning O
and O
nucleotide O
sequence O
analysis O
reveals O
that O
BUR6 B
encodes O
a O
homolog O
of O
DRAP1 B
( O
also O
called O
NC2alpha B
) O
, O
a O
mammalian O
repressor O
of O
basal O
transcription O
. O

Cloning O
and O
nucleotide O
sequence O
analysis O
reveals O
that O
BUR6 B
encodes O
a O
homolog O
of O
DRAP1 B
( O
also O
called O
NC2alpha B
) O
, O
a O
mammalian O
repressor O
of O
basal O
transcription O
. O

BRAP2 B
also O
shares O
significant O
homology O
with O
a O
hypothetical O
protein O
from O
yeast O
Saccharomyces O
cerevisiae O
, O
especially O
in O
the O
zinc O
finger O
region O
. O

Earlier O
published O
data O
, O
indicating O
Sp1 B
binding O
to O
the O
R1 B
alpha I
/ I
beta I
regions I
, O
could O
not O
be O
confirmed O
, O
suggesting O
that O
the O
R1 O
initiator O
element O
may O
function O
independent O
of O
Sp1 B
. O

Earlier O
published O
data O
, O
indicating O
Sp1 B
binding O
to O
the O
R1 B
alpha I
/ I
beta I
regions I
, O
could O
not O
be O
confirmed O
, O
suggesting O
that O
the O
R1 O
initiator O
element O
may O
function O
independent O
of O
Sp1 B
. O

The O
yeast B
mitochondrial I
Hsp70 I
, O
Ssc1p B
, O
functions O
as O
a O
molecular O
chaperone O
with O
its O
partner O
proteins O
, O
Mdj1p B
( O
DnaJ B
homologue I
) O
and O
Yge1p B
( O
GrpE B
homologue I
) O
. O

The O
yeast B
mitochondrial I
Hsp70 I
, O
Ssc1p B
, O
functions O
as O
a O
molecular O
chaperone O
with O
its O
partner O
proteins O
, O
Mdj1p B
( O
DnaJ B
homologue I
) O
and O
Yge1p B
( O
GrpE B
homologue I
) O
. O

The O
yeast B
mitochondrial I
Hsp70 I
, O
Ssc1p B
, O
functions O
as O
a O
molecular O
chaperone O
with O
its O
partner O
proteins O
, O
Mdj1p B
( O
DnaJ B
homologue I
) O
and O
Yge1p B
( O
GrpE B
homologue I
) O
. O

However O
, O
and O
in O
contrast O
to O
other O
MMP B
genes I
, O
no O
significative O
synergistic O
effect O
on O
CAT B
activity O
between O
the O
AP B
- I
1 I
and O
PEA B
- I
3 I
elements I
found O
in O
the O
collagenase B
- I
3 I
gene I
promoter I
was O
found O
. O

To O
examine O
the O
effect O
of O
the O
cAMP O
signal O
transduction O
pathway O
on O
transcription O
of O
the O
gene O
encoding O
the O
catalytic O
subunit O
of O
glucose B
- I
6 I
- I
phosphatase I
( O
G6Pase B
) O
, O
G6Pase B
- O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
fusion O
genes O
were O
transiently O
transfected O
into O
either O
the O
liver O
- O
derived O
HepG2 O
or O
kidney O
- O
derived O
LLC O
- O
PK O
cell O
line O
. O

To O
examine O
the O
effect O
of O
the O
cAMP O
signal O
transduction O
pathway O
on O
transcription O
of O
the O
gene O
encoding O
the O
catalytic O
subunit O
of O
glucose B
- I
6 I
- I
phosphatase I
( O
G6Pase B
) O
, O
G6Pase B
- O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
fusion O
genes O
were O
transiently O
transfected O
into O
either O
the O
liver O
- O
derived O
HepG2 O
or O
kidney O
- O
derived O
LLC O
- O
PK O
cell O
line O
. O

To O
examine O
the O
effect O
of O
the O
cAMP O
signal O
transduction O
pathway O
on O
transcription O
of O
the O
gene O
encoding O
the O
catalytic O
subunit O
of O
glucose B
- I
6 I
- I
phosphatase I
( O
G6Pase B
) O
, O
G6Pase B
- O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
fusion O
genes O
were O
transiently O
transfected O
into O
either O
the O
liver O
- O
derived O
HepG2 O
or O
kidney O
- O
derived O
LLC O
- O
PK O
cell O
line O
. O

( O
We O
observed O
a O
ferritin B
value O
as O
high O
as O
47 O
mg O
/ O
L O
in O
one O
patient O
. O
) O
Results O
with O
all O
these O
kits O
did O
not O
inter O
- O
compare O
well O
for O
ferritin B
concentrations O
greater O
than O
300 O
micrograms O
/ O
L O
, O
a O
finding O
that O
casts O
further O
doubt O
on O
the O
controversial O
use O
of O
serum B
ferritin I
measurement O
in O
cases O
of O
iron O
overload O
. O

( O
We O
observed O
a O
ferritin B
value O
as O
high O
as O
47 O
mg O
/ O
L O
in O
one O
patient O
. O
) O
Results O
with O
all O
these O
kits O
did O
not O
inter O
- O
compare O
well O
for O
ferritin B
concentrations O
greater O
than O
300 O
micrograms O
/ O
L O
, O
a O
finding O
that O
casts O
further O
doubt O
on O
the O
controversial O
use O
of O
serum B
ferritin I
measurement O
in O
cases O
of O
iron O
overload O
. O

ER B
beta I
was O
less O
potent O
than O
ER B
alpha I
in O
activating O
E2 O
- O
stimulated O
ERELuc B
activity O
( O
4 O
- O
vs O
. O

The O
expression O
pattern O
of O
LjEmx B
changed O
dramatically O
during O
embryogenesis O
; O
expression O
was O
seen O
initially O
in O
the O
entire O
neural O
tube O
and O
mesoderm O
, O
which O
were O
secondarily O
downregulated O
, O
and O
secondarily O
in O
cranial O
nerve O
ganglia O
and O
in O
the O
craniofacial O
mesenchyme O
. O

Disruption O
of O
PML B
subnuclear I
domains I
by O
the O
acidic B
IE1 I
protein I
of O
human O
cytomegalovirus O
is O
mediated O
through O
interaction O
with O
PML B
and O
may O
modulate O
a O
RING O
finger O
- O
dependent O
cryptic O
transactivator O
function O
of O
PML B
. O

Disruption O
of O
PML B
subnuclear I
domains I
by O
the O
acidic B
IE1 I
protein I
of O
human O
cytomegalovirus O
is O
mediated O
through O
interaction O
with O
PML B
and O
may O
modulate O
a O
RING O
finger O
- O
dependent O
cryptic O
transactivator O
function O
of O
PML B
. O

Furthermore O
, O
the O
GC O
- O
rich O
sequences O
could O
confer O
Sp1 B
- O
dependent O
transactivation O
to O
a O
heterologous O
prolactin B
minimal I
promoter I
. O

Twelve O
patients O
of O
leprosy O
with O
arthritis O
and O
161 O
patients O
without O
arthritis O
were O
studied O
for O
immunological O
parameters O
like O
immunoglobulins B
( O
IgG B
, O
IgM B
, O
IgA B
) O
, O
C B
- I
reactive I
proteins I
and O
rheumatoid B
factor I
. O

Twelve O
patients O
of O
leprosy O
with O
arthritis O
and O
161 O
patients O
without O
arthritis O
were O
studied O
for O
immunological O
parameters O
like O
immunoglobulins B
( O
IgG B
, O
IgM B
, O
IgA B
) O
, O
C B
- I
reactive I
proteins I
and O
rheumatoid B
factor I
. O

Twelve O
patients O
of O
leprosy O
with O
arthritis O
and O
161 O
patients O
without O
arthritis O
were O
studied O
for O
immunological O
parameters O
like O
immunoglobulins B
( O
IgG B
, O
IgM B
, O
IgA B
) O
, O
C B
- I
reactive I
proteins I
and O
rheumatoid B
factor I
. O

Twelve O
patients O
of O
leprosy O
with O
arthritis O
and O
161 O
patients O
without O
arthritis O
were O
studied O
for O
immunological O
parameters O
like O
immunoglobulins B
( O
IgG B
, O
IgM B
, O
IgA B
) O
, O
C B
- I
reactive I
proteins I
and O
rheumatoid B
factor I
. O

Several O
reports O
assert O
that O
prolactin B
affects O
the O
delta O
5 O
and O
delta O
4 O
pathways O
through O
its O
effect O
on O
the O
activity O
of O
3beta B
- I
hydroxysteroid I
dehydrogenase I
( O
3beta B
- I
OHSD I
) O
. O

( O
i O
) O
p60 B
bound O
fast O
- O
migrating O
, O
underprocessed O
wild B
- I
type I
ICP22 I
and O
ICP22 B
lacking O
the O
carboxyl O
- O
terminal O
24 O
amino O
acids O
but O
not O
ICP22 B
lacking O
the O
carboxyl O
- O
terminal O
40 O
amino O
acids O
, O
whereas O
the O
previously O
identified O
cellular B
protein I
p78 I
( O
R O
. O

( O
i O
) O
p60 B
bound O
fast O
- O
migrating O
, O
underprocessed O
wild B
- I
type I
ICP22 I
and O
ICP22 B
lacking O
the O
carboxyl O
- O
terminal O
24 O
amino O
acids O
but O
not O
ICP22 B
lacking O
the O
carboxyl O
- O
terminal O
40 O
amino O
acids O
, O
whereas O
the O
previously O
identified O
cellular B
protein I
p78 I
( O
R O
. O

( O
i O
) O
p60 B
bound O
fast O
- O
migrating O
, O
underprocessed O
wild B
- I
type I
ICP22 I
and O
ICP22 B
lacking O
the O
carboxyl O
- O
terminal O
24 O
amino O
acids O
but O
not O
ICP22 B
lacking O
the O
carboxyl O
- O
terminal O
40 O
amino O
acids O
, O
whereas O
the O
previously O
identified O
cellular B
protein I
p78 I
( O
R O
. O

Y1 B
, O
Y2 B
, O
and O
Y4 B
/ O
PP1 B
. O

Y1 B
, O
Y2 B
, O
and O
Y4 B
/ O
PP1 B
. O

Y1 B
, O
Y2 B
, O
and O
Y4 B
/ O
PP1 B
. O

Y1 B
, O
Y2 B
, O
and O
Y4 B
/ O
PP1 B
. O

Developmentally O
- O
regulated O
interaction O
of O
a O
transcription O
factor O
complex O
containing O
CDP B
/ O
cut B
with O
the O
early B
histone I
H3 I
gene I
promoter I
of I
the I
sea I
urchin I
Tetrapygus I
niger I
is O
associated O
with O
changes O
in O
chromatin O
structure O
and O
gene O
expression O
. O

Developmentally O
- O
regulated O
interaction O
of O
a O
transcription O
factor O
complex O
containing O
CDP B
/ O
cut B
with O
the O
early B
histone I
H3 I
gene I
promoter I
of I
the I
sea I
urchin I
Tetrapygus I
niger I
is O
associated O
with O
changes O
in O
chromatin O
structure O
and O
gene O
expression O
. O

The O
mRNA O
for O
this O
protein O
is O
expressed O
in O
the O
T O
- O
ALL O
cell O
line O
Jurkat O
and O
has O
been O
designated O
HUG1 B
, O
for O
HOX11 B
Upstream I
Gene I
. O

Its O
activity O
was O
twice O
that O
of O
a O
construct O
where O
the O
CAT B
gene I
was O
driven O
by O
the O
H B
- I
2Kb I
5 I
' I
enhancer I
region I
( O
H2TF1 B
/ O
KBF1 B
site O
) O
and O
comparable O
to O
that O
of O
pRSVCAT O
construct B
carrying I
the I
strong I
Rous I
sarcoma I
virus I
LTR I
enhancer I
. O

Its O
activity O
was O
twice O
that O
of O
a O
construct O
where O
the O
CAT B
gene I
was O
driven O
by O
the O
H B
- I
2Kb I
5 I
' I
enhancer I
region I
( O
H2TF1 B
/ O
KBF1 B
site O
) O
and O
comparable O
to O
that O
of O
pRSVCAT O
construct B
carrying I
the I
strong I
Rous I
sarcoma I
virus I
LTR I
enhancer I
. O

The O
tam B
A I
gene I
of I
Aspergillus I
nidulans I
encodes O
a O
739 O
- O
amino O
acid O
protein O
with O
similarity O
to O
Uga35p B
/ O
Dal81p B
/ O
DurLp B
of O
Saccharomyces O
cerevisiae O
. O

The O
tam B
A I
gene I
of I
Aspergillus I
nidulans I
encodes O
a O
739 O
- O
amino O
acid O
protein O
with O
similarity O
to O
Uga35p B
/ O
Dal81p B
/ O
DurLp B
of O
Saccharomyces O
cerevisiae O
. O

The O
tam B
A I
gene I
of I
Aspergillus I
nidulans I
encodes O
a O
739 O
- O
amino O
acid O
protein O
with O
similarity O
to O
Uga35p B
/ O
Dal81p B
/ O
DurLp B
of O
Saccharomyces O
cerevisiae O
. O

No O
promoter O
activity O
could O
be O
detected O
with O
various O
mouse B
Fli I
- I
1 I
promoter I
- O
CAT B
constructs O
containing O
600 O
bp O
of O
the O
5 O
' O
flanking O
region O
, O
the O
complete O
exon O
1 O
, O
the O
5 O
' O
end O
of O
intron O
1 O
and O
/ O
or O
retroviral O
LTR O
sequence O
. O

Cbl B
is O
a O
signaling O
molecule O
with O
multiple O
functional O
domains O
: O
an O
SH2 B
domain I
which O
binds O
phosphotyrosine O
residues O
, O
a O
RING O
finger O
domain O
which O
acts O
as O
a O
ubiquitin B
ligase I
, O
a O
proline O
- O
rich O
region O
which O
serves O
as O
a O
docking O
site O
for O
SH3 B
- I
containing I
proteins I
, O
phosphotyrosine O
residues O
which O
serve O
as O
docking O
sites O
for O
SH2 B
- I
containing I
proteins I
such O
a O
CrkL B
and O
the O
p85 B
subunit I
of O
PI B
3 I
- I
kinase I
, O
and O
a O
nuclear O
localization O
signal O
. O

Cbl B
is O
a O
signaling O
molecule O
with O
multiple O
functional O
domains O
: O
an O
SH2 B
domain I
which O
binds O
phosphotyrosine O
residues O
, O
a O
RING O
finger O
domain O
which O
acts O
as O
a O
ubiquitin B
ligase I
, O
a O
proline O
- O
rich O
region O
which O
serves O
as O
a O
docking O
site O
for O
SH3 B
- I
containing I
proteins I
, O
phosphotyrosine O
residues O
which O
serve O
as O
docking O
sites O
for O
SH2 B
- I
containing I
proteins I
such O
a O
CrkL B
and O
the O
p85 B
subunit I
of O
PI B
3 I
- I
kinase I
, O
and O
a O
nuclear O
localization O
signal O
. O

Our O
data O
are O
in O
line O
with O
the O
hypothesis O
that O
E2F B
functions O
as O
a O
growth O
- O
and O
cell O
cycle O
regulated O
tethering O
factor O
between O
Sp1 B
and O
the O
basic O
transcription O
machinery O
. O

Our O
data O
are O
in O
line O
with O
the O
hypothesis O
that O
E2F B
functions O
as O
a O
growth O
- O
and O
cell O
cycle O
regulated O
tethering O
factor O
between O
Sp1 B
and O
the O
basic O
transcription O
machinery O
. O

IRA2 B
, O
a O
second O
gene O
of O
Saccharomyces O
cerevisiae O
that O
encodes O
a O
protein O
with O
a O
domain O
homologous O
to O
mammalian O
ras B
GTPase I
- I
activating I
protein I
. O

Creatinine O
and O
creatine B
phosphokinase I
( O
CPK B
) O
. O

GAGA B
factor I
is O
known O
to O
remodel O
the O
chromatin O
structure O
in O
concert O
with O
nucleosome B
- I
remodeling I
factor I
NURF B
in O
a O
Drosophila O
embryonic O
S150 O
extract O
. O

Also O
, O
like O
TUB B
, O
it O
has O
a O
wider O
pattern O
of O
tissue O
expression O
than O
either O
TULP1 B
or O
TULP2 B
. O

Also O
, O
like O
TUB B
, O
it O
has O
a O
wider O
pattern O
of O
tissue O
expression O
than O
either O
TULP1 B
or O
TULP2 B
. O

Also O
, O
like O
TUB B
, O
it O
has O
a O
wider O
pattern O
of O
tissue O
expression O
than O
either O
TULP1 B
or O
TULP2 B
. O

First O
, O
ste12Delta B
cells O
differ O
from O
cells O
with O
disruptions O
of O
the O
upstream O
signaling O
elements O
( O
e O
. O
g O
. O
, O
ste4Delta B
, O
ste20Delta B
, O
ste5Delta B
, O
ste11Delta B
, O
ste7Delta B
, O
or O
fus3Delta B
kss1Delta B
cells O
) O
in O
that O
they O
clearly O
retain O
some O
capacity O
for O
inducing O
Ste3p B
phosphorylation O
. O

First O
, O
ste12Delta B
cells O
differ O
from O
cells O
with O
disruptions O
of O
the O
upstream O
signaling O
elements O
( O
e O
. O
g O
. O
, O
ste4Delta B
, O
ste20Delta B
, O
ste5Delta B
, O
ste11Delta B
, O
ste7Delta B
, O
or O
fus3Delta B
kss1Delta B
cells O
) O
in O
that O
they O
clearly O
retain O
some O
capacity O
for O
inducing O
Ste3p B
phosphorylation O
. O

First O
, O
ste12Delta B
cells O
differ O
from O
cells O
with O
disruptions O
of O
the O
upstream O
signaling O
elements O
( O
e O
. O
g O
. O
, O
ste4Delta B
, O
ste20Delta B
, O
ste5Delta B
, O
ste11Delta B
, O
ste7Delta B
, O
or O
fus3Delta B
kss1Delta B
cells O
) O
in O
that O
they O
clearly O
retain O
some O
capacity O
for O
inducing O
Ste3p B
phosphorylation O
. O

First O
, O
ste12Delta B
cells O
differ O
from O
cells O
with O
disruptions O
of O
the O
upstream O
signaling O
elements O
( O
e O
. O
g O
. O
, O
ste4Delta B
, O
ste20Delta B
, O
ste5Delta B
, O
ste11Delta B
, O
ste7Delta B
, O
or O
fus3Delta B
kss1Delta B
cells O
) O
in O
that O
they O
clearly O
retain O
some O
capacity O
for O
inducing O
Ste3p B
phosphorylation O
. O

First O
, O
ste12Delta B
cells O
differ O
from O
cells O
with O
disruptions O
of O
the O
upstream O
signaling O
elements O
( O
e O
. O
g O
. O
, O
ste4Delta B
, O
ste20Delta B
, O
ste5Delta B
, O
ste11Delta B
, O
ste7Delta B
, O
or O
fus3Delta B
kss1Delta B
cells O
) O
in O
that O
they O
clearly O
retain O
some O
capacity O
for O
inducing O
Ste3p B
phosphorylation O
. O

First O
, O
ste12Delta B
cells O
differ O
from O
cells O
with O
disruptions O
of O
the O
upstream O
signaling O
elements O
( O
e O
. O
g O
. O
, O
ste4Delta B
, O
ste20Delta B
, O
ste5Delta B
, O
ste11Delta B
, O
ste7Delta B
, O
or O
fus3Delta B
kss1Delta B
cells O
) O
in O
that O
they O
clearly O
retain O
some O
capacity O
for O
inducing O
Ste3p B
phosphorylation O
. O

First O
, O
ste12Delta B
cells O
differ O
from O
cells O
with O
disruptions O
of O
the O
upstream O
signaling O
elements O
( O
e O
. O
g O
. O
, O
ste4Delta B
, O
ste20Delta B
, O
ste5Delta B
, O
ste11Delta B
, O
ste7Delta B
, O
or O
fus3Delta B
kss1Delta B
cells O
) O
in O
that O
they O
clearly O
retain O
some O
capacity O
for O
inducing O
Ste3p B
phosphorylation O
. O

First O
, O
ste12Delta B
cells O
differ O
from O
cells O
with O
disruptions O
of O
the O
upstream O
signaling O
elements O
( O
e O
. O
g O
. O
, O
ste4Delta B
, O
ste20Delta B
, O
ste5Delta B
, O
ste11Delta B
, O
ste7Delta B
, O
or O
fus3Delta B
kss1Delta B
cells O
) O
in O
that O
they O
clearly O
retain O
some O
capacity O
for O
inducing O
Ste3p B
phosphorylation O
. O

First O
, O
ste12Delta B
cells O
differ O
from O
cells O
with O
disruptions O
of O
the O
upstream O
signaling O
elements O
( O
e O
. O
g O
. O
, O
ste4Delta B
, O
ste20Delta B
, O
ste5Delta B
, O
ste11Delta B
, O
ste7Delta B
, O
or O
fus3Delta B
kss1Delta B
cells O
) O
in O
that O
they O
clearly O
retain O
some O
capacity O
for O
inducing O
Ste3p B
phosphorylation O
. O

Herein O
, O
we O
report O
that O
CRE O
- O
decoy O
oligonucleotide O
treatment O
results O
in O
an O
increase O
in O
the O
p53 B
protein I
level O
in O
MCF O
- O
7 O
human O
breast O
cancer O
cells O
that O
express O
wild O
- O
type O
p53 B
. O

The O
primary O
structure O
of O
cholesterol B
esterase I
displayed O
no O
significant O
homology O
with O
other O
lipases B
, O
although O
the O
putative O
lipid O
interfacial O
recognition O
site O
of O
G O
- O
X O
- O
S O
- O
X O
- O
G O
is O
present O
in O
the O
cholesterol B
esterase I
sequence I
. O

The O
transcriptional O
initiation O
site O
of O
RAG1 B
was O
localized O
at O
A O
, O
26 O
bp O
upstream O
of O
the O
putative O
translational O
initiation O
codon O
, O
ATG O
, O
by O
the O
primer O
extension O
assay O
. O

Highly O
significant O
similarities O
were O
detected O
between O
the O
N O
- O
terminal O
region O
of O
P30 B
and O
those O
of O
GENA B
[ O
the O
product O
of O
another O
unidentified O
gene O
( O
geneA B
) O
located O
upstream O
of O
the O
aceEF B
- O
lpd B
operon O
] O
, O
and O
GNTR B
( O
a O
putative O
transcriptional O
repressor O
of O
the O
gluconate B
operon I
of O
Bacillus O
subtilis O
) O
. O

Highly O
significant O
similarities O
were O
detected O
between O
the O
N O
- O
terminal O
region O
of O
P30 B
and O
those O
of O
GENA B
[ O
the O
product O
of O
another O
unidentified O
gene O
( O
geneA B
) O
located O
upstream O
of O
the O
aceEF B
- O
lpd B
operon O
] O
, O
and O
GNTR B
( O
a O
putative O
transcriptional O
repressor O
of O
the O
gluconate B
operon I
of O
Bacillus O
subtilis O
) O
. O

Highly O
significant O
similarities O
were O
detected O
between O
the O
N O
- O
terminal O
region O
of O
P30 B
and O
those O
of O
GENA B
[ O
the O
product O
of O
another O
unidentified O
gene O
( O
geneA B
) O
located O
upstream O
of O
the O
aceEF B
- O
lpd B
operon O
] O
, O
and O
GNTR B
( O
a O
putative O
transcriptional O
repressor O
of O
the O
gluconate B
operon I
of O
Bacillus O
subtilis O
) O
. O

Highly O
significant O
similarities O
were O
detected O
between O
the O
N O
- O
terminal O
region O
of O
P30 B
and O
those O
of O
GENA B
[ O
the O
product O
of O
another O
unidentified O
gene O
( O
geneA B
) O
located O
upstream O
of O
the O
aceEF B
- O
lpd B
operon O
] O
, O
and O
GNTR B
( O
a O
putative O
transcriptional O
repressor O
of O
the O
gluconate B
operon I
of O
Bacillus O
subtilis O
) O
. O

Highly O
significant O
similarities O
were O
detected O
between O
the O
N O
- O
terminal O
region O
of O
P30 B
and O
those O
of O
GENA B
[ O
the O
product O
of O
another O
unidentified O
gene O
( O
geneA B
) O
located O
upstream O
of O
the O
aceEF B
- O
lpd B
operon O
] O
, O
and O
GNTR B
( O
a O
putative O
transcriptional O
repressor O
of O
the O
gluconate B
operon I
of O
Bacillus O
subtilis O
) O
. O

Highly O
significant O
similarities O
were O
detected O
between O
the O
N O
- O
terminal O
region O
of O
P30 B
and O
those O
of O
GENA B
[ O
the O
product O
of O
another O
unidentified O
gene O
( O
geneA B
) O
located O
upstream O
of O
the O
aceEF B
- O
lpd B
operon O
] O
, O
and O
GNTR B
( O
a O
putative O
transcriptional O
repressor O
of O
the O
gluconate B
operon I
of O
Bacillus O
subtilis O
) O
. O

The O
COR B
biosynthetic O
gene O
cluster O
in O
P O
. O
syringae O
pv O
. O
glycinea O
PG4180 O
is O
encoded O
by O
a O
32 O
- O
kb O
region O
which O
contains O
both O
the O
structural O
and O
regulatory O
genes O
needed O
for O
COR B
synthesis O
. O

The O
COR B
biosynthetic O
gene O
cluster O
in O
P O
. O
syringae O
pv O
. O
glycinea O
PG4180 O
is O
encoded O
by O
a O
32 O
- O
kb O
region O
which O
contains O
both O
the O
structural O
and O
regulatory O
genes O
needed O
for O
COR B
synthesis O
. O

Both O
claR B
and O
car B
are O
expressed O
as O
monocistronic O
transcripts O
; O
the O
level O
of O
transcript O
declined O
rapidly O
after O
48h O
in O
complex O
media O
, O
but O
low O
sustained O
levels O
of O
both O
transcripts O
were O
observed O
in O
defined O
GSPG O
medium O
until O
96h O
. O

Both O
claR B
and O
car B
are O
expressed O
as O
monocistronic O
transcripts O
; O
the O
level O
of O
transcript O
declined O
rapidly O
after O
48h O
in O
complex O
media O
, O
but O
low O
sustained O
levels O
of O
both O
transcripts O
were O
observed O
in O
defined O
GSPG O
medium O
until O
96h O
. O

claR B
and O
car B
were O
not O
significantly O
expressed O
in O
mutants O
disrupted O
in O
the O
ccaR B
gene I
, O
a O
regulatory O
gene O
that O
controls O
positively O
clavulanic O
acid O
and O
cephamycin O
biosynthesis O
. O

claR B
and O
car B
were O
not O
significantly O
expressed O
in O
mutants O
disrupted O
in O
the O
ccaR B
gene I
, O
a O
regulatory O
gene O
that O
controls O
positively O
clavulanic O
acid O
and O
cephamycin O
biosynthesis O
. O

The O
hepatic O
isoform O
of O
6 B
- I
phosphofructo I
- I
2 I
- I
kinase I
/ O
fructose B
- I
2 I
, I
6 I
- I
bisphosphatase I
( O
PF2K B
/ O
Fru B
- I
2 I
, I
6 I
- I
BPase I
) O
is O
transcriptionally O
stimulated O
by O
glucocorticoids O
, O
whereas O
insulin B
blocks O
this O
stimulatory O
effect O
. O

The O
hepatic O
isoform O
of O
6 B
- I
phosphofructo I
- I
2 I
- I
kinase I
/ O
fructose B
- I
2 I
, I
6 I
- I
bisphosphatase I
( O
PF2K B
/ O
Fru B
- I
2 I
, I
6 I
- I
BPase I
) O
is O
transcriptionally O
stimulated O
by O
glucocorticoids O
, O
whereas O
insulin B
blocks O
this O
stimulatory O
effect O
. O

Being O
implicated O
in O
insulin B
and O
GK B
gene I
regulations O
as O
a O
common O
transcription O
factor O
, O
IPF1 B
/ O
STF B
- I
1 I
/ O
PDX B
- I
1 I
is O
likely O
to O
play O
an O
essential O
role O
in O
maintaining O
normal O
beta O
- O
cell O
functions O
. O

Being O
implicated O
in O
insulin B
and O
GK B
gene I
regulations O
as O
a O
common O
transcription O
factor O
, O
IPF1 B
/ O
STF B
- I
1 I
/ O
PDX B
- I
1 I
is O
likely O
to O
play O
an O
essential O
role O
in O
maintaining O
normal O
beta O
- O
cell O
functions O
. O

Mouse O
embryo O
cells O
( O
C57BL O
/ O
6 O
, O
H O
- O
2b O
) O
transformed O
by O
the O
E1A B
and O
E1B B
genes O
of O
adenovirus O
type O
5 O
( O
Ad5E1 O
MEC O
) O
are O
highly O
immunogenic O
. O

Mouse O
embryo O
cells O
( O
C57BL O
/ O
6 O
, O
H O
- O
2b O
) O
transformed O
by O
the O
E1A B
and O
E1B B
genes O
of O
adenovirus O
type O
5 O
( O
Ad5E1 O
MEC O
) O
are O
highly O
immunogenic O
. O

To O
determine O
the O
transactivation O
potential O
of O
each O
of O
the O
four O
Ahr B
Sp1 B
sites I
, O
we O
fused O
the O
Ahr B
promoter I
to O
a O
luciferase B
( O
LUC B
) O
reporter O
gene O
and O
transfected O
the O
construct O
into O
the O
Drosophila O
cell O
line O
Schneider O
- O
2 O
, O
which O
contains O
no O
Sp1 B
or O
Sp1 B
- I
like I
factors I
. O

To O
determine O
the O
transactivation O
potential O
of O
each O
of O
the O
four O
Ahr B
Sp1 B
sites I
, O
we O
fused O
the O
Ahr B
promoter I
to O
a O
luciferase B
( O
LUC B
) O
reporter O
gene O
and O
transfected O
the O
construct O
into O
the O
Drosophila O
cell O
line O
Schneider O
- O
2 O
, O
which O
contains O
no O
Sp1 B
or O
Sp1 B
- I
like I
factors I
. O

To O
determine O
the O
transactivation O
potential O
of O
each O
of O
the O
four O
Ahr B
Sp1 B
sites I
, O
we O
fused O
the O
Ahr B
promoter I
to O
a O
luciferase B
( O
LUC B
) O
reporter O
gene O
and O
transfected O
the O
construct O
into O
the O
Drosophila O
cell O
line O
Schneider O
- O
2 O
, O
which O
contains O
no O
Sp1 B
or O
Sp1 B
- I
like I
factors I
. O

To O
determine O
the O
transactivation O
potential O
of O
each O
of O
the O
four O
Ahr B
Sp1 B
sites I
, O
we O
fused O
the O
Ahr B
promoter I
to O
a O
luciferase B
( O
LUC B
) O
reporter O
gene O
and O
transfected O
the O
construct O
into O
the O
Drosophila O
cell O
line O
Schneider O
- O
2 O
, O
which O
contains O
no O
Sp1 B
or O
Sp1 B
- I
like I
factors I
. O

The O
psh3 B
( I
+ I
) I
gene I
encodes O
a O
protein O
of O
215 O
amino O
acids O
, O
which O
shares O
a O
high O
degree O
of O
structural O
and O
functional O
similarity O
with O
Shr3p B
. O

The O
impairment O
of O
the O
nocturnal O
secretion O
was O
related O
to O
the O
subjects O
' O
age O
and O
, O
for O
the O
GH B
secretory O
pattern O
only O
, O
also O
to O
the O
MMSE O
score O
. O

Thus O
, O
the O
antibody O
class O
switch O
appears O
to O
be O
directed O
by O
induction O
of O
accessibility O
, O
as O
assayed O
by O
transcription O
of O
germ O
line O
CH B
genes O
. O

This O
growth O
- O
inhibitory O
effect O
was O
suppressed O
by O
the O
mpk1 B
delta I
mutation O
, O
suggesting O
that O
hyperactivation O
of O
the O
Mpk1 B
pathway O
is O
toxic O
to O
cells O
. O

Homodimers O
of O
RIP60 B
( O
replication B
initiation I
- I
region I
protein I
60 I
kDA I
) O
purified O
from O
nuclear O
extract O
bind O
two O
ATT O
- O
rich O
sites O
in O
oribeta O
and O
foster O
the O
formation O
of O
a O
twisted O
720 O
bp O
DNA O
loop O
in O
vitro O
. O

To O
test O
the O
role O
of O
myb B
family I
members I
in O
progression O
through O
the O
cell O
cycle O
, O
we O
comicroinjected O
c B
- I
myc I
and O
myb B
expression O
vectors O
into O
serum O
- O
deprived O
quiescent O
SMCs O
. O

LAC9 B
is O
a O
DNA O
- O
binding O
protein O
that O
regulates O
transcription O
of O
the O
lactose B
- I
galactose I
regulon I
in O
Kluyveromyces O
lactis O
. O

A O
group O
of O
factors O
known O
as O
activating B
transcription I
factors I
( O
ATF B
) O
have O
been O
found O
to O
bind O
to O
the O
latter O
and O
related O
sequences O
found O
upstream O
of O
early O
adenovirus O
promoters O
induced O
by O
E1A B
, O
and O
these O
factors O
are O
highly O
homologous O
to O
the O
CREB B
protein I
. O

A O
group O
of O
factors O
known O
as O
activating B
transcription I
factors I
( O
ATF B
) O
have O
been O
found O
to O
bind O
to O
the O
latter O
and O
related O
sequences O
found O
upstream O
of O
early O
adenovirus O
promoters O
induced O
by O
E1A B
, O
and O
these O
factors O
are O
highly O
homologous O
to O
the O
CREB B
protein I
. O

The O
vertebrate B
transcription I
factors I
TCF I
( O
T B
cell I
factor I
) O
and O
LEF B
( O
lymphocyte B
enhancer I
binding I
factor I
) O
interact O
with O
beta B
- I
catenin I
and O
are O
hypothesized O
to O
mediate O
Wingless B
/ O
Wnt B
signaling O
. O

The O
vertebrate B
transcription I
factors I
TCF I
( O
T B
cell I
factor I
) O
and O
LEF B
( O
lymphocyte B
enhancer I
binding I
factor I
) O
interact O
with O
beta B
- I
catenin I
and O
are O
hypothesized O
to O
mediate O
Wingless B
/ O
Wnt B
signaling O
. O

The O
vertebrate B
transcription I
factors I
TCF I
( O
T B
cell I
factor I
) O
and O
LEF B
( O
lymphocyte B
enhancer I
binding I
factor I
) O
interact O
with O
beta B
- I
catenin I
and O
are O
hypothesized O
to O
mediate O
Wingless B
/ O
Wnt B
signaling O
. O

Sequences O
within O
the O
UAS2 O
element O
of O
the O
ENO2 B
gene I
bound O
a O
second O
protein O
which O
corresponded O
to O
the O
ABFI B
( O
autonomously B
replicating I
sequence I
- I
binding I
factor I
) O
protein O
. O

The O
sequence O
of O
LZ321 B
matched O
that O
of O
RREB1 B
, O
a O
transcription O
factor O
that O
bound O
to O
a O
Ras B
responsive I
element I
( O
RRE B
) O
very O
different O
from O
the O
sequence O
with O
which O
we O
isolated O
LZ321 B
. O

The O
sequence O
of O
LZ321 B
matched O
that O
of O
RREB1 B
, O
a O
transcription O
factor O
that O
bound O
to O
a O
Ras B
responsive I
element I
( O
RRE B
) O
very O
different O
from O
the O
sequence O
with O
which O
we O
isolated O
LZ321 B
. O

The O
sequence O
of O
LZ321 B
matched O
that O
of O
RREB1 B
, O
a O
transcription O
factor O
that O
bound O
to O
a O
Ras B
responsive I
element I
( O
RRE B
) O
very O
different O
from O
the O
sequence O
with O
which O
we O
isolated O
LZ321 B
. O

The O
sequence O
of O
LZ321 B
matched O
that O
of O
RREB1 B
, O
a O
transcription O
factor O
that O
bound O
to O
a O
Ras B
responsive I
element I
( O
RRE B
) O
very O
different O
from O
the O
sequence O
with O
which O
we O
isolated O
LZ321 B
. O

Coronatine B
( O
COR B
) O
is O
a O
plasmid O
- O
encoded O
phytotoxin O
synthesized O
by O
several O
pathovars O
of O
phytopathogenic O
Pseudomonas O
syringae O
. O

Coronatine B
( O
COR B
) O
is O
a O
plasmid O
- O
encoded O
phytotoxin O
synthesized O
by O
several O
pathovars O
of O
phytopathogenic O
Pseudomonas O
syringae O
. O

This O
bud O
morphology O
results O
at O
least O
in O
part O
from O
a O
cell O
cycle O
delay O
imposed O
by O
the O
Cdc28p B
- O
inhibitory O
kinase O
Swe1p B
. O

This O
bud O
morphology O
results O
at O
least O
in O
part O
from O
a O
cell O
cycle O
delay O
imposed O
by O
the O
Cdc28p B
- O
inhibitory O
kinase O
Swe1p B
. O

The O
three O
proteins O
copurified O
through O
several O
biochemical O
fractionation O
steps O
and O
could O
be O
coimmunoprecipitated O
by O
using O
antibodies O
against O
GCD1 B
or O
GCD2 B
. O

The O
three O
proteins O
copurified O
through O
several O
biochemical O
fractionation O
steps O
and O
could O
be O
coimmunoprecipitated O
by O
using O
antibodies O
against O
GCD1 B
or O
GCD2 B
. O

Cellular O
fractionation O
and O
Percoll O
gradient O
centrifugation O
combined O
with O
immunoblotting O
show O
that O
p67 B
cofractionates O
with O
nuclei O
and O
is O
enriched O
in O
resistant O
structure O
that O
is O
insoluble O
in O
2 O
M O
NaCl O
, O
25 O
mM O
lithium O
3 O
, O
5 O
' O
- O
diiodosalicylate O
, O
and O
1 O
% O
Triton O
but O
is O
soluble O
in O
8 O
M O
urea O
. O

In O
vitro O
, O
c B
- I
Src I
phosphorylated O
FAK B
Tyr I
- I
925 I
in O
a O
glutathione B
S I
- I
transferase I
- O
FAK B
C O
- O
terminal O
domain O
fusion O
protein O
, O
whereas O
FAK O
did O
not O
. O

METHODS O
AND O
RESULTS O
: O
The O
effect O
of O
prolonged O
nitrate O
therapy O
between O
2 O
days O
and O
6 O
weeks O
during O
healing O
after O
infarction O
on O
serial O
parameters O
of O
ventricular O
remodeling O
( O
scar O
expansion O
, O
scar O
thinning O
, O
ventricular O
dilation O
, O
and O
hypertrophy O
) O
and O
function O
( O
asynergy O
or O
akinesis O
plus O
dyskinesis O
and O
ejection O
fraction O
) O
by O
serial O
two O
- O
dimensional O
echocardiography O
, O
hemodynamics O
, O
postmortem O
topography O
( O
computerized O
planimetry O
, O
geometric O
maps O
, O
and O
radiographs O
) O
, O
and O
collagen B
content O
( O
hydroxyproline O

The O
phP1 B
mutation O
was O
induced O
by O
insertion O
of O
a O
1 O
. O
2 O
- O
kb O
P B
element I
into O
the O
5 O
' O
transcribed O
nontranslated O
region O
of O
the O
proximal O
polyhomeotic B
gene I
. O

Initial O
computer O
based O
similarity O
searches O
identified O
human B
retinoblastoma I
binding I
protein I
1 I
( O
RBP B
- I
1 I
) O
, O
Drosophila B
melanogaster I
male I
specific I
lethal I
- I
3 I
( O
Msl B
- I
3 I
) O
, O
S B
. I
pombe I
altered I
polarity I
- I
13 I
( O
Alp13 B
) O
and O
S B
. I
cerevisiae I
Eaf3p I
, O
a O
component O
of O
the O
yeast B
NuA4 I
HAT B
complex O
( O
Galarneau O
et O
al O
. O
, O
2000 O
. O

Initial O
computer O
based O
similarity O
searches O
identified O
human B
retinoblastoma I
binding I
protein I
1 I
( O
RBP B
- I
1 I
) O
, O
Drosophila B
melanogaster I
male I
specific I
lethal I
- I
3 I
( O
Msl B
- I
3 I
) O
, O
S B
. I
pombe I
altered I
polarity I
- I
13 I
( O
Alp13 B
) O
and O
S B
. I
cerevisiae I
Eaf3p I
, O
a O
component O
of O
the O
yeast B
NuA4 I
HAT B
complex O
( O
Galarneau O
et O
al O
. O
, O
2000 O
. O

Serum O
prolactin B
rapidly O
decreased O
after O
institution O
of O
treatment O
, O
with O
actual O
normalization O
( O
less O
than O
20 O
ng O
/ O
ml O
) O
by O
the O
3rd O
month O
. O

Previously O
, O
a O
cDNA O
( O
GT2 B
) O
encoding O
this O
protein O
was O
isolated O
from O
a O
mouse O
3T3 O
- O
L1 O
adipocyte O
library O
and O
was O
sequenced O
. O

Expression O
of O
human B
complement I
receptor I
type I
2 I
( O
CR2 B
/ O
CD21 B
) O
is O
primarily O
restricted O
to O
mature O
B O
cells O
and O
follicular O
dendritic O
cells O
. O

Expression O
of O
human B
complement I
receptor I
type I
2 I
( O
CR2 B
/ O
CD21 B
) O
is O
primarily O
restricted O
to O
mature O
B O
cells O
and O
follicular O
dendritic O
cells O
. O

The O
6 O
. O
5 O
- O
kb O
genomic O
fragment O
contains O
the O
complete O
coding O
region O
of O
MyoD B
, O
distributed O
over O
three O
exons O
, O
plus O
2 O
. O
3 O
kb O
of O
5 O
' O
- O
noncoding O
sequence O
and O
1 O
. O
4 O
kb O
of O
3 O
' O
- O
noncoding O
sequence O
. O

The O
apparent O
binding O
constant O
of O
6 O
to O
calf O
thymus O
DNA O
is O
1 O
. O
68 O
X O
10 O
( O
5 O
) O
M O
- O
1 O
whereas O
netropsin B
under O
similar O
conditions O
gives O
a O
value O
of O
1 O
. O
85 O
X O
10 O
( O
7 O
) O
M O
- O
1 O
. O

Phenotypic O
screening O
of O
mutations O
in O
Pmr1 B
, O
the O
yeast B
secretory I
pathway I
Ca2 I
+ I
/ I
Mn2 I
+ I
- I
ATPase I
, O
reveals O
residues O
critical O
for O
ion O
selectivity O
and O
transport O
. O

No O
transactivation O
of O
the O
ovalbumin B
promoter I
( O
pLovTATA B
) O
template O
control O
was O
observed O
. O

Pros O
and O
cons O
of O
selective O
inhibition O
of O
cyclooxygenase B
- I
2 I
versus O
dual O
lipoxygenase B
/ O
cyclooxygenase B
inhibition O
: O
is O
two O
better O
than O
one O
? O

Pros O
and O
cons O
of O
selective O
inhibition O
of O
cyclooxygenase B
- I
2 I
versus O
dual O
lipoxygenase B
/ O
cyclooxygenase B
inhibition O
: O
is O
two O
better O
than O
one O
? O

HDE B
was O
found O
to O
be O
exclusively O
targeted O
to O
and O
imported O
into O
peroxisomes O
in O
both O
heterologous O
expression O
systems O
. O

The O
other O
regions O
include O
potential O
binding O
sites O
for O
transcription O
factors O
ATF B
, O
NF1 B
, O
and O
a O
CCAAT B
- I
binding I
protein I
. O

The O
other O
regions O
include O
potential O
binding O
sites O
for O
transcription O
factors O
ATF B
, O
NF1 B
, O
and O
a O
CCAAT B
- I
binding I
protein I
. O

Both O
purH B
and O
purD B
genes I
constitute O
a O
single O
operon O
and O
are O
coregulated O
in O
expression O
by O
purines O
as O
other O
purine B
genes I
are O
. O

UV O
- O
cross O
- O
linking O
studies O
suggested O
that O
these O
two O
complexes O
represent O
one O
and O
two O
molecules O
of O
ADR1 B
bound O
to O
DNA O
. O

As O
already O
available O
for O
the O
other O
known O
mammalian O
members O
of O
this O
enzyme O
family O
, O
we O
here O
define O
structural O
and O
functional O
features O
of O
human B
lymphoma I
proprotein I
convertase I
( O
LPC B
) O
. O

The O
M O
- O
phase O
induction O
activity O
of O
Cdc2 B
- O
Cdc13 B
is O
inhibited O
by O
Wee1 B
tyrosine I
kinase I
, O
which O
phosphorylates O
Cdc2 B
on O
tyrosine O
- O
15 O
. O

The O
M O
- O
phase O
induction O
activity O
of O
Cdc2 B
- O
Cdc13 B
is O
inhibited O
by O
Wee1 B
tyrosine I
kinase I
, O
which O
phosphorylates O
Cdc2 B
on O
tyrosine O
- O
15 O
. O

The O
M O
- O
phase O
induction O
activity O
of O
Cdc2 B
- O
Cdc13 B
is O
inhibited O
by O
Wee1 B
tyrosine I
kinase I
, O
which O
phosphorylates O
Cdc2 B
on O
tyrosine O
- O
15 O
. O

Single O
substitutions O
of O
three O
highly O
conserved O
phenylalanine O
residues O
( O
Phe O
- O
15 O
, O
Phe O
- O
17 O
, O
Phe O
- O
27 O
) O
by O
alanine O
and O
substitution O
of O
one O
histidine O
( O
His O
- O
29 O
) O
by O
glutamine O
, O
all O
located O
within O
the O
putative O
RNA O
- O
binding O
sites O
RNP B
- I
1 I
and O
RNP B
- I
2 I
, O
abolished O
the O
nucleic O
acid O
- O
binding O
activity O
of O
CspB B
. O

lacZ B
expression O
was O
first O
detected O
in O
the O
allantois O
at O
day O
7 O
. O
5 O
p O
. O
c O
. O
and O
in O
mesoderm O
and O
ectoderm O
at O
day O
8 O
. O
5 O
of O
gestation O
. O

The O
UL3 B
ORF I
of O
204 O
amino O
acids O
shows O
significant O
homology O
to O
UL3 B
( O
nuclear O
phosphoprotein O
) O
of O
HSV O
- O
1 O
( O
62 O
% O
) O
and O
PRV O
( O
53 O
% O
) O
. O

The O
biological O
actions O
of O
VHR B
in O
oocytes O
clearly O
distinguish O
it O
from O
other O
dual O
specificity O
phosphatases O
, O
which O
have O
shown O
inhibitory O
effects O
when O
tested O
in O
oocytes O
. O

The O
gp41 B
peptide I
( I
Glu I
- I
Leu I
- I
Asp I
- I
Lys I
- I
Trp I
- I
Ala I
) I
fused O
to O
the O
C O
- O
terminus O
of O
Sj B
GST I
forms O
a O
loop O
stabilized O
by O
symmetry O
- O
related O
GSTs B
. O

Comparison O
of O
bioreactive O
and O
immunoreactive O
gastrin B
. O

Also O
, O
PTx B
had O
no O
effect O
on O
shear O
- O
dependent O
activation O
of O
JNK B
. O

Also O
, O
PTx B
had O
no O
effect O
on O
shear O
- O
dependent O
activation O
of O
JNK B
. O

We O
analyzed O
the O
contribution O
of O
the O
three O
different O
types O
of O
UV O
- O
inducible O
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinases I
( O
ERK B
, O
JNK B
/ O
SAPK B
, O
and O
p38 B
) O
to O
the O
activation O
of O
the O
murine O
uPA B
promoter O
by O
UV O
. O

We O
analyzed O
the O
contribution O
of O
the O
three O
different O
types O
of O
UV O
- O
inducible O
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinases I
( O
ERK B
, O
JNK B
/ O
SAPK B
, O
and O
p38 B
) O
to O
the O
activation O
of O
the O
murine O
uPA B
promoter O
by O
UV O
. O

We O
analyzed O
the O
contribution O
of O
the O
three O
different O
types O
of O
UV O
- O
inducible O
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinases I
( O
ERK B
, O
JNK B
/ O
SAPK B
, O
and O
p38 B
) O
to O
the O
activation O
of O
the O
murine O
uPA B
promoter O
by O
UV O
. O

We O
analyzed O
the O
contribution O
of O
the O
three O
different O
types O
of O
UV O
- O
inducible O
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinases I
( O
ERK B
, O
JNK B
/ O
SAPK B
, O
and O
p38 B
) O
to O
the O
activation O
of O
the O
murine O
uPA B
promoter O
by O
UV O
. O

We O
analyzed O
the O
contribution O
of O
the O
three O
different O
types O
of O
UV O
- O
inducible O
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinases I
( O
ERK B
, O
JNK B
/ O
SAPK B
, O
and O
p38 B
) O
to O
the O
activation O
of O
the O
murine O
uPA B
promoter O
by O
UV O
. O

Characterization O
of O
a O
nuclear B
deformed I
epidermal I
autoregulatory I
factor I
- I
1 I
( O
DEAF B
- I
1 I
) O
- O
related O
( O
NUDR B
) O
transcriptional O
regulator O
protein O
. O

Here O
we O
show O
that O
the O
sck1 B
gene I
, O
cloned O
as O
a O
high O
copy O
number O
suppressor O
of O
a O
mutation O
in O
git3 B
, O
is O
able O
to O
suppress O
the O
defects O
conferred O
by O
a O
mutation O
in O
any O
of O
these O
git B
genes I
. O

In O
contrast O
to O
the O
p16 B
- O
mediated O
G1 O
block O
, O
G1 O
arrest O
mediated O
by O
the O
cdk B
inhibitors O
p21Cip1 B
or O
p27Kip1 B
cannot O
be O
bypassed O
either O
by O
inactivation O
of O
pRb B
or O
overexpression O
of O
E2F B
family I
members I
. O

In O
contrast O
to O
the O
p16 B
- O
mediated O
G1 O
block O
, O
G1 O
arrest O
mediated O
by O
the O
cdk B
inhibitors O
p21Cip1 B
or O
p27Kip1 B
cannot O
be O
bypassed O
either O
by O
inactivation O
of O
pRb B
or O
overexpression O
of O
E2F B
family I
members I
. O

In O
contrast O
to O
the O
p16 B
- O
mediated O
G1 O
block O
, O
G1 O
arrest O
mediated O
by O
the O
cdk B
inhibitors O
p21Cip1 B
or O
p27Kip1 B
cannot O
be O
bypassed O
either O
by O
inactivation O
of O
pRb B
or O
overexpression O
of O
E2F B
family I
members I
. O

In O
contrast O
to O
the O
p16 B
- O
mediated O
G1 O
block O
, O
G1 O
arrest O
mediated O
by O
the O
cdk B
inhibitors O
p21Cip1 B
or O
p27Kip1 B
cannot O
be O
bypassed O
either O
by O
inactivation O
of O
pRb B
or O
overexpression O
of O
E2F B
family I
members I
. O

In O
contrast O
to O
the O
p16 B
- O
mediated O
G1 O
block O
, O
G1 O
arrest O
mediated O
by O
the O
cdk B
inhibitors O
p21Cip1 B
or O
p27Kip1 B
cannot O
be O
bypassed O
either O
by O
inactivation O
of O
pRb B
or O
overexpression O
of O
E2F B
family I
members I
. O

To O
investigate O
the O
role O
of O
bHLH B
proteins I
in O
MC3T3 O
- O
E1 O
osteoblasts O
, O
which O
undergo O
a O
developmental O
sequence O
in O
vitro O
, O
we O
analyzed O
the O
transcriptional O
control O
of O
osteocalcin B
gene I
expression O
by O
stable O
transfection O
of O
an O
osteocalcin B
promoter I
- O
luciferase B
chimeric O
gene O
( O
p637OC B
- I
luc I
) O
and O
assessed O
the O
role O
of O
E O
- O
box O
cis O
- O
acting O
elements O
in O
osteocalcin B
promoter I
by O
DNA O
binding O
assays O
. O

We O
have O
previously O
shown O
that O
the O
transcriptional O
activator O
CREM B
is O
highly O
expressed O
in O
postmeiotic O
cells O
. O

We O
infer O
that O
RecA B
- O
mediated O
cleavage O
of O
UmuD B
is O
another O
role O
for O
RecA B
in O
SOS O
mutagenesis O
, O
probably O
activating O
UmuD B
for O
its O
mutagenic O
function O
. O

We O
infer O
that O
RecA B
- O
mediated O
cleavage O
of O
UmuD B
is O
another O
role O
for O
RecA B
in O
SOS O
mutagenesis O
, O
probably O
activating O
UmuD B
for O
its O
mutagenic O
function O
. O

We O
infer O
that O
RecA B
- O
mediated O
cleavage O
of O
UmuD B
is O
another O
role O
for O
RecA B
in O
SOS O
mutagenesis O
, O
probably O
activating O
UmuD B
for O
its O
mutagenic O
function O
. O

We O
infer O
that O
RecA B
- O
mediated O
cleavage O
of O
UmuD B
is O
another O
role O
for O
RecA B
in O
SOS O
mutagenesis O
, O
probably O
activating O
UmuD B
for O
its O
mutagenic O
function O
. O

The O
Rep B
proteins I
of O
adeno O
- O
associated O
virus O
type O
2 O
( O
AAV O
) O
are O
known O
to O
bind O
to O
Rep B
recognition I
sequences I
( O
RRSs B
) O
in O
the O
AAV O
inverted O
terminal O
repeats O
( O
ITRs O
) O
, O
the O
AAV B
p5 I
promoter I
, O
and O
the O
preferred O
AAV O
integration O
site O
in O
human O
chromosome O
19 O
, O
called O
AAVS1 O
. O

Southern O
hybridization O
analysis O
of O
BenR B
and O
BenS B
transformants I
suggested O
that O
plasmid O
integration O
occurred O
most O
frequently O
at O
the O
chromosomal O
bens B
locus I
, O
however O
evidence O
for O
gene O
conversion O
and O
heterologous O
recombination O
was O
also O
observed O
. O

The O
analysis O
of O
the O
effects O
of O
eight O
signaling O
molecules O
in O
the O
TGFbeta B
, O
FGF B
, O
Hh B
, O
Wnt B
, O
and O
EGF B
families I
in O
tooth O
explant O
cultures O
revealed O
that O
the O
expression O
of O
edar B
was O
induced O
by O
activinbetaA B
, O
whereas O
Wnt6 B
induced O
ectodysplasin B
expression O
. O

The O
analysis O
of O
the O
effects O
of O
eight O
signaling O
molecules O
in O
the O
TGFbeta B
, O
FGF B
, O
Hh B
, O
Wnt B
, O
and O
EGF B
families I
in O
tooth O
explant O
cultures O
revealed O
that O
the O
expression O
of O
edar B
was O
induced O
by O
activinbetaA B
, O
whereas O
Wnt6 B
induced O
ectodysplasin B
expression O
. O

The O
analysis O
of O
the O
effects O
of O
eight O
signaling O
molecules O
in O
the O
TGFbeta B
, O
FGF B
, O
Hh B
, O
Wnt B
, O
and O
EGF B
families I
in O
tooth O
explant O
cultures O
revealed O
that O
the O
expression O
of O
edar B
was O
induced O
by O
activinbetaA B
, O
whereas O
Wnt6 B
induced O
ectodysplasin B
expression O
. O

The O
analysis O
of O
the O
effects O
of O
eight O
signaling O
molecules O
in O
the O
TGFbeta B
, O
FGF B
, O
Hh B
, O
Wnt B
, O
and O
EGF B
families I
in O
tooth O
explant O
cultures O
revealed O
that O
the O
expression O
of O
edar B
was O
induced O
by O
activinbetaA B
, O
whereas O
Wnt6 B
induced O
ectodysplasin B
expression O
. O

The O
analysis O
of O
the O
effects O
of O
eight O
signaling O
molecules O
in O
the O
TGFbeta B
, O
FGF B
, O
Hh B
, O
Wnt B
, O
and O
EGF B
families I
in O
tooth O
explant O
cultures O
revealed O
that O
the O
expression O
of O
edar B
was O
induced O
by O
activinbetaA B
, O
whereas O
Wnt6 B
induced O
ectodysplasin B
expression O
. O

The O
analysis O
of O
the O
effects O
of O
eight O
signaling O
molecules O
in O
the O
TGFbeta B
, O
FGF B
, O
Hh B
, O
Wnt B
, O
and O
EGF B
families I
in O
tooth O
explant O
cultures O
revealed O
that O
the O
expression O
of O
edar B
was O
induced O
by O
activinbetaA B
, O
whereas O
Wnt6 B
induced O
ectodysplasin B
expression O
. O

The O
analysis O
of O
the O
effects O
of O
eight O
signaling O
molecules O
in O
the O
TGFbeta B
, O
FGF B
, O
Hh B
, O
Wnt B
, O
and O
EGF B
families I
in O
tooth O
explant O
cultures O
revealed O
that O
the O
expression O
of O
edar B
was O
induced O
by O
activinbetaA B
, O
whereas O
Wnt6 B
induced O
ectodysplasin B
expression O
. O

The O
analysis O
of O
the O
effects O
of O
eight O
signaling O
molecules O
in O
the O
TGFbeta B
, O
FGF B
, O
Hh B
, O
Wnt B
, O
and O
EGF B
families I
in O
tooth O
explant O
cultures O
revealed O
that O
the O
expression O
of O
edar B
was O
induced O
by O
activinbetaA B
, O
whereas O
Wnt6 B
induced O
ectodysplasin B
expression O
. O

In O
mouse O
, O
two O
high O
- O
affinity O
binding O
sites O
with O
an O
apparent O
dissociation O
constant O
( O
Kd O
) O
of O
50 O
to O
100 O
nM O
have O
been O
mapped O
in O
the O
5 O
' O
ETS B
upstream O
from O
the O
early O
pre O
- O
rRNA O
processing O
site O
. O

In O
turn O
, O
production O
of O
sufficient O
amounts O
of O
TraR B
apparently O
is O
sensitive O
to O
a O
cellular O
function O
requiring O
RNase B
D I
. O

The O
predicted O
product O
exhibits O
91 O
% O
amino O
acid O
identity O
to O
the O
murine B
voltage I
- I
gated I
potassium I
channel I
protein I
Kv1 I
. I
7 I
( O
Kcna7 B
) O
, O
which O
plays O
an O
important O
role O
in O
the O
repolarization O
of O
cell O
membranes O
. O

Phytohemagglutinin B
( O
PHA B
) O
, O
the O
seed B
lectin I
of O
the O
common O
bean O
, O
accumulates O
in O
protein O
storage O
vacuoles O
of O
storage O
parenchyma O
cells O
in O
cotyledons O
. O

Phytohemagglutinin B
( O
PHA B
) O
, O
the O
seed B
lectin I
of O
the O
common O
bean O
, O
accumulates O
in O
protein O
storage O
vacuoles O
of O
storage O
parenchyma O
cells O
in O
cotyledons O
. O

This O
dynamic O
nature O
may O
be O
relevant O
to O
the O
ability O
of O
E47 B
both O
to O
homodimerize O
and O
to O
heterodimerize O
with O
MyoD B
, O
Id B
, O
and O
Tal1 B
. O

This O
dynamic O
nature O
may O
be O
relevant O
to O
the O
ability O
of O
E47 B
both O
to O
homodimerize O
and O
to O
heterodimerize O
with O
MyoD B
, O
Id B
, O
and O
Tal1 B
. O

This O
dynamic O
nature O
may O
be O
relevant O
to O
the O
ability O
of O
E47 B
both O
to O
homodimerize O
and O
to O
heterodimerize O
with O
MyoD B
, O
Id B
, O
and O
Tal1 B
. O

This O
dynamic O
nature O
may O
be O
relevant O
to O
the O
ability O
of O
E47 B
both O
to O
homodimerize O
and O
to O
heterodimerize O
with O
MyoD B
, O
Id B
, O
and O
Tal1 B
. O

Overexpression O
of O
p50 B
in O
transient O
cotransfection O
studies O
using O
the O
proximal O
CRP B
promoter I
( O
- O
125 O
/ O
+ O
9 O
) O
linked O
to O
a O
luciferase B
reporter I
caused O
a O
3 O
- O
fold O
increase O
of O
luciferase B
activity O
, O
while O
C B
/ I
EBPbeta I
overexpression O
caused O
an O
18 O
- O
fold O
increase O
; O
simultaneous O
overexpression O
of O
both O
transcription O
factors O
increased O
luciferase B
activity O
approximately O
600 O
- O
fold O
. O

Overexpression O
of O
p50 B
in O
transient O
cotransfection O
studies O
using O
the O
proximal O
CRP B
promoter I
( O
- O
125 O
/ O
+ O
9 O
) O
linked O
to O
a O
luciferase B
reporter I
caused O
a O
3 O
- O
fold O
increase O
of O
luciferase B
activity O
, O
while O
C B
/ I
EBPbeta I
overexpression O
caused O
an O
18 O
- O
fold O
increase O
; O
simultaneous O
overexpression O
of O
both O
transcription O
factors O
increased O
luciferase B
activity O
approximately O
600 O
- O
fold O
. O

Overexpression O
of O
p50 B
in O
transient O
cotransfection O
studies O
using O
the O
proximal O
CRP B
promoter I
( O
- O
125 O
/ O
+ O
9 O
) O
linked O
to O
a O
luciferase B
reporter I
caused O
a O
3 O
- O
fold O
increase O
of O
luciferase B
activity O
, O
while O
C B
/ I
EBPbeta I
overexpression O
caused O
an O
18 O
- O
fold O
increase O
; O
simultaneous O
overexpression O
of O
both O
transcription O
factors O
increased O
luciferase B
activity O
approximately O
600 O
- O
fold O
. O

Our O
results O
suggest O
that O
it O
might O
be O
possible O
to O
augment O
IN B
function O
in O
vivo O
through O
a O
heterologous O
domain O
. O

While O
differential O
expression O
of O
the O
two O
transcripts O
was O
not O
found O
, O
the O
promoter O
controlling O
LT1 B
/ O
LT2 B
transcription O
is O
regulated O
in O
a O
cell O
cycle O
- O
dependent O
manner O
. O

While O
differential O
expression O
of O
the O
two O
transcripts O
was O
not O
found O
, O
the O
promoter O
controlling O
LT1 B
/ O
LT2 B
transcription O
is O
regulated O
in O
a O
cell O
cycle O
- O
dependent O
manner O
. O

Genetic O
analyses O
indicate O
that O
most O
of O
the O
dominant O
mutants O
are O
cis O
- O
acting O
and O
that O
the O
recessive O
mutants O
define O
a O
minimum O
of O
three O
complementation O
groups O
, O
indicating O
that O
defects O
in O
several O
different O
genes O
can O
restore O
higher O
levels O
of O
HIS4C B
expression O
. O

Pig O
uPA B
promoter O
- O
CAT B
constructs O
were O
more O
active O
than O
mouse O
constructs O
in O
this O
assay O
. O

Pig O
uPA B
promoter O
- O
CAT B
constructs O
were O
more O
active O
than O
mouse O
constructs O
in O
this O
assay O
. O

By O
computed O
homology O
search O
, O
we O
noticed O
significant O
similarities O
between O
US3 B
PK I
and O
p21 B
- I
activated I
kinase I
( O
PAK B
) O
, O
which O
is O
activated O
by O
the O
Cdc42 B
or O
Rac B
. O

By O
computed O
homology O
search O
, O
we O
noticed O
significant O
similarities O
between O
US3 B
PK I
and O
p21 B
- I
activated I
kinase I
( O
PAK B
) O
, O
which O
is O
activated O
by O
the O
Cdc42 B
or O
Rac B
. O

By O
computed O
homology O
search O
, O
we O
noticed O
significant O
similarities O
between O
US3 B
PK I
and O
p21 B
- I
activated I
kinase I
( O
PAK B
) O
, O
which O
is O
activated O
by O
the O
Cdc42 B
or O
Rac B
. O

These O
8 B
- I
oxoguanine I
DNA I
glycosylases I
, O
hOgg1 B
( O
human O
) O
and O
mOgg1 B
( O
murine O
) O
, O
are O
homologous O
to O
each O
other O
and O
to O
yeast B
Ogg1 I
. O

These O
8 B
- I
oxoguanine I
DNA I
glycosylases I
, O
hOgg1 B
( O
human O
) O
and O
mOgg1 B
( O
murine O
) O
, O
are O
homologous O
to O
each O
other O
and O
to O
yeast B
Ogg1 I
. O

We O
report O
that O
Gcn5 B
, O
a O
histone B
H3 I
acetylase I
, O
plays O
a O
central O
role O
in O
initiation O
of O
meiosis O
via O
effects O
on O
IME2 B
expression O
. O

We O
report O
that O
Gcn5 B
, O
a O
histone B
H3 I
acetylase I
, O
plays O
a O
central O
role O
in O
initiation O
of O
meiosis O
via O
effects O
on O
IME2 B
expression O
. O

The O
carboxy O
- O
proximal O
regions O
of O
the O
VP1 B
, O
which O
contain O
very O
low O
amino O
acid O
homology O
, O
displayed O
evidence O
of O
conservation O
in O
structural O
features O
such O
as O
a O
hydrophilic O
, O
highly O
basic O
domain O
. O

Interferon B
- I
alpha I
inducibility O
of O
IFI16 B
may O
be O
regulated O
by O
an O
interferon B
- I
alpha I
/ I
beta I
- O
stimulated O
response O
consensus O
element O
in O
the O
5 O
' O
UT O
exon O
, O
as O
a O
similar O
motif O
is O
conserved O
in O
the O
corresponding O
position O
in O
the O
related O
myeloid B
cell I
nuclear I
differentiation I
antigen I
gene O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

In O
the O
present O
study O
we O
use O
a O
tnaC B
- O
UGA O
- O
' B
lacZ I
construct O
lacking O
the O
tnaC B
- O
tnaA B
spacer O
region O
to O
analyze O
the O
effect O
of O
TnaC B
synthesis O
on O
the O
behavior O
of O
the O
ribosome O
that O
translates O
tnaC B
. O

In O
the O
present O
study O
we O
use O
a O
tnaC B
- O
UGA O
- O
' B
lacZ I
construct O
lacking O
the O
tnaC B
- O
tnaA B
spacer O
region O
to O
analyze O
the O
effect O
of O
TnaC B
synthesis O
on O
the O
behavior O
of O
the O
ribosome O
that O
translates O
tnaC B
. O

In O
the O
present O
study O
we O
use O
a O
tnaC B
- O
UGA O
- O
' B
lacZ I
construct O
lacking O
the O
tnaC B
- O
tnaA B
spacer O
region O
to O
analyze O
the O
effect O
of O
TnaC B
synthesis O
on O
the O
behavior O
of O
the O
ribosome O
that O
translates O
tnaC B
. O

In O
the O
present O
study O
we O
use O
a O
tnaC B
- O
UGA O
- O
' B
lacZ I
construct O
lacking O
the O
tnaC B
- O
tnaA B
spacer O
region O
to O
analyze O
the O
effect O
of O
TnaC B
synthesis O
on O
the O
behavior O
of O
the O
ribosome O
that O
translates O
tnaC B
. O

In O
the O
present O
study O
we O
use O
a O
tnaC B
- O
UGA O
- O
' B
lacZ I
construct O
lacking O
the O
tnaC B
- O
tnaA B
spacer O
region O
to O
analyze O
the O
effect O
of O
TnaC B
synthesis O
on O
the O
behavior O
of O
the O
ribosome O
that O
translates O
tnaC B
. O

Antisense O
oligonucleotides O
complementary O
to O
the O
5 O
' O
end O
of O
PKC B
- I
zeta I
mRNA I
sequences I
significantly O
reduced O
the O
collagen B
lattice O
- O
stimulated O
alpha2 O
and O
MMP B
- I
1 I
mRNA I
levels O
. O

Residues O
crucial O
for O
Ras B
interaction O
with O
GDP B
- I
GTP I
exchangers I
. O

It O
is O
also O
affected O
by O
the O
HAP2 B
/ I
3 I
/ I
4 I
transcription I
factor I
complex I
and O
by O
SNF1 B
and O
SSN6 B
. O

It O
is O
also O
affected O
by O
the O
HAP2 B
/ I
3 I
/ I
4 I
transcription I
factor I
complex I
and O
by O
SNF1 B
and O
SSN6 B
. O

Two O
different O
genes O
( O
polA B
and O
polB B
) O
encoding O
family B
B I
DNA I
polymerases I
were O
cloned O
from O
the O
organism O
by O
PCR O
using O
degenerated O
primers O
based O
on O
the O
two O
conserved O
motifs O
( O
motif O
A O
and O
B O
) O
. O

Two O
different O
genes O
( O
polA B
and O
polB B
) O
encoding O
family B
B I
DNA I
polymerases I
were O
cloned O
from O
the O
organism O
by O
PCR O
using O
degenerated O
primers O
based O
on O
the O
two O
conserved O
motifs O
( O
motif O
A O
and O
B O
) O
. O

Western O
immunoblot O
analysis O
detected O
p55gag B
and O
its O
cleavage O
products O
p39 B
and O
p27 B
in O
purified O
particles O
derived O
by O
expression O
of O
gag B
and O
gag B
- O
pol B
, O
respectively O
. O

Western O
immunoblot O
analysis O
detected O
p55gag B
and O
its O
cleavage O
products O
p39 B
and O
p27 B
in O
purified O
particles O
derived O
by O
expression O
of O
gag B
and O
gag B
- O
pol B
, O
respectively O
. O

Western O
immunoblot O
analysis O
detected O
p55gag B
and O
its O
cleavage O
products O
p39 B
and O
p27 B
in O
purified O
particles O
derived O
by O
expression O
of O
gag B
and O
gag B
- O
pol B
, O
respectively O
. O

Western O
immunoblot O
analysis O
detected O
p55gag B
and O
its O
cleavage O
products O
p39 B
and O
p27 B
in O
purified O
particles O
derived O
by O
expression O
of O
gag B
and O
gag B
- O
pol B
, O
respectively O
. O

Western O
immunoblot O
analysis O
detected O
p55gag B
and O
its O
cleavage O
products O
p39 B
and O
p27 B
in O
purified O
particles O
derived O
by O
expression O
of O
gag B
and O
gag B
- O
pol B
, O
respectively O
. O

Western O
immunoblot O
analysis O
detected O
p55gag B
and O
its O
cleavage O
products O
p39 B
and O
p27 B
in O
purified O
particles O
derived O
by O
expression O
of O
gag B
and O
gag B
- O
pol B
, O
respectively O
. O

3 O
- O
5 O
- O
fold O
increases O
in O
EGF B
receptor I
but O
not O
p185 B
( O
neu B
) O
tyrosine O
phosphorylation O
occur O
following O
Gi B
- I
coupled I
receptor I
stimulation O
. O

3 O
- O
5 O
- O
fold O
increases O
in O
EGF B
receptor I
but O
not O
p185 B
( O
neu B
) O
tyrosine O
phosphorylation O
occur O
following O
Gi B
- I
coupled I
receptor I
stimulation O
. O

Next O
, O
to O
examine O
the O
regulation O
mechanism O
of O
CD44 B
/ O
ERM B
interaction O
in O
vivo O
, O
we O
reexamined O
the O
immunoprecipitated O
CD44 B
/ O
ERM B
complex O
from O
BHK O
cells O
and O
found O
that O
it O
contains O
Rho B
- I
GDP I
dissociation I
inhibitor I
( O
GDI B
) O
, O
a O
regulator O
of O
Rho B
GTPase I
. O

Next O
, O
to O
examine O
the O
regulation O
mechanism O
of O
CD44 B
/ O
ERM B
interaction O
in O
vivo O
, O
we O
reexamined O
the O
immunoprecipitated O
CD44 B
/ O
ERM B
complex O
from O
BHK O
cells O
and O
found O
that O
it O
contains O
Rho B
- I
GDP I
dissociation I
inhibitor I
( O
GDI B
) O
, O
a O
regulator O
of O
Rho B
GTPase I
. O

Next O
, O
to O
examine O
the O
regulation O
mechanism O
of O
CD44 B
/ O
ERM B
interaction O
in O
vivo O
, O
we O
reexamined O
the O
immunoprecipitated O
CD44 B
/ O
ERM B
complex O
from O
BHK O
cells O
and O
found O
that O
it O
contains O
Rho B
- I
GDP I
dissociation I
inhibitor I
( O
GDI B
) O
, O
a O
regulator O
of O
Rho B
GTPase I
. O

Next O
, O
to O
examine O
the O
regulation O
mechanism O
of O
CD44 B
/ O
ERM B
interaction O
in O
vivo O
, O
we O
reexamined O
the O
immunoprecipitated O
CD44 B
/ O
ERM B
complex O
from O
BHK O
cells O
and O
found O
that O
it O
contains O
Rho B
- I
GDP I
dissociation I
inhibitor I
( O
GDI B
) O
, O
a O
regulator O
of O
Rho B
GTPase I
. O

Next O
, O
to O
examine O
the O
regulation O
mechanism O
of O
CD44 B
/ O
ERM B
interaction O
in O
vivo O
, O
we O
reexamined O
the O
immunoprecipitated O
CD44 B
/ O
ERM B
complex O
from O
BHK O
cells O
and O
found O
that O
it O
contains O
Rho B
- I
GDP I
dissociation I
inhibitor I
( O
GDI B
) O
, O
a O
regulator O
of O
Rho B
GTPase I
. O

TNF B
- I
alpha I
stimulated O
these O
changes O
in O
part O
by O
increasing O
transcription O
and O
stabilization O
of O
RNA O
for O
amphiregulin B
, O
an O
EGF B
receptor I
ligand O
, O
and O
amphiregulin B
directly O
increased O
HPV O
- O
16 O
E6 B
/ O
E7 B
and O
cyclin B
A I
RNAs I
. O

TNF B
- I
alpha I
stimulated O
these O
changes O
in O
part O
by O
increasing O
transcription O
and O
stabilization O
of O
RNA O
for O
amphiregulin B
, O
an O
EGF B
receptor I
ligand O
, O
and O
amphiregulin B
directly O
increased O
HPV O
- O
16 O
E6 B
/ O
E7 B
and O
cyclin B
A I
RNAs I
. O

TNF B
- I
alpha I
stimulated O
these O
changes O
in O
part O
by O
increasing O
transcription O
and O
stabilization O
of O
RNA O
for O
amphiregulin B
, O
an O
EGF B
receptor I
ligand O
, O
and O
amphiregulin B
directly O
increased O
HPV O
- O
16 O
E6 B
/ O
E7 B
and O
cyclin B
A I
RNAs I
. O

TNF B
- I
alpha I
stimulated O
these O
changes O
in O
part O
by O
increasing O
transcription O
and O
stabilization O
of O
RNA O
for O
amphiregulin B
, O
an O
EGF B
receptor I
ligand O
, O
and O
amphiregulin B
directly O
increased O
HPV O
- O
16 O
E6 B
/ O
E7 B
and O
cyclin B
A I
RNAs I
. O

BAG B
- I
1 I
also O
prevented O
growth O
arrest O
following O
UV O
- O
irradiation O
- O
induced O
genotoxic O
injury O
without O
interfering O
with O
accumulation O
of O
p53 B
protein I
or O
p21 B
( O
waf B
- I
1 I
) O
expression O
. O

In O
addition O
, O
two O
cis O
- O
acting O
elements O
direct O
the O
first O
zygotic O
expression O
of O
Kr B
in O
a O
striped O
subpattern O
within O
the O
central O
region O
of O
the O
blastoderm O
embryo O
. O

We O
have O
isolated O
a O
unique O
murine B
FLT3 I
cDNA I
that O
codes O
for O
a O
variant O
isoform O
of O
FLT3 B
, O
devoid O
of O
the O
fifth O
Ig B
- I
like I
domain I
, O
by O
comparison O
with O
the O
prototypic O
form O
. O

Particle O
bombardment O
of O
barley O
aleurone O
with O
a O
B22EL8 B
promoter I
- O
GUS B
( O
beta B
- I
glucuronidase I
) O
construct O
demonstrates O
that O
the O
promoter O
( O
3 O
kb O
) O
is O
active O
in O
developing O
barley O
grains O
. O

Characterization O
of O
regions O
of O
fibronectin B
besides O
the O
arginine O
- O
glycine O
- O
aspartic O
acid O
sequence O
required O
for O
adhesive O
function O
of O
the O
cell O
- O
binding O
domain O
using O
site O
- O
directed O
mutagenesis O
. O

Elements O
regulating O
cell O
- O
and O
stage O
- O
specific O
expression O
of O
the O
C O
. O
elegans O
MyoD B
family O
homolog O
hlh B
- I
1 I
. O

An O
analysis O
of O
the O
c B
- I
kit I
5 I
' I
flanking I
region I
using O
the O
bacterial B
chloramphenicol I
acetyltransferase I
gene I
( O
CAT B
assay O
) O
in O
human O
erythroleukemia O
HEL O
cells O
, O
which O
express O
the O
endogenous O
c B
- I
kit I
mRNA I
at O
high O
levels O
, O
showed O
that O
a O
region O
from O
- O
180 O
to O
- O
22 O
is O
important O
for O
the O
expression O
of O
the O
c B
- I
kit I
gene I
. O

However O
, O
the O
relative O
substrate O
specificity O
of O
RSK3 B
differed O
from O
that O
reported O
for O
other O
isoforms O
. O

Our O
data O
indicate O
that O
the O
various O
subunits O
of O
the O
human O
P B
- I
TEFb I
complex O
may O
play O
distinct O
roles O
at O
multiple O
stages O
to O
mediate O
Tat B
activation O
of O
HIV O
- O
1 O
transcription O
elongation O
. O

Sox8 B
maps O
to O
the O
t B
complex I
on O
mouse O
chromosome O
17 O
and O
to O
human O
chromosome O
16p13 O
. O
3 O
, O
a O
region O
associated O
with O
the O
microphthalmia O
- O
cataract O
syndrome O
CATM O
and O
the O
alpha O
- O
thalassemia O
/ O
mental O
retardation O
syndrome O
ATR O
- O
16 O
. O

Recently O
, O
we O
demonstrated O
that O
platelet B
- I
derived I
growth I
factor I
( I
PDGF I
) I
- I
beta I
receptor I
stimulation O
, O
but O
not O
various O
other O
growth O
factors O
, O
inhibits O
transcription O
of O
alpha1D B
- O
, O
but O
not O
alpha1A B
- O
or O
alpha1B B
- I
ARs I
, O
resulting O
in O
reduced O
norepinephrine O
- O
mediated O
SMC O
growth O
. O

Recently O
, O
we O
demonstrated O
that O
platelet B
- I
derived I
growth I
factor I
( I
PDGF I
) I
- I
beta I
receptor I
stimulation O
, O
but O
not O
various O
other O
growth O
factors O
, O
inhibits O
transcription O
of O
alpha1D B
- O
, O
but O
not O
alpha1A B
- O
or O
alpha1B B
- I
ARs I
, O
resulting O
in O
reduced O
norepinephrine O
- O
mediated O
SMC O
growth O
. O

Southern O
blot O
analysis O
following O
reverse O
transcription O
and O
PCR O
showed O
that O
B2R B
is O
expressed O
in O
most O
mouse O
tissues O
, O
except O
the O
liver O
and O
spleen O
, O
which O
is O
consistent O
with O
the O
wide O
distribution O
of O
B2R B
activity O
as O
deduced O
from O
pharmacological O
studies O
. O

Southern O
blot O
analysis O
following O
reverse O
transcription O
and O
PCR O
showed O
that O
B2R B
is O
expressed O
in O
most O
mouse O
tissues O
, O
except O
the O
liver O
and O
spleen O
, O
which O
is O
consistent O
with O
the O
wide O
distribution O
of O
B2R B
activity O
as O
deduced O
from O
pharmacological O
studies O
. O

Mean O
CD4 B
percentages O
were O
lower O
postpartum O
( O
21 O
. O
9 O
+ O
/ O
- O
3 O
. O
4 O
) O
than O
prepartum O
( O
45 O
. O
1 O
+ O
/ O
- O
6 O
. O
7 O
) O
in O
all O
five O
patients O
studied O
, O
although O
proliferative O
responses O
to O
the O
mitogens B
phytohemagglutinin I
and I
pokeweed I
were O
unchanged O
during O
the O
study O
period O
. O

The O
STP1 B
locus I
is O
located O
on O
chromosome O
IV O
close O
to O
at O
least O
two O
other O
genes O
involved O
in O
RNA O
splicing O
: O
PRP3 B
and O
SPP41 B
. O

The O
STP1 B
locus I
is O
located O
on O
chromosome O
IV O
close O
to O
at O
least O
two O
other O
genes O
involved O
in O
RNA O
splicing O
: O
PRP3 B
and O
SPP41 B
. O

In O
vitro O
, O
SHIP B
catalyzes O
the O
conversion O
of O
the O
phosphoinositide B
3 I
- I
kinase I
( O
PI3K B
) O
product O
phosphatidylinositol O
3 O
, O
4 O
, O
5 O
- O
trisphosphate O
( O
PIP3 O
) O
into O
phosphatidylinositol O
3 O
, O
4 O
- O
bisphosphate O
. O

In O
vitro O
, O
SHIP B
catalyzes O
the O
conversion O
of O
the O
phosphoinositide B
3 I
- I
kinase I
( O
PI3K B
) O
product O
phosphatidylinositol O
3 O
, O
4 O
, O
5 O
- O
trisphosphate O
( O
PIP3 O
) O
into O
phosphatidylinositol O
3 O
, O
4 O
- O
bisphosphate O
. O

Like O
pimethixene O
and O
cyproheptadine O
, O
WA O
335 O
has O
no O
distinct O
antagonistic O
qualities O
against O
bradykinin B
. O

These O
results O
demonstrate O
the O
preferential O
endometrial O
cell O
- O
type O
expression O
of O
BTEB B
and O
suggest O
its O
regulatory O
role O
in O
pregnancy O
- O
associated O
endometrial O
epithelial O
gene O
expression O
. O

Spen B
is O
the O
only O
known O
homeotic B
protein I
with O
RNP O
binding O
motifs O
, O
which O
indicates O
that O
splicing O
, O
transport O
, O
or O
other O
RNA O
regulatory O
steps O
are O
involved O
in O
the O
diversification O
of O
segmental O
morphology O
. O

None O
of O
the O
10 O
sequences O
has O
hitherto O
been O
recognized O
as O
part O
of O
the O
p53 B
signaling O
pathway O
. O

We O
have O
characterized O
21 O
mutations O
in O
the O
type B
VII I
collagen I
gene I
( O
COL7A1 B
) O
encoding O
the O
anchoring O
fibrils O
, O
18 O
of O
which O
were O
not O
previously O
reported O
, O
in O
patients O
from O
15 O
unrelated O
families O
with O
recessive O
dystrophic O
epidermolysis O
bullosa O
( O
RDEB O
) O
. O

Both O
residues O
are O
conserved O
in O
the O
three O
phosphorylated O
paralogs O
but O
are O
absent O
in O
the O
ones O
that O
were O
not O
substrates O
of O
RsbT B
: O
YetI B
and O
YezB B
, O
each O
of O
which O
bears O
only O
one O
of O
the O
conserved O
residues O
; O
and O
YtvA B
, O
which O
lacks O
both O
residues O
and O
instead O
possesses O
an O
N O
- O
terminal O
PAS B
domain O
. O

Both O
residues O
are O
conserved O
in O
the O
three O
phosphorylated O
paralogs O
but O
are O
absent O
in O
the O
ones O
that O
were O
not O
substrates O
of O
RsbT B
: O
YetI B
and O
YezB B
, O
each O
of O
which O
bears O
only O
one O
of O
the O
conserved O
residues O
; O
and O
YtvA B
, O
which O
lacks O
both O
residues O
and O
instead O
possesses O
an O
N O
- O
terminal O
PAS B
domain O
. O

Both O
residues O
are O
conserved O
in O
the O
three O
phosphorylated O
paralogs O
but O
are O
absent O
in O
the O
ones O
that O
were O
not O
substrates O
of O
RsbT B
: O
YetI B
and O
YezB B
, O
each O
of O
which O
bears O
only O
one O
of O
the O
conserved O
residues O
; O
and O
YtvA B
, O
which O
lacks O
both O
residues O
and O
instead O
possesses O
an O
N O
- O
terminal O
PAS B
domain O
. O

Both O
residues O
are O
conserved O
in O
the O
three O
phosphorylated O
paralogs O
but O
are O
absent O
in O
the O
ones O
that O
were O
not O
substrates O
of O
RsbT B
: O
YetI B
and O
YezB B
, O
each O
of O
which O
bears O
only O
one O
of O
the O
conserved O
residues O
; O
and O
YtvA B
, O
which O
lacks O
both O
residues O
and O
instead O
possesses O
an O
N O
- O
terminal O
PAS B
domain O
. O

Both O
residues O
are O
conserved O
in O
the O
three O
phosphorylated O
paralogs O
but O
are O
absent O
in O
the O
ones O
that O
were O
not O
substrates O
of O
RsbT B
: O
YetI B
and O
YezB B
, O
each O
of O
which O
bears O
only O
one O
of O
the O
conserved O
residues O
; O
and O
YtvA B
, O
which O
lacks O
both O
residues O
and O
instead O
possesses O
an O
N O
- O
terminal O
PAS B
domain O
. O

Consistently O
, O
we O
show O
that O
phosphorylation O
by O
protein B
kinase I
A I
inhibits O
Sfl1 B
DNA O
binding O
in O
vitro O
, O
and O
that O
a O
tpk2Delta B
mutation O
increases O
the O
levels O
of O
Sfl1 B
protein I
associated O
with O
specific O
promoter O
elements O
in O
vivo O
. O

Consistently O
, O
we O
show O
that O
phosphorylation O
by O
protein B
kinase I
A I
inhibits O
Sfl1 B
DNA O
binding O
in O
vitro O
, O
and O
that O
a O
tpk2Delta B
mutation O
increases O
the O
levels O
of O
Sfl1 B
protein I
associated O
with O
specific O
promoter O
elements O
in O
vivo O
. O

Some O
CHOP B
- O
C B
/ I
EBP I
heterodimers O
apparently O
bind O
to O
alternative O
DNA O
sequence O
and O
thereby O
regulate O
the O
transcription O
of O
other O
genes O
. O

To O
identify O
and O
determine O
the O
function O
of O
Ino2p B
in O
yeast O
cells O
, O
we O
raised O
antibodies O
to O
a O
beta B
- I
galactosidase I
/ O
Ino2 B
fusion O
protein O
. O

To O
identify O
and O
determine O
the O
function O
of O
Ino2p B
in O
yeast O
cells O
, O
we O
raised O
antibodies O
to O
a O
beta B
- I
galactosidase I
/ O
Ino2 B
fusion O
protein O
. O

The O
arrangement O
of O
amino O
acids O
in O
the O
helix O
1 O
and O
helix O
2 O
regions O
is O
quite O
similar O
to O
those O
of O
Mxi B
and O
Mad B
, O
but O
different O
from O
those O
of O
E2F B
- I
1 I
and O
DP B
- I
1 I
. O

The O
arrangement O
of O
amino O
acids O
in O
the O
helix O
1 O
and O
helix O
2 O
regions O
is O
quite O
similar O
to O
those O
of O
Mxi B
and O
Mad B
, O
but O
different O
from O
those O
of O
E2F B
- I
1 I
and O
DP B
- I
1 I
. O

Anovulatory O
cycles O
with O
an O
apparently O
normal O
level O
of O
blood O
prolactin B
. O

We O
further O
examined O
the O
interaction O
of O
JAK2 B
with O
the O
GHR B
cytoplasmic O
domain O
by O
two O
lines O
of O
investigation O
. O

We O
further O
examined O
the O
interaction O
of O
JAK2 B
with O
the O
GHR B
cytoplasmic O
domain O
by O
two O
lines O
of O
investigation O
. O

These O
p21 B
- O
E2F B
complexes O
, O
while O
present O
in O
young O
G1 O
cells O
at O
very O
low O
levels O
, O
were O
elevated O
in O
senescent O
cells O
. O

These O
p21 B
- O
E2F B
complexes O
, O
while O
present O
in O
young O
G1 O
cells O
at O
very O
low O
levels O
, O
were O
elevated O
in O
senescent O
cells O
. O

Our O
results O
indicate O
that O
GCN4 B
contains O
two O
activation O
domains O
of O
similar O
potency O
that O
can O
function O
independently O
to O
promote O
high O
- O
level O
transcription O
of O
the O
target O
genes O
HIS3 B
and O
HIS4 B
. O

Our O
results O
indicate O
that O
GCN4 B
contains O
two O
activation O
domains O
of O
similar O
potency O
that O
can O
function O
independently O
to O
promote O
high O
- O
level O
transcription O
of O
the O
target O
genes O
HIS3 B
and O
HIS4 B
. O

Our O
results O
indicate O
that O
GCN4 B
contains O
two O
activation O
domains O
of O
similar O
potency O
that O
can O
function O
independently O
to O
promote O
high O
- O
level O
transcription O
of O
the O
target O
genes O
HIS3 B
and O
HIS4 B
. O

Tax B
was O
demonstrated O
to O
interact O
directly O
with O
CREB1 B
but O
not O
with O
other O
bZIP B
proteins I
, O
including O
CREB2 B
and O
Jun B
. O

Tax B
was O
demonstrated O
to O
interact O
directly O
with O
CREB1 B
but O
not O
with O
other O
bZIP B
proteins I
, O
including O
CREB2 B
and O
Jun B
. O

Tax B
was O
demonstrated O
to O
interact O
directly O
with O
CREB1 B
but O
not O
with O
other O
bZIP B
proteins I
, O
including O
CREB2 B
and O
Jun B
. O

Tax B
was O
demonstrated O
to O
interact O
directly O
with O
CREB1 B
but O
not O
with O
other O
bZIP B
proteins I
, O
including O
CREB2 B
and O
Jun B
. O

We O
also O
demonstrate O
that O
a O
p110RB1 B
mutant I
, O
which O
is O
refractory O
to O
cell O
cycle O
phosphorylation O
but O
intact O
in O
E1a B
/ O
large B
T I
antigen I
- O
binding O
properties O
, O
represses O
EIIaE B
with O
50 O
- O
to O
80 O
- O
fold O
greater O
efficiency O
than O
wild B
- I
type I
p110RB1 I
. O

We O
also O
demonstrate O
that O
a O
p110RB1 B
mutant I
, O
which O
is O
refractory O
to O
cell O
cycle O
phosphorylation O
but O
intact O
in O
E1a B
/ O
large B
T I
antigen I
- O
binding O
properties O
, O
represses O
EIIaE B
with O
50 O
- O
to O
80 O
- O
fold O
greater O
efficiency O
than O
wild B
- I
type I
p110RB1 I
. O

The O
IGFBP B
- I
1 I
IRS B
and O
PEPCK B
IRS B
both O
bind O
the O
alpha O
and O
beta O
forms O
of O
hepatic B
nuclear I
factor I
3 I
( O
HNF B
- I
3 I
) O
, O
although O
the O
latter O
does O
so O
with O
a O
sixfold O
- O
lower O
relative O
affinity O
. O

The O
IGFBP B
- I
1 I
IRS B
and O
PEPCK B
IRS B
both O
bind O
the O
alpha O
and O
beta O
forms O
of O
hepatic B
nuclear I
factor I
3 I
( O
HNF B
- I
3 I
) O
, O
although O
the O
latter O
does O
so O
with O
a O
sixfold O
- O
lower O
relative O
affinity O
. O

The O
IGFBP B
- I
1 I
IRS B
and O
PEPCK B
IRS B
both O
bind O
the O
alpha O
and O
beta O
forms O
of O
hepatic B
nuclear I
factor I
3 I
( O
HNF B
- I
3 I
) O
, O
although O
the O
latter O
does O
so O
with O
a O
sixfold O
- O
lower O
relative O
affinity O
. O

Our O
aim O
was O
to O
check O
whether O
, O
during O
PG O
- O
DS O
administration O
, O
serum O
lipase B
activity O
changes O
simultaneously O
with O
serum O
amylase B
activity O
, O
and O
, O
if O
so O
, O
what O
the O
reason O
is O
for O
the O
detected O
change O
. O

Our O
aim O
was O
to O
check O
whether O
, O
during O
PG O
- O
DS O
administration O
, O
serum O
lipase B
activity O
changes O
simultaneously O
with O
serum O
amylase B
activity O
, O
and O
, O
if O
so O
, O
what O
the O
reason O
is O
for O
the O
detected O
change O
. O

Within O
any O
cell O
line O
, O
several O
Tcfs B
and O
TLEs B
are O
co O
- O
expressed O
. O

Within O
any O
cell O
line O
, O
several O
Tcfs B
and O
TLEs B
are O
co O
- O
expressed O
. O

We O
investigated O
the O
pattern O
of O
evolution O
of O
bronchial O
albumin B
, O
IgA B
, O
and O
IgG B
levels O
in O
ventilated O
ICU O
patients O
in O
relation O
to O
nosocomial O
pneumonia O
. O

We O
investigated O
the O
pattern O
of O
evolution O
of O
bronchial O
albumin B
, O
IgA B
, O
and O
IgG B
levels O
in O
ventilated O
ICU O
patients O
in O
relation O
to O
nosocomial O
pneumonia O
. O

We O
investigated O
the O
pattern O
of O
evolution O
of O
bronchial O
albumin B
, O
IgA B
, O
and O
IgG B
levels O
in O
ventilated O
ICU O
patients O
in O
relation O
to O
nosocomial O
pneumonia O
. O

Promoter O
, O
spliced O
leader O
, O
and O
coding O
sequence O
for O
BICP4 B
, O
the O
largest O
of O
the O
immediate B
- I
early I
proteins I
of I
bovine I
herpesvirus I
1 I
. O

There O
was O
no O
correlation O
between O
starting O
platelet O
- O
associated O
IgG B
levels O
or O
changes O
in O
platelet O
- O
associated O
IgG B
levels O
with O
therapy O
and O
the O
increment O
in O
the O
patient O
' O
s O
platelet O
count O
. O

There O
was O
no O
correlation O
between O
starting O
platelet O
- O
associated O
IgG B
levels O
or O
changes O
in O
platelet O
- O
associated O
IgG B
levels O
with O
therapy O
and O
the O
increment O
in O
the O
patient O
' O
s O
platelet O
count O
. O

In O
contrast O
translocation O
of O
G1 B
to O
the O
Golgi O
was O
not O
observed O
when O
G1 B
was O
coexpressed O
with O
NSm B
, O
although O
NSm B
itself O
was O
still O
detected O
in O
the O
Golgi O
. O

In O
contrast O
translocation O
of O
G1 B
to O
the O
Golgi O
was O
not O
observed O
when O
G1 B
was O
coexpressed O
with O
NSm B
, O
although O
NSm B
itself O
was O
still O
detected O
in O
the O
Golgi O
. O

In O
contrast O
translocation O
of O
G1 B
to O
the O
Golgi O
was O
not O
observed O
when O
G1 B
was O
coexpressed O
with O
NSm B
, O
although O
NSm B
itself O
was O
still O
detected O
in O
the O
Golgi O
. O

In O
contrast O
translocation O
of O
G1 B
to O
the O
Golgi O
was O
not O
observed O
when O
G1 B
was O
coexpressed O
with O
NSm B
, O
although O
NSm B
itself O
was O
still O
detected O
in O
the O
Golgi O
. O

RESULTS O
: O
There O
were O
no O
significant O
differences O
in O
the O
mean O
serum O
vitamin O
A O
, O
E O
concentrations O
and O
vitamin O
E O
/ O
cholesterol O
ratio O
between O
pregnant O
women O
with O
normal O
hemoglobin B
and O
hemoglobinopathies O
, O
while O
confounding O
variables O
that O
might O
affect O
serum O
vitamin O
levels O
i O
. O
e O
. O
maternal O
age O
, O
gravida O
, O
BMI O
, O
gestational O
age O
, O
hematocrit O
, O
hemoglobin B
, O
mean O
corpuscular O
hemoglobin B
concentration O
and O
blood O
group O
were O
not O
different O
. O

RESULTS O
: O
There O
were O
no O
significant O
differences O
in O
the O
mean O
serum O
vitamin O
A O
, O
E O
concentrations O
and O
vitamin O
E O
/ O
cholesterol O
ratio O
between O
pregnant O
women O
with O
normal O
hemoglobin B
and O
hemoglobinopathies O
, O
while O
confounding O
variables O
that O
might O
affect O
serum O
vitamin O
levels O
i O
. O
e O
. O
maternal O
age O
, O
gravida O
, O
BMI O
, O
gestational O
age O
, O
hematocrit O
, O
hemoglobin B
, O
mean O
corpuscular O
hemoglobin B
concentration O
and O
blood O
group O
were O
not O
different O
. O

RESULTS O
: O
There O
were O
no O
significant O
differences O
in O
the O
mean O
serum O
vitamin O
A O
, O
E O
concentrations O
and O
vitamin O
E O
/ O
cholesterol O
ratio O
between O
pregnant O
women O
with O
normal O
hemoglobin B
and O
hemoglobinopathies O
, O
while O
confounding O
variables O
that O
might O
affect O
serum O
vitamin O
levels O
i O
. O
e O
. O
maternal O
age O
, O
gravida O
, O
BMI O
, O
gestational O
age O
, O
hematocrit O
, O
hemoglobin B
, O
mean O
corpuscular O
hemoglobin B
concentration O
and O
blood O
group O
were O
not O
different O
. O

No O
significant O
difference O
in O
plasma O
ET B
levels O
was O
found O
between O
cardiac O
and O
peripheral O
sampling O
sites O
( O
pulmonary O
artery O
; O
1 O
. O
07 O
+ O
/ O
- O
0 O
. O
28 O
, O
right O
atrium O
; O
1 O
. O
02 O
+ O
/ O
- O
0 O
. O
28 O
, O
peripheral O
artery O
; O
1 O
. O
12 O
+ O
/ O
- O
0 O
. O
23 O
, O
peripheral O
vein O
; O
1 O
. O
14 O
+ O
/ O
- O
0 O
. O
38 O
fmol O
/ O
ml O
: O
N O
. O
S O
. O
) O
, O
or O
among O
patients O
with O
uncomplicated O
MI O
, O
unstable O
angina O
( O
1 O
. O
00 O
+ O
/ O
- O
0 O
. O
32 O
fmol O
/ O
ml O
) O
, O
and O
healthy O
subjects O
( O
1 O
. O
01 O
+ O
/ O
- O
0 O
. O
29 O

The O
gap B
protein O
knirps B
mediates O
both O
quenching O
and O
direct O
repression O
in O
the O
Drosophila O
embryo O
. O

The O
gap B
protein O
knirps B
mediates O
both O
quenching O
and O
direct O
repression O
in O
the O
Drosophila O
embryo O
. O

Here O
we O
demonstrate O
that O
CD40 B
or O
IgM B
receptor I
stimulation O
of O
primary O
B O
cells O
results O
in O
transactivation O
of O
this O
enhancer O
. O

Both O
RNA14 B
and O
RNA15 B
wild I
- I
type I
genes I
, O
when O
cloned O
on O
a O
multicopy O
plasmid O
, O
are O
able O
to O
suppress O
the O
temperature O
- O
sensitive O
phenotype O
of O
strains O
bearing O
either O
the O
rna14 B
or O
the O
rna15 B
mutation I
, O
suggesting O
that O
the O
encoded O
proteins O
could O
interact O
with O
each O
other O
. O

Both O
RNA14 B
and O
RNA15 B
wild I
- I
type I
genes I
, O
when O
cloned O
on O
a O
multicopy O
plasmid O
, O
are O
able O
to O
suppress O
the O
temperature O
- O
sensitive O
phenotype O
of O
strains O
bearing O
either O
the O
rna14 B
or O
the O
rna15 B
mutation I
, O
suggesting O
that O
the O
encoded O
proteins O
could O
interact O
with O
each O
other O
. O

Treatments O
were O
two O
adrenocorticotrophin B
( O
ACTH B
) O
preparations O
given O
intramuscularly O
at O
2 O
. O
2 O
U O
/ O
kg O
, O
one O
of O
the O
ACTH B
preparations O
given O
intramuscularly O
at O
1 O
U O
/ O
kg O
and O
a O
synthetic O
polypeptide O
with O
ACTH B
- I
like I
activity O
( O
tetracosactrin O
, O
cosyntropin O
) O
given O
intravenously O
at O
5 O
micrograms O
/ O
kg O
. O

Treatments O
were O
two O
adrenocorticotrophin B
( O
ACTH B
) O
preparations O
given O
intramuscularly O
at O
2 O
. O
2 O
U O
/ O
kg O
, O
one O
of O
the O
ACTH B
preparations O
given O
intramuscularly O
at O
1 O
U O
/ O
kg O
and O
a O
synthetic O
polypeptide O
with O
ACTH B
- I
like I
activity O
( O
tetracosactrin O
, O
cosyntropin O
) O
given O
intravenously O
at O
5 O
micrograms O
/ O
kg O
. O

Treatments O
were O
two O
adrenocorticotrophin B
( O
ACTH B
) O
preparations O
given O
intramuscularly O
at O
2 O
. O
2 O
U O
/ O
kg O
, O
one O
of O
the O
ACTH B
preparations O
given O
intramuscularly O
at O
1 O
U O
/ O
kg O
and O
a O
synthetic O
polypeptide O
with O
ACTH B
- I
like I
activity O
( O
tetracosactrin O
, O
cosyntropin O
) O
given O
intravenously O
at O
5 O
micrograms O
/ O
kg O
. O

PRIP B
contains O
two O
LXXLL O
signature O
motifs O
. O

Like O
the O
human O
gene O
, O
the O
Drosophila O
gene O
encodes O
at O
least O
three O
isoforms O
of O
full B
length I
dystrophin I
- I
like I
proteins I
( O
dmDLP1 B
, O
dmDLP2 B
and O
dmDLP3 B
, O
) O
, O
regulated O
by O
different O
promoters O
located O
at O
the O
5 O
' O
end O
of O
the O
gene O
, O
and O
a O
smaller O
product O
regulated O
by O
an O
internal O
promoter O
( O
dmDp186 B
) O
. O

Like O
the O
human O
gene O
, O
the O
Drosophila O
gene O
encodes O
at O
least O
three O
isoforms O
of O
full B
length I
dystrophin I
- I
like I
proteins I
( O
dmDLP1 B
, O
dmDLP2 B
and O
dmDLP3 B
, O
) O
, O
regulated O
by O
different O
promoters O
located O
at O
the O
5 O
' O
end O
of O
the O
gene O
, O
and O
a O
smaller O
product O
regulated O
by O
an O
internal O
promoter O
( O
dmDp186 B
) O
. O

Like O
the O
human O
gene O
, O
the O
Drosophila O
gene O
encodes O
at O
least O
three O
isoforms O
of O
full B
length I
dystrophin I
- I
like I
proteins I
( O
dmDLP1 B
, O
dmDLP2 B
and O
dmDLP3 B
, O
) O
, O
regulated O
by O
different O
promoters O
located O
at O
the O
5 O
' O
end O
of O
the O
gene O
, O
and O
a O
smaller O
product O
regulated O
by O
an O
internal O
promoter O
( O
dmDp186 B
) O
. O

Like O
the O
human O
gene O
, O
the O
Drosophila O
gene O
encodes O
at O
least O
three O
isoforms O
of O
full B
length I
dystrophin I
- I
like I
proteins I
( O
dmDLP1 B
, O
dmDLP2 B
and O
dmDLP3 B
, O
) O
, O
regulated O
by O
different O
promoters O
located O
at O
the O
5 O
' O
end O
of O
the O
gene O
, O
and O
a O
smaller O
product O
regulated O
by O
an O
internal O
promoter O
( O
dmDp186 B
) O
. O

Accordingly O
, O
infection O
of O
IFN B
- O
pretreated O
HeLa O
S3 O
cells O
with O
an O
E3L O
- O
deficient O
VV O
( O
VVDeltaE3L O
) O
resulted O
in O
increased O
phosphorylation O
levels O
of O
both O
PKR B
and O
eIF2alpha B
. O

Accordingly O
, O
infection O
of O
IFN B
- O
pretreated O
HeLa O
S3 O
cells O
with O
an O
E3L O
- O
deficient O
VV O
( O
VVDeltaE3L O
) O
resulted O
in O
increased O
phosphorylation O
levels O
of O
both O
PKR B
and O
eIF2alpha B
. O

Accordingly O
, O
infection O
of O
IFN B
- O
pretreated O
HeLa O
S3 O
cells O
with O
an O
E3L O
- O
deficient O
VV O
( O
VVDeltaE3L O
) O
resulted O
in O
increased O
phosphorylation O
levels O
of O
both O
PKR B
and O
eIF2alpha B
. O

Vibrio O
cholerae O
iron O
transport O
: O
haem O
transport O
genes O
are O
linked O
to O
one O
of O
two O
sets O
of O
tonB B
, O
exbB B
, O
exbD B
genes I
. O

Vibrio O
cholerae O
iron O
transport O
: O
haem O
transport O
genes O
are O
linked O
to O
one O
of O
two O
sets O
of O
tonB B
, O
exbB B
, O
exbD B
genes I
. O

The O
predicted O
amino O
- O
acid O
sequence O
includes O
an O
N O
- O
terminal O
signal O
sequence O
of O
27 O
amino O
acids O
, O
a O
27 O
amino O
- O
acid O
pro O
- O
region O
, O
a O
251 O
amino O
- O
acid O
catalytic O
domain O
typical O
of O
a O
serine B
protease I
with O
trypsin B
- O
like O
specificity O
, O
and O
a O
C O
- O
terminal O
hydrophobic O
extension O
which O
is O
predicted O
to O
function O
as O
a O
membrane O
anchor O
. O

To O
examine O
the O
biochemical O
mechanism O
of O
Tax1 B
transactivation O
, O
we O
have O
developed O
an O
in O
vitro O
transactivation O
assay O
in O
which O
wild O
- O
type O
Tax1 B
is O
able O
to O
specifically O
transactivate O
a O
polymerase B
II I
promoter O
through O
upstream O
Tax1 B
- I
responsive I
elements I
. O

To O
examine O
the O
biochemical O
mechanism O
of O
Tax1 B
transactivation O
, O
we O
have O
developed O
an O
in O
vitro O
transactivation O
assay O
in O
which O
wild O
- O
type O
Tax1 B
is O
able O
to O
specifically O
transactivate O
a O
polymerase B
II I
promoter O
through O
upstream O
Tax1 B
- I
responsive I
elements I
. O

Interestingly O
, O
PMA O
- O
, O
PDGF B
- O
, O
and O
serum O
- O
induced O
GHR B
proteolysis O
was O
associated O
with O
substantial O
decreases O
in O
GH B
- O
induced O
activation O
of O
Janus B
kinase I
- I
2 I
, O
which O
were O
also O
prevented O
by O
IC3 O
. O

Interestingly O
, O
PMA O
- O
, O
PDGF B
- O
, O
and O
serum O
- O
induced O
GHR B
proteolysis O
was O
associated O
with O
substantial O
decreases O
in O
GH B
- O
induced O
activation O
of O
Janus B
kinase I
- I
2 I
, O
which O
were O
also O
prevented O
by O
IC3 O
. O

Interestingly O
, O
PMA O
- O
, O
PDGF B
- O
, O
and O
serum O
- O
induced O
GHR B
proteolysis O
was O
associated O
with O
substantial O
decreases O
in O
GH B
- O
induced O
activation O
of O
Janus B
kinase I
- I
2 I
, O
which O
were O
also O
prevented O
by O
IC3 O
. O

Thus O
, O
IF O
- O
laser O
therapy O
has O
a O
certain O
antioxidative O
effect O
by O
increasing O
SOD B
activity O
in O
RA O
patients O
' O
blood O
cells O
and O
reducing O
the O
production O
of O
highly O
reactive O
oxygen O
and O
nitrogen O
forms O
. O

Reactive O
mesothelial O
cells O
, O
usually O
seen O
as O
exfoliated O
cells O
, O
were O
consistently O
strongly O
positive O
for O
alpha B
1 I
- I
antichymotrypsin I
and O
more O
variably O
for O
alpha B
1 I
- I
antitrypsin I
and O
lysozyme B
. O

We O
show O
that O
Fos B
down O
regulates O
several O
immediate B
- I
early I
genes I
( O
c B
- I
fos I
, O
Egr B
- I
1 I
, O
and O
Egr B
- I
2 I
) O
after O
mitogenic O
stimulation O
. O

This O
study O
demonstrates O
a O
novel O
link O
between O
alterations O
in O
platelet B
- I
derived I
growth I
factor I
( O
PDGF B
) O
regulation O
of O
ornithine B
decarboxylase I
( O
ODC B
) O
expression O
during O
malignant O
conversion O
. O

This O
study O
demonstrates O
a O
novel O
link O
between O
alterations O
in O
platelet B
- I
derived I
growth I
factor I
( O
PDGF B
) O
regulation O
of O
ornithine B
decarboxylase I
( O
ODC B
) O
expression O
during O
malignant O
conversion O
. O

The O
human B
IFI16 I
gene I
is O
a O
member O
of O
an O
interferon B
- O
inducible O
family O
of O
mouse O
and O
human O
genes O
closely O
linked O
on O
syntenic O
regions O
of O
chromosome O
1 O
. O

In O
agreement O
with O
this O
model O
, O
elimination O
of O
the O
ADAM13 B
cytoplasmic I
domain I
increased O
developmental O
alterations O
attributable O
to O
ADAM13 B
proteolytic O
activity O
. O

A O
third O
GEF B
, O
GRP3 B
( O
KIAA0846 B
) O
, O
activated O
both O
Ras B
and O
Rap1 B
and O
shared O
significant O
sequence O
homology O
with O
the O
calcium O
- O
and O
diacylglycerol O
- O
activated O
GEFs B
, O
GRP1 B
and O
GRP2 B
. O

A O
third O
GEF B
, O
GRP3 B
( O
KIAA0846 B
) O
, O
activated O
both O
Ras B
and O
Rap1 B
and O
shared O
significant O
sequence O
homology O
with O
the O
calcium O
- O
and O
diacylglycerol O
- O
activated O
GEFs B
, O
GRP1 B
and O
GRP2 B
. O

A O
third O
GEF B
, O
GRP3 B
( O
KIAA0846 B
) O
, O
activated O
both O
Ras B
and O
Rap1 B
and O
shared O
significant O
sequence O
homology O
with O
the O
calcium O
- O
and O
diacylglycerol O
- O
activated O
GEFs B
, O
GRP1 B
and O
GRP2 B
. O

A O
third O
GEF B
, O
GRP3 B
( O
KIAA0846 B
) O
, O
activated O
both O
Ras B
and O
Rap1 B
and O
shared O
significant O
sequence O
homology O
with O
the O
calcium O
- O
and O
diacylglycerol O
- O
activated O
GEFs B
, O
GRP1 B
and O
GRP2 B
. O

A O
third O
GEF B
, O
GRP3 B
( O
KIAA0846 B
) O
, O
activated O
both O
Ras B
and O
Rap1 B
and O
shared O
significant O
sequence O
homology O
with O
the O
calcium O
- O
and O
diacylglycerol O
- O
activated O
GEFs B
, O
GRP1 B
and O
GRP2 B
. O

A O
third O
GEF B
, O
GRP3 B
( O
KIAA0846 B
) O
, O
activated O
both O
Ras B
and O
Rap1 B
and O
shared O
significant O
sequence O
homology O
with O
the O
calcium O
- O
and O
diacylglycerol O
- O
activated O
GEFs B
, O
GRP1 B
and O
GRP2 B
. O

A O
third O
GEF B
, O
GRP3 B
( O
KIAA0846 B
) O
, O
activated O
both O
Ras B
and O
Rap1 B
and O
shared O
significant O
sequence O
homology O
with O
the O
calcium O
- O
and O
diacylglycerol O
- O
activated O
GEFs B
, O
GRP1 B
and O
GRP2 B
. O

A O
third O
GEF B
, O
GRP3 B
( O
KIAA0846 B
) O
, O
activated O
both O
Ras B
and O
Rap1 B
and O
shared O
significant O
sequence O
homology O
with O
the O
calcium O
- O
and O
diacylglycerol O
- O
activated O
GEFs B
, O
GRP1 B
and O
GRP2 B
. O

Reversal O
of O
biliary O
sphincter O
spasm O
with O
low O
dose O
glucagon B
during O
operative O
cholangiography O
. O

Second O
, O
CGGA O
- O
containing O
sequences O
placed O
at O
- O
88 O
in O
the O
delta B
MTV I
- I
CAT I
reporter I
plasmid O
conferred O
insulin B
responsiveness O
to O
the O
mammary B
tumor I
virus I
promoter I
. O

In O
the O
absence O
of O
c B
- I
fos I
gene I
expression O
, O
c B
- I
Fos I
protein I
appears O
to O
be O
replaced O
by O
proteins O
of O
Fos B
family I
( O
Fra B
- I
1 I
) O
and O
ATF B
family I
( O
ATF B
- I
2 I
and O
ATFa B
) O
. O

Characterization O
of O
Chlamydomonas O
reinhardtii O
zygote O
- O
specific O
cDNAs O
that O
encode O
novel O
proteins O
containing O
ankyrin B
repeats O
and O
WW O
domains O
. O

Using O
yeast O
two O
- O
hybrid O
screening O
, O
we O
isolated O
histone B
H3 I
as O
an O
interacting O
factor O
of O
CIA B
. O

Furthermore O
, O
Grap B
is O
associated O
with O
a O
Ras B
guanine I
nucleotide I
exchange I
factor I
mSos1 B
, O
primarily O
through O
its O
N B
- I
terminal I
SH3 I
domain I
. O

Furthermore O
, O
Grap B
is O
associated O
with O
a O
Ras B
guanine I
nucleotide I
exchange I
factor I
mSos1 B
, O
primarily O
through O
its O
N B
- I
terminal I
SH3 I
domain I
. O

After O
3 O
months O
of O
intervention O
, O
sustained O
physical O
training O
was O
associated O
with O
the O
decrease O
of O
FVII B
and O
PAI B
- I
1 I
levels O
. O

Xa4 B
is O
a O
dominantly O
inherited O
rice O
gene O
that O
confers O
resistance O
to O
Philippine O
race O
1 O
of O
the O
bacterial O
blight O
pathogen O
Xanthomonas O
oryzae O
pv O
. O
oryzae O
in O
rice O
. O

For O
il8ra B
, O
it O
is O
formed O
from O
two O
exons O
, O
whereas O
for O
il8rb B
, O
seven O
distinct O
neutrophil O
mRNAs O
are O
formed O
by O
alternative O
splicing O
of O
11 O
exons O
. O

For O
il8ra B
, O
it O
is O
formed O
from O
two O
exons O
, O
whereas O
for O
il8rb B
, O
seven O
distinct O
neutrophil O
mRNAs O
are O
formed O
by O
alternative O
splicing O
of O
11 O
exons O
. O

The O
gene O
encoding O
the O
cellulase B
( O
Avicelase B
) O
Cel1 B
from O
Streptomyces O
reticuli O
and O
analysis O
of O
protein O
domains O
. O

The O
gene O
encoding O
the O
cellulase B
( O
Avicelase B
) O
Cel1 B
from O
Streptomyces O
reticuli O
and O
analysis O
of O
protein O
domains O
. O

The O
gene O
encoding O
the O
cellulase B
( O
Avicelase B
) O
Cel1 B
from O
Streptomyces O
reticuli O
and O
analysis O
of O
protein O
domains O
. O

E1 B
recognition O
sequences O
in O
the O
bovine O
papillomavirus O
type O
1 O
origin O
of O
DNA O
replication O
: O
interaction O
between O
half O
sites O
of O
the O
inverted O
repeats O
. O

We O
found O
that O
secretion O
of O
chitinolytic O
enzymes O
by O
cultured O
L O
. O
major O
parasites O
is O
inhibited O
by O
blood O
or O
hemoglobin B
, O
and O
hence O
these O
enzymes O
are O
apparently O
absent O
from O
the O
blood O
- O
fed O
infected O
flies O
, O
where O
the O
cardiac O
valve O
appears O
undamaged O
. O

SATB1 B
interacted O
with O
CDP B
through O
its O
DNA O
- O
binding O
domain O
, O
as O
demonstrated O
by O
glutathione B
S I
- I
transferase I
( O
GST B
) O
pull O
- O
down O
assays O
. O

SATB1 B
interacted O
with O
CDP B
through O
its O
DNA O
- O
binding O
domain O
, O
as O
demonstrated O
by O
glutathione B
S I
- I
transferase I
( O
GST B
) O
pull O
- O
down O
assays O
. O

SATB1 B
interacted O
with O
CDP B
through O
its O
DNA O
- O
binding O
domain O
, O
as O
demonstrated O
by O
glutathione B
S I
- I
transferase I
( O
GST B
) O
pull O
- O
down O
assays O
. O

The O
predicted O
5 O
' O
and O
3 O
' O
ends O
of O
the O
transcript O
are O
in O
very O
good O
agreement O
with O
the O
previously O
determined O
size O
of O
the O
LEU3 B
message O
. O

Similar O
to O
what O
was O
observed O
for O
P O
. O
putida O
, O
a O
psrA B
null O
mutant O
of O
P O
. O
aeruginosa O
also O
showed O
a O
90 O
% O
reduction O
in O
rpoS B
promoter I
activity O
; O
both O
mutants O
could O
be O
complemented O
for O
rpoS B
promoter I
activity O
when O
the O
psrA B
gene I
was O
provided O
in O
trans O
. O

psrA B
mutants I
of O
both O
Pseudomonas O
species O
lost O
the O
ability O
to O
induce O
rpoS B
expression O
at O
stationary O
phase O
, O
but O
they O
retained O
the O
ability O
to O
produce O
quorum O
- O
sensing O
autoinducer O
molecules O
. O

The O
role O
of O
the O
putative O
C2 B
domain O
of O
Nedd4 B
has O
not O
been O
elucidated O
. O

The O
role O
of O
the O
putative O
C2 B
domain O
of O
Nedd4 B
has O
not O
been O
elucidated O
. O

ZF87 B
specifically O
binds O
the O
ME1a1 O
element O
with O
higher O
affinity O
than O
the O
ME1a2 O
element O
. O

This O
new O
receptor O
, O
TOR B
( O
thymus B
orphan I
receptor I
) O
, O
is O
most O
closely O
related O
in O
both O
its O
DNA O
- O
binding O
domain O
and O
ligand O
- O
binding O
domain O
, O
90 O
% O
and O
53 O
% O
, O
respectively O
, O
to O
ROR B
alpha I
/ O
RZR B
alpha I
and O
clusters O
with O
these O
two O
receptors O
and O
RZR B
beta I
in O
a O
phylogenetic O
tree O
, O
when O
both O
the O
DNA O
- O
binding O
domain O
and O
the O
ligand O
- O
binding O
domain O
sequences O
of O
nuclear O
receptors O
are O
compared O
. O

In O
this O
report O
, O
we O
have O
examined O
whether O
PTP1B B
effects O
transformation O
induced O
by O
p210 B
bcr B
- O
abl B
. O

In O
this O
report O
, O
we O
have O
examined O
whether O
PTP1B B
effects O
transformation O
induced O
by O
p210 B
bcr B
- O
abl B
. O

In O
this O
report O
, O
we O
have O
examined O
whether O
PTP1B B
effects O
transformation O
induced O
by O
p210 B
bcr B
- O
abl B
. O

In O
this O
report O
, O
we O
have O
examined O
whether O
PTP1B B
effects O
transformation O
induced O
by O
p210 B
bcr B
- O
abl B
. O

Association O
of O
Smads B
with O
lymphoid B
enhancer I
binding I
factor I
1 I
/ O
T B
cell I
- I
specific I
factor I
mediates O
cooperative O
signaling O
by O
the O
transforming B
growth I
factor I
- I
beta I
and O
wnt B
pathways O
. O

Association O
of O
Smads B
with O
lymphoid B
enhancer I
binding I
factor I
1 I
/ O
T B
cell I
- I
specific I
factor I
mediates O
cooperative O
signaling O
by O
the O
transforming B
growth I
factor I
- I
beta I
and O
wnt B
pathways O
. O

The O
three O
OAS B
genes I
are O
flanked O
by O
markers B
WI I
- I
10614 I
( O
cen B
) O
and O
D12S2293 B
( O
tel B
) O
and O
are O
contained O
within O
three O
sets O
of O
overlapping O
cosmid O
clones O
. O

The O
three O
OAS B
genes I
are O
flanked O
by O
markers B
WI I
- I
10614 I
( O
cen B
) O
and O
D12S2293 B
( O
tel B
) O
and O
are O
contained O
within O
three O
sets O
of O
overlapping O
cosmid O
clones O
. O

The O
three O
OAS B
genes I
are O
flanked O
by O
markers B
WI I
- I
10614 I
( O
cen B
) O
and O
D12S2293 B
( O
tel B
) O
and O
are O
contained O
within O
three O
sets O
of O
overlapping O
cosmid O
clones O
. O

22 O
. O
6 O
% O
of O
patients O
were O
found O
to O
be O
positive O
at O
histology O
in O
the O
corpus O
mucosa O
; O
all O
but O
one O
of O
these O
patients O
had O
elevated O
circulating O
IgG B
to O
H O
. O
pylori O
( O
Group O
C O
) O
. O

Rottlerin O
also O
inhibited O
the O
activation O
of O
MAP B
kinase I
kinase I
( O
MEK B
) O
in O
response O
to O
activated O
Raf B
, O
but O
had O
no O
effect O
upon O
c B
- I
Raf I
activity O
or O
ERK B
activation O
by O
activated O
MEK B
. O

Rottlerin O
also O
inhibited O
the O
activation O
of O
MAP B
kinase I
kinase I
( O
MEK B
) O
in O
response O
to O
activated O
Raf B
, O
but O
had O
no O
effect O
upon O
c B
- I
Raf I
activity O
or O
ERK B
activation O
by O
activated O
MEK B
. O

Rottlerin O
also O
inhibited O
the O
activation O
of O
MAP B
kinase I
kinase I
( O
MEK B
) O
in O
response O
to O
activated O
Raf B
, O
but O
had O
no O
effect O
upon O
c B
- I
Raf I
activity O
or O
ERK B
activation O
by O
activated O
MEK B
. O

Rottlerin O
also O
inhibited O
the O
activation O
of O
MAP B
kinase I
kinase I
( O
MEK B
) O
in O
response O
to O
activated O
Raf B
, O
but O
had O
no O
effect O
upon O
c B
- I
Raf I
activity O
or O
ERK B
activation O
by O
activated O
MEK B
. O

The O
isolation O
of O
crt5 B
- I
262 I
, O
an O
additional O
cdc B
allele I
of O
POL1 B
/ O
CDC17 B
, O
suggests O
for O
the O
first O
time O
that O
directly O
blocking O
DNA O
replication O
can O
provide O
a O
signal O
to O
induce O
the O
DNA O
damage O
response O
. O

The O
isolation O
of O
crt5 B
- I
262 I
, O
an O
additional O
cdc B
allele I
of O
POL1 B
/ O
CDC17 B
, O
suggests O
for O
the O
first O
time O
that O
directly O
blocking O
DNA O
replication O
can O
provide O
a O
signal O
to O
induce O
the O
DNA O
damage O
response O
. O

crt2 B
mutants I
show O
a O
defect O
in O
basal O
level O
expression O
of O
RNR1 B
- O
lacZ B
reporter O
constructs O
. O

crt2 B
mutants I
show O
a O
defect O
in O
basal O
level O
expression O
of O
RNR1 B
- O
lacZ B
reporter O
constructs O
. O

We O
prospectively O
studied O
serum B
prolactin I
( O
PRL B
) O
elevation O
after O
different O
types O
of O
documented O
seizures O
in O
17 O
patients O
. O

A O
GTP O
/ O
GDP O
exchange O
assay O
was O
used O
to O
assess O
the O
potential O
role O
of O
Ras B
in O
the O
pathway O
leading O
to O
ERK B
phosphorylation O
; O
DADLE O
failed O
to O
stimulate O
GTP O
/ O
GDP O
exchange O
in O
comparison O
to O
PMA O
. O

A O
GTP O
/ O
GDP O
exchange O
assay O
was O
used O
to O
assess O
the O
potential O
role O
of O
Ras B
in O
the O
pathway O
leading O
to O
ERK B
phosphorylation O
; O
DADLE O
failed O
to O
stimulate O
GTP O
/ O
GDP O
exchange O
in O
comparison O
to O
PMA O
. O

Phenotypic O
analysis O
demonstrates O
that O
trio B
and O
Abl B
cooperate O
in O
regulating O
axon O
outgrowth O
in O
the O
embryonic O
central O
nervous O
system O
( O
CNS O
) O
. O

Phenotypic O
analysis O
demonstrates O
that O
trio B
and O
Abl B
cooperate O
in O
regulating O
axon O
outgrowth O
in O
the O
embryonic O
central O
nervous O
system O
( O
CNS O
) O
. O

The O
gene O
encoding O
rat O
peptidylglycine B
alpha I
- I
amidating I
monooxygenase I
( O
PAM B
) O
contains O
26 O
protein O
- O
coding O
exons O
. O

The O
NF B
- I
kappa I
B I
precursor O
p100 B
( O
lyt B
- I
10 I
, O
p97 B
, O
p98 B
) O
generates O
after O
proteolytic O
processing O
a O
52 O
kDa O
subunit O
, O
which O
can O
bind O
to O
kappa B
B I
- I
motifs I
. O

The O
NF B
- I
kappa I
B I
precursor O
p100 B
( O
lyt B
- I
10 I
, O
p97 B
, O
p98 B
) O
generates O
after O
proteolytic O
processing O
a O
52 O
kDa O
subunit O
, O
which O
can O
bind O
to O
kappa B
B I
- I
motifs I
. O

The O
NF B
- I
kappa I
B I
precursor O
p100 B
( O
lyt B
- I
10 I
, O
p97 B
, O
p98 B
) O
generates O
after O
proteolytic O
processing O
a O
52 O
kDa O
subunit O
, O
which O
can O
bind O
to O
kappa B
B I
- I
motifs I
. O

CONCLUSION O
: O
The O
biodistribution O
of O
111In O
IgG B
is O
similar O
to O
that O
of O
99mTc O
- O
HMPAO O
- O
labeled O
leukocytes O
. O

Receptor B
- I
type I
serine I
/ I
threonine I
kinases I
( O
RSKs B
) O
have O
been O
organized O
into O
two O
distinct O
classes O
known O
as O
types O
I O
and O
II O
on O
the O
basis O
of O
sequence O
similarity O
. O

In O
a O
previous O
study O
of O
transforming B
growth I
factor I
- I
beta1 I
- O
mediated O
inhibition O
of O
the O
cyclin B
A I
promoter I
, O
we O
mapped O
the O
inhibitory O
effect O
to O
the O
ATF B
site I
; O
in O
the O
present O
study O
of O
IFN B
- I
gamma I
treatment O
, O
functional O
analysis O
by O
transient O
transfection O
showed O
that O
inhibition O
of O
the O
cyclin B
A I
promoter I
persisted O
despite O
mutation O
of O
the O
ATF B
, O
NF B
- I
Y I
, O
or O
CDE O
elements O
. O

This O
pattern O
of O
expression O
and O
differential O
processing O
suggests O
a O
role O
for O
inrpk1 B
in O
some O
aspect O
of O
SD O
photoperiodic O
- O
induced O
flowering O
in O
morning O
glory O
. O

Progressive O
immunodeficiency O
in O
a O
patient O
with O
IgA B
deficiency O

This O
paper O
describes O
a O
longitudinal O
study O
in O
which O
clinical O
parameters O
and O
aspartate B
aminotransferase I
( O
AST B
) O
in O
gingival O
crevicular O
fluid O
( O
GCF O
) O
were O
monitored O
bimonthly O
over O
a O
6 O
- O
12 O
months O
period O
in O
970 O
sites O
from O
7 O
treated O
periodontitis O
patients O
. O

These O
data O
show O
that O
the O
processing O
of O
specific O
target O
transcripts O
, O
such O
as O
the O
P B
- I
element I
mRNA I
, O
is O
regulated O
by O
a O
functional O
PSI B
- O
U1 B
snRNP O
interaction O
in O
Drosophila O
. O

These O
data O
show O
that O
the O
processing O
of O
specific O
target O
transcripts O
, O
such O
as O
the O
P B
- I
element I
mRNA I
, O
is O
regulated O
by O
a O
functional O
PSI B
- O
U1 B
snRNP O
interaction O
in O
Drosophila O
. O

These O
results O
strongly O
suggest O
that O
HSV O
- O
1 O
infection O
inhibits O
host O
cell O
splicing O
through O
the O
action O
of O
ICP27 B
. O

Transformation O
of O
chicken O
embryo O
fibroblasts O
( O
CEF O
) O
with O
the O
Gag B
- O
Crk B
fusion O
protein O
results O
in O
the O
elevation O
of O
tyrosine O
phosphorylation O
on O
specific O
cellular O
proteins O
with O
molecular O
weights O
of O
130 O
, O
000 O
, O
110 O
, O
000 O
, O
and O
70 O
, O
000 O
( O
p130 B
, O
p110 B
, O
and O
p70 B
, O
respectively O
) O
, O
an O
event O
which O
has O
been O
correlated O
with O
cell O
transformation O
. O

Transformation O
of O
chicken O
embryo O
fibroblasts O
( O
CEF O
) O
with O
the O
Gag B
- O
Crk B
fusion O
protein O
results O
in O
the O
elevation O
of O
tyrosine O
phosphorylation O
on O
specific O
cellular O
proteins O
with O
molecular O
weights O
of O
130 O
, O
000 O
, O
110 O
, O
000 O
, O
and O
70 O
, O
000 O
( O
p130 B
, O
p110 B
, O
and O
p70 B
, O
respectively O
) O
, O
an O
event O
which O
has O
been O
correlated O
with O
cell O
transformation O
. O

Transformation O
of O
chicken O
embryo O
fibroblasts O
( O
CEF O
) O
with O
the O
Gag B
- O
Crk B
fusion O
protein O
results O
in O
the O
elevation O
of O
tyrosine O
phosphorylation O
on O
specific O
cellular O
proteins O
with O
molecular O
weights O
of O
130 O
, O
000 O
, O
110 O
, O
000 O
, O
and O
70 O
, O
000 O
( O
p130 B
, O
p110 B
, O
and O
p70 B
, O
respectively O
) O
, O
an O
event O
which O
has O
been O
correlated O
with O
cell O
transformation O
. O

Transformation O
of O
chicken O
embryo O
fibroblasts O
( O
CEF O
) O
with O
the O
Gag B
- O
Crk B
fusion O
protein O
results O
in O
the O
elevation O
of O
tyrosine O
phosphorylation O
on O
specific O
cellular O
proteins O
with O
molecular O
weights O
of O
130 O
, O
000 O
, O
110 O
, O
000 O
, O
and O
70 O
, O
000 O
( O
p130 B
, O
p110 B
, O
and O
p70 B
, O
respectively O
) O
, O
an O
event O
which O
has O
been O
correlated O
with O
cell O
transformation O
. O

Transformation O
of O
chicken O
embryo O
fibroblasts O
( O
CEF O
) O
with O
the O
Gag B
- O
Crk B
fusion O
protein O
results O
in O
the O
elevation O
of O
tyrosine O
phosphorylation O
on O
specific O
cellular O
proteins O
with O
molecular O
weights O
of O
130 O
, O
000 O
, O
110 O
, O
000 O
, O
and O
70 O
, O
000 O
( O
p130 B
, O
p110 B
, O
and O
p70 B
, O
respectively O
) O
, O
an O
event O
which O
has O
been O
correlated O
with O
cell O
transformation O
. O

Urease B
activity O
, O
judged O
as O
the O
amount O
of O
ammonia O
production O
from O
urea O
, O
could O
be O
measured O
at O
25 O
ng O
per O
tube O
( O
S O
/ O
N O
= O
1 O
. O
5 O
) O
with O
Jack B
bean I
meal I
urease I
. O

Here O
, O
we O
provide O
direct O
evidence O
that O
the O
meiotic O
defect O
caused O
by O
either O
unregulated O
cAPK B
activity O
or O
unregulated O
ran1 B
+ I
kinase I
activity O
is O
due O
to O
inability O
to O
induce O
transcription O
of O
the O
mei2 B
+ I
gene I
, O
which O
is O
required O
for O
meiotic O
initiation O
. O

In O
K562 O
cells O
, O
using O
the O
bicistronic O
vector O
, O
selection O
with O
colchicine O
led O
to O
at O
least O
20 O
- O
fold O
higher O
expression O
of O
the O
MDR1 B
gene I
product I
than O
did O
selection O
with O
G418 O
, O
suggesting O
that O
the O
stringent O
MDR1 B
selection O
system O
is O
very O
efficient O
for O
obtaining O
overexpression O
of O
foreign O
genes O
. O

Our O
analysis O
indicates O
that O
a O
gene O
correction O
mechanism O
has O
been O
operating O
on O
the O
Hbbs B
chromosome O
to O
keep O
beta B
s I
and O
beta B
t I
evolving O
in O
concert O
, O
whereas O
on O
the O
Hbbd B
chromosome O
, O
beta B
dmin I
has O
diverged O
considerably O
from O
beta B
dmaj I
. O

Our O
analysis O
indicates O
that O
a O
gene O
correction O
mechanism O
has O
been O
operating O
on O
the O
Hbbs B
chromosome O
to O
keep O
beta B
s I
and O
beta B
t I
evolving O
in O
concert O
, O
whereas O
on O
the O
Hbbd B
chromosome O
, O
beta B
dmin I
has O
diverged O
considerably O
from O
beta B
dmaj I
. O

Structure O
and O
regulation O
of O
KGD2 B
, O
the O
structural O
gene O
for O
yeast B
dihydrolipoyl I
transsuccinylase I
. O

We O
identify O
YY1 B
recognition O
sequences O
within O
the O
vitamin O
D O
response O
element O
( O
VDRE O
) O
of O
the O
osteocalcin B
gene I
that O
are O
critical O
for O
YY1 B
- O
dependent O
repression O
of O
vitamin O
D O
- O
enhanced O
promoter O
activity O
. O

We O
identify O
YY1 B
recognition O
sequences O
within O
the O
vitamin O
D O
response O
element O
( O
VDRE O
) O
of O
the O
osteocalcin B
gene I
that O
are O
critical O
for O
YY1 B
- O
dependent O
repression O
of O
vitamin O
D O
- O
enhanced O
promoter O
activity O
. O

Point O
mutations O
of O
Stat3 B
within O
the O
interacting O
domains O
blocked O
both O
physical O
interaction O
of O
Stat3 B
with O
c B
- I
Jun I
and O
their O
cooperation O
in O
IL B
- I
6 I
- O
induced O
transcription O
directed O
by O
the O
alpha B
( I
2 I
) I
- I
macroglobulin I
enhancer I
. O

Point O
mutations O
of O
Stat3 B
within O
the O
interacting O
domains O
blocked O
both O
physical O
interaction O
of O
Stat3 B
with O
c B
- I
Jun I
and O
their O
cooperation O
in O
IL B
- I
6 I
- O
induced O
transcription O
directed O
by O
the O
alpha B
( I
2 I
) I
- I
macroglobulin I
enhancer I
. O

The O
prgX B
gene I
is O
adjacent O
to O
prgQ B
which O
provides O
the O
promoter O
for O
prgB B
expression O
. O

The O
prgX B
gene I
is O
adjacent O
to O
prgQ B
which O
provides O
the O
promoter O
for O
prgB B
expression O
. O

Cellular O
lysates O
were O
analyzed O
for O
luciferase B
and O
beta B
- I
galactosidase I
activities O
. O

Expression O
of O
putative O
constitutively O
active O
forms O
of O
DdMEK1 B
in O
a O
ddmek1 B
null O
background O
is O
capable O
, O
at O
least O
partially O
, O
of O
complementing O
the O
small O
aggregate O
size O
defect O
and O
the O
ability O
to O
activate O
guanylyl B
cyclase I
. O

Expression O
of O
putative O
constitutively O
active O
forms O
of O
DdMEK1 B
in O
a O
ddmek1 B
null O
background O
is O
capable O
, O
at O
least O
partially O
, O
of O
complementing O
the O
small O
aggregate O
size O
defect O
and O
the O
ability O
to O
activate O
guanylyl B
cyclase I
. O

Because O
of O
the O
structural O
similarities O
the O
new O
gene O
will O
be O
termed O
scERV2 B
from O
now O
on O
. O

Stress O
- O
induced O
suppression O
of O
the O
prolactin B
afternoon O
surge O
in O
ovariectomized O
, O
estrogen O
- O
treated O
rats O
and O
the O
nocturnal O
surge O
in O
pseudopregnant O
rats O
are O
accompanied O
by O
an O
increase O
in O
median O
eminence O
dihydroxyphenylacetic O
acid O
concentrations O
. O

Expression O
of O
the O
Asp O
but O
not O
the O
Ala O
gB B
mutation O
resulted O
in O
an O
increase O
in O
the O
steady O
- O
state O
expression O
of O
gB B
at O
the O
plasma O
membrane O
( O
PM O
) O
in O
U373 O
cells O
. O

Expression O
of O
the O
Asp O
but O
not O
the O
Ala O
gB B
mutation O
resulted O
in O
an O
increase O
in O
the O
steady O
- O
state O
expression O
of O
gB B
at O
the O
plasma O
membrane O
( O
PM O
) O
in O
U373 O
cells O
. O

Insulin B
therapy O
has O
been O
expanded O
by O
development O
of O
human B
insulin I
and O
new O
modes O
of O
injection O
, O
including O
insulin B
pumps O
. O

Insulin B
therapy O
has O
been O
expanded O
by O
development O
of O
human B
insulin I
and O
new O
modes O
of O
injection O
, O
including O
insulin B
pumps O
. O

However O
, O
coligation O
of O
Fc B
gamma I
RIIB1 I
with O
B B
cell I
Ag I
receptors I
( O
BCR B
) O
inhibits O
BCR B
- O
mediated O
signaling O
by O
a O
mechanism O
that O
may O
involve O
recruitment O
of O
phosphatases B
SHP I
- I
1 I
, O
SHP B
- I
2 I
, O
and O
the O
SH2 B
containing I
inositol I
5 I
' I
phosphatase I
( O
SHIP B
) O
to O
the O
phosphorylated O
Fc B
gamma I
RIIB1 I
immunoreceptor I
tyrosine I
- I
based I
inhibitory I
motif I
. O

However O
, O
coligation O
of O
Fc B
gamma I
RIIB1 I
with O
B B
cell I
Ag I
receptors I
( O
BCR B
) O
inhibits O
BCR B
- O
mediated O
signaling O
by O
a O
mechanism O
that O
may O
involve O
recruitment O
of O
phosphatases B
SHP I
- I
1 I
, O
SHP B
- I
2 I
, O
and O
the O
SH2 B
containing I
inositol I
5 I
' I
phosphatase I
( O
SHIP B
) O
to O
the O
phosphorylated O
Fc B
gamma I
RIIB1 I
immunoreceptor I
tyrosine I
- I
based I
inhibitory I
motif I
. O

However O
, O
coligation O
of O
Fc B
gamma I
RIIB1 I
with O
B B
cell I
Ag I
receptors I
( O
BCR B
) O
inhibits O
BCR B
- O
mediated O
signaling O
by O
a O
mechanism O
that O
may O
involve O
recruitment O
of O
phosphatases B
SHP I
- I
1 I
, O
SHP B
- I
2 I
, O
and O
the O
SH2 B
containing I
inositol I
5 I
' I
phosphatase I
( O
SHIP B
) O
to O
the O
phosphorylated O
Fc B
gamma I
RIIB1 I
immunoreceptor I
tyrosine I
- I
based I
inhibitory I
motif I
. O

11 O
: O
5801 O
- O
5812 O
, O
1991 O
) O
present O
evidence O
that O
the O
Vps18 B
/ O
Pep3 B
protein O
colocalizes O
with O
the O
Vps11 B
/ O
Pep5 B
protein O
to O
the O
cytosolic O
face O
of O
the O
vacuolar O
membrane O
. O

11 O
: O
5801 O
- O
5812 O
, O
1991 O
) O
present O
evidence O
that O
the O
Vps18 B
/ O
Pep3 B
protein O
colocalizes O
with O
the O
Vps11 B
/ O
Pep5 B
protein O
to O
the O
cytosolic O
face O
of O
the O
vacuolar O
membrane O
. O

11 O
: O
5801 O
- O
5812 O
, O
1991 O
) O
present O
evidence O
that O
the O
Vps18 B
/ O
Pep3 B
protein O
colocalizes O
with O
the O
Vps11 B
/ O
Pep5 B
protein O
to O
the O
cytosolic O
face O
of O
the O
vacuolar O
membrane O
. O

11 O
: O
5801 O
- O
5812 O
, O
1991 O
) O
present O
evidence O
that O
the O
Vps18 B
/ O
Pep3 B
protein O
colocalizes O
with O
the O
Vps11 B
/ O
Pep5 B
protein O
to O
the O
cytosolic O
face O
of O
the O
vacuolar O
membrane O
. O

We O
have O
identified O
the O
gene O
encoding O
sigma B
E I
using O
a O
genetic O
screen O
designed O
to O
isolate O
trans O
- O
acting O
mutations O
that O
abolish O
expression O
from O
either O
htrA B
or O
rpoHP3 B
, O
two O
promoters O
recognized O
uniquely O
by O
sigma B
E I
- O
containing O
RNA B
polymerase I
. O

We O
have O
identified O
the O
gene O
encoding O
sigma B
E I
using O
a O
genetic O
screen O
designed O
to O
isolate O
trans O
- O
acting O
mutations O
that O
abolish O
expression O
from O
either O
htrA B
or O
rpoHP3 B
, O
two O
promoters O
recognized O
uniquely O
by O
sigma B
E I
- O
containing O
RNA B
polymerase I
. O

These O
patients O
developed O
severe O
diabetic O
symptoms O
including O
glucose O
intolerance O
, O
weight O
loss O
, O
impaired O
energy O
utilization O
, O
and O
nerve O
and O
brain O
disorders O
that O
were O
refractory O
to O
insulin B
. O

One O
promoter O
, O
p53P1 B
, O
is O
located O
100 O
- O
250 O
bp O
upstream O
of O
the O
218 O
- O
bp O
noncoding O
first O
exon O
; O
a O
second O
, O
stronger O
promoter O
, O
p53P2 B
, O
maps O
within O
the O
first O
intron O
. O

One O
promoter O
, O
p53P1 B
, O
is O
located O
100 O
- O
250 O
bp O
upstream O
of O
the O
218 O
- O
bp O
noncoding O
first O
exon O
; O
a O
second O
, O
stronger O
promoter O
, O
p53P2 B
, O
maps O
within O
the O
first O
intron O
. O

The O
lipopolysaccharide O
- O
binding O
protein O
is O
a O
secretory B
class I
1 I
acute I
- I
phase I
protein I
whose O
gene O
is O
transcriptionally O
activated O
by O
APRF B
/ O
STAT B
/ I
3 I
and O
other O
cytokine O
- O
inducible O
nuclear O
proteins O
. O

This O
region O
does O
not O
contain O
a O
consensus O
estrogen O
response O
element O
, O
and O
ER B
binding O
to O
this O
DNA O
sequence O
was O
not O
observed O
. O

These O
proteins O
, O
called O
variant B
surface I
glycoproteins I
( O
VSGs B
) O
, O
are O
expressed O
from O
a O
specific O
locus O
, O
the O
VSG B
gene I
expression I
site I
( I
ES I
) I
. O

The O
strangulated O
intestinal O
pathologies O
of O
horses O
are O
accompanied O
by O
a O
local O
activation O
of O
the O
neutrophils O
, O
that O
can O
be O
revealed O
by O
measuring O
the O
tissular O
enzymatic O
activity O
of O
the O
granulocytic O
enzyme O
myeloperoxidase B
( O
MPO B
) O
. O

The O
strangulated O
intestinal O
pathologies O
of O
horses O
are O
accompanied O
by O
a O
local O
activation O
of O
the O
neutrophils O
, O
that O
can O
be O
revealed O
by O
measuring O
the O
tissular O
enzymatic O
activity O
of O
the O
granulocytic O
enzyme O
myeloperoxidase B
( O
MPO B
) O
. O

The O
homeodomain B
transcription I
factor I
CDP B
/ O
cut B
interacts O
with O
the O
cell O
cycle O
regulatory O
element O
of O
histone B
H4 I
genes I
packaged O
into O
nucleosomes O
. O

The O
homeodomain B
transcription I
factor I
CDP B
/ O
cut B
interacts O
with O
the O
cell O
cycle O
regulatory O
element O
of O
histone B
H4 I
genes I
packaged O
into O
nucleosomes O
. O

They O
encode O
proteins O
whose O
core O
regions O
display O
great O
similarity O
to O
Aspergillus B
HAPB I
, O
HAPC B
and O
HAPE B
and O
to O
known O
HAP B
homologs I
from O
other O
organisms O
. O

They O
encode O
proteins O
whose O
core O
regions O
display O
great O
similarity O
to O
Aspergillus B
HAPB I
, O
HAPC B
and O
HAPE B
and O
to O
known O
HAP B
homologs I
from O
other O
organisms O
. O

Transient O
cotransfection O
analyses O
indicate O
that O
the O
cooperative O
association O
of O
NF B
- I
IL I
- I
6 I
and O
RelA B
with O
the O
IL B
- I
8 I
promoter I
results O
in O
synergistic O
transcriptional O
activation O
. O

Cotransfection O
of O
pINV O
- O
2473 O
, O
a O
construct O
containing O
2473 O
base O
pairs O
of O
hINV B
upstream I
sequence I
linked O
to O
luciferase B
, O
with O
POU B
homeodomain I
transcription I
factors I
Oct1 B
, O
Oct2 B
, O
Brn4 B
, O
SCIP B
, O
Skn1a B
or O
Skn1i B
, O
results O
in O
a O
strong O
suppression O
of O
basal O
promoter O
activity O
. O

Cotransfection O
of O
pINV O
- O
2473 O
, O
a O
construct O
containing O
2473 O
base O
pairs O
of O
hINV B
upstream I
sequence I
linked O
to O
luciferase B
, O
with O
POU B
homeodomain I
transcription I
factors I
Oct1 B
, O
Oct2 B
, O
Brn4 B
, O
SCIP B
, O
Skn1a B
or O
Skn1i B
, O
results O
in O
a O
strong O
suppression O
of O
basal O
promoter O
activity O
. O

Cotransfection O
of O
pINV O
- O
2473 O
, O
a O
construct O
containing O
2473 O
base O
pairs O
of O
hINV B
upstream I
sequence I
linked O
to O
luciferase B
, O
with O
POU B
homeodomain I
transcription I
factors I
Oct1 B
, O
Oct2 B
, O
Brn4 B
, O
SCIP B
, O
Skn1a B
or O
Skn1i B
, O
results O
in O
a O
strong O
suppression O
of O
basal O
promoter O
activity O
. O

Cotransfection O
of O
pINV O
- O
2473 O
, O
a O
construct O
containing O
2473 O
base O
pairs O
of O
hINV B
upstream I
sequence I
linked O
to O
luciferase B
, O
with O
POU B
homeodomain I
transcription I
factors I
Oct1 B
, O
Oct2 B
, O
Brn4 B
, O
SCIP B
, O
Skn1a B
or O
Skn1i B
, O
results O
in O
a O
strong O
suppression O
of O
basal O
promoter O
activity O
. O

Cotransfection O
of O
pINV O
- O
2473 O
, O
a O
construct O
containing O
2473 O
base O
pairs O
of O
hINV B
upstream I
sequence I
linked O
to O
luciferase B
, O
with O
POU B
homeodomain I
transcription I
factors I
Oct1 B
, O
Oct2 B
, O
Brn4 B
, O
SCIP B
, O
Skn1a B
or O
Skn1i B
, O
results O
in O
a O
strong O
suppression O
of O
basal O
promoter O
activity O
. O

Cotransfection O
of O
pINV O
- O
2473 O
, O
a O
construct O
containing O
2473 O
base O
pairs O
of O
hINV B
upstream I
sequence I
linked O
to O
luciferase B
, O
with O
POU B
homeodomain I
transcription I
factors I
Oct1 B
, O
Oct2 B
, O
Brn4 B
, O
SCIP B
, O
Skn1a B
or O
Skn1i B
, O
results O
in O
a O
strong O
suppression O
of O
basal O
promoter O
activity O
. O

Cotransfection O
of O
pINV O
- O
2473 O
, O
a O
construct O
containing O
2473 O
base O
pairs O
of O
hINV B
upstream I
sequence I
linked O
to O
luciferase B
, O
with O
POU B
homeodomain I
transcription I
factors I
Oct1 B
, O
Oct2 B
, O
Brn4 B
, O
SCIP B
, O
Skn1a B
or O
Skn1i B
, O
results O
in O
a O
strong O
suppression O
of O
basal O
promoter O
activity O
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

We O
have O
compared O
the O
ability O
of O
GST B
- O
Bem3 B
to O
serve O
as O
a O
GAP B
for O
Cdc42Hs B
relative O
to O
other O
members O
of O
the O
rho B
- O
GAP B
subfamily O
and O
found O
the O
following O
order O
of O
potency O
: O
human B
platelet I
Cdc42Hs I
GAP I
> O
p190 B
> O
Bem3 B
> O
break B
point I
cluster I
region I
protein I
, O
whereas O
p85 B
, O
like O
Bem2 B
, O
shows O
no O
GAP B
activity O
or O
any O
ability O
to O
bind O
to O
the O
GTP O
- O
bound O
form O
of O
Cdc42Hs B
. O

Molecular O
cloning O
of O
the O
alpha B
- I
globin I
transcription I
factor I
CP2 B
. O

The O
most O
distal O
active O
site O
in O
TIGA B
is O
created O
by O
excision O
of O
a O
66 O
- O
bp O
intron O
. O

Denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
with O
sequence O
analysis O
showed O
that O
PGCL4 B
is O
a O
major O
member O
in O
the O
female O
mammary O
gland O
, O
and O
in O
the O
submaxillary O
and O
lachrymal O
glands O
of O
both O
sexes O
, O
while O
the O
counterpart O
in O
male O
liver O
and O
the O
coagulate O
glands O
was O
found O
to O
be O
PGCL1 B
. O

Denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
with O
sequence O
analysis O
showed O
that O
PGCL4 B
is O
a O
major O
member O
in O
the O
female O
mammary O
gland O
, O
and O
in O
the O
submaxillary O
and O
lachrymal O
glands O
of O
both O
sexes O
, O
while O
the O
counterpart O
in O
male O
liver O
and O
the O
coagulate O
glands O
was O
found O
to O
be O
PGCL1 B
. O

Ligand O
binding O
of O
multi O
- O
chain O
antigen O
receptors O
and O
hematopoietin B
/ O
cytokine O
receptors O
results O
in O
rapid O
activation O
of O
protein B
tyrosine I
kinase I
( O
PTK B
) O
- O
dependent O
signalling O
molecules O
such O
as O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
. O

Ligand O
binding O
of O
multi O
- O
chain O
antigen O
receptors O
and O
hematopoietin B
/ O
cytokine O
receptors O
results O
in O
rapid O
activation O
of O
protein B
tyrosine I
kinase I
( O
PTK B
) O
- O
dependent O
signalling O
molecules O
such O
as O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
. O

Previous O
data O
suggested O
a O
subtle O
increase O
in O
serum O
P O
at O
the O
time O
of O
hCG B
injection O
without O
LH B
surge O
reduces O
the O
PR O
of O
women O
having O
oocyte O
retrievals O
for O
IVF O
; O
this O
study O
compared O
PRs O
of O
recipients O
in O
a O
shared O
oocyte O
program O
according O
to O
the O
donors O
' O
pre B
- I
hCG I
P O
level O
. O

Previous O
data O
suggested O
a O
subtle O
increase O
in O
serum O
P O
at O
the O
time O
of O
hCG B
injection O
without O
LH B
surge O
reduces O
the O
PR O
of O
women O
having O
oocyte O
retrievals O
for O
IVF O
; O
this O
study O
compared O
PRs O
of O
recipients O
in O
a O
shared O
oocyte O
program O
according O
to O
the O
donors O
' O
pre B
- I
hCG I
P O
level O
. O

The O
architecture O
of O
the O
hRap1 B
Myb B
domain I
is O
very O
close O
to O
that O
of O
each O
of O
the O
Myb B
domains I
from O
TRF1 B
, O
scRap1p B
and O
c B
- I
Myb I
. O

The O
architecture O
of O
the O
hRap1 B
Myb B
domain I
is O
very O
close O
to O
that O
of O
each O
of O
the O
Myb B
domains I
from O
TRF1 B
, O
scRap1p B
and O
c B
- I
Myb I
. O

The O
architecture O
of O
the O
hRap1 B
Myb B
domain I
is O
very O
close O
to O
that O
of O
each O
of O
the O
Myb B
domains I
from O
TRF1 B
, O
scRap1p B
and O
c B
- I
Myb I
. O

80 O
v B
- I
ets I
- O
encoded O
amino O
- O
acids O
located O
immediately O
after O
the O
v B
- I
myb I
/ O
v B
- I
ets I
junction O
are O
not O
found O
in O
P54 B
/ O
56c B
- I
ets I
, O
the O
translation O
product O
of O
the O
c B
- I
ets I
proto I
- I
oncogene I
, O
nor O
in O
a O
set O
of O
cellular O
proteins O
of O
64 O
, O
62 O
, O
and O
60 O
kDa O
related O
to O
but O
distinct O
from O
P54 B
/ O
56c B
- I
ets I
. O

80 O
v B
- I
ets I
- O
encoded O
amino O
- O
acids O
located O
immediately O
after O
the O
v B
- I
myb I
/ O
v B
- I
ets I
junction O
are O
not O
found O
in O
P54 B
/ O
56c B
- I
ets I
, O
the O
translation O
product O
of O
the O
c B
- I
ets I
proto I
- I
oncogene I
, O
nor O
in O
a O
set O
of O
cellular O
proteins O
of O
64 O
, O
62 O
, O
and O
60 O
kDa O
related O
to O
but O
distinct O
from O
P54 B
/ O
56c B
- I
ets I
. O

Latex O
products O
( O
gloves O
, O
balloons O
, O
and O
condoms O
) O
directly O
bound O
IgE B
from O
all O
four O
patients O
. O

Previous O
studies O
have O
shown O
that O
TGFbeta1 B
expression O
is O
upregulated O
in O
mouse O
keratinocytes O
infected O
with O
a O
v B
- I
rasHa I
retrovirus O
, O
although O
the O
functional O
significance O
of O
this O
has O
not O
been O
clear O
. O

Regulation O
of O
the O
human B
stress I
response I
gene I
GADD153 I
expression O
: O
role O
of O
ETS1 B
and O
FLI B
- I
1 I
gene I
products I
. O

The O
PRP4 B
protein I
of I
Saccharomyces I
cerevisiae I
is O
an O
essential O
part O
of O
the O
U4 B
/ O
U6 B
snRNP O
, O
a O
component O
of O
the O
mRNA O
splicing O
apparatus O
. O

The O
PRP4 B
protein I
of I
Saccharomyces I
cerevisiae I
is O
an O
essential O
part O
of O
the O
U4 B
/ O
U6 B
snRNP O
, O
a O
component O
of O
the O
mRNA O
splicing O
apparatus O
. O

Here O
RFX B
/ O
X2BP B
/ O
DNA O
complexes O
were O
formed O
on O
all O
class O
II O
isotypes O
regardless O
of O
the O
ability O
of O
the O
X O
box O
region O
to O
bind O
either O
factor O
individually O
. O

Here O
RFX B
/ O
X2BP B
/ O
DNA O
complexes O
were O
formed O
on O
all O
class O
II O
isotypes O
regardless O
of O
the O
ability O
of O
the O
X O
box O
region O
to O
bind O
either O
factor O
individually O
. O

The O
psi B
zeta I
gene I
has O
a O
nonsense O
mutation O
in O
exon O
1 O
but O
has O
identical O
promoter O
sequence O
and O
RNA O
processing O
sites O
to O
the O
zeta B
gene I
, O
raising O
the O
possibility O
that O
both O
psi B
zeta I
and O
zeta B
are O
transcriptionally O
active O
. O

Serum O
PRL B
concentrations O
significantly O
increased O
after O
MCP O
administration O
in O
normal O
women O
, O
hyperprolactinemic O
patients O
with O
normal O
sella O
and O
patients O
with O
microadenoma O
, O
but O
not O
in O
macroadenoma O
patients O
with O
and O
without O
suprasellar O
expansion O
( O
SSE O
) O
. O

The O
coding O
region O
of O
nifA B
was O
determined O
using O
a O
translational O
lacZ B
fusion I
and O
by O
site O
- O
directed O
mutagenesis O
to O
identify O
which O
of O
four O
in O
frame O
AUG O
codons O
was O
used O
. O

Heterodimerization B
mutant I
RXR I
failed O
to O
alter O
GFP B
- O
VDR B
and O
nlsGFP B
- O
VDR B
distribution O
or O
activity O
. O

Heterodimerization B
mutant I
RXR I
failed O
to O
alter O
GFP B
- O
VDR B
and O
nlsGFP B
- O
VDR B
distribution O
or O
activity O
. O

Heterodimerization B
mutant I
RXR I
failed O
to O
alter O
GFP B
- O
VDR B
and O
nlsGFP B
- O
VDR B
distribution O
or O
activity O
. O

Heterodimerization B
mutant I
RXR I
failed O
to O
alter O
GFP B
- O
VDR B
and O
nlsGFP B
- O
VDR B
distribution O
or O
activity O
. O

Like O
troponin B
Cs I
and O
calmodulins B
, O
PfCPK B
also O
contains O
four O
EF O
hand O
calcium O
- O
binding O
motifs O
. O

Like O
troponin B
Cs I
and O
calmodulins B
, O
PfCPK B
also O
contains O
four O
EF O
hand O
calcium O
- O
binding O
motifs O
. O

In O
F9 O
, O
which O
is O
a O
prototype O
of O
embryonal O
carcinoma O
cells O
expressing O
hst B
, O
the O
expression O
of O
hst B
gene I
is O
positively O
regulated O
by O
a O
downstream O
octamer O
motif O
that O
functions O
as O
an O
enhancer O
. O

Purified O
phosphorylated O
PhoP B
( O
PhoPP B
) O
had O
a O
half O
- O
life O
of O
approximately O
2 O
. O
5 O
h O
, O
which O
was O
reduced O
to O
about O
15 O
min O
by O
addition O
of O
the O
same O
molar O
amount O
of O
* B
PhoR I
( O
the O
cytoplasmic O
region O
of O
PhoR B
) O
. O

Purified O
phosphorylated O
PhoP B
( O
PhoPP B
) O
had O
a O
half O
- O
life O
of O
approximately O
2 O
. O
5 O
h O
, O
which O
was O
reduced O
to O
about O
15 O
min O
by O
addition O
of O
the O
same O
molar O
amount O
of O
* B
PhoR I
( O
the O
cytoplasmic O
region O
of O
PhoR B
) O
. O

Purified O
phosphorylated O
PhoP B
( O
PhoPP B
) O
had O
a O
half O
- O
life O
of O
approximately O
2 O
. O
5 O
h O
, O
which O
was O
reduced O
to O
about O
15 O
min O
by O
addition O
of O
the O
same O
molar O
amount O
of O
* B
PhoR I
( O
the O
cytoplasmic O
region O
of O
PhoR B
) O
. O

This O
transformation O
suppression O
by O
Rb B
was O
further O
shown O
to O
be O
due O
to O
transcriptional O
repression O
of O
neu B
using O
Rb B
expressing O
effector O
plasmid O
and O
neu B
promoter O
- O
chloramphenicol B
acetyltransferase I
reporter O
gene O
. O

This O
transformation O
suppression O
by O
Rb B
was O
further O
shown O
to O
be O
due O
to O
transcriptional O
repression O
of O
neu B
using O
Rb B
expressing O
effector O
plasmid O
and O
neu B
promoter O
- O
chloramphenicol B
acetyltransferase I
reporter O
gene O
. O

This O
transformation O
suppression O
by O
Rb B
was O
further O
shown O
to O
be O
due O
to O
transcriptional O
repression O
of O
neu B
using O
Rb B
expressing O
effector O
plasmid O
and O
neu B
promoter O
- O
chloramphenicol B
acetyltransferase I
reporter O
gene O
. O

This O
transformation O
suppression O
by O
Rb B
was O
further O
shown O
to O
be O
due O
to O
transcriptional O
repression O
of O
neu B
using O
Rb B
expressing O
effector O
plasmid O
and O
neu B
promoter O
- O
chloramphenicol B
acetyltransferase I
reporter O
gene O
. O

Overexpression O
of O
N O
- O
terminal O
mutations O
disturbs O
mitosis O
and O
produces O
elongated O
cells O
, O
Using O
a O
PCR O
approach O
, O
we O
isolated O
a O
putative O
homologue O
of O
Prp4 B
from O
human O
and O
mouse O
cells O
. O

The O
N O
- O
terminal O
sequence O
of O
the O
extracellular B
MEP20 I
, O
TKVAS B
, O
was O
found O
at O
aa O
194 O
- O
198 O
within O
the O
ORF O
. O

The O
Synechococcus B
gene I
rps1 I
encoding O
S1 B
is O
located O
1 O
. O
1 O
kb O
downstream O
from O
psbB B
, O
which O
encodes O
the O
photosystem B
II I
P680 I
chlorophyll I
a I
apoprotein I
. O

The O
Synechococcus B
gene I
rps1 I
encoding O
S1 B
is O
located O
1 O
. O
1 O
kb O
downstream O
from O
psbB B
, O
which O
encodes O
the O
photosystem B
II I
P680 I
chlorophyll I
a I
apoprotein I
. O

As O
in O
IncP O
alpha O
plasmids O
, O
these O
operons O
are O
transcribed O
from O
a O
bidirectional O
promoter O
region O
consisting O
of O
trfAp B
for O
the O
trfA B
operon I
and O
trbAp B
and O
trbBp B
for O
the O
trb B
operon I
. O

As O
in O
IncP O
alpha O
plasmids O
, O
these O
operons O
are O
transcribed O
from O
a O
bidirectional O
promoter O
region O
consisting O
of O
trfAp B
for O
the O
trfA B
operon I
and O
trbAp B
and O
trbBp B
for O
the O
trb B
operon I
. O

As O
in O
IncP O
alpha O
plasmids O
, O
these O
operons O
are O
transcribed O
from O
a O
bidirectional O
promoter O
region O
consisting O
of O
trfAp B
for O
the O
trfA B
operon I
and O
trbAp B
and O
trbBp B
for O
the O
trb B
operon I
. O

The O
BHV B
- I
1 I
UL24 I
, O
UL25 B
, O
UL26 B
and O
UL26 B
. I
5 I
transcripts I
all O
terminated O
at O
a O
common O
3 O
' O
- O
polyadenylation O
site O
and O
varied O
significantly O
in O
their O
relative O
abundance O
. O

The O
BHV B
- I
1 I
UL24 I
, O
UL25 B
, O
UL26 B
and O
UL26 B
. I
5 I
transcripts I
all O
terminated O
at O
a O
common O
3 O
' O
- O
polyadenylation O
site O
and O
varied O
significantly O
in O
their O
relative O
abundance O
. O

These O
results O
suggest O
that O
both O
the O
distinct O
DNA O
binding O
properties O
of O
PMLRAR B
homodimers I
and O
the O
sequestration O
of O
RXR B
by O
PMLRARs B
may O
contribute O
to O
the O
molecular O
mechanisms O
which O
underlie O
the O
pathogenesis O
of O
APL O
. O

These O
results O
suggest O
that O
both O
the O
distinct O
DNA O
binding O
properties O
of O
PMLRAR B
homodimers I
and O
the O
sequestration O
of O
RXR B
by O
PMLRARs B
may O
contribute O
to O
the O
molecular O
mechanisms O
which O
underlie O
the O
pathogenesis O
of O
APL O
. O

Low O
- O
affinity O
E2 B
- I
binding I
site I
mediates O
downmodulation O
of O
E2 B
transactivation O
of O
the O
human B
papillomavirus I
type I
8 I
late I
promoter I
. O

Untransformed O
3T3 O
cells O
carry O
abundant O
1 O
. O
9 O
kb O
Hox B
1 I
. I
3 I
RNA O
, O
whereas O
the O
methylcholanthrene O
- O
transformed O
MB66 O
and O
LTK O
- O
cells O
or O
3T3 O
cells O
transformed O
by O
the O
oncogenes O
src B
, O
fos B
or O
SV40 B
T I
antigen I
express O
only O
low O
levels O
. O

Untransformed O
3T3 O
cells O
carry O
abundant O
1 O
. O
9 O
kb O
Hox B
1 I
. I
3 I
RNA O
, O
whereas O
the O
methylcholanthrene O
- O
transformed O
MB66 O
and O
LTK O
- O
cells O
or O
3T3 O
cells O
transformed O
by O
the O
oncogenes O
src B
, O
fos B
or O
SV40 B
T I
antigen I
express O
only O
low O
levels O
. O

Ureases B
were O
purified O
from O
the O
recombinant O
cells O
and O
shown O
to O
be O
identical O
to O
control O
enzyme O
when O
analyzed O
by O
gel O
filtration O
chromatography O
and O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
; O
however O
, O
in O
every O
case O
the O
activity O
levels O
correlated O
to O
nickel O
contents O
as O
analyzed O
by O
atomic O
absorption O
analysis O
. O

Finally O
, O
synthetic O
peptides O
corresponding O
to O
the O
mutant O
proteins O
were O
assessed O
for O
the O
ability O
to O
act O
as O
substrates O
for O
PR B
. O

A O
wide O
conservation O
of O
iscSUA B
genes I
in O
nature O
and O
evidence O
that O
NifU B
and O
NifS B
participate O
in O
the O
mobilization O
of O
iron O
and O
sulfur O
for O
nitrogenase B
- O
specific O
iron O
- O
sulfur O
cluster O
formation O
suggest O
that O
the O
products O
of O
the O
iscSUA B
genes I
could O
play O
a O
general O
role O
in O
the O
formation O
or O
repair O
of O
iron O
- O
sulfur O
clusters O
. O

A O
wide O
conservation O
of O
iscSUA B
genes I
in O
nature O
and O
evidence O
that O
NifU B
and O
NifS B
participate O
in O
the O
mobilization O
of O
iron O
and O
sulfur O
for O
nitrogenase B
- O
specific O
iron O
- O
sulfur O
cluster O
formation O
suggest O
that O
the O
products O
of O
the O
iscSUA B
genes I
could O
play O
a O
general O
role O
in O
the O
formation O
or O
repair O
of O
iron O
- O
sulfur O
clusters O
. O

A O
wide O
conservation O
of O
iscSUA B
genes I
in O
nature O
and O
evidence O
that O
NifU B
and O
NifS B
participate O
in O
the O
mobilization O
of O
iron O
and O
sulfur O
for O
nitrogenase B
- O
specific O
iron O
- O
sulfur O
cluster O
formation O
suggest O
that O
the O
products O
of O
the O
iscSUA B
genes I
could O
play O
a O
general O
role O
in O
the O
formation O
or O
repair O
of O
iron O
- O
sulfur O
clusters O
. O

These O
results O
suggest O
that O
camptothecin O
resistance O
in O
CEM O
/ O
DOX O
cells O
is O
due O
to O
different O
mechanism O
( O
s O
) O
than O
topoisomerase B
- O
or O
P B
- I
glycoprotein I
- O
associated O
multidrug O
resistance O
. O

The O
pattern O
of O
expression O
of O
this O
and O
other O
Chi26 B
/ O
Chi33 B
chimeric O
promoters O
suggest O
that O
the O
E B
- I
region I
contains O
cis O
- O
acting O
sequences O
which O
activate O
transcription O
in O
aleurone O
and O
silence O
transcription O
in O
leaves O
. O

The O
pattern O
of O
expression O
of O
this O
and O
other O
Chi26 B
/ O
Chi33 B
chimeric O
promoters O
suggest O
that O
the O
E B
- I
region I
contains O
cis O
- O
acting O
sequences O
which O
activate O
transcription O
in O
aleurone O
and O
silence O
transcription O
in O
leaves O
. O

Four O
newborns O
in O
this O
group O
became O
HBsAg B
carriers O
. O

Effectively O
, O
the O
upstream O
, O
housekeeping O
- O
type O
promoter O
responds O
to O
FIXK B
and O
positively O
regulates O
the O
downstream O
, O
sigma B
54 I
- I
type I
promoter I
. O

A O
5789 B
- I
nucleotide I
- I
long I
EcoRI I
fragment I
from O
the O
genome O
of O
Thermotoga O
maritima O
, O
identified O
by O
cross O
- O
hybridization O
to O
L11 B
, O
L1 B
, O
L10 B
, O
and O
L12 B
ribosomal I
protein I
gene I
sequences I
from I
Escherichia I
coli I
, O
was O
cloned O
and O
sequenced O
. O

A O
5789 B
- I
nucleotide I
- I
long I
EcoRI I
fragment I
from O
the O
genome O
of O
Thermotoga O
maritima O
, O
identified O
by O
cross O
- O
hybridization O
to O
L11 B
, O
L1 B
, O
L10 B
, O
and O
L12 B
ribosomal I
protein I
gene I
sequences I
from I
Escherichia I
coli I
, O
was O
cloned O
and O
sequenced O
. O

A O
5789 B
- I
nucleotide I
- I
long I
EcoRI I
fragment I
from O
the O
genome O
of O
Thermotoga O
maritima O
, O
identified O
by O
cross O
- O
hybridization O
to O
L11 B
, O
L1 B
, O
L10 B
, O
and O
L12 B
ribosomal I
protein I
gene I
sequences I
from I
Escherichia I
coli I
, O
was O
cloned O
and O
sequenced O
. O

The O
use O
of O
ALAD B
activity O
and O
EP O
as O
cumulative O
lead O
exposure O
indicators O
is O
suggested O
. O

Cell O
cycle O
regulatory O
components O
have O
been O
largely O
conserved O
in O
eukaryotes O
; O
however O
, O
orthologs O
of O
neither O
CAK1 B
nor O
csk1 B
have O
been O
identified O
in O
other O
species O
to O
date O
. O

Cell O
cycle O
regulatory O
components O
have O
been O
largely O
conserved O
in O
eukaryotes O
; O
however O
, O
orthologs O
of O
neither O
CAK1 B
nor O
csk1 B
have O
been O
identified O
in O
other O
species O
to O
date O
. O

In O
this O
study O
, O
we O
cloned O
the O
full O
- O
length O
cDNA O
of O
mouse O
PAX4 B
by O
RACE O
( O
rapid O
amplification O
of O
cDNA O
ends O
) O
using O
RNA O
from O
MIN6 O
cells O
, O
a O
mouse O
insulinoma O
cell O
line O
. O

The O
results O
suggest O
that O
proenzyme O
processing O
is O
not O
essential O
for O
secretion O
of O
PC2 B
, O
but O
peptides O
containing O
mutations O
that O
affect O
the O
ability O
of O
the O
propeptide O
( O
and O
cleavage O
sites O
) O
to O
fold O
within O
the O
catalytic O
pocket O
are O
not O
transferred O
beyond O
the O
early O
stages O
of O
the O
secretory O
pathway O
. O

Finally O
, O
in O
samples O
obtained O
from O
two O
patients O
with O
drug O
refractory O
ALL O
, O
BAC O
- O
derived O
probes O
applied O
to O
archived O
marrow O
cells O
demonstrated O
that O
a O
breakpoint O
occurred O
between O
MDR1 B
and O
sequences O
500 O
- O
1000 O
KB O
telomeric O
to O
MDR1 B
, O
consistent O
with O
a O
random O
chromosomal O
rearrangement O
. O

Finally O
, O
in O
samples O
obtained O
from O
two O
patients O
with O
drug O
refractory O
ALL O
, O
BAC O
- O
derived O
probes O
applied O
to O
archived O
marrow O
cells O
demonstrated O
that O
a O
breakpoint O
occurred O
between O
MDR1 B
and O
sequences O
500 O
- O
1000 O
KB O
telomeric O
to O
MDR1 B
, O
consistent O
with O
a O
random O
chromosomal O
rearrangement O
. O

The O
median O
levels O
of O
t B
- I
PA I
Ag I
and O
PAI B
in O
plasma O
were O
respectively O
10 O
. O
7 O
ng O
/ O
ml O
( O
interquartile O
range O
8 O
. O
6 O
ng O
/ O
ml O
) O
and O
15 O
. O
7 O
IU O
/ O
ml O
( O
interquartile O
range O
12 O
. O
2 O
IU O
/ O
ml O
) O
. O

In O
the O
remaining O
91 O
patients O
( O
group O
2 O
) O
, O
Pseudomonas O
( O
18 O
) O
, O
coagulase B
- O
negative O
Staphylococci O
( O
15 O
) O
, O
Staphylococcus O
epidermidis O
( O
23 O
) O
, O
Staphylococcus O
aureus O
( O
16 O
) O
, O
Corynebacterium O
species O
( O
12 O
) O
, O
and O
others O
( O
seven O
) O
were O
isolated O
. O

The O
leucine O
zipper O
region O
of O
ATF B
proteins I
is O
also O
similar O
to O
that O
of O
the O
AP B
- I
1 I
/ O
c B
- I
jun I
family O
of O
transcription O
factors O
, O
whose O
DNA O
- O
binding O
site O
differs O
from O
the O
ATF B
- O
binding O
site O
at O
a O
single O
position O
. O

Were O
this O
hypothesis O
correct O
, O
the O
requirement O
for O
elF4A B
should O
correlate O
with O
the O
degree O
of O
mRNA O
secondary O
structure O
. O

PKK B
exists O
in O
three O
discernible O
forms O
at O
steady O
state O
: O
an O
underphosphorylated O
form O
of O
100 O
kDa O
; O
a O
soluble O
, O
cytosolic O
, O
phosphorylated O
form O
of O
110 O
kDa O
; O
and O
a O
phosphorylated O
, O
detergent O
- O
insoluble O
form O
of O
112 O
kDa O
. O

The O
P B
- I
ITIM I
- I
compelled I
multi I
- I
phosphoprotein I
complex I
binds O
to O
and O
activates O
SHP B
- I
2 I
, O
which O
in O
turn O
dephosphorylates O
SHIP B
and O
Shc B
and O
probably O
other O
substrates O
. O

The O
P B
- I
ITIM I
- I
compelled I
multi I
- I
phosphoprotein I
complex I
binds O
to O
and O
activates O
SHP B
- I
2 I
, O
which O
in O
turn O
dephosphorylates O
SHIP B
and O
Shc B
and O
probably O
other O
substrates O
. O

We O
now O
report O
that O
both O
HSCR B
mutations O
impair O
the O
fixation O
of O
Shc B
to O
RET B
and O
consequently O
prevent O
its O
phosphorylation O
. O

We O
now O
report O
that O
both O
HSCR B
mutations O
impair O
the O
fixation O
of O
Shc B
to O
RET B
and O
consequently O
prevent O
its O
phosphorylation O
. O

We O
now O
report O
that O
both O
HSCR B
mutations O
impair O
the O
fixation O
of O
Shc B
to O
RET B
and O
consequently O
prevent O
its O
phosphorylation O
. O

We O
propose O
that O
U73 B
is O
involved O
in O
methylation O
of O
the O
G1739 O
residue O
of O
the O
human B
28S I
rRNA I
. O

Two O
SH2 B
domains I
of O
p120 B
Ras B
GTPase B
- I
activating I
protein I
bind O
synergistically O
to O
tyrosine O
phosphorylated O
p190 B
Rho O
GTPase B
- I
activating I
protein I
. O

Two O
SH2 B
domains I
of O
p120 B
Ras B
GTPase B
- I
activating I
protein I
bind O
synergistically O
to O
tyrosine O
phosphorylated O
p190 B
Rho O
GTPase B
- I
activating I
protein I
. O

Two O
SH2 B
domains I
of O
p120 B
Ras B
GTPase B
- I
activating I
protein I
bind O
synergistically O
to O
tyrosine O
phosphorylated O
p190 B
Rho O
GTPase B
- I
activating I
protein I
. O

p120 B
GTPase B
- I
activating I
protein I
( O
GAP B
) O
is O
a O
negative O
regulator O
of O
Ras B
that O
functions O
at O
a O
key O
relay O
point O
in O
signal O
transduction O
pathways O
that O
control O
cell O
proliferation O
. O

p120 B
GTPase B
- I
activating I
protein I
( O
GAP B
) O
is O
a O
negative O
regulator O
of O
Ras B
that O
functions O
at O
a O
key O
relay O
point O
in O
signal O
transduction O
pathways O
that O
control O
cell O
proliferation O
. O

p120 B
GTPase B
- I
activating I
protein I
( O
GAP B
) O
is O
a O
negative O
regulator O
of O
Ras B
that O
functions O
at O
a O
key O
relay O
point O
in O
signal O
transduction O
pathways O
that O
control O
cell O
proliferation O
. O

A O
homologue O
of O
the O
MAP B
/ O
ERK B
family O
of O
protein O
kinase O
genes O
is O
expressed O
in O
vegetative O
and O
in O
female O
reproductive O
organs O
of O
Petunia O
hybrida O
. O

A O
homologue O
of O
the O
MAP B
/ O
ERK B
family O
of O
protein O
kinase O
genes O
is O
expressed O
in O
vegetative O
and O
in O
female O
reproductive O
organs O
of O
Petunia O
hybrida O
. O

It O
encodes O
a O
sequence O
- O
specific O
transcription O
factor O
that O
controls O
, O
in O
concert O
with O
other O
gene O
products O
, O
differentiative O
pathways O
of O
tissues O
in O
which O
Scr B
is O
expressed O
. O

ALT B
( O
alanine B
aminotransferase I
) O
and O
Hb B
( O
hemoglobin B
) O
appeared O
to O
be O
predictive O
for O
efficacy O
. O

ALT B
( O
alanine B
aminotransferase I
) O
and O
Hb B
( O
hemoglobin B
) O
appeared O
to O
be O
predictive O
for O
efficacy O
. O

ALT B
( O
alanine B
aminotransferase I
) O
and O
Hb B
( O
hemoglobin B
) O
appeared O
to O
be O
predictive O
for O
efficacy O
. O

Escherichia O
coli O
cells O
expressing O
a O
mutant B
glyV I
( O
glycine B
tRNA I
) O
gene O
have O
a O
UVM O
- O
constitutive O
phenotype O
: O
implications O
for O
mechanisms O
underlying O
the O
mutA B
or O
mutC B
mutator I
effect O
. O

This O
result O
suggests O
that O
the O
target O
protein O
specificity O
of O
E2s B
can O
be O
altered O
by O
the O
addition O
of O
appropriate O
C O
- O
terminal O
extensions O
, O
thus O
providing O
a O
way O
to O
modify O
the O
selectivity O
of O
the O
ubiquitin B
system O
. O

This O
result O
suggests O
that O
the O
target O
protein O
specificity O
of O
E2s B
can O
be O
altered O
by O
the O
addition O
of O
appropriate O
C O
- O
terminal O
extensions O
, O
thus O
providing O
a O
way O
to O
modify O
the O
selectivity O
of O
the O
ubiquitin B
system O
. O

The O
atopic O
disposition O
, O
indicated O
by O
positive O
skin O
reactions O
and O
IgE B
antibody O
titers O
etc O
. O
, O
and O
the O
bronchial O
reactivity O
to O
inhaled O
acetylcholine O
were O
examined O
on O
the O
following O
three O
groups O
: O
( O
1 O
) O
20 O
young O
adults O
with O
a O
history O
of O
childhood O
asthma O
who O
have O
been O
symptom O
- O
free O
for O
more O
than O
4 O
yr O
; O
( O
2 O
) O
20 O
current O
asthmatics O
, O
and O
( O
3 O
) O
20 O
healthy O
young O
adults O
. O

We O
conclude O
that O
these O
cDNAs O
belong O
to O
a O
novel O
GST B
class O
hereby O
designated O
Kappa O
, O
with O
the O
rat B
GST I
subunit I
13 I
gene I
designated O
rGSTK1 B
and O
the O
human O
gene O
being O
called O
hGSTK1 B
. O

We O
conclude O
that O
these O
cDNAs O
belong O
to O
a O
novel O
GST B
class O
hereby O
designated O
Kappa O
, O
with O
the O
rat B
GST I
subunit I
13 I
gene I
designated O
rGSTK1 B
and O
the O
human O
gene O
being O
called O
hGSTK1 B
. O

We O
conclude O
that O
these O
cDNAs O
belong O
to O
a O
novel O
GST B
class O
hereby O
designated O
Kappa O
, O
with O
the O
rat B
GST I
subunit I
13 I
gene I
designated O
rGSTK1 B
and O
the O
human O
gene O
being O
called O
hGSTK1 B
. O

Previous O
studies O
using O
partial O
sequences O
have O
suggested O
the O
potential O
of O
26S B
or O
large B
- I
subunit I
( O
LSU B
) O
rDNA O
for O
phylogeny O
retrieval O
at O
taxonomic O
levels O
comparable O
to O
those O
investigated O
with O
18S B
rDNA I
. O

Previous O
studies O
using O
partial O
sequences O
have O
suggested O
the O
potential O
of O
26S B
or O
large B
- I
subunit I
( O
LSU B
) O
rDNA O
for O
phylogeny O
retrieval O
at O
taxonomic O
levels O
comparable O
to O
those O
investigated O
with O
18S B
rDNA I
. O

The O
sensitivity O
of O
99mTc O
- O
IgG B
scintigraphy O
ranged O
between O
71 O
% O
and O
100 O
% O
. O

Similarly O
, O
an O
increase O
in O
CAT B
expression O
from O
the O
same O
construct O
( O
pBLCAT O
- O
ENDOA B
) O
was O
also O
observed O
in O
7AQS2 O
. O
1 O
cells O
. O

Similarly O
, O
an O
increase O
in O
CAT B
expression O
from O
the O
same O
construct O
( O
pBLCAT O
- O
ENDOA B
) O
was O
also O
observed O
in O
7AQS2 O
. O
1 O
cells O
. O

The O
contractile O
effects O
of O
oxytocin B
, O
prostaglandin O
F2 O
alpha O
and O
their O
combined O
use O
on O
human O
pregnant O
myometrium O
were O
studied O
in O
vitro O
. O

These O
mutations O
prevent O
FKBP12 B
- O
rapamycin O
binding O
to O
TOR2 B
, O
as O
assayed O
with O
the O
two O
- O
hybrid O
system O
. O

These O
mutations O
prevent O
FKBP12 B
- O
rapamycin O
binding O
to O
TOR2 B
, O
as O
assayed O
with O
the O
two O
- O
hybrid O
system O
. O

High O
- O
level O
expression O
of O
sccypB B
as O
well O
as O
of O
sccypA B
cloned O
into O
the O
expression O
vector O
pIJ702 O
did O
not O
produce O
detectable O
changes O
in O
growth O
and O
morphology O
of O
S O
. O
chrysomallus O
and O
S O
. O
lividans O
. O

High O
- O
level O
expression O
of O
sccypB B
as O
well O
as O
of O
sccypA B
cloned O
into O
the O
expression O
vector O
pIJ702 O
did O
not O
produce O
detectable O
changes O
in O
growth O
and O
morphology O
of O
S O
. O
chrysomallus O
and O
S O
. O
lividans O
. O

Fas B
( O
APO B
- I
1 I
/ O
CD95 B
) O
, O
which O
is O
a O
member O
of O
the O
tumor B
necrosis I
factor I
receptor I
superfamily I
, O
is O
a O
cell O
surface O
receptor O
that O
induces O
apoptosis O
. O

Fas B
( O
APO B
- I
1 I
/ O
CD95 B
) O
, O
which O
is O
a O
member O
of O
the O
tumor B
necrosis I
factor I
receptor I
superfamily I
, O
is O
a O
cell O
surface O
receptor O
that O
induces O
apoptosis O
. O

Sequencing O
of O
this O
fragment O
showed O
that O
the O
MRP13 B
coding O
region O
specifies O
a O
324 O
- O
amino O
- O
acid O
basic O
protein O
with O
a O
calculated O
Mr O
of O
37 O
, O
366 O
. O

Retroviral O
vector O
producer O
cell O
populations O
and O
cell O
clones O
were O
established O
for O
each O
chLTR B
vector O
, O
and O
all O
were O
capable O
of O
yielding O
high O
vector O
titers O
( O
> O
10 O
( O
5 O
) O
G418R B
cfu O
/ O
ml O
on O
NIH O
- O
3T3 O
) O
. O

Retroviral O
vector O
producer O
cell O
populations O
and O
cell O
clones O
were O
established O
for O
each O
chLTR B
vector O
, O
and O
all O
were O
capable O
of O
yielding O
high O
vector O
titers O
( O
> O
10 O
( O
5 O
) O
G418R B
cfu O
/ O
ml O
on O
NIH O
- O
3T3 O
) O
. O

Increasing O
insulin B
sensitivity O
in O
type O
I O
diabetic O
patients O
should O
alert O
clinicians O
to O
the O
possibility O
of O
glucocorticoid O
deficiency O
. O

However O
, O
differential O
utilization O
of O
these O
determinants O
mediate O
RAR B
- O
RXR B
heterodimer O
binding O
to O
DR O
- O
2 O
and O
DR O
- O
5 O
RAREs O
. O

However O
, O
differential O
utilization O
of O
these O
determinants O
mediate O
RAR B
- O
RXR B
heterodimer O
binding O
to O
DR O
- O
2 O
and O
DR O
- O
5 O
RAREs O
. O

Several O
of O
the O
drugs O
used O
in O
the O
management O
of O
MAC O
have O
been O
associated O
with O
significant O
drug O
interactions O
involving O
the O
cytochrome B
P450 I
( O
CYP B
) O
enzyme O
system O
. O

The O
TaqI B
and O
HaeIII B
RFLPs O
will O
provide O
tools O
for O
the O
genetic O
analysis O
of O
CR2 B
. O

The O
TaqI B
and O
HaeIII B
RFLPs O
will O
provide O
tools O
for O
the O
genetic O
analysis O
of O
CR2 B
. O

The O
TaqI B
and O
HaeIII B
RFLPs O
will O
provide O
tools O
for O
the O
genetic O
analysis O
of O
CR2 B
. O

In O
addition O
, O
because O
SB203580 O
had O
no O
effect O
of O
TNF B
- O
or O
ceramide O
- O
induced O
apoptosis O
, O
our O
results O
strongly O
argue O
against O
a O
role O
for O
p38 B
MAPK I
in O
the O
induction O
of O
TNF B
- O
- O
or O
ceramide O
- O
induced O
apoptosis O
. O

In O
addition O
, O
because O
SB203580 O
had O
no O
effect O
of O
TNF B
- O
or O
ceramide O
- O
induced O
apoptosis O
, O
our O
results O
strongly O
argue O
against O
a O
role O
for O
p38 B
MAPK I
in O
the O
induction O
of O
TNF B
- O
- O
or O
ceramide O
- O
induced O
apoptosis O
. O

Ptx1 B
belongs O
to O
an O
expanding O
family O
of O
bicoid B
- I
related I
vertebrate O
homeobox O
genes O
. O

Sequential O
immunoprecipitation O
showed O
all O
detectable O
p53 B
to O
be O
of O
the O
PAb246 B
+ I
class O
in O
each O
LPV O
- O
transformed O
cell O
line O
, O
suggesting O
that O
the O
stable O
p53 B
was O
indeed O
wild O
type O
. O

Sequential O
immunoprecipitation O
showed O
all O
detectable O
p53 B
to O
be O
of O
the O
PAb246 B
+ I
class O
in O
each O
LPV O
- O
transformed O
cell O
line O
, O
suggesting O
that O
the O
stable O
p53 B
was O
indeed O
wild O
type O
. O

These O
results O
suggest O
that O
E6010 B
may O
be O
of O
clinical O
value O
in O
the O
treatment O
of O
coronary O
occlusion O
. O

To O
better O
understand O
the O
relationship O
between O
expression O
of O
an O
oncogene O
and O
genetic O
instability O
, O
we O
have O
studied O
a O
cell O
line O
expressing O
an O
activated B
human I
Ha I
- I
ras I
under O
the O
control O
of O
bacterial B
lactose I
operon I
regulatory I
elements I
for O
changes O
in O
methotrexate O
resistance O
and O
dihydrofolate B
reductase I
( O
dhfr B
) O
gene O
amplification O
following O
mutant B
Ha I
- I
ras I
induction O
. O

These O
data O
show O
that O
both O
Sp1 B
and O
Sp3 B
transcription I
factors I
upregulate O
HGF B
promoter I
activity O
by O
binding O
to O
the O
Sp1 B
binding I
site I
at O
position O
- O
318 O
to O
- O
303 O
bp O
in O
the O
HGF B
gene I
promoter I
. O

We O
conclude O
, O
therefore O
, O
that O
in O
the O
absence O
of O
E1A B
, O
E4orf4 B
is O
sufficient O
by O
itself O
to O
trigger O
a O
p53 B
- O
independent O
apoptosis O
pathway O
that O
may O
operate O
independently O
of O
the O
known O
zVAD O
- O
inhibitable O
caspases B
, O
and O
that O
may O
involve O
an O
as O
yet O
uncharacterized O
mechanism O
. O

We O
conclude O
, O
therefore O
, O
that O
in O
the O
absence O
of O
E1A B
, O
E4orf4 B
is O
sufficient O
by O
itself O
to O
trigger O
a O
p53 B
- O
independent O
apoptosis O
pathway O
that O
may O
operate O
independently O
of O
the O
known O
zVAD O
- O
inhibitable O
caspases B
, O
and O
that O
may O
involve O
an O
as O
yet O
uncharacterized O
mechanism O
. O

We O
conclude O
, O
therefore O
, O
that O
in O
the O
absence O
of O
E1A B
, O
E4orf4 B
is O
sufficient O
by O
itself O
to O
trigger O
a O
p53 B
- O
independent O
apoptosis O
pathway O
that O
may O
operate O
independently O
of O
the O
known O
zVAD O
- O
inhibitable O
caspases B
, O
and O
that O
may O
involve O
an O
as O
yet O
uncharacterized O
mechanism O
. O

We O
conclude O
, O
therefore O
, O
that O
in O
the O
absence O
of O
E1A B
, O
E4orf4 B
is O
sufficient O
by O
itself O
to O
trigger O
a O
p53 B
- O
independent O
apoptosis O
pathway O
that O
may O
operate O
independently O
of O
the O
known O
zVAD O
- O
inhibitable O
caspases B
, O
and O
that O
may O
involve O
an O
as O
yet O
uncharacterized O
mechanism O
. O

The O
nucleotide O
sequence O
of O
the O
estrogen B
receptor I
gene I
of I
Oreochromis I
aureus I
( O
OaER B
) O
indicates O
that O
the O
hormone O
- O
binding O
E O
domain O
is O
composed O
of O
4 O
exons O
interspersed O
by O
short O
introns O
of O
only O
0 O
. O
18 O
- O
1 O
. O
3 O
kb O
each O
. O

The O
expression O
of O
Scmh1 B
and O
rae28 B
/ O
mph1 B
is O
well O
correlated O
in O
most O
tissues O
of O
embryos O
. O

The O
expression O
of O
Scmh1 B
and O
rae28 B
/ O
mph1 B
is O
well O
correlated O
in O
most O
tissues O
of O
embryos O
. O

The O
expression O
of O
Scmh1 B
and O
rae28 B
/ O
mph1 B
is O
well O
correlated O
in O
most O
tissues O
of O
embryos O
. O

The O
nucleoporin B
98 I
gene I
( O
NUP98 B
) O
, O
which O
is O
rearranged O
in O
several O
acute O
myeloid O
leukemia O
translocations O
, O
is O
located O
within O
this O
region O
. O

A O
new O
direct O
hemagglutination O
test O
( O
HI O
- O
GONAVIS O
) O
for O
urinary O
LH B
was O
compared O
with O
the O
serum O
radioimmuno O
- O
assay O
of O
LH B
. O

A O
new O
direct O
hemagglutination O
test O
( O
HI O
- O
GONAVIS O
) O
for O
urinary O
LH B
was O
compared O
with O
the O
serum O
radioimmuno O
- O
assay O
of O
LH B
. O

CERIP B
interaction O
. O

Dmyd B
clone O
encodes O
a O
polypeptide O
of O
332 O
amino O
acids O
with O
82 O
% O
identity O
to O
MyoD B
in O
the O
41 O
amino O
acids O
of O
the O
putative O
helix O
- O
loop O
- O
helix O
region O
and O
100 O
% O
identity O
in O
the O
13 O
amino O
acids O
of O
the O
basic O
domain O
proposed O
to O
contain O
the O
essential O
recognition O
code O
for O
muscle O
- O
specific O
gene O
activation O
. O

Dmyd B
clone O
encodes O
a O
polypeptide O
of O
332 O
amino O
acids O
with O
82 O
% O
identity O
to O
MyoD B
in O
the O
41 O
amino O
acids O
of O
the O
putative O
helix O
- O
loop O
- O
helix O
region O
and O
100 O
% O
identity O
in O
the O
13 O
amino O
acids O
of O
the O
basic O
domain O
proposed O
to O
contain O
the O
essential O
recognition O
code O
for O
muscle O
- O
specific O
gene O
activation O
. O

Identification O
of O
an O
osteocalcin B
gene I
promoter I
sequence I
that O
binds O
AP1 B
. O

Mutations O
abolishing O
MalK B
function O
not O
only O
result O
in O
inability O
to O
transport O
maltose O
but O
also O
cause O
constitutive O
expression O
of O
the O
maltose B
regulon I
. O

Drosophila B
melanogaster I
casein I
kinase I
II I
( O
DmCKII B
) O
is O
composed O
of O
catalytic O
( O
alpha O
) O
and O
regulatory O
( O
beta O
) O
subunits O
associated O
as O
an O
alpha2beta2 O
heterotetramer O
. O

Three O
distinct O
human B
HDACs I
are O
homologous O
to O
RPD3 B
, O
a O
yeast O
transcriptional O
regulator O
. O

The O
pra2 B
gene I
encodes O
a O
pea B
( I
Pisum I
sativum I
) I
small I
GTPase I
belonging O
to O
the O
YPT B
/ O
rab B
family O
, O
and O
its O
expression O
is O
down O
- O
regulated O
by O
light O
, O
mediated O
by O
phytochrome B
. O

The O
pra2 B
gene I
encodes O
a O
pea B
( I
Pisum I
sativum I
) I
small I
GTPase I
belonging O
to O
the O
YPT B
/ O
rab B
family O
, O
and O
its O
expression O
is O
down O
- O
regulated O
by O
light O
, O
mediated O
by O
phytochrome B
. O

The O
pra2 B
gene I
encodes O
a O
pea B
( I
Pisum I
sativum I
) I
small I
GTPase I
belonging O
to O
the O
YPT B
/ O
rab B
family O
, O
and O
its O
expression O
is O
down O
- O
regulated O
by O
light O
, O
mediated O
by O
phytochrome B
. O

To O
explore O
further O
the O
role O
of O
the O
carboxyl O
- O
terminal O
domain O
in O
determining O
the O
cell O
cycle O
function O
of O
CDC34 B
, O
we O
constructed O
and O
characterized O
genes O
encoding O
chimeric B
E2s I
incorporating O
sequences O
from O
CDC34 B
and O
the O
related O
but O
functionally O
distinct O
E2 B
RAD6 B
( O
UBC2 B
) O
. O

To O
explore O
further O
the O
role O
of O
the O
carboxyl O
- O
terminal O
domain O
in O
determining O
the O
cell O
cycle O
function O
of O
CDC34 B
, O
we O
constructed O
and O
characterized O
genes O
encoding O
chimeric B
E2s I
incorporating O
sequences O
from O
CDC34 B
and O
the O
related O
but O
functionally O
distinct O
E2 B
RAD6 B
( O
UBC2 B
) O
. O

To O
explore O
further O
the O
role O
of O
the O
carboxyl O
- O
terminal O
domain O
in O
determining O
the O
cell O
cycle O
function O
of O
CDC34 B
, O
we O
constructed O
and O
characterized O
genes O
encoding O
chimeric B
E2s I
incorporating O
sequences O
from O
CDC34 B
and O
the O
related O
but O
functionally O
distinct O
E2 B
RAD6 B
( O
UBC2 B
) O
. O

To O
explore O
further O
the O
role O
of O
the O
carboxyl O
- O
terminal O
domain O
in O
determining O
the O
cell O
cycle O
function O
of O
CDC34 B
, O
we O
constructed O
and O
characterized O
genes O
encoding O
chimeric B
E2s I
incorporating O
sequences O
from O
CDC34 B
and O
the O
related O
but O
functionally O
distinct O
E2 B
RAD6 B
( O
UBC2 B
) O
. O

To O
explore O
further O
the O
role O
of O
the O
carboxyl O
- O
terminal O
domain O
in O
determining O
the O
cell O
cycle O
function O
of O
CDC34 B
, O
we O
constructed O
and O
characterized O
genes O
encoding O
chimeric B
E2s I
incorporating O
sequences O
from O
CDC34 B
and O
the O
related O
but O
functionally O
distinct O
E2 B
RAD6 B
( O
UBC2 B
) O
. O

MAPKK B
kinase I
/ O
MEKK B
phosphorylates O
and O
activates O
its O
downstream O
protein O
kinase O
, O
MAPK B
kinase I
/ O
MEK B
, O
which O
in O
turn O
activates O
MAPK B
. O

MAPKK B
kinase I
/ O
MEKK B
phosphorylates O
and O
activates O
its O
downstream O
protein O
kinase O
, O
MAPK B
kinase I
/ O
MEK B
, O
which O
in O
turn O
activates O
MAPK B
. O

MAPKK B
kinase I
/ O
MEKK B
phosphorylates O
and O
activates O
its O
downstream O
protein O
kinase O
, O
MAPK B
kinase I
/ O
MEK B
, O
which O
in O
turn O
activates O
MAPK B
. O

However O
, O
ADAR1 B
and O
the O
related O
deaminase B
ADAR2 I
showed O
significant O
expression O
in O
all O
regions O
of O
the O
brain O
examined O
, O
including O
cortex O
, O
hippocampus O
, O
olfactory O
bulb O
, O
and O
striatum O
, O
where O
the O
5 B
- I
HT2CR I
pre I
- I
mRNA I
was O
extensively O
edited O
. O

In O
contrast O
, O
corticotropin B
releasing I
factor I
( O
CRF B
) O
, O
injected O
centrally O
produces O
a O
suppression O
of O
punished O
and O
non O
- O
punished O
responding O
in O
the O
conflict O
test O
consistent O
with O
its O
hypothesized O
role O
in O
mediating O
behavioral O
responses O
to O
stress O
. O

Temporal O
recruitment O
of O
the O
mSin3A B
- O
histone B
deacetylase I
corepressor O
complex O
to O
the O
ETS B
domain I
transcription I
factor I
Elk B
- I
1 I
. O

In O
addition O
, O
FOP B
- O
FGFR1 B
- O
expressing O
cells O
show O
constitutive O
phosphorylation O
of O
the O
positive O
regulator O
of O
translation O
p70S6 B
kinase I
; O
this O
phosphorylation O
is O
inhibited O
by O
PI3 B
- I
kinase I
and O
mTOR B
( O
mammalian B
target I
of I
rapamycin I
) O
inhibitors O
. O

In O
addition O
, O
FOP B
- O
FGFR1 B
- O
expressing O
cells O
show O
constitutive O
phosphorylation O
of O
the O
positive O
regulator O
of O
translation O
p70S6 B
kinase I
; O
this O
phosphorylation O
is O
inhibited O
by O
PI3 B
- I
kinase I
and O
mTOR B
( O
mammalian B
target I
of I
rapamycin I
) O
inhibitors O
. O

In O
addition O
, O
FOP B
- O
FGFR1 B
- O
expressing O
cells O
show O
constitutive O
phosphorylation O
of O
the O
positive O
regulator O
of O
translation O
p70S6 B
kinase I
; O
this O
phosphorylation O
is O
inhibited O
by O
PI3 B
- I
kinase I
and O
mTOR B
( O
mammalian B
target I
of I
rapamycin I
) O
inhibitors O
. O

The O
newly O
identified O
repressor O
element O
is O
a O
rare O
example O
of O
a O
naturally O
occurring O
perfect O
palindromic O
binding O
motif O
for O
the O
NF B
- I
kappa I
B I
/ O
Rel B
family O
of O
transcription O
factors O
. O

Tryptophan O
induction O
prevents O
Rho B
- O
dependent O
transcription O
termination O
in O
the O
leader O
region O
of O
the O
operon O
. O

The O
majority O
of O
putative O
TSC2 B
mutations I
were O
found O
in O
sporadic O
rather O
than O
TSC2 B
- O
linked O
families O
. O

Basal O
JNK B
MAPK I
kinase I
activity O
was O
also O
specifically O
induced O
by O
deltaEGFR B
, O
which O
correlated O
with O
increased O
phosphorylation O
of O
a O
54 B
- I
kDa I
JNK2 I
protein I
observed O
in O
deltaEGFR B
- O
containing O
cells O
. O

Basal O
JNK B
MAPK I
kinase I
activity O
was O
also O
specifically O
induced O
by O
deltaEGFR B
, O
which O
correlated O
with O
increased O
phosphorylation O
of O
a O
54 B
- I
kDa I
JNK2 I
protein I
observed O
in O
deltaEGFR B
- O
containing O
cells O
. O

Glucose O
consumption O
of O
the O
human O
brain O
under O
the O
influence O
of O
intravenous O
infusions O
of O
glucose O
, O
glucagon B
and O
glucose O
- O
insulin B

These O
cDNAs O
were O
found O
to O
be O
derived O
from O
the O
3 O
" O
- O
untranslated O
region O
( O
3 O
" O
- O
UTR O
) O
of O
the O
methyl B
- I
CpG I
- I
binding I
protein I
2 I
gene I
( O
MeCP2 B
) O
. O

These O
observations O
suggest O
that O
the O
AF O
- O
1 O
region O
of O
PPARalpha B
is O
partially O
silenced O
by O
corepressor O
proteins O
, O
which O
might O
interact O
in O
a O
phosphorylation O
- O
dependent O
manner O
. O

Nucleotide O
sequence O
of O
the O
gag B
gene I
and O
gag B
- O
pol B
junction O
of O
feline O
leukemia O
virus O
. O

Nucleotide O
sequence O
of O
the O
gag B
gene I
and O
gag B
- O
pol B
junction O
of O
feline O
leukemia O
virus O
. O

On O
the O
basis O
of O
the O
physical O
interactions O
between O
Sxl B
and O
Snf B
, O
we O
present O
a O
model O
for O
Sxl B
splicing O
regulation O
. O

On O
the O
basis O
of O
the O
physical O
interactions O
between O
Sxl B
and O
Snf B
, O
we O
present O
a O
model O
for O
Sxl B
splicing O
regulation O
. O

On O
the O
basis O
of O
the O
physical O
interactions O
between O
Sxl B
and O
Snf B
, O
we O
present O
a O
model O
for O
Sxl B
splicing O
regulation O
. O

We O
cloned O
the O
BamHI B
- I
F I
fragment I
from O
the O
left O
end O
of O
Ad4 O
in O
pUC13 O
- O
1 O
between O
the O
SalI B
and O
BamHI B
sites I
in O
order O
to O
carry O
out O
the O
structural O
analysis O
of O
the O
E1A B
region I
of I
Ad4 I
. O

In O
both O
RAW O
cells O
and O
the O
microglia O
cell O
line O
EOC20 O
, O
two O
IFN B
- I
gamma I
- O
activated O
transcription O
factors O
, O
STAT B
- I
1alpha I
and O
IRF B
- I
1 I
, O
bind O
the O
GAS B
and O
IRF B
elements I
, O
respectively O
. O

The O
DF3 B
/ O
MUC1 B
gene O
encodes O
a O
high B
molecular I
weight I
mucin I
- I
like I
glycoprotein I
which O
is O
overexpressed O
at O
the O
transcriptional O
level O
in O
the O
majority O
of O
human O
breast O
cancers O
. O

The O
DF3 B
/ O
MUC1 B
gene O
encodes O
a O
high B
molecular I
weight I
mucin I
- I
like I
glycoprotein I
which O
is O
overexpressed O
at O
the O
transcriptional O
level O
in O
the O
majority O
of O
human O
breast O
cancers O
. O

These O
results O
indicate O
that O
patients O
with O
SS O
and O
evidence O
of O
exercise O
- O
induced O
ST O
- O
segment O
depression O
may O
have O
decreased O
myocardial O
oxygen O
supply O
due O
to O
low O
hemoglobin B
levels O
and O
increased O
myocardial O
oxygen O
demand O
( O
elevated O
double O
products O
) O
when O
compared O
to O
subjects O
with O
SS O
who O
do O
not O
have O
exercise O
- O
induced O
ST O
- O
segment O
depression O
. O

Although O
hSSTR5 B
displays O
approximately O
75 O
% O
sequence O
identity O
with O
rat B
SSTR5 I
, O
the O
two O
receptors O
display O
significantly O
different O
pharmacological O
profiles O
, O
especially O
with O
respect O
to O
their O
binding O
affinities O
for O
the O
SST B
analogue O
SMS O
201 O
- O
995 O
. O

Although O
hSSTR5 B
displays O
approximately O
75 O
% O
sequence O
identity O
with O
rat B
SSTR5 I
, O
the O
two O
receptors O
display O
significantly O
different O
pharmacological O
profiles O
, O
especially O
with O
respect O
to O
their O
binding O
affinities O
for O
the O
SST B
analogue O
SMS O
201 O
- O
995 O
. O

Using O
this O
oligonucleotide O
as O
a O
probe O
, O
an O
8 O
- O
kilobase O
HindIII B
fragment O
of O
genomic O
DNA O
was O
isolated O
and O
subjected O
to O
Sanger O
dideoxy O
DNA O
sequencing O
. O

Four O
cDNAs O
( O
Kox4 B
, O
Kox7 B
, O
Kox12 B
, O
and O
Kox15 B
) O
were O
identified O
that O
match O
one O
or O
more O
genomic O
clones O
; O
these O
matches O
were O
confirmed O
by O
nucleotide O
sequence O
analysis O
. O

Four O
cDNAs O
( O
Kox4 B
, O
Kox7 B
, O
Kox12 B
, O
and O
Kox15 B
) O
were O
identified O
that O
match O
one O
or O
more O
genomic O
clones O
; O
these O
matches O
were O
confirmed O
by O
nucleotide O
sequence O
analysis O
. O

Four O
cDNAs O
( O
Kox4 B
, O
Kox7 B
, O
Kox12 B
, O
and O
Kox15 B
) O
were O
identified O
that O
match O
one O
or O
more O
genomic O
clones O
; O
these O
matches O
were O
confirmed O
by O
nucleotide O
sequence O
analysis O
. O

Four O
cDNAs O
( O
Kox4 B
, O
Kox7 B
, O
Kox12 B
, O
and O
Kox15 B
) O
were O
identified O
that O
match O
one O
or O
more O
genomic O
clones O
; O
these O
matches O
were O
confirmed O
by O
nucleotide O
sequence O
analysis O
. O

Wild O
type O
MEKK1 B
enhances O
promoter O
activity O
and O
the O
activity O
can O
be O
inhibited O
by O
dominant O
negative O
MEKK1 B
, O
MEK1 B
, O
MEK7 B
, O
MEK3 B
, O
p38 B
/ O
RK B
, O
and O
c B
- I
Jun I
. O

Wild O
type O
MEKK1 B
enhances O
promoter O
activity O
and O
the O
activity O
can O
be O
inhibited O
by O
dominant O
negative O
MEKK1 B
, O
MEK1 B
, O
MEK7 B
, O
MEK3 B
, O
p38 B
/ O
RK B
, O
and O
c B
- I
Jun I
. O

Wild O
type O
MEKK1 B
enhances O
promoter O
activity O
and O
the O
activity O
can O
be O
inhibited O
by O
dominant O
negative O
MEKK1 B
, O
MEK1 B
, O
MEK7 B
, O
MEK3 B
, O
p38 B
/ O
RK B
, O
and O
c B
- I
Jun I
. O

Wild O
type O
MEKK1 B
enhances O
promoter O
activity O
and O
the O
activity O
can O
be O
inhibited O
by O
dominant O
negative O
MEKK1 B
, O
MEK1 B
, O
MEK7 B
, O
MEK3 B
, O
p38 B
/ O
RK B
, O
and O
c B
- I
Jun I
. O

Wild O
type O
MEKK1 B
enhances O
promoter O
activity O
and O
the O
activity O
can O
be O
inhibited O
by O
dominant O
negative O
MEKK1 B
, O
MEK1 B
, O
MEK7 B
, O
MEK3 B
, O
p38 B
/ O
RK B
, O
and O
c B
- I
Jun I
. O

Wild O
type O
MEKK1 B
enhances O
promoter O
activity O
and O
the O
activity O
can O
be O
inhibited O
by O
dominant O
negative O
MEKK1 B
, O
MEK1 B
, O
MEK7 B
, O
MEK3 B
, O
p38 B
/ O
RK B
, O
and O
c B
- I
Jun I
. O

Wild O
type O
MEKK1 B
enhances O
promoter O
activity O
and O
the O
activity O
can O
be O
inhibited O
by O
dominant O
negative O
MEKK1 B
, O
MEK1 B
, O
MEK7 B
, O
MEK3 B
, O
p38 B
/ O
RK B
, O
and O
c B
- I
Jun I
. O

An O
scrR B
promoter I
fragment I
, O
which O
dose O
not O
contain O
a O
sequence O
resembling O
OB B
, O
was O
not O
shifted O
by O
the O
fusion O
protein O
. O

Although O
several O
other O
signal O
transduction O
molecules O
also O
contain O
tandemly O
occurring O
SH3 B
and O
SH2 B
domains I
, O
the O
function O
of O
these O
closely O
spaced O
domains O
is O
not O
well O
understood O
. O

Glycoprotein O
biosynthesis O
in O
Saccharomyces O
cerevisiae O
: O
ngd29 B
, O
an O
N O
- O
glycosylation O
mutant O
allelic O
to O
och1 B
having O
a O
defect O
in O
the O
initiation O
of O
outer O
chain O
formation O
. O

Glycoprotein O
biosynthesis O
in O
Saccharomyces O
cerevisiae O
: O
ngd29 B
, O
an O
N O
- O
glycosylation O
mutant O
allelic O
to O
och1 B
having O
a O
defect O
in O
the O
initiation O
of O
outer O
chain O
formation O
. O

The O
uap100 B
cis O
- O
acting O
, O
up O
- O
promoter O
, O
constitutive O
mutation O
is O
a O
duplication O
that O
comprises O
two O
GATA O
sites O
and O
suppresses O
weakly O
the O
AREA B
zinc I
finger I
mutation I
but O
does O
not O
alleviate O
the O
need O
for O
functional O
UAY B
and O
AREA B
proteins I
. O

The O
uap100 B
cis O
- O
acting O
, O
up O
- O
promoter O
, O
constitutive O
mutation O
is O
a O
duplication O
that O
comprises O
two O
GATA O
sites O
and O
suppresses O
weakly O
the O
AREA B
zinc I
finger I
mutation I
but O
does O
not O
alleviate O
the O
need O
for O
functional O
UAY B
and O
AREA B
proteins I
. O

Transfection O
of O
both O
Calu O
- O
6 O
and O
JEG O
- O
3 O
cells O
with O
a O
PKA B
expression O
vector O
resulted O
in O
a O
10 O
- O
fold O
induction O
of O
human B
renin I
transcriptional O
activity O
in O
constructs O
containing O
the O
native O
or O
consensus O
CRE O
and O
5 O
- O
fold O
activation O
in O
a O
construct O
containing O
a O
nonfunctional O
CRE O
. O

V B
- I
ErbB I
- I
mediated I
complex I
formation O
and O
transformation O
have O
been O
shown O
to O
occur O
independently O
of O
Ras B
activation O
. O

Electron O
microscopy O
of O
pH O
7 O
. O
5 O
- O
treated O
TMV O
particles O
incubated O
in O
SPN B
- O
treated O
wheatgerm O
extract O
or O
rabbit O
reticulocyte O
lysate O
, O
showed O
that O
approximately O
10 O
% O
of O
virions O
complexed O
with O
one O
ribosome O
and O
approximately O
10 O
% O
with O
two O
bound O
ribosomes O
, O
confirming O
that O
omega O
at O
least O
had O
been O
uncoated O
. O

Deletion O
analysis O
revealed O
that O
only O
the O
TM O
domain O
of O
E2 B
was O
required O
for O
Golgi O
targeting O
. O

In O
addition O
, O
putative O
binding O
sites O
for O
SH3 B
and O
SH2 B
domains I
are O
present O
in O
the O
amino O
- O
terminal O
half O
of O
the O
molecule O
. O

One O
new O
ORF O
, O
YBR0224 B
, O
was O
detected O
, O
coding O
for O
a O
protein O
with O
918 O
amino O
acids O
. O

The O
MAP B
kinase I
kinase I
kinase I
MLK2 B
co O
- O
localizes O
with O
activated O
JNK B
along O
microtubules O
and O
associates O
with O
kinesin B
superfamily I
motor O
KIF3 B
. O

The O
MAP B
kinase I
kinase I
kinase I
MLK2 B
co O
- O
localizes O
with O
activated O
JNK B
along O
microtubules O
and O
associates O
with O
kinesin B
superfamily I
motor O
KIF3 B
. O

The O
MAP B
kinase I
kinase I
kinase I
MLK2 B
co O
- O
localizes O
with O
activated O
JNK B
along O
microtubules O
and O
associates O
with O
kinesin B
superfamily I
motor O
KIF3 B
. O

Although O
polyubiquitin B
chains I
linked O
through O
Lys O
( O
29 O
) O
of O
ubiquitin B
have O
been O
implicated O
in O
the O
targeting O
of O
certain O
substrates O
to O
proteasomes O
, O
the O
signaling O
properties O
of O
these O
chains O
are O
poorly O
understood O
. O

An O
in O
vitro O
Raf B
- I
1 I
kinase I
assay O
, O
however O
, O
failed O
to O
detect O
LPS O
- O
induced O
Raf B
- I
1 I
kinase I
activity O
in O
RAW O
264 O
. O
7 O
cells O
, O
suggesting O
that O
in O
RAW O
264 O
. O
7 O
cells O
, O
Raf B
- I
1 I
kinase I
is O
not O
an O
activating O
component O
of O
the O
LPS O
signaling O
pathway O
regulating O
MAPK B
activity O
or O
sIL B
- I
1Ra I
promoter I
activity O
. O

Phosphorylation O
of O
the O
ras B
GTPase B
- I
activating I
protein I
( O
GAP B
) O
by O
the O
p93c B
- I
fes I
protein B
- I
tyrosine I
kinase I
in O
vitro O
and O
formation O
of O
GAP B
- O
fes B
complexes O
via O
an O
SH2 B
domain O
- O
dependent O
mechanism O
. O

Phosphorylation O
of O
the O
ras B
GTPase B
- I
activating I
protein I
( O
GAP B
) O
by O
the O
p93c B
- I
fes I
protein B
- I
tyrosine I
kinase I
in O
vitro O
and O
formation O
of O
GAP B
- O
fes B
complexes O
via O
an O
SH2 B
domain O
- O
dependent O
mechanism O
. O

Phosphorylation O
of O
the O
ras B
GTPase B
- I
activating I
protein I
( O
GAP B
) O
by O
the O
p93c B
- I
fes I
protein B
- I
tyrosine I
kinase I
in O
vitro O
and O
formation O
of O
GAP B
- O
fes B
complexes O
via O
an O
SH2 B
domain O
- O
dependent O
mechanism O
. O

Phosphorylation O
of O
the O
ras B
GTPase B
- I
activating I
protein I
( O
GAP B
) O
by O
the O
p93c B
- I
fes I
protein B
- I
tyrosine I
kinase I
in O
vitro O
and O
formation O
of O
GAP B
- O
fes B
complexes O
via O
an O
SH2 B
domain O
- O
dependent O
mechanism O
. O

Phosphorylation O
of O
the O
ras B
GTPase B
- I
activating I
protein I
( O
GAP B
) O
by O
the O
p93c B
- I
fes I
protein B
- I
tyrosine I
kinase I
in O
vitro O
and O
formation O
of O
GAP B
- O
fes B
complexes O
via O
an O
SH2 B
domain O
- O
dependent O
mechanism O
. O

Two O
methods O
for O
the O
routine O
determination O
of O
blood O
hemoglobin B
oxygen O
affinity O
are O
described O
. O

RET B
/ O
PTC B
oncogenes O
, O
generated O
by O
chromosomal O
rearrangements O
in O
papillary O
thyroid O
carcinomas O
, O
are O
constitutively O
activated O
versions O
of O
proto B
- I
RET I
, O
a O
gene O
coding O
for O
a O
receptor B
- I
type I
tyrosine I
kinase I
( O
TK B
) O
whose O
ligand O
is O
still O
unknown O
. O

RET B
/ O
PTC B
oncogenes O
, O
generated O
by O
chromosomal O
rearrangements O
in O
papillary O
thyroid O
carcinomas O
, O
are O
constitutively O
activated O
versions O
of O
proto B
- I
RET I
, O
a O
gene O
coding O
for O
a O
receptor B
- I
type I
tyrosine I
kinase I
( O
TK B
) O
whose O
ligand O
is O
still O
unknown O
. O

RET B
/ O
PTC B
oncogenes O
, O
generated O
by O
chromosomal O
rearrangements O
in O
papillary O
thyroid O
carcinomas O
, O
are O
constitutively O
activated O
versions O
of O
proto B
- I
RET I
, O
a O
gene O
coding O
for O
a O
receptor B
- I
type I
tyrosine I
kinase I
( O
TK B
) O
whose O
ligand O
is O
still O
unknown O
. O

In O
rats O
exposed O
to O
Cd O
for O
30 O
d O
, O
the O
levels O
of O
urinary O
excretion O
of O
cAMP O
after O
treatment O
with O
parathyroid B
hormone I
( O
PTH B
) O
, O
parathyroidectomy O
( O
PTX O
) O
, O
or O
1 O
alpha O
- O
hydroxycholecalciferol O
( O
1 O
alpha O
- O
OH O
- O
D3 O
) O
showed O
almost O
the O
same O
patterns O
as O
those O
of O
control O
rats O
: O
the O
response O
of O
urinary O
cAMP O
to O
treatment O
with O
PTH B
was O
not O
influenced O
by O
continuous O
oral O
administration O
of O
Cd O
. O

In O
rats O
exposed O
to O
Cd O
for O
30 O
d O
, O
the O
levels O
of O
urinary O
excretion O
of O
cAMP O
after O
treatment O
with O
parathyroid B
hormone I
( O
PTH B
) O
, O
parathyroidectomy O
( O
PTX O
) O
, O
or O
1 O
alpha O
- O
hydroxycholecalciferol O
( O
1 O
alpha O
- O
OH O
- O
D3 O
) O
showed O
almost O
the O
same O
patterns O
as O
those O
of O
control O
rats O
: O
the O
response O
of O
urinary O
cAMP O
to O
treatment O
with O
PTH B
was O
not O
influenced O
by O
continuous O
oral O
administration O
of O
Cd O
. O

In O
the O
absence O
of O
shock O
, O
sepsis O
, O
or O
other O
identifiable O
causes O
of O
lactic O
acidosis O
, O
the O
severe O
anemia O
( O
hemoglobin B
1 O
. O
2 O
g O
/ O
dl O
) O
appeared O
to O
be O
the O
primary O
etiologic O
factor O
. O

Northern O
blot O
analysis O
of O
liver O
, O
muscle O
, O
fat O
, O
and O
pituitary O
RNA O
from O
normal O
( O
DwDw O
) O
chickens O
shows O
a O
major O
transcript O
of O
4 O
. O
3 O
kilobases O
( O
kb O
) O
and O
three O
minor O
transcripts O
( O
0 O
. O
8 O
, O
1 O
. O
7 O
, O
and O
3 O
. O
2 O
kb O
) O
, O
which O
correspond O
to O
the O
cGHR B
. O

Despite O
a O
lowering O
of O
her O
plasma O
ACTH B
concentration O
during O
therapy O
with O
valproic O
acid O
, O
the O
patient O
' O
s O
tumour O
showed O
no O
evidence O
of O
regression O
while O
she O
was O
taking O
the O
drug O
. O

Our O
studies O
suggest O
that O
the O
helicase B
assembly O
protein O
is O
responsible O
for O
loading O
T4 B
gene I
41 I
helicase I
specifically O
at O
replication O
forks O
, O
and O
that O
its O
binding O
sites O
for O
each O
arm O
must O
hold O
more O
than O
six O
, O
but O
not O
more O
than O
12 O
nucleotides O
. O

We O
find O
that O
Fus3p B
and O
Kss1p B
both O
control O
G1 O
arrest O
through O
multiple O
functions O
that O
operate O
in O
parallel O
with O
Far1p B
. O

We O
find O
that O
Fus3p B
and O
Kss1p B
both O
control O
G1 O
arrest O
through O
multiple O
functions O
that O
operate O
in O
parallel O
with O
Far1p B
. O

We O
find O
that O
Fus3p B
and O
Kss1p B
both O
control O
G1 O
arrest O
through O
multiple O
functions O
that O
operate O
in O
parallel O
with O
Far1p B
. O

Tag B
expression O
induced O
apoptosis O
in O
mammary O
epithelial O
cells O
during O
late O
pregnancy O
. O

The O
time O
- O
dependent O
changes O
in O
measured O
facility O
of O
outflow O
or O
" O
washout O
phenomenon O
" O
appeared O
to O
result O
from O
the O
gradual O
dissolution O
of O
the O
hyaluronidase B
- O
sensitive O
component O
of O
the O
barriers O
to O
aqueous O
outflow O
in O
the O
canine O
eye O
. O

The O
factors O
defective O
in O
groups O
A O
( O
CIITA B
) O
, O
C O
( O
RFX5 B
) O
and O
D O
( O
RFXAP B
) O
have O
been O
identified O
. O

The O
factors O
defective O
in O
groups O
A O
( O
CIITA B
) O
, O
C O
( O
RFX5 B
) O
and O
D O
( O
RFXAP B
) O
have O
been O
identified O
. O

The O
factors O
defective O
in O
groups O
A O
( O
CIITA B
) O
, O
C O
( O
RFX5 B
) O
and O
D O
( O
RFXAP B
) O
have O
been O
identified O
. O

To O
test O
for O
progesterone B
receptor I
- O
mediated O
activation O
of O
transcription O
in O
yeast O
, O
reporter O
plasmids O
were O
constructed O
to O
transform O
yeast O
cells O
expressing O
PRB B
or O
C1C2 B
receptors I
. O

The O
results O
corroborate O
the O
proposed O
physiological O
function O
of O
CCoAOMT B
in O
elicited O
plant O
cells O
and O
may O
shed O
new O
light O
on O
the O
sequential O
action O
of O
trans O
- O
active O
factors O
in O
the O
regulation O
of O
phenylpropanoid O
genes O
. O

In O
src B
- O
transformed O
cells O
GAP B
forms O
heteromeric O
complexes O
, O
notably O
with O
a O
highly O
tyrosine O
phosphorylated O
62 B
- I
kDa I
protein I
( I
p62 I
) I
. O

In O
src B
- O
transformed O
cells O
GAP B
forms O
heteromeric O
complexes O
, O
notably O
with O
a O
highly O
tyrosine O
phosphorylated O
62 B
- I
kDa I
protein I
( I
p62 I
) I
. O

PrRP B
rapidly O
and O
transiently O
activated O
extracellular B
signal I
- I
regulated I
protein I
kinase I
( O
ERK B
) O
in O
both O
types O
of O
cells O
. O

PrRP B
rapidly O
and O
transiently O
activated O
extracellular B
signal I
- I
regulated I
protein I
kinase I
( O
ERK B
) O
in O
both O
types O
of O
cells O
. O

Cell O
- O
free O
extracts O
of O
E O
. O
coli O
( O
fpg B
mutY B
) O
harboring O
pYSB10 O
possess O
an O
enzymatic O
activity O
that O
cleaves O
a O
34 O
- O
mer O
oligonucleotide O
containing O
a O
single O
8 O
- O
oxoG O
opposite O
a O
cytosine O
( O
8 O
- O
OxoG O
/ O
C O
) O
. O

Cell O
- O
free O
extracts O
of O
E O
. O
coli O
( O
fpg B
mutY B
) O
harboring O
pYSB10 O
possess O
an O
enzymatic O
activity O
that O
cleaves O
a O
34 O
- O
mer O
oligonucleotide O
containing O
a O
single O
8 O
- O
oxoG O
opposite O
a O
cytosine O
( O
8 O
- O
OxoG O
/ O
C O
) O
. O

Further O
comparative O
analysis O
identified O
an O
ADNP B
paralog O
( O
33 O
% O
identity O
and O
46 O
% O
similarity O
) O
, O
indicating O
that O
these O
genes O
belong O
to O
a O
novel O
protein O
family O
with O
a O
nine O
- O
zinc O
finger O
motif O
followed O
by O
a O
homeobox O
domain O
. O

All O
patients O
received O
marrow O
from O
HLA B
- O
identical O
sibling O
donors O
, O
underwent O
similar O
myeloablative O
regimens O
, O
and O
had O
similar O
pretreatment O
characteristics O
. O

Subclones O
stably O
expressing O
alpha1A B
- O
, O
alpha1B B
- O
, O
and O
alpha1D B
- O
ARs O
under O
control O
of O
an O
inducible O
promoter O
, O
or O
at O
high O
and O
low O
receptor O
density O
, O
were O
isolated O
and O
characterized O
. O

Subclones O
stably O
expressing O
alpha1A B
- O
, O
alpha1B B
- O
, O
and O
alpha1D B
- O
ARs O
under O
control O
of O
an O
inducible O
promoter O
, O
or O
at O
high O
and O
low O
receptor O
density O
, O
were O
isolated O
and O
characterized O
. O

Subclones O
stably O
expressing O
alpha1A B
- O
, O
alpha1B B
- O
, O
and O
alpha1D B
- O
ARs O
under O
control O
of O
an O
inducible O
promoter O
, O
or O
at O
high O
and O
low O
receptor O
density O
, O
were O
isolated O
and O
characterized O
. O

Soluble O
recombinant O
RI B
and O
soluble O
recombinant O
C B
alpha I
can O
associate O
in O
vitro O
and O
be O
activated O
by O
cyclic O
AMP O
. O

IRIS B
/ O
GAS B
DNA O
also O
formed O
a O
number O
of O
specific O
complexes O
with O
constitutively O
expressed O
factors O
, O
none O
of O
which O
were O
affected O
by O
the O
above O
Abs O
. O

IRIS B
/ O
GAS B
DNA O
also O
formed O
a O
number O
of O
specific O
complexes O
with O
constitutively O
expressed O
factors O
, O
none O
of O
which O
were O
affected O
by O
the O
above O
Abs O
. O

Electrophoretic O
mobility O
- O
shift O
assays O
with O
nuclear O
extracts O
from O
COS O
- O
1 O
cells O
transfected O
with O
expression O
vectors O
for O
SMADs B
1 I
- I
5 I
indicate O
that O
SMAD3 B
forms O
a O
complex O
with O
a O
migration O
similar O
to O
that O
of O
the O
endogenous B
TGF I
- I
beta I
- I
specific I
complex I
observed O
in O
fibroblast O
extracts O
. O

In O
the O
second O
group O
, O
which O
consisted O
of O
babies O
of O
33 O
to O
36 O
weeks O
of O
gestational O
age O
, O
haptoglobin B
was O
detected O
in O
6 O
infants O
, O
with O
levels O
less O
than O
25 O
mg O
/ O
dl O
in O
3 O
. O

However O
, O
H19 B
and O
IGF2 B
lie O
within O
a O
larger O
imprinted O
domain O
, O
and O
the O
gene O
specificity O
of O
H19 B
epimutation O
has O
been O
a O
persistent O
question O
. O

However O
, O
H19 B
and O
IGF2 B
lie O
within O
a O
larger O
imprinted O
domain O
, O
and O
the O
gene O
specificity O
of O
H19 B
epimutation O
has O
been O
a O
persistent O
question O
. O

However O
, O
H19 B
and O
IGF2 B
lie O
within O
a O
larger O
imprinted O
domain O
, O
and O
the O
gene O
specificity O
of O
H19 B
epimutation O
has O
been O
a O
persistent O
question O
. O

Here O
we O
report O
the O
cloning O
, O
by O
either O
peptide O
sequencing O
or O
by O
sequence O
similarity O
to O
the O
human O
cDNAs O
, O
of O
the O
S O
. O
cerevisiae O
genes O
RFC1 B
, O
RFC2 B
, O
RFC3 B
, O
RFC4 B
, O
and O
RFC5 B
. O

Here O
we O
report O
the O
cloning O
, O
by O
either O
peptide O
sequencing O
or O
by O
sequence O
similarity O
to O
the O
human O
cDNAs O
, O
of O
the O
S O
. O
cerevisiae O
genes O
RFC1 B
, O
RFC2 B
, O
RFC3 B
, O
RFC4 B
, O
and O
RFC5 B
. O

Here O
we O
report O
the O
cloning O
, O
by O
either O
peptide O
sequencing O
or O
by O
sequence O
similarity O
to O
the O
human O
cDNAs O
, O
of O
the O
S O
. O
cerevisiae O
genes O
RFC1 B
, O
RFC2 B
, O
RFC3 B
, O
RFC4 B
, O
and O
RFC5 B
. O

Here O
we O
report O
the O
cloning O
, O
by O
either O
peptide O
sequencing O
or O
by O
sequence O
similarity O
to O
the O
human O
cDNAs O
, O
of O
the O
S O
. O
cerevisiae O
genes O
RFC1 B
, O
RFC2 B
, O
RFC3 B
, O
RFC4 B
, O
and O
RFC5 B
. O

Here O
we O
report O
the O
cloning O
, O
by O
either O
peptide O
sequencing O
or O
by O
sequence O
similarity O
to O
the O
human O
cDNAs O
, O
of O
the O
S O
. O
cerevisiae O
genes O
RFC1 B
, O
RFC2 B
, O
RFC3 B
, O
RFC4 B
, O
and O
RFC5 B
. O

As O
much O
thrombin B
was O
formed O
during O
cardiopulmonary O
bypass O
( O
measured O
by O
the O
prothrombin B
activation I
fragment I
F1 I
+ I
2 I
and O
thrombin B
- O
antithrombin B
complexes O
) O
as O
in O
normal O
patients O
, O
showing O
that O
factor B
XII I
was O
not O
necessary O
for O
thrombin B
generation O
. O

As O
much O
thrombin B
was O
formed O
during O
cardiopulmonary O
bypass O
( O
measured O
by O
the O
prothrombin B
activation I
fragment I
F1 I
+ I
2 I
and O
thrombin B
- O
antithrombin B
complexes O
) O
as O
in O
normal O
patients O
, O
showing O
that O
factor B
XII I
was O
not O
necessary O
for O
thrombin B
generation O
. O

As O
much O
thrombin B
was O
formed O
during O
cardiopulmonary O
bypass O
( O
measured O
by O
the O
prothrombin B
activation I
fragment I
F1 I
+ I
2 I
and O
thrombin B
- O
antithrombin B
complexes O
) O
as O
in O
normal O
patients O
, O
showing O
that O
factor B
XII I
was O
not O
necessary O
for O
thrombin B
generation O
. O

As O
much O
thrombin B
was O
formed O
during O
cardiopulmonary O
bypass O
( O
measured O
by O
the O
prothrombin B
activation I
fragment I
F1 I
+ I
2 I
and O
thrombin B
- O
antithrombin B
complexes O
) O
as O
in O
normal O
patients O
, O
showing O
that O
factor B
XII I
was O
not O
necessary O
for O
thrombin B
generation O
. O

MUS81 B
encodes O
a O
novel O
helix B
- I
hairpin I
- I
helix I
protein I
involved O
in O
the O
response O
to O
UV O
- O
and O
methylation O
- O
induced O
DNA O
damage O
in O
Saccharomyces O
cerevisiae O
. O

Treatment O
of O
chronic O
hepatitis O
B O
with O
interferon B
: O
experience O
in O
western O
countries O
. O

Several O
positive O
clones O
were O
isolated O
, O
one O
of O
which O
encoded O
the O
C O
- O
terminal O
253 O
amino O
acids O
of O
a O
putative O
RNA B
helicase I
, O
a O
DEAD B
box I
protein I
designated O
DDX3 B
. O

In O
vitro O
binding O
studies O
previously O
showed O
that O
NF B
- I
kappa I
B I
p50 B
homodimer O
binds O
the O
switch B
nuclear I
B I
- I
site I
protein I
( O
SNIP B
) O
of O
the O
S B
gamma I
3 I
tandem I
repeat I
. O

In O
vitro O
binding O
studies O
previously O
showed O
that O
NF B
- I
kappa I
B I
p50 B
homodimer O
binds O
the O
switch B
nuclear I
B I
- I
site I
protein I
( O
SNIP B
) O
of O
the O
S B
gamma I
3 I
tandem I
repeat I
. O

In O
this O
case O
myogenic O
factors O
are O
not O
initially O
expressed O
and O
these O
migratory O
cells O
are O
characterized O
by O
the O
expression O
of O
the O
paired B
- O
box O
gene O
Pax3 B
. O

In O
this O
case O
myogenic O
factors O
are O
not O
initially O
expressed O
and O
these O
migratory O
cells O
are O
characterized O
by O
the O
expression O
of O
the O
paired B
- O
box O
gene O
Pax3 B
. O

It O
is O
concluded O
that O
the O
atherogenic O
process O
includes O
stimulation O
of O
collagen B
and O
elastin B
synthesis O
. O

It O
is O
concluded O
that O
the O
atherogenic O
process O
includes O
stimulation O
of O
collagen B
and O
elastin B
synthesis O
. O

These O
results O
indicate O
that O
( O
1 O
) O
RXR B
- O
TR B
heterodimers O
play O
a O
role O
in O
basal O
transactivation O
and O
T3 O
suppression O
of O
negatively O
regulated O
genes O
, O
and O
( O
2 O
) O
RXRs B
increase O
the O
dominant O
negative O
effect O
of O
some O
mutant O
TRs B
on O
specific O
negative O
TREs O
. O

These O
results O
indicate O
that O
( O
1 O
) O
RXR B
- O
TR B
heterodimers O
play O
a O
role O
in O
basal O
transactivation O
and O
T3 O
suppression O
of O
negatively O
regulated O
genes O
, O
and O
( O
2 O
) O
RXRs B
increase O
the O
dominant O
negative O
effect O
of O
some O
mutant O
TRs B
on O
specific O
negative O
TREs O
. O

These O
results O
indicate O
that O
( O
1 O
) O
RXR B
- O
TR B
heterodimers O
play O
a O
role O
in O
basal O
transactivation O
and O
T3 O
suppression O
of O
negatively O
regulated O
genes O
, O
and O
( O
2 O
) O
RXRs B
increase O
the O
dominant O
negative O
effect O
of O
some O
mutant O
TRs B
on O
specific O
negative O
TREs O
. O

These O
results O
indicate O
that O
( O
1 O
) O
RXR B
- O
TR B
heterodimers O
play O
a O
role O
in O
basal O
transactivation O
and O
T3 O
suppression O
of O
negatively O
regulated O
genes O
, O
and O
( O
2 O
) O
RXRs B
increase O
the O
dominant O
negative O
effect O
of O
some O
mutant O
TRs B
on O
specific O
negative O
TREs O
. O

Phenotypic O
responses O
of O
additional O
mutants O
, O
including O
exo1 B
, O
srs2 B
, O
rad5 B
, O
and O
rdh54 B
strains O
, O
suggest O
roles O
in O
recombinational O
repair O
, O
but O
not O
in O
NHEJ O
. O

Phenotypic O
responses O
of O
additional O
mutants O
, O
including O
exo1 B
, O
srs2 B
, O
rad5 B
, O
and O
rdh54 B
strains O
, O
suggest O
roles O
in O
recombinational O
repair O
, O
but O
not O
in O
NHEJ O
. O

Phenotypic O
responses O
of O
additional O
mutants O
, O
including O
exo1 B
, O
srs2 B
, O
rad5 B
, O
and O
rdh54 B
strains O
, O
suggest O
roles O
in O
recombinational O
repair O
, O
but O
not O
in O
NHEJ O
. O

Phenotypic O
responses O
of O
additional O
mutants O
, O
including O
exo1 B
, O
srs2 B
, O
rad5 B
, O
and O
rdh54 B
strains O
, O
suggest O
roles O
in O
recombinational O
repair O
, O
but O
not O
in O
NHEJ O
. O

To O
investigate O
whether O
the O
two O
RPG B
- I
boxes I
mediate O
transcription O
activation O
of O
both O
the O
L46 B
and O
S24 B
gene I
, O
two O
experimental O
strategies O
were O
followed O
: O
cloning O
of O
the O
respective O
genes O
on O
multicopy O
vectors O
and O
construction O
of O
fusion O
genes O
. O

Sequence O
analysis O
identifies O
a O
ras B
- I
associating I
( O
RA B
) O
- O
like O
domain O
in O
the O
N O
- O
termini O
of O
band B
4 I
. I
1 I
/ I
JEF I
domains I
and O
in O
the O
Grb7 B
/ I
10 I
/ I
14 I
adapter I
family I
. O

Patients O
received O
BPB O
using O
bupivacaine O
2 O
mg O
kg O
- O
1 O
with O
adrenaline O
1 O
in O
200 O
, O
000 O
, O
either O
with O
or O
without O
hyaluronidase B
3000 O
iu O
, O
in O
a O
volume O
of O
0 O
. O
5 O
ml O
per O
2 O
. O
54 O
cm O
of O
the O
patient O
' O
s O
height O
. O

Rhinovirus B
2A I
protease I
and O
foot B
- I
and I
- I
mouth I
- I
disease I
virus I
L I
protease I
were O
used O
to O
analyze O
the O
association O
of O
eIF4G B
with O
eIF4A B
, O
eIF4E B
, O
and O
eIF3 B
. O

Rhinovirus B
2A I
protease I
and O
foot B
- I
and I
- I
mouth I
- I
disease I
virus I
L I
protease I
were O
used O
to O
analyze O
the O
association O
of O
eIF4G B
with O
eIF4A B
, O
eIF4E B
, O
and O
eIF3 B
. O

Rhinovirus B
2A I
protease I
and O
foot B
- I
and I
- I
mouth I
- I
disease I
virus I
L I
protease I
were O
used O
to O
analyze O
the O
association O
of O
eIF4G B
with O
eIF4A B
, O
eIF4E B
, O
and O
eIF3 B
. O

Rhinovirus B
2A I
protease I
and O
foot B
- I
and I
- I
mouth I
- I
disease I
virus I
L I
protease I
were O
used O
to O
analyze O
the O
association O
of O
eIF4G B
with O
eIF4A B
, O
eIF4E B
, O
and O
eIF3 B
. O

One O
hundred O
cDNA O
clones O
were O
sequenced O
and O
8 O
RTKs B
were O
identified O
, O
as O
well O
as O
12 O
non O
- O
RTKs B
and O
2 O
serine B
/ I
threonine I
kinases I
. O

One O
hundred O
cDNA O
clones O
were O
sequenced O
and O
8 O
RTKs B
were O
identified O
, O
as O
well O
as O
12 O
non O
- O
RTKs B
and O
2 O
serine B
/ I
threonine I
kinases I
. O

Furthermore O
, O
it O
was O
found O
that O
the O
Shb B
- O
overexpressing O
cells O
extended O
neurites O
in O
response O
to O
epidermal B
growth I
factor I
. O

Levels O
of O
p53 B
were O
substantially O
increased O
by O
E1A B
expression O
during O
adenovirus O
infection O
. O

Levels O
of O
p53 B
were O
substantially O
increased O
by O
E1A B
expression O
during O
adenovirus O
infection O
. O

In O
cases O
of O
intracapsular O
prostatic O
cancer O
the O
level O
of O
prostatic B
acid I
phosphatase I
( O
PAP B
) O
measured O
by O
radioimmunoassay O
was O
1 O
. O
4 O
+ O
/ O
- O
0 O
. O
8 O
micrograms O
/ O
l O
. O

In O
EGF B
receptor I
- O
mediated O
signaling O
, O
the O
protein B
kinase I
PKB I
/ O
Akt B
and O
the O
mitogen B
- I
activated I
protein I
kinase I
c I
- I
Jun I
N I
- I
terminal I
kinase I
, O
but O
not O
extracellular B
signal I
- I
regulated I
kinase I
2 I
, O
function O
downstream O
of O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
. O

Immunoprecipitation O
of O
cell O
lysates O
with O
anti B
- I
phosphotyrosine I
and O
immunoblotting O
showed O
phosphorylated O
forms O
of O
the O
mitogenic O
pathway O
proteins O
Shc B
and O
MAPK B
in O
addition O
to O
p185 B
( O
neu B
) O
, O
suggesting O
that O
the O
Ras B
to O
MAPK B
mitogenic O
pathway O
is O
activated O
. O

Immunoprecipitation O
of O
cell O
lysates O
with O
anti B
- I
phosphotyrosine I
and O
immunoblotting O
showed O
phosphorylated O
forms O
of O
the O
mitogenic O
pathway O
proteins O
Shc B
and O
MAPK B
in O
addition O
to O
p185 B
( O
neu B
) O
, O
suggesting O
that O
the O
Ras B
to O
MAPK B
mitogenic O
pathway O
is O
activated O
. O

Immunoprecipitation O
of O
cell O
lysates O
with O
anti B
- I
phosphotyrosine I
and O
immunoblotting O
showed O
phosphorylated O
forms O
of O
the O
mitogenic O
pathway O
proteins O
Shc B
and O
MAPK B
in O
addition O
to O
p185 B
( O
neu B
) O
, O
suggesting O
that O
the O
Ras B
to O
MAPK B
mitogenic O
pathway O
is O
activated O
. O

Immunoprecipitation O
of O
cell O
lysates O
with O
anti B
- I
phosphotyrosine I
and O
immunoblotting O
showed O
phosphorylated O
forms O
of O
the O
mitogenic O
pathway O
proteins O
Shc B
and O
MAPK B
in O
addition O
to O
p185 B
( O
neu B
) O
, O
suggesting O
that O
the O
Ras B
to O
MAPK B
mitogenic O
pathway O
is O
activated O
. O

Immunoprecipitation O
of O
cell O
lysates O
with O
anti B
- I
phosphotyrosine I
and O
immunoblotting O
showed O
phosphorylated O
forms O
of O
the O
mitogenic O
pathway O
proteins O
Shc B
and O
MAPK B
in O
addition O
to O
p185 B
( O
neu B
) O
, O
suggesting O
that O
the O
Ras B
to O
MAPK B
mitogenic O
pathway O
is O
activated O
. O

Immunoprecipitation O
of O
cell O
lysates O
with O
anti B
- I
phosphotyrosine I
and O
immunoblotting O
showed O
phosphorylated O
forms O
of O
the O
mitogenic O
pathway O
proteins O
Shc B
and O
MAPK B
in O
addition O
to O
p185 B
( O
neu B
) O
, O
suggesting O
that O
the O
Ras B
to O
MAPK B
mitogenic O
pathway O
is O
activated O
. O

We O
suggest O
that O
this O
effect O
of O
Myc B
is O
mediated O
by O
its O
action O
upstream O
of O
cyclin B
E I
- O
CDK2 B
, O
and O
occurs O
via O
the O
neutralization O
of O
p27 B
( O
Kip1 B
) O
family O
proteins O
, O
rather O
than O
induction O
of O
Cdc25A B
. O

We O
suggest O
that O
this O
effect O
of O
Myc B
is O
mediated O
by O
its O
action O
upstream O
of O
cyclin B
E I
- O
CDK2 B
, O
and O
occurs O
via O
the O
neutralization O
of O
p27 B
( O
Kip1 B
) O
family O
proteins O
, O
rather O
than O
induction O
of O
Cdc25A B
. O

We O
suggest O
that O
this O
effect O
of O
Myc B
is O
mediated O
by O
its O
action O
upstream O
of O
cyclin B
E I
- O
CDK2 B
, O
and O
occurs O
via O
the O
neutralization O
of O
p27 B
( O
Kip1 B
) O
family O
proteins O
, O
rather O
than O
induction O
of O
Cdc25A B
. O

We O
suggest O
that O
this O
effect O
of O
Myc B
is O
mediated O
by O
its O
action O
upstream O
of O
cyclin B
E I
- O
CDK2 B
, O
and O
occurs O
via O
the O
neutralization O
of O
p27 B
( O
Kip1 B
) O
family O
proteins O
, O
rather O
than O
induction O
of O
Cdc25A B
. O

We O
suggest O
that O
this O
effect O
of O
Myc B
is O
mediated O
by O
its O
action O
upstream O
of O
cyclin B
E I
- O
CDK2 B
, O
and O
occurs O
via O
the O
neutralization O
of O
p27 B
( O
Kip1 B
) O
family O
proteins O
, O
rather O
than O
induction O
of O
Cdc25A B
. O

These O
data O
suggest O
that O
certain O
of O
the O
nuclear O
protein O
import O
functions O
of O
NTF2 B
and O
Ran B
/ O
TC4 B
are O
closely O
linked O
and O
that O
NTF2 B
may O
serve O
to O
modulate O
a O
transport O
step O
involving O
Ran B
/ O
TC4 B
. O

These O
data O
suggest O
that O
certain O
of O
the O
nuclear O
protein O
import O
functions O
of O
NTF2 B
and O
Ran B
/ O
TC4 B
are O
closely O
linked O
and O
that O
NTF2 B
may O
serve O
to O
modulate O
a O
transport O
step O
involving O
Ran B
/ O
TC4 B
. O

These O
data O
suggest O
that O
certain O
of O
the O
nuclear O
protein O
import O
functions O
of O
NTF2 B
and O
Ran B
/ O
TC4 B
are O
closely O
linked O
and O
that O
NTF2 B
may O
serve O
to O
modulate O
a O
transport O
step O
involving O
Ran B
/ O
TC4 B
. O

These O
data O
suggest O
that O
certain O
of O
the O
nuclear O
protein O
import O
functions O
of O
NTF2 B
and O
Ran B
/ O
TC4 B
are O
closely O
linked O
and O
that O
NTF2 B
may O
serve O
to O
modulate O
a O
transport O
step O
involving O
Ran B
/ O
TC4 B
. O

These O
data O
suggest O
that O
certain O
of O
the O
nuclear O
protein O
import O
functions O
of O
NTF2 B
and O
Ran B
/ O
TC4 B
are O
closely O
linked O
and O
that O
NTF2 B
may O
serve O
to O
modulate O
a O
transport O
step O
involving O
Ran B
/ O
TC4 B
. O

These O
data O
suggest O
that O
certain O
of O
the O
nuclear O
protein O
import O
functions O
of O
NTF2 B
and O
Ran B
/ O
TC4 B
are O
closely O
linked O
and O
that O
NTF2 B
may O
serve O
to O
modulate O
a O
transport O
step O
involving O
Ran B
/ O
TC4 B
. O

Both O
oligonucleotide O
cross O
- O
competition O
and O
antibody O
supershift O
experiments O
established O
that O
the O
double O
- O
strand O
binding O
protein O
is O
equivalent O
to O
Sp1 B
. O

Although O
FKH2 B
is O
redundant O
with O
FKH1 B
in O
controlling O
pseudohyphal O
growth O
, O
the O
two O
genes O
have O
different O
functions O
in O
silencing O
HMRa B
. O

Although O
FKH2 B
is O
redundant O
with O
FKH1 B
in O
controlling O
pseudohyphal O
growth O
, O
the O
two O
genes O
have O
different O
functions O
in O
silencing O
HMRa B
. O

Although O
FKH2 B
is O
redundant O
with O
FKH1 B
in O
controlling O
pseudohyphal O
growth O
, O
the O
two O
genes O
have O
different O
functions O
in O
silencing O
HMRa B
. O

Finally O
, O
antisense O
mediated O
reduction O
of O
Elk B
- I
1 I
in O
GH4 O
cells O
decreased O
insulin B
- O
increased O
prolactin B
gene I
expression O
and O
confirmed O
the O
requirement O
for O
Elk B
- I
1 I
for O
insulin B
- O
increased O
prolactin B
gene I
expression O
. O

Finally O
, O
antisense O
mediated O
reduction O
of O
Elk B
- I
1 I
in O
GH4 O
cells O
decreased O
insulin B
- O
increased O
prolactin B
gene I
expression O
and O
confirmed O
the O
requirement O
for O
Elk B
- I
1 I
for O
insulin B
- O
increased O
prolactin B
gene I
expression O
. O

The O
aromatic B
hydrocarbon I
receptor I
( O
AHR B
) O
is O
a O
ligand O
- O
activated O
transcription O
factor O
that O
regulates O
the O
expression O
of O
several O
drug O
- O
metabolizing O
enzymes O
and O
has O
been O
implicated O
in O
immunosuppression O
, O
teratogenesis O
, O
cell O
- O
specific O
hyperplasia O
, O
and O
certain O
types O
of O
malignancies O
and O
toxicities O
. O

Moreover O
, O
FACT B
specifically O
interacts O
with O
nucleosomes O
and O
histone O
H2A B
/ O
H2B B
dimers O
, O
indicating O
that O
it O
may O
work O
by O
promoting O
nucleosome O
disassembly O
upon O
transcription O
. O

Moreover O
, O
FACT B
specifically O
interacts O
with O
nucleosomes O
and O
histone O
H2A B
/ O
H2B B
dimers O
, O
indicating O
that O
it O
may O
work O
by O
promoting O
nucleosome O
disassembly O
upon O
transcription O
. O

Moreover O
, O
FACT B
specifically O
interacts O
with O
nucleosomes O
and O
histone O
H2A B
/ O
H2B B
dimers O
, O
indicating O
that O
it O
may O
work O
by O
promoting O
nucleosome O
disassembly O
upon O
transcription O
. O

Mutation O
of O
the O
distal O
E2F B
binding I
site I
in O
the O
cdc25A B
promoter I
abolished O
E2 B
- O
induced O
repression O
, O
whereas O
mutation O
of O
the O
proximal O
E2F B
site I
or O
the O
E2 B
site I
had O
no O
effect O
. O

Plasmid O
pNK21 O
, O
in O
which O
2 O
. O
05 O
- O
kb O
sequence O
covering O
the O
region O
encoding O
the O
nitrilase B
was O
was O
placed O
under O
the O
control O
of O
the O
lac B
promoter I
, O
directed O
overproduction O
of O
enzymatically B
active I
nitrilase I
in O
response O
to O
addition O
of O
isopropyl O
beta O
- O
D O
- O
thiogalactopyranoside O
in O
Escherichia O
coli O
. O

These O
results O
demonstrate O
a O
specific O
association O
of O
SIV O
and O
HIV B
- I
2 I
nef I
, O
but O
not O
HIV B
- I
1 I
nef I
, O
with O
TCRzeta B
. O

Upon O
incubation O
of O
the O
most O
highly O
purified O
fractions O
with O
Mn O
- O
ATP O
or O
Mg O
- O
ATP O
, O
p40 B
was O
the O
only O
protein O
phosphorylated O
on O
tyrosine O
. O

A O
p53 B
cDNA I
deletion O
mutant O
( O
delta O
pro O
AE O
) O
, O
which O
lacks O
this O
entire O
proline O
- O
rich O
domain O
( O
deleted O
for O
amino O
acids O
62 O
- O
91 O
) O
, O
was O
created O
and O
characterized O
for O
a O
variety O
of O
p53 B
functions O
. O

Multiple O
aortic O
thrombi O
associated O
with O
protein B
C I
and O
S B
deficiency O
. O

Our O
results O
suggest O
that O
Bry1 B
/ O
Skn7 B
can O
influence O
the O
expression O
of O
MCB O
- O
and O
SCB O
- O
driven O
gene O
expression O
in O
budding O
yeast O
, O
perhaps O
including O
genes O
involved O
in O
cell O
wall O
metabolism O
, O
via O
a O
two O
- O
component O
signal O
transduction O
pathway O
which O
activates O
Bry1 B
/ O
Skn7 B
in O
response O
to O
an O
unidentified O
signal O
. O

Our O
results O
suggest O
that O
Bry1 B
/ O
Skn7 B
can O
influence O
the O
expression O
of O
MCB O
- O
and O
SCB O
- O
driven O
gene O
expression O
in O
budding O
yeast O
, O
perhaps O
including O
genes O
involved O
in O
cell O
wall O
metabolism O
, O
via O
a O
two O
- O
component O
signal O
transduction O
pathway O
which O
activates O
Bry1 B
/ O
Skn7 B
in O
response O
to O
an O
unidentified O
signal O
. O

Our O
results O
suggest O
that O
Bry1 B
/ O
Skn7 B
can O
influence O
the O
expression O
of O
MCB O
- O
and O
SCB O
- O
driven O
gene O
expression O
in O
budding O
yeast O
, O
perhaps O
including O
genes O
involved O
in O
cell O
wall O
metabolism O
, O
via O
a O
two O
- O
component O
signal O
transduction O
pathway O
which O
activates O
Bry1 B
/ O
Skn7 B
in O
response O
to O
an O
unidentified O
signal O
. O

Our O
results O
suggest O
that O
Bry1 B
/ O
Skn7 B
can O
influence O
the O
expression O
of O
MCB O
- O
and O
SCB O
- O
driven O
gene O
expression O
in O
budding O
yeast O
, O
perhaps O
including O
genes O
involved O
in O
cell O
wall O
metabolism O
, O
via O
a O
two O
- O
component O
signal O
transduction O
pathway O
which O
activates O
Bry1 B
/ O
Skn7 B
in O
response O
to O
an O
unidentified O
signal O
. O

A O
constructed O
phylogenetic O
tree O
suggests O
that O
the O
UbcP1 B
protein I
may O
represent O
a O
member O
of O
a O
distinct O
subfamily O
of O
E2s B
. O

We O
functionally O
characterised O
AtXPO1 B
by O
its O
interaction O
with O
NESs O
of O
animal O
and O
plant O
proteins O
, O
which O
is O
inhibited O
by O
the O
cytotoxin O
leptomycin O
B O
( O
LMB O
) O
, O
and O
also O
by O
its O
interaction O
with O
the O
small B
GTPase I
Ran1 B
in O
the O
yeast O
two O
- O
hybrid O
system O
. O

We O
functionally O
characterised O
AtXPO1 B
by O
its O
interaction O
with O
NESs O
of O
animal O
and O
plant O
proteins O
, O
which O
is O
inhibited O
by O
the O
cytotoxin O
leptomycin O
B O
( O
LMB O
) O
, O
and O
also O
by O
its O
interaction O
with O
the O
small B
GTPase I
Ran1 B
in O
the O
yeast O
two O
- O
hybrid O
system O
. O

The O
expression O
of O
cor14b B
was O
strongly O
impaired O
in O
the O
barley O
albino O
mutant O
an O
, O
suggesting O
the O
involvement O
of O
a O
plastidial O
factor O
in O
the O
control O
of O
gene O
expression O
. O

In O
addition O
, O
the O
results O
suggest O
that O
N O
region O
diversity O
at O
V B
( O
D B
) O
J B
junctions O
within O
rearranged O
immunoglobulin B
and O
T B
cell I
receptor I
gene I
loci I
can O
only O
be O
introduced O
after O
the O
generation O
of O
RAG B
- O
catalyzed O
DNA O
double O
- O
strand O
breaks O
, O
i O
. O
e O
. O
during O
the O
DNA O
end O
joining O
phase O
of O
the O
V B
( O
D B
) O
J B
recombination O
reaction O
. O

In O
addition O
, O
the O
results O
suggest O
that O
N O
region O
diversity O
at O
V B
( O
D B
) O
J B
junctions O
within O
rearranged O
immunoglobulin B
and O
T B
cell I
receptor I
gene I
loci I
can O
only O
be O
introduced O
after O
the O
generation O
of O
RAG B
- O
catalyzed O
DNA O
double O
- O
strand O
breaks O
, O
i O
. O
e O
. O
during O
the O
DNA O
end O
joining O
phase O
of O
the O
V B
( O
D B
) O
J B
recombination O
reaction O
. O

In O
addition O
, O
the O
results O
suggest O
that O
N O
region O
diversity O
at O
V B
( O
D B
) O
J B
junctions O
within O
rearranged O
immunoglobulin B
and O
T B
cell I
receptor I
gene I
loci I
can O
only O
be O
introduced O
after O
the O
generation O
of O
RAG B
- O
catalyzed O
DNA O
double O
- O
strand O
breaks O
, O
i O
. O
e O
. O
during O
the O
DNA O
end O
joining O
phase O
of O
the O
V B
( O
D B
) O
J B
recombination O
reaction O
. O

In O
addition O
, O
the O
results O
suggest O
that O
N O
region O
diversity O
at O
V B
( O
D B
) O
J B
junctions O
within O
rearranged O
immunoglobulin B
and O
T B
cell I
receptor I
gene I
loci I
can O
only O
be O
introduced O
after O
the O
generation O
of O
RAG B
- O
catalyzed O
DNA O
double O
- O
strand O
breaks O
, O
i O
. O
e O
. O
during O
the O
DNA O
end O
joining O
phase O
of O
the O
V B
( O
D B
) O
J B
recombination O
reaction O
. O

In O
addition O
, O
the O
results O
suggest O
that O
N O
region O
diversity O
at O
V B
( O
D B
) O
J B
junctions O
within O
rearranged O
immunoglobulin B
and O
T B
cell I
receptor I
gene I
loci I
can O
only O
be O
introduced O
after O
the O
generation O
of O
RAG B
- O
catalyzed O
DNA O
double O
- O
strand O
breaks O
, O
i O
. O
e O
. O
during O
the O
DNA O
end O
joining O
phase O
of O
the O
V B
( O
D B
) O
J B
recombination O
reaction O
. O

In O
addition O
, O
the O
results O
suggest O
that O
N O
region O
diversity O
at O
V B
( O
D B
) O
J B
junctions O
within O
rearranged O
immunoglobulin B
and O
T B
cell I
receptor I
gene I
loci I
can O
only O
be O
introduced O
after O
the O
generation O
of O
RAG B
- O
catalyzed O
DNA O
double O
- O
strand O
breaks O
, O
i O
. O
e O
. O
during O
the O
DNA O
end O
joining O
phase O
of O
the O
V B
( O
D B
) O
J B
recombination O
reaction O
. O

In O
addition O
, O
the O
results O
suggest O
that O
N O
region O
diversity O
at O
V B
( O
D B
) O
J B
junctions O
within O
rearranged O
immunoglobulin B
and O
T B
cell I
receptor I
gene I
loci I
can O
only O
be O
introduced O
after O
the O
generation O
of O
RAG B
- O
catalyzed O
DNA O
double O
- O
strand O
breaks O
, O
i O
. O
e O
. O
during O
the O
DNA O
end O
joining O
phase O
of O
the O
V B
( O
D B
) O
J B
recombination O
reaction O
. O

In O
addition O
, O
the O
results O
suggest O
that O
N O
region O
diversity O
at O
V B
( O
D B
) O
J B
junctions O
within O
rearranged O
immunoglobulin B
and O
T B
cell I
receptor I
gene I
loci I
can O
only O
be O
introduced O
after O
the O
generation O
of O
RAG B
- O
catalyzed O
DNA O
double O
- O
strand O
breaks O
, O
i O
. O
e O
. O
during O
the O
DNA O
end O
joining O
phase O
of O
the O
V B
( O
D B
) O
J B
recombination O
reaction O
. O

Thus O
, O
Shp2 B
regulates O
phosphotyrosine O
- O
signalling O
events O
during O
the O
complex O
ectodermal O
- O
mesenchymal O
interactions O
that O
regulate O
mammalian O
budding O
morphogenesis O
. O

However O
, O
elimination O
of O
the O
kinase O
activity O
of O
DCAMKL1 B
has O
no O
detectable O
effect O
on O
its O
microtubule O
polymerization O
activity O
. O

Coexpression O
of O
CREB B
- I
binding I
protein I
( O
CBP B
) O
/ O
p300 B
with O
TReP B
- I
132 I
has O
an O
additive O
effect O
on O
promoter O
activity O
, O
and O
the O
proteins O
were O
demonstrated O
to O
interact O
physically O
. O

Coexpression O
of O
CREB B
- I
binding I
protein I
( O
CBP B
) O
/ O
p300 B
with O
TReP B
- I
132 I
has O
an O
additive O
effect O
on O
promoter O
activity O
, O
and O
the O
proteins O
were O
demonstrated O
to O
interact O
physically O
. O

Catalase B
plays O
a O
key O
role O
as O
an O
antioxidant O
, O
protecting O
aerobic O
organisms O
from O
the O
toxic O
effects O
of O
hydrogen O
peroxide O
, O
and O
in O
some O
cases O
has O
been O
postulated O
to O
be O
a O
virulence O
factor O
. O

Recent O
developments O
in O
the O
study O
of O
growth O
factors O
: O
GRF B
and O
somatomedins B
. O

Recent O
developments O
in O
the O
study O
of O
growth O
factors O
: O
GRF B
and O
somatomedins B
. O

Acetoacetate B
decarboxylase I
( O
ADC B
) O
( O
EC4 B
. I
1 I
. I
1 I
. I
4 I
) O
of O
Clostridium O
acetobutylicum O
DSM O
792 O
was O
purified O
to O
homogeneity O
, O
and O
its O
first O
25 O
N O
- O
terminal O
amino O
acids O
were O
determined O
. O

CAT B
assays O
demonstrated O
that O
overexpression O
of O
RXRalpha B
conferred O
the O
best O
RA O
response O
, O
consistent O
with O
our O
previous O
observation O
that O
9 O
- O
cis O
- O
RA O
is O
more O
potent O
than O
all O
- O
trans O
- O
RA O
for O
inducing O
the O
expression O
of O
the O
AFP B
gene I
. O

CAT B
assays O
demonstrated O
that O
overexpression O
of O
RXRalpha B
conferred O
the O
best O
RA O
response O
, O
consistent O
with O
our O
previous O
observation O
that O
9 O
- O
cis O
- O
RA O
is O
more O
potent O
than O
all O
- O
trans O
- O
RA O
for O
inducing O
the O
expression O
of O
the O
AFP B
gene I
. O

In O
the O
predicted O
amino O
acid O
sequence O
of O
NPS1 B
, O
sequences O
homologous O
to O
the O
catalytic O
domain O
of O
protein O
kinases O
were O
found O
. O

Lag O
phases O
were O
14 O
. O
89 O
hours O
+ O
/ O
- O
0 O
. O
77 O
, O
13 O
. O
33 O
hours O
+ O
/ O
- O
0 O
. O
50 O
, O
20 O
. O
22 O
hours O
+ O
/ O
- O
0 O
. O
76 O
, O
and O
20 O
. O
00 O
hours O
+ O
/ O
- O
0 O
. O
79 O
, O
respectively O
, O
for O
endothelial O
cell O
- O
induced O
LDL B
oxidation O
. O

The O
HPV O
E1 B
and O
E2 B
proteins O
along O
with O
cellular O
factors O
, O
are O
required O
for O
replication O
of O
the O
viral O
genome O
. O

The O
HPV O
E1 B
and O
E2 B
proteins O
along O
with O
cellular O
factors O
, O
are O
required O
for O
replication O
of O
the O
viral O
genome O
. O

In O
ten O
other O
endotoxin O
- O
albumin B
- O
treated O
pigs O
PGE1 O
infusion O
( O
0 O
. O
25 O
micrograms O
X O
kg O
- O
1 O
X O
min O
- O
1 O
) O
was O
begun O
after O
established O
pulmonary O
and O
cardiovascular O
dysfunction O
, O
for O
closer O
mimicking O
of O
clinical O
use O
. O

It O
is O
postulated O
that O
the O
synthesis O
of O
the O
peptidoglycan O
layer O
was O
affected O
by O
the O
antimetabolites O
since O
the O
morphological O
effects O
were O
strikingly O
similar O
to O
those O
caused O
by O
treatment O
of O
E O
. O
cloacae O
with O
disodium O
edetate O
plus O
lysozyme B
. O

DRAP27 B
is O
recognized O
by O
CD9 B
antibodies I
. O

These O
three O
chromosomes O
share O
the O
transferrin B
gene I
( O
TF B
) O
, O
the O
myosin B
light I
polypeptide I
3 I
gene I
( O
MYL3 B
) O
, O
and O
the O
acylpeptide B
hydrolase I
gene I
( O
APEH B
) O
. O

These O
three O
chromosomes O
share O
the O
transferrin B
gene I
( O
TF B
) O
, O
the O
myosin B
light I
polypeptide I
3 I
gene I
( O
MYL3 B
) O
, O
and O
the O
acylpeptide B
hydrolase I
gene I
( O
APEH B
) O
. O

These O
three O
chromosomes O
share O
the O
transferrin B
gene I
( O
TF B
) O
, O
the O
myosin B
light I
polypeptide I
3 I
gene I
( O
MYL3 B
) O
, O
and O
the O
acylpeptide B
hydrolase I
gene I
( O
APEH B
) O
. O

Together O
, O
these O
results O
indicate O
that O
YTS1 B
is O
a O
bifunctional O
protein O
active O
in O
both O
splicing O
and O
protein O
synthesis O
. O

Human B
myotonic I
dystrophy I
protein I
kinase I
( O
DMPK B
) O
is O
a O
member O
of O
a O
novel O
class O
of O
multidomain O
protein O
kinases O
that O
regulate O
cell O
size O
and O
shape O
in O
a O
variety O
of O
organisms O
. O

The O
human B
BRCA1 I
promoter I
also O
contains O
a O
conserved O
E2F B
site I
and O
is O
similarly O
regulated O
by O
E2F1 B
and O
Rb B
. O

The O
human B
BRCA1 I
promoter I
also O
contains O
a O
conserved O
E2F B
site I
and O
is O
similarly O
regulated O
by O
E2F1 B
and O
Rb B
. O

The O
translated O
sequence O
of O
the O
FLI B
LRR I
associated I
protein I
( O
FLAP B
) O
encodes O
a O
novel O
protein O
not O
represented O
in O
the O
data O
base O
. O

In O
vitro O
, O
cytokine O
- O
or O
hypoxia O
- O
induced O
up O
- O
regulation O
of O
Fas B
expression O
is O
associated O
with O
RTC O
apoptosis O
. O

The O
site O
of O
acetylation O
of O
Tat B
was O
mapped O
to O
the O
double O
- O
lysine O
motif O
in O
a O
highly O
conserved O
region O
, O
( O
49 O
) O
RKKRRQ O
( O
54 O
) O
, O
of O
the O
basic O
RNA O
- O
binding O
motif O
of O
Tat B
. O

The O
site O
of O
acetylation O
of O
Tat B
was O
mapped O
to O
the O
double O
- O
lysine O
motif O
in O
a O
highly O
conserved O
region O
, O
( O
49 O
) O
RKKRRQ O
( O
54 O
) O
, O
of O
the O
basic O
RNA O
- O
binding O
motif O
of O
Tat B
. O

Uptake O
of O
colicins B
required O
different O
domains O
in O
TonB B
, O
for O
colicin B
B I
and I
M I
around O
residue O
160 O
and O
for O
colicin B
Ia I
, O
a O
domain O
closer O
to O
the O
C O
- O
terminal O
end O
. O

Uptake O
of O
colicins B
required O
different O
domains O
in O
TonB B
, O
for O
colicin B
B I
and I
M I
around O
residue O
160 O
and O
for O
colicin B
Ia I
, O
a O
domain O
closer O
to O
the O
C O
- O
terminal O
end O
. O

It O
is O
dangerous O
to O
label O
such O
conditions O
as O
' O
inappropriate O
' O
secretion O
of O
ADH B
since O
the O
maintenance O
of O
circulating O
volume O
is O
at O
least O
as O
important O
a O
physiological O
requirement O
as O
the O
defence O
of O
tonicity O
. O

This O
C O
- O
terminal O
domain O
contains O
several O
YxxI O
/ O
L O
motifs O
reminiscent O
of O
LMP2A B
and O
a O
putative O
TRAF B
binding I
site I
as O
in O
LMP1 B
. O

This O
C O
- O
terminal O
domain O
contains O
several O
YxxI O
/ O
L O
motifs O
reminiscent O
of O
LMP2A B
and O
a O
putative O
TRAF B
binding I
site I
as O
in O
LMP1 B
. O

SCAN B
boxes O
are O
found O
in O
eight O
other O
genes O
in O
the O
GenBank O
database O
, O
five O
of O
which O
are O
also O
in O
the O
Kruppel B
family I
of O
zinc B
finger I
proteins I
lacking O
KRAB B
A I
and I
B I
domains O
and O
thereby O
define O
a O
new O
subclass O
of O
zinc B
finger I
proteins I
. O

The O
amount O
of O
ERCC1 B
detectable O
by O
immunoblotting O
is O
reduced O
in O
group O
1 O
, O
group O
4 O
and O
XP O
- O
F O
extracts O
. O

Optimized O
USF B
and O
MYC B
DNA O
- O
binding O
sites O
, O
which O
differ O
in O
the O
nucleotides O
bordering O
the O
hexanucleotide O
box O
displace O
the O
E B
- I
C4 I
factor I
in O
competition O
assays O
but O
with O
lesser O
efficiency O
than O
the O
E B
- I
C4 I
site I
itself O
. O

Optimized O
USF B
and O
MYC B
DNA O
- O
binding O
sites O
, O
which O
differ O
in O
the O
nucleotides O
bordering O
the O
hexanucleotide O
box O
displace O
the O
E B
- I
C4 I
factor I
in O
competition O
assays O
but O
with O
lesser O
efficiency O
than O
the O
E B
- I
C4 I
site I
itself O
. O

Vorozole O
( O
Rivizor O
) O
is O
a O
potent O
and O
stereospecific O
inhibitor O
of O
aromatase B
having O
shown O
promising O
endocrine O
effects O
in O
phase O
I O
studies O
. O

These O
findings O
suggest O
that O
T3R B
can O
repress O
or O
activate O
transcription O
while O
tethered O
to O
the O
LBD O
of O
GAL4 B
- O
RXR B
and O
that O
heterodimerization O
can O
occur O
in O
vivo O
without O
stabilization O
by O
hormone O
response O
elements O
. O

These O
findings O
suggest O
that O
T3R B
can O
repress O
or O
activate O
transcription O
while O
tethered O
to O
the O
LBD O
of O
GAL4 B
- O
RXR B
and O
that O
heterodimerization O
can O
occur O
in O
vivo O
without O
stabilization O
by O
hormone O
response O
elements O
. O

These O
findings O
suggest O
that O
T3R B
can O
repress O
or O
activate O
transcription O
while O
tethered O
to O
the O
LBD O
of O
GAL4 B
- O
RXR B
and O
that O
heterodimerization O
can O
occur O
in O
vivo O
without O
stabilization O
by O
hormone O
response O
elements O
. O

Most O
interestingly O
, O
although O
the O
effector O
plasmid O
containing O
the O
ICP27 B
gene I
had O
little O
effect O
on O
its O
own O
, O
two O
different O
and O
marked O
effects O
depending O
on O
the O
target O
were O
observed O
when O
ICP27 B
was O
combined O
with O
ICP4 B
or O
ICP0 B
or O
both O
. O

Most O
interestingly O
, O
although O
the O
effector O
plasmid O
containing O
the O
ICP27 B
gene I
had O
little O
effect O
on O
its O
own O
, O
two O
different O
and O
marked O
effects O
depending O
on O
the O
target O
were O
observed O
when O
ICP27 B
was O
combined O
with O
ICP4 B
or O
ICP0 B
or O
both O
. O

Most O
interestingly O
, O
although O
the O
effector O
plasmid O
containing O
the O
ICP27 B
gene I
had O
little O
effect O
on O
its O
own O
, O
two O
different O
and O
marked O
effects O
depending O
on O
the O
target O
were O
observed O
when O
ICP27 B
was O
combined O
with O
ICP4 B
or O
ICP0 B
or O
both O
. O

TOM1 B
encodes O
a O
member O
of O
the O
hect B
- O
domain O
- O
containing O
E3 B
ubiquitin B
- I
protein I
ligase I
family O
that O
is O
required O
for O
growth O
at O
elevated O
temperatures O
. O

TOM1 B
encodes O
a O
member O
of O
the O
hect B
- O
domain O
- O
containing O
E3 B
ubiquitin B
- I
protein I
ligase I
family O
that O
is O
required O
for O
growth O
at O
elevated O
temperatures O
. O

TOM1 B
encodes O
a O
member O
of O
the O
hect B
- O
domain O
- O
containing O
E3 B
ubiquitin B
- I
protein I
ligase I
family O
that O
is O
required O
for O
growth O
at O
elevated O
temperatures O
. O

In O
HMEC O
stably O
transfected O
with O
an O
ER B
mutant I
containing O
a O
deletion O
in O
the O
second O
zinc O
finger O
of O
the O
DNA O
- O
binding O
domain O
, O
E O
and O
HT O
had O
different O
effects O
on O
EBBP B
gene I
expression O
; O
EBBP B
regulation O
by O
E O
was O
dramatically O
reduced O
while O
the O
effects O
of O
HT O
were O
augmented O
. O

The O
gene B
atp6 I
, O
encoding O
subunit O
6 O
of O
the O
mitochondrial O
F0 B
- O
ATPase B
complex O
, O
has O
been O
characterized O
from O
both O
the O
normal O
( O
fertile O
) O
and O
Ogura O
( O
male O
- O
sterile O
) O
radish O
cytoplasms O
in O
order O
to O
determine O
if O
previously O
identified O
atp6 B
transcriptional O
differences O
could O
play O
a O
role O
in O
cytoplasmic O
male O
sterility O
. O

The O
gene B
atp6 I
, O
encoding O
subunit O
6 O
of O
the O
mitochondrial O
F0 B
- O
ATPase B
complex O
, O
has O
been O
characterized O
from O
both O
the O
normal O
( O
fertile O
) O
and O
Ogura O
( O
male O
- O
sterile O
) O
radish O
cytoplasms O
in O
order O
to O
determine O
if O
previously O
identified O
atp6 B
transcriptional O
differences O
could O
play O
a O
role O
in O
cytoplasmic O
male O
sterility O
. O

The O
gene B
atp6 I
, O
encoding O
subunit O
6 O
of O
the O
mitochondrial O
F0 B
- O
ATPase B
complex O
, O
has O
been O
characterized O
from O
both O
the O
normal O
( O
fertile O
) O
and O
Ogura O
( O
male O
- O
sterile O
) O
radish O
cytoplasms O
in O
order O
to O
determine O
if O
previously O
identified O
atp6 B
transcriptional O
differences O
could O
play O
a O
role O
in O
cytoplasmic O
male O
sterility O
. O

The O
gag B
- O
myc B
proteins O
encoded O
by O
these O
variants O
efficiently O
localized O
to O
the O
cell O
nucleus O
. O

The O
gag B
- O
myc B
proteins O
encoded O
by O
these O
variants O
efficiently O
localized O
to O
the O
cell O
nucleus O
. O

Hpr1 B
forms O
, O
together O
with O
Tho2 B
, O
Mft1 B
, O
and O
Thp2 B
, O
the O
THO B
complex I
, O
which O
controls O
transcription O
elongation O
and O
genome O
stability O
in O
Saccharomyces O
cerevisiae O
. O

Hpr1 B
forms O
, O
together O
with O
Tho2 B
, O
Mft1 B
, O
and O
Thp2 B
, O
the O
THO B
complex I
, O
which O
controls O
transcription O
elongation O
and O
genome O
stability O
in O
Saccharomyces O
cerevisiae O
. O

Hpr1 B
forms O
, O
together O
with O
Tho2 B
, O
Mft1 B
, O
and O
Thp2 B
, O
the O
THO B
complex I
, O
which O
controls O
transcription O
elongation O
and O
genome O
stability O
in O
Saccharomyces O
cerevisiae O
. O

Hpr1 B
forms O
, O
together O
with O
Tho2 B
, O
Mft1 B
, O
and O
Thp2 B
, O
the O
THO B
complex I
, O
which O
controls O
transcription O
elongation O
and O
genome O
stability O
in O
Saccharomyces O
cerevisiae O
. O

UPR O
elements O
present O
in O
other O
ER O
chaperone O
genes O
, O
such O
as O
yeast B
KAR2 I
( O
BiP B
) O
, O
mammalian B
GRP78 I
( O
BiP B
) O
, O
and O
GRP94 B
, O
function O
in O
an O
analogous O
manner O
to O
that O
in O
FKB2 B
. O

UPR O
elements O
present O
in O
other O
ER O
chaperone O
genes O
, O
such O
as O
yeast B
KAR2 I
( O
BiP B
) O
, O
mammalian B
GRP78 I
( O
BiP B
) O
, O
and O
GRP94 B
, O
function O
in O
an O
analogous O
manner O
to O
that O
in O
FKB2 B
. O

UPR O
elements O
present O
in O
other O
ER O
chaperone O
genes O
, O
such O
as O
yeast B
KAR2 I
( O
BiP B
) O
, O
mammalian B
GRP78 I
( O
BiP B
) O
, O
and O
GRP94 B
, O
function O
in O
an O
analogous O
manner O
to O
that O
in O
FKB2 B
. O

UPR O
elements O
present O
in O
other O
ER O
chaperone O
genes O
, O
such O
as O
yeast B
KAR2 I
( O
BiP B
) O
, O
mammalian B
GRP78 I
( O
BiP B
) O
, O
and O
GRP94 B
, O
function O
in O
an O
analogous O
manner O
to O
that O
in O
FKB2 B
. O

Plasmid O
subclones O
of O
the O
hr1a B
- O
containing O
AcMNPV O
HindIII B
- O
N O
fragment O
were O
examined O
for O
their O
ability O
to O
replicate O
in O
virus O
- O
infected O
( O
Spodoptera O
frugiperda O
) O
Sf9 O
cells O
, O
and O
to O
stimulate O
transcription O
when O
linked O
in O
cis O
with O
a O
39K B
gene I
promoter I
- I
beta I
- I
glucuronidase I
fusion I
and O
cotransfected O
into O
cells O
along O
with O
a O
plasmid O
( O
ple O
- O
1 O
) O
containing O
the O
gene O
encoding O
the O
trans O
- O
acting O
factor O
IE B
- I
1 I
. O

Plasmid O
subclones O
of O
the O
hr1a B
- O
containing O
AcMNPV O
HindIII B
- O
N O
fragment O
were O
examined O
for O
their O
ability O
to O
replicate O
in O
virus O
- O
infected O
( O
Spodoptera O
frugiperda O
) O
Sf9 O
cells O
, O
and O
to O
stimulate O
transcription O
when O
linked O
in O
cis O
with O
a O
39K B
gene I
promoter I
- I
beta I
- I
glucuronidase I
fusion I
and O
cotransfected O
into O
cells O
along O
with O
a O
plasmid O
( O
ple O
- O
1 O
) O
containing O
the O
gene O
encoding O
the O
trans O
- O
acting O
factor O
IE B
- I
1 I
. O

The O
adeno O
- O
associated O
virus O
type O
2 O
( O
AAV O
- O
2 O
) O
Rep78 B
/ O
Rep68 B
regulatory O
proteins O
are O
pleiotropic O
effectors O
of O
viral O
and O
cellular O
DNA O
replication O
, O
of O
cellular O
transformation O
by O
viral O
and O
cellular O
oncogenes O
, O
and O
of O
homologous O
and O
heterologous O
gene O
expression O
. O

The O
adeno O
- O
associated O
virus O
type O
2 O
( O
AAV O
- O
2 O
) O
Rep78 B
/ O
Rep68 B
regulatory O
proteins O
are O
pleiotropic O
effectors O
of O
viral O
and O
cellular O
DNA O
replication O
, O
of O
cellular O
transformation O
by O
viral O
and O
cellular O
oncogenes O
, O
and O
of O
homologous O
and O
heterologous O
gene O
expression O
. O

Role O
of O
the O
CCAAT B
/ I
enhancer I
binding I
protein I
- I
alpha I
transcription I
factor I
in O
the O
glucocorticoid O
stimulation O
of O
p21waf1 B
/ O
cip1 B
gene O
promoter O
activity O
in O
growth O
- O
arrested O
rat O
hepatoma O
cells O
. O

Role O
of O
the O
CCAAT B
/ I
enhancer I
binding I
protein I
- I
alpha I
transcription I
factor I
in O
the O
glucocorticoid O
stimulation O
of O
p21waf1 B
/ O
cip1 B
gene O
promoter O
activity O
in O
growth O
- O
arrested O
rat O
hepatoma O
cells O
. O

Here O
we O
show O
that O
one O
nudF B
suppressor I
also O
suppresses O
hs O
- O
mutations O
in O
nudA B
, O
nudC B
, O
and O
nudG B
and O
deletions O
in O
nudA B
and O
nudF B
. O

Here O
we O
show O
that O
one O
nudF B
suppressor I
also O
suppresses O
hs O
- O
mutations O
in O
nudA B
, O
nudC B
, O
and O
nudG B
and O
deletions O
in O
nudA B
and O
nudF B
. O

Here O
we O
show O
that O
one O
nudF B
suppressor I
also O
suppresses O
hs O
- O
mutations O
in O
nudA B
, O
nudC B
, O
and O
nudG B
and O
deletions O
in O
nudA B
and O
nudF B
. O

Here O
we O
show O
that O
one O
nudF B
suppressor I
also O
suppresses O
hs O
- O
mutations O
in O
nudA B
, O
nudC B
, O
and O
nudG B
and O
deletions O
in O
nudA B
and O
nudF B
. O

Here O
we O
show O
that O
one O
nudF B
suppressor I
also O
suppresses O
hs O
- O
mutations O
in O
nudA B
, O
nudC B
, O
and O
nudG B
and O
deletions O
in O
nudA B
and O
nudF B
. O

Treatment O
of O
cells O
for O
10 O
min O
with O
TNF B
- I
alpha I
resulted O
in O
activation O
of O
p44 B
/ I
42 I
MAPK O
, O
p38 B
, O
and O
JNK B
. O

Treatment O
of O
cells O
for O
10 O
min O
with O
TNF B
- I
alpha I
resulted O
in O
activation O
of O
p44 B
/ I
42 I
MAPK O
, O
p38 B
, O
and O
JNK B
. O

This O
report O
describes O
the O
isolation O
and O
recombinant O
expression O
of O
a O
cDNA O
clone O
encoding O
HER4 B
, O
the O
fourth O
member O
of O
the O
human B
epidermal I
growth I
factor I
receptor I
( O
EGFR B
) O
family O
. O

This O
report O
describes O
the O
isolation O
and O
recombinant O
expression O
of O
a O
cDNA O
clone O
encoding O
HER4 B
, O
the O
fourth O
member O
of O
the O
human B
epidermal I
growth I
factor I
receptor I
( O
EGFR B
) O
family O
. O

Sixtieth O
anniversary O
of O
Angiotensin B
. O

MDA O
- O
MB O
- O
468 O
cells O
were O
stably O
transfected O
with O
either O
a O
plasmid O
having O
a O
CMV B
promoter I
- O
driven O
rabbit B
beta I
- I
globin I
gene I
or O
plasmids O
having O
a O
CMV B
promoter I
- O
driven O
chimeric O
gadd45 B
5 O
" O
- O
UTR O
- O
rabbit B
beta I
- I
globin I
gene O
, O
where O
the O
entire B
gadd45 I
5 I
" I
- I
UTR I
( I
from I
+ I
1 I
to I
+ I
298 I
) I
or O
a O
45 O
bp O
subfragment O
of O
the O
gadd45 B
5 I
" I
- I
UTR I
( I
from I
+ I
10 I
to I
+ I
55 I
) I
was O
positioned O
at O
the O
5 O
" O
- O
end O
of O

Following O
EGF B
or O
NGF B
stimulation O
of O
the O
v O
- O
CrkPC12 O
cells O
, O
the O
v B
- I
Crk I
protein O
itself O
became O
tyrosine O
phosphorylated O
within O
1 O
min O
. O

Following O
EGF B
or O
NGF B
stimulation O
of O
the O
v O
- O
CrkPC12 O
cells O
, O
the O
v B
- I
Crk I
protein O
itself O
became O
tyrosine O
phosphorylated O
within O
1 O
min O
. O

BCR B
- O
ABL B
expression O
confers O
cross O
- O
resistance O
to O
multiple O
genotoxic O
anticancer O
drugs O
by O
inhibition O
of O
the O
apoptotic O
response O
to O
DNA O
damage O
in O
association O
with O
cell O
cycle O
arrest O
at O
the O
G2 O
- O
M O
restriction O
point O
. O

BCR B
- O
ABL B
expression O
confers O
cross O
- O
resistance O
to O
multiple O
genotoxic O
anticancer O
drugs O
by O
inhibition O
of O
the O
apoptotic O
response O
to O
DNA O
damage O
in O
association O
with O
cell O
cycle O
arrest O
at O
the O
G2 O
- O
M O
restriction O
point O
. O

The O
protein B
kinase I
C I
inhibitor O
GF O
- O
109203X O
abolished O
the O
activation O
by O
phorbol O
ester O
and O
inhibited O
the O
effect O
of O
CCK B
by O
78 O
% O
but O
had O
no O
effect O
on O
EGF B
- O
activated O
MAPK B
activity O
. O

The O
protein B
kinase I
C I
inhibitor O
GF O
- O
109203X O
abolished O
the O
activation O
by O
phorbol O
ester O
and O
inhibited O
the O
effect O
of O
CCK B
by O
78 O
% O
but O
had O
no O
effect O
on O
EGF B
- O
activated O
MAPK B
activity O
. O

The O
protein B
kinase I
C I
inhibitor O
GF O
- O
109203X O
abolished O
the O
activation O
by O
phorbol O
ester O
and O
inhibited O
the O
effect O
of O
CCK B
by O
78 O
% O
but O
had O
no O
effect O
on O
EGF B
- O
activated O
MAPK B
activity O
. O

Activated O
FGFR3 B
predominantly O
interacts O
with O
GRB2 B
. I
Sos I
in O
complex O
with O
a O
previously O
identified O
90 O
- O
kDa O
protein O
and O
designated O
protein B
80K I
- I
H I
. O

The O
rate O
of O
collagen B
synthesis O
in O
normal O
scar O
was O
approximately O
constant O
between O
6 O
months O
and O
20 O
years O
after O
the O
initial O
wounding O
, O
but O
in O
both O
hypertrophic O
scar O
and O
keloid O
the O
rate O
was O
initially O
approximately O
twice O
that O
in O
normal O
scar O
, O
and O
2 O
- O
3 O
years O
after O
wounding O
it O
fell O
to O
approximately O
the O
same O
level O
as O
in O
normal O
scar O
. O

Evidence O
for O
a O
role O
of O
Smad6 B
in O
chick O
cardiac O
development O
. O

The O
LIF B
appeared O
to O
be O
released O
by O
the O
patient O
' O
s O
peripheral O
blood O
lymphocytes O
when O
cultured O
with O
optimal O
doses O
of O
propranolol O
. O

Co O
- O
expression O
of O
PLD1 B
in O
COS O
- O
7 O
cells O
with O
the O
two O
recombinant B
CK2 I
subunits I
, O
alpha O
or O
beta O
, O
suggests O
that O
the O
association O
of O
PLD1 B
with O
the O
kinase O
is O
through O
the O
beta O
subunit O
. O

Co O
- O
expression O
of O
PLD1 B
in O
COS O
- O
7 O
cells O
with O
the O
two O
recombinant B
CK2 I
subunits I
, O
alpha O
or O
beta O
, O
suggests O
that O
the O
association O
of O
PLD1 B
with O
the O
kinase O
is O
through O
the O
beta O
subunit O
. O

Our O
objective O
was O
to O
find O
possible O
predictors O
for O
the O
expression O
and O
progression O
of O
LJM O
and O
to O
evaluate O
the O
relationship O
between O
LJM O
and O
other O
long O
- O
term O
complications O
of O
insulin B
- O
dependent O
diabetes O
mellitus O
. O

Human B
recombinant I
erythropoietin I
( O
r B
- I
HuEPO I
, O
EprexR B
) O
was O
administered O
to O
8 O
children O
with O
chronic O
renal O
failure O
and O
high O
transfusion O
requirement O
. O

Removal O
of O
cyclin B
- I
dependant I
kinases I
( O
cdks B
) O
or O
cdk2 B
from O
these O
extracts O
using O
affinity O
matrices O
severely O
inhibits O
initiation O
of O
S O
phase O
. O

Removal O
of O
cyclin B
- I
dependant I
kinases I
( O
cdks B
) O
or O
cdk2 B
from O
these O
extracts O
using O
affinity O
matrices O
severely O
inhibits O
initiation O
of O
S O
phase O
. O

Comparison O
of O
the O
genes O
coding O
for O
mouse O
and O
human O
p36 B
( O
annexin B
II I
) O
and O
mouse O
, O
rat O
and O
human O
p35 B
( O
annexin B
I I
) O
and O
pigeon O
cp35 B
( O
an O
annexin B
I I
- I
related I
protein I
) O
shows O
strong O
genomic O
structural O
conservation O
supporting O
the O
hypothesis O
that O
these O
genes O
had O
a O
common O
ancestor O
. O

Comparison O
of O
the O
genes O
coding O
for O
mouse O
and O
human O
p36 B
( O
annexin B
II I
) O
and O
mouse O
, O
rat O
and O
human O
p35 B
( O
annexin B
I I
) O
and O
pigeon O
cp35 B
( O
an O
annexin B
I I
- I
related I
protein I
) O
shows O
strong O
genomic O
structural O
conservation O
supporting O
the O
hypothesis O
that O
these O
genes O
had O
a O
common O
ancestor O
. O

Comparison O
of O
the O
genes O
coding O
for O
mouse O
and O
human O
p36 B
( O
annexin B
II I
) O
and O
mouse O
, O
rat O
and O
human O
p35 B
( O
annexin B
I I
) O
and O
pigeon O
cp35 B
( O
an O
annexin B
I I
- I
related I
protein I
) O
shows O
strong O
genomic O
structural O
conservation O
supporting O
the O
hypothesis O
that O
these O
genes O
had O
a O
common O
ancestor O
. O

Collectively O
, O
these O
studies O
suggest O
that O
the O
major O
EGF B
- O
stimulated O
mitotic O
growth O
pathways O
may O
not O
be O
absolutely O
linked O
to O
the O
stat91 B
signaling O
pathways O
and O
that O
such O
transcription O
complexes O
are O
more O
complex O
than O
previously O
reported O
. O

Collectively O
, O
these O
studies O
suggest O
that O
the O
major O
EGF B
- O
stimulated O
mitotic O
growth O
pathways O
may O
not O
be O
absolutely O
linked O
to O
the O
stat91 B
signaling O
pathways O
and O
that O
such O
transcription O
complexes O
are O
more O
complex O
than O
previously O
reported O
. O

In O
addition O
, O
we O
show O
that O
expression O
of O
antisense O
mRNA O
for O
p130CAS B
resulted O
in O
reversion O
of O
the O
transformed O
phenotype O
of O
all O
these O
cell O
lines O
. O

The O
amino O
acid O
sequence O
of O
the O
protein O
encoded O
by O
MSK1 B
is O
homologous O
to O
yeast B
cytoplasmic I
lysyl I
- I
tRNA I
synthetase I
and O
to O
the O
product O
of O
the O
herC B
gene I
, O
which O
has O
recently O
been O
suggested O
to O
code O
for O
the O
Escherichia O
coli O
enzyme O
. O

Similar O
to O
the O
D B
, O
B B
/ O
B B
' I
and O
E B
proteins I
, O
the O
F B
and O
G B
proteins I
do O
not O
possess O
any O
of O
the O
known O
RNA O
binding O
motifs O
, O
suggesting O
that O
other O
types O
of O
RNA O
- O
protein O
interactions O
occur O
in O
the O
snRNP O
core O
. O

Similar O
to O
the O
D B
, O
B B
/ O
B B
' I
and O
E B
proteins I
, O
the O
F B
and O
G B
proteins I
do O
not O
possess O
any O
of O
the O
known O
RNA O
binding O
motifs O
, O
suggesting O
that O
other O
types O
of O
RNA O
- O
protein O
interactions O
occur O
in O
the O
snRNP O
core O
. O

Similar O
to O
the O
D B
, O
B B
/ O
B B
' I
and O
E B
proteins I
, O
the O
F B
and O
G B
proteins I
do O
not O
possess O
any O
of O
the O
known O
RNA O
binding O
motifs O
, O
suggesting O
that O
other O
types O
of O
RNA O
- O
protein O
interactions O
occur O
in O
the O
snRNP O
core O
. O

These O
observations O
suggest O
that O
clr4 B
+ I
and O
rik1 B
+ I
must O
play O
a O
role O
in O
the O
assembly O
of O
Swi6p B
into O
a O
transcriptionally O
silent O
, O
inaccessible O
chromatin O
structure O
at O
fission O
yeast O
centromeres O
which O
is O
required O
to O
facilitate O
interactions O
with O
spindle O
microtubules O
and O
to O
ensure O
normal O
chromosome O
segregation O
. O

The O
AtNMT1 B
expression O
profile O
indicated O
ubiquity O
in O
roots O
, O
stem O
, O
leaves O
, O
flowers O
, O
and O
siliques O
( O
approximately O
1 O
. O
7 O
kb O
transcript O
and O
approximately O
50 O
kDa O
immunoreactive O
polypeptide O
) O
but O
a O
greater O
level O
in O
the O
younger O
tissue O
, O
which O
are O
developmentally O
very O
active O
. O

A O
. O
nidulans O
transformants O
secreted O
high O
amounts O
of O
PGI B
and O
PGII B
in O
comparison O
to O
the O
previously O
characterized O
A O
. O
niger O
transformants O
and O
a O
novel O
polygalacturonase B
( O
PGC B
) O
was O
produced O
at O
high O
levels O
by O
A O
. O
nidulans O
transformed O
with O
the O
subcloned O
pgaC B
gene I
. O

A O
. O
nidulans O
transformants O
secreted O
high O
amounts O
of O
PGI B
and O
PGII B
in O
comparison O
to O
the O
previously O
characterized O
A O
. O
niger O
transformants O
and O
a O
novel O
polygalacturonase B
( O
PGC B
) O
was O
produced O
at O
high O
levels O
by O
A O
. O
nidulans O
transformed O
with O
the O
subcloned O
pgaC B
gene I
. O

A O
. O
nidulans O
transformants O
secreted O
high O
amounts O
of O
PGI B
and O
PGII B
in O
comparison O
to O
the O
previously O
characterized O
A O
. O
niger O
transformants O
and O
a O
novel O
polygalacturonase B
( O
PGC B
) O
was O
produced O
at O
high O
levels O
by O
A O
. O
nidulans O
transformed O
with O
the O
subcloned O
pgaC B
gene I
. O

A O
. O
nidulans O
transformants O
secreted O
high O
amounts O
of O
PGI B
and O
PGII B
in O
comparison O
to O
the O
previously O
characterized O
A O
. O
niger O
transformants O
and O
a O
novel O
polygalacturonase B
( O
PGC B
) O
was O
produced O
at O
high O
levels O
by O
A O
. O
nidulans O
transformed O
with O
the O
subcloned O
pgaC B
gene I
. O

This O
interaction O
is O
functional O
as O
it O
leads O
to O
retargeting O
of O
NF B
- I
kappa I
B I
p50 B
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

The O
orf2 O
gene O
product O
is O
a O
protein O
of O
79 O
amino O
acids O
with O
characteristics O
similar O
to O
those O
of O
the O
Tat B
( O
transactivator B
) O
proteins O
of O
the O
ungulate O
lentiviruses O
. O

The O
orf2 O
gene O
product O
is O
a O
protein O
of O
79 O
amino O
acids O
with O
characteristics O
similar O
to O
those O
of O
the O
Tat B
( O
transactivator B
) O
proteins O
of O
the O
ungulate O
lentiviruses O
. O

Rac2 B
, O
a O
member O
of O
the O
Rho B
family I
of O
GTPases B
, O
is O
highly O
expressed O
in O
myeloid O
cells O
and O
is O
a O
regulator O
of O
the O
NADPH B
- I
oxidase I
complex I
. O

Rac2 B
, O
a O
member O
of O
the O
Rho B
family I
of O
GTPases B
, O
is O
highly O
expressed O
in O
myeloid O
cells O
and O
is O
a O
regulator O
of O
the O
NADPH B
- I
oxidase I
complex I
. O

In O
vitro O
kinase O
assays O
on O
isolated O
microvilli O
and O
microvillar O
fractions O
enriched O
in O
the O
putative O
signal O
transduction O
particle O
showed O
a O
high O
specific O
activity O
of O
tyrosine B
kinase I
activity O
compared O
to O
that O
of O
membranes O
from O
EGF B
receptor I
- O
overexpressing O
A431 O
cells O
maximally O
activated O
by O
EGF B
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
identified O
two O
potential O
Ets B
binding O
sites O
, O
EBS1 B
and O
EBS2 B
, O
which O
are O
conserved O
in O
both O
the O
human O
and O
murine O
interleukin B
- I
2 I
enhancers O
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
identified O
two O
potential O
Ets B
binding O
sites O
, O
EBS1 B
and O
EBS2 B
, O
which O
are O
conserved O
in O
both O
the O
human O
and O
murine O
interleukin B
- I
2 I
enhancers O
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
identified O
two O
potential O
Ets B
binding O
sites O
, O
EBS1 B
and O
EBS2 B
, O
which O
are O
conserved O
in O
both O
the O
human O
and O
murine O
interleukin B
- I
2 I
enhancers O
. O

KatA B
, O
AhpCF B
, O
heme O
biosynthesis O
enzymes O
, O
and O
MrgA B
are O
also O
induced O
upon O
entry O
into O
stationary O
phase O
under O
conditions O
of O
iron O
and O
manganese O
limitation O
. O

KatA B
, O
AhpCF B
, O
heme O
biosynthesis O
enzymes O
, O
and O
MrgA B
are O
also O
induced O
upon O
entry O
into O
stationary O
phase O
under O
conditions O
of O
iron O
and O
manganese O
limitation O
. O

KatA B
, O
AhpCF B
, O
heme O
biosynthesis O
enzymes O
, O
and O
MrgA B
are O
also O
induced O
upon O
entry O
into O
stationary O
phase O
under O
conditions O
of O
iron O
and O
manganese O
limitation O
. O

Scleraxis B
overexpression O
enhanced O
expression O
of O
the O
aggrecan B
gene I
, O
which O
is O
not O
normally O
expressed O
at O
high O
levels O
in O
these O
osteoblastic O
cells O
. O

This O
study O
demonstrates O
that O
the O
exposure O
to O
sulphur O
mustard O
results O
in O
very O
low O
androgen O
levels O
and O
hypo O
- O
responsiveness O
to O
GnRH B
in O
the O
first O
five O
weeks O
and O
normalization O
by O
the O
twelfth O
week O
after O
injury O
. O

Overexpression O
of O
eIF4E B
transforms O
cells O
, O
and O
mutations O
in O
eIF4E B
arrest O
cells O
in O
G O
, O
in O
cdc33 B
mutants I
. O

Overexpression O
of O
eIF4E B
transforms O
cells O
, O
and O
mutations O
in O
eIF4E B
arrest O
cells O
in O
G O
, O
in O
cdc33 B
mutants I
. O

Repression O
of O
the O
herpes B
simplex I
virus I
1 I
alpha I
4 I
gene I
by O
its O
gene O
product O
( O
ICP4 B
) O
within O
the O
context O
of O
the O
viral O
genome O
is O
conditioned O
by O
the O
distance O
and O
stereoaxial O
alignment O
of O
the O
ICP4 B
DNA I
binding I
site I
relative O
to O
the O
TATA O
box O
. O

As O
anticipated O
, O
both O
intracellular O
p54 B
- O
SAPKbeta B
activation O
and O
Bcl B
- I
2 I
phosphorylation O
are O
blocked O
by O
co O
- O
transfection O
with O
the O
MAP B
kinase I
specific O
phosphatase O
MKP3 B
/ O
PYST1 B
. O

As O
anticipated O
, O
both O
intracellular O
p54 B
- O
SAPKbeta B
activation O
and O
Bcl B
- I
2 I
phosphorylation O
are O
blocked O
by O
co O
- O
transfection O
with O
the O
MAP B
kinase I
specific O
phosphatase O
MKP3 B
/ O
PYST1 B
. O

As O
anticipated O
, O
both O
intracellular O
p54 B
- O
SAPKbeta B
activation O
and O
Bcl B
- I
2 I
phosphorylation O
are O
blocked O
by O
co O
- O
transfection O
with O
the O
MAP B
kinase I
specific O
phosphatase O
MKP3 B
/ O
PYST1 B
. O

As O
anticipated O
, O
both O
intracellular O
p54 B
- O
SAPKbeta B
activation O
and O
Bcl B
- I
2 I
phosphorylation O
are O
blocked O
by O
co O
- O
transfection O
with O
the O
MAP B
kinase I
specific O
phosphatase O
MKP3 B
/ O
PYST1 B
. O

Treatment O
of O
excessive O
bleeding O
after O
cardiopulmonary O
bypass O
was O
based O
on O
an O
algorithm O
using O
point O
- O
of O
- O
care O
testing O
with O
whole O
blood B
prothrombin I
time O
, O
activated O
partial O
thromboplastin B
time O
, O
heparinase B
activated O
clotting O
time O
, O
and O
platelet O
count O
. O

Treatment O
of O
excessive O
bleeding O
after O
cardiopulmonary O
bypass O
was O
based O
on O
an O
algorithm O
using O
point O
- O
of O
- O
care O
testing O
with O
whole O
blood B
prothrombin I
time O
, O
activated O
partial O
thromboplastin B
time O
, O
heparinase B
activated O
clotting O
time O
, O
and O
platelet O
count O
. O

Glucose O
may O
reduce O
slightly O
the O
pool O
of O
amino O
nitrogen O
available O
for O
albumin B
and O
urea O
synthesis O
by O
diverting O
some O
of O
the O
infused O
amino O
acids O
from O
protein O
synthesis O
by O
the O
liver O
to O
muscle O
. O

Antibodies O
specific O
to O
the O
different O
members O
of O
the O
Jun B
and O
Fos B
family I
of I
transcription I
factors I
show O
that O
, O
in O
gel O
retardation O
assays O
, O
a O
Jun B
- I
like I
factor I
is O
a O
component O
of O
the O
H3 B
. I
2 I
specific I
complex I
. O

In O
both O
study O
stages O
. O
post O
- O
exposure O
treatment O
consisted O
of O
five O
injections O
of O
vaccine O
[ O
( O
D O
) O
ays O
0 O
, O
3 O
, O
7 O
, O
14 O
, O
28 O
] O
, O
together O
with O
a O
dose O
of O
rabies B
immunoglobulin I
( O
RIG B
) O
of O
equine O
or O
human O
origin O
on O
D0 O
. O

In O
CYP7A1 B
transgenic O
mice O
, O
livers O
contained O
approximately O
3 O
- O
fold O
more O
sterol B
response I
element I
- I
binding I
protein I
- I
2 I
mRNA I
. O

This O
is O
a O
consensus O
casein B
kinase I
II I
( O
CKII B
) O
site O
and O
, O
using O
purified O
wild O
- O
type O
and O
mutant O
proteins O
, O
we O
show O
that O
it O
is O
the O
main O
CKII B
site I
in O
the O
body O
of O
the O
N O
- O
terminal O
complex O
- O
forming O
region O
. O

Treatment O
with O
polyinosinic O
- O
polycytidylic O
acid O
to O
induce O
expression O
of O
Cre B
resulted O
in O
complete O
disruption O
of O
the O
Arnt B
gene I
and O
loss O
of O
ARNT B
messenger I
RNA I
( O
mRNA O
) O
expression O
in O
liver O
. O

Tubular O
dysfunction O
in O
renal O
lithiasis O
: O
cause O
or O
consequence O
? O
] O
To O
investigate O
whether O
overall O
tubular O
dysfunction O
is O
encountered O
in O
a O
particular O
subgroup O
of O
patients O
with O
urolithiasis O
, O
the O
following O
parameters O
of O
renal O
tubular O
function O
have O
been O
measured O
in O
fasting O
morning O
urine O
in O
124 O
male O
stone O
formers O
: O
excretion O
of O
lysozyme B
and O
gamma B
- I
glutamyl I
transpeptidase I
( O
gamma B
- I
GT I
) O
, O
fractional O
excretion O
( O
FE O
) O
or O
glucose O
, O
insulin B
, O
bicarbonate O
after O
an O
alkali O
load O
, O
and O
theoretical O
phosphate O
threshold O
( O
TmP O
/ O

Tubular O
dysfunction O
in O
renal O
lithiasis O
: O
cause O
or O
consequence O
? O
] O
To O
investigate O
whether O
overall O
tubular O
dysfunction O
is O
encountered O
in O
a O
particular O
subgroup O
of O
patients O
with O
urolithiasis O
, O
the O
following O
parameters O
of O
renal O
tubular O
function O
have O
been O
measured O
in O
fasting O
morning O
urine O
in O
124 O
male O
stone O
formers O
: O
excretion O
of O
lysozyme B
and O
gamma B
- I
glutamyl I
transpeptidase I
( O
gamma B
- I
GT I
) O
, O
fractional O
excretion O
( O
FE O
) O
or O
glucose O
, O
insulin B
, O
bicarbonate O
after O
an O
alkali O
load O
, O
and O
theoretical O
phosphate O
threshold O
( O
TmP O
/ O

Interaction O
between O
the O
tobacco O
DNA O
- O
binding O
activity O
CBF B
and O
the O
cyt B
- I
1 I
promoter I
element I
of O
the O
Agrobacterium O
tumefaciens O
T O
- O
DNA O
gene O
T B
- I
CYT I
correlates O
with O
cyt B
- I
1 I
directed O
gene O
expression O
in O
multiple O
tobacco O
tissue O
types O
. O

Sequence O
analysis O
of O
AEBP2 B
cDNA I
revealed O
that O
it O
encodes O
a O
protein O
containing O
three O
Gli B
- O
Kruppel B
( O
Cys2 O
- O
His2 O
) O
- O
type O
zinc O
fingers O
. O

Sequence O
analysis O
of O
AEBP2 B
cDNA I
revealed O
that O
it O
encodes O
a O
protein O
containing O
three O
Gli B
- O
Kruppel B
( O
Cys2 O
- O
His2 O
) O
- O
type O
zinc O
fingers O
. O

Extracellular B
regulated I
kinases I
( I
ERK I
) I
1 I
and O
ERK2 B
are O
authentic O
substrates O
for O
the O
dual B
- I
specificity I
protein I
- I
tyrosine I
phosphatase I
VHR I
. O

Truncations O
from O
Hip B
' O
s O
N O
terminus O
resulted O
in O
an O
apparent O
loss O
of O
Hip B
homo O
- O
oligomerization O
, O
but O
these O
mutants O
retained O
association O
with O
hsp70 B
and O
were O
recovered O
in O
receptor O
complexes O
. O

Truncations O
from O
Hip B
' O
s O
N O
terminus O
resulted O
in O
an O
apparent O
loss O
of O
Hip B
homo O
- O
oligomerization O
, O
but O
these O
mutants O
retained O
association O
with O
hsp70 B
and O
were O
recovered O
in O
receptor O
complexes O
. O

Truncations O
from O
Hip B
' O
s O
N O
terminus O
resulted O
in O
an O
apparent O
loss O
of O
Hip B
homo O
- O
oligomerization O
, O
but O
these O
mutants O
retained O
association O
with O
hsp70 B
and O
were O
recovered O
in O
receptor O
complexes O
. O

The O
regulatory O
genes O
cnrYXH B
have O
been O
cloned O
, O
overexpressed O
, O
and O
purified O
in O
Escherichia O
coli O
. O

Examination O
of O
the O
Coomassie O
- O
stained O
gels O
revealed O
that O
the O
capsid O
- O
like O
particles O
composed O
of O
the O
N11 B
- I
VP1 I
protein O
did O
not O
contain O
any O
host O
- O
derived O
histones B
. O

Conversion O
of O
an O
NF B
- I
kappaB I
into O
a O
GABP B
binding O
site O
is O
likely O
to O
have O
occurred O
also O
during O
the O
worldwide O
spread O
of O
HIV O
- O
1 O
, O
as O
we O
noticed O
the O
same O
LTR O
modification O
in O
subtype O
E O
isolates O
from O
Thailand O
. O

Protein O
binding O
to O
UAS1MLS1 B
was O
observed O
with O
extracts O
from O
derepressed O
but O
not O
from O
repressed O
cells O
, O
and O
could O
be O
competed O
for O
by O
an O
excess O
of O
the O
unlabelled O
CSRE O
( O
ICL1 B
) O
sequence O
. O

Protein O
binding O
to O
UAS1MLS1 B
was O
observed O
with O
extracts O
from O
derepressed O
but O
not O
from O
repressed O
cells O
, O
and O
could O
be O
competed O
for O
by O
an O
excess O
of O
the O
unlabelled O
CSRE O
( O
ICL1 B
) O
sequence O
. O

The O
7 B
. I
2 I
kb I
EcoRI I
fragment I
of I
AfMNPV I
was O
cloned O
and O
the O
nucleotide O
sequences O
of O
the O
polyhedrin B
coding O
region O
and O
its O
flanking O
regions O
were O
determined O
. O

The O
increments O
in O
median O
plasma B
secretin I
concentration O
were O
1 O
. O
6 O
, O
3 O
. O
0 O
, O
and O
6 O
. O
4 O
pmol O
x O
1 O
( O
- O
1 O
) O
after O
secretin B
, O
125 O
, O
250 O
and O
500 O
fmol O
x O
kg O
- O
1 O
, O
and O
the O
corresponding O
15 O
- O
min O
bicarbonate O
output O
283 O
, O
442 O
, O
and O
1435 O
micromol O
, O
respectively O
. O

Coexpression O
of O
c B
- I
Rel I
in O
combination O
with O
ATF B
- I
1 I
, O
CREB2 B
, O
or O
ATF B
- I
1 I
/ O
CREB2 B
leads O
to O
synergistic O
transactivation O
of O
a O
CD28RE B
- I
TRE I
reporter I
plasmid O
in O
quiescent O
Jurkat O
T O
- O
cells O
. O

Coexpression O
of O
c B
- I
Rel I
in O
combination O
with O
ATF B
- I
1 I
, O
CREB2 B
, O
or O
ATF B
- I
1 I
/ O
CREB2 B
leads O
to O
synergistic O
transactivation O
of O
a O
CD28RE B
- I
TRE I
reporter I
plasmid O
in O
quiescent O
Jurkat O
T O
- O
cells O
. O

The O
genes O
on O
each O
chromosome O
involved O
in O
this O
translocation O
have O
been O
identified O
as O
the O
transcription O
factor O
- O
encoding O
genes O
PAX3 B
and O
FKHR B
. O

The O
genes O
on O
each O
chromosome O
involved O
in O
this O
translocation O
have O
been O
identified O
as O
the O
transcription O
factor O
- O
encoding O
genes O
PAX3 B
and O
FKHR B
. O

Paradoxically O
, O
loop O
3i O
from O
the O
M1Ach B
- I
muscarinic I
receptor I
also O
maximally O
inhibited O
GnRH B
agonist O
- O
stimulated O
cAMP O
accumulation O
and O
PRL B
release O
by O
40 O
% O
( O
both O
effects O
mediated O
through O
activation O
of O
the O
Gs B
protein I
) O
. O

Paradoxically O
, O
loop O
3i O
from O
the O
M1Ach B
- I
muscarinic I
receptor I
also O
maximally O
inhibited O
GnRH B
agonist O
- O
stimulated O
cAMP O
accumulation O
and O
PRL B
release O
by O
40 O
% O
( O
both O
effects O
mediated O
through O
activation O
of O
the O
Gs B
protein I
) O
. O

Three O
high O
- O
amylose O
rice O
varieties O
, O
IR42 O
, O
IR36 O
, O
and O
IR62 O
, O
with O
similar O
chemical O
composition O
including O
amylose O
content O
( O
26 O
. O
7 O
- O
27 O
. O
0 O
% O
) O
, O
were O
cooked O
under O
the O
same O
conditions O
and O
tested O
for O
in O
vitro O
digestibility O
as O
well O
as O
blood O
glucose O
and O
insulin B
responses O
in O
healthy O
human O
volunteers O
. O

Using O
beta B
1 I
- I
AR I
- O
luciferase B
reporter O
recombinants O
, O
we O
have O
previously O
determined O
that O
important O
beta B
1 I
- I
AR I
genetic O
elements O
controlling O
expression O
within O
the O
C6 O
glioma O
cell O
line O
are O
contained O
within O
the O
region O
- O
396 O
to O
- O
299 O
, O
relative O
to O
the O
translational O
start O
site O
. O

These O
results O
support O
an O
in O
vivo O
interaction O
between O
Nck B
and O
CKI B
- I
gamma2 I
and O
suggest O
that O
CKI B
- I
gamma2 I
could O
be O
involved O
in O
signaling O
pathways O
downstream O
of O
RTKs B
. O

These O
results O
support O
an O
in O
vivo O
interaction O
between O
Nck B
and O
CKI B
- I
gamma2 I
and O
suggest O
that O
CKI B
- I
gamma2 I
could O
be O
involved O
in O
signaling O
pathways O
downstream O
of O
RTKs B
. O

A O
minimal O
region O
which O
stimulates O
origin O
function O
mapped O
to O
50 O
amino O
acids O
within O
the O
C O
- O
terminus O
of O
Abf1p B
. O

Treatment O
of O
JEA2 O
cells O
with O
interleukin B
( I
IL I
) I
- I
7 I
induces O
CBLB B
phosphorylation O
as O
well O
. O

Phosphorylation O
by O
Cdc28 B
activates O
the O
Cdc20 B
- O
dependent O
activity O
of O
the O
anaphase O
- O
promoting O
complex O
. O

Phosphorylation O
by O
Cdc28 B
activates O
the O
Cdc20 B
- O
dependent O
activity O
of O
the O
anaphase O
- O
promoting O
complex O
. O

Assays O
of O
APRE O
- O
luciferase B
reporter O
plasmids O
transfected O
into O
HepG2 O
cells O
show O
that O
a O
mutated O
APRE O
that O
binds O
only O
BPi B
functions O
as O
an O
IL B
- I
1 I
alpha I
inducible O
enhancer O
, O
whereas O
a O
mutated O
APRE O
that O
binds O
only O
BPc B
does O
not O
. O

Assays O
of O
APRE O
- O
luciferase B
reporter O
plasmids O
transfected O
into O
HepG2 O
cells O
show O
that O
a O
mutated O
APRE O
that O
binds O
only O
BPi B
functions O
as O
an O
IL B
- I
1 I
alpha I
inducible O
enhancer O
, O
whereas O
a O
mutated O
APRE O
that O
binds O
only O
BPc B
does O
not O
. O

Assays O
of O
APRE O
- O
luciferase B
reporter O
plasmids O
transfected O
into O
HepG2 O
cells O
show O
that O
a O
mutated O
APRE O
that O
binds O
only O
BPi B
functions O
as O
an O
IL B
- I
1 I
alpha I
inducible O
enhancer O
, O
whereas O
a O
mutated O
APRE O
that O
binds O
only O
BPc B
does O
not O
. O

RNA O
unwinding O
in O
U4 B
/ O
U6 B
snRNPs O
requires O
ATP O
hydrolysis O
and O
the O
DEIH O
- O
box O
splicing O
factor O
Brr2 B
. O

RNA O
unwinding O
in O
U4 B
/ O
U6 B
snRNPs O
requires O
ATP O
hydrolysis O
and O
the O
DEIH O
- O
box O
splicing O
factor O
Brr2 B
. O

RNA O
unwinding O
in O
U4 B
/ O
U6 B
snRNPs O
requires O
ATP O
hydrolysis O
and O
the O
DEIH O
- O
box O
splicing O
factor O
Brr2 B
. O

Northern O
blot O
analysis O
linked O
Plk B
expression O
to O
the O
proliferative O
activity O
of O
cells O
and O
tissues O
. O

It O
also O
showed O
which O
amino O
acid O
residues O
would O
contact O
an O
extended O
TATA O
box O
with O
a O
B B
recognition I
element I
, O
and O
evolutionary O
conservation O
of O
the O
TBP B
- O
TFB B
- O
DNA O
complex O
orientation O
between O
two O
archaeal O
organisms O
with O
widely O
different O
optimal O
temperature O
for O
growth O
( O
37 O
and O
100 O
degrees O
C O
) O
. O

It O
also O
showed O
which O
amino O
acid O
residues O
would O
contact O
an O
extended O
TATA O
box O
with O
a O
B B
recognition I
element I
, O
and O
evolutionary O
conservation O
of O
the O
TBP B
- O
TFB B
- O
DNA O
complex O
orientation O
between O
two O
archaeal O
organisms O
with O
widely O
different O
optimal O
temperature O
for O
growth O
( O
37 O
and O
100 O
degrees O
C O
) O
. O

Comparison O
of O
this O
gene O
with O
the O
available O
databases O
reveals O
very O
significant O
homology O
to O
the O
ETS B
factor I
PE B
- I
1 I
and O
probable O
near O
- O
identity O
with O
the O
recently O
cloned O
factor O
ERF B
. O

Patients O
with O
Eales O
' O
disease O
, O
chorioretinitis O
, O
central O
serous O
retinopathy O
, O
or O
malignant O
choroidal O
melanoma O
were O
tested O
for O
HLA B
antigen O
deviation O
. O

These O
data O
also O
demonstrate O
that O
insulin B
and O
TPA O
activate O
MBP B
/ O
MAP2 B
kinase O
activity O
by O
de O
novo O
phosphorylation O
of O
threonine O
and O
tyrosine O
residues O
via O
a O
very O
similar O
pathway O
. O

These O
data O
also O
demonstrate O
that O
insulin B
and O
TPA O
activate O
MBP B
/ O
MAP2 B
kinase O
activity O
by O
de O
novo O
phosphorylation O
of O
threonine O
and O
tyrosine O
residues O
via O
a O
very O
similar O
pathway O
. O

These O
data O
also O
demonstrate O
that O
insulin B
and O
TPA O
activate O
MBP B
/ O
MAP2 B
kinase O
activity O
by O
de O
novo O
phosphorylation O
of O
threonine O
and O
tyrosine O
residues O
via O
a O
very O
similar O
pathway O
. O

Such O
tetranucleotides O
are O
common O
in O
promoter O
regions O
, O
particularly O
in O
activating B
transcription I
factor I
/ O
cyclic B
AMP I
response I
element I
- I
binding I
protein I
( O
ATF B
/ O
CREB B
) O
and O
E O
- O
box O
motifs O
, O
suggesting O
that O
PIF B
may O
modulate O
the O
transcription O
of O
many O
genes O
. O

Such O
tetranucleotides O
are O
common O
in O
promoter O
regions O
, O
particularly O
in O
activating B
transcription I
factor I
/ O
cyclic B
AMP I
response I
element I
- I
binding I
protein I
( O
ATF B
/ O
CREB B
) O
and O
E O
- O
box O
motifs O
, O
suggesting O
that O
PIF B
may O
modulate O
the O
transcription O
of O
many O
genes O
. O

Such O
tetranucleotides O
are O
common O
in O
promoter O
regions O
, O
particularly O
in O
activating B
transcription I
factor I
/ O
cyclic B
AMP I
response I
element I
- I
binding I
protein I
( O
ATF B
/ O
CREB B
) O
and O
E O
- O
box O
motifs O
, O
suggesting O
that O
PIF B
may O
modulate O
the O
transcription O
of O
many O
genes O
. O

The O
dominant O
inhibitory O
biological O
activity O
of O
the O
N O
terminus O
correlated O
with O
its O
ability O
to O
impair O
EGF B
- O
dependent O
activation O
of O
GTP B
- I
Ras I
and O
of O
MAP B
kinase I
, O
as O
well O
with O
the O
ability O
of O
endogenous O
Sos B
to O
form O
a O
stable O
complex O
with O
activated O
EGF B
receptors I
. O

The O
dominant O
inhibitory O
biological O
activity O
of O
the O
N O
terminus O
correlated O
with O
its O
ability O
to O
impair O
EGF B
- O
dependent O
activation O
of O
GTP B
- I
Ras I
and O
of O
MAP B
kinase I
, O
as O
well O
with O
the O
ability O
of O
endogenous O
Sos B
to O
form O
a O
stable O
complex O
with O
activated O
EGF B
receptors I
. O

SM B
binds O
RNA O
in O
vitro O
, O
suggesting O
that O
sequence O
- O
or O
structure O
- O
specific O
mRNA O
interactions O
might O
mediate O
SM B
specificity O
. O

SM B
binds O
RNA O
in O
vitro O
, O
suggesting O
that O
sequence O
- O
or O
structure O
- O
specific O
mRNA O
interactions O
might O
mediate O
SM B
specificity O
. O

The O
characterization O
of O
fly O
receptors O
with O
features O
similar O
to O
mammalian B
glycoprotein I
hormone I
receptors I
allows O
a O
better O
understanding O
of O
the O
evolution O
of O
this O
unique O
group O
of O
GPCRs B
and O
future O
elucidation O
of O
their O
ligand O
signaling O
mechanisms O
. O

Here O
we O
show O
that O
these O
sequences O
are O
essential O
for O
processing O
of O
U18 B
and O
snR38 B
snoRNAs I
and O
that O
they O
compensate O
for O
the O
lack O
of O
a O
canonical O
terminal O
stem O
. O

Ras B
involvement O
in O
signal O
transduction O
by O
the O
serotonin B
5 I
- I
HT2B I
receptor I
. O

Three O
putative O
ORFs O
have O
significant O
homology O
with O
known O
proteins O
: O
L0968 B
is O
a O
new O
member O
of O
the O
very O
large O
' B
seripauperins I
' I
family O
, O
comprising O
at O
least O
20 O
yeast O
members O
; O
L1313 B
is O
a O
new O
ABC B
transporter I
highly O
homologous O
to O
the O
yeast O
cadmium O
resistance O
protein O
Ycf1p B
and O
to O
the O
human B
multidrug I
resistance I
protein I
hMRP1 B
; O
the O
C O
- O
terminal O
part O
of O
L1325 B
present O
in O
our O
sequence O
is O
very O
homologous O
to O
the O
fruit O
fly O
abdominal O
segment O
formation O
protein O
Pumilio B
. O

Three O
putative O
ORFs O
have O
significant O
homology O
with O
known O
proteins O
: O
L0968 B
is O
a O
new O
member O
of O
the O
very O
large O
' B
seripauperins I
' I
family O
, O
comprising O
at O
least O
20 O
yeast O
members O
; O
L1313 B
is O
a O
new O
ABC B
transporter I
highly O
homologous O
to O
the O
yeast O
cadmium O
resistance O
protein O
Ycf1p B
and O
to O
the O
human B
multidrug I
resistance I
protein I
hMRP1 B
; O
the O
C O
- O
terminal O
part O
of O
L1325 B
present O
in O
our O
sequence O
is O
very O
homologous O
to O
the O
fruit O
fly O
abdominal O
segment O
formation O
protein O
Pumilio B
. O

Three O
putative O
ORFs O
have O
significant O
homology O
with O
known O
proteins O
: O
L0968 B
is O
a O
new O
member O
of O
the O
very O
large O
' B
seripauperins I
' I
family O
, O
comprising O
at O
least O
20 O
yeast O
members O
; O
L1313 B
is O
a O
new O
ABC B
transporter I
highly O
homologous O
to O
the O
yeast O
cadmium O
resistance O
protein O
Ycf1p B
and O
to O
the O
human B
multidrug I
resistance I
protein I
hMRP1 B
; O
the O
C O
- O
terminal O
part O
of O
L1325 B
present O
in O
our O
sequence O
is O
very O
homologous O
to O
the O
fruit O
fly O
abdominal O
segment O
formation O
protein O
Pumilio B
. O

Three O
putative O
ORFs O
have O
significant O
homology O
with O
known O
proteins O
: O
L0968 B
is O
a O
new O
member O
of O
the O
very O
large O
' B
seripauperins I
' I
family O
, O
comprising O
at O
least O
20 O
yeast O
members O
; O
L1313 B
is O
a O
new O
ABC B
transporter I
highly O
homologous O
to O
the O
yeast O
cadmium O
resistance O
protein O
Ycf1p B
and O
to O
the O
human B
multidrug I
resistance I
protein I
hMRP1 B
; O
the O
C O
- O
terminal O
part O
of O
L1325 B
present O
in O
our O
sequence O
is O
very O
homologous O
to O
the O
fruit O
fly O
abdominal O
segment O
formation O
protein O
Pumilio B
. O

Three O
putative O
ORFs O
have O
significant O
homology O
with O
known O
proteins O
: O
L0968 B
is O
a O
new O
member O
of O
the O
very O
large O
' B
seripauperins I
' I
family O
, O
comprising O
at O
least O
20 O
yeast O
members O
; O
L1313 B
is O
a O
new O
ABC B
transporter I
highly O
homologous O
to O
the O
yeast O
cadmium O
resistance O
protein O
Ycf1p B
and O
to O
the O
human B
multidrug I
resistance I
protein I
hMRP1 B
; O
the O
C O
- O
terminal O
part O
of O
L1325 B
present O
in O
our O
sequence O
is O
very O
homologous O
to O
the O
fruit O
fly O
abdominal O
segment O
formation O
protein O
Pumilio B
. O

Three O
putative O
ORFs O
have O
significant O
homology O
with O
known O
proteins O
: O
L0968 B
is O
a O
new O
member O
of O
the O
very O
large O
' B
seripauperins I
' I
family O
, O
comprising O
at O
least O
20 O
yeast O
members O
; O
L1313 B
is O
a O
new O
ABC B
transporter I
highly O
homologous O
to O
the O
yeast O
cadmium O
resistance O
protein O
Ycf1p B
and O
to O
the O
human B
multidrug I
resistance I
protein I
hMRP1 B
; O
the O
C O
- O
terminal O
part O
of O
L1325 B
present O
in O
our O
sequence O
is O
very O
homologous O
to O
the O
fruit O
fly O
abdominal O
segment O
formation O
protein O
Pumilio B
. O

This O
B O
- O
box O
is O
not O
present O
in O
ETS1 B
, O
ETS2 B
, O
PEA3 B
or O
PU B
. I
1 I
and O
these O
proteins O
were O
unable O
to O
form O
ternary O
complexes O
with O
SRF B
and O
Egrl B
- O
SREs O
or O
c B
- I
fos I
SRE O
. O

This O
B O
- O
box O
is O
not O
present O
in O
ETS1 B
, O
ETS2 B
, O
PEA3 B
or O
PU B
. I
1 I
and O
these O
proteins O
were O
unable O
to O
form O
ternary O
complexes O
with O
SRF B
and O
Egrl B
- O
SREs O
or O
c B
- I
fos I
SRE O
. O

This O
B O
- O
box O
is O
not O
present O
in O
ETS1 B
, O
ETS2 B
, O
PEA3 B
or O
PU B
. I
1 I
and O
these O
proteins O
were O
unable O
to O
form O
ternary O
complexes O
with O
SRF B
and O
Egrl B
- O
SREs O
or O
c B
- I
fos I
SRE O
. O

This O
B O
- O
box O
is O
not O
present O
in O
ETS1 B
, O
ETS2 B
, O
PEA3 B
or O
PU B
. I
1 I
and O
these O
proteins O
were O
unable O
to O
form O
ternary O
complexes O
with O
SRF B
and O
Egrl B
- O
SREs O
or O
c B
- I
fos I
SRE O
. O

This O
B O
- O
box O
is O
not O
present O
in O
ETS1 B
, O
ETS2 B
, O
PEA3 B
or O
PU B
. I
1 I
and O
these O
proteins O
were O
unable O
to O
form O
ternary O
complexes O
with O
SRF B
and O
Egrl B
- O
SREs O
or O
c B
- I
fos I
SRE O
. O

Viral B
protein I
U I
( O
Vpu B
) O
is O
a O
protein O
encoded O
by O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
that O
promotes O
the O
degradation O
of O
the O
virus O
receptor O
, O
CD4 B
, O
and O
enhances O
the O
release O
of O
virus O
particles O
from O
cells O
. O

Viral B
protein I
U I
( O
Vpu B
) O
is O
a O
protein O
encoded O
by O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
that O
promotes O
the O
degradation O
of O
the O
virus O
receptor O
, O
CD4 B
, O
and O
enhances O
the O
release O
of O
virus O
particles O
from O
cells O
. O

CSEn B
stimulated O
transcription O
of O
a O
variety O
of O
promoters O
, O
including O
the O
hCS B
, O
human B
growth I
hormone I
, O
thymidine B
kinase I
, O
and O
Rous B
sarcoma I
virus I
promoters I
, O
in O
human O
choriocarcinoma O
cell O
lines O
( O
BeWo O
and O
JEG O
- O
3 O
) O
but O
not O
HeLa O
cells O
or O
rat O
somatolactotrophes O
( O
GC O
) O
. O

CSEn B
stimulated O
transcription O
of O
a O
variety O
of O
promoters O
, O
including O
the O
hCS B
, O
human B
growth I
hormone I
, O
thymidine B
kinase I
, O
and O
Rous B
sarcoma I
virus I
promoters I
, O
in O
human O
choriocarcinoma O
cell O
lines O
( O
BeWo O
and O
JEG O
- O
3 O
) O
but O
not O
HeLa O
cells O
or O
rat O
somatolactotrophes O
( O
GC O
) O
. O

The O
absolute O
CD4 B
count O
of O
patients O
with O
de O
novo O
IBD O
was O
210 O
- O
700 O
cells O
/ O
ml O
at O
the O
time O
of O
IBD O
. O

Coexpression O
of O
a O
dominant B
negative I
c I
- I
jun I
antagonized O
the O
ras B
- O
dependent O
stimulation O
of O
the O
92 B
- I
kDa I
gelatinase I
B I
promoter O
- O
driven O
CAT B
reporter I
. O

However O
, O
LXRalpha B
inhibited O
binding O
of O
PPARalpha B
/ O
RXRalpha B
heterodimers O
to O
PPREs O
, O
and O
coexpression O
of O
LXRalpha B
in O
mammalian O
cells O
antagonized O
peroxisome O
proliferator O
signaling O
mediated O
by O
PPARalpha B
/ O
RXRalpha B
in O
vivo O
. O

However O
, O
LXRalpha B
inhibited O
binding O
of O
PPARalpha B
/ O
RXRalpha B
heterodimers O
to O
PPREs O
, O
and O
coexpression O
of O
LXRalpha B
in O
mammalian O
cells O
antagonized O
peroxisome O
proliferator O
signaling O
mediated O
by O
PPARalpha B
/ O
RXRalpha B
in O
vivo O
. O

However O
, O
LXRalpha B
inhibited O
binding O
of O
PPARalpha B
/ O
RXRalpha B
heterodimers O
to O
PPREs O
, O
and O
coexpression O
of O
LXRalpha B
in O
mammalian O
cells O
antagonized O
peroxisome O
proliferator O
signaling O
mediated O
by O
PPARalpha B
/ O
RXRalpha B
in O
vivo O
. O

However O
, O
LXRalpha B
inhibited O
binding O
of O
PPARalpha B
/ O
RXRalpha B
heterodimers O
to O
PPREs O
, O
and O
coexpression O
of O
LXRalpha B
in O
mammalian O
cells O
antagonized O
peroxisome O
proliferator O
signaling O
mediated O
by O
PPARalpha B
/ O
RXRalpha B
in O
vivo O
. O

However O
, O
LXRalpha B
inhibited O
binding O
of O
PPARalpha B
/ O
RXRalpha B
heterodimers O
to O
PPREs O
, O
and O
coexpression O
of O
LXRalpha B
in O
mammalian O
cells O
antagonized O
peroxisome O
proliferator O
signaling O
mediated O
by O
PPARalpha B
/ O
RXRalpha B
in O
vivo O
. O

However O
, O
LXRalpha B
inhibited O
binding O
of O
PPARalpha B
/ O
RXRalpha B
heterodimers O
to O
PPREs O
, O
and O
coexpression O
of O
LXRalpha B
in O
mammalian O
cells O
antagonized O
peroxisome O
proliferator O
signaling O
mediated O
by O
PPARalpha B
/ O
RXRalpha B
in O
vivo O
. O

CTDK1 B
and O
CTDK2 B
also O
differ O
in O
their O
protein O
substrate O
specificity O
. O

CTDK1 B
and O
CTDK2 B
also O
differ O
in O
their O
protein O
substrate O
specificity O
. O

This O
communication O
presents O
two O
patients O
with O
clinically O
massive O
PE O
of O
recent O
onset O
( O
confirmed O
by O
lung O
perfusion O
scans O
) O
who O
were O
successfully O
treated O
with O
a O
single O
i O
. O
v O
. O
dose O
of O
30 O
mg O
of O
anisoylated B
lys I
- I
plasminogen I
streptokinase I
activator I
complex I
( O
APSAC B
, O
comparable O
to O
1 O
, O
500 O
, O
000 O
U O
of O
streptokinase B
) O
followed O
by O
systemic O
heparinization O
for O
7 O
days O
. O

This O
communication O
presents O
two O
patients O
with O
clinically O
massive O
PE O
of O
recent O
onset O
( O
confirmed O
by O
lung O
perfusion O
scans O
) O
who O
were O
successfully O
treated O
with O
a O
single O
i O
. O
v O
. O
dose O
of O
30 O
mg O
of O
anisoylated B
lys I
- I
plasminogen I
streptokinase I
activator I
complex I
( O
APSAC B
, O
comparable O
to O
1 O
, O
500 O
, O
000 O
U O
of O
streptokinase B
) O
followed O
by O
systemic O
heparinization O
for O
7 O
days O
. O

A O
mean O
value O
for O
HbA1 B
greater O
than O
10 O
% O
was O
associated O
with O
an O
increased O
risk O
of O
progression O
of O
retinopathy O
and O
a O
mean O
value O
less O
than O
8 O
. O
7 O
% O
was O
associated O
with O
a O
diminished O
risk O
. O

NGF B
also O
induced O
a O
synthetic O
promoter O
with O
repeated O
Sp1 B
sites I
linked O
to O
a O
core O
promoter O
, O
and O
a O
plasmid O
regulated O
by O
a O
chimeric O
transactivator O
in O
which O
the O
Gal4 B
DNA I
binding I
domain I
is O
fused O
to O
the O
Sp1 B
transactivation I
domain I
, O
indicating O
that O
this O
transactivation O
domain O
is O
regulated O
by O
NGF B
. O

NGF B
also O
induced O
a O
synthetic O
promoter O
with O
repeated O
Sp1 B
sites I
linked O
to O
a O
core O
promoter O
, O
and O
a O
plasmid O
regulated O
by O
a O
chimeric O
transactivator O
in O
which O
the O
Gal4 B
DNA I
binding I
domain I
is O
fused O
to O
the O
Sp1 B
transactivation I
domain I
, O
indicating O
that O
this O
transactivation O
domain O
is O
regulated O
by O
NGF B
. O

In O
cotransfection O
assays O
, O
a O
small O
fragment O
of O
Sin B
retaining O
the O
Src B
- O
SH3 B
- O
binding O
site O
and O
one O
tyrosine O
- O
containing O
motif O
induced O
c B
- I
Src I
activation O
as O
measured O
by O
a O
transcriptional O
reporter O
. O

In O
cotransfection O
assays O
, O
a O
small O
fragment O
of O
Sin B
retaining O
the O
Src B
- O
SH3 B
- O
binding O
site O
and O
one O
tyrosine O
- O
containing O
motif O
induced O
c B
- I
Src I
activation O
as O
measured O
by O
a O
transcriptional O
reporter O
. O

In O
cotransfection O
assays O
, O
a O
small O
fragment O
of O
Sin B
retaining O
the O
Src B
- O
SH3 B
- O
binding O
site O
and O
one O
tyrosine O
- O
containing O
motif O
induced O
c B
- I
Src I
activation O
as O
measured O
by O
a O
transcriptional O
reporter O
. O

The O
related O
tumor O
suppressor O
, O
p130 B
, O
also O
effects O
this O
function O
. O

p107 B
levels O
increase O
substantially O
as O
cells O
progress O
through O
S O
phase O
. O

p107 B
induction O
of O
E2F B
DNA O
binding O
was O
observed O
primarily O
in O
S O
phase O
cells O
coincident O
with O
the O
increase O
in O
p107 B
protein I
levels O
. O

p107 B
induction O
of O
E2F B
DNA O
binding O
was O
observed O
primarily O
in O
S O
phase O
cells O
coincident O
with O
the O
increase O
in O
p107 B
protein I
levels O
. O

Further O
, O
cells O
cotransfected O
with O
a O
UF B
promoter I
- O
luciferase B
( O
- O
1935UF B
- O
Luc B
) O
reporter O
gene O
and O
the O
BTEB B
expression O
vector O
had O
2 O
- O
fold O
higher O
Luc B
activity O
than O
those O
cotransfected O
with O
reporter O
gene O
and O
pcDNA O
- O
3 O
. O

Further O
, O
cells O
cotransfected O
with O
a O
UF B
promoter I
- O
luciferase B
( O
- O
1935UF B
- O
Luc B
) O
reporter O
gene O
and O
the O
BTEB B
expression O
vector O
had O
2 O
- O
fold O
higher O
Luc B
activity O
than O
those O
cotransfected O
with O
reporter O
gene O
and O
pcDNA O
- O
3 O
. O

Further O
, O
cells O
cotransfected O
with O
a O
UF B
promoter I
- O
luciferase B
( O
- O
1935UF B
- O
Luc B
) O
reporter O
gene O
and O
the O
BTEB B
expression O
vector O
had O
2 O
- O
fold O
higher O
Luc B
activity O
than O
those O
cotransfected O
with O
reporter O
gene O
and O
pcDNA O
- O
3 O
. O

Further O
, O
cells O
cotransfected O
with O
a O
UF B
promoter I
- O
luciferase B
( O
- O
1935UF B
- O
Luc B
) O
reporter O
gene O
and O
the O
BTEB B
expression O
vector O
had O
2 O
- O
fold O
higher O
Luc B
activity O
than O
those O
cotransfected O
with O
reporter O
gene O
and O
pcDNA O
- O
3 O
. O

Further O
, O
cells O
cotransfected O
with O
a O
UF B
promoter I
- O
luciferase B
( O
- O
1935UF B
- O
Luc B
) O
reporter O
gene O
and O
the O
BTEB B
expression O
vector O
had O
2 O
- O
fold O
higher O
Luc B
activity O
than O
those O
cotransfected O
with O
reporter O
gene O
and O
pcDNA O
- O
3 O
. O

In O
agreement O
with O
this O
, O
archaea O
appear O
to O
lack O
eIF5 B
, O
eIF2B B
and O
the O
lysine O
- O
rich O
binding O
domain O
for O
these O
factors O
in O
their O
eIF2beta B
homolog I
. O

In O
agreement O
with O
this O
, O
archaea O
appear O
to O
lack O
eIF5 B
, O
eIF2B B
and O
the O
lysine O
- O
rich O
binding O
domain O
for O
these O
factors O
in O
their O
eIF2beta B
homolog I
. O

Derepression O
of O
RAR B
signaling O
by O
expressing O
a O
dominant O
- O
negative O
corepressor O
resulted O
in O
embryos O
that O
exhibited O
phenotypes O
similar O
to O
those O
treated O
by O
RA O
. O

Thus O
, O
the O
in O
vivo O
function O
of O
Gle2p B
is O
strictly O
coupled O
to O
the O
short O
GLEBS B
within O
Nup116p B
which O
links O
this O
putative O
mRNA O
transport O
factor O
to O
the O
nuclear O
pores O
. O

Thus O
, O
the O
in O
vivo O
function O
of O
Gle2p B
is O
strictly O
coupled O
to O
the O
short O
GLEBS B
within O
Nup116p B
which O
links O
this O
putative O
mRNA O
transport O
factor O
to O
the O
nuclear O
pores O
. O

Thus O
, O
the O
in O
vivo O
function O
of O
Gle2p B
is O
strictly O
coupled O
to O
the O
short O
GLEBS B
within O
Nup116p B
which O
links O
this O
putative O
mRNA O
transport O
factor O
to O
the O
nuclear O
pores O
. O

DNMT2 B
binds O
AdoHcy O
in O
the O
same O
conformation O
as O
confirmed O
m B
( I
5 I
) I
C I
MTases I
and O
, O
while O
DNMT2 B
shares O
all O
sequence O
and O
structural O
features O
with O
m B
( I
5 I
) I
C I
MTases I
, O
it O
has O
failed O
to O
demonstrate O
detectable O
transmethylase O
activity O
. O

DNMT2 B
binds O
AdoHcy O
in O
the O
same O
conformation O
as O
confirmed O
m B
( I
5 I
) I
C I
MTases I
and O
, O
while O
DNMT2 B
shares O
all O
sequence O
and O
structural O
features O
with O
m B
( I
5 I
) I
C I
MTases I
, O
it O
has O
failed O
to O
demonstrate O
detectable O
transmethylase O
activity O
. O

Regulation O
of O
the O
p21 B
- I
activated I
kinase I
( O
PAK B
) O
by O
a O
human B
Gbeta I
- I
like I
WD O
- O
repeat O
protein O
, O
hPIP1 B
. O

Regulation O
of O
the O
p21 B
- I
activated I
kinase I
( O
PAK B
) O
by O
a O
human B
Gbeta I
- I
like I
WD O
- O
repeat O
protein O
, O
hPIP1 B
. O

We O
have O
shown O
previously O
that O
EGF B
receptor I
activation O
stimulates O
gastrin B
gene O
expression O
through O
a O
GC O
- O
rich O
element O
called O
gERE O
. O

This O
demonstrates O
the O
presence O
of O
a O
PKC B
- O
dependent O
pathway O
which O
functions O
independently O
from O
Lck B
in O
MAP B
kinase I
activation O
. O

This O
demonstrates O
the O
presence O
of O
a O
PKC B
- O
dependent O
pathway O
which O
functions O
independently O
from O
Lck B
in O
MAP B
kinase I
activation O
. O

Cell O
lines O
expressing O
single O
amino O
acid O
substitutions O
of O
the O
carboxyl O
- O
terminal O
asparagine O
of O
CD2 B
are O
incapable O
of O
avidity O
regulation O
by O
TCR B
signaling O
, O
PMA O
treatment O
, O
or O
elevation O
of O
intracellular O
cAMP O
levels O
, O
demonstrating O
that O
each O
of O
these O
stimuli O
utilizes O
a O
common O
structural O
element O
for O
regulating O
CD2 B
avidity O
. O

Cell O
lines O
expressing O
single O
amino O
acid O
substitutions O
of O
the O
carboxyl O
- O
terminal O
asparagine O
of O
CD2 B
are O
incapable O
of O
avidity O
regulation O
by O
TCR B
signaling O
, O
PMA O
treatment O
, O
or O
elevation O
of O
intracellular O
cAMP O
levels O
, O
demonstrating O
that O
each O
of O
these O
stimuli O
utilizes O
a O
common O
structural O
element O
for O
regulating O
CD2 B
avidity O
. O

Cell O
lines O
expressing O
single O
amino O
acid O
substitutions O
of O
the O
carboxyl O
- O
terminal O
asparagine O
of O
CD2 B
are O
incapable O
of O
avidity O
regulation O
by O
TCR B
signaling O
, O
PMA O
treatment O
, O
or O
elevation O
of O
intracellular O
cAMP O
levels O
, O
demonstrating O
that O
each O
of O
these O
stimuli O
utilizes O
a O
common O
structural O
element O
for O
regulating O
CD2 B
avidity O
. O

The O
atpA B
reading O
frame O
ends O
with O
four O
tandem O
UGA O
codons O
which O
overlap O
four O
tandem O
AUG O
codons O
initiating O
an O
unidentified O
reading O
frame O
, O
orf214 O
. O

A O
heterologous O
promoter O
construct O
containing O
three O
repeats O
of O
a O
consensus O
Sp1 B
site I
, O
cloned O
upstream O
of O
a O
single O
copy O
of O
the O
ZII B
( O
CREB B
/ O
AP1 B
) O
element O
from O
the O
BZLF1 B
promoter I
linked O
to O
the O
beta B
- I
globin I
TATA O
box O
, O
exhibited O
phorbol O
ester O
inducibility O
. O

A O
heterologous O
promoter O
construct O
containing O
three O
repeats O
of O
a O
consensus O
Sp1 B
site I
, O
cloned O
upstream O
of O
a O
single O
copy O
of O
the O
ZII B
( O
CREB B
/ O
AP1 B
) O
element O
from O
the O
BZLF1 B
promoter I
linked O
to O
the O
beta B
- I
globin I
TATA O
box O
, O
exhibited O
phorbol O
ester O
inducibility O
. O

A O
heterologous O
promoter O
construct O
containing O
three O
repeats O
of O
a O
consensus O
Sp1 B
site I
, O
cloned O
upstream O
of O
a O
single O
copy O
of O
the O
ZII B
( O
CREB B
/ O
AP1 B
) O
element O
from O
the O
BZLF1 B
promoter I
linked O
to O
the O
beta B
- I
globin I
TATA O
box O
, O
exhibited O
phorbol O
ester O
inducibility O
. O

We O
also O
show O
that O
psbH B
and O
psbT B
are O
transcribed O
from O
the O
upstream O
psbB B
gene I
promoter I
, O
and O
that O
the O
psbH B
mRNA I
has O
its O
own O
target O
sequence O
for O
Mbb1 B
function O
. O

We O
also O
show O
that O
psbH B
and O
psbT B
are O
transcribed O
from O
the O
upstream O
psbB B
gene I
promoter I
, O
and O
that O
the O
psbH B
mRNA I
has O
its O
own O
target O
sequence O
for O
Mbb1 B
function O
. O

We O
also O
show O
that O
psbH B
and O
psbT B
are O
transcribed O
from O
the O
upstream O
psbB B
gene I
promoter I
, O
and O
that O
the O
psbH B
mRNA I
has O
its O
own O
target O
sequence O
for O
Mbb1 B
function O
. O

O5257 B
shows O
homology O
with O
the O
SAS2 B
protein I
and O
another O
hypothetical O
protein O
from O
yeast O
. O

Consistent O
with O
this O
hypothesis O
, O
stimulation O
of O
A B
( I
2A I
) I
- I
R I
or O
PKA B
enhanced O
nuclear B
aPKC I
activity O
. O

Samples O
( O
1 O
g O
) O
were O
extracted O
with O
0 O
. O
5 O
% O
potassium O
chloride O
( O
KCl O
) O
in O
70 O
% O
methanol O
( O
5 O
ml O
) O
and O
diluted O
subsequently O
to O
give O
two O
- O
fold O
to O
ten O
- O
fold O
step O
- O
wise O
dilutions O
in O
phosphate O
- O
buffered O
saline O
containing O
0 O
. O
05 O
% O
Tween O
20 O
and O
0 O
. O
2 O
% O
bovine B
serum I
albumin I
( O
PBS O
- O
T O
BSA B
) O
. O

Transforming B
growth I
factor I
beta I
activates O
the O
promoter O
of O
cyclin B
- I
dependent I
kinase I
inhibitor O
p15INK4B B
through O
an O
Sp1 B
consensus I
site I
. O

Possible O
or O
definite O
neglect O
or O
abuse O
before O
36 O
months O
of O
age O
was O
correlated O
with O
low O
DBH B
activity O
. O

Methylation O
interference O
analysis O
established O
at O
single O
nucleotide O
resolution O
that O
purified O
recombinant O
Fos B
and O
Jun B
proteins I
bind O
in O
a O
sequence O
- O
specific O
manner O
to O
the O
AP B
- I
1 I
sites I
within O
the O
VDRE O
and O
OC B
box I
. O

These O
include O
urinalysis O
, O
chest O
X O
- O
P O
, O
ECG O
, O
hematological O
examinations O
( O
RBC O
, O
WBC O
, O
Ht O
, O
Hb B
, O
PLT O
and O
ESR O
) O
and O
biochemical O
tests O
( O
AST B
, O
ALT B
, O
ALP B
, O
gamma B
GTP I
, O
LDH B
, O
CPK B
, O
Chol O
, O
T O
- O
Bil O
, O
TP O
, O
Alb B
, O
TG O
, O
BUN O
, O
Cr O
, O
Glu O
, O
Na O
, O
K O
, O
Ca O
, O
P O
and O
CRP B
) O
. O

These O
include O
urinalysis O
, O
chest O
X O
- O
P O
, O
ECG O
, O
hematological O
examinations O
( O
RBC O
, O
WBC O
, O
Ht O
, O
Hb B
, O
PLT O
and O
ESR O
) O
and O
biochemical O
tests O
( O
AST B
, O
ALT B
, O
ALP B
, O
gamma B
GTP I
, O
LDH B
, O
CPK B
, O
Chol O
, O
T O
- O
Bil O
, O
TP O
, O
Alb B
, O
TG O
, O
BUN O
, O
Cr O
, O
Glu O
, O
Na O
, O
K O
, O
Ca O
, O
P O
and O
CRP B
) O
. O

These O
include O
urinalysis O
, O
chest O
X O
- O
P O
, O
ECG O
, O
hematological O
examinations O
( O
RBC O
, O
WBC O
, O
Ht O
, O
Hb B
, O
PLT O
and O
ESR O
) O
and O
biochemical O
tests O
( O
AST B
, O
ALT B
, O
ALP B
, O
gamma B
GTP I
, O
LDH B
, O
CPK B
, O
Chol O
, O
T O
- O
Bil O
, O
TP O
, O
Alb B
, O
TG O
, O
BUN O
, O
Cr O
, O
Glu O
, O
Na O
, O
K O
, O
Ca O
, O
P O
and O
CRP B
) O
. O

These O
include O
urinalysis O
, O
chest O
X O
- O
P O
, O
ECG O
, O
hematological O
examinations O
( O
RBC O
, O
WBC O
, O
Ht O
, O
Hb B
, O
PLT O
and O
ESR O
) O
and O
biochemical O
tests O
( O
AST B
, O
ALT B
, O
ALP B
, O
gamma B
GTP I
, O
LDH B
, O
CPK B
, O
Chol O
, O
T O
- O
Bil O
, O
TP O
, O
Alb B
, O
TG O
, O
BUN O
, O
Cr O
, O
Glu O
, O
Na O
, O
K O
, O
Ca O
, O
P O
and O
CRP B
) O
. O

These O
include O
urinalysis O
, O
chest O
X O
- O
P O
, O
ECG O
, O
hematological O
examinations O
( O
RBC O
, O
WBC O
, O
Ht O
, O
Hb B
, O
PLT O
and O
ESR O
) O
and O
biochemical O
tests O
( O
AST B
, O
ALT B
, O
ALP B
, O
gamma B
GTP I
, O
LDH B
, O
CPK B
, O
Chol O
, O
T O
- O
Bil O
, O
TP O
, O
Alb B
, O
TG O
, O
BUN O
, O
Cr O
, O
Glu O
, O
Na O
, O
K O
, O
Ca O
, O
P O
and O
CRP B
) O
. O

These O
include O
urinalysis O
, O
chest O
X O
- O
P O
, O
ECG O
, O
hematological O
examinations O
( O
RBC O
, O
WBC O
, O
Ht O
, O
Hb B
, O
PLT O
and O
ESR O
) O
and O
biochemical O
tests O
( O
AST B
, O
ALT B
, O
ALP B
, O
gamma B
GTP I
, O
LDH B
, O
CPK B
, O
Chol O
, O
T O
- O
Bil O
, O
TP O
, O
Alb B
, O
TG O
, O
BUN O
, O
Cr O
, O
Glu O
, O
Na O
, O
K O
, O
Ca O
, O
P O
and O
CRP B
) O
. O

These O
include O
urinalysis O
, O
chest O
X O
- O
P O
, O
ECG O
, O
hematological O
examinations O
( O
RBC O
, O
WBC O
, O
Ht O
, O
Hb B
, O
PLT O
and O
ESR O
) O
and O
biochemical O
tests O
( O
AST B
, O
ALT B
, O
ALP B
, O
gamma B
GTP I
, O
LDH B
, O
CPK B
, O
Chol O
, O
T O
- O
Bil O
, O
TP O
, O
Alb B
, O
TG O
, O
BUN O
, O
Cr O
, O
Glu O
, O
Na O
, O
K O
, O
Ca O
, O
P O
and O
CRP B
) O
. O

These O
include O
urinalysis O
, O
chest O
X O
- O
P O
, O
ECG O
, O
hematological O
examinations O
( O
RBC O
, O
WBC O
, O
Ht O
, O
Hb B
, O
PLT O
and O
ESR O
) O
and O
biochemical O
tests O
( O
AST B
, O
ALT B
, O
ALP B
, O
gamma B
GTP I
, O
LDH B
, O
CPK B
, O
Chol O
, O
T O
- O
Bil O
, O
TP O
, O
Alb B
, O
TG O
, O
BUN O
, O
Cr O
, O
Glu O
, O
Na O
, O
K O
, O
Ca O
, O
P O
and O
CRP B
) O
. O

Mad3 B
and O
Mad4 B
: O
novel O
Max B
- O
interacting O
transcriptional O
repressors O
that O
suppress O
c B
- I
myc I
dependent O
transformation O
and O
are O
expressed O
during O
neural O
and O
epidermal O
differentiation O
. O

Mad3 B
and O
Mad4 B
: O
novel O
Max B
- O
interacting O
transcriptional O
repressors O
that O
suppress O
c B
- I
myc I
dependent O
transformation O
and O
are O
expressed O
during O
neural O
and O
epidermal O
differentiation O
. O

Mad3 B
and O
Mad4 B
: O
novel O
Max B
- O
interacting O
transcriptional O
repressors O
that O
suppress O
c B
- I
myc I
dependent O
transformation O
and O
are O
expressed O
during O
neural O
and O
epidermal O
differentiation O
. O

The O
pcaR B
regulatory I
locus I
has O
been O
found O
to O
be O
required O
for O
both O
induction O
of O
all O
of O
the O
genes O
within O
the O
pca B
regulon I
( O
pcaBDC B
, O
pcaIJ B
, O
and O
pcaF B
) O
and O
the O
chemotactic O
response O
of O
the O
bacteria O
to O
aromatic O
compounds O
. O

The O
pcaR B
regulatory I
locus I
has O
been O
found O
to O
be O
required O
for O
both O
induction O
of O
all O
of O
the O
genes O
within O
the O
pca B
regulon I
( O
pcaBDC B
, O
pcaIJ B
, O
and O
pcaF B
) O
and O
the O
chemotactic O
response O
of O
the O
bacteria O
to O
aromatic O
compounds O
. O

The O
pcaR B
regulatory I
locus I
has O
been O
found O
to O
be O
required O
for O
both O
induction O
of O
all O
of O
the O
genes O
within O
the O
pca B
regulon I
( O
pcaBDC B
, O
pcaIJ B
, O
and O
pcaF B
) O
and O
the O
chemotactic O
response O
of O
the O
bacteria O
to O
aromatic O
compounds O
. O

Furthermore O
, O
we O
have O
identified O
the O
major O
open O
reading O
frame O
( O
RF4 O
; O
2 O
. O
3 O
kb O
) O
as O
being O
essential O
for O
activation O
, O
and O
we O
have O
shown O
that O
the O
NF B
kappa I
B I
, O
SP1 B
, O
and O
TATA O
box O
motifs O
in O
the O
human B
immunodeficiency I
virus I
LTR I
are O
all O
required O
for O
full O
induction O
of O
the O
promoter O
by O
the O
HHV B
- I
6 I
- I
encoded I
transactivator I
. O

However O
, O
mutations O
of O
the O
C O
- O
rich O
element O
that O
disrupted O
a O
GC O
box O
located O
on O
the O
inverse O
strand O
eliminated O
PMA O
responsiveness O
and O
, O
in O
gel O
mobility O
shift O
assays O
, O
eliminated O
binding O
of O
Sp1 B
. O

TFIIB B
and O
VDR B
can O
also O
interact O
directly O
, O
and O
these O
factors O
synergize O
to O
mediate O
transactivation O
. O

TFIIB B
and O
VDR B
can O
also O
interact O
directly O
, O
and O
these O
factors O
synergize O
to O
mediate O
transactivation O
. O

Transfer O
of O
F O
- O
like O
plasmids O
is O
regulated O
by O
the O
FinOP B
system O
, O
which O
controls O
the O
expression O
of O
traJ B
, O
a O
positive O
regulator O
of O
the O
transfer O
operon O
. O

Transfer O
of O
F O
- O
like O
plasmids O
is O
regulated O
by O
the O
FinOP B
system O
, O
which O
controls O
the O
expression O
of O
traJ B
, O
a O
positive O
regulator O
of O
the O
transfer O
operon O
. O

Dual O
signal O
peptides O
mediate O
the O
signal B
recognition I
particle I
/ O
Sec B
- O
independent O
insertion O
of O
a O
thylakoid O
membrane O
polyprotein O
, O
PsbY B
. O

Dual O
signal O
peptides O
mediate O
the O
signal B
recognition I
particle I
/ O
Sec B
- O
independent O
insertion O
of O
a O
thylakoid O
membrane O
polyprotein O
, O
PsbY B
. O

In O
our O
case O
the O
development O
of O
the O
tumor O
at O
the O
posterior O
side O
of O
the O
prostate O
, O
the O
lack O
of O
PSA B
immunoreactivity O
and O
the O
presence O
of O
mucinous O
glands O
, O
sometimes O
" O
endocervical O
- O
like O
" O
, O
could O
suggest O
an O
origin O
from O
embryonic O
mullerian O
remnants O
in O
the O
prostatic O
utricle O
rather O
than O
urogenital O
sinus O
. O

Soluble O
extracts O
from O
FGF B
- O
treated O
as O
compared O
with O
quiescent O
fibroblasts O
exhibited O
up O
to O
3 O
- O
fold O
higher O
kinase O
activity O
towards O
S6 B
in O
exogenously O
added O
rat B
liver I
40S I
ribosomes I
and O
a O
synthetic O
peptide O
, O
RRLSSLRA O
. O

Soluble O
extracts O
from O
FGF B
- O
treated O
as O
compared O
with O
quiescent O
fibroblasts O
exhibited O
up O
to O
3 O
- O
fold O
higher O
kinase O
activity O
towards O
S6 B
in O
exogenously O
added O
rat B
liver I
40S I
ribosomes I
and O
a O
synthetic O
peptide O
, O
RRLSSLRA O
. O

In O
bell O
pepper O
, O
a O
gene O
encoding O
a O
major O
plastid O
- O
lipid O
associated O
protein O
is O
expressed O
as O
both O
partially O
and O
totally O
spliced O
transcripts O
( O
respectively O
PAP2 B
and O
PAP1 B
) O
. O

In O
bell O
pepper O
, O
a O
gene O
encoding O
a O
major O
plastid O
- O
lipid O
associated O
protein O
is O
expressed O
as O
both O
partially O
and O
totally O
spliced O
transcripts O
( O
respectively O
PAP2 B
and O
PAP1 B
) O
. O

Candidate O
factors O
have O
been O
identified O
by O
the O
observation O
that O
changes O
in O
glucocorticoid O
induction O
parameters O
in O
CV O
- O
1 O
cells O
could O
be O
reproduced O
by O
varying O
the O
cellular O
levels O
of O
coactivators O
[ O
transcriptional B
intermediary I
factor I
2 I
( O
TIF2 B
) O
, O
steroid B
receptor I
coactivator I
1 I
( O
SRC B
- I
1 I
) O
, O
and O
amplified B
in I
breast I
cancer I
1 I
( O
AIB1 B
) O
] O
, O
comodulator O
[ O
CREB B
- I
binding I
protein I
( O
CBP B
) O
] O
, O
or O
corepressor O
[ O
silencing B
mediator I
for I
retinoid I
and I
thyroid I
- I
hormone I
receptors I
( O
SMRT B
) O
] O
without O

Candidate O
factors O
have O
been O
identified O
by O
the O
observation O
that O
changes O
in O
glucocorticoid O
induction O
parameters O
in O
CV O
- O
1 O
cells O
could O
be O
reproduced O
by O
varying O
the O
cellular O
levels O
of O
coactivators O
[ O
transcriptional B
intermediary I
factor I
2 I
( O
TIF2 B
) O
, O
steroid B
receptor I
coactivator I
1 I
( O
SRC B
- I
1 I
) O
, O
and O
amplified B
in I
breast I
cancer I
1 I
( O
AIB1 B
) O
] O
, O
comodulator O
[ O
CREB B
- I
binding I
protein I
( O
CBP B
) O
] O
, O
or O
corepressor O
[ O
silencing B
mediator I
for I
retinoid I
and I
thyroid I
- I
hormone I
receptors I
( O
SMRT B
) O
] O
without O

Candidate O
factors O
have O
been O
identified O
by O
the O
observation O
that O
changes O
in O
glucocorticoid O
induction O
parameters O
in O
CV O
- O
1 O
cells O
could O
be O
reproduced O
by O
varying O
the O
cellular O
levels O
of O
coactivators O
[ O
transcriptional B
intermediary I
factor I
2 I
( O
TIF2 B
) O
, O
steroid B
receptor I
coactivator I
1 I
( O
SRC B
- I
1 I
) O
, O
and O
amplified B
in I
breast I
cancer I
1 I
( O
AIB1 B
) O
] O
, O
comodulator O
[ O
CREB B
- I
binding I
protein I
( O
CBP B
) O
] O
, O
or O
corepressor O
[ O
silencing B
mediator I
for I
retinoid I
and I
thyroid I
- I
hormone I
receptors I
( O
SMRT B
) O
] O
without O

Candidate O
factors O
have O
been O
identified O
by O
the O
observation O
that O
changes O
in O
glucocorticoid O
induction O
parameters O
in O
CV O
- O
1 O
cells O
could O
be O
reproduced O
by O
varying O
the O
cellular O
levels O
of O
coactivators O
[ O
transcriptional B
intermediary I
factor I
2 I
( O
TIF2 B
) O
, O
steroid B
receptor I
coactivator I
1 I
( O
SRC B
- I
1 I
) O
, O
and O
amplified B
in I
breast I
cancer I
1 I
( O
AIB1 B
) O
] O
, O
comodulator O
[ O
CREB B
- I
binding I
protein I
( O
CBP B
) O
] O
, O
or O
corepressor O
[ O
silencing B
mediator I
for I
retinoid I
and I
thyroid I
- I
hormone I
receptors I
( O
SMRT B
) O
] O
without O

concomitant O
increases O
in O
GR B
. O

Immunoblot O
analyses O
revealed O
that O
the O
loss O
of O
activator O
function O
coincides O
with O
selective O
removal O
of O
the O
C B
- I
terminal I
domain I
( I
CTD I
) I
- I
hyperphosphorylated I
RNAP I
IIO I
along O
with O
NC2 B
. O

At O
9 O
months O
postpartum O
, O
serum O
fT4 O
and O
fT3 O
levels O
were O
low O
normal O
( O
8 O
. O
0 O
and O
1 O
. O
7 O
pmol O
/ O
L O
, O
respectively O
) O
, O
but O
TSH B
was O
not O
raised O
( O
0 O
. O
4 O
mU O
/ O
L O
) O
. O

TFIIIB B
assembles O
autonomously O
on O
the O
upstream O
promoter O
of O
the O
yeast B
U6 I
snRNA I
( O
SNR6 B
) O
gene O
in O
vitro O
, O
through O
the O
interaction O
of O
its O
TBP B
subunit I
with O
a O
consensus O
TATA O
box O
located O
at O
base O
pair O
- O
30 O
. O

TFIIIB B
assembles O
autonomously O
on O
the O
upstream O
promoter O
of O
the O
yeast B
U6 I
snRNA I
( O
SNR6 B
) O
gene O
in O
vitro O
, O
through O
the O
interaction O
of O
its O
TBP B
subunit I
with O
a O
consensus O
TATA O
box O
located O
at O
base O
pair O
- O
30 O
. O

Our O
results O
show O
that O
a O
combination O
of O
Pfu B
exo I
( I
- I
) I
at O
the O
primer O
extension O
step O
and O
Taq B
at O
the O
PCR O
amplification O
step O
is O
ideal O
for O
in O
vivo O
DNA O
analysis O
and O
DNA O
damage O
mapping O
using O
LMPCR O
. O

Effect O
of O
TNF B
, O
IL B
- I
1 I
, O
and O
IL B
- I
6 I
on O
the O
proliferation O
of O
human O
Tenon O
' O
s O
capsule O
fibroblasts O
in O
tissue O
culture O
. O

Using O
lacZ B
- O
inducible O
T O
cells O
as O
a O
probe O
, O
we O
screened O
a O
splenic O
cDNA O
library O
in O
transiently O
transfected O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
and O
isolated O
a O
cDNA O
clone O
that O
allowed O
expression O
of O
the O
appropriate O
peptide B
/ I
Kb I
MHC I
complex I
in O
APC O
. O

A O
significant O
reduction O
in O
total O
cellular O
p27 B
protein I
levels O
and O
a O
moderate O
reduction O
in O
p27 B
mRNA I
are O
observed O
, O
but O
no O
changes O
in O
Cdk B
regulatory O
kinases O
and O
phosphatases O
occur O
. O

Genetic O
linkage O
mapping O
of O
the O
CYP11A1 B
gene I
encoding O
the O
cholesterol O
side O
- O
chain O
cleavage O
P450scc B
close O
to O
the O
CYP1A1 B
gene I
and O
D15S204 B
in O
the O
chromosome O
15q22 O
. O
33 O
- O
q23 O
region O
. O

Genetic O
linkage O
mapping O
of O
the O
CYP11A1 B
gene I
encoding O
the O
cholesterol O
side O
- O
chain O
cleavage O
P450scc B
close O
to O
the O
CYP1A1 B
gene I
and O
D15S204 B
in O
the O
chromosome O
15q22 O
. O
33 O
- O
q23 O
region O
. O

Evidence O
for O
Gcr1p B
/ O
Gcr2p B
interaction O
has O
been O
presented O
earlier O
and O
is O
now O
supported O
by O
the O
isolation O
of O
mutations O
in O
Gcr1p B
suppressing O
gcr2 B
, O
as O
assessed O
by O
growth O
and O
enzyme O
assay O
. O

Evidence O
for O
Gcr1p B
/ O
Gcr2p B
interaction O
has O
been O
presented O
earlier O
and O
is O
now O
supported O
by O
the O
isolation O
of O
mutations O
in O
Gcr1p B
suppressing O
gcr2 B
, O
as O
assessed O
by O
growth O
and O
enzyme O
assay O
. O

Evidence O
for O
Gcr1p B
/ O
Gcr2p B
interaction O
has O
been O
presented O
earlier O
and O
is O
now O
supported O
by O
the O
isolation O
of O
mutations O
in O
Gcr1p B
suppressing O
gcr2 B
, O
as O
assessed O
by O
growth O
and O
enzyme O
assay O
. O

Evidence O
for O
Gcr1p B
/ O
Gcr2p B
interaction O
has O
been O
presented O
earlier O
and O
is O
now O
supported O
by O
the O
isolation O
of O
mutations O
in O
Gcr1p B
suppressing O
gcr2 B
, O
as O
assessed O
by O
growth O
and O
enzyme O
assay O
. O

Plasma O
prolactin B
in O
patients O
with O
colorectal O
cancer O
. O

Reality O
and O
clinical O
application O
of O
immunoglobulin B
preparations O

Nuclear O
transcription O
assays O
confirmed O
that O
cys B
- I
3 I
+ I
was O
under O
sulfur O
- O
regulated O
transcriptional O
control O
and O
that O
cys B
- I
3 I
+ I
transcription O
was O
constitutive O
in O
sulfur B
controller I
( O
scon B
) O
- O
negative O
regulator O
mutants O
. O

The O
rifampicin O
resistance O
of O
uvsW B
- O
repressed O
replication O
suggests O
that O
it O
involves O
either O
tertiary O
initiation O
or O
some O
novel O
mode O
of O
initiation O
. O

The O
inhibition O
of O
monoamine B
oxidase I
( O
MAO B
) O
by O
tranylcypromine O
was O
studied O
in O
6 O
healthy O
volunteers O
given O
increasing O
doses O
of O
10 O
, O
15 O
, O
20 O
and O
25 O
mg O
/ O
day O
over O
a O
4 O
- O
week O
period O
. O

Expression O
of O
Helios B
was O
detected O
in O
the O
earliest O
hematopoietic O
sites O
of O
the O
embryo O
, O
in O
hematopoietic O
stem O
cells O
in O
the O
adult O
and O
was O
subsequently O
restricted O
to O
a O
subset O
of O
cells O
in O
the O
T O
cell O
lineage O
. O

The O
Pi O
signals O
are O
conveyed O
to O
PHO8 B
by O
binding O
of O
PHO4 B
protein I
, O
a O
positive O
regulatory O
factor O
, O
to O
a O
promoter O
region O
of O
PHO8 B
( O
PHO8p B
) O
under O
the O
influence O
of O
the O
PHO B
regulatory O
circuit O
. O

The O
Pi O
signals O
are O
conveyed O
to O
PHO8 B
by O
binding O
of O
PHO4 B
protein I
, O
a O
positive O
regulatory O
factor O
, O
to O
a O
promoter O
region O
of O
PHO8 B
( O
PHO8p B
) O
under O
the O
influence O
of O
the O
PHO B
regulatory O
circuit O
. O

The O
Pi O
signals O
are O
conveyed O
to O
PHO8 B
by O
binding O
of O
PHO4 B
protein I
, O
a O
positive O
regulatory O
factor O
, O
to O
a O
promoter O
region O
of O
PHO8 B
( O
PHO8p B
) O
under O
the O
influence O
of O
the O
PHO B
regulatory O
circuit O
. O

The O
Pi O
signals O
are O
conveyed O
to O
PHO8 B
by O
binding O
of O
PHO4 B
protein I
, O
a O
positive O
regulatory O
factor O
, O
to O
a O
promoter O
region O
of O
PHO8 B
( O
PHO8p B
) O
under O
the O
influence O
of O
the O
PHO B
regulatory O
circuit O
. O

It O
would O
seem O
that O
caution O
should O
be O
exercised O
in O
using O
HPL B
values O
as O
an O
index O
of O
placental O
function O
in O
anaemic O
women O
. O

The O
adenovirus B
E1B I
19 I
, I
000 I
- I
molecular I
- I
weight I
( I
19K I
) I
protein I
is O
a O
potent O
inhibitor O
of O
apoptosis O
and O
cooperates O
with O
E1A B
to O
transform O
primary O
rodent O
cells O
. O

Desensitization O
of O
the O
growth B
hormone I
- O
induced O
Janus B
kinase I
2 I
( O
Jak B
2 I
) O
/ O
signal B
transducer I
and I
activator I
of I
transcription I
5 I
( O
Stat5 B
) O
- O
signaling O
pathway O
requires O
protein O
synthesis O
and O
phospholipase B
C I
. O

In O
two O
separate O
studies O
, O
specimens O
of O
saliva O
from O
57 O
individuals O
over O
the O
age O
of O
65 O
years O
( O
mean O
age O
, O
76 O
. O
7 O
years O
) O
and O
37 O
persons O
under O
the O
age O
of O
40 O
years O
( O
mean O
age O
, O
28 O
. O
8 O
years O
) O
were O
examined O
for O
concentrations O
of O
IgA B
as O
functions O
of O
volume O
, O
total O
protein O
, O
and O
electrolyte O
conductivity O
; O
some O
were O
also O
tested O
for O
IgG B
and O
IgM B
content O
. O

In O
two O
separate O
studies O
, O
specimens O
of O
saliva O
from O
57 O
individuals O
over O
the O
age O
of O
65 O
years O
( O
mean O
age O
, O
76 O
. O
7 O
years O
) O
and O
37 O
persons O
under O
the O
age O
of O
40 O
years O
( O
mean O
age O
, O
28 O
. O
8 O
years O
) O
were O
examined O
for O
concentrations O
of O
IgA B
as O
functions O
of O
volume O
, O
total O
protein O
, O
and O
electrolyte O
conductivity O
; O
some O
were O
also O
tested O
for O
IgG B
and O
IgM B
content O
. O

In O
two O
separate O
studies O
, O
specimens O
of O
saliva O
from O
57 O
individuals O
over O
the O
age O
of O
65 O
years O
( O
mean O
age O
, O
76 O
. O
7 O
years O
) O
and O
37 O
persons O
under O
the O
age O
of O
40 O
years O
( O
mean O
age O
, O
28 O
. O
8 O
years O
) O
were O
examined O
for O
concentrations O
of O
IgA B
as O
functions O
of O
volume O
, O
total O
protein O
, O
and O
electrolyte O
conductivity O
; O
some O
were O
also O
tested O
for O
IgG B
and O
IgM B
content O
. O

E2A B
- O
HLF B
- O
mediated O
cell O
transformation O
requires O
both O
the O
trans O
- O
activation O
domains O
of O
E2A B
and O
the O
leucine O
zipper O
dimerization O
domain O
of O
HLF B
. O

E2A B
- O
HLF B
- O
mediated O
cell O
transformation O
requires O
both O
the O
trans O
- O
activation O
domains O
of O
E2A B
and O
the O
leucine O
zipper O
dimerization O
domain O
of O
HLF B
. O

E2A B
- O
HLF B
- O
mediated O
cell O
transformation O
requires O
both O
the O
trans O
- O
activation O
domains O
of O
E2A B
and O
the O
leucine O
zipper O
dimerization O
domain O
of O
HLF B
. O

E2A B
- O
HLF B
- O
mediated O
cell O
transformation O
requires O
both O
the O
trans O
- O
activation O
domains O
of O
E2A B
and O
the O
leucine O
zipper O
dimerization O
domain O
of O
HLF B
. O

Two O
adjacent O
, O
highly O
homologous B
endoglucanase I
genes I
, O
celD B
and O
celE B
from O
Fibrobacter O
succinogenes O
S85 O
, O
which O
were O
separated O
by O
an O
AT O
- O
rich O
223 O
- O
nucleotide O
intergenic O
region O
were O
characterized O
. O

Two O
adjacent O
, O
highly O
homologous B
endoglucanase I
genes I
, O
celD B
and O
celE B
from O
Fibrobacter O
succinogenes O
S85 O
, O
which O
were O
separated O
by O
an O
AT O
- O
rich O
223 O
- O
nucleotide O
intergenic O
region O
were O
characterized O
. O

We O
generated O
" O
signature O
" O
oligonucleotides O
from O
these O
CDR3s B
and O
probed O
PCR O
amplified O
V B
kappa I
products I
from O
the O
synovium O
and O
PBLs O
of O
the O
same O
patient O
, O
and O
from O
PBLs O
and O
spleen O
of O
individuals O
without O
rheumatic O
disease O
. O

One O
of O
the O
major O
transcripts O
encodes O
MEQ B
, O
a O
339 O
- O
amino O
- O
acid O
bZIP B
protein I
which O
is O
homologous O
to O
the O
Jun B
/ O
Fos B
family O
of O
transcription O
factors O
. O

One O
of O
the O
major O
transcripts O
encodes O
MEQ B
, O
a O
339 O
- O
amino O
- O
acid O
bZIP B
protein I
which O
is O
homologous O
to O
the O
Jun B
/ O
Fos B
family O
of O
transcription O
factors O
. O

One O
of O
the O
major O
transcripts O
encodes O
MEQ B
, O
a O
339 O
- O
amino O
- O
acid O
bZIP B
protein I
which O
is O
homologous O
to O
the O
Jun B
/ O
Fos B
family O
of O
transcription O
factors O
. O

Induction O
of O
interferon B
- I
alpha I
( O
IFNalpha B
) O
gene O
expression O
in O
virus O
- O
infected O
cells O
requires O
phosphorylation O
- O
induced O
activation O
of O
the O
transcription O
factors O
IRF3 B
and O
IRF7 B
. O

Induction O
of O
interferon B
- I
alpha I
( O
IFNalpha B
) O
gene O
expression O
in O
virus O
- O
infected O
cells O
requires O
phosphorylation O
- O
induced O
activation O
of O
the O
transcription O
factors O
IRF3 B
and O
IRF7 B
. O

Induction O
of O
interferon B
- I
alpha I
( O
IFNalpha B
) O
gene O
expression O
in O
virus O
- O
infected O
cells O
requires O
phosphorylation O
- O
induced O
activation O
of O
the O
transcription O
factors O
IRF3 B
and O
IRF7 B
. O

Moreover O
, O
since O
the O
integrated O
transforming O
DNA O
was O
not O
altered O
or O
lost O
expression O
of O
the O
RbcS2 B
: O
: O
aadA B
: O
: O
RbcS2 B
gene I
( I
s I
) I
appears O
to O
be O
repressed O
. O

Moreover O
, O
since O
the O
integrated O
transforming O
DNA O
was O
not O
altered O
or O
lost O
expression O
of O
the O
RbcS2 B
: O
: O
aadA B
: O
: O
RbcS2 B
gene I
( I
s I
) I
appears O
to O
be O
repressed O
. O

Mutations O
in O
nifR1 B
( O
ntrC B
) O
and O
nifR4 B
( O
rpoN B
, O
encoding O
sigma54 B
) O
had O
no O
influence O
on O
xdh B
gene I
expression O
. O

Mutations O
in O
nifR1 B
( O
ntrC B
) O
and O
nifR4 B
( O
rpoN B
, O
encoding O
sigma54 B
) O
had O
no O
influence O
on O
xdh B
gene I
expression O
. O

Mutations O
in O
nifR1 B
( O
ntrC B
) O
and O
nifR4 B
( O
rpoN B
, O
encoding O
sigma54 B
) O
had O
no O
influence O
on O
xdh B
gene I
expression O
. O

Mutations O
in O
nifR1 B
( O
ntrC B
) O
and O
nifR4 B
( O
rpoN B
, O
encoding O
sigma54 B
) O
had O
no O
influence O
on O
xdh B
gene I
expression O
. O

Mutations O
in O
nifR1 B
( O
ntrC B
) O
and O
nifR4 B
( O
rpoN B
, O
encoding O
sigma54 B
) O
had O
no O
influence O
on O
xdh B
gene I
expression O
. O

We O
therefore O
propose O
that O
PRR2 B
, O
and O
not O
PVR B
, O
is O
the O
true O
human O
homolog O
of O
MPH B
. O

We O
therefore O
propose O
that O
PRR2 B
, O
and O
not O
PVR B
, O
is O
the O
true O
human O
homolog O
of O
MPH B
. O

We O
therefore O
propose O
that O
PRR2 B
, O
and O
not O
PVR B
, O
is O
the O
true O
human O
homolog O
of O
MPH B
. O

In O
contrast O
, O
vRel B
lacks O
a O
strong O
C O
- O
terminal O
gene O
activation O
function O
, O
since O
a O
LexA B
fusion I
protein I
containing O
C B
- I
terminal I
vRel I
sequences I
alone O
only O
weakly O
activated O
transcription O
. O

Oral O
basal O
body O
temperature O
( O
BBT O
) O
recordings O
of O
46 O
women O
that O
conceived O
by O
donor O
insemination O
and O
who O
had O
midcycle O
monitoring O
of O
luteinising B
hormone I
( O
LH B
) O
were O
analysed O
to O
establish O
features O
associated O
with O
an O
optimal O
cycle O
. O

The O
human B
lbc I
oncogene I
product I
is O
a O
guanine B
nucleotide I
exchange I
factor I
that O
specifically O
activates O
the O
Rho B
small I
GTP I
binding I
protein I
, O
thus O
resulting O
in O
biologically O
active O
, O
GTP O
- O
bound O
Rho B
, O
which O
in O
turn O
mediates O
actin B
cytoskeletal O
reorganization O
, O
gene O
transcription O
, O
and O
entry O
into O
the O
mitotic O
S O
phase O
. O

The O
human B
lbc I
oncogene I
product I
is O
a O
guanine B
nucleotide I
exchange I
factor I
that O
specifically O
activates O
the O
Rho B
small I
GTP I
binding I
protein I
, O
thus O
resulting O
in O
biologically O
active O
, O
GTP O
- O
bound O
Rho B
, O
which O
in O
turn O
mediates O
actin B
cytoskeletal O
reorganization O
, O
gene O
transcription O
, O
and O
entry O
into O
the O
mitotic O
S O
phase O
. O

Insulin B
- O
stimulated O
autophosphorylation O
at O
specific O
sites O
in O
the O
tyrosine B
kinase I
domain I
of O
the O
receptor O
' O
s O
beta O
- O
subunit O
is O
correlated O
kinetically O
with O
activation O
of O
kinase O
- O
catalyzed O
phosphorylation O
of O
a O
model O
substrate O
( O
reduced O
and O
carboxyamidomethylated O
lysozyme B
; O
RCAM B
- I
lysozyme I
) O
. O

Insulin B
- O
stimulated O
autophosphorylation O
at O
specific O
sites O
in O
the O
tyrosine B
kinase I
domain I
of O
the O
receptor O
' O
s O
beta O
- O
subunit O
is O
correlated O
kinetically O
with O
activation O
of O
kinase O
- O
catalyzed O
phosphorylation O
of O
a O
model O
substrate O
( O
reduced O
and O
carboxyamidomethylated O
lysozyme B
; O
RCAM B
- I
lysozyme I
) O
. O

The O
gene O
responsible O
for O
multiple O
endocrine O
neoplasia O
type O
1 O
( O
MEN1 B
) O
, O
a O
heritable O
predisposition O
to O
endocrine O
tumours O
in O
man O
, O
has O
recently O
been O
identified O
. O

AST B
activity O
in O
PMNs O
was O
significantly O
low O
, O
approximately O
2 O
% O
of O
that O
observed O
in O
HPLFs O
. O

Highly O
conserved O
regions O
called O
src B
homology I
2 I
and O
3 O
( O
SH2 B
and O
SH3 B
) O
, O
comprising O
amino O
acid O
residues O
88 O
to O
250 O
, O
are O
believed O
to O
modulate O
the O
protein B
- I
tyrosine I
kinase I
activity O
present O
in O
the O
carboxy O
- O
terminal O
halves O
of O
the O
src B
proteins I
. O

Highly O
conserved O
regions O
called O
src B
homology I
2 I
and O
3 O
( O
SH2 B
and O
SH3 B
) O
, O
comprising O
amino O
acid O
residues O
88 O
to O
250 O
, O
are O
believed O
to O
modulate O
the O
protein B
- I
tyrosine I
kinase I
activity O
present O
in O
the O
carboxy O
- O
terminal O
halves O
of O
the O
src B
proteins I
. O

Interestingly O
, O
the O
NES B
mutant I
proteins I
appeared O
to O
have O
altered O
interactions O
with O
the O
splicing O
complex O
, O
binding O
more O
tightly O
to O
SC35 B
in O
co O
- O
immunoprecipitation O
assays O
. O

G6620 B
is O
the O
3 O
' O
end O
of O
the O
MOL1 B
gene I
coding O
for O
a O
polypeptide O
similar O
to O
stress O
- O
inducible O
proteins O
from O
Fusarium O
; O
G6630 B
is O
the O
NAT2 B
gene I
which O
encodes O
a O
methionine B
N I
- I
acetyltransferase I
; O
G6635 B
is O
the O
RPL30B B
gene I
coding O
for O
the O
ribosomal B
protein I
L30 I
; O
G6658 B
is O
RSR1 B
encoding O
a O
ras B
- I
related I
protein I
; O
G6667 B
is O
CYS4 B
, O
the O
gene O
for O
cystathionine B
beta I
- I
synthase I

G6620 B
is O
the O
3 O
' O
end O
of O
the O
MOL1 B
gene I
coding O
for O
a O
polypeptide O
similar O
to O
stress O
- O
inducible O
proteins O
from O
Fusarium O
; O
G6630 B
is O
the O
NAT2 B
gene I
which O
encodes O
a O
methionine B
N I
- I
acetyltransferase I
; O
G6635 B
is O
the O
RPL30B B
gene I
coding O
for O
the O
ribosomal B
protein I
L30 I
; O
G6658 B
is O
RSR1 B
encoding O
a O
ras B
- I
related I
protein I
; O
G6667 B
is O
CYS4 B
, O
the O
gene O
for O
cystathionine B
beta I
- I
synthase I

G6620 B
is O
the O
3 O
' O
end O
of O
the O
MOL1 B
gene I
coding O
for O
a O
polypeptide O
similar O
to O
stress O
- O
inducible O
proteins O
from O
Fusarium O
; O
G6630 B
is O
the O
NAT2 B
gene I
which O
encodes O
a O
methionine B
N I
- I
acetyltransferase I
; O
G6635 B
is O
the O
RPL30B B
gene I
coding O
for O
the O
ribosomal B
protein I
L30 I
; O
G6658 B
is O
RSR1 B
encoding O
a O
ras B
- I
related I
protein I
; O
G6667 B
is O
CYS4 B
, O
the O
gene O
for O
cystathionine B
beta I
- I
synthase I

G6620 B
is O
the O
3 O
' O
end O
of O
the O
MOL1 B
gene I
coding O
for O
a O
polypeptide O
similar O
to O
stress O
- O
inducible O
proteins O
from O
Fusarium O
; O
G6630 B
is O
the O
NAT2 B
gene I
which O
encodes O
a O
methionine B
N I
- I
acetyltransferase I
; O
G6635 B
is O
the O
RPL30B B
gene I
coding O
for O
the O
ribosomal B
protein I
L30 I
; O
G6658 B
is O
RSR1 B
encoding O
a O
ras B
- I
related I
protein I
; O
G6667 B
is O
CYS4 B
, O
the O
gene O
for O
cystathionine B
beta I
- I
synthase I

G6620 B
is O
the O
3 O
' O
end O
of O
the O
MOL1 B
gene I
coding O
for O
a O
polypeptide O
similar O
to O
stress O
- O
inducible O
proteins O
from O
Fusarium O
; O
G6630 B
is O
the O
NAT2 B
gene I
which O
encodes O
a O
methionine B
N I
- I
acetyltransferase I
; O
G6635 B
is O
the O
RPL30B B
gene I
coding O
for O
the O
ribosomal B
protein I
L30 I
; O
G6658 B
is O
RSR1 B
encoding O
a O
ras B
- I
related I
protein I
; O
G6667 B
is O
CYS4 B
, O
the O
gene O
for O
cystathionine B
beta I
- I
synthase I

G6620 B
is O
the O
3 O
' O
end O
of O
the O
MOL1 B
gene I
coding O
for O
a O
polypeptide O
similar O
to O
stress O
- O
inducible O
proteins O
from O
Fusarium O
; O
G6630 B
is O
the O
NAT2 B
gene I
which O
encodes O
a O
methionine B
N I
- I
acetyltransferase I
; O
G6635 B
is O
the O
RPL30B B
gene I
coding O
for O
the O
ribosomal B
protein I
L30 I
; O
G6658 B
is O
RSR1 B
encoding O
a O
ras B
- I
related I
protein I
; O
G6667 B
is O
CYS4 B
, O
the O
gene O
for O
cystathionine B
beta I
- I
synthase I

G6620 B
is O
the O
3 O
' O
end O
of O
the O
MOL1 B
gene I
coding O
for O
a O
polypeptide O
similar O
to O
stress O
- O
inducible O
proteins O
from O
Fusarium O
; O
G6630 B
is O
the O
NAT2 B
gene I
which O
encodes O
a O
methionine B
N I
- I
acetyltransferase I
; O
G6635 B
is O
the O
RPL30B B
gene I
coding O
for O
the O
ribosomal B
protein I
L30 I
; O
G6658 B
is O
RSR1 B
encoding O
a O
ras B
- I
related I
protein I
; O
G6667 B
is O
CYS4 B
, O
the O
gene O
for O
cystathionine B
beta I
- I
synthase I

; O
G6670 B
is O
identical O
to O
ORF2 O
located O
close O
to O
CYS4 B
; O
G6673 B
is O
PEM1 B
/ O
CHO2 B
encoding O
a O
phosphatidylethanolamine B
methyltransferase I
; O
G7001 B
is O
the O
NSR1 B
gene I
coding O
for O
a O
nuclear O
signal O
recognition O
protein O
. O

; O
G6670 B
is O
identical O
to O
ORF2 O
located O
close O
to O
CYS4 B
; O
G6673 B
is O
PEM1 B
/ O
CHO2 B
encoding O
a O
phosphatidylethanolamine B
methyltransferase I
; O
G7001 B
is O
the O
NSR1 B
gene I
coding O
for O
a O
nuclear O
signal O
recognition O
protein O
. O

; O
G6670 B
is O
identical O
to O
ORF2 O
located O
close O
to O
CYS4 B
; O
G6673 B
is O
PEM1 B
/ O
CHO2 B
encoding O
a O
phosphatidylethanolamine B
methyltransferase I
; O
G7001 B
is O
the O
NSR1 B
gene I
coding O
for O
a O
nuclear O
signal O
recognition O
protein O
. O

; O
G6670 B
is O
identical O
to O
ORF2 O
located O
close O
to O
CYS4 B
; O
G6673 B
is O
PEM1 B
/ O
CHO2 B
encoding O
a O
phosphatidylethanolamine B
methyltransferase I
; O
G7001 B
is O
the O
NSR1 B
gene I
coding O
for O
a O
nuclear O
signal O
recognition O
protein O
. O

; O
G6670 B
is O
identical O
to O
ORF2 O
located O
close O
to O
CYS4 B
; O
G6673 B
is O
PEM1 B
/ O
CHO2 B
encoding O
a O
phosphatidylethanolamine B
methyltransferase I
; O
G7001 B
is O
the O
NSR1 B
gene I
coding O
for O
a O
nuclear O
signal O
recognition O
protein O
. O

Transcriptional O
analysis O
of O
this O
gene O
cluster O
was O
performed O
by O
detecting O
the O
presence O
of O
mRNAs O
spanning O
adjacent O
genes O
as O
well O
as O
by O
using O
a O
promoterless O
lacZ B
reporter I
gene I
fused O
to O
each O
of O
the O
seven O
genes O
contained O
in O
the O
tol B
- O
oprL B
locus O
. O

Transcriptional O
analysis O
of O
this O
gene O
cluster O
was O
performed O
by O
detecting O
the O
presence O
of O
mRNAs O
spanning O
adjacent O
genes O
as O
well O
as O
by O
using O
a O
promoterless O
lacZ B
reporter I
gene I
fused O
to O
each O
of O
the O
seven O
genes O
contained O
in O
the O
tol B
- O
oprL B
locus O
. O

Serum O
IgG B
and O
IgA B
level O
were O
decreased O
. O

Serum O
IgG B
and O
IgA B
level O
were O
decreased O
. O

Therefore O
the O
effect O
of O
GAL11 B
on O
PGK B
transcription O
must O
be O
mediated O
at O
the O
PGK B
UAS I
, O
presumably O
as O
part O
of O
the O
activation O
complex O
. O

Therefore O
the O
effect O
of O
GAL11 B
on O
PGK B
transcription O
must O
be O
mediated O
at O
the O
PGK B
UAS I
, O
presumably O
as O
part O
of O
the O
activation O
complex O
. O

Wingless B
/ O
Wnt B
signaling O
directs O
cell O
- O
fate O
choices O
during O
embryonic O
development O
. O

Wingless B
/ O
Wnt B
signaling O
directs O
cell O
- O
fate O
choices O
during O
embryonic O
development O
. O

RNase B
protection O
analysis O
reveals O
a O
10 O
- O
fold O
increase O
in O
the O
expression O
of O
SCD2 B
mRNA I
during O
3T3 O
- O
L1 O
preadipocyte O
differentiation O
. O

To O
determine O
whether O
transcription O
of O
orfX O
and O
vfr B
are O
controlled O
by O
the O
same O
mechanisms O
that O
control O
transcription O
of O
the O
region O
of O
the O
divergent O
ORF O
( O
dorf O
) O
and O
of O
crp B
, O
we O
compared O
the O
vfr B
- O
orfX O
and O
crp B
- O
dorf O
intergenic O
regions O
. O

To O
determine O
whether O
transcription O
of O
orfX O
and O
vfr B
are O
controlled O
by O
the O
same O
mechanisms O
that O
control O
transcription O
of O
the O
region O
of O
the O
divergent O
ORF O
( O
dorf O
) O
and O
of O
crp B
, O
we O
compared O
the O
vfr B
- O
orfX O
and O
crp B
- O
dorf O
intergenic O
regions O
. O

To O
determine O
whether O
transcription O
of O
orfX O
and O
vfr B
are O
controlled O
by O
the O
same O
mechanisms O
that O
control O
transcription O
of O
the O
region O
of O
the O
divergent O
ORF O
( O
dorf O
) O
and O
of O
crp B
, O
we O
compared O
the O
vfr B
- O
orfX O
and O
crp B
- O
dorf O
intergenic O
regions O
. O

To O
determine O
whether O
transcription O
of O
orfX O
and O
vfr B
are O
controlled O
by O
the O
same O
mechanisms O
that O
control O
transcription O
of O
the O
region O
of O
the O
divergent O
ORF O
( O
dorf O
) O
and O
of O
crp B
, O
we O
compared O
the O
vfr B
- O
orfX O
and O
crp B
- O
dorf O
intergenic O
regions O
. O

As O
a O
member O
of O
the O
uncoupling B
protein I
family I
, O
UCP2 B
is O
ubiquitously O
expressed O
in O
rodents O
and O
humans O
, O
implicating O
a O
major O
role O
in O
thermogenesis O
. O

Parental O
and O
vector O
- O
transfected O
MCF7 O
cells O
, O
which O
were O
sensitive O
to O
the O
growth O
- O
inhibitory O
effects O
of O
atRA O
, O
exhibited O
atRA O
- O
dependent O
retinoic B
acid I
receptor I
( O
RAR B
) O
transactivation O
and O
transrepression O
of O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
- O
induced O
AP B
- I
1 I
activity O
. O

99Tcm O
- O
labelled O
albumin B
colloid O
, O
albures O
( O
radius O
250 O
nm O
) O
or O
nanocoll O
( O
radius O
25 O
nm O
) O
, O
or O
both O
were O
used O
as O
test O
substances O
to O
study O
the O
kinetics O
of O
vascular O
clearance O
after O
RES O
stimulation O
. O

Meq B
/ O
c B
- I
Jun I
heterodimers O
bind O
to O
an O
AP1 B
- I
like I
sequence I
in O
the O
meq B
promoter I
region I
with O
an O
affinity O
much O
greater O
than O
that O
of O
Meq B
/ O
Meq B
or O
c B
- I
Jun I
/ O
c B
- I
Jun I
homodimers O
. O

Meq B
/ O
c B
- I
Jun I
heterodimers O
bind O
to O
an O
AP1 B
- I
like I
sequence I
in O
the O
meq B
promoter I
region I
with O
an O
affinity O
much O
greater O
than O
that O
of O
Meq B
/ O
Meq B
or O
c B
- I
Jun I
/ O
c B
- I
Jun I
homodimers O
. O

Meq B
/ O
c B
- I
Jun I
heterodimers O
bind O
to O
an O
AP1 B
- I
like I
sequence I
in O
the O
meq B
promoter I
region I
with O
an O
affinity O
much O
greater O
than O
that O
of O
Meq B
/ O
Meq B
or O
c B
- I
Jun I
/ O
c B
- I
Jun I
homodimers O
. O

Moreover O
, O
the O
noncoordinate O
effects O
of O
FSK B
on O
PMA O
- O
stimulated O
MKK B
and O
MAPK B
activities O
indicates O
the O
presence O
of O
a O
additional O
distal O
cAMP O
- O
dependent O
inhibitory O
mechanisms O
. O

Moreover O
, O
the O
noncoordinate O
effects O
of O
FSK B
on O
PMA O
- O
stimulated O
MKK B
and O
MAPK B
activities O
indicates O
the O
presence O
of O
a O
additional O
distal O
cAMP O
- O
dependent O
inhibitory O
mechanisms O
. O

Moreover O
, O
the O
noncoordinate O
effects O
of O
FSK B
on O
PMA O
- O
stimulated O
MKK B
and O
MAPK B
activities O
indicates O
the O
presence O
of O
a O
additional O
distal O
cAMP O
- O
dependent O
inhibitory O
mechanisms O
. O

These O
findings O
indicated O
that O
p35 B
is O
a O
trans O
- O
dominant O
factor O
that O
facilitates O
AcMNPV O
growth O
in O
a O
cell O
line O
- O
specific O
manner O
. O

Site O
- O
directed O
mutagenesis O
shows O
that O
sites O
throughout O
the O
IRE B
alter O
negative O
control O
and O
IRE B
- I
BP I
binding O
reflecting O
the O
fact O
that O
the O
footprint O
of O
the O
IRE B
- I
BP I
is O
over O
the O
entire O
IRE B
. O

Site O
- O
directed O
mutagenesis O
shows O
that O
sites O
throughout O
the O
IRE B
alter O
negative O
control O
and O
IRE B
- I
BP I
binding O
reflecting O
the O
fact O
that O
the O
footprint O
of O
the O
IRE B
- I
BP I
is O
over O
the O
entire O
IRE B
. O

An O
alternative O
approach O
to O
random O
integration O
of O
large O
DNA O
fragments O
into O
plants O
is O
to O
utilize O
one O
of O
several O
site O
- O
specific O
recombination O
( O
SSR O
) O
systems O
, O
such O
as O
Cre B
/ O
lox B
. O

An O
alternative O
approach O
to O
random O
integration O
of O
large O
DNA O
fragments O
into O
plants O
is O
to O
utilize O
one O
of O
several O
site O
- O
specific O
recombination O
( O
SSR O
) O
systems O
, O
such O
as O
Cre B
/ O
lox B
. O

Nonlethal O
sec71 B
- I
1 I
and O
sec72 B
- I
1 I
mutations I
eliminate O
proteins O
associated O
with O
the O
Sec63p B
- O
BiP B
complex O
from O
S O
. O
cerevisiae O
. O

Nonlethal O
sec71 B
- I
1 I
and O
sec72 B
- I
1 I
mutations I
eliminate O
proteins O
associated O
with O
the O
Sec63p B
- O
BiP B
complex O
from O
S O
. O
cerevisiae O
. O

Sequence O
and O
deletion O
analysis O
of O
the O
recombination B
enhancement I
gene I
( O
ref B
) O
of O
bacteriophage O
P1 O
: O
evidence O
for O
promoter O
- O
operator O
and O
attenuator O
- O
antiterminator O
control O
. O

The O
amino O
acid O
residues O
and O
subdomains O
important O
for O
DNA O
binding O
, O
hormone O
binding O
, O
dimerization O
, O
and O
transactivation O
are O
mostly O
conserved O
among O
all O
VDR B
species O
. O

Transcripts O
appear O
to O
be O
initiated O
from O
an O
upstream O
promoter O
, O
P1 O
, O
located O
in O
front O
of O
the O
tRNA B
( I
met1 I
) I
gene I
and O
from O
three O
internal O
promoters O
: O
P2 O
is O
located O
immediately O
in O
front O
of O
the O
tRNA B
( I
met2 I
) I
gene I
; O
PL10 O
is O
near O
the O
beginning O
of O
the O
L1 B
- O
L10 B
intergenic O
space O
, O
and O
PL12 O
is O
at O
the O
end O
of O
the O
L10 B
gene I
sequence I
. O

Transcripts O
appear O
to O
be O
initiated O
from O
an O
upstream O
promoter O
, O
P1 O
, O
located O
in O
front O
of O
the O
tRNA B
( I
met1 I
) I
gene I
and O
from O
three O
internal O
promoters O
: O
P2 O
is O
located O
immediately O
in O
front O
of O
the O
tRNA B
( I
met2 I
) I
gene I
; O
PL10 O
is O
near O
the O
beginning O
of O
the O
L1 B
- O
L10 B
intergenic O
space O
, O
and O
PL12 O
is O
at O
the O
end O
of O
the O
L10 B
gene I
sequence I
. O

Based O
on O
the O
deduced O
amino O
acid O
sequence O
identity O
we O
designated O
GAPC1 B
and O
GAPC2 B
as O
group O
I O
( O
97 O
% O
identical O
) O
and O
GAPC3 B
and O
GAPC4 B
as O
group O
II O
( O
99 O
. O
4 O
% O
identical O
) O
. O

Based O
on O
the O
deduced O
amino O
acid O
sequence O
identity O
we O
designated O
GAPC1 B
and O
GAPC2 B
as O
group O
I O
( O
97 O
% O
identical O
) O
and O
GAPC3 B
and O
GAPC4 B
as O
group O
II O
( O
99 O
. O
4 O
% O
identical O
) O
. O

Based O
on O
the O
deduced O
amino O
acid O
sequence O
identity O
we O
designated O
GAPC1 B
and O
GAPC2 B
as O
group O
I O
( O
97 O
% O
identical O
) O
and O
GAPC3 B
and O
GAPC4 B
as O
group O
II O
( O
99 O
. O
4 O
% O
identical O
) O
. O

Based O
on O
the O
deduced O
amino O
acid O
sequence O
identity O
we O
designated O
GAPC1 B
and O
GAPC2 B
as O
group O
I O
( O
97 O
% O
identical O
) O
and O
GAPC3 B
and O
GAPC4 B
as O
group O
II O
( O
99 O
. O
4 O
% O
identical O
) O
. O

Saturated O
fatty O
acids O
induce O
a O
1 O
. O
6 O
- O
fold O
increase O
in O
transcription O
activity O
, O
whereas O
a O
large O
family O
of O
unsaturated O
fatty O
acids O
repress O
OLE1 B
transcription O
as O
much O
as O
60 O
- O
fold O
. O

In O
both O
liver O
and O
pancreatic O
islet O
, O
glucokinase B
is O
subject O
to O
inhibition O
by O
a O
regulatory O
protein O
( O
GCKR B
) O
. O

In O
both O
liver O
and O
pancreatic O
islet O
, O
glucokinase B
is O
subject O
to O
inhibition O
by O
a O
regulatory O
protein O
( O
GCKR B
) O
. O

Cotransfection O
of O
expression O
plasmids O
encoding O
the O
protein B
kinase I
A I
inhibitor O
, O
or O
an O
inactive O
protein B
kinase I
A I
( O
PKA B
) O
catalytic O
beta O
subunit O
, O
inhibited O
both O
forskolin O
and O
PACAP B
activation O
of O
chromogranin B
A I
transcription O
, O
revealing O
that O
PACAP B
- O
induced O
trans O
- O
activation O
is O
highly O
dependent O
on O
PKA B
. O

Cotransfection O
of O
expression O
plasmids O
encoding O
the O
protein B
kinase I
A I
inhibitor O
, O
or O
an O
inactive O
protein B
kinase I
A I
( O
PKA B
) O
catalytic O
beta O
subunit O
, O
inhibited O
both O
forskolin O
and O
PACAP B
activation O
of O
chromogranin B
A I
transcription O
, O
revealing O
that O
PACAP B
- O
induced O
trans O
- O
activation O
is O
highly O
dependent O
on O
PKA B
. O

Cotransfection O
of O
expression O
plasmids O
encoding O
the O
protein B
kinase I
A I
inhibitor O
, O
or O
an O
inactive O
protein B
kinase I
A I
( O
PKA B
) O
catalytic O
beta O
subunit O
, O
inhibited O
both O
forskolin O
and O
PACAP B
activation O
of O
chromogranin B
A I
transcription O
, O
revealing O
that O
PACAP B
- O
induced O
trans O
- O
activation O
is O
highly O
dependent O
on O
PKA B
. O

Cotransfection O
of O
expression O
plasmids O
encoding O
the O
protein B
kinase I
A I
inhibitor O
, O
or O
an O
inactive O
protein B
kinase I
A I
( O
PKA B
) O
catalytic O
beta O
subunit O
, O
inhibited O
both O
forskolin O
and O
PACAP B
activation O
of O
chromogranin B
A I
transcription O
, O
revealing O
that O
PACAP B
- O
induced O
trans O
- O
activation O
is O
highly O
dependent O
on O
PKA B
. O

GH B
induced O
rapid O
tyrosine O
phosphorylation O
of O
a O
protein O
at O
approximately O
93 O
kDa O
in O
normal O
fibroblasts O
, O
and O
Western O
blotting O
with O
STAT B
- I
specific I
antibodies I
revealed O
STAT5 B
activation O
( O
phosphorylation O
) O
by O
GH O
. O

GH B
induced O
rapid O
tyrosine O
phosphorylation O
of O
a O
protein O
at O
approximately O
93 O
kDa O
in O
normal O
fibroblasts O
, O
and O
Western O
blotting O
with O
STAT B
- I
specific I
antibodies I
revealed O
STAT5 B
activation O
( O
phosphorylation O
) O
by O
GH O
. O

Furthermore O
, O
CBP B
/ O
p300 B
stimulated O
both O
TGF B
- I
beta I
- O
and O
Smad B
- O
induced O
transcription O
in O
a O
Smad4 B
/ O
DPC4 B
- O
dependent O
fashion O
. O

Furthermore O
, O
CBP B
/ O
p300 B
stimulated O
both O
TGF B
- I
beta I
- O
and O
Smad B
- O
induced O
transcription O
in O
a O
Smad4 B
/ O
DPC4 B
- O
dependent O
fashion O
. O

Furthermore O
, O
CBP B
/ O
p300 B
stimulated O
both O
TGF B
- I
beta I
- O
and O
Smad B
- O
induced O
transcription O
in O
a O
Smad4 B
/ O
DPC4 B
- O
dependent O
fashion O
. O

Furthermore O
, O
CBP B
/ O
p300 B
stimulated O
both O
TGF B
- I
beta I
- O
and O
Smad B
- O
induced O
transcription O
in O
a O
Smad4 B
/ O
DPC4 B
- O
dependent O
fashion O
. O

Furthermore O
, O
CBP B
/ O
p300 B
stimulated O
both O
TGF B
- I
beta I
- O
and O
Smad B
- O
induced O
transcription O
in O
a O
Smad4 B
/ O
DPC4 B
- O
dependent O
fashion O
. O

Sequence O
analysis O
revealed O
100 O
% O
homology O
of O
all O
RA O
- O
derived O
PTEN B
fragments I
to O
those O
from O
normal O
SF O
as O
well O
as O
to O
the O
published O
GenBank O
sequence O
( O
accession O
number O
U93051 B
) O
. O

The O
most O
frequent O
abnormality O
was O
GH B
deficiency O
( O
six O
cases O
) O
, O
followed O
by O
gonadotropin B
( O
four O
cases O
) O
, O
cortisol O
( O
four O
cases O
) O
, O
and O
TSH B
( O
one O
case O
) O
, O
whereas O
four O
patients O
showed O
high O
serum B
PRL I
values O
. O

The O
most O
frequent O
abnormality O
was O
GH B
deficiency O
( O
six O
cases O
) O
, O
followed O
by O
gonadotropin B
( O
four O
cases O
) O
, O
cortisol O
( O
four O
cases O
) O
, O
and O
TSH B
( O
one O
case O
) O
, O
whereas O
four O
patients O
showed O
high O
serum B
PRL I
values O
. O

The O
most O
frequent O
abnormality O
was O
GH B
deficiency O
( O
six O
cases O
) O
, O
followed O
by O
gonadotropin B
( O
four O
cases O
) O
, O
cortisol O
( O
four O
cases O
) O
, O
and O
TSH B
( O
one O
case O
) O
, O
whereas O
four O
patients O
showed O
high O
serum B
PRL I
values O
. O

In O
both O
cell O
types O
, O
insulin B
led O
to O
a O
dose O
- O
dependent O
increase O
in O
the O
association O
of O
tyrosine B
phosphorylated I
IRS I
- I
1 I
with O
the O
SH2 B
domain I
of O
the O
p85 B
regulatory I
subunit I
of O
PI B
- I
3 I
kinase I
, O
and O
also O
increased O
the O
amount O
of O
PI B
kinase I
activity O
detected O
in O
anti B
- I
IRS I
- I
1 I
immunoprecipitates O
. O

No O
bafilomycin O
- O
sensitive O
ATPase B
is O
detected O
in O
a O
vacuolar O
fraction O
. O

Detailed O
comparison O
of O
the O
sequences O
of O
cp35 B
and O
human B
calpactin I
II I
shows O
that O
the O
only O
substantial O
sequence O
dissimilarity O
is O
a O
domain O
encoding O
amino O
acids O
between O
residues O
20 O
and O
40 O
which O
includes O
a O
tyrosine O
phosphorylation O
site O
in O
the O
human O
molecule O
, O
along O
with O
other O
residues O
of O
possible O
physiological O
significance O
. O

The O
implication O
of O
Rac B
and O
Cdc42 B
was O
analyzed O
in O
transient O
transfection O
experiments O
using O
either O
constitutively O
active O
( O
V12 O
) O
or O
dominant O
- O
interfering O
( O
N17 O
) O
mutants O
. O

The O
implication O
of O
Rac B
and O
Cdc42 B
was O
analyzed O
in O
transient O
transfection O
experiments O
using O
either O
constitutively O
active O
( O
V12 O
) O
or O
dominant O
- O
interfering O
( O
N17 O
) O
mutants O
. O

In O
lyzozyme B
activity O
there O
was O
periodicity O
in O
three O
groups O
but O
not O
in O
the O
youngest O
foals O
. O

GBF1 B
and O
GBF2 B
mRNA I
is O
present O
in O
light O
and O
dark O
grown O
leaves O
as O
well O
as O
in O
roots O
. O

The O
isomerization O
of O
the O
pre O
- O
existing O
closed O
complex O
to O
an O
open O
promoter O
form O
, O
as O
judged O
by O
the O
local O
denaturation O
of O
promoter O
DNA O
which O
rendered O
sequences O
from O
+ O
5 O
to O
- O
10 O
reactive O
towards O
KMnO4 O
, O
was O
shown O
to O
be O
fully O
dependent O
on O
NifA B
. O

These O
data O
suggest O
that O
overexpression O
of O
MT B
potentiates O
the O
growth O
of O
MCF7 O
cells O
, O
whereas O
downregulation O
of O
MT B
elicits O
antiproliferative O
effects O
. O

These O
data O
suggest O
that O
overexpression O
of O
MT B
potentiates O
the O
growth O
of O
MCF7 O
cells O
, O
whereas O
downregulation O
of O
MT B
elicits O
antiproliferative O
effects O
. O

Such O
unique O
recognition O
capabilities O
are O
generated O
with O
minimal O
alterations O
in O
the O
CDR3 B
loops O
of O
the O
TCR B
. O

Such O
unique O
recognition O
capabilities O
are O
generated O
with O
minimal O
alterations O
in O
the O
CDR3 B
loops O
of O
the O
TCR B
. O

For O
this O
interaction O
, O
the O
C O
- O
terminal O
part O
of O
Sp1 B
and O
the O
N O
terminus O
of O
E2F1 B
, O
a O
domain O
also O
present O
in O
E2F2 B
and O
E2F3 B
but O
absent O
in O
E2F4 B
and O
E2F5 B
, O
were O
essential O
. O

For O
this O
interaction O
, O
the O
C O
- O
terminal O
part O
of O
Sp1 B
and O
the O
N O
terminus O
of O
E2F1 B
, O
a O
domain O
also O
present O
in O
E2F2 B
and O
E2F3 B
but O
absent O
in O
E2F4 B
and O
E2F5 B
, O
were O
essential O
. O

For O
this O
interaction O
, O
the O
C O
- O
terminal O
part O
of O
Sp1 B
and O
the O
N O
terminus O
of O
E2F1 B
, O
a O
domain O
also O
present O
in O
E2F2 B
and O
E2F3 B
but O
absent O
in O
E2F4 B
and O
E2F5 B
, O
were O
essential O
. O

For O
this O
interaction O
, O
the O
C O
- O
terminal O
part O
of O
Sp1 B
and O
the O
N O
terminus O
of O
E2F1 B
, O
a O
domain O
also O
present O
in O
E2F2 B
and O
E2F3 B
but O
absent O
in O
E2F4 B
and O
E2F5 B
, O
were O
essential O
. O

For O
this O
interaction O
, O
the O
C O
- O
terminal O
part O
of O
Sp1 B
and O
the O
N O
terminus O
of O
E2F1 B
, O
a O
domain O
also O
present O
in O
E2F2 B
and O
E2F3 B
but O
absent O
in O
E2F4 B
and O
E2F5 B
, O
were O
essential O
. O

For O
this O
interaction O
, O
the O
C O
- O
terminal O
part O
of O
Sp1 B
and O
the O
N O
terminus O
of O
E2F1 B
, O
a O
domain O
also O
present O
in O
E2F2 B
and O
E2F3 B
but O
absent O
in O
E2F4 B
and O
E2F5 B
, O
were O
essential O
. O

Oncogenic O
activation O
of O
RET B
is O
detected O
in O
human O
papillary O
thyroid O
tumours O
and O
in O
multiple O
endocrine O
neoplasia O
type O
2 O
syndromes O
. O

CD4 B
degradation O
mediated O
by O
Vpu B
does O
not O
require O
the O
ER O
chaperone O
calnexin B
and O
is O
dependent O
on O
an O
intact O
ubiquitin B
- O
conjugating O
system O
. O

CD4 B
degradation O
mediated O
by O
Vpu B
does O
not O
require O
the O
ER O
chaperone O
calnexin B
and O
is O
dependent O
on O
an O
intact O
ubiquitin B
- O
conjugating O
system O
. O

CD4 B
degradation O
mediated O
by O
Vpu B
does O
not O
require O
the O
ER O
chaperone O
calnexin B
and O
is O
dependent O
on O
an O
intact O
ubiquitin B
- O
conjugating O
system O
. O

CD4 B
degradation O
mediated O
by O
Vpu B
does O
not O
require O
the O
ER O
chaperone O
calnexin B
and O
is O
dependent O
on O
an O
intact O
ubiquitin B
- O
conjugating O
system O
. O

Gel O
shift O
and O
southwestern O
experiments O
revealed O
nuclear O
proteins O
of O
43 O
kDa O
and O
30 O
kDa O
in O
GC O
and O
fish O
cells O
, O
respectively O
, O
that O
bind O
specifically O
to O
the O
tGH B
CRE O
, O
suggesting O
the O
involvement O
of O
CRE B
- I
binding I
- I
protein I
/ O
activating B
- I
transcription I
- I
factor I
- I
l I
- O
related O
peptides O
in O
cAMP O
response O
. O

The O
coding O
sequence O
of O
rat B
MEK I
kinase I
1 I
( O
MEKK1 B
) O
has O
been O
determined O
from O
multiple O
, O
independent O
cDNA O
clones O
. O

On O
the O
basis O
of O
experiments O
with O
mutant O
virus O
and O
transfection O
with O
isolated O
genes O
, O
the O
herpes B
simplex I
virus I
immediate I
- I
early I
gene I
product O
ICP4 B
is O
known O
to O
positively O
regulate O
the O
transcription O
of O
viral B
early I
and I
late I
genes I
and O
negatively O
regulate O
expression O
from O
its O
own O
promoter O
. O

The O
POU B
- O
specific O
domain O
of O
Pit B
- I
1 I
is O
essential O
for O
sequence O
- O
specific O
, O
high O
affinity O
DNA O
binding O
and O
DNA O
- O
dependent O
Pit B
- I
1 I
- O
Pit B
- I
1 I
interactions O
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
have O
isolated O
an O
835 O
amino O
acid O
RING O
finger O
( O
C3HC4 O
zinc O
finger O
) O
protein O
, O
TIF1 B
beta I
( O
also O
named O
KAP B
- I
1 I
) O
, O
that O
specifically O
interacts O
with O
the O
KRAB B
domain I
of O
the O
human O
zinc O
finger O
factor O
KOX1 B
/ O
ZNF10 B
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
have O
isolated O
an O
835 O
amino O
acid O
RING O
finger O
( O
C3HC4 O
zinc O
finger O
) O
protein O
, O
TIF1 B
beta I
( O
also O
named O
KAP B
- I
1 I
) O
, O
that O
specifically O
interacts O
with O
the O
KRAB B
domain I
of O
the O
human O
zinc O
finger O
factor O
KOX1 B
/ O
ZNF10 B
. O

The O
reduced O
expression O
caused O
by O
multimerization O
of O
UAS2 O
in O
the O
native O
promoter O
was O
observed O
only O
in O
the O
presence O
of O
ADR1 B
. O

VP4 B
differentially O
regulates O
TRAF2 B
signaling O
, O
disengaging O
JNK B
activation O
while O
directing O
NF B
- I
kappa I
B I
to O
effect O
rotavirus O
- O
specific O
cellular O
responses O
. O

VP4 B
differentially O
regulates O
TRAF2 B
signaling O
, O
disengaging O
JNK B
activation O
while O
directing O
NF B
- I
kappa I
B I
to O
effect O
rotavirus O
- O
specific O
cellular O
responses O
. O

VP4 B
differentially O
regulates O
TRAF2 B
signaling O
, O
disengaging O
JNK B
activation O
while O
directing O
NF B
- I
kappa I
B I
to O
effect O
rotavirus O
- O
specific O
cellular O
responses O
. O

The O
purified O
RAG1 B
protein I
overexpressed O
in O
E O
. O
coli O
exhibited O
the O
expected O
cleavage O
activity O
when O
combined O
with O
RAG2 B
purified O
from O
transfected O
293T O
cells O
. O

Moreover O
, O
we O
show O
that O
GATA B
- I
1 I
and O
Sp1 B
synergize O
from O
a O
distance O
in O
constructs O
designed O
to O
mimic O
the O
architecture O
of O
globin B
locus I
control I
regions I
and O
downstream O
globin B
promoters I
. O

Mammalian O
chromosome O
ends O
contain O
long O
arrays O
of O
TTAGGG O
repeats O
that O
are O
complexed O
to O
a O
telomere O
specific O
protein O
, O
the O
TTAGGG B
repeat I
binding I
factor I
, O
TRF1 B
. O

Adhesion O
was O
inhibited O
by O
mAbs O
against O
the O
COOH O
- O
terminus O
and O
central O
cell O
binding O
domains O
of O
fibronectin B
, O
as O
well O
as O
by O
the O
corresponding O
CS1 B
and O
RGD B
peptides I
. O

Adhesion O
was O
inhibited O
by O
mAbs O
against O
the O
COOH O
- O
terminus O
and O
central O
cell O
binding O
domains O
of O
fibronectin B
, O
as O
well O
as O
by O
the O
corresponding O
CS1 B
and O
RGD B
peptides I
. O

Activation O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
pathway O
enhances O
long O
- O
range O
transactivation O
by O
the O
beta B
- I
globin I
locus I
control I
region I
( O
LCR O
) O
( O
W O
. O

In O
situ O
hybridization O
of O
whole O
- O
mount O
mouse O
embryos O
with O
Mex5 B
antisense I
RNA I
provide O
no O
evidence O
for O
the O
exclusion O
of O
Mex5 B
during O
embryonic O
development O
. O

The O
Ick B
protein B
tyrosine I
kinase I
is O
not O
involved O
in O
antibody O
- O
mediated O
CD4 B
( O
CDR3 B
- I
loop I
) O
signal O
transduction O
that O
inhibits O
HIV O
- O
1 O
transcription O
. O

The O
Ick B
protein B
tyrosine I
kinase I
is O
not O
involved O
in O
antibody O
- O
mediated O
CD4 B
( O
CDR3 B
- I
loop I
) O
signal O
transduction O
that O
inhibits O
HIV O
- O
1 O
transcription O
. O

The O
model O
therefore O
predicts O
that O
1 O
) O
on O
- O
line O
calculation O
of O
airway O
dead O
space O
and O
end O
- O
expired O
lung O
volume O
can O
be O
made O
by O
the O
addition O
of O
an O
oxygen O
sine O
- O
wave O
perturbation O
component O
to O
the O
mean O
FIO2 O
; O
and O
( O
2 O
) O
QS O
/ O
QT O
can O
be O
measured O
from O
the O
resultant O
oxygen O
perturbation O
sine O
- O
wave O
amplitudes O
in O
the O
expired O
gas O
and O
in O
arterial O
and O
mixed O
- O
venous O
blood O
and O
is O
independent O
of O
the O
mean O
blood O
oxygen O
partial O
pressure O
and O
oxyhemoglobin B
saturation O
values O
. O

Consistent O
with O
this O
, O
rh5 B
expression O
in O
R8 B
disappears O
when O
R7 O
cells O
are O
absent O
( O
in O
sevenless B
mutant I
) O
. O

Consistent O
with O
this O
, O
rh5 B
expression O
in O
R8 B
disappears O
when O
R7 O
cells O
are O
absent O
( O
in O
sevenless B
mutant I
) O
. O

Fulminant O
hepatic O
failure O
in O
these O
cases O
could O
be O
characterized O
by O
: O
( O
1 O
) O
rapid O
decrease O
in O
serum B
alanine I
transaminase I
( O
ALT B
) O
level O
after O
discontinuation O
of O
ecarazine O
, O
( O
2 O
) O
prolonged O
jaundice O
despite O
discontinuation O
of O
ecarazine O
, O
( O
3 O
) O
high O
incidence O
of O
anti B
- I
nuclear I
antibody I
( O
ANA B
) O
( O
57 O
% O
) O
, O
and O
( O
4 O
) O
histological O
findings O
of O
extensive O
hepatocellular O
necrosis O
ranging O
from O
bridging O
necrosis O
to O
massive O
necrosis O
. O

Fulminant O
hepatic O
failure O
in O
these O
cases O
could O
be O
characterized O
by O
: O
( O
1 O
) O
rapid O
decrease O
in O
serum B
alanine I
transaminase I
( O
ALT B
) O
level O
after O
discontinuation O
of O
ecarazine O
, O
( O
2 O
) O
prolonged O
jaundice O
despite O
discontinuation O
of O
ecarazine O
, O
( O
3 O
) O
high O
incidence O
of O
anti B
- I
nuclear I
antibody I
( O
ANA B
) O
( O
57 O
% O
) O
, O
and O
( O
4 O
) O
histological O
findings O
of O
extensive O
hepatocellular O
necrosis O
ranging O
from O
bridging O
necrosis O
to O
massive O
necrosis O
. O

A O
close O
homologue O
of O
the O
APK2a B
gene I
, O
named O
APK2b B
, O
was O
also O
isolated O
from O
the O
Arabidopsis O
cDNA O
library O
. O

Thus O
, O
the O
rates O
of O
a B
- I
factor I
receptor I
endocytosis O
and O
consequent O
vacuolar O
turnover O
depend O
on O
the O
available O
level O
of O
ubiquitin B
in O
the O
cell O
. O

Using O
the O
same O
approach O
we O
have O
shown O
that O
hFIRE B
binds O
the O
stimulatory O
proteins O
Sp1 B
and O
Sp3 B
in O
addition O
to O
CBF B
. O

Using O
the O
same O
approach O
we O
have O
shown O
that O
hFIRE B
binds O
the O
stimulatory O
proteins O
Sp1 B
and O
Sp3 B
in O
addition O
to O
CBF B
. O

Using O
the O
same O
approach O
we O
have O
shown O
that O
hFIRE B
binds O
the O
stimulatory O
proteins O
Sp1 B
and O
Sp3 B
in O
addition O
to O
CBF B
. O

Using O
the O
same O
approach O
we O
have O
shown O
that O
hFIRE B
binds O
the O
stimulatory O
proteins O
Sp1 B
and O
Sp3 B
in O
addition O
to O
CBF B
. O

The O
cyclin B
- I
dependent I
kinase I
Cdk2 B
associates O
with O
cyclins B
A I
, I
D I
, I
and I
E I
and O
has O
been O
implicated O
in O
the O
control O
of O
the O
G1 O
to O
S O
phase O
transition O
in O
mammals O
. O

The O
amino B
- I
terminal I
gag I
- I
encoded I
region I
of O
P140gag B
- O
fps B
contains O
a O
phosphotyrosine O
residue O
in O
addition O
to O
normal O
gag B
phosphorylation O
sites O
. O

The O
amino B
- I
terminal I
gag I
- I
encoded I
region I
of O
P140gag B
- O
fps B
contains O
a O
phosphotyrosine O
residue O
in O
addition O
to O
normal O
gag B
phosphorylation O
sites O
. O

The O
amino B
- I
terminal I
gag I
- I
encoded I
region I
of O
P140gag B
- O
fps B
contains O
a O
phosphotyrosine O
residue O
in O
addition O
to O
normal O
gag B
phosphorylation O
sites O
. O

Rad18 B
is O
required O
for O
DNA O
repair O
and O
checkpoint O
responses O
in O
fission O
yeast O
. O

All O
three O
SSV O
- O
transformed O
cells O
secreted O
v B
- I
sis I
gene I
product I
( O
p44 B
) O
. O

p44 B
was O
secreted O
but O
remained O
tightly O
associated O
with O
the O
cell O
surface O
. O

To O
determine O
the O
role O
of O
elevated O
FAK B
expression O
in O
facilitating O
epidermal B
growth I
factor I
( O
EGF B
) O
- O
stimulated O
human O
adenocarcinoma O
( O
A549 O
) O
cell O
motility O
, O
antisense O
oligonucleotides O
were O
used O
to O
reduce O
FAK B
protein I
expression O
> O
75 O
% O
. O

To O
determine O
the O
role O
of O
elevated O
FAK B
expression O
in O
facilitating O
epidermal B
growth I
factor I
( O
EGF B
) O
- O
stimulated O
human O
adenocarcinoma O
( O
A549 O
) O
cell O
motility O
, O
antisense O
oligonucleotides O
were O
used O
to O
reduce O
FAK B
protein I
expression O
> O
75 O
% O
. O

To O
further O
study O
the O
role O
of O
tTG B
in O
liver O
disease O
, O
we O
initiated O
investigations O
into O
the O
effect O
of O
a O
proinflammatory O
mediator O
, O
tumor B
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
on O
tTG B
activity O
in O
cultured O
liver O
cells O
. O

To O
further O
study O
the O
role O
of O
tTG B
in O
liver O
disease O
, O
we O
initiated O
investigations O
into O
the O
effect O
of O
a O
proinflammatory O
mediator O
, O
tumor B
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
on O
tTG B
activity O
in O
cultured O
liver O
cells O
. O

By O
contrast O
, O
CIS B
failed O
to O
affect O
the O
IL B
- I
9 I
response O
. O

Despite O
the O
fact O
that O
biochemical O
estimates O
of O
bone O
turnover O
indicate O
that O
( O
short O
- O
term O
) O
administration O
of O
rhGH B
and O
IGF B
- I
I I
stimulates O
bone O
metabolism O
in O
non O
- O
osteoporotic O
older O
people O
, O
no O
significant O
changes O
have O
been O
observed O
in O
bone O
mineral O
density O
at O
the O
proximal O
femur O
. O

However O
, O
FosB B
- I
L I
and O
FosB B
- I
S I
do O
not O
differ O
in O
all O
trans O
- O
regulatory O
properties O
: O
Trans O
- O
activation O
of O
a O
5x O
TRE B
- I
CAT I
reporter O
construct O
in O
HeLa O
and O
NIH O
- O
3T3 O
cells O
was O
found O
with O
both O
FosB B
forms O
. O

Mutations O
in O
glnB B
, O
nifR1 B
( O
ntrC B
) O
, O
and O
NifR4 B
( O
ntrA B
encoding O
sigma B
54 I
) O
had O
no O
influence O
on O
put B
gene I
expression O
. O

Mutations O
in O
glnB B
, O
nifR1 B
( O
ntrC B
) O
, O
and O
NifR4 B
( O
ntrA B
encoding O
sigma B
54 I
) O
had O
no O
influence O
on O
put B
gene I
expression O
. O

Mutations O
in O
glnB B
, O
nifR1 B
( O
ntrC B
) O
, O
and O
NifR4 B
( O
ntrA B
encoding O
sigma B
54 I
) O
had O
no O
influence O
on O
put B
gene I
expression O
. O

Mutations O
in O
glnB B
, O
nifR1 B
( O
ntrC B
) O
, O
and O
NifR4 B
( O
ntrA B
encoding O
sigma B
54 I
) O
had O
no O
influence O
on O
put B
gene I
expression O
. O

Mutations O
in O
glnB B
, O
nifR1 B
( O
ntrC B
) O
, O
and O
NifR4 B
( O
ntrA B
encoding O
sigma B
54 I
) O
had O
no O
influence O
on O
put B
gene I
expression O
. O

Disruption O
of O
INP53 B
, O
but O
not O
the O
related O
INP51 B
and O
INP52 B
genes I
, O
resulted O
in O
alpha B
- I
factor I
maturation O
defects O
and O
exacerbated O
alpha B
- I
factor I
maturation O
defects O
when O
combined O
with O
chc1 B
- I
521 I
. O

Disruption O
of O
INP53 B
, O
but O
not O
the O
related O
INP51 B
and O
INP52 B
genes I
, O
resulted O
in O
alpha B
- I
factor I
maturation O
defects O
and O
exacerbated O
alpha B
- I
factor I
maturation O
defects O
when O
combined O
with O
chc1 B
- I
521 I
. O

Cotransfection O
of O
a O
junB B
stimulated O
the O
basal O
activity O
of O
the O
alpha B
2 I
( I
I I
) I
collagen I
promoter I
93 O
- O
fold O
, O
respectively O
. O

Glutathione B
reductase I
( O
GR B
) O
was O
purified O
from O
the O
cyanobacterium O
Anabaena O
PCC O
7120 O
. O

5 O
' O
- O
Deletion O
of O
the O
Stat B
- I
binding I
sites I
abolished O
all O
promoter O
- O
reporter O
activity O
in O
response O
to O
PRL B
. O

Finally O
, O
we O
demonstrate O
that O
animals O
carrying O
a O
snf B
mutation O
that O
converts O
SNF B
from O
a O
bifunctional O
protein O
to O
a O
U1 B
snRNP I
- I
specific I
protein I
are O
viable O
. O

Finally O
, O
we O
demonstrate O
that O
animals O
carrying O
a O
snf B
mutation O
that O
converts O
SNF B
from O
a O
bifunctional O
protein O
to O
a O
U1 B
snRNP I
- I
specific I
protein I
are O
viable O
. O

This O
pathway O
has O
been O
reported O
to O
mediate O
heterodimer O
interactions O
with O
the O
proapoptotic O
regulator O
, O
Bad B
. O

Recently O
, O
we O
reported O
that O
SMRT B
also O
directly O
associates O
with O
LAZ3 B
( O
BCL B
- I
6 I
) O
, O
a O
POZ O
/ O
Zn O
finger O
transcriptional O
repressor O
involvedin O
the O
pathogenesis O
of O
non O
- O
Hodgkin O
lymphomas O
. O

Recently O
, O
we O
reported O
that O
SMRT B
also O
directly O
associates O
with O
LAZ3 B
( O
BCL B
- I
6 I
) O
, O
a O
POZ O
/ O
Zn O
finger O
transcriptional O
repressor O
involvedin O
the O
pathogenesis O
of O
non O
- O
Hodgkin O
lymphomas O
. O

Characterization O
of O
a O
cDNA B
encoding I
CNN I
predicts O
a O
novel O
structural O
protein O
with O
three O
leucine O
zipper O
motifs O
and O
several O
coiled O
- O
coil O
domains O
exhibiting O
limited O
homology O
to O
the O
rod O
portion O
of O
myosin B
. O

A O
preformed O
SREBP B
- I
1a I
: I
[ I
32P I
] I
DNA I
complex I
bound O
specifically O
to O
membrane O
- O
immobilized O
GST B
- O
CBP B
fusion O
proteins O
that O
contained O
amino O
- O
terminal O
portions O
of O
CBP B
. O

A O
preformed O
SREBP B
- I
1a I
: I
[ I
32P I
] I
DNA I
complex I
bound O
specifically O
to O
membrane O
- O
immobilized O
GST B
- O
CBP B
fusion O
proteins O
that O
contained O
amino O
- O
terminal O
portions O
of O
CBP B
. O

A O
preformed O
SREBP B
- I
1a I
: I
[ I
32P I
] I
DNA I
complex I
bound O
specifically O
to O
membrane O
- O
immobilized O
GST B
- O
CBP B
fusion O
proteins O
that O
contained O
amino O
- O
terminal O
portions O
of O
CBP B
. O

When O
cotransfected O
with O
the O
HIV B
LTR I
CAT B
into O
CV O
- O
1 O
cells O
, O
both O
the O
pCD41 B
and O
pGD41 B
clones O
trans O
- O
activated O
the O
HIV B
LTR I
. O

When O
cotransfected O
with O
the O
HIV B
LTR I
CAT B
into O
CV O
- O
1 O
cells O
, O
both O
the O
pCD41 B
and O
pGD41 B
clones O
trans O
- O
activated O
the O
HIV B
LTR I
. O

When O
cotransfected O
with O
the O
HIV B
LTR I
CAT B
into O
CV O
- O
1 O
cells O
, O
both O
the O
pCD41 B
and O
pGD41 B
clones O
trans O
- O
activated O
the O
HIV B
LTR I
. O

The O
induction O
of O
the O
composite O
H B
- I
PK I
/ O
Tag B
and O
SV B
- I
PK I
/ O
Tag B
transgenes O
by O
a O
carbohydrate O
- O
rich O
diet O
in O
the O
liver O
was O
similar O
to O
that O
of O
the O
endogenous B
L I
- I
PK I
gene I
. O

The O
induction O
of O
the O
composite O
H B
- I
PK I
/ O
Tag B
and O
SV B
- I
PK I
/ O
Tag B
transgenes O
by O
a O
carbohydrate O
- O
rich O
diet O
in O
the O
liver O
was O
similar O
to O
that O
of O
the O
endogenous B
L I
- I
PK I
gene I
. O

Exit O
from O
mitosis O
in O
Drosophila O
syncytial O
embryos O
requires O
proteolysis O
and O
cyclin B
degradation O
, O
and O
is O
associated O
with O
localized O
dephosphorylation O
. O

To O
understand O
this O
dramatic O
effect O
, O
we O
examined O
the O
localization O
of O
SR B
proteins I
and O
found O
that O
SC35 B
was O
shifted O
to O
the O
cytoplasm O
in O
sky1Delta B
yeast O
, O
although O
this O
phenomenon O
was O
not O
obvious O
with O
ASF B
/ O
SF2 B
, O
indicating O
that O
nuclear O
import O
of O
SR B
proteins I
may O
be O
differentially O
regulated O
by O
phosphorylation O
. O

To O
understand O
this O
dramatic O
effect O
, O
we O
examined O
the O
localization O
of O
SR B
proteins I
and O
found O
that O
SC35 B
was O
shifted O
to O
the O
cytoplasm O
in O
sky1Delta B
yeast O
, O
although O
this O
phenomenon O
was O
not O
obvious O
with O
ASF B
/ O
SF2 B
, O
indicating O
that O
nuclear O
import O
of O
SR B
proteins I
may O
be O
differentially O
regulated O
by O
phosphorylation O
. O

To O
understand O
this O
dramatic O
effect O
, O
we O
examined O
the O
localization O
of O
SR B
proteins I
and O
found O
that O
SC35 B
was O
shifted O
to O
the O
cytoplasm O
in O
sky1Delta B
yeast O
, O
although O
this O
phenomenon O
was O
not O
obvious O
with O
ASF B
/ O
SF2 B
, O
indicating O
that O
nuclear O
import O
of O
SR B
proteins I
may O
be O
differentially O
regulated O
by O
phosphorylation O
. O

To O
understand O
this O
dramatic O
effect O
, O
we O
examined O
the O
localization O
of O
SR B
proteins I
and O
found O
that O
SC35 B
was O
shifted O
to O
the O
cytoplasm O
in O
sky1Delta B
yeast O
, O
although O
this O
phenomenon O
was O
not O
obvious O
with O
ASF B
/ O
SF2 B
, O
indicating O
that O
nuclear O
import O
of O
SR B
proteins I
may O
be O
differentially O
regulated O
by O
phosphorylation O
. O

On O
the O
contrary O
i O
. O
v O
. O
administration O
of O
calcitonin B
increased O
intrapyloric O
pressure O
via O
vagal O
nerves O
in O
atropinized O
or O
gallaminized O
animals O
. O

We O
conclude O
that O
in O
the O
presence O
of O
fatty O
acids O
in O
the O
medium O
transcription O
of O
SPS19 B
is O
directly O
regulated O
by O
both O
Pip2p B
- O
Oaf1p B
and O
Adr1p B
. O

We O
conclude O
that O
in O
the O
presence O
of O
fatty O
acids O
in O
the O
medium O
transcription O
of O
SPS19 B
is O
directly O
regulated O
by O
both O
Pip2p B
- O
Oaf1p B
and O
Adr1p B
. O

We O
conclude O
that O
in O
the O
presence O
of O
fatty O
acids O
in O
the O
medium O
transcription O
of O
SPS19 B
is O
directly O
regulated O
by O
both O
Pip2p B
- O
Oaf1p B
and O
Adr1p B
. O

We O
conclude O
that O
in O
the O
presence O
of O
fatty O
acids O
in O
the O
medium O
transcription O
of O
SPS19 B
is O
directly O
regulated O
by O
both O
Pip2p B
- O
Oaf1p B
and O
Adr1p B
. O

We O
found O
that O
in O
premature O
infants O
plasminogen B
levels O
are O
low O
; O
thus O
, O
defense O
against O
intra O
- O
alveolar O
fibrin B
deposition O
during O
birth O
trauma O
is O
reduced O
. O

We O
found O
that O
in O
premature O
infants O
plasminogen B
levels O
are O
low O
; O
thus O
, O
defense O
against O
intra O
- O
alveolar O
fibrin B
deposition O
during O
birth O
trauma O
is O
reduced O
. O

However O
, O
both O
RAR B
- O
and O
RXR B
- O
specific O
ligands O
increase O
CaSki O
number O
by O
> O
or O
= O
20 O
% O
. O

However O
, O
both O
RAR B
- O
and O
RXR B
- O
specific O
ligands O
increase O
CaSki O
number O
by O
> O
or O
= O
20 O
% O
. O

The O
primary O
structures O
of O
the O
human B
KB I
cell I
( I
FR I
- I
KB1 I
) I
folate I
receptor I
( O
FR B
) O
and O
of O
a O
human B
placental I
( I
FR I
- I
P2 I
) I
FR I
, O
proteins O
important O
in O
cellular O
accumulation O
of O
folates O
, O
have O
been O
deduced O
from O
cDNA O
sequences O
. O

The O
general O
concept O
of O
RARE B
- O
cleavage O
mapping O
as O
well O
as O
its O
applications O
and O
limitations O
are O
discussed O
. O

To O
further O
investigate O
the O
role O
of O
PKR B
in O
transcriptional O
signaling O
, O
we O
expressed O
the O
wild B
type I
human I
PKR I
and O
a O
catalytically O
inactive O
dominant O
negative O
PKR B
mutant I
in O
the O
murine O
pre O
- O
B O
lymphoma O
70Z O
/ O
3 O
cells O
. O

Interestingly O
, O
VDR B
was O
able O
to O
bind O
to O
VDREs O
with O
high O
affinity O
and O
to O
fully O
activate O
transcription O
in O
intact O
yeast O
cells O
in O
the O
presence O
of O
the O
retinoid B
X I
receptor I
( O
RXR B
) O
. O

Interestingly O
, O
VDR B
was O
able O
to O
bind O
to O
VDREs O
with O
high O
affinity O
and O
to O
fully O
activate O
transcription O
in O
intact O
yeast O
cells O
in O
the O
presence O
of O
the O
retinoid B
X I
receptor I
( O
RXR B
) O
. O

A O
fine O
- O
structure O
radiation O
hybrid O
map O
for O
the O
region O
that O
extends O
from O
D8S520 B
( O
distal O
) O
to O
D8S1759 B
( O
proximal O
) O
was O
prepared O
, O
followed O
by O
construction O
of O
a O
single O
, O
integrated O
YAC O
/ O
BAC O
contig O
for O
the O
interval O
. O

A O
fine O
- O
structure O
radiation O
hybrid O
map O
for O
the O
region O
that O
extends O
from O
D8S520 B
( O
distal O
) O
to O
D8S1759 B
( O
proximal O
) O
was O
prepared O
, O
followed O
by O
construction O
of O
a O
single O
, O
integrated O
YAC O
/ O
BAC O
contig O
for O
the O
interval O
. O

It O
has O
been O
shown O
that O
renin B
secretion O
is O
stimulated O
by O
endothelin B
, O
a O
recently O
discovered O
peptide O
with O
strong O
vasoconstrictive O
properties O
and O
stimulating O
effects O
on O
renin B
secretion O
. O

It O
has O
been O
shown O
that O
renin B
secretion O
is O
stimulated O
by O
endothelin B
, O
a O
recently O
discovered O
peptide O
with O
strong O
vasoconstrictive O
properties O
and O
stimulating O
effects O
on O
renin B
secretion O
. O

It O
has O
been O
shown O
that O
renin B
secretion O
is O
stimulated O
by O
endothelin B
, O
a O
recently O
discovered O
peptide O
with O
strong O
vasoconstrictive O
properties O
and O
stimulating O
effects O
on O
renin B
secretion O
. O

Here O
we O
describe O
the O
cloning O
and O
initial O
characterization O
of O
IPP B
, O
a O
novel O
human O
gene O
that O
predicts O
a O
kelch B
family I
protein I
homologous O
to O
the O
mouse B
Ipp I
gene I
, O
a O
previously O
described O
kelch B
family I
member I
. O

Instead O
, O
the O
large O
difference O
in O
ssDNA O
- O
binding O
affinities O
reflects O
the O
loss O
of O
hexamerization O
ability O
by O
uvsY B
, O
suggesting O
that O
a O
form O
of O
intrahexamer O
synergism O
or O
cooperativity O
between O
binding O
sites O
within O
the O
uvsY B
hexamer I
leads O
to O
its O
high O
observed O
affinity O
for O
ssDNA O
. O

The O
PK O
domain O
showed O
pairwise O
in O
vitro O
binding O
interactions O
with O
the O
pseudokinase O
, O
HisRS B
, O
and O
C O
- O
term O
domains O
; O
additionally O
, O
the O
HisRS B
domain I
interacted O
with O
the O
C O
- O
term O
region O
. O

The O
AmyI B
specific O
3 O
' O
- O
UTR O
is O
characterized O
by O
the O
absence O
of O
IR O
sequences O
and O
the O
presence O
of O
a O
putative O
' O
AATAAA O
' O
polyadenylation O
signal O
. O

Our O
results O
suggest O
that O
Sp1 B
binding I
site I
can O
function O
as O
a O
distinct O
TGF B
- I
beta I
responsive I
element I
for O
TGF B
- I
beta I
mediated O
promoter O
expression O
and O
Sp1 B
per O
se O
can O
mediate O
this O
response O
. O

Prolongation O
of O
prothrombin B
time O
was O
not O
due O
to O
depletion O
of O
vitamin O
K O
- O
dependent O
coagulation O
factors O
or O
manifest O
fibrinolysis O
, O
but O
due O
to O
the O
presence O
of O
circulating O
fibrinogen B
fibrinmonomer I
- O
FDP O
complexes O
. O

Mutation O
of O
K14 O
in O
H3 B
, O
which O
serves O
as O
the O
major O
target O
of O
recombinant B
Gcn5p I
acetylation O
in O
vitro O
, O
confers O
a O
strong O
, O
synthetic O
growth O
defect O
in O
gcn5 B
cells O
. O

Mutation O
of O
K14 O
in O
H3 B
, O
which O
serves O
as O
the O
major O
target O
of O
recombinant B
Gcn5p I
acetylation O
in O
vitro O
, O
confers O
a O
strong O
, O
synthetic O
growth O
defect O
in O
gcn5 B
cells O
. O

All O
patients O
whose O
PSA B
levels O
reached O
0 O
. O
1 O
ng O
. O
/ O
ml O
. O

In O
addition O
, O
we O
found O
that O
the O
transactivation O
mediated O
by O
the O
p68c B
- I
ets I
- I
1 I
pr I
p55erg B
through O
the O
Polyomavirus B
enhancer I
sequence I
is O
specifically O
inhibited O
by O
the O
p46kDaPax B
- I
QNR I
in O
transient O
transfection O
assay O
. O

Treatment O
with O
ACE B
inhibitors O
after O
acute O
myocardial O
infarction O

Conversely O
, O
as O
a O
GAL B
- I
4 I
chimera I
, O
the O
isolated O
LAZ3 B
/ O
BCL6 B
BTB B
/ O
POZ O
domain O
appears O
nearly O
as O
efficient O
as O
the O
entire O
protein O
at O
inducing O
transcriptional O
repression O
. O

Conversely O
, O
as O
a O
GAL B
- I
4 I
chimera I
, O
the O
isolated O
LAZ3 B
/ O
BCL6 B
BTB B
/ O
POZ O
domain O
appears O
nearly O
as O
efficient O
as O
the O
entire O
protein O
at O
inducing O
transcriptional O
repression O
. O

Conversely O
, O
as O
a O
GAL B
- I
4 I
chimera I
, O
the O
isolated O
LAZ3 B
/ O
BCL6 B
BTB B
/ O
POZ O
domain O
appears O
nearly O
as O
efficient O
as O
the O
entire O
protein O
at O
inducing O
transcriptional O
repression O
. O

Diclofenac O
sodium O
: O
blood O
concentration O
of O
the O
slow O
- O
release O
form O
and O
influence O
on O
the O
metabolism O
of O
kallikrein B
. O

Overexpression O
of O
either O
Sp1 B
or O
phosphorylated B
CREB I
transactivated O
the O
mCgA B
promoter I
dose O
dependently O
, O
while O
coexpression O
of O
both O
transcription O
factors O
resulted O
in O
an O
additive O
mCgA B
promoter I
response O
. O

mCgA B
- O
92 O
to O
- O
64 O
bp O
, O
comprising O
the O
Sp1 B
/ O
Egr B
- I
1 I
site O
and O
the O
CRE O
motif O
, O
conferred O
gastrin B
responsiveness O
to O
a O
heterologous B
thymidine I
kinase I
promoter I
system O
, O
and O
therefore O
functions O
as O
a O
" O
true O
" O
enhancer O
element O
. O

mCgA B
- O
92 O
to O
- O
64 O
bp O
, O
comprising O
the O
Sp1 B
/ O
Egr B
- I
1 I
site O
and O
the O
CRE O
motif O
, O
conferred O
gastrin B
responsiveness O
to O
a O
heterologous B
thymidine I
kinase I
promoter I
system O
, O
and O
therefore O
functions O
as O
a O
" O
true O
" O
enhancer O
element O
. O

mCgA B
- O
92 O
to O
- O
64 O
bp O
, O
comprising O
the O
Sp1 B
/ O
Egr B
- I
1 I
site O
and O
the O
CRE O
motif O
, O
conferred O
gastrin B
responsiveness O
to O
a O
heterologous B
thymidine I
kinase I
promoter I
system O
, O
and O
therefore O
functions O
as O
a O
" O
true O
" O
enhancer O
element O
. O

Together O
with O
the O
up O
- O
regulation O
of O
the O
cAMP B
response I
element I
modulator I
protein I
( O
CREM B
) O
mRNA O
and O
protein O
levels O
demonstrated O
previously O
in O
CREB B
mutant I
mice O
, O
we O
suggest O
that O
the O
up O
- O
regulation O
of O
CREB B
beta I
may O
also O
contribute O
to O
compensation O
within O
the O
CREB B
/ O
ATF B
family O
of O
transcription O
factors O
, O
when O
CREB B
delta I
and O
CREB B
alpha I
are O
absent O
. O

Together O
with O
the O
up O
- O
regulation O
of O
the O
cAMP B
response I
element I
modulator I
protein I
( O
CREM B
) O
mRNA O
and O
protein O
levels O
demonstrated O
previously O
in O
CREB B
mutant I
mice O
, O
we O
suggest O
that O
the O
up O
- O
regulation O
of O
CREB B
beta I
may O
also O
contribute O
to O
compensation O
within O
the O
CREB B
/ O
ATF B
family O
of O
transcription O
factors O
, O
when O
CREB B
delta I
and O
CREB B
alpha I
are O
absent O
. O

Together O
with O
the O
up O
- O
regulation O
of O
the O
cAMP B
response I
element I
modulator I
protein I
( O
CREM B
) O
mRNA O
and O
protein O
levels O
demonstrated O
previously O
in O
CREB B
mutant I
mice O
, O
we O
suggest O
that O
the O
up O
- O
regulation O
of O
CREB B
beta I
may O
also O
contribute O
to O
compensation O
within O
the O
CREB B
/ O
ATF B
family O
of O
transcription O
factors O
, O
when O
CREB B
delta I
and O
CREB B
alpha I
are O
absent O
. O

It O
is O
hypothesized O
this O
occurs O
through O
antagonism O
of O
PML B
/ O
RAR B
alpha I
actions O
in O
these O
leukemic O
cells O
. O

The O
Grb2 B
SH3 B
( I
C I
) I
binding I
region I
of O
Gab1 B
has O
significant O
homology O
to O
a O
region O
of O
the O
adapter B
protein I
SLP I
- I
76 I
. O

The O
Grb2 B
SH3 B
( I
C I
) I
binding I
region I
of O
Gab1 B
has O
significant O
homology O
to O
a O
region O
of O
the O
adapter B
protein I
SLP I
- I
76 I
. O

The O
practice O
of O
measuring O
of O
AChE B
levels O
in O
acute O
poisoning O
is O
limited O
. O

When O
furA B
alone O
was O
introduced O
into O
the O
Delta O
( O
furA B
- O
katG B
) O
mutant O
, O
survival O
in O
mouse O
lungs O
was O
moderately O
increased O
, O
suggesting O
that O
FurA B
could O
regulate O
genes O
, O
other O
than O
katG B
, O
that O
are O
involved O
in O
pathogenesis O
. O

When O
furA B
alone O
was O
introduced O
into O
the O
Delta O
( O
furA B
- O
katG B
) O
mutant O
, O
survival O
in O
mouse O
lungs O
was O
moderately O
increased O
, O
suggesting O
that O
FurA B
could O
regulate O
genes O
, O
other O
than O
katG B
, O
that O
are O
involved O
in O
pathogenesis O
. O

When O
furA B
alone O
was O
introduced O
into O
the O
Delta O
( O
furA B
- O
katG B
) O
mutant O
, O
survival O
in O
mouse O
lungs O
was O
moderately O
increased O
, O
suggesting O
that O
FurA B
could O
regulate O
genes O
, O
other O
than O
katG B
, O
that O
are O
involved O
in O
pathogenesis O
. O

When O
furA B
alone O
was O
introduced O
into O
the O
Delta O
( O
furA B
- O
katG B
) O
mutant O
, O
survival O
in O
mouse O
lungs O
was O
moderately O
increased O
, O
suggesting O
that O
FurA B
could O
regulate O
genes O
, O
other O
than O
katG B
, O
that O
are O
involved O
in O
pathogenesis O
. O

When O
furA B
alone O
was O
introduced O
into O
the O
Delta O
( O
furA B
- O
katG B
) O
mutant O
, O
survival O
in O
mouse O
lungs O
was O
moderately O
increased O
, O
suggesting O
that O
FurA B
could O
regulate O
genes O
, O
other O
than O
katG B
, O
that O
are O
involved O
in O
pathogenesis O
. O

The O
authors O
recommend O
in O
cases O
with O
an O
elevated O
transaminase O
serum O
activity O
more O
frequent O
check O
- O
up O
examinations O
to O
avoid O
missing O
of O
a O
relapse O
, O
and O
to O
examine O
repeatedly O
IgM B
anti B
- I
HAV I
as O
in O
protracted O
forms O
of O
hepatitis O
IgM B
anti B
- I
HAV I
may O
persist O
even O
when O
the O
transaminase O
activity O
is O
normal O
. O

The O
authors O
recommend O
in O
cases O
with O
an O
elevated O
transaminase O
serum O
activity O
more O
frequent O
check O
- O
up O
examinations O
to O
avoid O
missing O
of O
a O
relapse O
, O
and O
to O
examine O
repeatedly O
IgM B
anti B
- I
HAV I
as O
in O
protracted O
forms O
of O
hepatitis O
IgM B
anti B
- I
HAV I
may O
persist O
even O
when O
the O
transaminase O
activity O
is O
normal O
. O

More O
important O
, O
ligand O
- O
activated O
insulin B
and O
IGF B
- I
I I
receptors I
phosphorylate O
SHC B
proteins I
in O
vitro O
, O
indicating O
that O
SHC B
proteins I
could O
be O
direct O
substrates O
for O
insulin B
and O
IGF B
- I
I I
receptors I
. O

More O
important O
, O
ligand O
- O
activated O
insulin B
and O
IGF B
- I
I I
receptors I
phosphorylate O
SHC B
proteins I
in O
vitro O
, O
indicating O
that O
SHC B
proteins I
could O
be O
direct O
substrates O
for O
insulin B
and O
IGF B
- I
I I
receptors I
. O

This O
chimera O
transduced O
IL B
- I
4 I
- O
specific O
signals O
in O
response O
to O
IL B
- I
2 I
binding O
and O
dramatically O
enhanced O
type O
2 O
responses O
( O
IL B
- I
4 I
, O
IL B
- I
5 I
, O
and O
immunoglobulin B
E I
production O
) O
upon O
in O
vitro O
TCR B
stimulation O
or O
in O
vivo O
antigen O
challenge O
. O

Two O
human B
beta I
- I
1 I
, I
6 I
- I
N I
- I
acetylglucosaminyltransferases I
forming O
the O
core O
2 O
O O
- O
glycan O
branch O
, O
C2GnT O
and O
the O
I B
antigen I
, O
IGnT B
, O
are O
homologous O
to O
each O
other O
in O
three O
regions O
of O
the O
catalytic O
domain O
( O
A O
, O
B O
, O
C O
) O
and O
their O
genes O
reside O
at O
the O
same O
locus O
, O
chromosome O
9 O
, O
band O
q21 O
( O
Bierhuizen O
, O
M O
. O
F O
. O
A O
. O
, O
Mattei O
, O
M O
. O
- O
G O
. O
and O
Fukuda O
, O
M O
. O
, O
Genes O
Dev O
. O
, O
7 O
, O

Significantly O
higher O
levels O
of O
vitamin O
C O
and O
catalase B
activity O
were O
found O
in O
vegetarians O
( O
C O
- O
63 O
. O
6 O
and O
86 O
. O
5 O
mumol O
/ O
l O
; O
CAT O
- O
1497 O
and O
1313 O
U O
/ O
ml O
for O
males O
and O
females O
, O
respectively O
) O
when O
compared O
to O
nonvegetarians O
( O
C O
- O
41 O
. O
3 O
and O
54 O
. O
4 O
mumol O
/ O
l O
; O
CAT O
- O
1192 O
and O
1086 O
U O
/ O
ml O
) O
. O

In O
contrast O
, O
no O
change O
in O
the O
level O
of O
either O
p53 B
or O
activation O
of O
mdm2 B
protein I
by O
p53 B
was O
observed O
in O
hamster O
UV61 O
cells O
after O
UV O
exposure O
. O

In O
contrast O
, O
no O
change O
in O
the O
level O
of O
either O
p53 B
or O
activation O
of O
mdm2 B
protein I
by O
p53 B
was O
observed O
in O
hamster O
UV61 O
cells O
after O
UV O
exposure O
. O

The O
NF1 B
family I
members O
and O
HNF4 B
interacted O
with O
overlapping O
sequences O
of O
the O
L O
- O
II O
element O
, O
wherein O
the O
5 O
' O
half O
- O
site O
was O
more O
critical O
for O
NF1 B
binding O
, O
and O
the O
3 O
' O
site O
was O
more O
important O
for O
HNF4 B
binding O
. O

The O
NF1 B
family I
members O
and O
HNF4 B
interacted O
with O
overlapping O
sequences O
of O
the O
L O
- O
II O
element O
, O
wherein O
the O
5 O
' O
half O
- O
site O
was O
more O
critical O
for O
NF1 B
binding O
, O
and O
the O
3 O
' O
site O
was O
more O
important O
for O
HNF4 B
binding O
. O

The O
NF1 B
family I
members O
and O
HNF4 B
interacted O
with O
overlapping O
sequences O
of O
the O
L O
- O
II O
element O
, O
wherein O
the O
5 O
' O
half O
- O
site O
was O
more O
critical O
for O
NF1 B
binding O
, O
and O
the O
3 O
' O
site O
was O
more O
important O
for O
HNF4 B
binding O
. O

RAP B
has O
been O
shown O
to O
be O
a O
useful O
vaccine O
target O
site O
, O
and O
RIP B
and O
inhibitory O
AIPs B
as O
therapeutic O
molecules O
to O
prevent O
and O
suppress O
S O
. O
aureus O
infections O
. O

RAP B
has O
been O
shown O
to O
be O
a O
useful O
vaccine O
target O
site O
, O
and O
RIP B
and O
inhibitory O
AIPs B
as O
therapeutic O
molecules O
to O
prevent O
and O
suppress O
S O
. O
aureus O
infections O
. O

RAP B
has O
been O
shown O
to O
be O
a O
useful O
vaccine O
target O
site O
, O
and O
RIP B
and O
inhibitory O
AIPs B
as O
therapeutic O
molecules O
to O
prevent O
and O
suppress O
S O
. O
aureus O
infections O
. O

After O
institution O
of O
insulin B
treatment O
, O
diabetic O
control O
was O
improved O
as O
demonstrated O
by O
decreasing O
levels O
of O
HbA1 B
. O

After O
institution O
of O
insulin B
treatment O
, O
diabetic O
control O
was O
improved O
as O
demonstrated O
by O
decreasing O
levels O
of O
HbA1 B
. O

The O
mouse O
lactoferrin B
gene O
promoter O
was O
active O
in O
human O
endometrium O
carcinoma O
RL O
95 O
- O
2 O
cells O
and O
in O
rat O
glioma O
C6 O
cells O
. O

Km O
values O
of O
the O
uncoupled O
enzymes O
IIGlc B
for O
glucose O
ranged O
from O
0 O
. O
5 O
to O
2 O
. O
5 O
mM O
, O
2 O
orders O
of O
magnitude O
higher O
than O
the O
value O
of O
normal O
IIGlc B
. O

Km O
values O
of O
the O
uncoupled O
enzymes O
IIGlc B
for O
glucose O
ranged O
from O
0 O
. O
5 O
to O
2 O
. O
5 O
mM O
, O
2 O
orders O
of O
magnitude O
higher O
than O
the O
value O
of O
normal O
IIGlc B
. O

Cytochrome B
bd I
biosynthesis O
in O
Escherichia O
coli O
: O
the O
sequences O
of O
the O
cydC B
and O
cydD B
genes I
suggest O
that O
they O
encode O
the O
components O
of O
an O
ABC B
membrane I
transporter I
. O

In O
contrast O
, O
inhibition O
of O
MAPK B
activity O
by O
MAPK B
kinase I
inhibitor O
( O
PD O
98059 O
) O
or O
by O
overexpression O
of O
kinase O
- O
deficient O
MAPKs B
activated O
basal O
and O
GnRH B
- I
A I
- O
stimulated O
GnRHR B
- O
Luc B
activity O
. O

In O
contrast O
, O
inhibition O
of O
MAPK B
activity O
by O
MAPK B
kinase I
inhibitor O
( O
PD O
98059 O
) O
or O
by O
overexpression O
of O
kinase O
- O
deficient O
MAPKs B
activated O
basal O
and O
GnRH B
- I
A I
- O
stimulated O
GnRHR B
- O
Luc B
activity O
. O

In O
contrast O
, O
inhibition O
of O
MAPK B
activity O
by O
MAPK B
kinase I
inhibitor O
( O
PD O
98059 O
) O
or O
by O
overexpression O
of O
kinase O
- O
deficient O
MAPKs B
activated O
basal O
and O
GnRH B
- I
A I
- O
stimulated O
GnRHR B
- O
Luc B
activity O
. O

In O
contrast O
, O
inhibition O
of O
MAPK B
activity O
by O
MAPK B
kinase I
inhibitor O
( O
PD O
98059 O
) O
or O
by O
overexpression O
of O
kinase O
- O
deficient O
MAPKs B
activated O
basal O
and O
GnRH B
- I
A I
- O
stimulated O
GnRHR B
- O
Luc B
activity O
. O

Historically O
, O
Cyps B
were O
first O
identified O
by O
their O
ability O
to O
bind O
the O
immunosuppressive O
agent O
cyclosporin O
A O
( O
CsA O
) O
with O
high O
affinity O
; O
they O
later O
were O
found O
to O
have O
peptidyl B
- I
prolyl I
cis I
- I
trans I
isomerase I
( O
PPIase B
) O
activity O
, O
which O
catalyzes O
the O
folding O
of O
oligopeptides O
at O
proline O
- O
peptide O
bonds O
in O
vitro O
and O
may O
be O
important O
for O
protein O
folding O
in O
vivo O
. O

Historically O
, O
Cyps B
were O
first O
identified O
by O
their O
ability O
to O
bind O
the O
immunosuppressive O
agent O
cyclosporin O
A O
( O
CsA O
) O
with O
high O
affinity O
; O
they O
later O
were O
found O
to O
have O
peptidyl B
- I
prolyl I
cis I
- I
trans I
isomerase I
( O
PPIase B
) O
activity O
, O
which O
catalyzes O
the O
folding O
of O
oligopeptides O
at O
proline O
- O
peptide O
bonds O
in O
vitro O
and O
may O
be O
important O
for O
protein O
folding O
in O
vivo O
. O

Thus O
, O
oxyR B
mutants I
are O
locked O
on O
for O
Ag43 B
expression O
, O
whereas O
dam B
mutants I
are O
locked O
off O
for O
Ag43 B
expression O
. O

Thus O
, O
oxyR B
mutants I
are O
locked O
on O
for O
Ag43 B
expression O
, O
whereas O
dam B
mutants I
are O
locked O
off O
for O
Ag43 B
expression O
. O

A O
rare O
tRNA B
- I
Arg I
( I
CCU I
) I
that O
regulates O
Ty1 B
element I
ribosomal O
frameshifting O
is O
essential O
for O
Ty1 B
retrotransposition O
in O
Saccharomyces O
cerevisiae O
. O

Several O
35 O
- O
mm O
slides O
of O
dystrophin B
- O
, O
laminin B
- O
, O
and O
concanavalin B
A I
( O
ConA B
) O
- O
stained O
muscle O
sections O
were O
used O
to O
calculate O
myofiber O
cross O
- O
sectional O
areas O
and O
to O
compare O
different O
techniques O
and O
settings O
of O
an O
image O
capture O
system O
. O

Several O
35 O
- O
mm O
slides O
of O
dystrophin B
- O
, O
laminin B
- O
, O
and O
concanavalin B
A I
( O
ConA B
) O
- O
stained O
muscle O
sections O
were O
used O
to O
calculate O
myofiber O
cross O
- O
sectional O
areas O
and O
to O
compare O
different O
techniques O
and O
settings O
of O
an O
image O
capture O
system O
. O

Several O
35 O
- O
mm O
slides O
of O
dystrophin B
- O
, O
laminin B
- O
, O
and O
concanavalin B
A I
( O
ConA B
) O
- O
stained O
muscle O
sections O
were O
used O
to O
calculate O
myofiber O
cross O
- O
sectional O
areas O
and O
to O
compare O
different O
techniques O
and O
settings O
of O
an O
image O
capture O
system O
. O

Laser O
soldering O
with O
exogenous O
fibrinogen B
is O
feasible O
without O
topical O
administration O
of O
additional O
clotting O
agents O
, O
significantly O
improves O
the O
bursting O
strength O
of O
primary O
laser O
welded O
anastomoses O
, O
and O
appears O
to O
result O
from O
urokinase B
- O
resistant O
fibrinogen B
cross O
- O
linking O
. O

Laser O
soldering O
with O
exogenous O
fibrinogen B
is O
feasible O
without O
topical O
administration O
of O
additional O
clotting O
agents O
, O
significantly O
improves O
the O
bursting O
strength O
of O
primary O
laser O
welded O
anastomoses O
, O
and O
appears O
to O
result O
from O
urokinase B
- O
resistant O
fibrinogen B
cross O
- O
linking O
. O

Laser O
soldering O
with O
exogenous O
fibrinogen B
is O
feasible O
without O
topical O
administration O
of O
additional O
clotting O
agents O
, O
significantly O
improves O
the O
bursting O
strength O
of O
primary O
laser O
welded O
anastomoses O
, O
and O
appears O
to O
result O
from O
urokinase B
- O
resistant O
fibrinogen B
cross O
- O
linking O
. O

We O
describe O
a O
novel O
stat B
- I
related I
factor I
, O
p93 B
, O
that O
is O
found O
in O
EGF B
- O
treated O
A431 O
cell O
extracts O
but O
appears O
to O
be O
absent O
in O
bovine B
fibroblast I
growth I
factor I
( O
bFGF B
) O
, O
IFN B
- I
gamma I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
untreated O
cells O
. O

We O
describe O
a O
novel O
stat B
- I
related I
factor I
, O
p93 B
, O
that O
is O
found O
in O
EGF B
- O
treated O
A431 O
cell O
extracts O
but O
appears O
to O
be O
absent O
in O
bovine B
fibroblast I
growth I
factor I
( O
bFGF B
) O
, O
IFN B
- I
gamma I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
untreated O
cells O
. O

We O
describe O
a O
novel O
stat B
- I
related I
factor I
, O
p93 B
, O
that O
is O
found O
in O
EGF B
- O
treated O
A431 O
cell O
extracts O
but O
appears O
to O
be O
absent O
in O
bovine B
fibroblast I
growth I
factor I
( O
bFGF B
) O
, O
IFN B
- I
gamma I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
untreated O
cells O
. O

p93 B
appears O
to O
be O
antigenically O
related O
to O
stat91 B
. O

p93 B
appears O
to O
be O
antigenically O
related O
to O
stat91 B
. O

p185c B
- O
neu B
+ O
, O
EGFr B
+ I
( O
M1 B
) O
, O
and O
p185c B
- O
neu B
- O
kinase O
inactive O
, O
EGFr B
+ I
( O
NEN757 B
) O
expressing O
cells O
undergo O
different O
mitotic O
responses O
to O
EGF B
. O

p185c B
- O
neu B
+ O
, O
EGFr B
+ I
( O
M1 B
) O
, O
and O
p185c B
- O
neu B
- O
kinase O
inactive O
, O
EGFr B
+ I
( O
NEN757 B
) O
expressing O
cells O
undergo O
different O
mitotic O
responses O
to O
EGF B
. O

p185c B
- O
neu B
+ O
, O
EGFr B
+ I
( O
M1 B
) O
, O
and O
p185c B
- O
neu B
- O
kinase O
inactive O
, O
EGFr B
+ I
( O
NEN757 B
) O
expressing O
cells O
undergo O
different O
mitotic O
responses O
to O
EGF B
. O

p185c B
- O
neu B
+ O
, O
EGFr B
+ I
( O
M1 B
) O
, O
and O
p185c B
- O
neu B
- O
kinase O
inactive O
, O
EGFr B
+ I
( O
NEN757 B
) O
expressing O
cells O
undergo O
different O
mitotic O
responses O
to O
EGF B
. O

p185c B
- O
neu B
+ O
, O
EGFr B
+ I
( O
M1 B
) O
, O
and O
p185c B
- O
neu B
- O
kinase O
inactive O
, O
EGFr B
+ I
( O
NEN757 B
) O
expressing O
cells O
undergo O
different O
mitotic O
responses O
to O
EGF B
. O

p185c B
- O
neu B
+ O
, O
EGFr B
+ I
( O
M1 B
) O
, O
and O
p185c B
- O
neu B
- O
kinase O
inactive O
, O
EGFr B
+ I
( O
NEN757 B
) O
expressing O
cells O
undergo O
different O
mitotic O
responses O
to O
EGF B
. O

p185c B
- O
neu B
+ O
, O
EGFr B
+ I
( O
M1 B
) O
, O
and O
p185c B
- O
neu B
- O
kinase O
inactive O
, O
EGFr B
+ I
( O
NEN757 B
) O
expressing O
cells O
undergo O
different O
mitotic O
responses O
to O
EGF B
. O

When O
single O
- O
point O
mutation O
was O
introduced O
to O
each O
GC O
box O
, O
EBS B
, O
and O
GT O
box O
in O
PFP9a20 B
, O
at O
least O
3 O
- O
fold O
less O
CAT B
activity O
was O
observed O
in O
CTLL O
- O
R8 O
cells O
. O

When O
single O
- O
point O
mutation O
was O
introduced O
to O
each O
GC O
box O
, O
EBS B
, O
and O
GT O
box O
in O
PFP9a20 B
, O
at O
least O
3 O
- O
fold O
less O
CAT B
activity O
was O
observed O
in O
CTLL O
- O
R8 O
cells O
. O

When O
single O
- O
point O
mutation O
was O
introduced O
to O
each O
GC O
box O
, O
EBS B
, O
and O
GT O
box O
in O
PFP9a20 B
, O
at O
least O
3 O
- O
fold O
less O
CAT B
activity O
was O
observed O
in O
CTLL O
- O
R8 O
cells O
. O

Treatment O
with O
H7 O
did O
not O
affect O
IL B
- I
4R I
- O
mediated O
immediate O
signaling O
events O
such O
as O
tyrosine O
phosphorylation O
of O
Jak1 B
, O
Jak3 B
, O
insulin B
receptor I
substrate I
( I
IRS I
) I
- I
1 I
and O
IRS B
- I
2 I
, O
or O
tyrosine O
phosphorylation O
and O
DNA O
binding O
of O
Stat6 B
. O

Treatment O
with O
H7 O
did O
not O
affect O
IL B
- I
4R I
- O
mediated O
immediate O
signaling O
events O
such O
as O
tyrosine O
phosphorylation O
of O
Jak1 B
, O
Jak3 B
, O
insulin B
receptor I
substrate I
( I
IRS I
) I
- I
1 I
and O
IRS B
- I
2 I
, O
or O
tyrosine O
phosphorylation O
and O
DNA O
binding O
of O
Stat6 B
. O

Treatment O
with O
H7 O
did O
not O
affect O
IL B
- I
4R I
- O
mediated O
immediate O
signaling O
events O
such O
as O
tyrosine O
phosphorylation O
of O
Jak1 B
, O
Jak3 B
, O
insulin B
receptor I
substrate I
( I
IRS I
) I
- I
1 I
and O
IRS B
- I
2 I
, O
or O
tyrosine O
phosphorylation O
and O
DNA O
binding O
of O
Stat6 B
. O

Thus O
, O
STK1 B
is O
most O
likely O
the O
human B
homologue I
of I
MO15 I
. O

BACKGROUND O
: O
Recent O
iterative O
methods O
for O
sequence O
alignment O
have O
indicated O
that O
the O
380 O
kDa O
motor O
unit O
of O
dynein B
belongs O
to O
the O
AAA B
class I
of O
chaperone B
- I
like I
ATPases I
. O

Transfection O
assays O
using O
the O
first O
600 O
bp O
of O
the O
upstream O
nucleotide O
sequences O
indicated O
that O
a O
region O
from O
- O
75 O
to O
- O
120 O
was O
necessary O
for O
the O
ALDH2 B
gene I
expression O
, O
and O
especially O
NF B
- I
Y I
/ O
CP1 B
binding O
site O
from O
- O
92 O
to O
- O
96 O
( O
CCAAT O
box O
) O
is O
important O
in O
the O
expression O
of O
the O
gene O
. O

This O
distinct O
biochemical O
difference O
between O
STAT5A B
and O
STAT5B B
was O
confirmed O
with O
purified O
activated O
STAT5 B
recombinant I
proteins I
. O

This O
distinct O
biochemical O
difference O
between O
STAT5A B
and O
STAT5B B
was O
confirmed O
with O
purified O
activated O
STAT5 B
recombinant I
proteins I
. O

The O
three O
more O
slower O
migrating O
Stat5B B
bands O
observed O
in O
response O
to O
GH B
contain O
phosphorylated O
tyrosyl O
residues O
. O

The O
three O
more O
slower O
migrating O
Stat5B B
bands O
observed O
in O
response O
to O
GH B
contain O
phosphorylated O
tyrosyl O
residues O
. O

Sin4 B
and O
Srb10 B
, O
components O
of O
specific O
RNA B
polymerase I
II I
sub I
- I
complexes I
that O
are O
required O
for O
Ssn6 B
- O
Tup1 B
repression O
activity O
, O
are O
found O
to O
be O
required O
for O
Sfl1 B
repression O
function O
. O

Sin4 B
and O
Srb10 B
, O
components O
of O
specific O
RNA B
polymerase I
II I
sub I
- I
complexes I
that O
are O
required O
for O
Ssn6 B
- O
Tup1 B
repression O
activity O
, O
are O
found O
to O
be O
required O
for O
Sfl1 B
repression O
function O
. O

Sin4 B
and O
Srb10 B
, O
components O
of O
specific O
RNA B
polymerase I
II I
sub I
- I
complexes I
that O
are O
required O
for O
Ssn6 B
- O
Tup1 B
repression O
activity O
, O
are O
found O
to O
be O
required O
for O
Sfl1 B
repression O
function O
. O

Sin4 B
and O
Srb10 B
, O
components O
of O
specific O
RNA B
polymerase I
II I
sub I
- I
complexes I
that O
are O
required O
for O
Ssn6 B
- O
Tup1 B
repression O
activity O
, O
are O
found O
to O
be O
required O
for O
Sfl1 B
repression O
function O
. O

Sin4 B
and O
Srb10 B
, O
components O
of O
specific O
RNA B
polymerase I
II I
sub I
- I
complexes I
that O
are O
required O
for O
Ssn6 B
- O
Tup1 B
repression O
activity O
, O
are O
found O
to O
be O
required O
for O
Sfl1 B
repression O
function O
. O

Translation O
of O
mok B
is O
tightly O
regulated O
by O
Sok B
RNA I
, O
and O
Sok B
RNA I
thus O
regulates O
hok B
translation O
indirectly O
through O
mok B
. O

Translation O
of O
mok B
is O
tightly O
regulated O
by O
Sok B
RNA I
, O
and O
Sok B
RNA I
thus O
regulates O
hok B
translation O
indirectly O
through O
mok B
. O

Translation O
of O
mok B
is O
tightly O
regulated O
by O
Sok B
RNA I
, O
and O
Sok B
RNA I
thus O
regulates O
hok B
translation O
indirectly O
through O
mok B
. O

In O
this O
study O
, O
transcriptional O
fusions O
were O
constructed O
between O
the O
xcpP B
and O
xcpR B
genes I
and O
the O
lacZ B
reporter I
. O

It O
is O
pathogenetically O
proved O
to O
use O
antithrombin B
III I
concentrate O
preparations O
with O
anti O
- O
and O
dysaggregatory O
properties O
, O
fibronectin B
preparations O
, O
trasylol O
or O
its O
analogs O
during O
complex O
preoperative O
preparation O
of O
patients O
. O

Hematopoietic B
progenitor I
kinase I
1 I
( O
HPK1 B
) O
is O
a O
member O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
kinase I
kinase I
kinase I
( O
MAP4K B
) O
family O
and O
an O
upstream O
activator O
of O
the O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
signaling O
cascade O
. O

Hematopoietic B
progenitor I
kinase I
1 I
( O
HPK1 B
) O
is O
a O
member O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
kinase I
kinase I
kinase I
( O
MAP4K B
) O
family O
and O
an O
upstream O
activator O
of O
the O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
signaling O
cascade O
. O

Hematopoietic B
progenitor I
kinase I
1 I
( O
HPK1 B
) O
is O
a O
member O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
kinase I
kinase I
kinase I
( O
MAP4K B
) O
family O
and O
an O
upstream O
activator O
of O
the O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( O
JNK B
) O
signaling O
cascade O
. O

We O
have O
used O
the O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
reporter O
gene O
system O
to O
study O
the O
effect O
of O
T B
on O
the O
long O
terminal O
repeats O
( O
LTRs O
) O
of O
a O
large O
family O
of O
human O
endogenous O
retrovirus O
- O
like O
sequences O
, O
RTVL O
- O
H O
. O

We O
have O
used O
the O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
reporter O
gene O
system O
to O
study O
the O
effect O
of O
T B
on O
the O
long O
terminal O
repeats O
( O
LTRs O
) O
of O
a O
large O
family O
of O
human O
endogenous O
retrovirus O
- O
like O
sequences O
, O
RTVL O
- O
H O
. O

Based O
on O
the O
requirement O
for O
CREM B
/ O
ICER B
and O
Rad6B B
proteins I
in O
spermatogenesis O
, O
we O
determined O
expression O
of O
Cdc34 B
, O
Rad6B B
, O
CREM B
/ O
ICER B
isoforms O
, O
and O
the O
Skp1 B
- O
Cullin B
- O
F O
- O
box O
ubiquitin B
protein O
ligase O
subunits O
Cul B
- I
1 I
and O
Cul B
- I
2 I
, O
which O
are O
associated O
with O
Cdc34 B
activity O
during O
murine O
testicular O
development O
. O

Based O
on O
the O
requirement O
for O
CREM B
/ O
ICER B
and O
Rad6B B
proteins I
in O
spermatogenesis O
, O
we O
determined O
expression O
of O
Cdc34 B
, O
Rad6B B
, O
CREM B
/ O
ICER B
isoforms O
, O
and O
the O
Skp1 B
- O
Cullin B
- O
F O
- O
box O
ubiquitin B
protein O
ligase O
subunits O
Cul B
- I
1 I
and O
Cul B
- I
2 I
, O
which O
are O
associated O
with O
Cdc34 B
activity O
during O
murine O
testicular O
development O
. O

Based O
on O
the O
requirement O
for O
CREM B
/ O
ICER B
and O
Rad6B B
proteins I
in O
spermatogenesis O
, O
we O
determined O
expression O
of O
Cdc34 B
, O
Rad6B B
, O
CREM B
/ O
ICER B
isoforms O
, O
and O
the O
Skp1 B
- O
Cullin B
- O
F O
- O
box O
ubiquitin B
protein O
ligase O
subunits O
Cul B
- I
1 I
and O
Cul B
- I
2 I
, O
which O
are O
associated O
with O
Cdc34 B
activity O
during O
murine O
testicular O
development O
. O

Based O
on O
the O
requirement O
for O
CREM B
/ O
ICER B
and O
Rad6B B
proteins I
in O
spermatogenesis O
, O
we O
determined O
expression O
of O
Cdc34 B
, O
Rad6B B
, O
CREM B
/ O
ICER B
isoforms O
, O
and O
the O
Skp1 B
- O
Cullin B
- O
F O
- O
box O
ubiquitin B
protein O
ligase O
subunits O
Cul B
- I
1 I
and O
Cul B
- I
2 I
, O
which O
are O
associated O
with O
Cdc34 B
activity O
during O
murine O
testicular O
development O
. O

Based O
on O
the O
requirement O
for O
CREM B
/ O
ICER B
and O
Rad6B B
proteins I
in O
spermatogenesis O
, O
we O
determined O
expression O
of O
Cdc34 B
, O
Rad6B B
, O
CREM B
/ O
ICER B
isoforms O
, O
and O
the O
Skp1 B
- O
Cullin B
- O
F O
- O
box O
ubiquitin B
protein O
ligase O
subunits O
Cul B
- I
1 I
and O
Cul B
- I
2 I
, O
which O
are O
associated O
with O
Cdc34 B
activity O
during O
murine O
testicular O
development O
. O

Based O
on O
the O
requirement O
for O
CREM B
/ O
ICER B
and O
Rad6B B
proteins I
in O
spermatogenesis O
, O
we O
determined O
expression O
of O
Cdc34 B
, O
Rad6B B
, O
CREM B
/ O
ICER B
isoforms O
, O
and O
the O
Skp1 B
- O
Cullin B
- O
F O
- O
box O
ubiquitin B
protein O
ligase O
subunits O
Cul B
- I
1 I
and O
Cul B
- I
2 I
, O
which O
are O
associated O
with O
Cdc34 B
activity O
during O
murine O
testicular O
development O
. O

Based O
on O
the O
requirement O
for O
CREM B
/ O
ICER B
and O
Rad6B B
proteins I
in O
spermatogenesis O
, O
we O
determined O
expression O
of O
Cdc34 B
, O
Rad6B B
, O
CREM B
/ O
ICER B
isoforms O
, O
and O
the O
Skp1 B
- O
Cullin B
- O
F O
- O
box O
ubiquitin B
protein O
ligase O
subunits O
Cul B
- I
1 I
and O
Cul B
- I
2 I
, O
which O
are O
associated O
with O
Cdc34 B
activity O
during O
murine O
testicular O
development O
. O

Based O
on O
the O
requirement O
for O
CREM B
/ O
ICER B
and O
Rad6B B
proteins I
in O
spermatogenesis O
, O
we O
determined O
expression O
of O
Cdc34 B
, O
Rad6B B
, O
CREM B
/ O
ICER B
isoforms O
, O
and O
the O
Skp1 B
- O
Cullin B
- O
F O
- O
box O
ubiquitin B
protein O
ligase O
subunits O
Cul B
- I
1 I
and O
Cul B
- I
2 I
, O
which O
are O
associated O
with O
Cdc34 B
activity O
during O
murine O
testicular O
development O
. O

Based O
on O
the O
requirement O
for O
CREM B
/ O
ICER B
and O
Rad6B B
proteins I
in O
spermatogenesis O
, O
we O
determined O
expression O
of O
Cdc34 B
, O
Rad6B B
, O
CREM B
/ O
ICER B
isoforms O
, O
and O
the O
Skp1 B
- O
Cullin B
- O
F O
- O
box O
ubiquitin B
protein O
ligase O
subunits O
Cul B
- I
1 I
and O
Cul B
- I
2 I
, O
which O
are O
associated O
with O
Cdc34 B
activity O
during O
murine O
testicular O
development O
. O

Based O
on O
the O
requirement O
for O
CREM B
/ O
ICER B
and O
Rad6B B
proteins I
in O
spermatogenesis O
, O
we O
determined O
expression O
of O
Cdc34 B
, O
Rad6B B
, O
CREM B
/ O
ICER B
isoforms O
, O
and O
the O
Skp1 B
- O
Cullin B
- O
F O
- O
box O
ubiquitin B
protein O
ligase O
subunits O
Cul B
- I
1 I
and O
Cul B
- I
2 I
, O
which O
are O
associated O
with O
Cdc34 B
activity O
during O
murine O
testicular O
development O
. O

Transcription B
factor I
IIIC I
( O
TFIIIC B
) O
is O
required O
for O
the O
assembly O
of O
a O
preinitiation O
complex O
on O
5S B
RNA I
, O
tRNA O
, O
and O
adenovirus B
VA I
RNA O
genes O
and O
contains O
two O
separable O
components O
, O
TFIIIC1 B
and O
TFIIIC2 B
. O

Transcription B
factor I
IIIC I
( O
TFIIIC B
) O
is O
required O
for O
the O
assembly O
of O
a O
preinitiation O
complex O
on O
5S B
RNA I
, O
tRNA O
, O
and O
adenovirus B
VA I
RNA O
genes O
and O
contains O
two O
separable O
components O
, O
TFIIIC1 B
and O
TFIIIC2 B
. O

Transcription B
factor I
IIIC I
( O
TFIIIC B
) O
is O
required O
for O
the O
assembly O
of O
a O
preinitiation O
complex O
on O
5S B
RNA I
, O
tRNA O
, O
and O
adenovirus B
VA I
RNA O
genes O
and O
contains O
two O
separable O
components O
, O
TFIIIC1 B
and O
TFIIIC2 B
. O

Protein O
sequencing O
, O
electrophoretic O
mobility O
shift O
assay O
, O
and O
immunoblot O
analyses O
identify O
p54 B
and O
p47 B
/ I
48 I
as O
members O
of O
the O
hepatocyte B
nuclear I
factor I
3 I
( O
HNF3 B
[ O
forkhead B
] O
) O
family O
of O
transcription O
factors O
. O

Protein O
sequencing O
, O
electrophoretic O
mobility O
shift O
assay O
, O
and O
immunoblot O
analyses O
identify O
p54 B
and O
p47 B
/ I
48 I
as O
members O
of O
the O
hepatocyte B
nuclear I
factor I
3 I
( O
HNF3 B
[ O
forkhead B
] O
) O
family O
of O
transcription O
factors O
. O

Protein O
sequencing O
, O
electrophoretic O
mobility O
shift O
assay O
, O
and O
immunoblot O
analyses O
identify O
p54 B
and O
p47 B
/ I
48 I
as O
members O
of O
the O
hepatocyte B
nuclear I
factor I
3 I
( O
HNF3 B
[ O
forkhead B
] O
) O
family O
of O
transcription O
factors O
. O

p54 B
belongs O
to O
the O
subfamily O
of O
HNF3 B
beta I
proteins I
, O
while O
p47 B
/ I
48 I
binding O
activity O
includes O
HNF3 B
gamma I
. O

Although O
the O
elevated O
signalling O
is O
eliminated O
by O
deletion O
of O
Ste20p B
( O
or O
components O
downstream O
of O
Ste20p B
) O
, O
the O
growth O
and O
morphological O
abnormalities O
of O
cells O
lacking O
Akr1p B
are O
not O
rescued O
by O
deletion O
of O
any O
of O
the O
known O
pheromone O
response O
pathway O
components O
. O

Although O
the O
elevated O
signalling O
is O
eliminated O
by O
deletion O
of O
Ste20p B
( O
or O
components O
downstream O
of O
Ste20p B
) O
, O
the O
growth O
and O
morphological O
abnormalities O
of O
cells O
lacking O
Akr1p B
are O
not O
rescued O
by O
deletion O
of O
any O
of O
the O
known O
pheromone O
response O
pathway O
components O
. O

Although O
the O
elevated O
signalling O
is O
eliminated O
by O
deletion O
of O
Ste20p B
( O
or O
components O
downstream O
of O
Ste20p B
) O
, O
the O
growth O
and O
morphological O
abnormalities O
of O
cells O
lacking O
Akr1p B
are O
not O
rescued O
by O
deletion O
of O
any O
of O
the O
known O
pheromone O
response O
pathway O
components O
. O

Southern O
hybridization O
of O
genomic O
DNA O
from O
WT O
and O
Lp B
/ O
Lp B
embryos O
failed O
to O
identify O
specific O
rearrangements O
at O
or O
near O
the O
Nhlh1 B
locus I
, O
and O
Northern O
RNA O
blotting O
and O
RT O
- O
PCR O
evaluation O
of O
Nhlh1 B
mRNA I
expression O
indicated O
that O
both O
the O
levels O
and O
types O
of O
Nhlh1 B
mRNAs I
produced O
in O
WT O
and O
Lp B
/ O
Lp B
embryos O
were O
indistinguishable O
. O

Southern O
hybridization O
of O
genomic O
DNA O
from O
WT O
and O
Lp B
/ O
Lp B
embryos O
failed O
to O
identify O
specific O
rearrangements O
at O
or O
near O
the O
Nhlh1 B
locus I
, O
and O
Northern O
RNA O
blotting O
and O
RT O
- O
PCR O
evaluation O
of O
Nhlh1 B
mRNA I
expression O
indicated O
that O
both O
the O
levels O
and O
types O
of O
Nhlh1 B
mRNAs I
produced O
in O
WT O
and O
Lp B
/ O
Lp B
embryos O
were O
indistinguishable O
. O

Southern O
hybridization O
of O
genomic O
DNA O
from O
WT O
and O
Lp B
/ O
Lp B
embryos O
failed O
to O
identify O
specific O
rearrangements O
at O
or O
near O
the O
Nhlh1 B
locus I
, O
and O
Northern O
RNA O
blotting O
and O
RT O
- O
PCR O
evaluation O
of O
Nhlh1 B
mRNA I
expression O
indicated O
that O
both O
the O
levels O
and O
types O
of O
Nhlh1 B
mRNAs I
produced O
in O
WT O
and O
Lp B
/ O
Lp B
embryos O
were O
indistinguishable O
. O

Southern O
hybridization O
of O
genomic O
DNA O
from O
WT O
and O
Lp B
/ O
Lp B
embryos O
failed O
to O
identify O
specific O
rearrangements O
at O
or O
near O
the O
Nhlh1 B
locus I
, O
and O
Northern O
RNA O
blotting O
and O
RT O
- O
PCR O
evaluation O
of O
Nhlh1 B
mRNA I
expression O
indicated O
that O
both O
the O
levels O
and O
types O
of O
Nhlh1 B
mRNAs I
produced O
in O
WT O
and O
Lp B
/ O
Lp B
embryos O
were O
indistinguishable O
. O

Fluorescent O
in O
situ O
hybridization O
( O
FISH O
) O
analysis O
showed O
that O
the O
novel O
regions O
involved O
in O
the O
NFKB2 B
rearrangement O
originated O
from O
chromosome O
7q34 O
, O
thus O
implying O
the O
occurrence O
of O
a O
t O
( O
7 O
; O
10 O
) O
( O
q34 O
; O
q24 O
) O
reciprocal O
chromosomal O
translocation O
. O

MGF B
is O
a O
novel O
member O
of O
the O
cytokine B
- I
regulated I
transcription I
factor I
gene I
family I
. O

This O
is O
the O
first O
report O
that O
the O
PH B
domain I
of O
an O
IRS B
protein I
can O
function O
in O
a O
dominant O
negative O
manner O
to O
inhibit O
insulin B
signaling O
. O

SF1 B
/ O
mBBP B
utilizes O
a O
" B
maxi I
- I
K I
homology I
" I
( O
maxi B
- I
KH I
) O
domain O
for O
recognition O
of O
the O
single O
- O
stranded O
BPS O
and O
requires O
a O
cooperative O
interaction O
with O
splicing O
factor O
U2AF65 B
bound O
to O
an O
adjacent O
polypyrimidine O
tract O
( O
PPT O
) O
for O
high O
- O
affinity O
binding O
. O

SF1 B
/ O
mBBP B
utilizes O
a O
" B
maxi I
- I
K I
homology I
" I
( O
maxi B
- I
KH I
) O
domain O
for O
recognition O
of O
the O
single O
- O
stranded O
BPS O
and O
requires O
a O
cooperative O
interaction O
with O
splicing O
factor O
U2AF65 B
bound O
to O
an O
adjacent O
polypyrimidine O
tract O
( O
PPT O
) O
for O
high O
- O
affinity O
binding O
. O

SF1 B
/ O
mBBP B
utilizes O
a O
" B
maxi I
- I
K I
homology I
" I
( O
maxi B
- I
KH I
) O
domain O
for O
recognition O
of O
the O
single O
- O
stranded O
BPS O
and O
requires O
a O
cooperative O
interaction O
with O
splicing O
factor O
U2AF65 B
bound O
to O
an O
adjacent O
polypyrimidine O
tract O
( O
PPT O
) O
for O
high O
- O
affinity O
binding O
. O

An O
X O
- O
linked O
zinc B
finger I
gene I
mapping O
to O
Xq21 O
. O
1 O
- O
q21 O
. O
3 O
closely O
related O
to O
ZFX B
and O
ZFY B
: O
possible O
origins O
from O
a O
common O
ancestral O
gene O
. O

An O
X O
- O
linked O
zinc B
finger I
gene I
mapping O
to O
Xq21 O
. O
1 O
- O
q21 O
. O
3 O
closely O
related O
to O
ZFX B
and O
ZFY B
: O
possible O
origins O
from O
a O
common O
ancestral O
gene O
. O

In O
addition O
, O
there O
was O
an O
increase O
in O
the O
amount O
of O
p120 B
Ras I
- O
specific O
GTPase B
- I
activating I
protein I
( O
GAP B
) O
and O
GAP B
- O
associated O
p190 O
. O

In O
addition O
, O
there O
was O
an O
increase O
in O
the O
amount O
of O
p120 B
Ras I
- O
specific O
GTPase B
- I
activating I
protein I
( O
GAP B
) O
and O
GAP B
- O
associated O
p190 O
. O

Treatment O
of O
steroid O
resistant O
rejection O
following O
renal O
transplantation O
: O
benefits O
and O
risks O
of O
OKT3 B
therapy O
. O

SH3A B
competes O
with O
the O
SH3 B
domains I
of O
Grb2 B
in O
binding O
to O
mSos1 B
, O
and O
the O
intersectin B
- O
mSos1 B
complex O
can O
be O
separated O
from O
Grb2 B
by O
sucrose O
gradient O
centrifugation O
. O

SH3A B
competes O
with O
the O
SH3 B
domains I
of O
Grb2 B
in O
binding O
to O
mSos1 B
, O
and O
the O
intersectin B
- O
mSos1 B
complex O
can O
be O
separated O
from O
Grb2 B
by O
sucrose O
gradient O
centrifugation O
. O

SH3A B
competes O
with O
the O
SH3 B
domains I
of O
Grb2 B
in O
binding O
to O
mSos1 B
, O
and O
the O
intersectin B
- O
mSos1 B
complex O
can O
be O
separated O
from O
Grb2 B
by O
sucrose O
gradient O
centrifugation O
. O

SH3A B
competes O
with O
the O
SH3 B
domains I
of O
Grb2 B
in O
binding O
to O
mSos1 B
, O
and O
the O
intersectin B
- O
mSos1 B
complex O
can O
be O
separated O
from O
Grb2 B
by O
sucrose O
gradient O
centrifugation O
. O

SH3A B
competes O
with O
the O
SH3 B
domains I
of O
Grb2 B
in O
binding O
to O
mSos1 B
, O
and O
the O
intersectin B
- O
mSos1 B
complex O
can O
be O
separated O
from O
Grb2 B
by O
sucrose O
gradient O
centrifugation O
. O

SH3A B
competes O
with O
the O
SH3 B
domains I
of O
Grb2 B
in O
binding O
to O
mSos1 B
, O
and O
the O
intersectin B
- O
mSos1 B
complex O
can O
be O
separated O
from O
Grb2 B
by O
sucrose O
gradient O
centrifugation O
. O

This O
resulted O
in O
a O
shift O
of O
C1 O
/ O
C2 O
, O
so O
that O
the O
effect O
of O
collagen B
was O
more O
pronounced O
( O
maximal O
increase O
of O
C1 O
/ O
C2 O
= O
134 O
% O
) O
than O
ADP O
( O
maximal O
increase O
of O
C1 O
/ O
C2 O
= O
79 O
% O
) O
. O

Xnr3 B
is O
transcriptionally O
activated O
by O
wnt B
signaling O
during O
gastrulation O
in O
the O
Xenopus O
embryo O
. O

Xnr3 B
is O
transcriptionally O
activated O
by O
wnt B
signaling O
during O
gastrulation O
in O
the O
Xenopus O
embryo O
. O

The O
sequences O
of O
two O
previously O
known O
tail B
genes I
, O
R B
and O
S B
, O
of O
the O
temperate O
bacteriophage O
P2 O
and O
the O
sequence O
of O
an O
additional O
open O
reading O
frame O
( O
orf O
- O
30 O
) O
located O
between O
S B
and O
V B
, O
were O
determined O
. O

The O
sequences O
of O
two O
previously O
known O
tail B
genes I
, O
R B
and O
S B
, O
of O
the O
temperate O
bacteriophage O
P2 O
and O
the O
sequence O
of O
an O
additional O
open O
reading O
frame O
( O
orf O
- O
30 O
) O
located O
between O
S B
and O
V B
, O
were O
determined O
. O

The O
sequences O
of O
two O
previously O
known O
tail B
genes I
, O
R B
and O
S B
, O
of O
the O
temperate O
bacteriophage O
P2 O
and O
the O
sequence O
of O
an O
additional O
open O
reading O
frame O
( O
orf O
- O
30 O
) O
located O
between O
S B
and O
V B
, O
were O
determined O
. O

The O
sequences O
of O
two O
previously O
known O
tail B
genes I
, O
R B
and O
S B
, O
of O
the O
temperate O
bacteriophage O
P2 O
and O
the O
sequence O
of O
an O
additional O
open O
reading O
frame O
( O
orf O
- O
30 O
) O
located O
between O
S B
and O
V B
, O
were O
determined O
. O

GH B
signals O
by O
interacting O
with O
GH B
receptor I
( O
GHR B
) O
. O

GH B
signals O
by O
interacting O
with O
GH B
receptor I
( O
GHR B
) O
. O

The O
extraordinary O
high O
substrate O
specificity O
of O
rPulA B
together O
with O
its O
thermal O
stability O
makes O
this O
enzyme O
a O
good O
candidate O
for O
biotechnological O
applications O
in O
the O
starch O
- O
processing O
industry O
. O

Consistent O
with O
an O
effect O
on O
transcription O
, O
p21 B
was O
localized O
in O
nuclei O
of O
transfected O
cells O
. O

A O
new O
B O
- O
cell O
- O
specific O
enhancer O
element O
has O
been O
identified O
3 O
' O
of O
E4 B
and O
the O
octamerlike O
motifs O
in O
the O
human B
immunoglobulin I
heavy I
- I
chain I
gene I
enhancer I
. O

Genetic O
mutation O
or O
loss O
of O
activin B
/ O
transforming B
growth I
factor I
- I
beta I
( I
TGFbeta I
) I
receptor I
function O
has O
been O
shown O
in O
human O
lymphoid O
, O
breast O
, O
and O
colorectal O
tumors O
as O
well O
as O
Hep2B O
and O
Mv1Lu O
cell O
lines O
. O

Brome B
mosaic I
virus I
polymerase I
- O
like O
protein B
2a I
is O
directed O
to O
the O
endoplasmic O
reticulum O
by O
helicase B
- O
like O
viral B
protein I
1a I
. O

The O
Mer1 B
protein I
contains O
the O
KH O
motif O
found O
in O
some O
RNA O
- O
binding O
proteins O
, O
and O
RNA O
gel O
mobility O
shift O
assays O
demonstrate O
that O
Mer1 B
binds O
specifically O
to O
MER2 B
RNA I
. O

From O
this O
asymmetry O
, O
we O
suggested O
previously O
that O
GCN4 B
interacts O
with O
nonequivalent O
and O
possibly O
overlapping O
half O
- O
sites O
( O
ATGAC O
and O
ATGAG O
) O
that O
have O
different O
affinities O
. O

Furthermore O
the O
aldosterone O
stimulating O
effect O
of O
low O
sodium O
diet O
( O
17 O
children O
) O
, O
severe O
and O
prolonged O
vomiting O
( O
19 O
children O
) O
and O
synthetic O
ACTH B
( O
10 O
children O
) O
has O
been O
studied O
by O
our O
modified O
method O
. O

The O
mutant O
strain O
carries O
three O
tandem O
copies O
of O
the O
18 O
bp O
sequence O
that O
is O
duplicated O
in O
the O
amdI66 B
mutation O
. O

A O
small O
molecule O
ILK B
inhibitor O
suppresses O
the O
phosphorylation O
of O
PKB B
at O
the O
Ser O
- O
473 O
but O
not O
the O
Thr O
- O
308 O
site O
in O
the O
PTEN B
mutant O
cells O
. O

A O
small O
molecule O
ILK B
inhibitor O
suppresses O
the O
phosphorylation O
of O
PKB B
at O
the O
Ser O
- O
473 O
but O
not O
the O
Thr O
- O
308 O
site O
in O
the O
PTEN B
mutant O
cells O
. O

A O
small O
molecule O
ILK B
inhibitor O
suppresses O
the O
phosphorylation O
of O
PKB B
at O
the O
Ser O
- O
473 O
but O
not O
the O
Thr O
- O
308 O
site O
in O
the O
PTEN B
mutant O
cells O
. O

The O
avian O
carcinoma O
virus O
MH2 O
contains O
a O
hybrid O
gene O
delta B
gag I
- O
mht B
with O
a O
contiguous O
open O
reading O
frame O
of O
2682 O
base O
pairs O
as O
well O
as O
v B
- I
myc I
and O
avian O
helper O
virus O
- O
related O
sequences O
. O
delta B
gag I
is O
a O
partial O
retroviral B
core I
protein I
gene I
while O
v B
- I
mht I
and O
v B
- I
myc I
are O
cell O
- O
drived O
sequences O
. O

In O
this O
group O
of O
patients O
, O
the O
mean O
LH B
( O
9 O
. O
3 O
+ O
/ O
- O
5 O
. O
9 O
IU O
/ O
l O
) O
and O
sex B
- I
hormone I
binding I
globulin I
( O
SHBG B
) O
( O
54 O
. O
5 O
+ O
/ O
- O
22 O
. O
9 O
nmol O
/ O
l O
) O
concentrations O
were O
significantly O
greater O
than O
those O
of O
five O
normal O
control O
subjects O
( O
4 O
. O
7 O
+ O
/ O
- O
1 O
. O
11 O
IU O
/ O
l O
and O
26 O
. O
0 O
+ O
/ O
- O
7 O
. O
0 O
nmol O
/ O
l O
respectively O
) O
. O

In O
this O
group O
of O
patients O
, O
the O
mean O
LH B
( O
9 O
. O
3 O
+ O
/ O
- O
5 O
. O
9 O
IU O
/ O
l O
) O
and O
sex B
- I
hormone I
binding I
globulin I
( O
SHBG B
) O
( O
54 O
. O
5 O
+ O
/ O
- O
22 O
. O
9 O
nmol O
/ O
l O
) O
concentrations O
were O
significantly O
greater O
than O
those O
of O
five O
normal O
control O
subjects O
( O
4 O
. O
7 O
+ O
/ O
- O
1 O
. O
11 O
IU O
/ O
l O
and O
26 O
. O
0 O
+ O
/ O
- O
7 O
. O
0 O
nmol O
/ O
l O
respectively O
) O
. O

We O
have O
now O
completed O
the O
primary O
structure O
of O
fibrillin B
, O
elucidated O
the O
exon O
/ O
intron O
organization O
of O
the O
gene O
and O
derived O
a O
physical O
map O
of O
the O
genetic O
locus O
. O

The O
BCL B
- I
6 I
POZ O
domain O
and O
other O
POZ O
domains O
interact O
with O
the O
co O
- O
repressors O
N B
- I
CoR I
and O
SMRT B
. O

Cytokine O
inducibility O
of O
VCAM1 B
in O
endothelial O
cells O
utilizes O
the O
interaction O
of O
heterodimeric O
p50 B
/ O
p65 B
proteins O
with O
IRF B
- I
1 I
. O

Cytokine O
inducibility O
of O
VCAM1 B
in O
endothelial O
cells O
utilizes O
the O
interaction O
of O
heterodimeric O
p50 B
/ O
p65 B
proteins O
with O
IRF B
- I
1 I
. O

Cytokine O
inducibility O
of O
VCAM1 B
in O
endothelial O
cells O
utilizes O
the O
interaction O
of O
heterodimeric O
p50 B
/ O
p65 B
proteins O
with O
IRF B
- I
1 I
. O

Localized O
Bicaudal B
- I
C I
RNA I
encodes O
a O
protein O
containing O
a O
KH O
domain O
, O
the O
RNA O
binding O
motif O
of O
FMR1 B
. O

To O
facilitate O
the O
characterization O
of O
NF B
- I
E2 I
functions O
in O
human O
cells O
, O
we O
isolated O
cDNAs O
encoding O
two O
members O
of O
the O
small B
Maf I
family I
, O
MafK B
and O
MafG B
. O

To O
facilitate O
the O
characterization O
of O
NF B
- I
E2 I
functions O
in O
human O
cells O
, O
we O
isolated O
cDNAs O
encoding O
two O
members O
of O
the O
small B
Maf I
family I
, O
MafK B
and O
MafG B
. O

In O
contrast O
to O
the O
restricted O
tissue O
expression O
of O
gonadotropin B
and O
TSH B
receptors I
in O
gonads O
and O
thyroid O
, O
respectively O
, O
LGR4 B
is O
expressed O
in O
diverse O
tissues O
including O
ovary O
, O
testis O
, O
adrenal O
, O
placenta O
, O
thymus O
, O
spinal O
cord O
, O
and O
thyroid O
, O
whereas O
LGR5 B
is O
found O
in O
muscle O
, O
placenta O
, O
spinal O
cord O
, O
and O
brain O
. O

In O
contrast O
to O
the O
restricted O
tissue O
expression O
of O
gonadotropin B
and O
TSH B
receptors I
in O
gonads O
and O
thyroid O
, O
respectively O
, O
LGR4 B
is O
expressed O
in O
diverse O
tissues O
including O
ovary O
, O
testis O
, O
adrenal O
, O
placenta O
, O
thymus O
, O
spinal O
cord O
, O
and O
thyroid O
, O
whereas O
LGR5 B
is O
found O
in O
muscle O
, O
placenta O
, O
spinal O
cord O
, O
and O
brain O
. O

In O
contrast O
to O
the O
restricted O
tissue O
expression O
of O
gonadotropin B
and O
TSH B
receptors I
in O
gonads O
and O
thyroid O
, O
respectively O
, O
LGR4 B
is O
expressed O
in O
diverse O
tissues O
including O
ovary O
, O
testis O
, O
adrenal O
, O
placenta O
, O
thymus O
, O
spinal O
cord O
, O
and O
thyroid O
, O
whereas O
LGR5 B
is O
found O
in O
muscle O
, O
placenta O
, O
spinal O
cord O
, O
and O
brain O
. O

The O
JNK B
/ O
SAPK B
activator O
mixed B
lineage I
kinase I
3 I
( O
MLK3 B
) O
transforms O
NIH O
3T3 O
cells O
in O
a O
MEK B
- O
dependent O
fashion O
. O

The O
JNK B
/ O
SAPK B
activator O
mixed B
lineage I
kinase I
3 I
( O
MLK3 B
) O
transforms O
NIH O
3T3 O
cells O
in O
a O
MEK B
- O
dependent O
fashion O
. O

The O
JNK B
/ O
SAPK B
activator O
mixed B
lineage I
kinase I
3 I
( O
MLK3 B
) O
transforms O
NIH O
3T3 O
cells O
in O
a O
MEK B
- O
dependent O
fashion O
. O

The O
JNK B
/ O
SAPK B
activator O
mixed B
lineage I
kinase I
3 I
( O
MLK3 B
) O
transforms O
NIH O
3T3 O
cells O
in O
a O
MEK B
- O
dependent O
fashion O
. O

In O
contrast O
to O
the O
effect O
on O
DNA O
replication O
, O
the O
L13V O
substitution O
in O
large B
T I
antigen I
did O
not O
prevent O
complex O
formation O
with O
Hsc70 B
and O
the O
Rb B
protein I
. O

CYP51P1 B
is O
96 O
. O
5 O
% O
identical O
to O
the O
human B
CYP51 I
coding O
sequence O
and O
is O
not O
interrupted O
with O
introns O
but O
has O
six O
in O
- O
frame O
stop O
codons O
resulting O
from O
point O
mutations O
. O

We O
report O
here O
that O
AChE B
activity O
tends O
to O
decrease O
in O
individuals O
sampled O
in O
tanks O
at O
a O
salinity O
of O
30 O
per O
thousand O
as O
temperature O
increases O
. O

Three O
RasV12 B
mutants I
( O
S35 B
, O
G37 B
, O
and O
C40 B
) O
which O
differ O
by O
their O
ability O
to O
bind O
to O
Ras B
effectors I
( O
Raf B
, O
Ral B
- I
GEFs I
, O
and O
the O
p110 B
subunit I
of I
PI I
3 I
- I
kinase I
, O
respectively O
) O
were O
able O
to O
induce O
sustained O
NR O
cell O
proliferation O
, O
although O
none O
of O
these O
mutants O
was O
reported O
to O
transform O
NIH O
3T3 O
cells O
. O

Three O
RasV12 B
mutants I
( O
S35 B
, O
G37 B
, O
and O
C40 B
) O
which O
differ O
by O
their O
ability O
to O
bind O
to O
Ras B
effectors I
( O
Raf B
, O
Ral B
- I
GEFs I
, O
and O
the O
p110 B
subunit I
of I
PI I
3 I
- I
kinase I
, O
respectively O
) O
were O
able O
to O
induce O
sustained O
NR O
cell O
proliferation O
, O
although O
none O
of O
these O
mutants O
was O
reported O
to O
transform O
NIH O
3T3 O
cells O
. O

Three O
RasV12 B
mutants I
( O
S35 B
, O
G37 B
, O
and O
C40 B
) O
which O
differ O
by O
their O
ability O
to O
bind O
to O
Ras B
effectors I
( O
Raf B
, O
Ral B
- I
GEFs I
, O
and O
the O
p110 B
subunit I
of I
PI I
3 I
- I
kinase I
, O
respectively O
) O
were O
able O
to O
induce O
sustained O
NR O
cell O
proliferation O
, O
although O
none O
of O
these O
mutants O
was O
reported O
to O
transform O
NIH O
3T3 O
cells O
. O

Three O
RasV12 B
mutants I
( O
S35 B
, O
G37 B
, O
and O
C40 B
) O
which O
differ O
by O
their O
ability O
to O
bind O
to O
Ras B
effectors I
( O
Raf B
, O
Ral B
- I
GEFs I
, O
and O
the O
p110 B
subunit I
of I
PI I
3 I
- I
kinase I
, O
respectively O
) O
were O
able O
to O
induce O
sustained O
NR O
cell O
proliferation O
, O
although O
none O
of O
these O
mutants O
was O
reported O
to O
transform O
NIH O
3T3 O
cells O
. O

A O
significant O
difference O
in O
the O
distribution O
of O
antibodies O
to O
thyroglobulin B
and O
thyroid B
peroxidase I
was O
found O
in O
subgroup O
2 O
. O

Here O
, O
we O
characterize O
TCR B
/ O
CD48 B
and O
TCR B
/ O
CD28 B
costimulation O
in O
T O
cells O
expressing O
Lck B
Src B
homology I
3 I
( O
SH3 B
) O
mutants O
. O

Here O
, O
we O
characterize O
TCR B
/ O
CD48 B
and O
TCR B
/ O
CD28 B
costimulation O
in O
T O
cells O
expressing O
Lck B
Src B
homology I
3 I
( O
SH3 B
) O
mutants O
. O

Here O
, O
we O
characterize O
TCR B
/ O
CD48 B
and O
TCR B
/ O
CD28 B
costimulation O
in O
T O
cells O
expressing O
Lck B
Src B
homology I
3 I
( O
SH3 B
) O
mutants O
. O

Here O
, O
we O
characterize O
TCR B
/ O
CD48 B
and O
TCR B
/ O
CD28 B
costimulation O
in O
T O
cells O
expressing O
Lck B
Src B
homology I
3 I
( O
SH3 B
) O
mutants O
. O

Here O
, O
we O
characterize O
TCR B
/ O
CD48 B
and O
TCR B
/ O
CD28 B
costimulation O
in O
T O
cells O
expressing O
Lck B
Src B
homology I
3 I
( O
SH3 B
) O
mutants O
. O

Here O
, O
we O
characterize O
TCR B
/ O
CD48 B
and O
TCR B
/ O
CD28 B
costimulation O
in O
T O
cells O
expressing O
Lck B
Src B
homology I
3 I
( O
SH3 B
) O
mutants O
. O

High O
expression O
of O
p51A B
( O
TAp63gamma B
) O
in O
the O
skeletal O
muscle O
tissue O
drove O
us O
to O
investigate O
a O
differentiation O
- O
inducible O
myoblastic O
cell O
line O
which O
showed O
increased O
p51A B
expression O
after O
differentiation O
induction O
. O

High O
expression O
of O
p51A B
( O
TAp63gamma B
) O
in O
the O
skeletal O
muscle O
tissue O
drove O
us O
to O
investigate O
a O
differentiation O
- O
inducible O
myoblastic O
cell O
line O
which O
showed O
increased O
p51A B
expression O
after O
differentiation O
induction O
. O

High O
expression O
of O
p51A B
( O
TAp63gamma B
) O
in O
the O
skeletal O
muscle O
tissue O
drove O
us O
to O
investigate O
a O
differentiation O
- O
inducible O
myoblastic O
cell O
line O
which O
showed O
increased O
p51A B
expression O
after O
differentiation O
induction O
. O

Using O
the O
interaction O
- O
trap O
assay O
to O
identify O
candidate O
proteins O
that O
bind O
the O
cytoplasmic O
region O
of O
the O
LAR B
transmembrane I
protein I
tyrosine I
phosphatase I
( O
PT B
- I
Pase I
) O
, O
we O
isolated O
a O
cDNA O
encoding O
a O
2861 O
- O
amino O
acid O
protein O
termed O
Trio B
that O
contains O
three O
enzyme O
domains O
: O
two O
functional O
GEF B
domains I
and O
a O
protein B
serine I
/ I
threonine I
kinase I
( O
PSK B
) O
domain O
. O

Using O
the O
interaction O
- O
trap O
assay O
to O
identify O
candidate O
proteins O
that O
bind O
the O
cytoplasmic O
region O
of O
the O
LAR B
transmembrane I
protein I
tyrosine I
phosphatase I
( O
PT B
- I
Pase I
) O
, O
we O
isolated O
a O
cDNA O
encoding O
a O
2861 O
- O
amino O
acid O
protein O
termed O
Trio B
that O
contains O
three O
enzyme O
domains O
: O
two O
functional O
GEF B
domains I
and O
a O
protein B
serine I
/ I
threonine I
kinase I
( O
PSK B
) O
domain O
. O

We O
have O
isolated O
two O
H19 B
cDNAs I
( O
AP B
and O
ES B
) O
that O
contain O
this O
ORF4 O
and O
correspond O
to O
incomplete O
copies O
of O
the O
unique O
2 B
. I
3 I
kb I
H19 I
RNA I
. O

We O
have O
isolated O
two O
H19 B
cDNAs I
( O
AP B
and O
ES B
) O
that O
contain O
this O
ORF4 O
and O
correspond O
to O
incomplete O
copies O
of O
the O
unique O
2 B
. I
3 I
kb I
H19 I
RNA I
. O

The O
related O
adhesion B
focal I
tyrosine I
kinase I
is O
tyrosine O
- O
phosphorylated O
after O
beta1 B
- I
integrin I
stimulation O
in O
B O
cells O
and O
binds O
to O
p130cas B
. O

Analysis O
of O
a O
Het B
- O
mutation O
in O
Anabaena O
sp O
. O
strain O
PCC O
7120 O
implicates O
a O
secondary O
metabolite O
in O
the O
regulation O
of O
heterocyst O
spacing O
. O

Here O
we O
report O
that O
components O
of O
the O
Ras B
/ O
Raf B
/ O
MAPK B
pathway O
are O
constitutively O
activated O
in O
these O
lck B
- O
transformed O
immature O
thymoblasts O
. O

Here O
we O
report O
that O
components O
of O
the O
Ras B
/ O
Raf B
/ O
MAPK B
pathway O
are O
constitutively O
activated O
in O
these O
lck B
- O
transformed O
immature O
thymoblasts O
. O

Here O
we O
report O
that O
components O
of O
the O
Ras B
/ O
Raf B
/ O
MAPK B
pathway O
are O
constitutively O
activated O
in O
these O
lck B
- O
transformed O
immature O
thymoblasts O
. O

Here O
we O
report O
that O
components O
of O
the O
Ras B
/ O
Raf B
/ O
MAPK B
pathway O
are O
constitutively O
activated O
in O
these O
lck B
- O
transformed O
immature O
thymoblasts O
. O

p56 B
( O
lck B
) O
utilizes O
Shc B
and O
Grb2 B
adaptors I
to O
mediate O
activation O
of O
p21 B
( O
ras B
) O
in O
the O
thymoblast O
lines O
by O
promoting O
tyrosine O
phosphorylation O
of O
the O
Shc B
protein I
and O
constitutive O
interaction O
between O
Shc B
and O
Grb2 B
. O

p56 B
( O
lck B
) O
utilizes O
Shc B
and O
Grb2 B
adaptors I
to O
mediate O
activation O
of O
p21 B
( O
ras B
) O
in O
the O
thymoblast O
lines O
by O
promoting O
tyrosine O
phosphorylation O
of O
the O
Shc B
protein I
and O
constitutive O
interaction O
between O
Shc B
and O
Grb2 B
. O

p56 B
( O
lck B
) O
utilizes O
Shc B
and O
Grb2 B
adaptors I
to O
mediate O
activation O
of O
p21 B
( O
ras B
) O
in O
the O
thymoblast O
lines O
by O
promoting O
tyrosine O
phosphorylation O
of O
the O
Shc B
protein I
and O
constitutive O
interaction O
between O
Shc B
and O
Grb2 B
. O

p56 B
( O
lck B
) O
utilizes O
Shc B
and O
Grb2 B
adaptors I
to O
mediate O
activation O
of O
p21 B
( O
ras B
) O
in O
the O
thymoblast O
lines O
by O
promoting O
tyrosine O
phosphorylation O
of O
the O
Shc B
protein I
and O
constitutive O
interaction O
between O
Shc B
and O
Grb2 B
. O

p56 B
( O
lck B
) O
utilizes O
Shc B
and O
Grb2 B
adaptors I
to O
mediate O
activation O
of O
p21 B
( O
ras B
) O
in O
the O
thymoblast O
lines O
by O
promoting O
tyrosine O
phosphorylation O
of O
the O
Shc B
protein I
and O
constitutive O
interaction O
between O
Shc B
and O
Grb2 B
. O

p56 B
( O
lck B
) O
utilizes O
Shc B
and O
Grb2 B
adaptors I
to O
mediate O
activation O
of O
p21 B
( O
ras B
) O
in O
the O
thymoblast O
lines O
by O
promoting O
tyrosine O
phosphorylation O
of O
the O
Shc B
protein I
and O
constitutive O
interaction O
between O
Shc B
and O
Grb2 B
. O

p56 B
( O
lck B
) O
utilizes O
Shc B
and O
Grb2 B
adaptors I
to O
mediate O
activation O
of O
p21 B
( O
ras B
) O
in O
the O
thymoblast O
lines O
by O
promoting O
tyrosine O
phosphorylation O
of O
the O
Shc B
protein I
and O
constitutive O
interaction O
between O
Shc B
and O
Grb2 B
. O

Based O
on O
the O
results O
of O
this O
analysis O
, O
we O
also O
predict O
that O
the O
budding B
yeast I
arsenate I
resistance I
protein I
Acr2 B
and O
the O
ORF B
Ygr203w I
encode O
protein O
phosphatases O
with O
catalytic O
properties O
similar O
to O
that O
of O
the O
Cdc25 B
family I
. O

The O
PHO5 B
gene I
is O
activated O
by O
the O
Pho4p B
transcription I
factor I
, O
which O
itself O
is O
negatively O
regulated O
through O
phosphorylation O
by O
the O
products O
of O
PHO80 B
and O
PHO85 B
. O

The O
PHO5 B
gene I
is O
activated O
by O
the O
Pho4p B
transcription I
factor I
, O
which O
itself O
is O
negatively O
regulated O
through O
phosphorylation O
by O
the O
products O
of O
PHO80 B
and O
PHO85 B
. O

Analysis O
of O
the O
DNA O
sequence O
upstream O
of O
the O
narQ B
gene I
, O
which O
encodes O
the O
second O
nitrate O
- O
responsive O
sensor O
- O
transmitter O
protein O
in O
Escherichia O
coli O
, O
revealed O
an O
open O
reading O
frame O
( O
ORF O
) O
whose O
product O
shows O
a O
high O
degree O
of O
similarity O
to O
a O
number O
of O
iron B
- I
sulfur I
proteins I
as O
well O
as O
to O
the O
beta O
subunit O
of O
glutamate B
synthase I
( O
gltD B
) O
of O
E O
. O
coli O
. O

The O
5 O
' O
half O
of O
the O
EWS B
gene I
has O
recently O
been O
described O
to O
be O
fused O
to O
the O
3 O
' O
regions O
of O
genes O
encoding O
the O
DNA O
- O
binding O
domain O
of O
several O
transcriptional O
regulators O
, O
including O
ATF1 B
, O
FLI B
- I
1 I
, O
and O
ERG B
, O
in O
several O
human O
tumors O
. O

The O
5 O
' O
half O
of O
the O
EWS B
gene I
has O
recently O
been O
described O
to O
be O
fused O
to O
the O
3 O
' O
regions O
of O
genes O
encoding O
the O
DNA O
- O
binding O
domain O
of O
several O
transcriptional O
regulators O
, O
including O
ATF1 B
, O
FLI B
- I
1 I
, O
and O
ERG B
, O
in O
several O
human O
tumors O
. O

PDGF B
stimulated O
CDK2 B
activity O
in O
mesangial O
cells O
and O
decreased O
the O
level O
of O
p27 B
( O
kip1 B
) O
cyclin O
kinase O
inhibitor O
protein O
. O

PDGF B
stimulated O
CDK2 B
activity O
in O
mesangial O
cells O
and O
decreased O
the O
level O
of O
p27 B
( O
kip1 B
) O
cyclin O
kinase O
inhibitor O
protein O
. O

PDGF B
stimulated O
CDK2 B
activity O
in O
mesangial O
cells O
and O
decreased O
the O
level O
of O
p27 B
( O
kip1 B
) O
cyclin O
kinase O
inhibitor O
protein O
. O

PDGF B
stimulated O
CDK2 B
activity O
in O
mesangial O
cells O
and O
decreased O
the O
level O
of O
p27 B
( O
kip1 B
) O
cyclin O
kinase O
inhibitor O
protein O
. O

The O
influence O
of O
different O
temperatures O
between O
13 O
degrees O
C O
and O
45 O
degrees O
C O
on O
coagulation O
factors O
in O
vitro O
was O
studied O
by O
measuring O
clotting O
time O
with O
the O
recalcification O
time O
, O
partial O
thromboplastin B
time O
( O
PTT O
) O
, O
and O
thromboplastin B
time O
test O
. O

The O
influence O
of O
different O
temperatures O
between O
13 O
degrees O
C O
and O
45 O
degrees O
C O
on O
coagulation O
factors O
in O
vitro O
was O
studied O
by O
measuring O
clotting O
time O
with O
the O
recalcification O
time O
, O
partial O
thromboplastin B
time O
( O
PTT O
) O
, O
and O
thromboplastin B
time O
test O
. O

Thus O
, O
transgene O
expression O
directed O
by O
both O
the O
human O
and O
mouse B
Rb I
promoters I
is O
restricted O
to O
a O
subset O
of O
tissues O
in O
which O
Rb B
is O
normally O
expressed O
during O
embryogenesis O
. O

Thus O
, O
Tax1 B
activates O
CArG O
- O
mediated O
transcription O
without O
mitogenic O
signals O
through O
interaction O
with O
a O
CArG B
- I
binding I
factor I
, O
p67SRF B
. O

Thus O
, O
Tax1 B
activates O
CArG O
- O
mediated O
transcription O
without O
mitogenic O
signals O
through O
interaction O
with O
a O
CArG B
- I
binding I
factor I
, O
p67SRF B
. O

The O
transcription O
start O
site O
was O
localized O
224 O
bp O
upstream O
the O
ATG O
codon O
by O
RNase B
protection O
and O
primer O
extension O
mapping O
. O

Rising O
antibody O
titres O
to O
the O
astrovirus O
particles O
were O
demonstrated O
in O
one O
child O
, O
and O
IgM B
was O
also O
demonstrated O
in O
this O
patient O
' O
s O
serum O
. O

Although O
RAD17 B
, O
RAD24 B
and O
MEC3 B
are O
not O
required O
for O
cell O
cycle O
arrest O
when O
S O
phase O
is O
inhibited O
by O
hydroxyurea O
( O
HU O
) O
, O
they O
do O
contribute O
to O
the O
viability O
of O
yeast O
cells O
grown O
in O
the O
presence O
of O
HU O
, O
possibly O
because O
they O
are O
required O
for O
the O
repair O
of O
HU O
- O
induced O
DNA O
damage O
. O

Although O
RAD17 B
, O
RAD24 B
and O
MEC3 B
are O
not O
required O
for O
cell O
cycle O
arrest O
when O
S O
phase O
is O
inhibited O
by O
hydroxyurea O
( O
HU O
) O
, O
they O
do O
contribute O
to O
the O
viability O
of O
yeast O
cells O
grown O
in O
the O
presence O
of O
HU O
, O
possibly O
because O
they O
are O
required O
for O
the O
repair O
of O
HU O
- O
induced O
DNA O
damage O
. O

Although O
RAD17 B
, O
RAD24 B
and O
MEC3 B
are O
not O
required O
for O
cell O
cycle O
arrest O
when O
S O
phase O
is O
inhibited O
by O
hydroxyurea O
( O
HU O
) O
, O
they O
do O
contribute O
to O
the O
viability O
of O
yeast O
cells O
grown O
in O
the O
presence O
of O
HU O
, O
possibly O
because O
they O
are O
required O
for O
the O
repair O
of O
HU O
- O
induced O
DNA O
damage O
. O

PTP1 B
- O
lacZ B
studies O
indicate O
that O
PTP1 B
is O
spatially O
localized O
to O
prestalk O
and O
anterior O
- O
like O
cell O
types O
. O

PTP1 B
- O
lacZ B
studies O
indicate O
that O
PTP1 B
is O
spatially O
localized O
to O
prestalk O
and O
anterior O
- O
like O
cell O
types O
. O

PTP1 B
- O
lacZ B
studies O
indicate O
that O
PTP1 B
is O
spatially O
localized O
to O
prestalk O
and O
anterior O
- O
like O
cell O
types O
. O

Like O
Rev B
- O
Erb B
, O
BD73 B
binds O
as O
a O
monomer O
to O
a O
DNA O
sequence O
which O
consists O
of O
a O
specific O
A O
/ O
T O
- O
rich O
sequence O
upstream O
of O
the O
consensus O
hexameric O
half O
- O
site O
specified O
by O
the O
P O
box O
of O
the O
DNA O
- O
binding O
domain O
. O

Like O
Rev B
- O
Erb B
, O
BD73 B
binds O
as O
a O
monomer O
to O
a O
DNA O
sequence O
which O
consists O
of O
a O
specific O
A O
/ O
T O
- O
rich O
sequence O
upstream O
of O
the O
consensus O
hexameric O
half O
- O
site O
specified O
by O
the O
P O
box O
of O
the O
DNA O
- O
binding O
domain O
. O

Like O
Rev B
- O
Erb B
, O
BD73 B
binds O
as O
a O
monomer O
to O
a O
DNA O
sequence O
which O
consists O
of O
a O
specific O
A O
/ O
T O
- O
rich O
sequence O
upstream O
of O
the O
consensus O
hexameric O
half O
- O
site O
specified O
by O
the O
P O
box O
of O
the O
DNA O
- O
binding O
domain O
. O

In O
contrast O
, O
the O
holo B
- I
dTFIIA I
( O
L O
/ O
S O
) O
binds O
TBP B
with O
high O
affinity O
. O

Western O
and O
immunocytochemical O
analysis O
implied O
that O
PREB B
accumulates O
specifically O
in O
GH3 O
cell O
nuclei O
. O

A O
novel O
serine B
kinase I
activated O
by O
rac1 B
/ O
CDC42Hs B
- O
dependent O
autophosphorylation O
is O
related O
to O
PAK65 B
and O
STE20 B
. O

A O
novel O
serine B
kinase I
activated O
by O
rac1 B
/ O
CDC42Hs B
- O
dependent O
autophosphorylation O
is O
related O
to O
PAK65 B
and O
STE20 B
. O

A O
novel O
serine B
kinase I
activated O
by O
rac1 B
/ O
CDC42Hs B
- O
dependent O
autophosphorylation O
is O
related O
to O
PAK65 B
and O
STE20 B
. O

A O
novel O
serine B
kinase I
activated O
by O
rac1 B
/ O
CDC42Hs B
- O
dependent O
autophosphorylation O
is O
related O
to O
PAK65 B
and O
STE20 B
. O

Overexpression O
of O
SNURF B
in O
cultured O
mammalian O
cells O
enhanced O
not O
only O
androgen O
, O
glucocorticoid O
, O
and O
progesterone B
receptor I
- O
dependent O
transactivation O
but O
also O
basal O
transcription O
from O
steroid O
- O
regulated O
promoters O
. O

These O
data O
show O
that O
tyrosine O
phosphorylation O
by O
FES B
affects O
the O
interaction O
of O
BCR B
with O
multiple O
signaling O
partners O
and O
suggest O
a O
general O
role O
for O
BCR B
in O
non O
- O
receptor O
protein B
- I
tyrosine I
kinase I
regulation O
and O
signal O
transduction O
. O

These O
data O
show O
that O
tyrosine O
phosphorylation O
by O
FES B
affects O
the O
interaction O
of O
BCR B
with O
multiple O
signaling O
partners O
and O
suggest O
a O
general O
role O
for O
BCR B
in O
non O
- O
receptor O
protein B
- I
tyrosine I
kinase I
regulation O
and O
signal O
transduction O
. O

These O
data O
show O
that O
tyrosine O
phosphorylation O
by O
FES B
affects O
the O
interaction O
of O
BCR B
with O
multiple O
signaling O
partners O
and O
suggest O
a O
general O
role O
for O
BCR B
in O
non O
- O
receptor O
protein B
- I
tyrosine I
kinase I
regulation O
and O
signal O
transduction O
. O

In O
addition O
to O
TAK1 B
, O
TGF B
- I
beta I
also O
stimulated O
JNK B
activity O
. O

In O
addition O
to O
TAK1 B
, O
TGF B
- I
beta I
also O
stimulated O
JNK B
activity O
. O

Foamy O
viruses O
( O
FVs O
) O
express O
the O
Gag B
protein I
as O
a O
precursor O
with O
a O
molecular O
mass O
of O
74 O
kDa O
( O
pr74 B
) O
from O
which O
a O
70 O
- O
kDa O
protein O
( O
p70 B
) O
is O
cleaved O
by O
the O
viral O
protease O
. O

Foamy O
viruses O
( O
FVs O
) O
express O
the O
Gag B
protein I
as O
a O
precursor O
with O
a O
molecular O
mass O
of O
74 O
kDa O
( O
pr74 B
) O
from O
which O
a O
70 O
- O
kDa O
protein O
( O
p70 B
) O
is O
cleaved O
by O
the O
viral O
protease O
. O

The O
occurrence O
of O
the O
different O
types O
of O
TCRB B
rearrangement O
patterns O
has O
implications O
for O
PCR O
- O
based O
clonality O
assessment O
and O
for O
PCR O
- O
based O
detection O
of O
minimal O
residual O
disease O
via O
TCRB B
gene I
analysis O
. O

No O
patient O
demonstrated O
a O
decrease O
in O
bone O
marrow O
fibrosis O
as O
determined O
by O
serial O
procollagen B
( O
PC B
III I
) O
serum O
level O
analysis O
. O

Ectopic O
expression O
of O
cyclin B
D1 I
in O
progestin O
- O
inhibited O
cells O
led O
to O
the O
reappearance O
of O
the O
120 O
- O
kDa O
active O
form O
of O
cyclin B
E I
- O
Cdk2 B
preceding O
the O
resumption O
of O
cell O
cycle O
progression O
. O

Because O
the O
wa B
- I
2 I
mutation I
was O
mapped O
previously O
to O
the O
vicinity O
of O
the O
EGF B
/ I
TGF I
- I
alpha I
receptor I
( O
EGFR B
) O
gene O
on O
mouse O
chromosome O
11 O
, O
we O
hypothesized O
that O
the O
wa B
- I
2 I
phenotype I
might O
result O
from O
a O
defect O
in O
either O
the O
expression O
or O
activity O
of O
EGFR B
, O
or O
both O
. O

Because O
the O
wa B
- I
2 I
mutation I
was O
mapped O
previously O
to O
the O
vicinity O
of O
the O
EGF B
/ I
TGF I
- I
alpha I
receptor I
( O
EGFR B
) O
gene O
on O
mouse O
chromosome O
11 O
, O
we O
hypothesized O
that O
the O
wa B
- I
2 I
phenotype I
might O
result O
from O
a O
defect O
in O
either O
the O
expression O
or O
activity O
of O
EGFR B
, O
or O
both O
. O

Southern O
zoo O
blot O
analysis O
indicated O
that O
ZNF236 B
is O
conserved O
in O
the O
genomes O
of O
all O
mammalian O
species O
tested O
, O
but O
not O
in O
yeast O
. O

RNA O
determinants O
required O
for O
L4 B
- O
mediated O
attenuation O
control O
of O
the O
S10 B
r I
- I
protein I
operon I
of I
Escherichia I
coli I
. O

INTERVENTIONS O
: O
Postoperative O
follow O
- O
up O
consisted O
of O
serial O
determination O
of O
different O
biochemical O
markers O
( O
CK B
, O
CK B
- I
MB I
, O
cTnI B
) O
, O
ECGs O
, O
and O
echocardiography O
. O

INTERVENTIONS O
: O
Postoperative O
follow O
- O
up O
consisted O
of O
serial O
determination O
of O
different O
biochemical O
markers O
( O
CK B
, O
CK B
- I
MB I
, O
cTnI B
) O
, O
ECGs O
, O
and O
echocardiography O
. O

The O
recruitment O
of O
constitutively O
phosphorylated O
p185 B
( O
neu B
) O
and O
the O
activated O
mitogenic O
pathway O
proteins O
to O
this O
membrane O
- O
microfilament O
interaction O
site O
provides O
a O
physical O
model O
for O
integrating O
the O
assembly O
of O
the O
mitogenic O
pathway O
with O
the O
transmission O
of O
growth O
factor O
signal O
to O
the O
cytoskeleton O
. O

The O
recruitment O
of O
constitutively O
phosphorylated O
p185 B
( O
neu B
) O
and O
the O
activated O
mitogenic O
pathway O
proteins O
to O
this O
membrane O
- O
microfilament O
interaction O
site O
provides O
a O
physical O
model O
for O
integrating O
the O
assembly O
of O
the O
mitogenic O
pathway O
with O
the O
transmission O
of O
growth O
factor O
signal O
to O
the O
cytoskeleton O
. O

Deletion O
of O
the O
region O
from O
amino O
acid O
residues O
2 O
- O
67 O
in O
E1A B
, O
which O
has O
been O
postulated O
to O
interact O
with O
p300 B
/ O
CBP B
, O
also O
abolished O
the O
inhibitory O
effect O
of O
E1A B
, O
whereas O
deletion O
of O
the O
region O
from O
residues O
120 O
to O
140 O
had O
no O
effect O
. O

Deletion O
of O
the O
region O
from O
amino O
acid O
residues O
2 O
- O
67 O
in O
E1A B
, O
which O
has O
been O
postulated O
to O
interact O
with O
p300 B
/ O
CBP B
, O
also O
abolished O
the O
inhibitory O
effect O
of O
E1A B
, O
whereas O
deletion O
of O
the O
region O
from O
residues O
120 O
to O
140 O
had O
no O
effect O
. O

Deletion O
of O
the O
region O
from O
amino O
acid O
residues O
2 O
- O
67 O
in O
E1A B
, O
which O
has O
been O
postulated O
to O
interact O
with O
p300 B
/ O
CBP B
, O
also O
abolished O
the O
inhibitory O
effect O
of O
E1A B
, O
whereas O
deletion O
of O
the O
region O
from O
residues O
120 O
to O
140 O
had O
no O
effect O
. O

Deletion O
of O
the O
region O
from O
amino O
acid O
residues O
2 O
- O
67 O
in O
E1A B
, O
which O
has O
been O
postulated O
to O
interact O
with O
p300 B
/ O
CBP B
, O
also O
abolished O
the O
inhibitory O
effect O
of O
E1A B
, O
whereas O
deletion O
of O
the O
region O
from O
residues O
120 O
to O
140 O
had O
no O
effect O
. O

The O
point O
mutation O
Asp O
- O
316 O
- O
- O
> O
Asn O
in O
the O
C O
- O
terminus O
of O
p38 B
, O
analogous O
to O
the O
ERK2 B
( O
extracellular B
- I
signal I
- I
regulated I
kinase I
2 I
) O
sevenmaker B
mutation O
, O
dramatically O
decreases O
its O
binding O
to O
MKP B
- I
1 I
and O
substantially O
compromises O
its O
stimulatory O
effect O
on O
the O
catalytic O
activity O
of O
this O
phosphatase O
. O

The O
point O
mutation O
Asp O
- O
316 O
- O
- O
> O
Asn O
in O
the O
C O
- O
terminus O
of O
p38 B
, O
analogous O
to O
the O
ERK2 B
( O
extracellular B
- I
signal I
- I
regulated I
kinase I
2 I
) O
sevenmaker B
mutation O
, O
dramatically O
decreases O
its O
binding O
to O
MKP B
- I
1 I
and O
substantially O
compromises O
its O
stimulatory O
effect O
on O
the O
catalytic O
activity O
of O
this O
phosphatase O
. O

The O
point O
mutation O
Asp O
- O
316 O
- O
- O
> O
Asn O
in O
the O
C O
- O
terminus O
of O
p38 B
, O
analogous O
to O
the O
ERK2 B
( O
extracellular B
- I
signal I
- I
regulated I
kinase I
2 I
) O
sevenmaker B
mutation O
, O
dramatically O
decreases O
its O
binding O
to O
MKP B
- I
1 I
and O
substantially O
compromises O
its O
stimulatory O
effect O
on O
the O
catalytic O
activity O
of O
this O
phosphatase O
. O

BCR B
- O
ABL B
elicits O
transformation O
of O
both O
fibroblast O
and O
hematopoietic O
cells O
and O
blocks O
apoptosis O
following O
cytokine O
deprivation O
in O
various O
factor O
- O
dependent O
cells O
. O

BCR B
- O
ABL B
elicits O
transformation O
of O
both O
fibroblast O
and O
hematopoietic O
cells O
and O
blocks O
apoptosis O
following O
cytokine O
deprivation O
in O
various O
factor O
- O
dependent O
cells O
. O

Mutations O
in O
Saccharomyces O
cerevisiae O
that O
block O
meiotic O
prophase O
chromosome O
metabolism O
and O
confer O
cell O
cycle O
arrest O
at O
pachytene O
identify O
two O
new O
meiosis B
- I
specific I
genes I
SAE1 I
and O
SAE3 B
. O

Isolation O
and O
characterization O
of O
human O
orthologs O
of O
yeast O
CCR4 B
- O
NOT B
complex O
subunits O
. O

Isolation O
and O
characterization O
of O
human O
orthologs O
of O
yeast O
CCR4 B
- O
NOT B
complex O
subunits O
. O

Expression O
of O
the O
E2 B
protein I
resulted O
in O
rapid O
repression O
of O
HPV B
E6 I
and O
E7 B
expression O
, O
followed O
approximately O
12 O
h O
later O
by O
profound O
inhibition O
of O
cellular O
DNA O
synthesis O
. O

In O
cells O
co O
- O
expressing O
high O
levels O
of O
the O
p38 B
( O
MAPK B
) O
kinase O
( O
MKK3 B
) O
together O
with O
the O
p38 B
( O
MAPK B
) O
, O
a O
significant O
inhibition O
of O
mitogen O
- O
induced O
cyclin B
D1 I
expression O
was O
observed O
. O

In O
cells O
co O
- O
expressing O
high O
levels O
of O
the O
p38 B
( O
MAPK B
) O
kinase O
( O
MKK3 B
) O
together O
with O
the O
p38 B
( O
MAPK B
) O
, O
a O
significant O
inhibition O
of O
mitogen O
- O
induced O
cyclin B
D1 I
expression O
was O
observed O
. O

In O
cells O
co O
- O
expressing O
high O
levels O
of O
the O
p38 B
( O
MAPK B
) O
kinase O
( O
MKK3 B
) O
together O
with O
the O
p38 B
( O
MAPK B
) O
, O
a O
significant O
inhibition O
of O
mitogen O
- O
induced O
cyclin B
D1 I
expression O
was O
observed O
. O

In O
cells O
co O
- O
expressing O
high O
levels O
of O
the O
p38 B
( O
MAPK B
) O
kinase O
( O
MKK3 B
) O
together O
with O
the O
p38 B
( O
MAPK B
) O
, O
a O
significant O
inhibition O
of O
mitogen O
- O
induced O
cyclin B
D1 I
expression O
was O
observed O
. O

In O
cells O
co O
- O
expressing O
high O
levels O
of O
the O
p38 B
( O
MAPK B
) O
kinase O
( O
MKK3 B
) O
together O
with O
the O
p38 B
( O
MAPK B
) O
, O
a O
significant O
inhibition O
of O
mitogen O
- O
induced O
cyclin B
D1 I
expression O
was O
observed O
. O

As O
regards O
the O
short O
stature O
, O
they O
have O
proved O
that O
the O
syndrome O
is O
related O
to O
low O
levels O
of O
somatomedin B
C I
( O
SmC B
) O
. O

HBO O
had O
marked O
effects O
on O
these O
enzymes O
: O
lung B
SOD I
increased O
( O
guinea O
pigs O
47 O
% O
, O
rats O
88 O
% O
) O
and O
CAT B
and O
GSHPx B
activities O
decreased O
( O
33 O
% O
) O
in O
brain O
and O
lung O
. O

HBO O
had O
marked O
effects O
on O
these O
enzymes O
: O
lung B
SOD I
increased O
( O
guinea O
pigs O
47 O
% O
, O
rats O
88 O
% O
) O
and O
CAT B
and O
GSHPx B
activities O
decreased O
( O
33 O
% O
) O
in O
brain O
and O
lung O
. O

Phylogenetic O
analysis O
of O
yeast O
, O
invertebrate O
, O
and O
multiple O
mammalian O
isoforms O
of O
SNF4 B
shows O
that O
the O
gene O
duplication O
likely O
occurred O
early O
in O
the O
metazoan O
lineage O
, O
as O
the O
protein O
products O
of O
the O
different O
loci O
are O
relatively O
divergent O
. O

The O
structural O
intestinal O
defects O
are O
presumed O
to O
be O
the O
result O
of O
defective O
collagen B
synthesis O
in O
these O
hereditary O
connective O
tissue O
disorders O
. O

An O
hcr1 B
null O
mutant O
was O
viable O
, O
but O
showed O
slight O
reduction O
of O
growth O
when O
compared O
with O
the O
wild O
- O
type O
strain O
. O

Serum O
levels O
of O
total O
and O
specific B
immunoglobulin I
E I
( O
IgE B
) O
have O
been O
determined O
by O
radioimmunoassays O
in O
sixty O
- O
nine O
allergic O
subjects O
. O

Indeed O
, O
ectopic O
expression O
of O
MOX4 B
in O
aerobic O
cells O
resulted O
in O
partially O
constitutive O
expression O
of O
DAN1 B
. O

Indeed O
, O
ectopic O
expression O
of O
MOX4 B
in O
aerobic O
cells O
resulted O
in O
partially O
constitutive O
expression O
of O
DAN1 B
. O

Hybridization O
was O
detected O
between O
polyadenylated B
H I
chain I
mRNA I
, O
isolated O
from O
the O
majority O
of O
the O
hybridomas O
, O
and O
the O
VH B
probe O
. O

Identification O
of O
a O
putative O
infC B
- O
rpmI B
- O
rplT B
operon O
flanked O
by O
long O
inverted O
repeats O
in O
Mycoplasma O
fermentans O
( O
incognitus O
strain O
) O
. O

Identification O
of O
a O
putative O
infC B
- O
rpmI B
- O
rplT B
operon O
flanked O
by O
long O
inverted O
repeats O
in O
Mycoplasma O
fermentans O
( O
incognitus O
strain O
) O
. O

Identification O
of O
a O
putative O
infC B
- O
rpmI B
- O
rplT B
operon O
flanked O
by O
long O
inverted O
repeats O
in O
Mycoplasma O
fermentans O
( O
incognitus O
strain O
) O
. O

Loss O
of O
pRb B
or O
p107 B
binding O
results O
in O
the O
loss O
of O
transforming O
activity O
. O

Loss O
of O
pRb B
or O
p107 B
binding O
results O
in O
the O
loss O
of O
transforming O
activity O
. O

Peak O
insulin B
response O
to O
glucose O
infusion O
declined O
from O
Groups O
1 O
to O
3 O
( O
51 O
+ O
/ O
- O
14 O
, O
42 O
. O
4 O
+ O
/ O
- O
31 O
, O
20 O
. O
4 O
+ O
/ O
- O
6 O
. O
8 O
microU O
/ O
ml O
, O
respectively O
) O
with O
Group O
3 O
exhibiting O
a O
significantly O
decreased O
mean O
peak O
level O
compared O
to O
the O
other O
groups O
. O

RESULTS O
: O
Here O
, O
we O
report O
the O
identification O
of O
two O
major O
and O
novel O
Shc B
tyrosine O
phosphorylation O
sites O
, O
Y239 O
and O
Y240 O
. O

Dominant O
- O
negative O
upf1 B
mutations O
were O
isolated O
following O
in O
vitro O
mutagenesis O
of O
a O
plasmid O
containing O
the O
UPF1 B
gene I
. O

Papillomavirus O
type O
16 O
oncogenes O
downregulate O
expression O
of O
interferon B
- O
responsive O
genes O
and O
upregulate O
proliferation O
- O
associated O
and O
NF B
- I
kappaB I
- O
responsive O
genes O
in O
cervical O
keratinocytes O
. O

The O
human B
CA11 I
gene I
appears O
to O
be O
located O
between O
the O
secretor B
type I
alpha I
( I
1 I
, I
2 I
) I
- I
fucosyltransferase I
gene I
cluster I
( O
FUT1 B
- O
FUT2 B
- O
FUT2P B
) O
and O
the O
D B
- I
site I
binding I
protein I
gene I
( O
DBP B
) O
on O
chromosome O
19q13 O
. O
3 O
. O

The O
human B
CA11 I
gene I
appears O
to O
be O
located O
between O
the O
secretor B
type I
alpha I
( I
1 I
, I
2 I
) I
- I
fucosyltransferase I
gene I
cluster I
( O
FUT1 B
- O
FUT2 B
- O
FUT2P B
) O
and O
the O
D B
- I
site I
binding I
protein I
gene I
( O
DBP B
) O
on O
chromosome O
19q13 O
. O
3 O
. O

The O
human B
CA11 I
gene I
appears O
to O
be O
located O
between O
the O
secretor B
type I
alpha I
( I
1 I
, I
2 I
) I
- I
fucosyltransferase I
gene I
cluster I
( O
FUT1 B
- O
FUT2 B
- O
FUT2P B
) O
and O
the O
D B
- I
site I
binding I
protein I
gene I
( O
DBP B
) O
on O
chromosome O
19q13 O
. O
3 O
. O

The O
human B
CA11 I
gene I
appears O
to O
be O
located O
between O
the O
secretor B
type I
alpha I
( I
1 I
, I
2 I
) I
- I
fucosyltransferase I
gene I
cluster I
( O
FUT1 B
- O
FUT2 B
- O
FUT2P B
) O
and O
the O
D B
- I
site I
binding I
protein I
gene I
( O
DBP B
) O
on O
chromosome O
19q13 O
. O
3 O
. O

The O
fusion O
of O
AML1 B
to O
MDS1 B
is O
in O
frame O
, O
and O
adds O
127 O
codons O
to O
the O
interrupted O
AML1 B
. O

The O
fusion O
of O
AML1 B
to O
MDS1 B
is O
in O
frame O
, O
and O
adds O
127 O
codons O
to O
the O
interrupted O
AML1 B
. O

The O
fusion O
of O
AML1 B
to O
MDS1 B
is O
in O
frame O
, O
and O
adds O
127 O
codons O
to O
the O
interrupted O
AML1 B
. O

Second O
, O
overexpression O
of O
RIM11 B
can O
suppress O
an O
ime1 B
missense O
mutation O
( O
ime1 B
- I
L321F I
) O
but O
not O
an O
ime1 B
deletion O
. O

Second O
, O
overexpression O
of O
RIM11 B
can O
suppress O
an O
ime1 B
missense O
mutation O
( O
ime1 B
- I
L321F I
) O
but O
not O
an O
ime1 B
deletion O
. O

Second O
, O
overexpression O
of O
RIM11 B
can O
suppress O
an O
ime1 B
missense O
mutation O
( O
ime1 B
- I
L321F I
) O
but O
not O
an O
ime1 B
deletion O
. O

This O
50 O
- O
kDa O
protein O
contains O
two O
SH2 B
domains I
and O
an O
inter B
- I
SH2 I
domain I
of O
p85alpha B
, O
but O
the O
SH3 B
and O
bcr B
homology I
domains I
of O
p85alpha B
were O
replaced O
by O
a O
unique O
6 O
- O
amino O
acid O
sequence O
. O

This O
50 O
- O
kDa O
protein O
contains O
two O
SH2 B
domains I
and O
an O
inter B
- I
SH2 I
domain I
of O
p85alpha B
, O
but O
the O
SH3 B
and O
bcr B
homology I
domains I
of O
p85alpha B
were O
replaced O
by O
a O
unique O
6 O
- O
amino O
acid O
sequence O
. O

This O
50 O
- O
kDa O
protein O
contains O
two O
SH2 B
domains I
and O
an O
inter B
- I
SH2 I
domain I
of O
p85alpha B
, O
but O
the O
SH3 B
and O
bcr B
homology I
domains I
of O
p85alpha B
were O
replaced O
by O
a O
unique O
6 O
- O
amino O
acid O
sequence O
. O

The O
more O
sustained O
effect O
of O
cyclofenil O
on O
prolactin B
secretion O
with O
a O
reduced O
frequency O
of O
relapse O
, O
and O
the O
lower O
oestradiol O
level O
, O
which O
might O
indicate O
a O
reduced O
risk O
of O
thromboembolism O
, O
suggest O
that O
this O
drug O
has O
some O
advantage O
over O
bromocriptine O
in O
the O
inhibition O
of O
postpartum O
lactation O
. O

In O
the O
present O
study O
, O
we O
report O
the O
entire O
genomic O
structure O
of O
KCNQ1 B
, O
which O
consists O
of O
19 O
exons O
spanning O
400 O
kb O
on O
chromosome O
11p15 O
. O
5 O
. O

Northern O
( O
RNA O
) O
blot O
hybridization O
analysis O
with O
the O
p68c B
- I
ets I
- I
1 I
- O
specific O
sequence O
and O
RNase B
protection O
experiments O
showed O
that O
the O
corresponding O
mRNA O
was O
expressed O
in O
normal O
chicken O
spleen O
and O
not O
in O
normal O
chicken O
thymus O
or O
in O
various O
T O
lymphoid O
cell O
lines O
. O

Kettin B
is O
a O
large O
modular O
protein O
associated O
with O
thin O
filaments O
in O
the O
Z O
- O
disc O
region O
of O
insect O
muscles O
. O

However O
, O
microinjection O
of O
reconstituted O
mRNPs O
into O
Xenopus O
oocytes O
demonstrates O
that O
although O
translational O
repression O
occurs O
in O
the O
absence O
of O
consensus O
RNA O
binding O
sequences O
for O
FRGY2 B
, O
the O
presence O
of O
FRGY2 B
recognition I
elements I
within O
mRNA O
potentiates O
translational O
repression O
. O

In O
contrast O
to O
p62 B
( O
dok B
) O
, O
DOKL B
lacks O
YxxP O
motifs O
in O
the O
C O
terminus O
and O
does O
not O
bind O
to O
Ras B
GTPase I
- I
activating I
protein I
( O
RasGAP B
) O
upon O
phosphorylation O
. O

In O
contrast O
to O
p62 B
( O
dok B
) O
, O
DOKL B
lacks O
YxxP O
motifs O
in O
the O
C O
terminus O
and O
does O
not O
bind O
to O
Ras B
GTPase I
- I
activating I
protein I
( O
RasGAP B
) O
upon O
phosphorylation O
. O

In O
contrast O
to O
p62 B
( O
dok B
) O
, O
DOKL B
lacks O
YxxP O
motifs O
in O
the O
C O
terminus O
and O
does O
not O
bind O
to O
Ras B
GTPase I
- I
activating I
protein I
( O
RasGAP B
) O
upon O
phosphorylation O
. O

In O
contrast O
to O
p62 B
( O
dok B
) O
, O
DOKL B
lacks O
YxxP O
motifs O
in O
the O
C O
terminus O
and O
does O
not O
bind O
to O
Ras B
GTPase I
- I
activating I
protein I
( O
RasGAP B
) O
upon O
phosphorylation O
. O

These O
observations O
demonstrate O
that O
KSR B
is O
capable O
of O
uncoupling O
the O
MAP B
kinase I
activation O
from O
its O
target O
phosphorylation O
, O
and O
thus O
provide O
a O
novel O
mechanism O
for O
modulating O
the O
Ras B
- O
MAP B
kinase I
signaling O
pathway O
. O

These O
observations O
demonstrate O
that O
KSR B
is O
capable O
of O
uncoupling O
the O
MAP B
kinase I
activation O
from O
its O
target O
phosphorylation O
, O
and O
thus O
provide O
a O
novel O
mechanism O
for O
modulating O
the O
Ras B
- O
MAP B
kinase I
signaling O
pathway O
. O

A O
higher O
percentage O
of O
children O
with O
cerebral O
malaria O
( O
40 O
per O
cent O
) O
than O
with O
non O
- O
cerebral O
malaria O
( O
29 O
per O
cent O
) O
or O
controls O
( O
20 O
per O
cent O
) O
also O
had O
either O
serum B
ferritin I
< O
100 O
micrograms O
/ O
l O
and O
inflammation O
or O
sTfR B
> O
7 O
. O
3 O
mg O
/ O
l O
or O
both O
. O

UV O
cross O
- O
linking O
and O
Southwestern O
analysis O
suggested O
that O
KTP1 B
is O
a O
DNA O
- O
binding O
protein O
clearly O
distinct O
from O
AP2 B
, O
and O
this O
protein O
may O
be O
responsible O
for O
the O
basal O
keratinocyte O
- O
specific O
expression O
of O
the O
BPAG1 B
gene I
. O

UV O
cross O
- O
linking O
and O
Southwestern O
analysis O
suggested O
that O
KTP1 B
is O
a O
DNA O
- O
binding O
protein O
clearly O
distinct O
from O
AP2 B
, O
and O
this O
protein O
may O
be O
responsible O
for O
the O
basal O
keratinocyte O
- O
specific O
expression O
of O
the O
BPAG1 B
gene I
. O

The O
model O
of O
the O
complex O
provides O
a O
rationale O
for O
conserved O
ITAM B
residues O
, O
substrate O
specificity O
, O
and O
suggests O
that O
substrate O
binds O
only O
the O
active O
conformation O
of O
the O
Src B
family I
tyrosine I
kinase I
, O
unlike O
the O
ATP O
cofactor O
, O
which O
can O
bind O
the O
inactive O
form O
. O

Here O
we O
demonstrate O
that O
a O
region O
of O
high O
homology O
between O
the O
members O
of O
this O
class O
of O
proteins O
contains O
a O
type O
A O
nucleotide O
binding O
site O
consensus O
sequence O
which O
has O
ATPase B
activity O
and O
is O
sufficient O
to O
bind O
DNA O
containing O
specific O
mismatched O
residues O
. O

S O
- O
phase O
- O
promoting O
cyclin B
- I
dependent I
kinases I
( O
Cdks B
) O
and O
the O
kinase O
Dbf4 B
- O
Cdc7 B
then O
act O
to O
initiate O
replication O
. O

S O
- O
phase O
- O
promoting O
cyclin B
- I
dependent I
kinases I
( O
Cdks B
) O
and O
the O
kinase O
Dbf4 B
- O
Cdc7 B
then O
act O
to O
initiate O
replication O
. O

S O
- O
phase O
- O
promoting O
cyclin B
- I
dependent I
kinases I
( O
Cdks B
) O
and O
the O
kinase O
Dbf4 B
- O
Cdc7 B
then O
act O
to O
initiate O
replication O
. O

Purified O
fER B
exhibited O
a O
distribution O
constant O
( O
KD O
) O
for O
17 O
beta O
- O
estradiol O
of O
0 O
. O
45 O
nM O
. O

The O
peptides O
are O
generated O
in O
the O
cytosol O
, O
then O
translocated O
across O
the O
membrane O
of O
the O
endoplasmic O
reticulum O
by O
the O
transporter B
associated I
with I
antigen I
processing I
( O
TAP B
) O
. O

Injection O
of O
horseradish B
peroxidase I
( O
HRP B
) O
into O
the O
cerebellar O
flocculus O
of O
the O
rat O
was O
employed O
to O
identify O
neurons O
in O
the O
abducens O
nucleus O
that O
project O
to O
the O
flocculus O
. O

Our O
previous O
studies O
demonstrated O
that O
the O
promyelocytic O
leukemia O
gene O
, O
PML B
which O
involved O
in O
the O
15 O
; O
17 O
translocation O
in O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
is O
a O
growth O
and O
transformation O
suppressor O
. O

In O
the O
yeast O
two O
- O
hybrid O
assays O
, O
PNRC B
interacted O
with O
the O
orphan O
receptors O
SF1 B
and O
ERRalpha1 B
in O
a O
ligand O
- O
independent O
manner O
. O

In O
the O
yeast O
two O
- O
hybrid O
assays O
, O
PNRC B
interacted O
with O
the O
orphan O
receptors O
SF1 B
and O
ERRalpha1 B
in O
a O
ligand O
- O
independent O
manner O
. O

In O
the O
yeast O
two O
- O
hybrid O
assays O
, O
PNRC B
interacted O
with O
the O
orphan O
receptors O
SF1 B
and O
ERRalpha1 B
in O
a O
ligand O
- O
independent O
manner O
. O

Nuclear O
export O
of O
proteins O
in O
plants O
: O
AtXPO1 B
is O
the O
export O
receptor O
for O
leucine O
- O
rich O
nuclear O
export O
signals O
in O
Arabidopsis O
thaliana O
. O

Thus O
, O
CR2 B
possesses O
an O
essential O
function O
besides O
pRb B
- O
binding O
. O

Thus O
, O
CR2 B
possesses O
an O
essential O
function O
besides O
pRb B
- O
binding O
. O

K562 O
erythroleukemia O
cells O
stably O
transfected O
with O
constructs O
containing O
the O
human B
Agamma I
- I
globin I
promoter I
linked O
to O
an O
enhanced B
green I
fluorescent I
protein I
( O
EGFP B
) O
reporter O
, O
with O
or O
without O
HS2 O
, O
were O
analyzed O
for O
EGFP B
expression O
by O
flow O
cytometry O
. O

K562 O
erythroleukemia O
cells O
stably O
transfected O
with O
constructs O
containing O
the O
human B
Agamma I
- I
globin I
promoter I
linked O
to O
an O
enhanced B
green I
fluorescent I
protein I
( O
EGFP B
) O
reporter O
, O
with O
or O
without O
HS2 O
, O
were O
analyzed O
for O
EGFP B
expression O
by O
flow O
cytometry O
. O

Gastrin B
stimulates O
transcription O
of O
the O
human B
histidine I
decarboxylase I
( O
HDC B
) O
gene O
through O
binding O
to O
the O
G B
- I
protein I
- O
coupled O
cholecystokinin B
- I
B I
/ O
gastrin B
receptor I
. O

Gastrin B
stimulates O
transcription O
of O
the O
human B
histidine I
decarboxylase I
( O
HDC B
) O
gene O
through O
binding O
to O
the O
G B
- I
protein I
- O
coupled O
cholecystokinin B
- I
B I
/ O
gastrin B
receptor I
. O

Here O
, O
we O
report O
the O
isolation O
of O
a O
new O
spindle O
checkpoint O
gene O
, O
mph1 B
( O
Mps1p B
- I
like I
pombe I
homolog I
) O
, O
in O
the O
fission O
yeast O
Schizosaccharomyces O
pombe O
, O
that O
is O
required O
for O
checkpoint O
activation O
in O
response O
to O
spindle O
defects O
. O

mph1 B
functions O
upstream O
of O
mad2 B
, O
a O
previously O
characterized O
component O
of O
the O
spindle O
checkpoint O
. O

mph1 B
functions O
upstream O
of O
mad2 B
, O
a O
previously O
characterized O
component O
of O
the O
spindle O
checkpoint O
. O

Hepatocyte B
growth I
factor I
( O
HGF B
) O
is O
an O
inducible O
cytokine O
that O
is O
essential O
for O
the O
normal O
growth O
and O
development O
of O
various O
tissues O
, O
such O
as O
the O
liver O
. O

Reduced O
concentrations O
of O
antithrombin B
III I
, O
plasminogen B
, O
( O
free O
) O
protein B
S I
, O
and O
protein B
C I
were O
found O
in O
some O
patients O
but O
were O
not O
associated O
with O
either O
thrombosis O
or O
lupus O
anticoagulant O
. O

Structure O
and O
chromosomal O
localization O
of O
the O
human O
gene O
of O
the O
phosphotyrosyl B
phosphatase I
activator I
( O
PTPA B
) O
of O
protein B
phosphatase I
2A I
. O

The O
unusual O
properties O
of O
TRAC B
activity O
and O
its O
relationship O
, O
if O
any O
, O
with O
the O
enigmatic O
Ku B
protein I
, O
are O
discussed O
. O

We O
have O
isolated O
and O
determined O
the O
complete O
nucleotide O
sequence O
of O
another O
operon O
, O
cpeCD B
, O
that O
encodes O
the O
linker O
proteins O
associated O
with O
phycoerythrin B
hexamers I
in O
the O
phycobilisome B
. O

We O
have O
isolated O
and O
determined O
the O
complete O
nucleotide O
sequence O
of O
another O
operon O
, O
cpeCD B
, O
that O
encodes O
the O
linker O
proteins O
associated O
with O
phycoerythrin B
hexamers I
in O
the O
phycobilisome B
. O

When O
expressed O
in O
thymidine B
kinase I
- O
deficient O
L O
cells O
or O
3T3 O
cells O
, O
C B
/ I
EBPalpha I
is O
detected O
in O
a O
protein O
complex O
which O
binds O
to O
the O
E2F B
binding I
sites I
found O
in O
the O
promoters O
of O
the O
genes O
for O
E2F B
- I
1 I
and O
dihydrofolate B
reductase I
( O
DHFR B
) O
. O

Members O
of O
the O
CRE B
- I
binding I
protein I
( O
CREB B
) O
/ O
activating B
transcription I
factor I
transcription O
family O
as O
well O
as O
members O
of O
the O
Jun B
/ O
Fos B
family O
have O
been O
shown O
to O
bind O
to O
this O
sequence O
. O

Members O
of O
the O
CRE B
- I
binding I
protein I
( O
CREB B
) O
/ O
activating B
transcription I
factor I
transcription O
family O
as O
well O
as O
members O
of O
the O
Jun B
/ O
Fos B
family O
have O
been O
shown O
to O
bind O
to O
this O
sequence O
. O

Members O
of O
the O
CRE B
- I
binding I
protein I
( O
CREB B
) O
/ O
activating B
transcription I
factor I
transcription O
family O
as O
well O
as O
members O
of O
the O
Jun B
/ O
Fos B
family O
have O
been O
shown O
to O
bind O
to O
this O
sequence O
. O

Csk B
( O
C B
- I
terminal I
Src I
kinase I
) O
is O
a O
protein B
tyrosine I
kinase I
that O
phosphorylates O
Src B
family I
member I
C I
- I
terminal I
tails I
, O
resulting O
in O
downregulation O
of O
Src B
family O
members O
. O

Csk B
( O
C B
- I
terminal I
Src I
kinase I
) O
is O
a O
protein B
tyrosine I
kinase I
that O
phosphorylates O
Src B
family I
member I
C I
- I
terminal I
tails I
, O
resulting O
in O
downregulation O
of O
Src B
family O
members O
. O

In O
the O
present O
study O
we O
have O
used O
Southern O
blot O
analysis O
to O
demonstrate O
that O
TSG6 B
is O
a O
single O
- O
copy O
gene O
in O
the O
human O
and O
murine O
species O
. O

Reaction O
of O
aromatic O
/ O
heterocyclic O
sulfonamides O
possessing O
free O
amino O
, O
imino O
or O
hydrazino O
moieties O
with O
7 O
- O
chloro O
- O
4 O
- O
chloromethylcoumarin O
afforded O
a O
series O
of O
N O
- O
[ O
( O
7 O
- O
chloro O
- O
4 O
- O
coumarinyl O
) O
- O
methyl O
] O
- O
derivatives O
which O
showed O
effective O
inhibition O
of O
three O
carbonic B
anhydrase I
( O
CA B
) O
isozymes O
. O

It O
is O
noteworthy O
that O
under O
more O
physiological O
conditions O
mimicking O
the O
cellular O
GDP O
/ O
GTP O
ratio O
, O
Raf B
enhances O
the O
GEF B
- O
stimulated O
GDP O
/ O
GTP O
exchange O
on O
Ha B
- I
Ras I
, O
in O
agreement O
with O
the O
sequestration O
of O
Ras B
. I
GTP I
by O
Raf B
. O

It O
is O
noteworthy O
that O
under O
more O
physiological O
conditions O
mimicking O
the O
cellular O
GDP O
/ O
GTP O
ratio O
, O
Raf B
enhances O
the O
GEF B
- O
stimulated O
GDP O
/ O
GTP O
exchange O
on O
Ha B
- I
Ras I
, O
in O
agreement O
with O
the O
sequestration O
of O
Ras B
. I
GTP I
by O
Raf B
. O

It O
is O
noteworthy O
that O
under O
more O
physiological O
conditions O
mimicking O
the O
cellular O
GDP O
/ O
GTP O
ratio O
, O
Raf B
enhances O
the O
GEF B
- O
stimulated O
GDP O
/ O
GTP O
exchange O
on O
Ha B
- I
Ras I
, O
in O
agreement O
with O
the O
sequestration O
of O
Ras B
. I
GTP I
by O
Raf B
. O

Site O
- O
directed O
mutagenesis O
of O
the O
conserved O
cysteine O
residue O
( O
tom1C3235A B
) O
in O
the O
hect B
- I
domain I
, O
supposed O
to O
be O
necessary O
for O
thioester O
- O
bond O
formation O
with O
ubiquitin B
, O
abolished O
the O
gene O
function O
. O

Site O
- O
directed O
mutagenesis O
of O
the O
conserved O
cysteine O
residue O
( O
tom1C3235A B
) O
in O
the O
hect B
- I
domain I
, O
supposed O
to O
be O
necessary O
for O
thioester O
- O
bond O
formation O
with O
ubiquitin B
, O
abolished O
the O
gene O
function O
. O

Moreover O
, O
the O
formation O
of O
the O
complex O
between O
IclR B
and O
the O
operator O
/ O
promoter O
region O
has O
been O
found O
to O
be O
impaired O
by O
phosphoenol O
pyruvate O
but O
insensitive O
to O
acetate O
, O
acetyl O
- O
CoA O
, O
pyruvate O
, O
and O
oxaloacetate O
. O

In O
this O
report O
, O
we O
establish O
that O
the O
heteromeric O
CCAAT B
- I
binding I
factor I
CBF B
is O
the O
major O
component O
of O
the O
C1 B
- I
binding I
factor I
( O
C1F B
) O
in O
human O
cells O
. O

In O
this O
report O
, O
we O
establish O
that O
the O
heteromeric O
CCAAT B
- I
binding I
factor I
CBF B
is O
the O
major O
component O
of O
the O
C1 B
- I
binding I
factor I
( O
C1F B
) O
in O
human O
cells O
. O

A O
40 O
- O
fold O
stimulation O
of O
chloramphenicol B
acetyltransferase I
activity O
mediated O
by O
four O
tandem O
repeats O
of O
the O
SNE B
could O
be O
induced O
within O
2 O
h O
( O
and O
up O
to O
250 O
- O
fold O
within O
6 O
h O
) O
after O
addition O
of O
TPA O
in O
DNA O
- O
transfected O
U O
- O
937 O
cells O
, O
indicating O
that O
the O
stimulation O
appeared O
likely O
to O
be O
a O
true O
protein B
kinase I
C I
- O
mediated O
signal O
transduction O
event O
rather O
than O
a O
differentiation O
response O
. O

Disorganization O
scores O
of O
the O
hypertrophy O
zone O
and O
trabecular O
bone O
were O
low O
, O
approaching O
normal O
( O
P O
< O
0 O
. O
05 O
) O
, O
for O
turkey O
poults O
fed O
on O
diets O
with O
phytase B
supplementation O
, O
and O
tibial O
abnormality O
scores O
were O
linearly O
decreased O
( O
P O
< O
0 O
. O
001 O
) O
as O
nP O
levels O
increased O
( O
zero O
score O
is O
considered O
normal O
) O
. O

Repression O
was O
strictly O
dependent O
on O
the O
presence O
of O
upstream O
Oshox1 B
binding O
sites O
in O
the O
reporter O
gene O
constructs O
and O
a O
function O
of O
the O
N O
- O
terminal O
region O
of O
Oshox1 B
, O
preceding O
the O
homeodomain B
. O

Repression O
was O
strictly O
dependent O
on O
the O
presence O
of O
upstream O
Oshox1 B
binding O
sites O
in O
the O
reporter O
gene O
constructs O
and O
a O
function O
of O
the O
N O
- O
terminal O
region O
of O
Oshox1 B
, O
preceding O
the O
homeodomain B
. O

Repression O
was O
strictly O
dependent O
on O
the O
presence O
of O
upstream O
Oshox1 B
binding O
sites O
in O
the O
reporter O
gene O
constructs O
and O
a O
function O
of O
the O
N O
- O
terminal O
region O
of O
Oshox1 B
, O
preceding O
the O
homeodomain B
. O

To O
elucidate O
the O
molecular O
mechanism O
by O
which O
the O
Ras B
signaling O
pathway O
activates O
a O
cell O
- O
type O
- O
specific O
gene O
, O
we O
have O
used O
the O
pituitary B
- I
specific I
rat I
prolactin I
( O
rPRL B
) O
promoter O
as O
a O
target O
of O
oncogenic B
Ras I
and O
Raf B
in O
GH4 O
rat O
pituitary O
cells O
. O

To O
elucidate O
the O
molecular O
mechanism O
by O
which O
the O
Ras B
signaling O
pathway O
activates O
a O
cell O
- O
type O
- O
specific O
gene O
, O
we O
have O
used O
the O
pituitary B
- I
specific I
rat I
prolactin I
( O
rPRL B
) O
promoter O
as O
a O
target O
of O
oncogenic B
Ras I
and O
Raf B
in O
GH4 O
rat O
pituitary O
cells O
. O

To O
elucidate O
the O
molecular O
mechanism O
by O
which O
the O
Ras B
signaling O
pathway O
activates O
a O
cell O
- O
type O
- O
specific O
gene O
, O
we O
have O
used O
the O
pituitary B
- I
specific I
rat I
prolactin I
( O
rPRL B
) O
promoter O
as O
a O
target O
of O
oncogenic B
Ras I
and O
Raf B
in O
GH4 O
rat O
pituitary O
cells O
. O

HGF B
treatment O
increased O
cyclin B
A I
, O
cyclin B
G1 I
and O
nuclear O
transcriptional O
factor O
( O
NFkappaB B
) O
protein O
expression O
. O

HGF B
treatment O
increased O
cyclin B
A I
, O
cyclin B
G1 I
and O
nuclear O
transcriptional O
factor O
( O
NFkappaB B
) O
protein O
expression O
. O

Despite O
these O
high O
initial O
rates O
of O
transcription O
, O
of O
all O
the O
promoter O
constructs O
only O
LAT B
- O
LTR O
was O
able O
to O
remain O
transcriptionally O
active O
after O
the O
establishment O
of O
a O
latent O
state O
. O

Effects O
of O
timepidium O
bromide O
( O
TB O
; O
anticholinergic O
agent O
) O
, O
acetylcholine O
( O
ACh O
) O
and O
neostigmine O
( O
Neost O
) O
on O
gastric O
and O
duodenal O
blood O
flow O
distribution O
were O
studied O
by O
the O
use O
of O
131I O
- O
labeled O
macroaggregated O
human O
serum O
albumin O
( O
MAA B
) O
in O
rabbits O
. O

The O
Valpha B
and O
Vbeta B
domains I
have O
the O
canonical O
features O
of O
known O
teleost B
and I
mammalian I
TCR I
V I
domains I
, O
including O
conserved O
residues O
in O
the O
beginning O
of O
FR2 B
and O
at O
the O
end O
of O
FR3 B
. O

The O
Valpha B
and O
Vbeta B
domains I
have O
the O
canonical O
features O
of O
known O
teleost B
and I
mammalian I
TCR I
V I
domains I
, O
including O
conserved O
residues O
in O
the O
beginning O
of O
FR2 B
and O
at O
the O
end O
of O
FR3 B
. O

The O
Valpha B
and O
Vbeta B
domains I
have O
the O
canonical O
features O
of O
known O
teleost B
and I
mammalian I
TCR I
V I
domains I
, O
including O
conserved O
residues O
in O
the O
beginning O
of O
FR2 B
and O
at O
the O
end O
of O
FR3 B
. O

In O
this O
report O
, O
we O
demonstrate O
that O
FRS2 B
forms O
a O
complex O
with O
the O
N B
- I
terminal I
SH2 I
domain I
of O
the O
protein B
tyrosine I
phosphatase I
Shp2 I
in O
response O
to O
FGF B
stimulation O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
FRS2 B
forms O
a O
complex O
with O
the O
N B
- I
terminal I
SH2 I
domain I
of O
the O
protein B
tyrosine I
phosphatase I
Shp2 I
in O
response O
to O
FGF B
stimulation O
. O

The O
H5 B
mutants I
were O
: O
DH5 B
( O
all O
amino O
acids O
in O
D O
configuration O
) O
and O
H5F B
( O
where O
all O
His O
are O
replaced O
by O
Phe O
at O
positions O
3 O
, O
7 O
, O
8 O
, O
15 O
, O
18 O
, O
19 O
, O
21 O
) O
. O

The O
H5 B
mutants I
were O
: O
DH5 B
( O
all O
amino O
acids O
in O
D O
configuration O
) O
and O
H5F B
( O
where O
all O
His O
are O
replaced O
by O
Phe O
at O
positions O
3 O
, O
7 O
, O
8 O
, O
15 O
, O
18 O
, O
19 O
, O
21 O
) O
. O

These O
results O
establish O
that O
the O
DNA O
fragment O
we O
have O
isolated O
contains O
the O
human B
gp130 I
promoter I
and O
that O
interleukin B
- I
6 I
type I
cytokines I
may O
influence O
the O
activity O
of O
this O
promoter O
via O
activated O
STATs B
. O

When O
targeted O
to O
the O
GAL1 B
promoter I
by O
fusing O
with O
the O
Gal4p B
DNA I
- I
binding I
domain I
, O
Sko1p B
acts O
as O
an O
Ssn6 B
/ O
Tup1p B
- O
dependent O
repressor O
regulated O
by O
osmotic O
stress O
. O

When O
targeted O
to O
the O
GAL1 B
promoter I
by O
fusing O
with O
the O
Gal4p B
DNA I
- I
binding I
domain I
, O
Sko1p B
acts O
as O
an O
Ssn6 B
/ O
Tup1p B
- O
dependent O
repressor O
regulated O
by O
osmotic O
stress O
. O

When O
targeted O
to O
the O
GAL1 B
promoter I
by O
fusing O
with O
the O
Gal4p B
DNA I
- I
binding I
domain I
, O
Sko1p B
acts O
as O
an O
Ssn6 B
/ O
Tup1p B
- O
dependent O
repressor O
regulated O
by O
osmotic O
stress O
. O

Growth O
factors O
promote O
cell O
survival O
through O
phosphorylation O
of O
Bad B
, O
resulting O
in O
its O
dissociation O
from O
Bcl B
- I
2 I
and O
Bcl B
- I
x I
( I
L I
) I
and O
its O
association O
with O
14 B
- I
3 I
- I
3tau I
. O

Only O
the O
native O
structure O
of O
phosphorylated O
ERK B
was O
recognized O
by O
VHR B
and O
was O
inactivated O
with O
a O
second O
- O
order O
rate O
constant O
of O
40 O
, O
000 O
M O
- O
1 O
s O
- O
1 O
. O

Only O
the O
native O
structure O
of O
phosphorylated O
ERK B
was O
recognized O
by O
VHR B
and O
was O
inactivated O
with O
a O
second O
- O
order O
rate O
constant O
of O
40 O
, O
000 O
M O
- O
1 O
s O
- O
1 O
. O

We O
used O
an O
immobilized O
template O
- O
based O
assay O
to O
examine O
transcription O
termination O
by O
VA1 B
, O
7SL B
, O
and O
Alu B
class I
III I
templates O
and O
the O
role O
of O
transcript O
release O
in O
the O
pol B
III I
terminator O
- O
dependent O
inhibition O
of O
processing O
of O
B1 B
- O
Alu B
transcripts O
. O

We O
used O
an O
immobilized O
template O
- O
based O
assay O
to O
examine O
transcription O
termination O
by O
VA1 B
, O
7SL B
, O
and O
Alu B
class I
III I
templates O
and O
the O
role O
of O
transcript O
release O
in O
the O
pol B
III I
terminator O
- O
dependent O
inhibition O
of O
processing O
of O
B1 B
- O
Alu B
transcripts O
. O

We O
used O
an O
immobilized O
template O
- O
based O
assay O
to O
examine O
transcription O
termination O
by O
VA1 B
, O
7SL B
, O
and O
Alu B
class I
III I
templates O
and O
the O
role O
of O
transcript O
release O
in O
the O
pol B
III I
terminator O
- O
dependent O
inhibition O
of O
processing O
of O
B1 B
- O
Alu B
transcripts O
. O

We O
used O
an O
immobilized O
template O
- O
based O
assay O
to O
examine O
transcription O
termination O
by O
VA1 B
, O
7SL B
, O
and O
Alu B
class I
III I
templates O
and O
the O
role O
of O
transcript O
release O
in O
the O
pol B
III I
terminator O
- O
dependent O
inhibition O
of O
processing O
of O
B1 B
- O
Alu B
transcripts O
. O

Although O
IL B
- I
6 I
can O
activate O
ERK B
- I
1 I
in O
HepG2 O
cells O
, O
STAT3 B
transactivation O
and O
Ser O
( O
727 O
) O
phosphorylation O
were O
not O
reduced O
by O
using O
the O
MAP B
kinase I
/ O
ERK B
kinase I
( O
MEK B
) O
inhibitor O
PD98059 O
or O
by O
overexpression O
of O
dominant O
- O
negative O
Raf B
. O

Although O
IL B
- I
6 I
can O
activate O
ERK B
- I
1 I
in O
HepG2 O
cells O
, O
STAT3 B
transactivation O
and O
Ser O
( O
727 O
) O
phosphorylation O
were O
not O
reduced O
by O
using O
the O
MAP B
kinase I
/ O
ERK B
kinase I
( O
MEK B
) O
inhibitor O
PD98059 O
or O
by O
overexpression O
of O
dominant O
- O
negative O
Raf B
. O

Although O
IL B
- I
6 I
can O
activate O
ERK B
- I
1 I
in O
HepG2 O
cells O
, O
STAT3 B
transactivation O
and O
Ser O
( O
727 O
) O
phosphorylation O
were O
not O
reduced O
by O
using O
the O
MAP B
kinase I
/ O
ERK B
kinase I
( O
MEK B
) O
inhibitor O
PD98059 O
or O
by O
overexpression O
of O
dominant O
- O
negative O
Raf B
. O

Functional O
uncoupling O
of O
the O
Janus B
kinase I
3 I
- O
Stat5 B
pathway O
in O
malignant O
growth O
of O
human O
T O
cell O
leukemia O
virus O
type O
1 O
- O
transformed O
human O
T O
cells O
. O

The O
herpesvirus B
entry I
mediator I
C I
( O
HveC B
) O
, O
previously O
known O
as O
poliovirus B
receptor I
- I
related I
protein I
1 I
( O
PRR1 B
) O
, O
and O
the O
herpesvirus B
Ig I
- I
like I
receptor I
( O
HIgR B
) O
are O
the O
bona O
fide O
receptors O
employed O
by O
herpes O
simplex O
virus O
- O
1 O
and O
- O
2 O
( O
HSV O
- O
1 O
and O
- O
2 O
) O
for O
entry O
into O
the O
human O
cell O
lines O
most O
frequently O
used O
in O
HSV O
studies O
. O

The O
herpesvirus B
entry I
mediator I
C I
( O
HveC B
) O
, O
previously O
known O
as O
poliovirus B
receptor I
- I
related I
protein I
1 I
( O
PRR1 B
) O
, O
and O
the O
herpesvirus B
Ig I
- I
like I
receptor I
( O
HIgR B
) O
are O
the O
bona O
fide O
receptors O
employed O
by O
herpes O
simplex O
virus O
- O
1 O
and O
- O
2 O
( O
HSV O
- O
1 O
and O
- O
2 O
) O
for O
entry O
into O
the O
human O
cell O
lines O
most O
frequently O
used O
in O
HSV O
studies O
. O

The O
herpesvirus B
entry I
mediator I
C I
( O
HveC B
) O
, O
previously O
known O
as O
poliovirus B
receptor I
- I
related I
protein I
1 I
( O
PRR1 B
) O
, O
and O
the O
herpesvirus B
Ig I
- I
like I
receptor I
( O
HIgR B
) O
are O
the O
bona O
fide O
receptors O
employed O
by O
herpes O
simplex O
virus O
- O
1 O
and O
- O
2 O
( O
HSV O
- O
1 O
and O
- O
2 O
) O
for O
entry O
into O
the O
human O
cell O
lines O
most O
frequently O
used O
in O
HSV O
studies O
. O

4 O
- O
Hydroxyproline O
assays O
were O
performed O
to O
determine O
collagen B
content O
. O

The O
combination O
of O
ICP47 B
and O
US11 B
rendered O
fibroblasts O
negative O
for O
surface B
class I
I I
MHC I
and O
allowed O
a O
class B
I I
MHC I
- O
low O
population O
of O
T O
cells O
to O
be O
sorted O
by O
flow O
cytometry O
. O

The O
combination O
of O
ICP47 B
and O
US11 B
rendered O
fibroblasts O
negative O
for O
surface B
class I
I I
MHC I
and O
allowed O
a O
class B
I I
MHC I
- O
low O
population O
of O
T O
cells O
to O
be O
sorted O
by O
flow O
cytometry O
. O

In O
addition O
, O
we O
mapped O
a O
putative O
hnRNP B
A1 I
binding I
site I
in O
U5 B
RNA I
and O
demonstrated O
that O
p40CRS B
( O
hnRNP B
A1 I
) O
binding O
to O
that O
site O
correlates O
with O
CRS B
function O
. O

In O
addition O
, O
we O
mapped O
a O
putative O
hnRNP B
A1 I
binding I
site I
in O
U5 B
RNA I
and O
demonstrated O
that O
p40CRS B
( O
hnRNP B
A1 I
) O
binding O
to O
that O
site O
correlates O
with O
CRS B
function O
. O

In O
HepG2 O
cells O
, O
SREBP B
- I
1c I
mRNA I
and O
precursor O
protein O
levels O
were O
induced O
by O
treatment O
with O
22 O
( O
R O
) O
- O
hydroxycholesterol O
and O
9 O
- O
cis O
- O
retinoic O
acid O
, O
confirming O
that O
endogenous O
LXR B
- O
RXR B
activation O
can O
induce O
endogenous B
SREBP I
- I
1c I
expression O
. O

In O
HepG2 O
cells O
, O
SREBP B
- I
1c I
mRNA I
and O
precursor O
protein O
levels O
were O
induced O
by O
treatment O
with O
22 O
( O
R O
) O
- O
hydroxycholesterol O
and O
9 O
- O
cis O
- O
retinoic O
acid O
, O
confirming O
that O
endogenous O
LXR B
- O
RXR B
activation O
can O
induce O
endogenous B
SREBP I
- I
1c I
expression O
. O

Four O
of O
15 O
patients O
with O
R2 B
had O
rheumatoid O
arthritis O
and O
in O
two O
of O
these O
four O
cases O
the O
antibody O
was O
of O
the O
IgA B
class O
. O

Four O
of O
15 O
patients O
with O
R2 B
had O
rheumatoid O
arthritis O
and O
in O
two O
of O
these O
four O
cases O
the O
antibody O
was O
of O
the O
IgA B
class O
. O

Vav B
and O
Dbl B
are O
members O
of O
a O
novel O
class O
of O
oncogene O
proteins O
that O
share O
significant O
sequence O
identity O
in O
a O
approximately O
250 O
- O
amino O
- O
acid O
domain O
, O
designated O
the O
Dbl B
homology I
domain I
. O

Vav B
and O
Dbl B
are O
members O
of O
a O
novel O
class O
of O
oncogene O
proteins O
that O
share O
significant O
sequence O
identity O
in O
a O
approximately O
250 O
- O
amino O
- O
acid O
domain O
, O
designated O
the O
Dbl B
homology I
domain I
. O

Serum O
AFP B
is O
a O
useful O
tumor O
marker O
for O
monitoring O
the O
results O
of O
therapy O
. O

Unlike O
LANA1 B
, O
LANA2 B
does O
not O
elicit O
a O
serologic O
response O
from O
patients O
with O
KS O
, O
PEL O
, O
or O
CD O
as O
measured O
by O
Western O
blot O
hybridization O
. O

Unlike O
LANA1 B
, O
LANA2 B
does O
not O
elicit O
a O
serologic O
response O
from O
patients O
with O
KS O
, O
PEL O
, O
or O
CD O
as O
measured O
by O
Western O
blot O
hybridization O
. O

The O
deduced O
amino O
acid O
sequence O
of O
PutR B
( O
154 O
amino O
acid O
residues O
) O
showed O
homology O
to O
the O
small O
regulatory O
proteins O
Lrp B
, O
BkdR B
, O
and O
AsnC B
. O

The O
deduced O
amino O
acid O
sequence O
of O
PutR B
( O
154 O
amino O
acid O
residues O
) O
showed O
homology O
to O
the O
small O
regulatory O
proteins O
Lrp B
, O
BkdR B
, O
and O
AsnC B
. O

The O
deduced O
amino O
acid O
sequence O
of O
PutR B
( O
154 O
amino O
acid O
residues O
) O
showed O
homology O
to O
the O
small O
regulatory O
proteins O
Lrp B
, O
BkdR B
, O
and O
AsnC B
. O

The O
deduced O
amino O
acid O
sequence O
of O
PutR B
( O
154 O
amino O
acid O
residues O
) O
showed O
homology O
to O
the O
small O
regulatory O
proteins O
Lrp B
, O
BkdR B
, O
and O
AsnC B
. O

When O
yeast O
cells O
reach O
a O
critical O
size O
in O
late O
G1 O
they O
simultaneously O
start O
budding O
, O
initiate O
DNA O
synthesis O
, O
and O
activate O
transcription O
of O
a O
set O
of O
genes O
that O
includes O
G1 B
cyclins I
CLN1 B
, O
CLN2 B
, O
and O
many O
DNA O
synthesis O
genes O
. O

When O
yeast O
cells O
reach O
a O
critical O
size O
in O
late O
G1 O
they O
simultaneously O
start O
budding O
, O
initiate O
DNA O
synthesis O
, O
and O
activate O
transcription O
of O
a O
set O
of O
genes O
that O
includes O
G1 B
cyclins I
CLN1 B
, O
CLN2 B
, O
and O
many O
DNA O
synthesis O
genes O
. O

Accordingly O
, O
superpeptide O
antigenic O
material O
was O
readily O
detected O
by O
immunoblotting O
cell O
extracts O
and O
enriched O
in O
vacuolar O
preparations O
of O
PrA B
deficient O
mutant O
cells O
. O

Blockade O
of O
T O
cell O
activation O
using O
a O
surface O
- O
linked O
single O
- O
chain O
antibody O
to O
CTLA B
- I
4 I
( O
CD152 B
) O
. O

In O
this O
work O
, O
we O
have O
used O
Xenopus O
oocyte O
maturation O
as O
a O
read O
- O
out O
for O
examining O
the O
ability O
of O
the O
neu B
tyrosine B
kinase I
( O
p185neu B
) O
to O
participate O
with O
the O
epidermal B
growth I
factor I
( I
EGF I
) I
receptor I
in O
a O
common O
signal O
transduction O
pathway O
. O

In O
this O
work O
, O
we O
have O
used O
Xenopus O
oocyte O
maturation O
as O
a O
read O
- O
out O
for O
examining O
the O
ability O
of O
the O
neu B
tyrosine B
kinase I
( O
p185neu B
) O
to O
participate O
with O
the O
epidermal B
growth I
factor I
( I
EGF I
) I
receptor I
in O
a O
common O
signal O
transduction O
pathway O
. O

The O
best O
- O
studied O
neurotrophin O
, O
nerve B
growth I
factor I
( O
NGF B
) O
, O
is O
a O
major O
survival O
factor O
in O
sympathetic O
and O
sensory O
neurons O
and O
promotes O
differentiation O
in O
a O
well O
- O
studied O
model O
system O
, O
PC12 O
cells O
. O

In O
contrast O
, O
MAPK B
activation O
stimulated O
by O
the O
Gq B
- O
coupled O
alpha O
1B O
AR O
or O
M1 B
muscarinic B
cholinergic I
receptor I
is O
unaffected O
by O
expression O
of O
beta B
ARKct I
or O
RasN17 B
expression O
or O
by O
PTK B
inhibitors O
, O
but O
is O
blocked O
by O
expression O
of O
N B
delta I
Raf I
or O
by O
PKC B
depletion O
. O

In O
contrast O
, O
MAPK B
activation O
stimulated O
by O
the O
Gq B
- O
coupled O
alpha O
1B O
AR O
or O
M1 B
muscarinic B
cholinergic I
receptor I
is O
unaffected O
by O
expression O
of O
beta B
ARKct I
or O
RasN17 B
expression O
or O
by O
PTK B
inhibitors O
, O
but O
is O
blocked O
by O
expression O
of O
N B
delta I
Raf I
or O
by O
PKC B
depletion O
. O

In O
contrast O
, O
MAPK B
activation O
stimulated O
by O
the O
Gq B
- O
coupled O
alpha O
1B O
AR O
or O
M1 B
muscarinic B
cholinergic I
receptor I
is O
unaffected O
by O
expression O
of O
beta B
ARKct I
or O
RasN17 B
expression O
or O
by O
PTK B
inhibitors O
, O
but O
is O
blocked O
by O
expression O
of O
N B
delta I
Raf I
or O
by O
PKC B
depletion O
. O

In O
contrast O
, O
MAPK B
activation O
stimulated O
by O
the O
Gq B
- O
coupled O
alpha O
1B O
AR O
or O
M1 B
muscarinic B
cholinergic I
receptor I
is O
unaffected O
by O
expression O
of O
beta B
ARKct I
or O
RasN17 B
expression O
or O
by O
PTK B
inhibitors O
, O
but O
is O
blocked O
by O
expression O
of O
N B
delta I
Raf I
or O
by O
PKC B
depletion O
. O

In O
contrast O
, O
MAPK B
activation O
stimulated O
by O
the O
Gq B
- O
coupled O
alpha O
1B O
AR O
or O
M1 B
muscarinic B
cholinergic I
receptor I
is O
unaffected O
by O
expression O
of O
beta B
ARKct I
or O
RasN17 B
expression O
or O
by O
PTK B
inhibitors O
, O
but O
is O
blocked O
by O
expression O
of O
N B
delta I
Raf I
or O
by O
PKC B
depletion O
. O

In O
contrast O
, O
MAPK B
activation O
stimulated O
by O
the O
Gq B
- O
coupled O
alpha O
1B O
AR O
or O
M1 B
muscarinic B
cholinergic I
receptor I
is O
unaffected O
by O
expression O
of O
beta B
ARKct I
or O
RasN17 B
expression O
or O
by O
PTK B
inhibitors O
, O
but O
is O
blocked O
by O
expression O
of O
N B
delta I
Raf I
or O
by O
PKC B
depletion O
. O

The O
steady O
- O
state O
levels O
of O
Cdk2 B
, O
Cdk4 B
and O
Cyclin B
A I
proteins I
were O
unaffected O
by O
HPR O
, O
while O
those O
of O
Cyclin B
D1 I
were O
significantly O
reduced O
in O
all O
three O
cell O
lines O
. O

The O
steady O
- O
state O
levels O
of O
Cdk2 B
, O
Cdk4 B
and O
Cyclin B
A I
proteins I
were O
unaffected O
by O
HPR O
, O
while O
those O
of O
Cyclin B
D1 I
were O
significantly O
reduced O
in O
all O
three O
cell O
lines O
. O

These O
proteins O
were O
detected O
by O
an O
antibody O
which O
recognizes O
the O
N O
- O
terminus O
of O
SRK3 B
and O
, O
in O
an O
F2 O
progeny O
segregating O
for O
the O
S3 B
haplotype I
, O
were O
only O
expressed O
in O
plants O
possessing O
the O
S3 B
haplotype I
. O

The O
animals O
were O
followed O
over O
a O
1 O
- O
to O
6 O
- O
h O
posttraumatic O
course O
, O
and O
processed O
for O
the O
LM O
and O
TEM O
visualization O
of O
HRP B
. O

Three O
experiments O
using O
20 O
microM O
2 O
- O
( O
hydroxyamino O
) O
- O
1 O
- O
methyl O
- O
6 O
- O
phenylimidazo O
[ O
4 O
, O
5 O
- O
b O
] O
pyridine O
( O
N O
- O
OH O
- O
PhIP O
) O
were O
performed O
to O
induce O
mutations O
in O
the O
dihydrofolate B
reductase I
( O
DHFR B
) O
gene O
of O
a O
hemizygous O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cell O
line O
( O
UA21 O
) O
. O

Our O
results O
separate O
these O
factors O
into O
four O
regulatory O
classes O
: O
( O
i O
) O
constitutive O
factors O
, O
such O
as O
Oct B
- I
1 I
and O
probably O
Sp1 B
, O
that O
are O
expressed O
in O
thymocytes O
at O
all O
stages O
; O
( O
ii O
) O
inducible O
factors O
, O
such O
as O
NF B
- I
kappa I
B I
and O
complexes O
binding O
to O
the O
region O
of O
a O
CD28 B
response I
element I
, O
that O
can O
be O
activated O
in O
all O
thymocytes O
, O
including O
those O
cells O
( O
CD4 B
+ I
CD8 B
+ I
TcRlow B
) O
that O
can O
undergo O
selection O
; O
( O
iii O
) O
inducible O
factors O
, O
such O
as O
NF B
- I
AT I
and O
AP B
- I
1 I
, O
that O
can O
be O
activated O

Our O
results O
separate O
these O
factors O
into O
four O
regulatory O
classes O
: O
( O
i O
) O
constitutive O
factors O
, O
such O
as O
Oct B
- I
1 I
and O
probably O
Sp1 B
, O
that O
are O
expressed O
in O
thymocytes O
at O
all O
stages O
; O
( O
ii O
) O
inducible O
factors O
, O
such O
as O
NF B
- I
kappa I
B I
and O
complexes O
binding O
to O
the O
region O
of O
a O
CD28 B
response I
element I
, O
that O
can O
be O
activated O
in O
all O
thymocytes O
, O
including O
those O
cells O
( O
CD4 B
+ I
CD8 B
+ I
TcRlow B
) O
that O
can O
undergo O
selection O
; O
( O
iii O
) O
inducible O
factors O
, O
such O
as O
NF B
- I
AT I
and O
AP B
- I
1 I
, O
that O
can O
be O
activated O

in O
mature O
( O
CD4 B
+ I
CD8 B
- I
TcRhigh B
) O
and O
immature O
( O
CD4 B
- I
CD8 B
- I
TcR B
- I
) O
thymocytes O
alike O
but O
not O
in O
the O
transitional O
stages O
when O
the O
cells O
( O
CD4 B
+ I
CD8 B
+ I
TcRlow B
) O
are O
subject O
to O
selection O
; O
and O
( O
iv O
) O
a O
factor O
containing O
CREB B
, O
which O
can O
be O
activated O
in O
thymocytes O
of O
all O
developmental O
stages O
by O
culture O
but O
does O
not O
require O
specific O
induction O
. O

in O
mature O
( O
CD4 B
+ I
CD8 B
- I
TcRhigh B
) O
and O
immature O
( O
CD4 B
- I
CD8 B
- I
TcR B
- I
) O
thymocytes O
alike O
but O
not O
in O
the O
transitional O
stages O
when O
the O
cells O
( O
CD4 B
+ I
CD8 B
+ I
TcRlow B
) O
are O
subject O
to O
selection O
; O
and O
( O
iv O
) O
a O
factor O
containing O
CREB B
, O
which O
can O
be O
activated O
in O
thymocytes O
of O
all O
developmental O
stages O
by O
culture O
but O
does O
not O
require O
specific O
induction O
. O

in O
mature O
( O
CD4 B
+ I
CD8 B
- I
TcRhigh B
) O
and O
immature O
( O
CD4 B
- I
CD8 B
- I
TcR B
- I
) O
thymocytes O
alike O
but O
not O
in O
the O
transitional O
stages O
when O
the O
cells O
( O
CD4 B
+ I
CD8 B
+ I
TcRlow B
) O
are O
subject O
to O
selection O
; O
and O
( O
iv O
) O
a O
factor O
containing O
CREB B
, O
which O
can O
be O
activated O
in O
thymocytes O
of O
all O
developmental O
stages O
by O
culture O
but O
does O
not O
require O
specific O
induction O
. O

We O
also O
show O
that O
in O
fusions O
with O
the O
DNA O
binding O
domain O
of O
GAL4 B
, O
full O
activity O
requires O
the O
entire O
BHV B
- I
alpha I
TIF I
, O
although O
both O
amino O
and O
carboxyl O
termini O
display O
some O
activity O
on O
their O
own O
. O

The O
induction O
by O
dexamethasone O
of O
rat B
liver I
CYP3A1 I
differs O
from O
classical O
glucocorticoid O
gene O
regulation O
in O
part O
because O
both O
glucocorticoids O
and O
antiglucocorticoids O
such O
as O
pregnenolone O
16 O
alpha O
- O
carbonitrile O
( O
PCN O
) O
induce O
CYP3A1 B
through O
transcriptional O
gene O
activation O
. O

The O
transcriptional B
transactivator I
( O
Tas B
) O
of O
simian O
foamy O
virus O
type O
1 O
strongly O
augments O
gene O
expression O
directed O
by O
both O
the O
promoter O
in O
the O
viral O
long O
terminal O
repeat O
and O
the O
newly O
discovered O
internal O
promoter O
located O
within O
the O
env B
gene I
. O

We O
have O
generated O
transgenic O
fly O
strains O
with O
mutations O
affecting O
specific O
TRA B
- I
2 I
isoforms I
to O
investigate O
their O
individual O
roles O
in O
regulating O
the O
alternative O
processing O
of O
doublesex B
, O
exuperantia B
and O
tra B
- I
2 I
pre I
- I
mRNA I
. O

We O
have O
generated O
transgenic O
fly O
strains O
with O
mutations O
affecting O
specific O
TRA B
- I
2 I
isoforms I
to O
investigate O
their O
individual O
roles O
in O
regulating O
the O
alternative O
processing O
of O
doublesex B
, O
exuperantia B
and O
tra B
- I
2 I
pre I
- I
mRNA I
. O

The O
IR4 O
ORF O
exhibits O
significant O
homology O
to O
the O
immediate B
- I
early I
gene I
US1 B
( O
ICP22 B
) O
of O
herpes O
simplex O
virus O
type O
1 O
and O
to O
the O
ICP22 B
homologs O
of O
varicella O
- O
zoster O
virus O
( O
ORF63 B
) O
, O
pseudorabies O
virus O
( O
RSp40 B
) O
, O
and O
equine O
herpesvirus O
4 O
( O
ORF4 O
) O
. O

The O
IR4 O
ORF O
exhibits O
significant O
homology O
to O
the O
immediate B
- I
early I
gene I
US1 B
( O
ICP22 B
) O
of O
herpes O
simplex O
virus O
type O
1 O
and O
to O
the O
ICP22 B
homologs O
of O
varicella O
- O
zoster O
virus O
( O
ORF63 B
) O
, O
pseudorabies O
virus O
( O
RSp40 B
) O
, O
and O
equine O
herpesvirus O
4 O
( O
ORF4 O
) O
. O

The O
IR4 O
ORF O
exhibits O
significant O
homology O
to O
the O
immediate B
- I
early I
gene I
US1 B
( O
ICP22 B
) O
of O
herpes O
simplex O
virus O
type O
1 O
and O
to O
the O
ICP22 B
homologs O
of O
varicella O
- O
zoster O
virus O
( O
ORF63 B
) O
, O
pseudorabies O
virus O
( O
RSp40 B
) O
, O
and O
equine O
herpesvirus O
4 O
( O
ORF4 O
) O
. O

The O
IR4 O
ORF O
exhibits O
significant O
homology O
to O
the O
immediate B
- I
early I
gene I
US1 B
( O
ICP22 B
) O
of O
herpes O
simplex O
virus O
type O
1 O
and O
to O
the O
ICP22 B
homologs O
of O
varicella O
- O
zoster O
virus O
( O
ORF63 B
) O
, O
pseudorabies O
virus O
( O
RSp40 B
) O
, O
and O
equine O
herpesvirus O
4 O
( O
ORF4 O
) O
. O

The O
IR4 O
ORF O
exhibits O
significant O
homology O
to O
the O
immediate B
- I
early I
gene I
US1 B
( O
ICP22 B
) O
of O
herpes O
simplex O
virus O
type O
1 O
and O
to O
the O
ICP22 B
homologs O
of O
varicella O
- O
zoster O
virus O
( O
ORF63 B
) O
, O
pseudorabies O
virus O
( O
RSp40 B
) O
, O
and O
equine O
herpesvirus O
4 O
( O
ORF4 O
) O
. O

A O
series O
of O
mutations O
were O
constructed O
within O
the O
E2 B
open O
reading O
frame O
which O
delete O
various O
regions O
of O
the O
conserved O
DNA O
binding O
and O
transactivation O
domains O
as O
well O
as O
the O
internal O
hinge O
region O
. O

CrkII B
and O
CrkL B
constitutively O
formed O
complex O
with O
the O
guanine B
nucleotide I
exchange I
factor I
C3G B
, O
in O
unstimulated O
as O
well O
as O
PDGF B
- O
stimulated O
cells O
. O

CrkII B
and O
CrkL B
constitutively O
formed O
complex O
with O
the O
guanine B
nucleotide I
exchange I
factor I
C3G B
, O
in O
unstimulated O
as O
well O
as O
PDGF B
- O
stimulated O
cells O
. O

CrkII B
and O
CrkL B
constitutively O
formed O
complex O
with O
the O
guanine B
nucleotide I
exchange I
factor I
C3G B
, O
in O
unstimulated O
as O
well O
as O
PDGF B
- O
stimulated O
cells O
. O

CrkII B
and O
CrkL B
constitutively O
formed O
complex O
with O
the O
guanine B
nucleotide I
exchange I
factor I
C3G B
, O
in O
unstimulated O
as O
well O
as O
PDGF B
- O
stimulated O
cells O
. O

In O
further O
support O
of O
the O
biological O
significance O
of O
these O
DNA O
- O
protein O
interactions O
, O
the O
IL2RA B
oligonucleotide O
from O
- O
291 O
to O
- O
245 O
proved O
to O
be O
sufficient O
in O
either O
orientation O
to O
confer O
PMA O
inducibility O
to O
the O
mitogen O
- O
insensitive O
thymidine B
kinase I
gene I
promoter I
in O
Jurkat O
cells O
. O

As O
to O
the O
side O
effects O
of O
SISO O
, O
cylindruria O
with O
aggravation O
of O
microscopic O
hematuria O
and O
elevations O
of O
GOT B
, O
GPT B
and O
A1 B
- I
P I
were O
observed O
each O
one O
of O
them O
, O
respectively O
. O

As O
to O
the O
side O
effects O
of O
SISO O
, O
cylindruria O
with O
aggravation O
of O
microscopic O
hematuria O
and O
elevations O
of O
GOT B
, O
GPT B
and O
A1 B
- I
P I
were O
observed O
each O
one O
of O
them O
, O
respectively O
. O

We O
have O
demonstrated O
that O
a O
putative O
HOX B
cofactor I
, O
PBX1A B
, O
participates O
in O
cooperative O
DNA O
binding O
with O
HOXA B
- I
1 I
and O
the O
Deformed B
group O
protein O
HOXD B
- I
4 I
. O

We O
have O
demonstrated O
that O
a O
putative O
HOX B
cofactor I
, O
PBX1A B
, O
participates O
in O
cooperative O
DNA O
binding O
with O
HOXA B
- I
1 I
and O
the O
Deformed B
group O
protein O
HOXD B
- I
4 I
. O

There O
was O
a O
highly O
significant O
decrease O
in O
serum B
eosinophil I
cationic I
protein I
in O
patients O
with O
elevated O
AGA B
. O

Small B
t I
also O
inhibited O
the O
dephosphorylation O
of O
cAMP B
- I
dependent I
protein I
kinase I
( O
PKA B
) O
- O
phosphorylated O
CREB B
in O
rat O
liver O
nuclear O
extracts O
. O

Small B
t I
also O
inhibited O
the O
dephosphorylation O
of O
cAMP B
- I
dependent I
protein I
kinase I
( O
PKA B
) O
- O
phosphorylated O
CREB B
in O
rat O
liver O
nuclear O
extracts O
. O

Fos B
/ O
Jun B
bound O
to O
an O
unacetylated O
nucleosome O
with O
only O
a O
4 O
- O
to O
5 O
- O
fold O
reduction O
in O
DNA O
binding O
affinity O
compared O
with O
naked O
DNA O
. O

Fos B
/ O
Jun B
bound O
to O
an O
unacetylated O
nucleosome O
with O
only O
a O
4 O
- O
to O
5 O
- O
fold O
reduction O
in O
DNA O
binding O
affinity O
compared O
with O
naked O
DNA O
. O

Electromobility O
shift O
analysis O
using O
oligonucleotides O
encompassing O
the O
proximal O
, O
distal O
, O
and O
BED O
/ O
AP B
- I
1 I
- O
binding O
regions O
failed O
to O
demonstrate O
selective O
transactivation O
after O
CD2 B
signaling O
of O
LPMC O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein I
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many O
B O
lineage O
genes O
, O
including O
EBF B
, O
IL7Ralpha B
, O
lambda5 B
, O
and O
Rag B
- I
1 I
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein I
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many O
B O
lineage O
genes O
, O
including O
EBF B
, O
IL7Ralpha B
, O
lambda5 B
, O
and O
Rag B
- I
1 I
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein I
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many O
B O
lineage O
genes O
, O
including O
EBF B
, O
IL7Ralpha B
, O
lambda5 B
, O
and O
Rag B
- I
1 I
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein I
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many O
B O
lineage O
genes O
, O
including O
EBF B
, O
IL7Ralpha B
, O
lambda5 B
, O
and O
Rag B
- I
1 I
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

One O
of O
the O
ORFs O
in O
the O
Methanococcus O
jannaschii O
genome O
possesses O
high O
similarity O
to O
the O
M B
. I
aeolicus I
ilvB I
, O
indicating O
that O
it O
is O
an O
authentic O
AHAS B
. O

PRP20 B
is O
related O
, O
both O
in O
structure O
and O
function O
, O
to O
the O
RCC1 B
gene I
of O
mammals O
and O
the O
PIM1 B
gene I
of O
Schizosaccharomyces O
pombe O
, O
both O
of O
which O
appear O
to O
regulate O
entry O
into O
mitosis O
and O
chromosome O
condensation O
. O

A O
selective O
transcriptional O
induction O
system O
for O
mammalian O
cells O
based O
on O
Gal4 B
- O
estrogen B
receptor I
fusion O
proteins O
. O

Kinase O
renaturation O
tests O
designed O
to O
detect O
reactivated O
protein O
kinases O
after O
electrophoresis O
in O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gels O
revealed O
the O
presence O
of O
a O
60 O
- O
kDa O
kinase O
in O
the O
washed O
immunoprecipitate O
obtained O
from O
liver O
cytosol O
using O
anti B
- I
AHR I
antibody I
( O
IgG B
) O
and O
protein O
A O
/ O
G O
/ O
agarose O
beads O
but O
not O
when O
a O
nonspecific O
IgG B
was O
used O
instead O
of O
anti B
- I
AHR I
antibody I
. O

Kinase O
renaturation O
tests O
designed O
to O
detect O
reactivated O
protein O
kinases O
after O
electrophoresis O
in O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gels O
revealed O
the O
presence O
of O
a O
60 O
- O
kDa O
kinase O
in O
the O
washed O
immunoprecipitate O
obtained O
from O
liver O
cytosol O
using O
anti B
- I
AHR I
antibody I
( O
IgG B
) O
and O
protein O
A O
/ O
G O
/ O
agarose O
beads O
but O
not O
when O
a O
nonspecific O
IgG B
was O
used O
instead O
of O
anti B
- I
AHR I
antibody I
. O

Immunoblotting O
using O
a O
phosphospecific B
anti I
- I
Src I
( I
416Y I
) I
antibody I
showed O
a O
ceramide O
- O
induced O
increase O
in O
pp60 B
( O
src B
) O
tyrosine O
phosphorylation O
. O

Immunoblotting O
using O
a O
phosphospecific B
anti I
- I
Src I
( I
416Y I
) I
antibody I
showed O
a O
ceramide O
- O
induced O
increase O
in O
pp60 B
( O
src B
) O
tyrosine O
phosphorylation O
. O

In O
contrast O
, O
dominant B
negative I
Rac I
( O
N17Rac1 B
) O
inhibited O
JNK B
activation O
by O
Galpha12 B
in O
HEK293 O
cells O
as O
well O
as O
three O
other O
cell O
lines O
. O

In O
contrast O
, O
dominant B
negative I
Rac I
( O
N17Rac1 B
) O
inhibited O
JNK B
activation O
by O
Galpha12 B
in O
HEK293 O
cells O
as O
well O
as O
three O
other O
cell O
lines O
. O

In O
contrast O
, O
dominant B
negative I
Rac I
( O
N17Rac1 B
) O
inhibited O
JNK B
activation O
by O
Galpha12 B
in O
HEK293 O
cells O
as O
well O
as O
three O
other O
cell O
lines O
. O

These O
results O
suggest O
that O
1a B
, O
which O
also O
interacts O
independently O
with O
the O
ER O
and O
viral O
RNA O
, O
is O
a O
key O
organizer O
of O
RNA O
replication O
complex O
assembly O
. O

HrpE B
is O
similar O
to O
YscL B
of O
Yersinia O
spp O
. O

HrpE B
is O
similar O
to O
YscL B
of O
Yersinia O
spp O
. O

The O
results O
indicate O
that O
expression O
of O
proU B
in O
E O
. O
coli O
is O
directed O
from O
two O
promoters O
, O
one O
( O
P2 O
) O
characterized O
earlier O
by O
other O
workers O
with O
the O
start O
site O
of O
transcription O
60 O
nucleotides O
upstream O
of O
the O
initiation O
codon O
of O
the O
first O
structural O
gene O
( O
proV B
) O
, O
and O
the O
other O
( O
P1 O
) O
situated O
250 O
nucleotides O
upstream O
of O
proV B
. O

The O
results O
indicate O
that O
expression O
of O
proU B
in O
E O
. O
coli O
is O
directed O
from O
two O
promoters O
, O
one O
( O
P2 O
) O
characterized O
earlier O
by O
other O
workers O
with O
the O
start O
site O
of O
transcription O
60 O
nucleotides O
upstream O
of O
the O
initiation O
codon O
of O
the O
first O
structural O
gene O
( O
proV B
) O
, O
and O
the O
other O
( O
P1 O
) O
situated O
250 O
nucleotides O
upstream O
of O
proV B
. O

The O
results O
indicate O
that O
expression O
of O
proU B
in O
E O
. O
coli O
is O
directed O
from O
two O
promoters O
, O
one O
( O
P2 O
) O
characterized O
earlier O
by O
other O
workers O
with O
the O
start O
site O
of O
transcription O
60 O
nucleotides O
upstream O
of O
the O
initiation O
codon O
of O
the O
first O
structural O
gene O
( O
proV B
) O
, O
and O
the O
other O
( O
P1 O
) O
situated O
250 O
nucleotides O
upstream O
of O
proV B
. O

Expression O
of O
Msx B
- I
1 I
and O
Msx B
- I
2 I
has O
been O
studied O
during O
development O
of O
the O
osteoblast O
phenotype O
, O
but O
the O
role O
of O
Dlx B
in O
this O
context O
and O
in O
the O
regulation O
of O
bone O
- O
expressed O
genes O
is O
unknown O
. O

DESIGN O
: O
Activating B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
and O
Tat B
- O
induced O
transcription O
were O
assessed O
using O
Jun B
and O
hybrid O
Tat B
/ O
Jun B
- O
expression O
plasmids O
and O
reporter O
gene O
constructs O
which O
contained O
AP B
- I
1 I
binding I
sites I
upstream O
of O
the O
rat B
prolactin I
TATAA I
element I
or O
an O
HIV B
- I
1 I
LTR I
construct I
in O
which O
AP B
- I
1 I
binding I
sites I
replaced O
the O
TAR O
element O
. O

DESIGN O
: O
Activating B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
and O
Tat B
- O
induced O
transcription O
were O
assessed O
using O
Jun B
and O
hybrid O
Tat B
/ O
Jun B
- O
expression O
plasmids O
and O
reporter O
gene O
constructs O
which O
contained O
AP B
- I
1 I
binding I
sites I
upstream O
of O
the O
rat B
prolactin I
TATAA I
element I
or O
an O
HIV B
- I
1 I
LTR I
construct I
in O
which O
AP B
- I
1 I
binding I
sites I
replaced O
the O
TAR O
element O
. O

DESIGN O
: O
Activating B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
and O
Tat B
- O
induced O
transcription O
were O
assessed O
using O
Jun B
and O
hybrid O
Tat B
/ O
Jun B
- O
expression O
plasmids O
and O
reporter O
gene O
constructs O
which O
contained O
AP B
- I
1 I
binding I
sites I
upstream O
of O
the O
rat B
prolactin I
TATAA I
element I
or O
an O
HIV B
- I
1 I
LTR I
construct I
in O
which O
AP B
- I
1 I
binding I
sites I
replaced O
the O
TAR O
element O
. O

DESIGN O
: O
Activating B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
and O
Tat B
- O
induced O
transcription O
were O
assessed O
using O
Jun B
and O
hybrid O
Tat B
/ O
Jun B
- O
expression O
plasmids O
and O
reporter O
gene O
constructs O
which O
contained O
AP B
- I
1 I
binding I
sites I
upstream O
of O
the O
rat B
prolactin I
TATAA I
element I
or O
an O
HIV B
- I
1 I
LTR I
construct I
in O
which O
AP B
- I
1 I
binding I
sites I
replaced O
the O
TAR O
element O
. O

Mycobacterium O
tuberculosis O
inhibits O
IFN B
- I
gamma I
transcriptional O
responses O
without O
inhibiting O
activation O
of O
STAT1 B
. O

Rabbit B
KCC1 I
( O
rbKCC1 B
) O
and O
rat B
KCC1 I
( O
rtKCC1 B
) O
were O
cloned O
by O
screening O
rabbit O
kidney O
and O
rat O
brain O
cDNA O
libraries O
using O
homologous O
cDNA O
probes O
. O

Rabbit B
KCC1 I
( O
rbKCC1 B
) O
and O
rat B
KCC1 I
( O
rtKCC1 B
) O
were O
cloned O
by O
screening O
rabbit O
kidney O
and O
rat O
brain O
cDNA O
libraries O
using O
homologous O
cDNA O
probes O
. O

GH B
stimulated O
the O
activity O
of O
promoter O
fragments O
with O
5 O
' O
- O
ends O
between O
nucleotide O
( O
nt O
) O
- O
2001 O
and O
nt O
- O
653 O
by O
1 O
. O
9 O
- O
to O
2 O
. O
7 O
- O
fold O
. O

We O
have O
recently O
shown O
that O
induced O
expression O
of O
a O
CDK B
target O
site O
- O
deficient O
mutant O
, O
Op18 B
- O
S25A O
, O
S38A O
, O
blocks O
human O
cell O
lines O
during O
G2 O
/ O
M O
transition O
. O

We O
have O
recently O
shown O
that O
induced O
expression O
of O
a O
CDK B
target O
site O
- O
deficient O
mutant O
, O
Op18 B
- O
S25A O
, O
S38A O
, O
blocks O
human O
cell O
lines O
during O
G2 O
/ O
M O
transition O
. O

The O
serum O
levels O
of O
cortisol O
and O
prolactin B
after O
nasal O
instillation O
of O
a O
suspension O
of O
vaginal O
exudate O
showed O
lower O
values O
than O
in O
control O
conditions O
( O
nasal O
instillation O
of O
saline O
) O
. O

Pendulin B
, O
a O
Drosophila O
protein O
with O
cell O
cycle O
- O
dependent O
nuclear O
localization O
, O
is O
required O
for O
normal O
cell O
proliferation O
. O

Signaling O
through O
mitogen B
- I
activated I
protein I
kinase I
and O
Rac B
/ O
Rho B
does O
not O
duplicate O
the O
effects O
of O
activated O
Ras B
on O
skeletal O
myogenesis O
. O

Signaling O
through O
mitogen B
- I
activated I
protein I
kinase I
and O
Rac B
/ O
Rho B
does O
not O
duplicate O
the O
effects O
of O
activated O
Ras B
on O
skeletal O
myogenesis O
. O

Signaling O
through O
mitogen B
- I
activated I
protein I
kinase I
and O
Rac B
/ O
Rho B
does O
not O
duplicate O
the O
effects O
of O
activated O
Ras B
on O
skeletal O
myogenesis O
. O

Internalization O
of O
prolactin B
receptor I
and O
prolactin B
in O
transfected O
cells O
does O
not O
involve O
nuclear O
translocation O
. O

Using O
mammalian O
expression O
vectors O
( O
pRSV O
- O
neo O
and O
pSV2 O
- O
neo O
) O
, O
antisense O
constructs O
for O
perforin B
and O
granzyme B
B I
were O
independently O
electroporated O
into O
YT O
- O
INDY O
, O
a O
human O
non O
- O
MHC B
- O
restricted O
, O
IL B
- I
2 I
- O
independent O
, O
cytotoxic O
lymphocyte O
. O

Using O
mammalian O
expression O
vectors O
( O
pRSV O
- O
neo O
and O
pSV2 O
- O
neo O
) O
, O
antisense O
constructs O
for O
perforin B
and O
granzyme B
B I
were O
independently O
electroporated O
into O
YT O
- O
INDY O
, O
a O
human O
non O
- O
MHC B
- O
restricted O
, O
IL B
- I
2 I
- O
independent O
, O
cytotoxic O
lymphocyte O
. O

The O
biological O
activity O
of O
these O
mutants O
was O
tested O
by O
determining O
their O
capacity O
to O
( O
i O
) O
reconstitute O
RNA B
polymerase I
activity O
in O
vivo O
by O
cotransfection O
with O
proteins O
NP B
, O
PB1 B
, O
and O
PA B
and O
a O
virion O
- O
like O
RNA O
encoding O
the O
cat B
gene O
into O
vaccinia O
virus O
T7 O
- O
infected O
COS O
- O
1 O
cells O
and O
( O
ii O
) O
complete O
with O
the O
wild B
- I
type I
PB2 I
activity O
. O

The O
biological O
activity O
of O
these O
mutants O
was O
tested O
by O
determining O
their O
capacity O
to O
( O
i O
) O
reconstitute O
RNA B
polymerase I
activity O
in O
vivo O
by O
cotransfection O
with O
proteins O
NP B
, O
PB1 B
, O
and O
PA B
and O
a O
virion O
- O
like O
RNA O
encoding O
the O
cat B
gene O
into O
vaccinia O
virus O
T7 O
- O
infected O
COS O
- O
1 O
cells O
and O
( O
ii O
) O
complete O
with O
the O
wild B
- I
type I
PB2 I
activity O
. O

The O
biological O
activity O
of O
these O
mutants O
was O
tested O
by O
determining O
their O
capacity O
to O
( O
i O
) O
reconstitute O
RNA B
polymerase I
activity O
in O
vivo O
by O
cotransfection O
with O
proteins O
NP B
, O
PB1 B
, O
and O
PA B
and O
a O
virion O
- O
like O
RNA O
encoding O
the O
cat B
gene O
into O
vaccinia O
virus O
T7 O
- O
infected O
COS O
- O
1 O
cells O
and O
( O
ii O
) O
complete O
with O
the O
wild B
- I
type I
PB2 I
activity O
. O

The O
biological O
activity O
of O
these O
mutants O
was O
tested O
by O
determining O
their O
capacity O
to O
( O
i O
) O
reconstitute O
RNA B
polymerase I
activity O
in O
vivo O
by O
cotransfection O
with O
proteins O
NP B
, O
PB1 B
, O
and O
PA B
and O
a O
virion O
- O
like O
RNA O
encoding O
the O
cat B
gene O
into O
vaccinia O
virus O
T7 O
- O
infected O
COS O
- O
1 O
cells O
and O
( O
ii O
) O
complete O
with O
the O
wild B
- I
type I
PB2 I
activity O
. O

We O
were O
unable O
to O
construct O
chvI B
or O
chvG B
insertion I
mutants I
of O
R O
. O
meliloti O
, O
whereas O
mutants O
carrying O
insertions O
outside O
of O
these O
genes O
were O
readily O
obtained O
. O

Western O
blot O
analyses O
reveals O
that O
cJun B
and O
the O
C B
/ I
EBP I
family I
member I
C B
/ I
EBP I
- I
beta I
are O
physiologically O
relevant O
transcription O
factors O
whose O
expression O
corresponds O
with O
mda B
- I
7 I
mRNA I
expression O
. O

In O
isolated O
olfactory O
cilia O
certain O
odorants O
elicit O
a O
rapid O
and O
transient O
cAMP O
response O
, O
terminated O
by O
a O
concerted O
process O
which O
requires O
the O
action O
of O
two O
protein O
kinases O
, O
protein B
kinase I
A I
( O
PKA B
) O
and O
a O
receptor B
- I
specific I
kinase I
( O
GRK3 B
) O
( O
Schleicher O
, O
S O
. O
, O
Boekhoff O
, O
I O
. O

In O
isolated O
olfactory O
cilia O
certain O
odorants O
elicit O
a O
rapid O
and O
transient O
cAMP O
response O
, O
terminated O
by O
a O
concerted O
process O
which O
requires O
the O
action O
of O
two O
protein O
kinases O
, O
protein B
kinase I
A I
( O
PKA B
) O
and O
a O
receptor B
- I
specific I
kinase I
( O
GRK3 B
) O
( O
Schleicher O
, O
S O
. O
, O
Boekhoff O
, O
I O
. O

We O
propose O
that O
GCD7 B
and O
GCD2 B
play O
important O
roles O
in O
the O
regulatory O
interaction O
between O
eIF B
- I
2 I
and O
eIF B
- I
2B I
and O
that O
the O
suppressor O
mutations O
we O
isolated O
in O
these O
genes O
decrease O
the O
susceptibility O
of O
eIF B
- I
2B I
to O
the O
inhibitory O
effects O
of O
phosphorylated O
eIF B
- I
2 I
without O
impairing O
the O
essential O
catalytic O
function O
of O
eIF B
- I
2B I
in O
translation O
initiation O
. O

We O
propose O
that O
GCD7 B
and O
GCD2 B
play O
important O
roles O
in O
the O
regulatory O
interaction O
between O
eIF B
- I
2 I
and O
eIF B
- I
2B I
and O
that O
the O
suppressor O
mutations O
we O
isolated O
in O
these O
genes O
decrease O
the O
susceptibility O
of O
eIF B
- I
2B I
to O
the O
inhibitory O
effects O
of O
phosphorylated O
eIF B
- I
2 I
without O
impairing O
the O
essential O
catalytic O
function O
of O
eIF B
- I
2B I
in O
translation O
initiation O
. O

These O
data O
demonstrate O
that O
CCTalpha B
can O
be O
regulated O
by O
lipids O
by O
two O
independent O
domains O
: O
( O
i O
) O
the O
three O
amphipathic O
alpha O
- O
helical O
repeats O
that O
interact O
with O
both O
neutral O
and O
anionic O
lipid O
mixtures O
and O
( O
ii O
) O
the O
last O
57 O
residues O
that O
interact O
with O
anionic O
lipids O
. O

Sorting O
information O
to O
the O
chloroplastic O
inner O
envelope O
is O
contained O
in O
an O
NH2 O
- O
proximal O
part O
of O
mature B
IEP110 I
( O
110N B
) O
. O

Lack O
of O
changes O
in O
milk O
production O
and O
milk O
composition O
suggest O
that O
acute O
increases O
in O
somatotropin B
with O
concomitant O
increases O
in O
insulin B
are O
not O
sufficient O
to O
stimulate O
synthesis O
of O
milk O
and O
milk O
components O
by O
cows O
during O
established O
lactation O
. O

Lack O
of O
changes O
in O
milk O
production O
and O
milk O
composition O
suggest O
that O
acute O
increases O
in O
somatotropin B
with O
concomitant O
increases O
in O
insulin B
are O
not O
sufficient O
to O
stimulate O
synthesis O
of O
milk O
and O
milk O
components O
by O
cows O
during O
established O
lactation O
. O

Since O
RIP140 B
generally O
down O
- O
regulates O
receptor O
activity O
in O
mammalian O
cells O
and O
specifically O
down O
- O
regulates O
coactivation O
mediated O
by O
SRC B
- I
1 I
, O
we O
propose O
a O
model O
in O
which O
RIP140 B
indirectly O
regulates O
nuclear B
receptor I
AF I
- I
2 I
activity O
by O
competition O
for O
coactivators O
such O
as O
SRC B
- I
1 I
. O

Since O
RIP140 B
generally O
down O
- O
regulates O
receptor O
activity O
in O
mammalian O
cells O
and O
specifically O
down O
- O
regulates O
coactivation O
mediated O
by O
SRC B
- I
1 I
, O
we O
propose O
a O
model O
in O
which O
RIP140 B
indirectly O
regulates O
nuclear B
receptor I
AF I
- I
2 I
activity O
by O
competition O
for O
coactivators O
such O
as O
SRC B
- I
1 I
. O

As O
in O
the O
case O
of O
the O
chicken O
homologue O
, O
there O
are O
two O
hPR B
forms O
, O
A O
and O
B O
, O
which O
originate O
from O
translational O
initiation O
at O
AUG2 O
( O
codon O
165 O
) O
and O
AUG1 O
, O
respectively O
. O

In O
cells O
stably O
transfected O
with O
G B
alpha I
i I
- I
2 I
or O
G B
alpha I
i I
- I
3 I
gene I
5 O
' O
- O
flanking O
sequences O
fused O
to O
firefly O
luciferase B
cDNA O
reporter O
, O
temporal O
10 O
- O
15 O
- O
fold O
transcriptional O
activation O
of O
both O
genes O
occurred O
before O
cellular O
polarization O
. O

There O
are O
two O
regulatory O
regions O
between O
the O
US3 B
and O
the O
US6 B
transcription I
units I
. O

We O
established O
that O
, O
in O
unstimulated O
lymphocytes O
, O
the O
Src B
homology I
2 I
( O
SH2 B
) O
and O
SH3 B
domain I
- I
containing I
protein I
Grb2 B
and O
the O
p85 B
subunit O
of O
phosphatidylinositol B
3 I
- I
kinase I
, O
associate O
constitutively O
with O
Cbl B
via O
their O
SH3 B
domains I
. O

We O
established O
that O
, O
in O
unstimulated O
lymphocytes O
, O
the O
Src B
homology I
2 I
( O
SH2 B
) O
and O
SH3 B
domain I
- I
containing I
protein I
Grb2 B
and O
the O
p85 B
subunit O
of O
phosphatidylinositol B
3 I
- I
kinase I
, O
associate O
constitutively O
with O
Cbl B
via O
their O
SH3 B
domains I
. O

We O
established O
that O
, O
in O
unstimulated O
lymphocytes O
, O
the O
Src B
homology I
2 I
( O
SH2 B
) O
and O
SH3 B
domain I
- I
containing I
protein I
Grb2 B
and O
the O
p85 B
subunit O
of O
phosphatidylinositol B
3 I
- I
kinase I
, O
associate O
constitutively O
with O
Cbl B
via O
their O
SH3 B
domains I
. O

We O
established O
that O
, O
in O
unstimulated O
lymphocytes O
, O
the O
Src B
homology I
2 I
( O
SH2 B
) O
and O
SH3 B
domain I
- I
containing I
protein I
Grb2 B
and O
the O
p85 B
subunit O
of O
phosphatidylinositol B
3 I
- I
kinase I
, O
associate O
constitutively O
with O
Cbl B
via O
their O
SH3 B
domains I
. O

Zta B
stimulated O
the O
HAT B
activity O
of O
CBP B
that O
had O
been O
partially O
purified O
or O
immunoprecipitated O
from O
mammalian O
cells O
as O
well O
as O
from O
affinity O
- O
purified O
, O
baculovirus O
expressed O
CBP B
. O

Zta B
stimulated O
the O
HAT B
activity O
of O
CBP B
that O
had O
been O
partially O
purified O
or O
immunoprecipitated O
from O
mammalian O
cells O
as O
well O
as O
from O
affinity O
- O
purified O
, O
baculovirus O
expressed O
CBP B
. O

Zta B
stimulated O
the O
HAT B
activity O
of O
CBP B
that O
had O
been O
partially O
purified O
or O
immunoprecipitated O
from O
mammalian O
cells O
as O
well O
as O
from O
affinity O
- O
purified O
, O
baculovirus O
expressed O
CBP B
. O

Zta B
stimulated O
the O
HAT B
activity O
of O
CBP B
that O
had O
been O
partially O
purified O
or O
immunoprecipitated O
from O
mammalian O
cells O
as O
well O
as O
from O
affinity O
- O
purified O
, O
baculovirus O
expressed O
CBP B
. O

3 O
patients O
with O
acute O
leukaemia O
, O
HLA B
antibodies O
and O
thrombocytopenia O
refractory O
to O
random O
donor O
platelet O
transfusions O
were O
treated O
with O
high O
- O
dose O
i O
. O
v O
. O
immunoglobulin B
. O

3 O
patients O
with O
acute O
leukaemia O
, O
HLA B
antibodies O
and O
thrombocytopenia O
refractory O
to O
random O
donor O
platelet O
transfusions O
were O
treated O
with O
high O
- O
dose O
i O
. O
v O
. O
immunoglobulin B
. O

Two O
genes O
( O
ptsI B
and O
ptsA B
) O
that O
encode O
homologues O
of O
the O
energy O
coupling O
Enzyme B
I I
of O
the O
phosphoenolpyruvate B
- I
dependent I
sugar I
- I
transporting I
phosphotransferase I
system O
( O
PTS O
) O
have O
previously O
been O
identified O
on O
the O
Escherichia O
coli O
chromosome O
. O

Two O
genes O
( O
ptsI B
and O
ptsA B
) O
that O
encode O
homologues O
of O
the O
energy O
coupling O
Enzyme B
I I
of O
the O
phosphoenolpyruvate B
- I
dependent I
sugar I
- I
transporting I
phosphotransferase I
system O
( O
PTS O
) O
have O
previously O
been O
identified O
on O
the O
Escherichia O
coli O
chromosome O
. O

Eight O
of O
these O
suppressors O
for O
into O
two O
complementation O
groups O
, O
designated O
KCS1 B
and O
KCS2 B
. O

Eight O
of O
these O
suppressors O
for O
into O
two O
complementation O
groups O
, O
designated O
KCS1 B
and O
KCS2 B
. O

These O
results O
point O
towards O
post O
- O
translational O
steric O
and O
/ O
or O
allosteric O
control O
of O
EKLF B
function O
that O
may O
be O
important O
not O
just O
for O
its O
DNA O
binding O
ability O
, O
but O
also O
for O
its O
potential O
to O
interact O
with O
other O
proteins O
that O
fully O
establish O
the O
correct O
stereospecific O
array O
leading O
to O
efficient O
switching O
of O
beta B
- I
globin I
transcription O
during O
development O
. O

Western O
blot O
experiments O
detected O
SMBP B
as O
a O
70 O
kDa O
protein O
that O
may O
be O
further O
cleaved O
into O
an O
active O
34 O
kDa O
N O
- O
terminal O
polypeptide O
. O

The O
activated O
glucocorticoid B
receptor I
forms O
a O
complex O
with O
Stat5 B
and O
enhances O
Stat5 B
- O
mediated O
transcriptional O
induction O
. O

The O
activated O
glucocorticoid B
receptor I
forms O
a O
complex O
with O
Stat5 B
and O
enhances O
Stat5 B
- O
mediated O
transcriptional O
induction O
. O

Taken O
together O
, O
these O
findings O
demonstrate O
that O
ZNF76 B
and O
ZNF143 B
are O
two O
members O
of O
a O
same O
family O
of O
transactivator O
proteins O
. O

Taken O
together O
, O
these O
findings O
demonstrate O
that O
ZNF76 B
and O
ZNF143 B
are O
two O
members O
of O
a O
same O
family O
of O
transactivator O
proteins O
. O

For O
example O
, O
the O
presence O
of O
two O
related O
genes O
, O
b B
and O
b B
' I
, O
in O
the O
cyanobacterium O
suggests O
that O
its O
ATP B
synthase I
is O
a O
complex O
of O
nine O
polypeptides O
, O
and O
that O
it O
may O
have O
single O
copies O
of O
related O
b B
and O
b B
' I
proteins I
rather O
than O
two O
copies O
of O
identical O
b B
subunits I
as O
found O
in O
the O
E O
. O
coli O
enzyme O
. O
4 O
+ O
off O

For O
example O
, O
the O
presence O
of O
two O
related O
genes O
, O
b B
and O
b B
' I
, O
in O
the O
cyanobacterium O
suggests O
that O
its O
ATP B
synthase I
is O
a O
complex O
of O
nine O
polypeptides O
, O
and O
that O
it O
may O
have O
single O
copies O
of O
related O
b B
and O
b B
' I
proteins I
rather O
than O
two O
copies O
of O
identical O
b B
subunits I
as O
found O
in O
the O
E O
. O
coli O
enzyme O
. O
4 O
+ O
off O

CRKL B
, O
an O
SH2 B
- O
SH3 B
- O
SH3 B
adapter O
protein O
, O
is O
one O
of O
the O
major O
tyrosine B
phosphoproteins I
detected O
in O
primary O
leukemic O
neutrophils O
from O
patients O
with O
CML O
. O

CRKL B
, O
an O
SH2 B
- O
SH3 B
- O
SH3 B
adapter O
protein O
, O
is O
one O
of O
the O
major O
tyrosine B
phosphoproteins I
detected O
in O
primary O
leukemic O
neutrophils O
from O
patients O
with O
CML O
. O

CRKL B
, O
an O
SH2 B
- O
SH3 B
- O
SH3 B
adapter O
protein O
, O
is O
one O
of O
the O
major O
tyrosine B
phosphoproteins I
detected O
in O
primary O
leukemic O
neutrophils O
from O
patients O
with O
CML O
. O

CRKL B
, O
an O
SH2 B
- O
SH3 B
- O
SH3 B
adapter O
protein O
, O
is O
one O
of O
the O
major O
tyrosine B
phosphoproteins I
detected O
in O
primary O
leukemic O
neutrophils O
from O
patients O
with O
CML O
. O

In O
contrast O
, O
inactivation O
of O
the O
Sir4p B
- I
interacting I
protein I
Rap1p I
reduces O
partitioning O
by O
a O
LexA B
- O
Sir4p B
fusion O
. O

In O
contrast O
, O
inactivation O
of O
the O
Sir4p B
- I
interacting I
protein I
Rap1p I
reduces O
partitioning O
by O
a O
LexA B
- O
Sir4p B
fusion O
. O

BACKGROUND O
: O
Murine B
Nramp I
is O
a O
candidate O
for O
the O
macrophage O
resistance O
gene O
Ity B
/ O
Lsh B
/ O
Bcg B
. O

BACKGROUND O
: O
Murine B
Nramp I
is O
a O
candidate O
for O
the O
macrophage O
resistance O
gene O
Ity B
/ O
Lsh B
/ O
Bcg B
. O

BACKGROUND O
: O
Murine B
Nramp I
is O
a O
candidate O
for O
the O
macrophage O
resistance O
gene O
Ity B
/ O
Lsh B
/ O
Bcg B
. O

In O
cases O
in O
which O
it O
was O
identified O
, O
insulitis O
affected O
23 O
% O
of O
islets O
containing O
insulin B
, O
but O
affected O
only O
1 O
% O
of O
islets O
which O
were O
insulin B
deficient O
, O
thus O
supporting O
the O
concept O
that O
insulitis O
represents O
an O
immunologically O
mediated O
destruction O
of O
insulin B
secreting O
B O
cells O
. O

In O
cases O
in O
which O
it O
was O
identified O
, O
insulitis O
affected O
23 O
% O
of O
islets O
containing O
insulin B
, O
but O
affected O
only O
1 O
% O
of O
islets O
which O
were O
insulin B
deficient O
, O
thus O
supporting O
the O
concept O
that O
insulitis O
represents O
an O
immunologically O
mediated O
destruction O
of O
insulin B
secreting O
B O
cells O
. O

In O
cases O
in O
which O
it O
was O
identified O
, O
insulitis O
affected O
23 O
% O
of O
islets O
containing O
insulin B
, O
but O
affected O
only O
1 O
% O
of O
islets O
which O
were O
insulin B
deficient O
, O
thus O
supporting O
the O
concept O
that O
insulitis O
represents O
an O
immunologically O
mediated O
destruction O
of O
insulin B
secreting O
B O
cells O
. O

To O
investigate O
possible O
roles O
for O
HCP B
during O
late O
erythroid O
differentiation O
, O
effects O
of O
manipulating O
HCP B
expression O
or O
recruitment O
on O
EPO B
- O
induced O
hemoglobinization O
in O
erythroleukemic O
SKT6 O
cells O
have O
been O
investigated O
. O

To O
investigate O
possible O
roles O
for O
HCP B
during O
late O
erythroid O
differentiation O
, O
effects O
of O
manipulating O
HCP B
expression O
or O
recruitment O
on O
EPO B
- O
induced O
hemoglobinization O
in O
erythroleukemic O
SKT6 O
cells O
have O
been O
investigated O
. O

To O
investigate O
possible O
roles O
for O
HCP B
during O
late O
erythroid O
differentiation O
, O
effects O
of O
manipulating O
HCP B
expression O
or O
recruitment O
on O
EPO B
- O
induced O
hemoglobinization O
in O
erythroleukemic O
SKT6 O
cells O
have O
been O
investigated O
. O

The O
other O
end O
of O
this O
cluster O
contained O
the O
human B
type I
I I
cytokeratin I
K20 B
and O
K12 B
gene I
loci O
. O

However O
, O
in O
transient O
transfection O
assays O
, O
a O
truncation O
of O
as O
little O
as O
15 O
Nurr1 B
COOH O
- O
terminal O
amino O
acids O
diminished O
transcriptional O
activation O
of O
B1A B
- O
thymidine B
kinase I
- O
chloramphenicol B
acetyltransferase I
reporter O
. O

However O
, O
in O
transient O
transfection O
assays O
, O
a O
truncation O
of O
as O
little O
as O
15 O
Nurr1 B
COOH O
- O
terminal O
amino O
acids O
diminished O
transcriptional O
activation O
of O
B1A B
- O
thymidine B
kinase I
- O
chloramphenicol B
acetyltransferase I
reporter O
. O

Characterization O
of O
human B
activating I
transcription I
factor I
4 I
, O
a O
transcriptional O
activator O
that O
interacts O
with O
multiple O
domains O
of O
cAMP B
- I
responsive I
element I
- I
binding I
protein I
( O
CREB B
) O
- O
binding O
protein O
. O

In O
contrast O
to O
the O
reciprocal O
effects O
of O
Gab1 B
and O
Gab2 B
in O
mediating O
Elk B
- I
1 I
induction O
, O
these O
two O
molecules O
have O
a O
similar O
function O
in O
extracellular B
signal I
- I
regulated I
kinase I
activation O
induced O
by O
either O
oncogenic O
Ras B
or O
growth O
factor O
stimulation O
. O

In O
contrast O
to O
the O
reciprocal O
effects O
of O
Gab1 B
and O
Gab2 B
in O
mediating O
Elk B
- I
1 I
induction O
, O
these O
two O
molecules O
have O
a O
similar O
function O
in O
extracellular B
signal I
- I
regulated I
kinase I
activation O
induced O
by O
either O
oncogenic O
Ras B
or O
growth O
factor O
stimulation O
. O

In O
contrast O
to O
the O
reciprocal O
effects O
of O
Gab1 B
and O
Gab2 B
in O
mediating O
Elk B
- I
1 I
induction O
, O
these O
two O
molecules O
have O
a O
similar O
function O
in O
extracellular B
signal I
- I
regulated I
kinase I
activation O
induced O
by O
either O
oncogenic O
Ras B
or O
growth O
factor O
stimulation O
. O

Chromaffin O
cells O
transfected O
with O
a O
plasmid O
with O
the O
entire O
coding O
sequence O
of O
c B
- I
Rabphilin3a I
inserted O
in O
the O
antisense O
orientation O
inhibited O
secretion O
of O
co O
- O
expressed O
GH B
by O
approximately O
30 O
% O
. O

The O
in O
vivo O
response O
of O
the O
PacC B
- I
like I
decamers I
to O
external O
pH O
was O
dependent O
on O
the O
status O
of O
the O
pH O
- O
regulated O
activator O
YlRim101p B
, O
which O
is O
homologous O
to O
the O
A O
. O
nidulans O
PacC B
regulator O
. O

The O
in O
vivo O
response O
of O
the O
PacC B
- I
like I
decamers I
to O
external O
pH O
was O
dependent O
on O
the O
status O
of O
the O
pH O
- O
regulated O
activator O
YlRim101p B
, O
which O
is O
homologous O
to O
the O
A O
. O
nidulans O
PacC B
regulator O
. O

Having O
demonstrated O
proper O
localization O
of O
GFP B
- O
calmodulin B
in O
budding O
yeast O
, O
we O
examined O
the O
localization O
of O
a O
fusion O
between O
GFP B
and O
calmodulin B
( O
GFP B
- I
Camlp I
) O
in O
fission O
yeast O
, O
where O
calmodulin B
had O
not O
been O
localized O
by O
any O
method O
. O

Having O
demonstrated O
proper O
localization O
of O
GFP B
- O
calmodulin B
in O
budding O
yeast O
, O
we O
examined O
the O
localization O
of O
a O
fusion O
between O
GFP B
and O
calmodulin B
( O
GFP B
- I
Camlp I
) O
in O
fission O
yeast O
, O
where O
calmodulin B
had O
not O
been O
localized O
by O
any O
method O
. O

Having O
demonstrated O
proper O
localization O
of O
GFP B
- O
calmodulin B
in O
budding O
yeast O
, O
we O
examined O
the O
localization O
of O
a O
fusion O
between O
GFP B
and O
calmodulin B
( O
GFP B
- I
Camlp I
) O
in O
fission O
yeast O
, O
where O
calmodulin B
had O
not O
been O
localized O
by O
any O
method O
. O

Having O
demonstrated O
proper O
localization O
of O
GFP B
- O
calmodulin B
in O
budding O
yeast O
, O
we O
examined O
the O
localization O
of O
a O
fusion O
between O
GFP B
and O
calmodulin B
( O
GFP B
- I
Camlp I
) O
in O
fission O
yeast O
, O
where O
calmodulin B
had O
not O
been O
localized O
by O
any O
method O
. O

Having O
demonstrated O
proper O
localization O
of O
GFP B
- O
calmodulin B
in O
budding O
yeast O
, O
we O
examined O
the O
localization O
of O
a O
fusion O
between O
GFP B
and O
calmodulin B
( O
GFP B
- I
Camlp I
) O
in O
fission O
yeast O
, O
where O
calmodulin B
had O
not O
been O
localized O
by O
any O
method O
. O

Sera O
from O
33 O
newborn O
infants O
with O
gestational O
ages O
ranging O
from O
27 O
to O
41 O
weeks O
were O
tested O
by O
radioimmunoassay O
for O
IgG B
antibodies O
to O
surface O
antigens O
of O
group O
B O
streptococci O
( O
GBS O
) O
types O
Ia O
, O
Ib O
, O
II O
and O
III O
. O

Seminal O
prolactin B
levels O
were O
significantly O
elevated O
in O
all O
infertile O
males O
. O

In O
the O
univariate O
models O
of O
either O
fixed O
or O
time O
dependent O
covariates O
, O
many O
variables O
were O
significantly O
associated O
with O
risk O
of O
progression O
to O
AIDS O
( O
T4 O
cell O
count O
, O
T4 O
/ O
T8 O
ratio O
, O
blastogenic O
responses O
to O
phytohemagglutinin B
, O
concanavalin B
A I
, O
and O
pokeweed B
mitogen I
, O
serum B
IgA I
, O
appearance O
of O
p24 B
antigen I
, O
and O
the O
development O
of O
oral O
hairy O
leukoplakia O
, O
thrush O
, O
or O
herpes O
zoster O
) O
. O

Adenovirus O
- O
mediated O
gene O
transfer O
of O
MMAC1 B
/ O
PTEN B
to O
glioblastoma O
cells O
inhibits O
S O
phase O
entry O
by O
the O
recruitment O
of O
p27Kip1 B
into O
cyclin B
E I
/ O
CDK2 B
complexes O
. O

Adenovirus O
- O
mediated O
gene O
transfer O
of O
MMAC1 B
/ O
PTEN B
to O
glioblastoma O
cells O
inhibits O
S O
phase O
entry O
by O
the O
recruitment O
of O
p27Kip1 B
into O
cyclin B
E I
/ O
CDK2 B
complexes O
. O

Adenovirus O
- O
mediated O
gene O
transfer O
of O
MMAC1 B
/ O
PTEN B
to O
glioblastoma O
cells O
inhibits O
S O
phase O
entry O
by O
the O
recruitment O
of O
p27Kip1 B
into O
cyclin B
E I
/ O
CDK2 B
complexes O
. O

Adenovirus O
- O
mediated O
gene O
transfer O
of O
MMAC1 B
/ O
PTEN B
to O
glioblastoma O
cells O
inhibits O
S O
phase O
entry O
by O
the O
recruitment O
of O
p27Kip1 B
into O
cyclin B
E I
/ O
CDK2 B
complexes O
. O

Characterization O
of O
a O
tonB B
- O
phoA B
gene O
fusion O
suggests O
that O
the O
amino O
- O
terminal O
41 O
amino O
acids O
of O
TonB B
are O
sufficient O
to O
promote O
export O
of O
the O
fusion O
protein O
and O
presumably O
TonB B
as O
well O
. O

Characterization O
of O
a O
tonB B
- O
phoA B
gene O
fusion O
suggests O
that O
the O
amino O
- O
terminal O
41 O
amino O
acids O
of O
TonB B
are O
sufficient O
to O
promote O
export O
of O
the O
fusion O
protein O
and O
presumably O
TonB B
as O
well O
. O

Characterization O
of O
a O
tonB B
- O
phoA B
gene O
fusion O
suggests O
that O
the O
amino O
- O
terminal O
41 O
amino O
acids O
of O
TonB B
are O
sufficient O
to O
promote O
export O
of O
the O
fusion O
protein O
and O
presumably O
TonB B
as O
well O
. O

Characterization O
of O
a O
tonB B
- O
phoA B
gene O
fusion O
suggests O
that O
the O
amino O
- O
terminal O
41 O
amino O
acids O
of O
TonB B
are O
sufficient O
to O
promote O
export O
of O
the O
fusion O
protein O
and O
presumably O
TonB B
as O
well O
. O

Both O
genes B
ARO3 I
and O
ARO4 B
are O
strongly O
regulated O
under O
the O
general O
control O
regulatory O
system O
. O

Polar O
effects O
of O
transposon O
insertions O
demonstrated O
that O
all O
of O
these O
mRNAs O
arose O
from O
a O
single O
promoter O
region O
, O
where O
transcription O
initiated O
80 O
bp O
5 O
' O
to O
nifH B
. O

Co O
- O
expression O
of O
a O
gag B
- O
TRalpha B
fusion O
protein O
in O
AEV O
- O
transformed O
cells O
and O
addition O
of O
ligand O
derepresses O
CAII B
transcription O
. O

Co O
- O
expression O
of O
a O
gag B
- O
TRalpha B
fusion O
protein O
in O
AEV O
- O
transformed O
cells O
and O
addition O
of O
ligand O
derepresses O
CAII B
transcription O
. O

Co O
- O
expression O
of O
a O
gag B
- O
TRalpha B
fusion O
protein O
in O
AEV O
- O
transformed O
cells O
and O
addition O
of O
ligand O
derepresses O
CAII B
transcription O
. O

The O
IB2 B
gene I
( O
HGMW O
- O
approved O
symbol O
MAPK8IP2 B
) O
maps O
to O
human O
chromosome O
22q13 O
and O
contains O
10 O
coding O
exons O
. O

Transcription O
start O
sites O
of O
sal B
and O
salR B
genes I
were O
determined O
to O
lie O
30 O
- O
and O
24 O
- O
bp O
upstream O
of O
the O
respective O
initiation O
codons O
and O
separated O
from O
each O
other O
by O
78 O
nucleotides O
. O

Here O
we O
demonstrate O
that O
the O
T B
cell I
antigen I
receptor I
zeta I
- I
chain I
- I
associated I
ZAP I
- I
70 I
kinase I
and O
T B
cell I
antigen I
receptor I
zeta I
- I
chain I
immunoreceptor I
tyrosine I
- I
based I
activation I
motifs I
are O
essential O
for O
the O
membrane O
recruitment O
of O
SOS B
and O
Vav B
. O

Here O
we O
demonstrate O
that O
the O
T B
cell I
antigen I
receptor I
zeta I
- I
chain I
- I
associated I
ZAP I
- I
70 I
kinase I
and O
T B
cell I
antigen I
receptor I
zeta I
- I
chain I
immunoreceptor I
tyrosine I
- I
based I
activation I
motifs I
are O
essential O
for O
the O
membrane O
recruitment O
of O
SOS B
and O
Vav B
. O

A O
mammalian O
protein O
called O
RFX B
or O
NF B
- I
X I
binds O
to O
the O
X O
box O
( O
or O
X1 O
box O
) O
in O
the O
promoters O
of O
a O
number O
of O
major B
histocompatibility I
( I
MHC I
) I
class I
II I
genes I
. O

The O
incidence O
of O
the O
variability O
of O
the O
free O
PSA B
/ O
total O
PSA B
ratio O
on O
the O
early O
diagnosis O
of O
prostate O
cancer O

The O
incidence O
of O
the O
variability O
of O
the O
free O
PSA B
/ O
total O
PSA B
ratio O
on O
the O
early O
diagnosis O
of O
prostate O
cancer O

VBP B
and O
a1 B
/ I
EBP I
could O
mediate O
the O
high O
rates O
of O
ALV O
and O
RSV B
LTR I
- O
enhanced O
transcription O
in O
bursal O
lymphoma O
cells O
and O
many O
other O
cell O
types O
. O

The O
contribution O
of O
residues O
outside O
the O
Ras B
binding I
domain I
of O
Raf B
( O
RafRBD B
) O
to O
Ras B
- O
Raf B
interaction O
and O
Ras B
- O
dependent O
Raf B
activation O
has O
remained O
unresolved O
. O

The O
contribution O
of O
residues O
outside O
the O
Ras B
binding I
domain I
of O
Raf B
( O
RafRBD B
) O
to O
Ras B
- O
Raf B
interaction O
and O
Ras B
- O
dependent O
Raf B
activation O
has O
remained O
unresolved O
. O

The O
contribution O
of O
residues O
outside O
the O
Ras B
binding I
domain I
of O
Raf B
( O
RafRBD B
) O
to O
Ras B
- O
Raf B
interaction O
and O
Ras B
- O
dependent O
Raf B
activation O
has O
remained O
unresolved O
. O

The O
contribution O
of O
residues O
outside O
the O
Ras B
binding I
domain I
of O
Raf B
( O
RafRBD B
) O
to O
Ras B
- O
Raf B
interaction O
and O
Ras B
- O
dependent O
Raf B
activation O
has O
remained O
unresolved O
. O

The O
contribution O
of O
residues O
outside O
the O
Ras B
binding I
domain I
of O
Raf B
( O
RafRBD B
) O
to O
Ras B
- O
Raf B
interaction O
and O
Ras B
- O
dependent O
Raf B
activation O
has O
remained O
unresolved O
. O

The O
contribution O
of O
residues O
outside O
the O
Ras B
binding I
domain I
of O
Raf B
( O
RafRBD B
) O
to O
Ras B
- O
Raf B
interaction O
and O
Ras B
- O
dependent O
Raf B
activation O
has O
remained O
unresolved O
. O

To O
obtain O
information O
on O
the O
functional O
role O
of O
the O
Rac1 B
/ O
p38 B
/ O
MAPKAPK B
- I
2 I
pathway O
in O
RA O
signaling O
, O
the O
effects O
of O
pharmacological O
inhibition O
of O
p38 B
on O
RA O
- O
induced O
gene O
transcription O
and O
cell O
differentiation O
were O
determined O
. O

To O
obtain O
information O
on O
the O
functional O
role O
of O
the O
Rac1 B
/ O
p38 B
/ O
MAPKAPK B
- I
2 I
pathway O
in O
RA O
signaling O
, O
the O
effects O
of O
pharmacological O
inhibition O
of O
p38 B
on O
RA O
- O
induced O
gene O
transcription O
and O
cell O
differentiation O
were O
determined O
. O

To O
obtain O
information O
on O
the O
functional O
role O
of O
the O
Rac1 B
/ O
p38 B
/ O
MAPKAPK B
- I
2 I
pathway O
in O
RA O
signaling O
, O
the O
effects O
of O
pharmacological O
inhibition O
of O
p38 B
on O
RA O
- O
induced O
gene O
transcription O
and O
cell O
differentiation O
were O
determined O
. O

The O
ATF B
/ O
CRE O
site O
is O
also O
essential O
for O
CD4 B
promoter I
activation O
by O
forskolin O
, O
an O
activator O
of O
adenylate B
cyclase I
. O

YLL031c B
is O
an O
essential O
gene O
. O

We O
report O
the O
genomic O
organization O
of O
the O
mouse O
orphan B
receptor I
related I
to I
tyrosine I
kinases I
( O
Ryk B
) O
, O
a O
structurally O
unclassified O
member O
of O
the O
growth B
factor I
receptor I
family O
. O

Incubation O
of O
HeLa O
cell O
cytoplasmic O
extracts O
with O
a O
purified O
recombinant O
glutathione B
S I
- I
transferase I
- O
raf B
fusion O
protein O
in O
the O
presence O
of O
ATP O
released O
active O
NF B
- I
kappa I
B I
that O
could O
be O
detected O
by O
electrophoretic O
gel O
mobility O
shift O
assay O
. O

Despite O
this O
loss O
, O
YEpFAS1 B
is O
still O
able O
to O
complement O
a O
fas1 B
mutation O
at O
the O
enoyl B
reductase I
domain O
. O

Despite O
this O
loss O
, O
YEpFAS1 B
is O
still O
able O
to O
complement O
a O
fas1 B
mutation O
at O
the O
enoyl B
reductase I
domain O
. O

In O
contrast O
, O
a O
similar O
fusion O
protein O
( O
hGH B
- O
LDLR B
- O
DAF17 B
, O
abbreviated O
HLD B
) O
containing O
a O
fragment O
of O
the O
serine O
/ O
threonine O
- O
rich O
domain O
of O
the O
LDL B
receptor I
( O
LDLR B
) O
in O
place O
of O
the O
DAF B
- I
derived I
serine I
/ I
threonine I
- I
rich I
sequences I
, O
does O
not O
become O
GPI O
anchored O
. O

In O
contrast O
, O
a O
similar O
fusion O
protein O
( O
hGH B
- O
LDLR B
- O
DAF17 B
, O
abbreviated O
HLD B
) O
containing O
a O
fragment O
of O
the O
serine O
/ O
threonine O
- O
rich O
domain O
of O
the O
LDL B
receptor I
( O
LDLR B
) O
in O
place O
of O
the O
DAF B
- I
derived I
serine I
/ I
threonine I
- I
rich I
sequences I
, O
does O
not O
become O
GPI O
anchored O
. O

In O
contrast O
, O
a O
similar O
fusion O
protein O
( O
hGH B
- O
LDLR B
- O
DAF17 B
, O
abbreviated O
HLD B
) O
containing O
a O
fragment O
of O
the O
serine O
/ O
threonine O
- O
rich O
domain O
of O
the O
LDL B
receptor I
( O
LDLR B
) O
in O
place O
of O
the O
DAF B
- I
derived I
serine I
/ I
threonine I
- I
rich I
sequences I
, O
does O
not O
become O
GPI O
anchored O
. O

In O
contrast O
, O
a O
similar O
fusion O
protein O
( O
hGH B
- O
LDLR B
- O
DAF17 B
, O
abbreviated O
HLD B
) O
containing O
a O
fragment O
of O
the O
serine O
/ O
threonine O
- O
rich O
domain O
of O
the O
LDL B
receptor I
( O
LDLR B
) O
in O
place O
of O
the O
DAF B
- I
derived I
serine I
/ I
threonine I
- I
rich I
sequences I
, O
does O
not O
become O
GPI O
anchored O
. O

In O
contrast O
, O
a O
similar O
fusion O
protein O
( O
hGH B
- O
LDLR B
- O
DAF17 B
, O
abbreviated O
HLD B
) O
containing O
a O
fragment O
of O
the O
serine O
/ O
threonine O
- O
rich O
domain O
of O
the O
LDL B
receptor I
( O
LDLR B
) O
in O
place O
of O
the O
DAF B
- I
derived I
serine I
/ I
threonine I
- I
rich I
sequences I
, O
does O
not O
become O
GPI O
anchored O
. O

Thus O
, O
the O
pathway O
to O
Fc B
epsilonRI I
- O
mediated O
MEK B
/ O
ERK B
and O
ERK B
activation O
can O
apparently O
bypass O
Ras B
and O
Raf B
- I
1 I
. O

Thus O
, O
the O
pathway O
to O
Fc B
epsilonRI I
- O
mediated O
MEK B
/ O
ERK B
and O
ERK B
activation O
can O
apparently O
bypass O
Ras B
and O
Raf B
- I
1 I
. O

Thus O
, O
the O
pathway O
to O
Fc B
epsilonRI I
- O
mediated O
MEK B
/ O
ERK B
and O
ERK B
activation O
can O
apparently O
bypass O
Ras B
and O
Raf B
- I
1 I
. O

Thus O
, O
the O
pathway O
to O
Fc B
epsilonRI I
- O
mediated O
MEK B
/ O
ERK B
and O
ERK B
activation O
can O
apparently O
bypass O
Ras B
and O
Raf B
- I
1 I
. O

Ftz B
, O
on O
the O
other O
hand O
, O
influences O
Ftz B
- O
F1 B
activity O
by O
interacting O
with O
its O
AF O
- O
2 O
domain O
in O
a O
manner O
that O
mimics O
a O
nuclear O
receptor O
coactivator O
. O

Ftz B
, O
on O
the O
other O
hand O
, O
influences O
Ftz B
- O
F1 B
activity O
by O
interacting O
with O
its O
AF O
- O
2 O
domain O
in O
a O
manner O
that O
mimics O
a O
nuclear O
receptor O
coactivator O
. O

Ftz B
, O
on O
the O
other O
hand O
, O
influences O
Ftz B
- O
F1 B
activity O
by O
interacting O
with O
its O
AF O
- O
2 O
domain O
in O
a O
manner O
that O
mimics O
a O
nuclear O
receptor O
coactivator O
. O

The O
cloning O
of O
CWH43 B
showed O
that O
it O
corresponds O
to O
YCR017c B
and O
encodes O
a O
protein O
with O
14 O
- O
16 O
transmembrane O
segments O
containing O
several O
putative O
phosphorylation O
and O
glycosylation O
sites O
. O

The O
cloning O
of O
CWH43 B
showed O
that O
it O
corresponds O
to O
YCR017c B
and O
encodes O
a O
protein O
with O
14 O
- O
16 O
transmembrane O
segments O
containing O
several O
putative O
phosphorylation O
and O
glycosylation O
sites O
. O

However O
, O
strains O
in O
which O
both O
of O
the O
two O
most O
highly O
related O
genes O
, O
DdPIK1 B
and O
DdPIK2 B
, O
were O
disrupted O
showed O
both O
growth O
and O
developmental O
defects O
, O
while O
double O
knockouts O
of O
DdPIK1 B
and O
DdPIK3 B
and O
DdPIK2 B
and O
DdPIK3 B
appear O
to O
be O
lethal O
. O

However O
, O
strains O
in O
which O
both O
of O
the O
two O
most O
highly O
related O
genes O
, O
DdPIK1 B
and O
DdPIK2 B
, O
were O
disrupted O
showed O
both O
growth O
and O
developmental O
defects O
, O
while O
double O
knockouts O
of O
DdPIK1 B
and O
DdPIK3 B
and O
DdPIK2 B
and O
DdPIK3 B
appear O
to O
be O
lethal O
. O

However O
, O
strains O
in O
which O
both O
of O
the O
two O
most O
highly O
related O
genes O
, O
DdPIK1 B
and O
DdPIK2 B
, O
were O
disrupted O
showed O
both O
growth O
and O
developmental O
defects O
, O
while O
double O
knockouts O
of O
DdPIK1 B
and O
DdPIK3 B
and O
DdPIK2 B
and O
DdPIK3 B
appear O
to O
be O
lethal O
. O

However O
, O
strains O
in O
which O
both O
of O
the O
two O
most O
highly O
related O
genes O
, O
DdPIK1 B
and O
DdPIK2 B
, O
were O
disrupted O
showed O
both O
growth O
and O
developmental O
defects O
, O
while O
double O
knockouts O
of O
DdPIK1 B
and O
DdPIK3 B
and O
DdPIK2 B
and O
DdPIK3 B
appear O
to O
be O
lethal O
. O

However O
, O
strains O
in O
which O
both O
of O
the O
two O
most O
highly O
related O
genes O
, O
DdPIK1 B
and O
DdPIK2 B
, O
were O
disrupted O
showed O
both O
growth O
and O
developmental O
defects O
, O
while O
double O
knockouts O
of O
DdPIK1 B
and O
DdPIK3 B
and O
DdPIK2 B
and O
DdPIK3 B
appear O
to O
be O
lethal O
. O

However O
, O
strains O
in O
which O
both O
of O
the O
two O
most O
highly O
related O
genes O
, O
DdPIK1 B
and O
DdPIK2 B
, O
were O
disrupted O
showed O
both O
growth O
and O
developmental O
defects O
, O
while O
double O
knockouts O
of O
DdPIK1 B
and O
DdPIK3 B
and O
DdPIK2 B
and O
DdPIK3 B
appear O
to O
be O
lethal O
. O

This O
mechanism O
seems O
to O
be O
involved O
in O
VIP B
- O
induced O
PRL B
gene I
regulation O
. O

These O
properties O
prompted O
us O
to O
investigate O
Ets B
- I
1 I
expression O
in O
32 O
human O
astroglial O
tumors O
of O
WHO O
grades O
I O
- O
IV O
and O
to O
correlate O
the O
data O
with O
the O
expression O
pattern O
of O
VEGF B
, O
Flt B
- I
1 I
, O
and O
KDR B
. O

These O
properties O
prompted O
us O
to O
investigate O
Ets B
- I
1 I
expression O
in O
32 O
human O
astroglial O
tumors O
of O
WHO O
grades O
I O
- O
IV O
and O
to O
correlate O
the O
data O
with O
the O
expression O
pattern O
of O
VEGF B
, O
Flt B
- I
1 I
, O
and O
KDR B
. O

Mean O
concentration O
of O
insulin B
in O
maternal O
plasma O
across O
all O
sampling O
times O
was O
higher O
in O
ethanol O
treated O
animals O
. O

E1A B
+ O
cHa B
- I
ras I
transformed O
rat O
embryo O
fibroblast O
cells O
are O
characterized O
by O
high O
and O
constitutive O
DNA O
binding O
activities O
of O
AP B
- I
1 I
dimers I
with O
significantly O
altered O
composition O
. O

Nuclear O
localization O
of O
this O
SNF2 B
- I
like I
putative O
helicase B
is O
dependent O
on O
a O
nuclear O
localization O
sequence O
located O
in O
the O
NH2 O
- O
terminal O
region O
. O

The O
feasibility O
of O
creating O
CR1 B
/ O
Ig B
chimeras O
makes O
possible O
a O
new O
strategy O
of O
targeting O
complement O
inhibition O
by O
the O
use O
of O
Ig B
fusion I
partners I
having O
particular O
antigenic O
specificities O
. O

The O
feasibility O
of O
creating O
CR1 B
/ O
Ig B
chimeras O
makes O
possible O
a O
new O
strategy O
of O
targeting O
complement O
inhibition O
by O
the O
use O
of O
Ig B
fusion I
partners I
having O
particular O
antigenic O
specificities O
. O

Here O
we O
show O
that O
inhibition O
occurs O
with O
a O
NS1 B
- O
Rev B
chimera O
in O
which O
the O
78 O
amino O
- O
terminal O
amino O
acids O
of O
the O
NS1A B
protein I
comprising O
its O
entire O
RNA O
- O
binding O
domain O
is O
deleted O
, O
thereby O
establishing O
that O
this O
carboxyl O
portion O
of O
the O
NS1A B
protein I
can O
function O
as O
an O
independent O
effector O
domain O
. O

Here O
we O
show O
that O
inhibition O
occurs O
with O
a O
NS1 B
- O
Rev B
chimera O
in O
which O
the O
78 O
amino O
- O
terminal O
amino O
acids O
of O
the O
NS1A B
protein I
comprising O
its O
entire O
RNA O
- O
binding O
domain O
is O
deleted O
, O
thereby O
establishing O
that O
this O
carboxyl O
portion O
of O
the O
NS1A B
protein I
can O
function O
as O
an O
independent O
effector O
domain O
. O

The O
testes O
of O
8 O
specimens O
of O
Triturus O
marmoratus O
were O
collected O
during O
each O
month O
of O
1987 O
and O
processed O
for O
electron O
microscopy O
and O
light O
microscopy O
demonstration O
of O
testosterone O
( O
T O
) O
following O
the O
ABC B
( O
avidin B
- I
biotin I
peroxidase I
complex I
) O
method O
. O

Primer O
extension O
analysis O
and O
subcloning O
of O
the O
virJ B
- O
phoA B
fusion O
indicate O
that O
the O
acetosyringone O
- O
inducible O
promoter O
lies O
directly O
upstream O
of O
the O
virJ B
structural I
gene I
. O

Primer O
extension O
analysis O
and O
subcloning O
of O
the O
virJ B
- O
phoA B
fusion O
indicate O
that O
the O
acetosyringone O
- O
inducible O
promoter O
lies O
directly O
upstream O
of O
the O
virJ B
structural I
gene I
. O

Using O
in O
vivo O
screening O
, O
we O
first O
identified O
a O
gene O
that O
appeared O
to O
interfere O
with O
the O
His O
- O
Asp O
phosphorelay O
between O
the O
HPt O
domain O
and O
the O
receiver O
domain O
of O
OmpR B
, O
provided O
that O
the O
gene O
product O
was O
expressed O
through O
a O
multicopy O
plasmid O
. O

The O
non B
- I
major I
histocompatibility I
complex I
( O
MHC B
) O
- O
encoded O
CD1 B
family I
has O
recently O
emerged O
as O
a O
new O
antigen O
- O
presenting O
system O
that O
is O
distinct O
from O
either O
MHC B
class I
I I
or I
class I
II I
molecules I
. O

The O
predicted O
amino O
acid O
sequence O
of O
Pst1p B
possessed O
high O
sequence O
homology O
with O
the O
Sin3 B
family I
of O
proteins O
, O
known O
for O
their O
interaction O
with O
histone B
deacetylases I
. O

Removal O
of O
ink4a B
dramatically O
reduces O
the O
lymphoid O
and O
neurological O
defects O
seen O
in O
bmi B
- I
1 I
- O
deficient O
mice O
, O
indicating O
that O
ink4a B
is O
a O
critical O
in O
vivo O
target O
for O
Bmi B
- I
1 I
. O

Removal O
of O
ink4a B
dramatically O
reduces O
the O
lymphoid O
and O
neurological O
defects O
seen O
in O
bmi B
- I
1 I
- O
deficient O
mice O
, O
indicating O
that O
ink4a B
is O
a O
critical O
in O
vivo O
target O
for O
Bmi B
- I
1 I
. O

We O
found O
that O
RXR B
and O
VDR B
transactivated O
selectively O
from O
VDRE O
- O
linked O
templates O
exclusively O
as O
a O
heterodimeric O
complex O
, O
since O
neither O
receptor O
alone O
enhanced O
transcription O
in O
vitro O
. O

We O
found O
that O
RXR B
and O
VDR B
transactivated O
selectively O
from O
VDRE O
- O
linked O
templates O
exclusively O
as O
a O
heterodimeric O
complex O
, O
since O
neither O
receptor O
alone O
enhanced O
transcription O
in O
vitro O
. O

Early O
complement O
components O
, O
C1q B
and O
C4 B
, O
and O
IgA B
secretory O
piece O
were O
absent O
. O

Early O
complement O
components O
, O
C1q B
and O
C4 B
, O
and O
IgA B
secretory O
piece O
were O
absent O
. O

Early O
complement O
components O
, O
C1q B
and O
C4 B
, O
and O
IgA B
secretory O
piece O
were O
absent O
. O

Using O
a O
dominant O
negative O
form O
of O
Sp3 B
and O
transcriptional O
activation O
assays O
in O
Schneider O
SL O
- O
2 O
insect O
cells O
, O
it O
was O
confirmed O
that O
ERalpha B
- O
Sp3 B
interactions O
define O
a O
pathway O
for O
E2 B
- O
mediated O
inhibition O
of O
gene O
expression O
, O
and O
this O
represents O
a O
new O
mechanism O
for O
decreased O
gene O
expression O
by O
E2 B
. O

Using O
a O
dominant O
negative O
form O
of O
Sp3 B
and O
transcriptional O
activation O
assays O
in O
Schneider O
SL O
- O
2 O
insect O
cells O
, O
it O
was O
confirmed O
that O
ERalpha B
- O
Sp3 B
interactions O
define O
a O
pathway O
for O
E2 B
- O
mediated O
inhibition O
of O
gene O
expression O
, O
and O
this O
represents O
a O
new O
mechanism O
for O
decreased O
gene O
expression O
by O
E2 B
. O

Using O
a O
dominant O
negative O
form O
of O
Sp3 B
and O
transcriptional O
activation O
assays O
in O
Schneider O
SL O
- O
2 O
insect O
cells O
, O
it O
was O
confirmed O
that O
ERalpha B
- O
Sp3 B
interactions O
define O
a O
pathway O
for O
E2 B
- O
mediated O
inhibition O
of O
gene O
expression O
, O
and O
this O
represents O
a O
new O
mechanism O
for O
decreased O
gene O
expression O
by O
E2 B
. O

Using O
a O
dominant O
negative O
form O
of O
Sp3 B
and O
transcriptional O
activation O
assays O
in O
Schneider O
SL O
- O
2 O
insect O
cells O
, O
it O
was O
confirmed O
that O
ERalpha B
- O
Sp3 B
interactions O
define O
a O
pathway O
for O
E2 B
- O
mediated O
inhibition O
of O
gene O
expression O
, O
and O
this O
represents O
a O
new O
mechanism O
for O
decreased O
gene O
expression O
by O
E2 B
. O

Using O
a O
dominant O
negative O
form O
of O
Sp3 B
and O
transcriptional O
activation O
assays O
in O
Schneider O
SL O
- O
2 O
insect O
cells O
, O
it O
was O
confirmed O
that O
ERalpha B
- O
Sp3 B
interactions O
define O
a O
pathway O
for O
E2 B
- O
mediated O
inhibition O
of O
gene O
expression O
, O
and O
this O
represents O
a O
new O
mechanism O
for O
decreased O
gene O
expression O
by O
E2 B
. O

In O
this O
study O
, O
we O
verified O
that O
PI B
3 I
- I
kinase I
associates O
with O
the O
CD4 B
: O
p56lck B
complex I
as O
judged O
by O
the O
presence O
of O
PI O
3 O
- O
phosphate O
generated O
from O
anti B
- I
CD4 I
immunoprecipitates O
and O
detected O
by O
high O
- O
pressure O
liquid O
chromatographic O
analysis O
. O

In O
this O
study O
, O
a O
site O
of O
PDGF B
- O
induced O
tyrosine O
phosphorylation O
was O
mapped O
to O
Tyr O
138 O
in O
the O
SH3 B
domain I
; O
Tyr O
138 O
is O
exposed O
on O
the O
SH3 B
peptide I
binding I
surface I
. O

YDL003w B
( O
also O
termed O
MCD1 B
) O
is O
a O
homologue O
of O
Schizosaccharomyces B
pombe I
rad21 I
, O
an O
essential O
gene O
implicated O
in O
DNA O
double O
- O
strand O
break O
repair O
and O
nuclear O
organization O
in O
fission O
yeast O
. O

YDL003w B
( O
also O
termed O
MCD1 B
) O
is O
a O
homologue O
of O
Schizosaccharomyces B
pombe I
rad21 I
, O
an O
essential O
gene O
implicated O
in O
DNA O
double O
- O
strand O
break O
repair O
and O
nuclear O
organization O
in O
fission O
yeast O
. O

Indications O
for O
therapy O
using O
MAO B
inhibitors O

Footprints O
on O
the O
HPV B
18 I
enhancer I
show O
five O
protected O
regions O
with O
homologies O
to O
NF1 B
, O
AP1 B
and O
EFII B
transcription I
factor I
binding I
motifs I
. O

Footprints O
on O
the O
HPV B
18 I
enhancer I
show O
five O
protected O
regions O
with O
homologies O
to O
NF1 B
, O
AP1 B
and O
EFII B
transcription I
factor I
binding I
motifs I
. O

Insulin B
binding O
to O
the O
alpha O
- O
subunit O
of O
its O
receptor O
stimulates O
the O
receptor B
tyrosine I
kinase I
to O
phosphorylate O
the O
beta O
- O
subunit O
and O
several O
endogenous O
protein O
substrates O
, O
including O
pp120 B
/ O
HA4 B
, O
a O
liver O
- O
specific O
plasma O
membrane O
glycoprotein O
of O
M O
( O
r O
) O
20 O
, O
000 O
. O

Insulin B
binding O
to O
the O
alpha O
- O
subunit O
of O
its O
receptor O
stimulates O
the O
receptor B
tyrosine I
kinase I
to O
phosphorylate O
the O
beta O
- O
subunit O
and O
several O
endogenous O
protein O
substrates O
, O
including O
pp120 B
/ O
HA4 B
, O
a O
liver O
- O
specific O
plasma O
membrane O
glycoprotein O
of O
M O
( O
r O
) O
20 O
, O
000 O
. O

Insulin B
binding O
to O
the O
alpha O
- O
subunit O
of O
its O
receptor O
stimulates O
the O
receptor B
tyrosine I
kinase I
to O
phosphorylate O
the O
beta O
- O
subunit O
and O
several O
endogenous O
protein O
substrates O
, O
including O
pp120 B
/ O
HA4 B
, O
a O
liver O
- O
specific O
plasma O
membrane O
glycoprotein O
of O
M O
( O
r O
) O
20 O
, O
000 O
. O

Motilin B
serum O
levels O
were O
measured O
for O
one O
hour O
. O

We O
have O
analyzed O
herein O
the O
roles O
that O
four O
different O
PIAS B
proteins I
( O
ARIP3 B
/ O
PIASx B
alpha I
, O
Miz1 B
/ O
PIASx B
beta I
, O
GBP B
/ O
PIAS1 B
, O
and O
PIAS3 B
) O
play O
in O
the O
regulation O
of O
steroid B
receptor I
- O
or O
STAT B
- O
mediated O
transcriptional O
activation O
. O

We O
have O
analyzed O
herein O
the O
roles O
that O
four O
different O
PIAS B
proteins I
( O
ARIP3 B
/ O
PIASx B
alpha I
, O
Miz1 B
/ O
PIASx B
beta I
, O
GBP B
/ O
PIAS1 B
, O
and O
PIAS3 B
) O
play O
in O
the O
regulation O
of O
steroid B
receptor I
- O
or O
STAT B
- O
mediated O
transcriptional O
activation O
. O

We O
have O
analyzed O
herein O
the O
roles O
that O
four O
different O
PIAS B
proteins I
( O
ARIP3 B
/ O
PIASx B
alpha I
, O
Miz1 B
/ O
PIASx B
beta I
, O
GBP B
/ O
PIAS1 B
, O
and O
PIAS3 B
) O
play O
in O
the O
regulation O
of O
steroid B
receptor I
- O
or O
STAT B
- O
mediated O
transcriptional O
activation O
. O

We O
have O
analyzed O
herein O
the O
roles O
that O
four O
different O
PIAS B
proteins I
( O
ARIP3 B
/ O
PIASx B
alpha I
, O
Miz1 B
/ O
PIASx B
beta I
, O
GBP B
/ O
PIAS1 B
, O
and O
PIAS3 B
) O
play O
in O
the O
regulation O
of O
steroid B
receptor I
- O
or O
STAT B
- O
mediated O
transcriptional O
activation O
. O

We O
have O
analyzed O
herein O
the O
roles O
that O
four O
different O
PIAS B
proteins I
( O
ARIP3 B
/ O
PIASx B
alpha I
, O
Miz1 B
/ O
PIASx B
beta I
, O
GBP B
/ O
PIAS1 B
, O
and O
PIAS3 B
) O
play O
in O
the O
regulation O
of O
steroid B
receptor I
- O
or O
STAT B
- O
mediated O
transcriptional O
activation O
. O

We O
have O
analyzed O
herein O
the O
roles O
that O
four O
different O
PIAS B
proteins I
( O
ARIP3 B
/ O
PIASx B
alpha I
, O
Miz1 B
/ O
PIASx B
beta I
, O
GBP B
/ O
PIAS1 B
, O
and O
PIAS3 B
) O
play O
in O
the O
regulation O
of O
steroid B
receptor I
- O
or O
STAT B
- O
mediated O
transcriptional O
activation O
. O

Previously O
, O
we O
had O
shown O
that O
interleukin B
8 I
( O
IL B
- I
8 I
) O
is O
constitutively O
expressed O
in O
HTLV O
- O
I O
- O
infected O
cells O
and O
in O
cells O
transiently O
expressing O
Tax B
. O

Unlike O
JNK B
activation O
, O
ERK B
activation O
could O
not O
be O
mapped O
to O
specific O
reovirus O
gene O
segments O
, O
suggesting O
that O
ERK B
activation O
and O
JNK B
activation O
are O
triggered O
by O
different O
events O
during O
virus O
- O
host O
cell O
interaction O
. O

Unlike O
JNK B
activation O
, O
ERK B
activation O
could O
not O
be O
mapped O
to O
specific O
reovirus O
gene O
segments O
, O
suggesting O
that O
ERK B
activation O
and O
JNK B
activation O
are O
triggered O
by O
different O
events O
during O
virus O
- O
host O
cell O
interaction O
. O

Unlike O
JNK B
activation O
, O
ERK B
activation O
could O
not O
be O
mapped O
to O
specific O
reovirus O
gene O
segments O
, O
suggesting O
that O
ERK B
activation O
and O
JNK B
activation O
are O
triggered O
by O
different O
events O
during O
virus O
- O
host O
cell O
interaction O
. O

Unlike O
JNK B
activation O
, O
ERK B
activation O
could O
not O
be O
mapped O
to O
specific O
reovirus O
gene O
segments O
, O
suggesting O
that O
ERK B
activation O
and O
JNK B
activation O
are O
triggered O
by O
different O
events O
during O
virus O
- O
host O
cell O
interaction O
. O

B B
and O
C1 B
fusions I
with O
yeast B
GAL4 I
DNA I
- I
binding I
and I
transcriptional I
activation I
domains I
were O
also O
found O
to O
interact O
when O
synthesized O
and O
assayed O
in O
yeast O
. O

Because O
of O
the O
data O
, O
we O
suggest O
that O
LAC9 B
contacts O
positions O
6 O
, O
7 O
, O
and O
8 O
, O
both O
plus O
and O
minus O
, O
of O
the O
UAS O
, O
which O
are O
separated O
by O
more O
than O
one O
turn O
of O
the O
DNA O
helix O
, O
and O
twists O
part O
way O
around O
the O
DNA O
, O
thus O
protecting O
the O
broad O
region O
of O
the O
minor O
groove O
between O
the O
major O
- O
groove O
contacts O
. O

In O
addition O
, O
these O
results O
suggest O
that O
the O
interactions O
, O
and O
consequently O
the O
mechanisms O
, O
governing O
transcriptional O
activation O
by O
CTF B
are O
distinct O
from O
those O
mediating O
DNA O
replication O
. O

The O
reconstituted O
enzyme O
binds O
DNA O
with O
an O
affinity O
that O
is O
approximately O
20 O
- O
fold O
lower O
than O
that O
of O
the O
intact O
topo70 B
. O

We O
propose O
that O
optimal O
transcription O
of O
the O
gD B
gene I
depends O
on O
the O
interaction O
of O
ICP4 B
with O
multiple O
binding O
sites O
across O
the O
gene O
and O
cellular O
factors O
that O
recognize O
specific O
sequence O
elements O
in O
the O
promoter O
. O

Recently O
, O
we O
and O
other O
laboratories O
have O
identified O
a O
family O
of O
caveolin B
- I
related I
proteins I
; O
caveolin B
has O
been O
re O
- O
termed O
caveolin B
- I
1 I
. O

Role O
of O
zinc B
- I
finger I
proteins I
Sp1 I
and O
zif268 B
/ O
egr B
- I
1 I
in O
transcriptional O
regulation O
of O
the O
human B
synaptobrevin I
II I
gene I
. O

E O
. O
granulosus O
infection O
has O
been O
confirmed O
in O
25 O
patients O
( O
20 O
. O
6 O
% O
) O
, O
in O
16 O
cases O
by O
finding O
parasite O
protoscoleces O
or O
hooks O
and O
in O
nine O
cases O
by O
detection O
of O
an O
antigen O
specific O
for O
E B
. I
granulosus I
, I
antigen I
5 I
( O
Ag5 B
) O
. O

First O
, O
mutations O
in O
the O
IFNgamma B
- I
activated I
sequence I
( O
GAS B
) O
, O
either O
multimerized O
or O
in O
the O
context O
of O
the O
1 B
. I
7 I
- I
kb I
IRF I
- I
1 I
promoter I
, O
failed O
to O
mediate O
a O
PRL B
response O
, O
showing O
that O
the O
IRF B
- I
1 I
GAS B
is O
a O
target O
of O
PRL B
signaling O
. O

First O
, O
mutations O
in O
the O
IFNgamma B
- I
activated I
sequence I
( O
GAS B
) O
, O
either O
multimerized O
or O
in O
the O
context O
of O
the O
1 B
. I
7 I
- I
kb I
IRF I
- I
1 I
promoter I
, O
failed O
to O
mediate O
a O
PRL B
response O
, O
showing O
that O
the O
IRF B
- I
1 I
GAS B
is O
a O
target O
of O
PRL B
signaling O
. O

First O
, O
mutations O
in O
the O
IFNgamma B
- I
activated I
sequence I
( O
GAS B
) O
, O
either O
multimerized O
or O
in O
the O
context O
of O
the O
1 B
. I
7 I
- I
kb I
IRF I
- I
1 I
promoter I
, O
failed O
to O
mediate O
a O
PRL B
response O
, O
showing O
that O
the O
IRF B
- I
1 I
GAS B
is O
a O
target O
of O
PRL B
signaling O
. O

First O
, O
mutations O
in O
the O
IFNgamma B
- I
activated I
sequence I
( O
GAS B
) O
, O
either O
multimerized O
or O
in O
the O
context O
of O
the O
1 B
. I
7 I
- I
kb I
IRF I
- I
1 I
promoter I
, O
failed O
to O
mediate O
a O
PRL B
response O
, O
showing O
that O
the O
IRF B
- I
1 I
GAS B
is O
a O
target O
of O
PRL B
signaling O
. O

This O
selective O
squelching O
activity O
suggests O
that O
GRIM B
can O
interact O
with O
an O
essential O
component O
of O
the O
RNA B
polymerase I
II I
transcription O
machinery O
. O

A O
360 O
- O
bp O
DNA O
fragment O
located O
over O
500 O
bp O
upstream O
from O
the O
cfl B
transcriptional O
start O
site O
was O
used O
in O
DNase B
I I
protection O
assays O
to O
define O
the O
specific O
bases O
bound O
by O
CorR B
. O

A O
360 O
- O
bp O
DNA O
fragment O
located O
over O
500 O
bp O
upstream O
from O
the O
cfl B
transcriptional O
start O
site O
was O
used O
in O
DNase B
I I
protection O
assays O
to O
define O
the O
specific O
bases O
bound O
by O
CorR B
. O

Nramp2 B
contains O
a O
classical O
iron O
responsive O
element O
in O
the O
3 O
' O
untranslated O
region O
that O
confers O
iron O
dependent O
mRNA O
stabilization O
. O

A O
mutated B
ABF1 I
site I
that O
displays O
a O
very O
low O
affinity O
for O
ABF1 B
does O
not O
functionally O
replace O
the O
ILV1 B
REB1 B
site I
. O

A O
mutated B
ABF1 I
site I
that O
displays O
a O
very O
low O
affinity O
for O
ABF1 B
does O
not O
functionally O
replace O
the O
ILV1 B
REB1 B
site I
. O

A O
nationwide O
survey O
uncovered O
a O
tenfold O
variation O
between O
counties O
in O
the O
prescribing O
of O
IFNB B
. O

This O
is O
the O
first O
report O
which O
clearly O
proved O
CEA B
synthesis O
in O
the O
cells O
of O
HCC O
. O

By O
screening O
a O
human O
testis O
cDNA O
library O
with O
a O
probe O
containing O
the O
mouse B
PEA3 I
ETS B
domain O
, O
we O
isolated O
a O
2 O
. O
2 O
kb O
clone O
containing O
a O
510 O
AA O
open O
reading O
frame O
. O

These O
findings O
suggest O
that O
IL B
- I
1 I
- O
stimulated O
, O
Rho B
- O
dependent O
cytoskeletal O
reorganization O
may O
cluster O
signaling O
molecules O
in O
specific O
architectures O
that O
are O
necessary O
for O
persistent O
cell O
activation O
in O
chronic O
inflammatory O
disease O
. O

The O
requirement O
for O
an O
essential O
interaction O
between O
NPH B
I I
and O
H4L B
provides O
an O
explanation O
for O
the O
observed O
restriction O
of O
transcription O
termination O
to O
early O
viral O
genes O
. O

After O
birth O
, O
there O
was O
a O
significantly O
higher O
increase O
of O
IgA B
and O
IgM B
anti I
- I
M I
. I
leprae I
antibody I
activity O
in O
sera O
taken O
3 O
- O
6 O
months O
after O
birth O
from O
babies O
of O
Group O
1 O
compared O
to O
Group O
2 O
, O
but O
the O
IgA B
and O
IgM B
activity O
in O
sera O
taken O
after O
6 O
months O
of O
age O
showed O
the O
same O
increase O
in O
the O
two O
groups O
. O

After O
birth O
, O
there O
was O
a O
significantly O
higher O
increase O
of O
IgA B
and O
IgM B
anti I
- I
M I
. I
leprae I
antibody I
activity O
in O
sera O
taken O
3 O
- O
6 O
months O
after O
birth O
from O
babies O
of O
Group O
1 O
compared O
to O
Group O
2 O
, O
but O
the O
IgA B
and O
IgM B
activity O
in O
sera O
taken O
after O
6 O
months O
of O
age O
showed O
the O
same O
increase O
in O
the O
two O
groups O
. O

After O
birth O
, O
there O
was O
a O
significantly O
higher O
increase O
of O
IgA B
and O
IgM B
anti I
- I
M I
. I
leprae I
antibody I
activity O
in O
sera O
taken O
3 O
- O
6 O
months O
after O
birth O
from O
babies O
of O
Group O
1 O
compared O
to O
Group O
2 O
, O
but O
the O
IgA B
and O
IgM B
activity O
in O
sera O
taken O
after O
6 O
months O
of O
age O
showed O
the O
same O
increase O
in O
the O
two O
groups O
. O

The O
relation O
between O
the O
changes O
of O
bone O
density O
and O
the O
level O
of O
blood O
calcium O
, O
blood O
phosphorus O
and O
alkaline B
phosphatase I
( O
AKP B
) O
as O
well O
as O
the O
metabolism O
of O
vitamin O
D O
was O
studied O
. O

NSD1 B
contains O
a O
SET B
domain I
and O
multiple O
PHD O
fingers O
. O

This O
evaluation O
examines O
several O
analytical O
and O
cost O
parameters O
for O
five O
representative O
assays O
: O
IgG B
, O
IgA B
, O
IgM B
, O
phenytoin O
, O
and O
phenobarbital O
. O

This O
evaluation O
examines O
several O
analytical O
and O
cost O
parameters O
for O
five O
representative O
assays O
: O
IgG B
, O
IgA B
, O
IgM B
, O
phenytoin O
, O
and O
phenobarbital O
. O

This O
evaluation O
examines O
several O
analytical O
and O
cost O
parameters O
for O
five O
representative O
assays O
: O
IgG B
, O
IgA B
, O
IgM B
, O
phenytoin O
, O
and O
phenobarbital O
. O

These O
results O
suggest O
that O
UvrA B
is O
involved O
in O
triplet O
repeat O
instability O
in O
cells O
. O

A O
novel O
protein B
kinase I
C I
( O
PKC B
) O
- O
interacting O
protein O
was O
identified O
by O
the O
yeast O
two O
- O
hybrid O
screening O
using O
the O
regulatory O
domain O
of O
PKC B
beta I
I I
as O
a O
bait O
. O

One O
of O
the O
repeating O
domains O
( O
Yheb1 B
) O
, O
consisting O
of O
67 O
amino O
acids O
, O
was O
cloned O
from O
the O
E O
. O
coli O
chromosome O
and O
purified O
by O
metal O
chelating O
chromatography O
. O

Phosphorylation O
at O
Ser O
( O
670 O
) O
impairs O
the O
ability O
of O
GRK2 B
to O
phosphorylate O
both O
soluble O
and O
membrane O
- O
incorporated O
receptor O
substrates O
and O
dramatically O
attenuates O
Gbetagamma B
- O
mediated O
activation O
of O
this O
enzyme O
. O

Phosphorylation O
at O
Ser O
( O
670 O
) O
impairs O
the O
ability O
of O
GRK2 B
to O
phosphorylate O
both O
soluble O
and O
membrane O
- O
incorporated O
receptor O
substrates O
and O
dramatically O
attenuates O
Gbetagamma B
- O
mediated O
activation O
of O
this O
enzyme O
. O

METHODS O
: O
CD4 B
cell O
counts O
and O
interview O
data O
were O
recorded O
in O
a O
survey O
of O
136 O
adult O
patients O
attending O
a O
community O
hospital O
- O
based O
HIV O
outpatient O
clinic O
. O

The O
binding O
of O
PTB B
was O
antagonistic O
to O
the O
binding O
of O
U2AF B
to O
the O
enhancer O
- O
located O
pyrimidine O
tract O
. O

The O
binding O
of O
PTB B
was O
antagonistic O
to O
the O
binding O
of O
U2AF B
to O
the O
enhancer O
- O
located O
pyrimidine O
tract O
. O

However O
, O
studies O
using O
the O
A20 B
promoter I
demonstrated O
that O
LMP1 B
transcriptionally O
activates O
the O
A20 B
gene I
through O
cis O
- O
acting O
kappa B
B I
sites I
. O

Southern O
blot O
analysis O
revealed O
that O
CCaMK B
is O
encoded O
by O
a O
single O
gene O
. O

Phenazopyridine O
- O
induced O
hemolytic O
anemia O
in O
a O
patient O
with O
G6PD B
deficiency O
. O

The O
activation O
of O
NF B
- I
kappaB I
- O
dependent O
reporter O
gene O
transcription O
by O
E1A B
was O
potently O
suppressed O
upon O
coexpression O
of O
the O
E1B B
19 I
- I
kDa I
protein I
( I
19K I
) I
. O

The O
myeloid B
zinc I
finger I
gene I
1 I
( O
MZF1 B
) O
encodes O
a O
C B
( I
2 I
) I
H I
( I
2 I
) I
zinc I
finger I
transcription I
factor I
that O
regulates O
granulopoiesis O
and O
may O
have O
a O
regulatory O
role O
in O
cellular O
proliferation O
and O
oncogenesis O
. O

We O
conclude O
that O
GRF1 B
and O
GRF2 B
can O
form O
homo O
- O
and O
hetero O
- O
oligomers O
via O
their O
DH B
domains I
, O
that O
mutational O
inactivation O
of O
oligomer O
formation O
by O
GRF1 B
is O
associated O
with O
impaired O
biological O
and O
signaling O
activities O
, O
and O
that O
in O
293T O
cells O
GRF1 B
mediates O
at O
least O
two O
pathways O
for O
Raf B
activation O
: O
one O
a O
constitutive O
signal O
that O
is O
mainly O
Ras B
- O
dependent O
, O
and O
one O
an O
ionomycin O
- O
induced O
signal O
that O
cooperates O
with O
the O
constitutive O
signal O
without O
further O
augmenting O
the O
level O
of O
GTP B
- I
Ras I

We O
conclude O
that O
GRF1 B
and O
GRF2 B
can O
form O
homo O
- O
and O
hetero O
- O
oligomers O
via O
their O
DH B
domains I
, O
that O
mutational O
inactivation O
of O
oligomer O
formation O
by O
GRF1 B
is O
associated O
with O
impaired O
biological O
and O
signaling O
activities O
, O
and O
that O
in O
293T O
cells O
GRF1 B
mediates O
at O
least O
two O
pathways O
for O
Raf B
activation O
: O
one O
a O
constitutive O
signal O
that O
is O
mainly O
Ras B
- O
dependent O
, O
and O
one O
an O
ionomycin O
- O
induced O
signal O
that O
cooperates O
with O
the O
constitutive O
signal O
without O
further O
augmenting O
the O
level O
of O
GTP B
- I
Ras I

We O
conclude O
that O
GRF1 B
and O
GRF2 B
can O
form O
homo O
- O
and O
hetero O
- O
oligomers O
via O
their O
DH B
domains I
, O
that O
mutational O
inactivation O
of O
oligomer O
formation O
by O
GRF1 B
is O
associated O
with O
impaired O
biological O
and O
signaling O
activities O
, O
and O
that O
in O
293T O
cells O
GRF1 B
mediates O
at O
least O
two O
pathways O
for O
Raf B
activation O
: O
one O
a O
constitutive O
signal O
that O
is O
mainly O
Ras B
- O
dependent O
, O
and O
one O
an O
ionomycin O
- O
induced O
signal O
that O
cooperates O
with O
the O
constitutive O
signal O
without O
further O
augmenting O
the O
level O
of O
GTP B
- I
Ras I

We O
conclude O
that O
GRF1 B
and O
GRF2 B
can O
form O
homo O
- O
and O
hetero O
- O
oligomers O
via O
their O
DH B
domains I
, O
that O
mutational O
inactivation O
of O
oligomer O
formation O
by O
GRF1 B
is O
associated O
with O
impaired O
biological O
and O
signaling O
activities O
, O
and O
that O
in O
293T O
cells O
GRF1 B
mediates O
at O
least O
two O
pathways O
for O
Raf B
activation O
: O
one O
a O
constitutive O
signal O
that O
is O
mainly O
Ras B
- O
dependent O
, O
and O
one O
an O
ionomycin O
- O
induced O
signal O
that O
cooperates O
with O
the O
constitutive O
signal O
without O
further O
augmenting O
the O
level O
of O
GTP B
- I
Ras I

We O
conclude O
that O
GRF1 B
and O
GRF2 B
can O
form O
homo O
- O
and O
hetero O
- O
oligomers O
via O
their O
DH B
domains I
, O
that O
mutational O
inactivation O
of O
oligomer O
formation O
by O
GRF1 B
is O
associated O
with O
impaired O
biological O
and O
signaling O
activities O
, O
and O
that O
in O
293T O
cells O
GRF1 B
mediates O
at O
least O
two O
pathways O
for O
Raf B
activation O
: O
one O
a O
constitutive O
signal O
that O
is O
mainly O
Ras B
- O
dependent O
, O
and O
one O
an O
ionomycin O
- O
induced O
signal O
that O
cooperates O
with O
the O
constitutive O
signal O
without O
further O
augmenting O
the O
level O
of O
GTP B
- I
Ras I

We O
conclude O
that O
GRF1 B
and O
GRF2 B
can O
form O
homo O
- O
and O
hetero O
- O
oligomers O
via O
their O
DH B
domains I
, O
that O
mutational O
inactivation O
of O
oligomer O
formation O
by O
GRF1 B
is O
associated O
with O
impaired O
biological O
and O
signaling O
activities O
, O
and O
that O
in O
293T O
cells O
GRF1 B
mediates O
at O
least O
two O
pathways O
for O
Raf B
activation O
: O
one O
a O
constitutive O
signal O
that O
is O
mainly O
Ras B
- O
dependent O
, O
and O
one O
an O
ionomycin O
- O
induced O
signal O
that O
cooperates O
with O
the O
constitutive O
signal O
without O
further O
augmenting O
the O
level O
of O
GTP B
- I
Ras I

These O
observed O
changes O
were O
not O
found O
when O
assessing O
NPY B
level O
in O
plasma O
fluid O
. O

Protein B
kinase I
C I
( O
PKC B
) O
activation O
after O
treatment O
of O
human O
neuroblastoma O
SK O
- O
N O
- O
BE O
( O
2 O
) O
C O
cells O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
was O
found O
to O
enhance O
transcription O
of O
the O
human O
dopamine B
beta I
- I
hydroxylase I
( O
DBH B
) O
in O
those O
cells O
. O

Protein B
kinase I
C I
( O
PKC B
) O
activation O
after O
treatment O
of O
human O
neuroblastoma O
SK O
- O
N O
- O
BE O
( O
2 O
) O
C O
cells O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
was O
found O
to O
enhance O
transcription O
of O
the O
human O
dopamine B
beta I
- I
hydroxylase I
( O
DBH B
) O
in O
those O
cells O
. O

The O
genomic O
organization O
in O
this O
region O
is O
similar O
to O
the O
neural O
- O
restricted O
family O
members O
, O
Hel B
- I
N1 I
( O
ELAVL2 B
) O
and O
mHuD B
( O
Elavl4 B
) O
. O

The O
genomic O
organization O
in O
this O
region O
is O
similar O
to O
the O
neural O
- O
restricted O
family O
members O
, O
Hel B
- I
N1 I
( O
ELAVL2 B
) O
and O
mHuD B
( O
Elavl4 B
) O
. O

The O
genomic O
organization O
in O
this O
region O
is O
similar O
to O
the O
neural O
- O
restricted O
family O
members O
, O
Hel B
- I
N1 I
( O
ELAVL2 B
) O
and O
mHuD B
( O
Elavl4 B
) O
. O

Synergistic O
induction O
of O
apoptosis O
in O
human O
leukemia O
cells O
( O
U937 O
) O
exposed O
to O
bryostatin O
1 O
and O
the O
proteasome O
inhibitor O
lactacystin O
involves O
dysregulation O
of O
the O
PKC B
/ O
MAPK B
cascade O
. O

Synergistic O
induction O
of O
apoptosis O
in O
human O
leukemia O
cells O
( O
U937 O
) O
exposed O
to O
bryostatin O
1 O
and O
the O
proteasome O
inhibitor O
lactacystin O
involves O
dysregulation O
of O
the O
PKC B
/ O
MAPK B
cascade O
. O

The O
role O
of O
haptoglobin B
in O
asphyxia O
mechanism O
( O
II O
) O
- O
- O
Acute O
drowning O
and O
hanging O

Thus O
, O
BCR B
ligation O
initiates O
a O
PI B
3 I
- I
kinase I
/ O
Akt B
/ O
GSK B
- I
3 I
signaling O
pathway O
. O

Thus O
, O
BCR B
ligation O
initiates O
a O
PI B
3 I
- I
kinase I
/ O
Akt B
/ O
GSK B
- I
3 I
signaling O
pathway O
. O

cDNA O
cloning O
and O
transcriptional O
properties O
of O
a O
novel O
GC B
box I
- I
binding I
protein I
, O
BTEB2 B
. O

In O
contrast O
SF B
, O
but O
not O
GM B
- I
CSF I
or O
IL B
- I
3 I
, O
induced O
tyrosine O
phosphorylation O
of O
phospholipase B
C I
- I
gamma I
( O
PLC B
- I
gamma I
) O
. O

Replacement O
of O
Val20 O
- O
Leu21 O
with O
Ala O
- O
Ala O
produced O
a O
dimeric B
RII I
beta I
protein I
that O
binds O
AKAP75 B
approximately O
4 O
% O
as O
avidly O
as O
wild B
- I
type I
RII I
beta I
. O

The O
temporal O
expression O
of O
CRAlBP B
is O
similar O
to O
IRBP B
while O
bFGF B
is O
not O
expressed O
until O
after O
photoreceptor O
differentiation O
is O
complete O
. O

The O
temporal O
expression O
of O
CRAlBP B
is O
similar O
to O
IRBP B
while O
bFGF B
is O
not O
expressed O
until O
after O
photoreceptor O
differentiation O
is O
complete O
. O

The O
temporal O
expression O
of O
CRAlBP B
is O
similar O
to O
IRBP B
while O
bFGF B
is O
not O
expressed O
until O
after O
photoreceptor O
differentiation O
is O
complete O
. O

Replacement O
of O
a O
valine O
( O
V68 O
) O
in O
the O
ETS B
domain O
of O
SAP1a B
by O
aspartic O
acid O
( O
as O
found O
in O
c B
- I
Ets I
- I
1 I
, O
Elk B
- I
1 I
, O
and O
Net B
) O
enhanced O
ternary O
complex O
formation O
by O
more O
than O
60 O
- O
fold O
. O

Replacement O
of O
a O
valine O
( O
V68 O
) O
in O
the O
ETS B
domain O
of O
SAP1a B
by O
aspartic O
acid O
( O
as O
found O
in O
c B
- I
Ets I
- I
1 I
, O
Elk B
- I
1 I
, O
and O
Net B
) O
enhanced O
ternary O
complex O
formation O
by O
more O
than O
60 O
- O
fold O
. O

Replacement O
of O
a O
valine O
( O
V68 O
) O
in O
the O
ETS B
domain O
of O
SAP1a B
by O
aspartic O
acid O
( O
as O
found O
in O
c B
- I
Ets I
- I
1 I
, O
Elk B
- I
1 I
, O
and O
Net B
) O
enhanced O
ternary O
complex O
formation O
by O
more O
than O
60 O
- O
fold O
. O

The O
NF B
- I
kappaB I
/ O
Rel B
transcription O
factors O
participate O
in O
the O
activation O
of O
immune O
system O
regulatory O
genes O
and O
viral B
early I
genes I
including O
the O
human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeat I
. O

Like O
other O
known O
GCD B
genes I
, O
GCD14 B
and O
GCD15 B
are O
therefore O
probably O
required O
for O
general O
translation O
initiation O
in O
addition O
to O
their O
roles O
in O
GCN4 B
- O
specific O
translational O
control O
. O

Like O
other O
known O
GCD B
genes I
, O
GCD14 B
and O
GCD15 B
are O
therefore O
probably O
required O
for O
general O
translation O
initiation O
in O
addition O
to O
their O
roles O
in O
GCN4 B
- O
specific O
translational O
control O
. O

Like O
other O
known O
GCD B
genes I
, O
GCD14 B
and O
GCD15 B
are O
therefore O
probably O
required O
for O
general O
translation O
initiation O
in O
addition O
to O
their O
roles O
in O
GCN4 B
- O
specific O
translational O
control O
. O

This O
gene O
is O
named O
PKNOX1 B
by O
the O
Human O
Nomenclature O
Committee O
. O

The O
D443N B
substitution I
is O
an O
activating O
mutation O
that O
increases O
the O
activity O
of O
SCAP B
and O
renders O
it O
resistant O
to O
inhibition O
by O
25 O
- O
hydroxycholesterol O
. O

Serum B
amyloid I
A I
( O
SAA B
) O
is O
a O
plasma O
protein O
which O
has O
been O
associated O
with O
several O
diseases O
, O
including O
amyloidosis O
, O
arthritis O
, O
and O
atherosclerosis O
, O
and O
its O
abnormal O
expression O
, O
particularly O
in O
nonhepatic O
cells O
, O
is O
implicated O
in O
the O
pathogenesis O
of O
these O
diseases O
. O

Like O
Mdm2 B
, O
MdmX B
is O
able O
to O
bind O
p53 B
and O
inhibit O
p53 B
transactivation O
; O
however O
, O
the O
ability O
of O
MdmX B
to O
degrade O
p53 B
has O
yet O
to O
be O
examined O
. O

Like O
Mdm2 B
, O
MdmX B
is O
able O
to O
bind O
p53 B
and O
inhibit O
p53 B
transactivation O
; O
however O
, O
the O
ability O
of O
MdmX B
to O
degrade O
p53 B
has O
yet O
to O
be O
examined O
. O

Like O
Mdm2 B
, O
MdmX B
is O
able O
to O
bind O
p53 B
and O
inhibit O
p53 B
transactivation O
; O
however O
, O
the O
ability O
of O
MdmX B
to O
degrade O
p53 B
has O
yet O
to O
be O
examined O
. O

Like O
Mdm2 B
, O
MdmX B
is O
able O
to O
bind O
p53 B
and O
inhibit O
p53 B
transactivation O
; O
however O
, O
the O
ability O
of O
MdmX B
to O
degrade O
p53 B
has O
yet O
to O
be O
examined O
. O

Like O
Mdm2 B
, O
MdmX B
is O
able O
to O
bind O
p53 B
and O
inhibit O
p53 B
transactivation O
; O
however O
, O
the O
ability O
of O
MdmX B
to O
degrade O
p53 B
has O
yet O
to O
be O
examined O
. O

Like O
Mdm2 B
, O
MdmX B
is O
able O
to O
bind O
p53 B
and O
inhibit O
p53 B
transactivation O
; O
however O
, O
the O
ability O
of O
MdmX B
to O
degrade O
p53 B
has O
yet O
to O
be O
examined O
. O

The O
nucleotide O
sequence O
of O
a O
PCR O
- O
amplified O
SMT3A B
genomic O
DNA O
fragment O
was O
found O
to O
be O
identical O
to O
that O
of O
SMT3A B
cDNA I
, O
indicating O
the O
absence O
of O
intron O
( O
s O
) O
in O
its O
protein O
coding O
region O
. O

Mutant O
p53 B
DNA I
clones O
from O
human O
colon O
carcinomas O
cooperate O
with O
ras B
in O
transforming O
primary O
rat O
cells O
: O
a O
comparison O
of O
the O
" O
hot O
spot O
" O
mutant O
phenotypes O
. O

Although O
paclitaxel O
alone O
failed O
to O
induce O
p38 B
MAPK O
activation O
, O
subsequent O
( O
but O
not O
prior O
) O
exposure O
to O
PD98059 O
induced O
a O
dramatic O
increase O
in O
p38 B
MAPK O
phosphorylation O
. O

Although O
paclitaxel O
alone O
failed O
to O
induce O
p38 B
MAPK O
activation O
, O
subsequent O
( O
but O
not O
prior O
) O
exposure O
to O
PD98059 O
induced O
a O
dramatic O
increase O
in O
p38 B
MAPK O
phosphorylation O
. O

The O
promoter O
for O
HMG B
- I
CoA I
synthase I
contains O
two O
binding O
sites O
for O
the O
sterol B
regulatory I
element I
- I
binding I
proteins I
( O
SREBPs B
) O
. O

Characterization O
and O
targeted O
disruption O
of O
murine B
Nup50 I
, O
a O
p27 B
( O
Kip1 B
) O
- O
interacting O
component O
of O
the O
nuclear O
pore O
complex O
. O

Characterization O
and O
targeted O
disruption O
of O
murine B
Nup50 I
, O
a O
p27 B
( O
Kip1 B
) O
- O
interacting O
component O
of O
the O
nuclear O
pore O
complex O
. O

p27 B
( O
Kip1 B
) O
is O
a O
member O
of O
the O
Cip B
- O
Kip B
family O
of O
cyclin B
- I
dependent I
kinase I
( O
Cdk B
) O
inhibitors O
that O
binds O
to O
cyclin B
- O
Cdk B
complexes O
and O
inhibits O
their O
catalytic O
activity O
in O
response O
to O
antiproliferative O
stimuli O
. O

p27 B
( O
Kip1 B
) O
is O
a O
member O
of O
the O
Cip B
- O
Kip B
family O
of O
cyclin B
- I
dependent I
kinase I
( O
Cdk B
) O
inhibitors O
that O
binds O
to O
cyclin B
- O
Cdk B
complexes O
and O
inhibits O
their O
catalytic O
activity O
in O
response O
to O
antiproliferative O
stimuli O
. O

p27 B
( O
Kip1 B
) O
is O
a O
member O
of O
the O
Cip B
- O
Kip B
family O
of O
cyclin B
- I
dependent I
kinase I
( O
Cdk B
) O
inhibitors O
that O
binds O
to O
cyclin B
- O
Cdk B
complexes O
and O
inhibits O
their O
catalytic O
activity O
in O
response O
to O
antiproliferative O
stimuli O
. O

p27 B
( O
Kip1 B
) O
is O
a O
member O
of O
the O
Cip B
- O
Kip B
family O
of O
cyclin B
- I
dependent I
kinase I
( O
Cdk B
) O
inhibitors O
that O
binds O
to O
cyclin B
- O
Cdk B
complexes O
and O
inhibits O
their O
catalytic O
activity O
in O
response O
to O
antiproliferative O
stimuli O
. O

p27 B
( O
Kip1 B
) O
is O
a O
member O
of O
the O
Cip B
- O
Kip B
family O
of O
cyclin B
- I
dependent I
kinase I
( O
Cdk B
) O
inhibitors O
that O
binds O
to O
cyclin B
- O
Cdk B
complexes O
and O
inhibits O
their O
catalytic O
activity O
in O
response O
to O
antiproliferative O
stimuli O
. O

p27 B
( O
Kip1 B
) O
is O
a O
member O
of O
the O
Cip B
- O
Kip B
family O
of O
cyclin B
- I
dependent I
kinase I
( O
Cdk B
) O
inhibitors O
that O
binds O
to O
cyclin B
- O
Cdk B
complexes O
and O
inhibits O
their O
catalytic O
activity O
in O
response O
to O
antiproliferative O
stimuli O
. O

p27 B
( O
Kip1 B
) O
is O
a O
member O
of O
the O
Cip B
- O
Kip B
family O
of O
cyclin B
- I
dependent I
kinase I
( O
Cdk B
) O
inhibitors O
that O
binds O
to O
cyclin B
- O
Cdk B
complexes O
and O
inhibits O
their O
catalytic O
activity O
in O
response O
to O
antiproliferative O
stimuli O
. O

p27 B
( O
Kip1 B
) O
is O
regulated O
by O
several O
posttranscriptional O
mechanisms O
, O
including O
subcellular O
localization O
. O

p27 B
( O
Kip1 B
) O
is O
regulated O
by O
several O
posttranscriptional O
mechanisms O
, O
including O
subcellular O
localization O
. O

Mutations O
of O
SIN4 B
, O
ROX3 B
, O
SRB8 B
, O
SRB9 B
, O
SRB10 B
, O
SRB11 B
, O
and O
two O
novel O
genes O
, O
NUT1 B
and O
NUT2 B
, O
relieve O
the O
requirement O
of O
Swi4p B
for O
expression O
of O
this O
reporter O
. O

Mutations O
of O
SIN4 B
, O
ROX3 B
, O
SRB8 B
, O
SRB9 B
, O
SRB10 B
, O
SRB11 B
, O
and O
two O
novel O
genes O
, O
NUT1 B
and O
NUT2 B
, O
relieve O
the O
requirement O
of O
Swi4p B
for O
expression O
of O
this O
reporter O
. O

Mutations O
of O
SIN4 B
, O
ROX3 B
, O
SRB8 B
, O
SRB9 B
, O
SRB10 B
, O
SRB11 B
, O
and O
two O
novel O
genes O
, O
NUT1 B
and O
NUT2 B
, O
relieve O
the O
requirement O
of O
Swi4p B
for O
expression O
of O
this O
reporter O
. O

Mutations O
of O
SIN4 B
, O
ROX3 B
, O
SRB8 B
, O
SRB9 B
, O
SRB10 B
, O
SRB11 B
, O
and O
two O
novel O
genes O
, O
NUT1 B
and O
NUT2 B
, O
relieve O
the O
requirement O
of O
Swi4p B
for O
expression O
of O
this O
reporter O
. O

Mutations O
of O
SIN4 B
, O
ROX3 B
, O
SRB8 B
, O
SRB9 B
, O
SRB10 B
, O
SRB11 B
, O
and O
two O
novel O
genes O
, O
NUT1 B
and O
NUT2 B
, O
relieve O
the O
requirement O
of O
Swi4p B
for O
expression O
of O
this O
reporter O
. O

Mutations O
of O
SIN4 B
, O
ROX3 B
, O
SRB8 B
, O
SRB9 B
, O
SRB10 B
, O
SRB11 B
, O
and O
two O
novel O
genes O
, O
NUT1 B
and O
NUT2 B
, O
relieve O
the O
requirement O
of O
Swi4p B
for O
expression O
of O
this O
reporter O
. O

Mutations O
of O
SIN4 B
, O
ROX3 B
, O
SRB8 B
, O
SRB9 B
, O
SRB10 B
, O
SRB11 B
, O
and O
two O
novel O
genes O
, O
NUT1 B
and O
NUT2 B
, O
relieve O
the O
requirement O
of O
Swi4p B
for O
expression O
of O
this O
reporter O
. O

Mutations O
of O
SIN4 B
, O
ROX3 B
, O
SRB8 B
, O
SRB9 B
, O
SRB10 B
, O
SRB11 B
, O
and O
two O
novel O
genes O
, O
NUT1 B
and O
NUT2 B
, O
relieve O
the O
requirement O
of O
Swi4p B
for O
expression O
of O
this O
reporter O
. O

Mutations O
of O
SIN4 B
, O
ROX3 B
, O
SRB8 B
, O
SRB9 B
, O
SRB10 B
, O
SRB11 B
, O
and O
two O
novel O
genes O
, O
NUT1 B
and O
NUT2 B
, O
relieve O
the O
requirement O
of O
Swi4p B
for O
expression O
of O
this O
reporter O
. O

For O
Thermus O
strain O
ZO5 B
dihydroorotase I
( O
DHOase B
; O
encoded O
by O
pyrC B
) O
, O
the O
highest O
similarity O
scores O
( O
about O
40 O
% O
identity O
) O
were O
obtained O
with O
DHOases B
from O
B O
. O
caldolyticus O
and O
Bacillus O
subtilis O
. O

For O
Thermus O
strain O
ZO5 B
dihydroorotase I
( O
DHOase B
; O
encoded O
by O
pyrC B
) O
, O
the O
highest O
similarity O
scores O
( O
about O
40 O
% O
identity O
) O
were O
obtained O
with O
DHOases B
from O
B O
. O
caldolyticus O
and O
Bacillus O
subtilis O
. O

For O
Thermus O
strain O
ZO5 B
dihydroorotase I
( O
DHOase B
; O
encoded O
by O
pyrC B
) O
, O
the O
highest O
similarity O
scores O
( O
about O
40 O
% O
identity O
) O
were O
obtained O
with O
DHOases B
from O
B O
. O
caldolyticus O
and O
Bacillus O
subtilis O
. O

These O
data O
suggest O
that O
the O
fibrinogen B
gamma I
chain I
region I
Gly190 I
- I
Val202 I
functions O
as O
a O
minimal O
recognition O
sequence O
for O
the O
leukocyte O
integrin O
CD11b B
/ O
CD18 B
. O

These O
data O
suggest O
that O
the O
fibrinogen B
gamma I
chain I
region I
Gly190 I
- I
Val202 I
functions O
as O
a O
minimal O
recognition O
sequence O
for O
the O
leukocyte O
integrin O
CD11b B
/ O
CD18 B
. O

Attenuated O
serum O
cortisol O
responses O
were O
found O
in O
six O
of O
the O
patients O
despite O
a O
normal O
ACTH B
test O
. O

The O
genes O
expressed O
during O
the O
embryonic O
( O
zeta B
) O
or O
fetal O
and O
adult O
stage O
( O
alpha B
2 I
and O
alpha B
1 I
) O
can O
be O
modified O
by O
point O
mutations O
which O
affect O
either O
the O
processing O
- O
translation O
of O
mRNA O
or O
make O
the O
polypeptide O
chains O
extremely O
unstable O
. O

Kaposi O
' O
s O
sarcoma O
- O
associated O
herpesvirus O
/ O
human O
herpesvirus O
- O
8 O
ORF50 B
gene O
product O
contains O
a O
potent O
C O
- O
terminal O
activation O
domain O
which O
activates O
gene O
expression O
via O
a O
specific O
target O
sequence O
. O

The O
efficiency O
of O
transfections O
was O
normalized O
relative O
to O
the O
net O
amount O
of O
CAT B
plasmid O
actually O
transfected O
into O
recipient O
cells O
, O
determined O
by O
a O
modified O
Southern O
hybridization O
procedure O
. O

In O
the O
present O
study O
we O
found O
that O
CD34 B
downregulation O
during O
hematopoiesis O
occured O
at O
the O
level O
of O
transcriptional O
initiation O
. O

Immunoblotting O
showed O
that O
both O
the O
( O
1 O
- O
404 O
) O
- O
peptide O
and O
( O
1 O
- O
506 O
) O
- O
peptide O
are O
recognized O
by O
95J10 B
, O
a O
monoclonal O
antibody O
that O
was O
previously O
raised O
against O
perlecan B
- I
( I
24 I
- I
404 I
) I
- I
peptide I
expressed O
in O
Escherichia O
coli O
. O

Many O
human O
malignant O
cells O
lack O
methylthioadenosine B
phosphorylase I
( O
MTAP B
) O
enzyme O
activity O
. O

G B
- I
box I
binding I
factors I
( O
GBFs B
) O
constitute O
a O
family O
of O
plant O
DNA O
- O
binding O
proteins O
that O
bind O
to O
the O
G O
- O
box O
motif O
, O
a O
regulatory O
cis O
element O
present O
in O
many O
plant O
genes O
with O
a O
palindromic O
DNA O
motif O
of O
CACGTG O
. O

These O
results O
extend O
our O
knowledge O
of O
this O
SNF2 B
- I
like I
family I
member I
and O
suggest O
a O
role O
for O
PASG B
in O
leukemogenesis O
. O

The O
difference O
between O
the O
results O
in O
the O
high O
dose O
AHLG B
and O
in O
the O
control O
group O
was O
significant O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

Immunoprecipitation O
of O
spinophilin B
or O
neurabin B
from O
crude O
brain O
extracts O
selectively O
coprecipitated O
PP1gamma B
( I
1 I
) I
over O
PP1beta B
. O

Immunoprecipitation O
of O
spinophilin B
or O
neurabin B
from O
crude O
brain O
extracts O
selectively O
coprecipitated O
PP1gamma B
( I
1 I
) I
over O
PP1beta B
. O

Immunoprecipitation O
of O
spinophilin B
or O
neurabin B
from O
crude O
brain O
extracts O
selectively O
coprecipitated O
PP1gamma B
( I
1 I
) I
over O
PP1beta B
. O

Reduction O
of O
p53 B
protein I
was O
detected O
after O
1 O
day O
of O
OM B
treatment O
and O
reached O
maximal O
suppression O
of O
10 O
- O
20 O
% O
of O
control O
after O
3 O
days O
in O
H3922 O
and O
40 O
% O
of O
control O
after O
4 O
days O
in O
MCF O
- O
7 O
cells O
. O

Association O
of O
Syk B
protein B
tyrosine I
kinase I
( O
PTK B
) O
with O
LMP2A B
occurs O
at O
the O
two O
tyrosines O
of O
the O
LMP2A B
immunoreceptor I
tyrosine O
- O
based O
activation O
motif O
, O
and O
it O
is O
hypothesized O
that O
Lyn B
PTK B
associates O
with O
the O
YEEA O
amino O
acid O
motif O
at O
LMP2A B
tyrosine O
112 O
( O
Y112 O
) O
. O

Association O
of O
Syk B
protein B
tyrosine I
kinase I
( O
PTK B
) O
with O
LMP2A B
occurs O
at O
the O
two O
tyrosines O
of O
the O
LMP2A B
immunoreceptor I
tyrosine O
- O
based O
activation O
motif O
, O
and O
it O
is O
hypothesized O
that O
Lyn B
PTK B
associates O
with O
the O
YEEA O
amino O
acid O
motif O
at O
LMP2A B
tyrosine O
112 O
( O
Y112 O
) O
. O

Association O
of O
Syk B
protein B
tyrosine I
kinase I
( O
PTK B
) O
with O
LMP2A B
occurs O
at O
the O
two O
tyrosines O
of O
the O
LMP2A B
immunoreceptor I
tyrosine O
- O
based O
activation O
motif O
, O
and O
it O
is O
hypothesized O
that O
Lyn B
PTK B
associates O
with O
the O
YEEA O
amino O
acid O
motif O
at O
LMP2A B
tyrosine O
112 O
( O
Y112 O
) O
. O

Association O
of O
Syk B
protein B
tyrosine I
kinase I
( O
PTK B
) O
with O
LMP2A B
occurs O
at O
the O
two O
tyrosines O
of O
the O
LMP2A B
immunoreceptor I
tyrosine O
- O
based O
activation O
motif O
, O
and O
it O
is O
hypothesized O
that O
Lyn B
PTK B
associates O
with O
the O
YEEA O
amino O
acid O
motif O
at O
LMP2A B
tyrosine O
112 O
( O
Y112 O
) O
. O

Association O
of O
Syk B
protein B
tyrosine I
kinase I
( O
PTK B
) O
with O
LMP2A B
occurs O
at O
the O
two O
tyrosines O
of O
the O
LMP2A B
immunoreceptor I
tyrosine O
- O
based O
activation O
motif O
, O
and O
it O
is O
hypothesized O
that O
Lyn B
PTK B
associates O
with O
the O
YEEA O
amino O
acid O
motif O
at O
LMP2A B
tyrosine O
112 O
( O
Y112 O
) O
. O

Association O
of O
Syk B
protein B
tyrosine I
kinase I
( O
PTK B
) O
with O
LMP2A B
occurs O
at O
the O
two O
tyrosines O
of O
the O
LMP2A B
immunoreceptor I
tyrosine O
- O
based O
activation O
motif O
, O
and O
it O
is O
hypothesized O
that O
Lyn B
PTK B
associates O
with O
the O
YEEA O
amino O
acid O
motif O
at O
LMP2A B
tyrosine O
112 O
( O
Y112 O
) O
. O

In O
this O
study O
, O
we O
investigated O
the O
mechanism O
by O
which O
Tax B
activates O
gene O
expression O
in O
conjunction O
with O
members O
of O
the O
ATF B
/ O
CREB B
family O
. O

In O
this O
study O
, O
we O
investigated O
the O
mechanism O
by O
which O
Tax B
activates O
gene O
expression O
in O
conjunction O
with O
members O
of O
the O
ATF B
/ O
CREB B
family O
. O

In O
this O
study O
, O
we O
investigated O
the O
mechanism O
by O
which O
Tax B
activates O
gene O
expression O
in O
conjunction O
with O
members O
of O
the O
ATF B
/ O
CREB B
family O
. O

Suppression O
of O
the O
cka1 B
delta I
cka2 I
- I
8 I
mutant I
phenotype O
occurs O
by O
interaction O
of O
CKB1 B
with O
the O
defective O
, O
cka2 B
- I
8 I
- O
encoded O
, O
catalytic O
subunit O
. O

Taken O
together O
, O
these O
results O
indicate O
that O
ICSBP B
and O
PU B
. I
1 I
are O
critical O
elements O
for O
IL B
- I
18 I
gene I
expression O
. O

To O
determine O
the O
role O
of O
the O
transmembrane O
region O
of O
HN B
on O
fusion O
- O
promoting O
activity O
, O
mutant B
HN I
proteins I
were O
expressed O
and O
their O
biological O
activities O
examined O
. O

Transient O
transfection O
assays O
indicated O
that O
the O
( O
- O
4551 O
) O
UCP1 B
- O
CAT B
construct O
, O
containing O
the O
5 O
' O
- O
regulatory O
region O
of O
the O
rat B
ucp I
- I
1 I
gene I
, O
was O
activated O
by O
PPARalpha B
co O
- O
transfection O
in O
a O
dose O
- O
dependent O
manner O
and O
this O
activation O
was O
potentiated O
by O
Wy O
14 O
, O
643 O
and O
retinoid B
X I
receptor I
alpha I
. O

Transient O
transfection O
assays O
indicated O
that O
the O
( O
- O
4551 O
) O
UCP1 B
- O
CAT B
construct O
, O
containing O
the O
5 O
' O
- O
regulatory O
region O
of O
the O
rat B
ucp I
- I
1 I
gene I
, O
was O
activated O
by O
PPARalpha B
co O
- O
transfection O
in O
a O
dose O
- O
dependent O
manner O
and O
this O
activation O
was O
potentiated O
by O
Wy O
14 O
, O
643 O
and O
retinoid B
X I
receptor I
alpha I
. O

Transient O
transfection O
assays O
indicated O
that O
the O
( O
- O
4551 O
) O
UCP1 B
- O
CAT B
construct O
, O
containing O
the O
5 O
' O
- O
regulatory O
region O
of O
the O
rat B
ucp I
- I
1 I
gene I
, O
was O
activated O
by O
PPARalpha B
co O
- O
transfection O
in O
a O
dose O
- O
dependent O
manner O
and O
this O
activation O
was O
potentiated O
by O
Wy O
14 O
, O
643 O
and O
retinoid B
X I
receptor I
alpha I
. O

ADR1 B
in O
extracts O
made O
from O
glucose O
- O
repressed O
and O
- O
derepressed O
cells O
bound O
UAS1 O
DNA O
with O
similar O
affinities O
despite O
having O
greatly O
different O
abilities O
to O
activate O
ADH2 B
gene I
expression O
in O
vivo O
. O

We O
have O
demonstrated O
that O
the O
specific O
determination O
and O
identification O
of O
plasma O
FbDP B
alone O
is O
not O
sufficient O
to O
follow O
the O
effectiveness O
of O
thrombolytic O
therapy O
. O

Insulin B
- O
secreting O
islet O
- O
cell O
tumours O
of O
the O
pancreas O
. O

We O
have O
previously O
demonstrated O
that O
pyrene O
in O
diesel O
- O
exhaust O
particles O
( O
DEP O
) O
has O
an O
adjuvant O
activity O
on O
immunoglobulin B
E I
( O
IgE B
) O
antibody O
production O
in O
mice O
immunized O
with O
Japanese O
cedar O
pollen O
allergen O
( O
JCPA O
) O
or O
ovalbumin B
( O
OA B
) O
intraperitoneally O
. O

We O
have O
previously O
demonstrated O
that O
pyrene O
in O
diesel O
- O
exhaust O
particles O
( O
DEP O
) O
has O
an O
adjuvant O
activity O
on O
immunoglobulin B
E I
( O
IgE B
) O
antibody O
production O
in O
mice O
immunized O
with O
Japanese O
cedar O
pollen O
allergen O
( O
JCPA O
) O
or O
ovalbumin B
( O
OA B
) O
intraperitoneally O
. O

We O
have O
previously O
demonstrated O
that O
pyrene O
in O
diesel O
- O
exhaust O
particles O
( O
DEP O
) O
has O
an O
adjuvant O
activity O
on O
immunoglobulin B
E I
( O
IgE B
) O
antibody O
production O
in O
mice O
immunized O
with O
Japanese O
cedar O
pollen O
allergen O
( O
JCPA O
) O
or O
ovalbumin B
( O
OA B
) O
intraperitoneally O
. O

We O
conclude O
that O
transcription O
of O
both O
SCD1 B
and O
SCD2 B
genes I
is O
responsive O
to O
cellular O
sterol O
levels O
and O
to O
the O
levels O
of O
nuclear O
SREBP B
/ O
ADD1 B
and O
that O
transcriptional O
induction O
requires O
three O
spatially O
conserved O
cis O
elements O
, O
that O
bind O
SREBP B
and O
NF B
- I
Y I
. O

We O
conclude O
that O
transcription O
of O
both O
SCD1 B
and O
SCD2 B
genes I
is O
responsive O
to O
cellular O
sterol O
levels O
and O
to O
the O
levels O
of O
nuclear O
SREBP B
/ O
ADD1 B
and O
that O
transcriptional O
induction O
requires O
three O
spatially O
conserved O
cis O
elements O
, O
that O
bind O
SREBP B
and O
NF B
- I
Y I
. O

We O
conclude O
that O
transcription O
of O
both O
SCD1 B
and O
SCD2 B
genes I
is O
responsive O
to O
cellular O
sterol O
levels O
and O
to O
the O
levels O
of O
nuclear O
SREBP B
/ O
ADD1 B
and O
that O
transcriptional O
induction O
requires O
three O
spatially O
conserved O
cis O
elements O
, O
that O
bind O
SREBP B
and O
NF B
- I
Y I
. O

We O
conclude O
that O
transcription O
of O
both O
SCD1 B
and O
SCD2 B
genes I
is O
responsive O
to O
cellular O
sterol O
levels O
and O
to O
the O
levels O
of O
nuclear O
SREBP B
/ O
ADD1 B
and O
that O
transcriptional O
induction O
requires O
three O
spatially O
conserved O
cis O
elements O
, O
that O
bind O
SREBP B
and O
NF B
- I
Y I
. O

Three O
transcriptional O
control O
elements O
within O
300 O
base O
pairs O
of O
the O
5 O
' O
- O
flanking O
region O
of O
the O
rat B
glucagon I
gene I
interact O
with O
regulatory O
cellular O
proteins O
and O
direct O
transcription O
only O
in O
glucagon B
- O
producing O
islet O
cells O
. O

A O
role O
for O
phosphatidylinositol B
3 I
- I
kinase I
in O
the O
regulation O
of O
beta B
1 I
integrin I
activity O
by O
the O
CD2 B
antigen O
. O

In O
contrast O
, O
the O
sequences O
essential O
for O
the O
transcription O
of O
EFT1 B
were O
localized O
to O
the O
region O
between O
the O
start O
ATG O
and O
the O
stop O
codon O
of O
the O
VPS17 B
gene I
that O
terminates O
267 O
nt O
upstream O
on O
the O
same O
strand O
. O

In O
each O
of O
the O
studied O
HPV O
types O
, O
the O
two O
CDP B
/ O
Cut B
binding O
sites O
of O
PSM B
overlap O
with O
the O
known O
or O
presumed O
binding O
sites O
of O
the O
replication B
initiator I
protein I
E1 I
. O

In O
each O
of O
the O
studied O
HPV O
types O
, O
the O
two O
CDP B
/ O
Cut B
binding O
sites O
of O
PSM B
overlap O
with O
the O
known O
or O
presumed O
binding O
sites O
of O
the O
replication B
initiator I
protein I
E1 I
. O

In O
each O
of O
the O
studied O
HPV O
types O
, O
the O
two O
CDP B
/ O
Cut B
binding O
sites O
of O
PSM B
overlap O
with O
the O
known O
or O
presumed O
binding O
sites O
of O
the O
replication B
initiator I
protein I
E1 I
. O

ATF O
is O
formulated O
from O
the O
prothrombin B
time O
( O
PT O
) O
, O
fibrinogen B
transformation O
rate O
( O
FTR O
) O
( O
a O
representation O
of O
thrombin B
activity O
) O
, O
and O
a O
consideration O
of O
the O
fibrinogen B
( O
FBG B
) O
content O
of O
blood O
plasma O
. O

ATF O
is O
formulated O
from O
the O
prothrombin B
time O
( O
PT O
) O
, O
fibrinogen B
transformation O
rate O
( O
FTR O
) O
( O
a O
representation O
of O
thrombin B
activity O
) O
, O
and O
a O
consideration O
of O
the O
fibrinogen B
( O
FBG B
) O
content O
of O
blood O
plasma O
. O

ATF O
is O
formulated O
from O
the O
prothrombin B
time O
( O
PT O
) O
, O
fibrinogen B
transformation O
rate O
( O
FTR O
) O
( O
a O
representation O
of O
thrombin B
activity O
) O
, O
and O
a O
consideration O
of O
the O
fibrinogen B
( O
FBG B
) O
content O
of O
blood O
plasma O
. O

ATF O
is O
formulated O
from O
the O
prothrombin B
time O
( O
PT O
) O
, O
fibrinogen B
transformation O
rate O
( O
FTR O
) O
( O
a O
representation O
of O
thrombin B
activity O
) O
, O
and O
a O
consideration O
of O
the O
fibrinogen B
( O
FBG B
) O
content O
of O
blood O
plasma O
. O

ATF O
is O
formulated O
from O
the O
prothrombin B
time O
( O
PT O
) O
, O
fibrinogen B
transformation O
rate O
( O
FTR O
) O
( O
a O
representation O
of O
thrombin B
activity O
) O
, O
and O
a O
consideration O
of O
the O
fibrinogen B
( O
FBG B
) O
content O
of O
blood O
plasma O
. O

( O
LH B
P O
< O
0 O
. O
05 O
, O
LH B
/ O
FSH B
P O
< O
0 O
. O
01 O
) O
. O

( O
LH B
P O
< O
0 O
. O
05 O
, O
LH B
/ O
FSH B
P O
< O
0 O
. O
01 O
) O
. O

( O
LH B
P O
< O
0 O
. O
05 O
, O
LH B
/ O
FSH B
P O
< O
0 O
. O
01 O
) O
. O

Inhibition O
of O
Raf B
- I
1 I
signaling O
by O
a O
monoclonal O
antibody O
, O
which O
interferes O
with O
Raf B
- I
1 I
activation O
and O
with O
Mek B
substrate O
binding O
. O

Phenotypic O
and O
molecular O
analyses O
of O
patients O
with O
partial O
chromosome O
21 O
monosomy O
enabled O
us O
to O
define O
a O
region O
, O
spanning O
2 O
. O
4 O
Mb O
between O
D21S190 B
and O
D21S226 B
, O
associated O
with O
arthrogryposis O
, O
mental O
retardation O
, O
hypertonia O
, O
and O
several O
facial O
anomalies O
. O

Phenotypic O
and O
molecular O
analyses O
of O
patients O
with O
partial O
chromosome O
21 O
monosomy O
enabled O
us O
to O
define O
a O
region O
, O
spanning O
2 O
. O
4 O
Mb O
between O
D21S190 B
and O
D21S226 B
, O
associated O
with O
arthrogryposis O
, O
mental O
retardation O
, O
hypertonia O
, O
and O
several O
facial O
anomalies O
. O

The O
classic O
sterol O
regulatory O
cis O
element O
( O
sre O
- O
1 O
) O
in O
the O
LDL B
receptor I
promoter O
mediates O
sterol B
regulatory I
element I
binding I
protein I
( O
SREBP B
) O
- O
binding O
and O
the O
effects O
of O
insulin B
and O
platelet B
derived I
growth I
factor I
( O
PDGF B
) O
. O

The O
classic O
sterol O
regulatory O
cis O
element O
( O
sre O
- O
1 O
) O
in O
the O
LDL B
receptor I
promoter O
mediates O
sterol B
regulatory I
element I
binding I
protein I
( O
SREBP B
) O
- O
binding O
and O
the O
effects O
of O
insulin B
and O
platelet B
derived I
growth I
factor I
( O
PDGF B
) O
. O

The O
classic O
sterol O
regulatory O
cis O
element O
( O
sre O
- O
1 O
) O
in O
the O
LDL B
receptor I
promoter O
mediates O
sterol B
regulatory I
element I
binding I
protein I
( O
SREBP B
) O
- O
binding O
and O
the O
effects O
of O
insulin B
and O
platelet B
derived I
growth I
factor I
( O
PDGF B
) O
. O

In O
Cos O
7 O
cells O
transfected O
with O
oCRF1var B
, O
cAMP O
accumulation O
was O
only O
observed O
at O
the O
highest O
concentration O
of O
oCRF B
utilized O
( O
100 O
nM O
) O
. O

In O
Cos O
7 O
cells O
transfected O
with O
oCRF1var B
, O
cAMP O
accumulation O
was O
only O
observed O
at O
the O
highest O
concentration O
of O
oCRF B
utilized O
( O
100 O
nM O
) O
. O

This O
is O
probably O
because O
, O
in O
vivo O
, O
some O
bacteria O
( O
perhaps O
dormant O
forms O
) O
are O
not O
entirely O
dependent O
upon O
urease B
for O
survival O
. O

The O
system O
consists O
of O
a O
microcomputer O
and O
six O
laboratory O
analyzers O
: O
a O
blood O
gas O
analyzer O
, O
a O
flame O
photometer O
, O
a O
plasma O
osmotic O
pressure O
meter O
, O
a O
chloride O
ion O
titrator O
, O
a O
blood O
sugar O
analyzer O
, O
and O
a O
hemoglobin B
concentration O
and O
saturation O
meter O
. O

Peak O
plasma O
ACTH B
responses O
were O
not O
significantly O
different O
between O
control O
and O
patient O
groups O
. O

These O
results O
suggest O
that O
the O
Reg1 B
- O
Glc7 B
phosphatase O
is O
a O
cytoplasmic O
component O
of O
the O
machinery O
responsible O
for O
returning O
Snf1 B
kinase I
activity O
to O
its O
basal O
level O
and O
reestablishing O
glucose O
repression O
. O

These O
results O
suggest O
that O
the O
Reg1 B
- O
Glc7 B
phosphatase O
is O
a O
cytoplasmic O
component O
of O
the O
machinery O
responsible O
for O
returning O
Snf1 B
kinase I
activity O
to O
its O
basal O
level O
and O
reestablishing O
glucose O
repression O
. O

The O
majority O
of O
these O
cells O
were O
also O
OKT4 B
positive O
( O
helper O
/ O
inducer O
T O
lymphocytes O
) O
, O
while O
the O
minority O
were O
OKT8 B
positive O
( O
suppressor O
/ O
cytotoxic O
T O
lymphocytes O
) O
. O

The O
majority O
of O
these O
cells O
were O
also O
OKT4 B
positive O
( O
helper O
/ O
inducer O
T O
lymphocytes O
) O
, O
while O
the O
minority O
were O
OKT8 B
positive O
( O
suppressor O
/ O
cytotoxic O
T O
lymphocytes O
) O
. O

The O
structure O
of O
the O
mAR B
ORF O
was O
confirmed O
by O
sequence O
analysis O
of O
mAR B
cDNA O
fragments O
, O
which O
were O
obtained O
by O
PCR O
amplification O
of O
mouse O
testis O
cDNA O
, O
using O
mAR B
specific O
primers O
. O

The O
structure O
of O
the O
mAR B
ORF O
was O
confirmed O
by O
sequence O
analysis O
of O
mAR B
cDNA O
fragments O
, O
which O
were O
obtained O
by O
PCR O
amplification O
of O
mouse O
testis O
cDNA O
, O
using O
mAR B
specific O
primers O
. O

The O
structure O
of O
the O
mAR B
ORF O
was O
confirmed O
by O
sequence O
analysis O
of O
mAR B
cDNA O
fragments O
, O
which O
were O
obtained O
by O
PCR O
amplification O
of O
mouse O
testis O
cDNA O
, O
using O
mAR B
specific O
primers O
. O

The O
role O
of O
NUT1 B
and O
regulation O
of O
nitrogen O
metabolism O
in O
the O
disease O
process O
was O
evaluated O
by O
pathogenicity O
assays O
. O

These O
three O
phases O
of O
cyclin B
E I
association O
with O
chromatin O
may O
facilitate O
the O
diverse O
activities O
of O
cyclin B
E I
- O
- O
Cdk2 B
in O
initiating O
replication O
, O
blocking O
rereplication O
, O
and O
allowing O
resetting O
of O
origins O
after O
mitosis O
. O

Plasma B
LH I
and O
progesterone O
levels O
after O
single O
or O
multiple O
injections O
of O
synthetic O
LH B
- O
RH B
in O
anoestrous O
ewes O
and O
comparison O
with O
levels O
during O
the O
oestrous O
cycle O
. O

Plasma B
LH I
and O
progesterone O
levels O
after O
single O
or O
multiple O
injections O
of O
synthetic O
LH B
- O
RH B
in O
anoestrous O
ewes O
and O
comparison O
with O
levels O
during O
the O
oestrous O
cycle O
. O

The O
promyelocytic B
leukemia I
protein I
interacts O
with O
Sp1 B
and O
inhibits O
its O
transactivation O
of O
the O
epidermal B
growth I
factor I
receptor I
promoter O
. O

The O
Saccharomyces O
cerevisiae O
targets O
of O
rapamycin O
, O
TOR1 B
and O
TOR2 B
, O
signal O
activation O
of O
cell O
growth O
in O
response O
to O
nutrient O
availability O
. O

The O
Saccharomyces O
cerevisiae O
targets O
of O
rapamycin O
, O
TOR1 B
and O
TOR2 B
, O
signal O
activation O
of O
cell O
growth O
in O
response O
to O
nutrient O
availability O
. O

Taken O
together O
, O
these O
data O
suggest O
that O
the O
Smad3 B
/ O
Smad4 B
complex O
has O
at O
least O
two O
separable O
nuclear O
functions O
: O
it O
forms O
a O
rapid O
, O
yet O
transient O
sequence O
- O
specific O
DNA O
binding O
complex O
, O
and O
it O
potentiates O
AP1 B
- O
dependent O
transcriptional O
activation O
. O

Taken O
together O
, O
these O
data O
suggest O
that O
the O
Smad3 B
/ O
Smad4 B
complex O
has O
at O
least O
two O
separable O
nuclear O
functions O
: O
it O
forms O
a O
rapid O
, O
yet O
transient O
sequence O
- O
specific O
DNA O
binding O
complex O
, O
and O
it O
potentiates O
AP1 B
- O
dependent O
transcriptional O
activation O
. O

Taken O
together O
, O
these O
data O
suggest O
that O
the O
Smad3 B
/ O
Smad4 B
complex O
has O
at O
least O
two O
separable O
nuclear O
functions O
: O
it O
forms O
a O
rapid O
, O
yet O
transient O
sequence O
- O
specific O
DNA O
binding O
complex O
, O
and O
it O
potentiates O
AP1 B
- O
dependent O
transcriptional O
activation O
. O

When O
phentermine O
was O
mixed O
with O
other O
unlabeled O
reversible O
MAO B
inhibitors O
( O
e O
. O
g O
. O
pseudoephedrine O
, O
ephedrine O
, O
norephedrine O
; O
estradiol O
benzoate O
) O
, O
the O
degree O
of O
MAO B
inhibition O
was O
additive O
. O

When O
phentermine O
was O
mixed O
with O
other O
unlabeled O
reversible O
MAO B
inhibitors O
( O
e O
. O
g O
. O
pseudoephedrine O
, O
ephedrine O
, O
norephedrine O
; O
estradiol O
benzoate O
) O
, O
the O
degree O
of O
MAO B
inhibition O
was O
additive O
. O

4 O
382 O
new O
mothers O
were O
examined O
retrospectively O
with O
the O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
for O
IgG B
activity O
to O
cytomegalovirus O
( O
CMV O
) O
during O
pregnancy O
. O

Alterations O
in O
TCR B
- O
MHC B
contacts O
subsequent O
to O
cross O
- O
recognition O
of O
class B
I I
MHC I
and O
singly O
substituted O
peptide O
variants O
. O

Alterations O
in O
TCR B
- O
MHC B
contacts O
subsequent O
to O
cross O
- O
recognition O
of O
class B
I I
MHC I
and O
singly O
substituted O
peptide O
variants O
. O

Patients O
with O
the O
chronic O
photosensitivity O
dermatitis O
with O
actinic O
reticuloid O
syndrome O
have O
high O
total O
serum O
IgE B
concentrations O
. O

Tax B
and O
the O
active O
Tax B
mutants I
were O
able O
to O
abrogate O
the O
G1 O
arrest O
and O
apoptosis O
induced O
by O
p53 B
, O
and O
this O
effect O
does O
not O
correlate O
with O
an O
altered O
localization O
of O
nuclear B
p53 I
or O
with O
the O
disruption O
of O
p53 B
- I
DNA I
complexes I
. O

Tax B
and O
the O
active O
Tax B
mutants I
were O
able O
to O
abrogate O
the O
G1 O
arrest O
and O
apoptosis O
induced O
by O
p53 B
, O
and O
this O
effect O
does O
not O
correlate O
with O
an O
altered O
localization O
of O
nuclear B
p53 I
or O
with O
the O
disruption O
of O
p53 B
- I
DNA I
complexes I
. O

Biochemical O
studies O
have O
identified O
a O
cellular O
non B
- I
P I
element I
- I
encoded I
DNA I
binding I
protein I
, O
termed O
the O
inverted B
repeat I
binding I
protein I
( O
IRBP B
) O
, O
that O
specifically O
interacts O
with O
the O
outer O
half O
of O
the O
31 O
- O
bp O
terminal O
inverted O
repeats O
. O

In O
cells O
infected O
with O
a O
recombinant O
vaccinia O
virus O
expressing O
HCV O
structural O
proteins O
( O
core B
, O
E1 B
, O
and O
E2 B
) O
, O
DDX3 B
and O
core B
colocalized O
in O
distinct O
spots O
in O
the O
perinuclear O
region O
of O
the O
cytoplasm O
. O

In O
cells O
infected O
with O
a O
recombinant O
vaccinia O
virus O
expressing O
HCV O
structural O
proteins O
( O
core B
, O
E1 B
, O
and O
E2 B
) O
, O
DDX3 B
and O
core B
colocalized O
in O
distinct O
spots O
in O
the O
perinuclear O
region O
of O
the O
cytoplasm O
. O

In O
cells O
infected O
with O
a O
recombinant O
vaccinia O
virus O
expressing O
HCV O
structural O
proteins O
( O
core B
, O
E1 B
, O
and O
E2 B
) O
, O
DDX3 B
and O
core B
colocalized O
in O
distinct O
spots O
in O
the O
perinuclear O
region O
of O
the O
cytoplasm O
. O

In O
cells O
infected O
with O
a O
recombinant O
vaccinia O
virus O
expressing O
HCV O
structural O
proteins O
( O
core B
, O
E1 B
, O
and O
E2 B
) O
, O
DDX3 B
and O
core B
colocalized O
in O
distinct O
spots O
in O
the O
perinuclear O
region O
of O
the O
cytoplasm O
. O

In O
cells O
infected O
with O
a O
recombinant O
vaccinia O
virus O
expressing O
HCV O
structural O
proteins O
( O
core B
, O
E1 B
, O
and O
E2 B
) O
, O
DDX3 B
and O
core B
colocalized O
in O
distinct O
spots O
in O
the O
perinuclear O
region O
of O
the O
cytoplasm O
. O

Due O
to O
significant O
homology O
to O
the O
C O
- O
terminus O
of O
the O
Mutator B
transposase I
this O
alternative O
gene O
product O
was O
named O
Trap B
( O
transposon B
- I
associated I
protein I
) O
. O

Using O
gel O
retardation O
analysis O
, O
four O
binding O
sites O
for O
Rap1p B
have O
been O
identified O
within O
the O
promoter O
of O
the O
RAP1 B
gene I
. O

Subsequent O
analysis O
revealed O
that O
MyD88 B
possesses O
a O
unique O
modular O
structure O
, O
which O
consists O
of O
an O
N O
- O
terminal O
" O
death O
domain O
, O
" O
similar O
to O
the O
intracellular O
segments O
of O
TNF B
receptor I
1 I
and O
Fas B
, O
and O
a O
C O
- O
terminal O
region O
related O
to O
the O
cytoplasmic O
domains O
of O
the O
Drosophila B
morphogen I
Toll I
and O
vertebrate O
interleukin B
- I
1 I
receptors I
. O

Subsequent O
analysis O
revealed O
that O
MyD88 B
possesses O
a O
unique O
modular O
structure O
, O
which O
consists O
of O
an O
N O
- O
terminal O
" O
death O
domain O
, O
" O
similar O
to O
the O
intracellular O
segments O
of O
TNF B
receptor I
1 I
and O
Fas B
, O
and O
a O
C O
- O
terminal O
region O
related O
to O
the O
cytoplasmic O
domains O
of O
the O
Drosophila B
morphogen I
Toll I
and O
vertebrate O
interleukin B
- I
1 I
receptors I
. O

In O
human O
myxoid O
liposarcoma O
, O
a O
chromosomal O
rearrangement O
leads O
to O
fusion O
of O
the O
growth O
- O
arresting O
and O
DNA O
- O
damage O
- O
inducible O
transcription O
factor O
CHOP B
( O
GADD153 B
) O
to O
a O
peptide O
fragment O
encoded O
by O
the O
TLS B
gene I
. O

In O
human O
myxoid O
liposarcoma O
, O
a O
chromosomal O
rearrangement O
leads O
to O
fusion O
of O
the O
growth O
- O
arresting O
and O
DNA O
- O
damage O
- O
inducible O
transcription O
factor O
CHOP B
( O
GADD153 B
) O
to O
a O
peptide O
fragment O
encoded O
by O
the O
TLS B
gene I
. O

The O
p58 B
( O
PITSLRE B
beta I
1 I
) O
protein O
kinase O
( O
PK O
) O
is O
a O
member O
of O
a O
large O
supergene O
family O
related O
to O
the O
master B
mitotic I
protein I
kinase I
, O
p34cdc2 B
. O

The O
p58 B
( O
PITSLRE B
beta I
1 I
) O
protein O
kinase O
( O
PK O
) O
is O
a O
member O
of O
a O
large O
supergene O
family O
related O
to O
the O
master B
mitotic I
protein I
kinase I
, O
p34cdc2 B
. O

The O
plants O
were O
then O
brought O
to O
our O
Houston O
laboratory O
where O
they O
were O
measured O
and O
analyzed O
for O
lignin O
and O
protein O
content O
and O
for O
phenylalanine B
ammonia I
- I
lyase I
( O
PAL B
) O
and O
peroxidase B
activities O
. O

The O
plants O
were O
then O
brought O
to O
our O
Houston O
laboratory O
where O
they O
were O
measured O
and O
analyzed O
for O
lignin O
and O
protein O
content O
and O
for O
phenylalanine B
ammonia I
- I
lyase I
( O
PAL B
) O
and O
peroxidase B
activities O
. O

Pax B
- I
6 I
constructs O
lacking O
the O
C O
- O
terminal O
activation O
domain O
repressed O
betaB1 B
- I
crystallin I
promoter I
activity O
as O
effectively O
as O
the O
full O
- O
length O
protein O
, O
but O
the O
PD B
alone O
or O
Pax B
- I
6 I
( I
5a I
) I
, O
a O
splice O
variant O
with O
an O
altered O
PD B
affecting O
its O
DNA O
binding O
specificity O
, O
did O
not O
. O

Pax B
- I
6 I
constructs O
lacking O
the O
C O
- O
terminal O
activation O
domain O
repressed O
betaB1 B
- I
crystallin I
promoter I
activity O
as O
effectively O
as O
the O
full O
- O
length O
protein O
, O
but O
the O
PD B
alone O
or O
Pax B
- I
6 I
( I
5a I
) I
, O
a O
splice O
variant O
with O
an O
altered O
PD B
affecting O
its O
DNA O
binding O
specificity O
, O
did O
not O
. O

The O
predicted O
amino O
acid O
sequence O
contained O
all O
consensus O
regions O
for O
S B
- I
adenosyl I
methionine I
methyltransferases I
and O
presented O
26 O
% O
identity O
with O
Saccharomyces B
cerevisiae I
DHHB I
- I
methyltransferase I
and O
38 O
% O
identity O
with O
the O
rat O
protein O
, O
as O
well O
as O
with O
a O
bacterial O
( O
Escherichia O
coli O
and O
Salmonella O
typhimurium O
) O
methyltransferase B
encoded O
by O
the O
UBIG B
gene I
. O

The O
introduction O
of O
FWD1 B
into O
cells O
significantly O
promotes O
ubiquitination O
and O
degradation O
of O
IkappaBalpha B
in O
concert O
with O
IkappaB B
kinases I
, O
resulting O
in O
nuclear O
translocation O
of O
NF B
- I
kappaB I
. O

The O
introduction O
of O
FWD1 B
into O
cells O
significantly O
promotes O
ubiquitination O
and O
degradation O
of O
IkappaBalpha B
in O
concert O
with O
IkappaB B
kinases I
, O
resulting O
in O
nuclear O
translocation O
of O
NF B
- I
kappaB I
. O

To O
assess O
the O
effect O
on O
thrombus O
growth O
, O
we O
determined O
the O
accretion O
of O
125I O
- O
labeled O
fibrinogen B
onto O
autologous O
non O
- O
radioactive O
thrombi O
preformed O
in O
the O
jugular O
veins O
of O
rabbits O
. O

Two O
plasmids O
, O
one O
containing O
the O
amino O
terminus O
of O
P O
fused O
to O
the O
DNA O
- O
binding O
domain O
of O
the O
yeast O
transactivator O
, O
GAL4 B
, O
and O
the O
other O
containing O
the O
amino O
terminus O
of O
NP B
fused O
to O
the O
herpesvirus O
transactivator O
, O
VP16 B
, O
were O
transfected O
in O
COS O
- O
1 O
cells O
along O
with O
a O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
reporter O
plasmid O
containing O
GAL4 B
DNA O
- O
binding O
sites O
. O

Two O
plasmids O
, O
one O
containing O
the O
amino O
terminus O
of O
P O
fused O
to O
the O
DNA O
- O
binding O
domain O
of O
the O
yeast O
transactivator O
, O
GAL4 B
, O
and O
the O
other O
containing O
the O
amino O
terminus O
of O
NP B
fused O
to O
the O
herpesvirus O
transactivator O
, O
VP16 B
, O
were O
transfected O
in O
COS O
- O
1 O
cells O
along O
with O
a O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
reporter O
plasmid O
containing O
GAL4 B
DNA O
- O
binding O
sites O
. O

Two O
plasmids O
, O
one O
containing O
the O
amino O
terminus O
of O
P O
fused O
to O
the O
DNA O
- O
binding O
domain O
of O
the O
yeast O
transactivator O
, O
GAL4 B
, O
and O
the O
other O
containing O
the O
amino O
terminus O
of O
NP B
fused O
to O
the O
herpesvirus O
transactivator O
, O
VP16 B
, O
were O
transfected O
in O
COS O
- O
1 O
cells O
along O
with O
a O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
reporter O
plasmid O
containing O
GAL4 B
DNA O
- O
binding O
sites O
. O

Two O
plasmids O
, O
one O
containing O
the O
amino O
terminus O
of O
P O
fused O
to O
the O
DNA O
- O
binding O
domain O
of O
the O
yeast O
transactivator O
, O
GAL4 B
, O
and O
the O
other O
containing O
the O
amino O
terminus O
of O
NP B
fused O
to O
the O
herpesvirus O
transactivator O
, O
VP16 B
, O
were O
transfected O
in O
COS O
- O
1 O
cells O
along O
with O
a O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
reporter O
plasmid O
containing O
GAL4 B
DNA O
- O
binding O
sites O
. O

Two O
plasmids O
, O
one O
containing O
the O
amino O
terminus O
of O
P O
fused O
to O
the O
DNA O
- O
binding O
domain O
of O
the O
yeast O
transactivator O
, O
GAL4 B
, O
and O
the O
other O
containing O
the O
amino O
terminus O
of O
NP B
fused O
to O
the O
herpesvirus O
transactivator O
, O
VP16 B
, O
were O
transfected O
in O
COS O
- O
1 O
cells O
along O
with O
a O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
reporter O
plasmid O
containing O
GAL4 B
DNA O
- O
binding O
sites O
. O

Biochemical O
experiments O
and O
genome O
sequencing O
have O
shown O
that O
, O
despite O
the O
prokaryotic O
cell O
and O
genome O
organization O
, O
basal O
transcriptional O
elements O
of O
members O
of O
the O
domain O
Archaea O
( O
i O
. O
e O
. O
, O
TATA O
box O
- O
like O
sequences O
, O
RNA B
polymerase I
, O
and O
transcription O
factors O
TBP B
, O
TFIIB B
, O
and O
TFIIS B
) O
are O
of O
the O
eukaryotic O
type O
. O

Biochemical O
experiments O
and O
genome O
sequencing O
have O
shown O
that O
, O
despite O
the O
prokaryotic O
cell O
and O
genome O
organization O
, O
basal O
transcriptional O
elements O
of O
members O
of O
the O
domain O
Archaea O
( O
i O
. O
e O
. O
, O
TATA O
box O
- O
like O
sequences O
, O
RNA B
polymerase I
, O
and O
transcription O
factors O
TBP B
, O
TFIIB B
, O
and O
TFIIS B
) O
are O
of O
the O
eukaryotic O
type O
. O

Biochemical O
experiments O
and O
genome O
sequencing O
have O
shown O
that O
, O
despite O
the O
prokaryotic O
cell O
and O
genome O
organization O
, O
basal O
transcriptional O
elements O
of O
members O
of O
the O
domain O
Archaea O
( O
i O
. O
e O
. O
, O
TATA O
box O
- O
like O
sequences O
, O
RNA B
polymerase I
, O
and O
transcription O
factors O
TBP B
, O
TFIIB B
, O
and O
TFIIS B
) O
are O
of O
the O
eukaryotic O
type O
. O

Humoral O
immunity O
is O
altered O
with O
the O
drop O
in O
IgG B
levels O
. O

The O
entire O
coding O
region O
of O
an O
ovine B
endometrial I
oxytocin I
receptor I
( O
OTR B
) O
cDNA O
was O
generated O
by O
PCR O
, O
subcloned O
into O
the O
SV40 B
major I
late I
promoter I
expression O
vector O
pSVLJ O
and O
transiently O
expressed O
in O
Cos O
- O
7 O
cells O
. O

These O
operons O
encode O
subunits O
of O
photosystems B
I I
( O
psa B
) O
and O
II O
( O
psb B
) O
, O
the O
cytochrome B
bGf I
complex I
( O
pet B
) O
, O
the O
plastid O
NAD B
( I
P I
) I
H I
dehydrogenase I
( O
ndh B
) O
, O
and O
the O
unidentified O
open O
reading O
frame O
ycf9 B
. O

These O
operons O
encode O
subunits O
of O
photosystems B
I I
( O
psa B
) O
and O
II O
( O
psb B
) O
, O
the O
cytochrome B
bGf I
complex I
( O
pet B
) O
, O
the O
plastid O
NAD B
( I
P I
) I
H I
dehydrogenase I
( O
ndh B
) O
, O
and O
the O
unidentified O
open O
reading O
frame O
ycf9 B
. O

These O
operons O
encode O
subunits O
of O
photosystems B
I I
( O
psa B
) O
and O
II O
( O
psb B
) O
, O
the O
cytochrome B
bGf I
complex I
( O
pet B
) O
, O
the O
plastid O
NAD B
( I
P I
) I
H I
dehydrogenase I
( O
ndh B
) O
, O
and O
the O
unidentified O
open O
reading O
frame O
ycf9 B
. O

These O
operons O
encode O
subunits O
of O
photosystems B
I I
( O
psa B
) O
and O
II O
( O
psb B
) O
, O
the O
cytochrome B
bGf I
complex I
( O
pet B
) O
, O
the O
plastid O
NAD B
( I
P I
) I
H I
dehydrogenase I
( O
ndh B
) O
, O
and O
the O
unidentified O
open O
reading O
frame O
ycf9 B
. O

These O
operons O
encode O
subunits O
of O
photosystems B
I I
( O
psa B
) O
and O
II O
( O
psb B
) O
, O
the O
cytochrome B
bGf I
complex I
( O
pet B
) O
, O
the O
plastid O
NAD B
( I
P I
) I
H I
dehydrogenase I
( O
ndh B
) O
, O
and O
the O
unidentified O
open O
reading O
frame O
ycf9 B
. O

The O
phosphatidylglycerol B
/ I
phosphatidylinositol I
transfer I
protein I
( O
PG B
/ I
PI I
- I
TP I
) O
is O
a O
new O
and O
original O
phospholipid B
transfer I
protein I
( O
PLTP B
) O
isolated O
from O
the O
Deuteromycete O
, O
Aspergillus O
oryzae O
. O

Transcriptional O
modulation O
of O
the O
anti B
- I
apoptotic I
protein I
BCL I
- I
XL I
by O
the O
paired B
box I
transcription I
factors I
PAX3 B
and O
PAX3 B
/ O
FKHR B
. O

Transcriptional O
modulation O
of O
the O
anti B
- I
apoptotic I
protein I
BCL I
- I
XL I
by O
the O
paired B
box I
transcription I
factors I
PAX3 B
and O
PAX3 B
/ O
FKHR B
. O

Transcriptional O
modulation O
of O
the O
anti B
- I
apoptotic I
protein I
BCL I
- I
XL I
by O
the O
paired B
box I
transcription I
factors I
PAX3 B
and O
PAX3 B
/ O
FKHR B
. O

The O
level O
of O
expression O
of O
the O
PDE B
protein I
was O
monitored O
by O
immunoblot O
analysis O
using O
two O
specific O
cAMP B
- I
PDE I
polyclonal I
antibodies I
and O
by O
measuring O
the O
PDE B
activity O
. O

Blotting O
analysis O
of O
intestinal O
RNA O
and O
hybridization O
of O
the O
blots O
with O
carboxy O
apoB B
cDNA O
probes O
produced O
a O
single O
15 O
- O
kb O
hybridization O
band O
whereas O
hybridization O
with O
amino O
terminal O
probes O
produced O
two O
hybridization O
bands O
of O
15 O
and O
8 O
kb O
. O

Since O
UmuD B
protein I
is O
proteolytically O
processed O
to O
an O
active O
form O
( O
UmuD B
* I
) O
in O
a O
RecA B
* O
- O
dependent O
fashion O
, O
and O
MucA B
shares O
extensive O
amino O
acid O
homology O
with O
UmuD B
, O
we O
examined O
whether O
MucA B
is O
similarly O
processed O
in O
the O
cell O
, O
using O
antiserum O
against O
a O
LacZ B
' I
- O
' B
MucA I
fusion O
protein O
. O

Since O
UmuD B
protein I
is O
proteolytically O
processed O
to O
an O
active O
form O
( O
UmuD B
* I
) O
in O
a O
RecA B
* O
- O
dependent O
fashion O
, O
and O
MucA B
shares O
extensive O
amino O
acid O
homology O
with O
UmuD B
, O
we O
examined O
whether O
MucA B
is O
similarly O
processed O
in O
the O
cell O
, O
using O
antiserum O
against O
a O
LacZ B
' I
- O
' B
MucA I
fusion O
protein O
. O

Since O
UmuD B
protein I
is O
proteolytically O
processed O
to O
an O
active O
form O
( O
UmuD B
* I
) O
in O
a O
RecA B
* O
- O
dependent O
fashion O
, O
and O
MucA B
shares O
extensive O
amino O
acid O
homology O
with O
UmuD B
, O
we O
examined O
whether O
MucA B
is O
similarly O
processed O
in O
the O
cell O
, O
using O
antiserum O
against O
a O
LacZ B
' I
- O
' B
MucA I
fusion O
protein O
. O

Since O
UmuD B
protein I
is O
proteolytically O
processed O
to O
an O
active O
form O
( O
UmuD B
* I
) O
in O
a O
RecA B
* O
- O
dependent O
fashion O
, O
and O
MucA B
shares O
extensive O
amino O
acid O
homology O
with O
UmuD B
, O
we O
examined O
whether O
MucA B
is O
similarly O
processed O
in O
the O
cell O
, O
using O
antiserum O
against O
a O
LacZ B
' I
- O
' B
MucA I
fusion O
protein O
. O

We O
have O
determined O
the O
molecular O
organization O
and O
transcription O
start O
points O
( O
tsp O
) O
for O
the O
murine O
gene O
( O
TK B
) O
encoding O
thymidine B
kinase I
. O

These O
studies O
reveal O
that O
CREM B
, O
a O
tissue O
- O
specific O
factor O
, O
is O
expressed O
and O
regulated O
by O
gonadotropins B
in O
the O
ovary O
, O
that O
the O
predominant O
CREM B
transcripts O
encode O
the O
repressor B
protein I
ICER I
, O
and O
that O
ICER B
is O
capable O
of O
inhibiting O
cAMP O
- O
induced O
expression O
of O
the O
inhibin B
alpha I
- I
subunit I
gene I
. O

These O
studies O
reveal O
that O
CREM B
, O
a O
tissue O
- O
specific O
factor O
, O
is O
expressed O
and O
regulated O
by O
gonadotropins B
in O
the O
ovary O
, O
that O
the O
predominant O
CREM B
transcripts O
encode O
the O
repressor B
protein I
ICER I
, O
and O
that O
ICER B
is O
capable O
of O
inhibiting O
cAMP O
- O
induced O
expression O
of O
the O
inhibin B
alpha I
- I
subunit I
gene I
. O

These O
studies O
reveal O
that O
CREM B
, O
a O
tissue O
- O
specific O
factor O
, O
is O
expressed O
and O
regulated O
by O
gonadotropins B
in O
the O
ovary O
, O
that O
the O
predominant O
CREM B
transcripts O
encode O
the O
repressor B
protein I
ICER I
, O
and O
that O
ICER B
is O
capable O
of O
inhibiting O
cAMP O
- O
induced O
expression O
of O
the O
inhibin B
alpha I
- I
subunit I
gene I
. O

These O
studies O
reveal O
that O
CREM B
, O
a O
tissue O
- O
specific O
factor O
, O
is O
expressed O
and O
regulated O
by O
gonadotropins B
in O
the O
ovary O
, O
that O
the O
predominant O
CREM B
transcripts O
encode O
the O
repressor B
protein I
ICER I
, O
and O
that O
ICER B
is O
capable O
of O
inhibiting O
cAMP O
- O
induced O
expression O
of O
the O
inhibin B
alpha I
- I
subunit I
gene I
. O

Acanthamoeba B
myosin I
I I
heavy I
chain I
kinase I
( O
MIHCK B
) O
phosphorylates O
the O
heavy O
chains O
of O
amoeba B
myosins I
I I
, O
increasing O
their O
actin B
- O
activated O
ATPase B
activities O
. O

Acanthamoeba B
myosin I
I I
heavy I
chain I
kinase I
( O
MIHCK B
) O
phosphorylates O
the O
heavy O
chains O
of O
amoeba B
myosins I
I I
, O
increasing O
their O
actin B
- O
activated O
ATPase B
activities O
. O

Acanthamoeba B
myosin I
I I
heavy I
chain I
kinase I
( O
MIHCK B
) O
phosphorylates O
the O
heavy O
chains O
of O
amoeba B
myosins I
I I
, O
increasing O
their O
actin B
- O
activated O
ATPase B
activities O
. O

Mutation O
of O
the O
HNF3 B
element I
significantly O
reduced O
promoter O
activity O
in O
HepG2 O
cells O
, O
whereas O
this O
element O
in O
isolation O
conferred O
HNF3beta B
responsiveness O
to O
a O
heterologous O
promoter O
. O

However O
, O
technical O
advances O
have O
shown O
the O
limitations O
of O
these O
tests O
as O
tests O
for O
IgM B
can O
be O
positive O
because O
of O
residual O
specific O
IgM B
or O
even O
in O
subjects O
free O
of O
acute O
infection O
due O
to O
the O
existence O
of O
natural O
interfering O
IgM B
. O

However O
, O
technical O
advances O
have O
shown O
the O
limitations O
of O
these O
tests O
as O
tests O
for O
IgM B
can O
be O
positive O
because O
of O
residual O
specific O
IgM B
or O
even O
in O
subjects O
free O
of O
acute O
infection O
due O
to O
the O
existence O
of O
natural O
interfering O
IgM B
. O

However O
, O
technical O
advances O
have O
shown O
the O
limitations O
of O
these O
tests O
as O
tests O
for O
IgM B
can O
be O
positive O
because O
of O
residual O
specific O
IgM B
or O
even O
in O
subjects O
free O
of O
acute O
infection O
due O
to O
the O
existence O
of O
natural O
interfering O
IgM B
. O

We O
have O
utilized O
transient O
transfections O
, O
mutation O
analysis O
, O
electromobility O
gel O
- O
shifts O
, O
and O
immunoblot O
analysis O
to O
test O
the O
hypothesis O
that O
expression O
of O
the O
CTalpha B
gene I
is O
controlled O
in O
part O
by O
the O
binding O
of O
three O
trans O
- O
acting O
nuclear O
factors O
, O
Sp1 B
, O
Sp2 B
, O
and O
Sp3 B
. O

We O
have O
utilized O
transient O
transfections O
, O
mutation O
analysis O
, O
electromobility O
gel O
- O
shifts O
, O
and O
immunoblot O
analysis O
to O
test O
the O
hypothesis O
that O
expression O
of O
the O
CTalpha B
gene I
is O
controlled O
in O
part O
by O
the O
binding O
of O
three O
trans O
- O
acting O
nuclear O
factors O
, O
Sp1 B
, O
Sp2 B
, O
and O
Sp3 B
. O

We O
have O
utilized O
transient O
transfections O
, O
mutation O
analysis O
, O
electromobility O
gel O
- O
shifts O
, O
and O
immunoblot O
analysis O
to O
test O
the O
hypothesis O
that O
expression O
of O
the O
CTalpha B
gene I
is O
controlled O
in O
part O
by O
the O
binding O
of O
three O
trans O
- O
acting O
nuclear O
factors O
, O
Sp1 B
, O
Sp2 B
, O
and O
Sp3 B
. O

AMPK B
is O
a O
heterotrimer O
composed O
of O
a O
catalytic O
subunit O
( O
alpha O
) O
and O
two O
regulatory O
subunits O
( O
beta O
and O
gamma O
) O
. O

Adenovirus O
infection O
of O
hepatoma O
cells O
inhibited O
transcription O
of O
the O
phosphoenolpyruvate B
carboxykinase I
( O
GTP O
) O
( O
EC B
4 I
. I
1 I
. I
1 I
. I
32 I
) O
( O
PEPCK B
) O
gene O
and O
virtually O
eliminated O
transcription O
of O
a O
chimeric O
gene O
which O
contained O
the O
PEPCK B
promoter I
linked O
to O
the O
structural O
gene O
for O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
. O

Adenovirus O
infection O
of O
hepatoma O
cells O
inhibited O
transcription O
of O
the O
phosphoenolpyruvate B
carboxykinase I
( O
GTP O
) O
( O
EC B
4 I
. I
1 I
. I
1 I
. I
32 I
) O
( O
PEPCK B
) O
gene O
and O
virtually O
eliminated O
transcription O
of O
a O
chimeric O
gene O
which O
contained O
the O
PEPCK B
promoter I
linked O
to O
the O
structural O
gene O
for O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
. O

Expression O
of O
the O
gene O
encoding O
transcription B
factor I
cyclic I
adenosine I
3 I
' I
, I
5 I
' I
- I
monophosphate I
( I
cAMP I
) I
response I
element I
- I
binding I
protein I
( O
CREB B
) O
: O
regulation O
by O
follicle B
- I
stimulating I
hormone I
- O
induced O
cAMP O
signaling O
in O
primary O
rat O
Sertoli O
cells O
. O

High O
and O
pathological O
PAI B
- I
1 I
levels O
before O
and O
after O
the O
VO O
test O
were O
consistent O
with O
a O
defective O
fibrinolytic O
potential O
due O
to O
the O
inhibitory O
effect O
of O
PAI B
- I
1 I
on O
plasminogen B
activation O
. O

Nuclear O
proteins O
bound O
the O
cad B
+ I
55 I
/ I
+ I
75 I
element I
in O
a O
cell O
cycle O
- O
dependent O
manner O
in O
electromobility O
shift O
assays O
; O
antibodies O
specific O
to O
USF B
and O
Max B
blocked O
the O
DNA O
- O
binding O
activity O
of O
different O
growth O
- O
regulated O
protein O
- O
DNA O
complexes O
. O

Nuclear O
proteins O
bound O
the O
cad B
+ I
55 I
/ I
+ I
75 I
element I
in O
a O
cell O
cycle O
- O
dependent O
manner O
in O
electromobility O
shift O
assays O
; O
antibodies O
specific O
to O
USF B
and O
Max B
blocked O
the O
DNA O
- O
binding O
activity O
of O
different O
growth O
- O
regulated O
protein O
- O
DNA O
complexes O
. O

Thus O
, O
an O
unmodified O
threonine O
at O
position O
169 O
in O
Cdc28 B
is O
important O
for O
interaction O
with O
G1 B
cyclins I
. O

Additional O
genetic O
analyses O
described O
herein O
suggest O
that O
Skb1 B
is O
a O
component O
of O
the O
morphology O
control O
branch O
of O
the O
Ras B
signaling O
cascade O
in O
S O
. O
pombe O
and O
that O
it O
positively O
modulates O
Shk1 B
function O
. O

Additional O
genetic O
analyses O
described O
herein O
suggest O
that O
Skb1 B
is O
a O
component O
of O
the O
morphology O
control O
branch O
of O
the O
Ras B
signaling O
cascade O
in O
S O
. O
pombe O
and O
that O
it O
positively O
modulates O
Shk1 B
function O
. O

Additional O
genetic O
analyses O
described O
herein O
suggest O
that O
Skb1 B
is O
a O
component O
of O
the O
morphology O
control O
branch O
of O
the O
Ras B
signaling O
cascade O
in O
S O
. O
pombe O
and O
that O
it O
positively O
modulates O
Shk1 B
function O
. O

From O
a O
chromosomal O
cosmid O
library O
of O
Streptomyces O
argillaceus O
, O
a O
Mtm B
producer O
, O
a O
clone O
( O
cosAR7 O
) O
was O
isolated O
by O
homology O
to O
the O
actI B
/ I
III I
region I
of O
S O
. O
coelicolor O
and O
the O
strDEM B
genes I
of O
S O
. O
griseus O
. O

Escherichia O
coli O
strains O
carrying O
recA730 B
( O
or O
other O
recA B
* I
alleles I
) O
exhibit O
dramatic O
increases O
in O
SOS O
- O
dependent O
spontaneous O
mutator O
activity O
. O

gp170 B
is O
generated O
by O
an O
alternatively O
spliced O
Env B
mRNA I
using O
a O
splice O
donor O
and O
splice O
acceptor O
pair O
localized O
within O
the O
env B
open I
reading I
frame I
( I
ORF I
) I
, O
which O
is O
normally O
used O
to O
generate O
Bell B
and O
Bet B
transcripts I
derived O
from O
the O
internal O
promoter O
within O
the O
env B
ORF I
. O

gp170 B
is O
generated O
by O
an O
alternatively O
spliced O
Env B
mRNA I
using O
a O
splice O
donor O
and O
splice O
acceptor O
pair O
localized O
within O
the O
env B
open I
reading I
frame I
( I
ORF I
) I
, O
which O
is O
normally O
used O
to O
generate O
Bell B
and O
Bet B
transcripts I
derived O
from O
the O
internal O
promoter O
within O
the O
env B
ORF I
. O

gp170 B
is O
expressed O
at O
a O
level O
30 O
to O
50 O
% O
of O
the O
Env B
precursor I
gp130 B
. O

gp170 B
is O
expressed O
at O
a O
level O
30 O
to O
50 O
% O
of O
the O
Env B
precursor I
gp130 B
. O

Residues O
that O
affect O
PLCbeta B
and O
adenylyl B
cyclase I
II I
activity O
are O
found O
on O
opposite O
sides O
of O
the O
central O
tunnel O
, O
suggesting O
that O
PLC B
and O
adenylyl B
cyclase I
, O
like O
the O
alpha O
subunit O
, O
make O
many O
contacts O
on O
the O
top O
surface O
. O

Residues O
that O
affect O
PLCbeta B
and O
adenylyl B
cyclase I
II I
activity O
are O
found O
on O
opposite O
sides O
of O
the O
central O
tunnel O
, O
suggesting O
that O
PLC B
and O
adenylyl B
cyclase I
, O
like O
the O
alpha O
subunit O
, O
make O
many O
contacts O
on O
the O
top O
surface O
. O

The O
CBS B
- I
1 I
gene I
was O
mapped O
to O
human O
chromosome O
10p12 O
between O
markers O
WI B
- I
8535 I
and O
WI B
- I
4724 I
, O
and O
is O
tightly O
linked O
to O
the O
two O
STRP O
markers O
of O
D10S1789 B
and O
D10S550 B
. O

The O
CBS B
- I
1 I
gene I
was O
mapped O
to O
human O
chromosome O
10p12 O
between O
markers O
WI B
- I
8535 I
and O
WI B
- I
4724 I
, O
and O
is O
tightly O
linked O
to O
the O
two O
STRP O
markers O
of O
D10S1789 B
and O
D10S550 B
. O

The O
ferric B
uptake I
regulation I
( O
fur B
) O
gene O
product O
participates O
in O
regulating O
expression O
of O
the O
manganese O
- O
and O
iron O
- O
containing O
superoxide B
dismutase I
genes I
of I
Escherichia I
coli I
. O

To O
date O
, O
6 O
mammalian O
GRKs B
have O
been O
identified O
by O
molecular O
cloning O
. O

Elements O
of O
the O
hAT B
transposon I
family I
, O
such O
as O
the O
maize B
activator I
( O
Ac B
) O
, O
have O
been O
discovered O
in O
a O
large O
number O
of O
eukaryotic O
species O
. O

We O
found O
both O
the O
v B
- I
Ras I
- O
and O
PC B
- I
PLC I
- O
transformed O
cells O
to O
be O
insensitive O
to O
stimulation O
with O
platelet B
- I
derived I
growth I
factor I
( O
PDGF B
) O
. O

Sequence O
analysis O
of O
the O
catfish O
JH B
- O
CH B
intron O
suggests O
that O
several O
sequences O
are O
present O
which O
appear O
similar O
to O
important O
transcriptional O
regulatory O
elements O
found O
within O
JH B
- O
CH B
introns O
of O
higher O
vertebrates O
. O

Sequence O
analysis O
of O
the O
catfish O
JH B
- O
CH B
intron O
suggests O
that O
several O
sequences O
are O
present O
which O
appear O
similar O
to O
important O
transcriptional O
regulatory O
elements O
found O
within O
JH B
- O
CH B
introns O
of O
higher O
vertebrates O
. O

Sequence O
analysis O
of O
the O
catfish O
JH B
- O
CH B
intron O
suggests O
that O
several O
sequences O
are O
present O
which O
appear O
similar O
to O
important O
transcriptional O
regulatory O
elements O
found O
within O
JH B
- O
CH B
introns O
of O
higher O
vertebrates O
. O

Sequence O
analysis O
of O
the O
catfish O
JH B
- O
CH B
intron O
suggests O
that O
several O
sequences O
are O
present O
which O
appear O
similar O
to O
important O
transcriptional O
regulatory O
elements O
found O
within O
JH B
- O
CH B
introns O
of O
higher O
vertebrates O
. O

The O
tro B
operon I
is O
flanked O
by O
a O
Holliday B
structure I
DNA I
helicase I
homolog O
( O
upstream O
) O
and O
two O
ORFs O
representing O
a O
purine B
nucleoside I
phosphorylase I
homolog O
and O
tpp15 B
, O
a O
previously O
characterized O
gene O
encoding O
a O
membrane O
lipoprotein O
( O
downstream O
) O
. O

By O
RT O
- O
PCR O
, O
different O
levels O
of O
E75 B
expression O
can O
be O
detected O
in O
the O
epidermis O
, O
nerve O
cord O
and O
the O
eyestalk O
of O
early O
pre O
- O
molt O
shrimp O
. O

No O
cleavage O
of O
gp B
130 I
was O
observed O
in O
analogous O
pulse O
- O
chase O
radiolabelling O
of O
Ad O
- O
gB B
- O
infected O
human O
fibroblasts O
, O
even O
though O
these O
cells O
are O
permissive O
for O
HCMV O
replication O
and O
can O
process O
the O
native B
gB I
molecule I
. O

These O
include O
the O
genes O
, O
undefined B
1 I
( O
UD1 B
) O
, O
UD2 B
, O
and O
UD3 B
, O
each O
coding O
for O
proteins O
of O
unknown O
function O
, O
the O
ken B
gene I
encoding O
a O
new O
Kruppel B
- I
like I
putative I
transcription I
factor I
, O
the O
fly O
homologues O
of O
the O
mammalian B
mitochondrial I
trifunctional I
enzyme I
( O
thiolase B
) O
, O
and O
the O
TAR B
DNA I
- I
binding I
protein I
- I
43 I
( O
TBPH B
) O
, O
the O
first O
nonvertebrate O
member O
of O
the O
transmembrane B
4 I
superfamily I
( O
TM4SF B
) O
gene O
, O
a O
new O
homeodomain B
gene I
, O
and O
a O
gene O
coding O
for O

These O
include O
the O
genes O
, O
undefined B
1 I
( O
UD1 B
) O
, O
UD2 B
, O
and O
UD3 B
, O
each O
coding O
for O
proteins O
of O
unknown O
function O
, O
the O
ken B
gene I
encoding O
a O
new O
Kruppel B
- I
like I
putative I
transcription I
factor I
, O
the O
fly O
homologues O
of O
the O
mammalian B
mitochondrial I
trifunctional I
enzyme I
( O
thiolase B
) O
, O
and O
the O
TAR B
DNA I
- I
binding I
protein I
- I
43 I
( O
TBPH B
) O
, O
the O
first O
nonvertebrate O
member O
of O
the O
transmembrane B
4 I
superfamily I
( O
TM4SF B
) O
gene O
, O
a O
new O
homeodomain B
gene I
, O
and O
a O
gene O
coding O
for O

These O
include O
the O
genes O
, O
undefined B
1 I
( O
UD1 B
) O
, O
UD2 B
, O
and O
UD3 B
, O
each O
coding O
for O
proteins O
of O
unknown O
function O
, O
the O
ken B
gene I
encoding O
a O
new O
Kruppel B
- I
like I
putative I
transcription I
factor I
, O
the O
fly O
homologues O
of O
the O
mammalian B
mitochondrial I
trifunctional I
enzyme I
( O
thiolase B
) O
, O
and O
the O
TAR B
DNA I
- I
binding I
protein I
- I
43 I
( O
TBPH B
) O
, O
the O
first O
nonvertebrate O
member O
of O
the O
transmembrane B
4 I
superfamily I
( O
TM4SF B
) O
gene O
, O
a O
new O
homeodomain B
gene I
, O
and O
a O
gene O
coding O
for O

These O
include O
the O
genes O
, O
undefined B
1 I
( O
UD1 B
) O
, O
UD2 B
, O
and O
UD3 B
, O
each O
coding O
for O
proteins O
of O
unknown O
function O
, O
the O
ken B
gene I
encoding O
a O
new O
Kruppel B
- I
like I
putative I
transcription I
factor I
, O
the O
fly O
homologues O
of O
the O
mammalian B
mitochondrial I
trifunctional I
enzyme I
( O
thiolase B
) O
, O
and O
the O
TAR B
DNA I
- I
binding I
protein I
- I
43 I
( O
TBPH B
) O
, O
the O
first O
nonvertebrate O
member O
of O
the O
transmembrane B
4 I
superfamily I
( O
TM4SF B
) O
gene O
, O
a O
new O
homeodomain B
gene I
, O
and O
a O
gene O
coding O
for O

These O
include O
the O
genes O
, O
undefined B
1 I
( O
UD1 B
) O
, O
UD2 B
, O
and O
UD3 B
, O
each O
coding O
for O
proteins O
of O
unknown O
function O
, O
the O
ken B
gene I
encoding O
a O
new O
Kruppel B
- I
like I
putative I
transcription I
factor I
, O
the O
fly O
homologues O
of O
the O
mammalian B
mitochondrial I
trifunctional I
enzyme I
( O
thiolase B
) O
, O
and O
the O
TAR B
DNA I
- I
binding I
protein I
- I
43 I
( O
TBPH B
) O
, O
the O
first O
nonvertebrate O
member O
of O
the O
transmembrane B
4 I
superfamily I
( O
TM4SF B
) O
gene O
, O
a O
new O
homeodomain B
gene I
, O
and O
a O
gene O
coding O
for O

These O
include O
the O
genes O
, O
undefined B
1 I
( O
UD1 B
) O
, O
UD2 B
, O
and O
UD3 B
, O
each O
coding O
for O
proteins O
of O
unknown O
function O
, O
the O
ken B
gene I
encoding O
a O
new O
Kruppel B
- I
like I
putative I
transcription I
factor I
, O
the O
fly O
homologues O
of O
the O
mammalian B
mitochondrial I
trifunctional I
enzyme I
( O
thiolase B
) O
, O
and O
the O
TAR B
DNA I
- I
binding I
protein I
- I
43 I
( O
TBPH B
) O
, O
the O
first O
nonvertebrate O
member O
of O
the O
transmembrane B
4 I
superfamily I
( O
TM4SF B
) O
gene O
, O
a O
new O
homeodomain B
gene I
, O
and O
a O
gene O
coding O
for O

a O
putative O
nuclear O
binding O
protein O
( O
PNBP O
) O
that O
is O
homologous O
to O
maleless B
, O
and O
a O
Copia B
- I
like I
element I
. O

TRAF2 B
has O
previously O
been O
demonstrated O
to O
activate O
both O
transcription O
factor O
nuclear B
factor I
kappaB I
( O
NFkappaB B
) O
and O
the O
c B
- I
Jun I
N I
- I
terminal I
kinase I
/ O
stress B
- I
activated I
protein I
kinase I
( O
JNK B
/ O
SAPK B
) O
pathway O
, O
which O
in O
turn O
stimulates O
transcription B
factor I
activating I
protein I
1 I
( O
AP1 B
) O
mainly O
via O
phosphorylation O
of O
the O
c B
- I
Jun I
component O
. O

TRAF2 B
has O
previously O
been O
demonstrated O
to O
activate O
both O
transcription O
factor O
nuclear B
factor I
kappaB I
( O
NFkappaB B
) O
and O
the O
c B
- I
Jun I
N I
- I
terminal I
kinase I
/ O
stress B
- I
activated I
protein I
kinase I
( O
JNK B
/ O
SAPK B
) O
pathway O
, O
which O
in O
turn O
stimulates O
transcription B
factor I
activating I
protein I
1 I
( O
AP1 B
) O
mainly O
via O
phosphorylation O
of O
the O
c B
- I
Jun I
component O
. O

TRAF2 B
has O
previously O
been O
demonstrated O
to O
activate O
both O
transcription O
factor O
nuclear B
factor I
kappaB I
( O
NFkappaB B
) O
and O
the O
c B
- I
Jun I
N I
- I
terminal I
kinase I
/ O
stress B
- I
activated I
protein I
kinase I
( O
JNK B
/ O
SAPK B
) O
pathway O
, O
which O
in O
turn O
stimulates O
transcription B
factor I
activating I
protein I
1 I
( O
AP1 B
) O
mainly O
via O
phosphorylation O
of O
the O
c B
- I
Jun I
component O
. O

TRAF2 B
has O
previously O
been O
demonstrated O
to O
activate O
both O
transcription O
factor O
nuclear B
factor I
kappaB I
( O
NFkappaB B
) O
and O
the O
c B
- I
Jun I
N I
- I
terminal I
kinase I
/ O
stress B
- I
activated I
protein I
kinase I
( O
JNK B
/ O
SAPK B
) O
pathway O
, O
which O
in O
turn O
stimulates O
transcription B
factor I
activating I
protein I
1 I
( O
AP1 B
) O
mainly O
via O
phosphorylation O
of O
the O
c B
- I
Jun I
component O
. O

TRAF2 B
has O
previously O
been O
demonstrated O
to O
activate O
both O
transcription O
factor O
nuclear B
factor I
kappaB I
( O
NFkappaB B
) O
and O
the O
c B
- I
Jun I
N I
- I
terminal I
kinase I
/ O
stress B
- I
activated I
protein I
kinase I
( O
JNK B
/ O
SAPK B
) O
pathway O
, O
which O
in O
turn O
stimulates O
transcription B
factor I
activating I
protein I
1 I
( O
AP1 B
) O
mainly O
via O
phosphorylation O
of O
the O
c B
- I
Jun I
component O
. O

A O
procaryotic O
regulatory O
factor O
with O
a O
histone B
H1 I
- I
like I
carboxy I
- I
terminal I
domain I
: O
clonal O
variation O
of O
repeats O
within O
algP B
, O
a O
gene O
involved O
in O
regulation O
of O
mucoidy O
in O
Pseudomonas O
aeruginosa O
. O

The O
host O
range O
( O
HR O
) O
of O
poliovirus O
is O
thought O
to O
be O
primarily O
determined O
by O
a O
cell O
surface O
molecule O
that O
functions O
as O
poliovirus B
receptor I
( O
PVR B
) O
, O
since O
it O
has O
been O
shown O
that O
transgenic O
mice O
are O
made O
poliovirus O
sensitive O
by O
introducing O
the O
human B
PVR I
gene I
into O
the O
genome O
. O

Human B
alcohol I
dehydrogenase I
( O
ADH B
) O
exists O
as O
a O
heterogeneous O
group O
of O
isozymes O
capable O
of O
oxidizing O
a O
wide O
variety O
of O
aliphatic O
and O
aromatic O
alcohols O
. O

The O
control O
of O
human B
aromatase I
expression O
is O
complex O
in O
that O
several O
promoters O
drive O
aromatase B
expression O
in O
a O
tissue O
- O
specific O
manner O
. O

This O
incompatibility O
phenotype O
requires O
the O
global O
transcriptional O
repressor O
, O
KorB B
, O
and O
the O
target O
for O
incC B
- O
mediated O
incompatibility O
is O
a O
KorB B
- I
binding I
site I
( I
O I
( I
B I
) I
) I
. O

This O
incompatibility O
phenotype O
requires O
the O
global O
transcriptional O
repressor O
, O
KorB B
, O
and O
the O
target O
for O
incC B
- O
mediated O
incompatibility O
is O
a O
KorB B
- I
binding I
site I
( I
O I
( I
B I
) I
) I
. O

RXRalpha B
/ O
RARalpha B
heterodimers O
and O
HNF B
- I
4 I
homodimers I
bind O
to O
DR O
- O
1 O
motifs O
on O
elements O
B O
and O
I4 O
, O
respectively O
. O

RXRalpha B
/ O
RARalpha B
heterodimers O
and O
HNF B
- I
4 I
homodimers I
bind O
to O
DR O
- O
1 O
motifs O
on O
elements O
B O
and O
I4 O
, O
respectively O
. O

Evidence O
for O
involvement O
of O
proteins O
HU B
and O
RpoS B
in O
transcription O
of O
the O
osmoresponsive O
proU B
operon I
in O
Escherichia O
coli O
. O

Evidence O
for O
involvement O
of O
proteins O
HU B
and O
RpoS B
in O
transcription O
of O
the O
osmoresponsive O
proU B
operon I
in O
Escherichia O
coli O
. O

Although O
immunoglobulin B
and O
CRP B
concentration O
increased O
, O
anemia O
obviously O
improved O
with O
hemoglobin B
levels O
increasing O
from O
4 O
. O
8 O
g O
/ O
dl O
to O
8 O
. O
5 O
g O
/ O
dl O
without O
any O
side O
effects O
. O

Although O
immunoglobulin B
and O
CRP B
concentration O
increased O
, O
anemia O
obviously O
improved O
with O
hemoglobin B
levels O
increasing O
from O
4 O
. O
8 O
g O
/ O
dl O
to O
8 O
. O
5 O
g O
/ O
dl O
without O
any O
side O
effects O
. O

Although O
immunoglobulin B
and O
CRP B
concentration O
increased O
, O
anemia O
obviously O
improved O
with O
hemoglobin B
levels O
increasing O
from O
4 O
. O
8 O
g O
/ O
dl O
to O
8 O
. O
5 O
g O
/ O
dl O
without O
any O
side O
effects O
. O

Together O
, O
these O
results O
implicate O
Fal1p B
in O
the O
18S B
rRNA I
maturation O
pathway O
rather O
than O
in O
translation O
initiation O
. O

The O
expression O
of O
CAPL B
, O
a O
second O
protein O
involved O
in O
calcium O
metabolism O
, O
was O
only O
moderately O
elevated O
in O
the O
doxorubicin O
- O
resistant O
cells O
. O

Screening O
of O
a O
human O
foetal O
brain O
genomic O
DNA O
library O
allowed O
us O
to O
isolate O
an O
EcoRI B
- O
EcoRI B
fragment O
containing O
6 O
kb O
of O
the O
5 O
' O
- O
flanking O
region O
, O
the O
open O
reading O
frame O
and O
4 O
kb O
of O
the O
3 O
' O
- O
flanking O
region O
of O
the O
alpha2C4 B
gene I
. O

Screening O
of O
a O
human O
foetal O
brain O
genomic O
DNA O
library O
allowed O
us O
to O
isolate O
an O
EcoRI B
- O
EcoRI B
fragment O
containing O
6 O
kb O
of O
the O
5 O
' O
- O
flanking O
region O
, O
the O
open O
reading O
frame O
and O
4 O
kb O
of O
the O
3 O
' O
- O
flanking O
region O
of O
the O
alpha2C4 B
gene I
. O

The O
rate O
of O
decrease O
of O
PRA O
after O
REM O
onset O
closely O
approximates O
the O
most O
recent O
estimations O
of O
PRA O
half O
- O
life O
, O
which O
suggests O
that O
REM O
onset O
is O
associated O
with O
a O
virtual O
cessation O
in O
renin B
production O
. O

Similarly O
, O
interfering O
with O
MEKK B
, O
which O
lies O
upstream O
of O
JNK1 B
, O
using O
a O
dominant O
negative O
expression O
vector O
reduced O
MMP B
- I
9 I
promoter I
activity O
over O
the O
same O
concentration O
range O
which O
repressed O
the O
AP B
- I
1 I
- O
thymidine B
kinase I
CAT B
reporter O
construct O
. O

Similarly O
, O
interfering O
with O
MEKK B
, O
which O
lies O
upstream O
of O
JNK1 B
, O
using O
a O
dominant O
negative O
expression O
vector O
reduced O
MMP B
- I
9 I
promoter I
activity O
over O
the O
same O
concentration O
range O
which O
repressed O
the O
AP B
- I
1 I
- O
thymidine B
kinase I
CAT B
reporter O
construct O
. O

Similarly O
, O
interfering O
with O
MEKK B
, O
which O
lies O
upstream O
of O
JNK1 B
, O
using O
a O
dominant O
negative O
expression O
vector O
reduced O
MMP B
- I
9 I
promoter I
activity O
over O
the O
same O
concentration O
range O
which O
repressed O
the O
AP B
- I
1 I
- O
thymidine B
kinase I
CAT B
reporter O
construct O
. O

There O
was O
no O
difference O
in O
serum B
albumin I
and O
transferrin B
levels O
, O
but O
serum B
prealbumin I
levels O
in O
the O
group O
fed O
early O
were O
more O
desirable O
than O
those O
of O
the O
control O
group O
( O
from O
15 O
. O
8 O
+ O
/ O
- O
2 O
. O
5 O
mg O
/ O
dl O
to O
28 O
. O
9 O
+ O
/ O
- O
3 O
. O
8 O
mg O
/ O
dl O
vs O
from O
18 O
. O
0 O
+ O
/ O
- O
2 O
. O
0 O
mg O
/ O
dl O
to O
25 O
. O
9 O
+ O
/ O
- O
3 O
. O
9 O
mg O
/ O
dl O
) O
. O

This O
constant O
expression O
profile O
, O
coupled O
with O
the O
observation O
that O
over O
- O
expression O
of O
mSin3A B
does O
not O
augment O
the O
anti B
- I
Myc I
activity O
of O
Mxi1 B
- O
SR O
in O
the O
rat O
embryo O
fibroblast O
( O
REF O
) O
transformation O
assay O
, O
suggests O
that O
mSin3A B
is O
not O
a O
limiting O
factor O
in O
the O
regulation O
of O
Myc B
superfamily I
function O
. O

This O
constant O
expression O
profile O
, O
coupled O
with O
the O
observation O
that O
over O
- O
expression O
of O
mSin3A B
does O
not O
augment O
the O
anti B
- I
Myc I
activity O
of O
Mxi1 B
- O
SR O
in O
the O
rat O
embryo O
fibroblast O
( O
REF O
) O
transformation O
assay O
, O
suggests O
that O
mSin3A B
is O
not O
a O
limiting O
factor O
in O
the O
regulation O
of O
Myc B
superfamily I
function O
. O

This O
constant O
expression O
profile O
, O
coupled O
with O
the O
observation O
that O
over O
- O
expression O
of O
mSin3A B
does O
not O
augment O
the O
anti B
- I
Myc I
activity O
of O
Mxi1 B
- O
SR O
in O
the O
rat O
embryo O
fibroblast O
( O
REF O
) O
transformation O
assay O
, O
suggests O
that O
mSin3A B
is O
not O
a O
limiting O
factor O
in O
the O
regulation O
of O
Myc B
superfamily I
function O
. O

Mutational O
analysis O
of O
the O
putative O
effector O
domain O
of O
the O
GTP B
- I
binding I
Ypt1 I
protein I
in O
yeast O
suggests O
specific O
regulation O
by O
a O
novel O
GAP B
activity O
. O

The O
broad O
range O
protein B
tyrosine I
kinase I
inhibitor O
genistein O
and O
the O
phosphatidylinositol B
3 I
- I
kinase I
inhibitors O
wortmannin O
and O
LY O
294002 O
( O
2 O
- O
( O
4 O
- O
morpholinyl O
) O
- O
8 O
- O
phenyl O
- O
4H O
- O
1 O
- O
benzopyran O
- O
4 O
- O
one O
) O
also O
blocked O
adenosine B
A3 I
receptor I
stimulation O
of O
p42 B
/ O
p44 B
MAPK O
. O

The O
broad O
range O
protein B
tyrosine I
kinase I
inhibitor O
genistein O
and O
the O
phosphatidylinositol B
3 I
- I
kinase I
inhibitors O
wortmannin O
and O
LY O
294002 O
( O
2 O
- O
( O
4 O
- O
morpholinyl O
) O
- O
8 O
- O
phenyl O
- O
4H O
- O
1 O
- O
benzopyran O
- O
4 O
- O
one O
) O
also O
blocked O
adenosine B
A3 I
receptor I
stimulation O
of O
p42 B
/ O
p44 B
MAPK O
. O

Surprisingly O
, O
although O
Mist1 B
binds O
to O
E O
- O
boxes O
in O
vivo O
, O
the O
Mist1 B
protein I
lacks O
a O
functional O
transcription O
activation O
domain O
. O

As O
exogenously O
expressed O
PKR B
can O
form O
heterodimers O
with O
endogenous B
PKR I
, O
the O
results O
obtained O
on O
the O
functional O
characterization O
of O
mutant O
forms O
of O
PKR B
have O
been O
taken O
with O
caution O
. O

As O
exogenously O
expressed O
PKR B
can O
form O
heterodimers O
with O
endogenous B
PKR I
, O
the O
results O
obtained O
on O
the O
functional O
characterization O
of O
mutant O
forms O
of O
PKR B
have O
been O
taken O
with O
caution O
. O

Orlistat O
is O
a O
specific O
lipase B
inhibitor O
that O
impairs O
fat O
absorption O
, O
thereby O
reducing O
fat O
uptake O
. O

The O
metalloproteinase B
mediating O
Met B
cleavage O
was O
specifically O
inhibited O
by O
the O
tissue B
inhibitor I
of I
metalloproteinases I
( I
TIMP I
) I
- I
3 I
, O
but O
not O
by O
TIMP B
- I
1 I
or O
TIMP B
- I
2 I
. O

The O
metalloproteinase B
mediating O
Met B
cleavage O
was O
specifically O
inhibited O
by O
the O
tissue B
inhibitor I
of I
metalloproteinases I
( I
TIMP I
) I
- I
3 I
, O
but O
not O
by O
TIMP B
- I
1 I
or O
TIMP B
- I
2 I
. O

It O
is O
also O
conceivable O
that O
elevated O
insulin B
levels O
may O
cause O
hypertriglyceridaemia O
and O
possibly O
other O
abnormalities O
of O
lipid O
metabolism O
. O

Instead O
, O
HBx B
is O
shown O
to O
activate O
the O
cyclin B
A I
promoter I
, O
induce O
cyclin B
A I
- O
cyclin B
- I
dependent I
kinase I
2 I
complexes O
, O
and O
promote O
cycling O
of O
growth O
- O
arrested O
cells O
into O
G1 O
through O
a O
pathway O
involving O
activation O
of O
Src B
tyrosine I
kinases I
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
impact O
of O
the O
ESRD O
treatment O
modality O
on O
the O
quality O
of O
life O
in O
patients O
with O
Type O
I O
( O
insulin B
- O
dependent O
) O
diabetes O
mellitus O
. O

Fluorescence O
in O
situ O
hybridization O
was O
used O
to O
investigate O
the O
physical O
distribution O
and O
revealed O
that O
both O
retrotransposon O
families O
are O
present O
on O
all O
sugar O
beet O
chromosomes O
and O
largely O
excluded O
from O
chromosomal O
regions O
harbouring O
the O
18S B
- O
5 B
. I
8S I
- O
25S B
rRNA O
genes O
. O

Fluorescence O
in O
situ O
hybridization O
was O
used O
to O
investigate O
the O
physical O
distribution O
and O
revealed O
that O
both O
retrotransposon O
families O
are O
present O
on O
all O
sugar O
beet O
chromosomes O
and O
largely O
excluded O
from O
chromosomal O
regions O
harbouring O
the O
18S B
- O
5 B
. I
8S I
- O
25S B
rRNA O
genes O
. O

Most O
significantly O
, O
the O
cyclin B
E I
- O
Cdk2 B
complex O
is O
maximally O
active O
at O
the O
G1 O
/ O
S O
transition O
, O
and O
overexpression O
of O
cyclin B
E I
decreases O
the O
time O
it O
takes O
the O
cell O
to O
complete O
G1 O
and O
enter O
S O
phase O
. O

A O
genomic O
clone O
of O
the O
chicken B
osteopontin I
- I
encoding I
gene I
( O
opn B
) O
was O
isolated O
and O
found O
to O
be O
organized O
as O
follows O
: O
an O
untranslated O
5 O
' O
exon O
; O
a O
signal O
peptide O
; O
a O
recognition O
sequence O
for O
phosphorylation O
by O
casein B
kinase I
II I
; O
a O
domain O
containing O
a O
possible O
O O
- O
linkage O
site O
for O
glycosylation O
; O
a O
second O
casein B
kinase I
II I
phosphorylation I
site I
; O
an O
exon O
containing O
three O
functional O
regions O
, O
the O
poly O
- O
Asp O
sequence O
of O
seven O
consecutive O
Asp O
residues O
, O
the O
RGD B
integrin I
recognition I
site I
and O
a O
potential O
N O

In O
addition O
, O
while O
GCN1 B
is O
required O
in O
vivo O
for O
phosphorylation O
of O
eIF B
- I
2 I
alpha I
by O
GCN2 B
, O
cell O
extracts O
from O
gcn1 B
delta I
strains O
contained O
wild O
- O
type O
levels O
of O
GCN2 B
eIF B
- I
2 I
alpha I
- O
kinase O
activity O
. O

In O
addition O
, O
while O
GCN1 B
is O
required O
in O
vivo O
for O
phosphorylation O
of O
eIF B
- I
2 I
alpha I
by O
GCN2 B
, O
cell O
extracts O
from O
gcn1 B
delta I
strains O
contained O
wild O
- O
type O
levels O
of O
GCN2 B
eIF B
- I
2 I
alpha I
- O
kinase O
activity O
. O

In O
addition O
, O
while O
GCN1 B
is O
required O
in O
vivo O
for O
phosphorylation O
of O
eIF B
- I
2 I
alpha I
by O
GCN2 B
, O
cell O
extracts O
from O
gcn1 B
delta I
strains O
contained O
wild O
- O
type O
levels O
of O
GCN2 B
eIF B
- I
2 I
alpha I
- O
kinase O
activity O
. O

Furthermore O
, O
we O
detect O
hCoch B
- I
5B2 I
on O
three O
overlapping O
YACs O
, O
two O
of O
which O
also O
contain O
one O
of O
the O
markers O
linked O
to O
DFNA9 B
. O

mCoch B
- I
5B2 I
was O
genetically O
mapped O
in O
the O
mouse O
to O
chromosome O
12 O
, O
in O
a O
region O
of O
homologous O
synteny O
with O
human O
14q11 O
. O
2 O
- O
q13 O
, O
which O
contains O
the O
asp1 B
( O
audiogenic B
seizure I
prone I
) O
locus O
in O
the O
mouse O
. O

Although O
no O
detectable O
phenotypes O
are O
associated O
with O
a O
disruption O
allele O
of O
ABP1 B
, O
mutations O
that O
create O
a O
requirement O
for O
this O
protein O
have O
now O
been O
isolated O
in O
the O
previously O
identified O
gene B
SAC6 I
and O
in O
two O
new O
genes O
, O
SLA1 B
and O
SLA2 B
. O

Although O
no O
detectable O
phenotypes O
are O
associated O
with O
a O
disruption O
allele O
of O
ABP1 B
, O
mutations O
that O
create O
a O
requirement O
for O
this O
protein O
have O
now O
been O
isolated O
in O
the O
previously O
identified O
gene B
SAC6 I
and O
in O
two O
new O
genes O
, O
SLA1 B
and O
SLA2 B
. O

Although O
no O
detectable O
phenotypes O
are O
associated O
with O
a O
disruption O
allele O
of O
ABP1 B
, O
mutations O
that O
create O
a O
requirement O
for O
this O
protein O
have O
now O
been O
isolated O
in O
the O
previously O
identified O
gene B
SAC6 I
and O
in O
two O
new O
genes O
, O
SLA1 B
and O
SLA2 B
. O

Furthermore O
, O
CL100 B
suppresses O
the O
[ O
val12 O
] O
ras B
- O
induced O
activation O
of O
MAP B
kinase I
in O
a O
cell O
- O
free O
system O
from O
Xenopus O
oocytes O
. O

Furthermore O
, O
CL100 B
suppresses O
the O
[ O
val12 O
] O
ras B
- O
induced O
activation O
of O
MAP B
kinase I
in O
a O
cell O
- O
free O
system O
from O
Xenopus O
oocytes O
. O

The O
Xenopus B
homeobox I
gene I
twin I
mediates O
Wnt B
induction O
of O
goosecoid B
in O
establishment O
of O
Spemann O
' O
s O
organizer O
. O

The O
Xenopus B
homeobox I
gene I
twin I
mediates O
Wnt B
induction O
of O
goosecoid B
in O
establishment O
of O
Spemann O
' O
s O
organizer O
. O

The O
vaccinia O
virus O
D6R B
open O
reading O
frame O
encodes O
the O
small O
subunit O
of O
the O
heterodimeric O
vaccinia B
virus I
early I
transcription I
factor I
( O
VETF B
) O
that O
activates O
transcription O
of O
early B
genes I
in O
vitro O
. O

The O
vaccinia O
virus O
D6R B
open O
reading O
frame O
encodes O
the O
small O
subunit O
of O
the O
heterodimeric O
vaccinia B
virus I
early I
transcription I
factor I
( O
VETF B
) O
that O
activates O
transcription O
of O
early B
genes I
in O
vitro O
. O

We O
show O
that O
GCNF B
binds O
to O
one O
of O
the O
two O
DRO O
sequences O
in O
the O
Prm1 B
promoter I
, O
and O
to O
the O
DRO O
sequence O
in O
the O
Prm2 B
promoter I
in O
a O
specific O
manner O
. O

Octamer O
recognition O
is O
mediated O
by O
the O
POU B
domain O
, O
a O
conserved O
structural O
motif O
which O
- O
- O
like O
the O
zinc O
finger O
and O
leucine O
zipper O
- O
- O
defines O
a O
family O
of O
related O
transcription O
factors O
. O

The O
major O
promoter O
element O
of O
the O
Xenopus B
laevis I
5S I
RNA I
gene I
is O
located O
within O
the O
transcribed O
region O
of O
the O
gene O
and O
forms O
the O
binding O
site O
for O
the O
transcription O
initiation O
factor O
TFIIIA B
. O

During O
each O
step O
of O
the O
pulse O
infusion O
the O
osteocalcin B
responses O
to O
changes O
in O
CaI O
in O
general O
were O
parallel O
to O
the O
changes O
in O
PTH B
( O
r O
= O
0 O
. O
462 O
; O
P O
= O
0 O
. O
02 O
) O
and O
were O
inversely O
correlated O
to O
CaI O
( O
r O
= O
- O
0 O
. O
562 O
; O
P O
= O
0 O
. O
003 O
) O
. O

During O
each O
step O
of O
the O
pulse O
infusion O
the O
osteocalcin B
responses O
to O
changes O
in O
CaI O
in O
general O
were O
parallel O
to O
the O
changes O
in O
PTH B
( O
r O
= O
0 O
. O
462 O
; O
P O
= O
0 O
. O
02 O
) O
and O
were O
inversely O
correlated O
to O
CaI O
( O
r O
= O
- O
0 O
. O
562 O
; O
P O
= O
0 O
. O
003 O
) O
. O

The O
gamma B
- I
GCS I
gene I
is O
expressed O
ubiquitously O
and O
induced O
coordinately O
with O
NAD B
( I
P I
) I
H I
: I
quinone I
oxidoreductase I
( I
1 I
) I
( O
NQO1 B
) O
and O
glutathione B
S I
- I
transferase I
Ya I
( O
GST B
Ya I
) O
in O
response O
to O
xenobiotics O
and O
antioxidants O
. O

Interestingly O
, O
the O
expression O
of O
Id4 B
in O
Sertoli O
cells O
is O
only O
detectable O
after O
stimulation O
with O
FSH B
or O
cAMP O
. O

Interestingly O
, O
the O
expression O
of O
Id4 B
in O
Sertoli O
cells O
is O
only O
detectable O
after O
stimulation O
with O
FSH B
or O
cAMP O
. O

We O
determined O
their O
N O
- O
terminal O
amino O
acid O
sequence O
and O
found O
that O
these O
polypeptides O
were O
CotT B
, O
YeeK B
, O
YxeE B
, O
CotF B
, O
YrbA B
( O
31 O
and O
45 O
kDa O
) O
, O
and O
SpoIVA B
, O
respectively O
. O

We O
determined O
their O
N O
- O
terminal O
amino O
acid O
sequence O
and O
found O
that O
these O
polypeptides O
were O
CotT B
, O
YeeK B
, O
YxeE B
, O
CotF B
, O
YrbA B
( O
31 O
and O
45 O
kDa O
) O
, O
and O
SpoIVA B
, O
respectively O
. O

We O
determined O
their O
N O
- O
terminal O
amino O
acid O
sequence O
and O
found O
that O
these O
polypeptides O
were O
CotT B
, O
YeeK B
, O
YxeE B
, O
CotF B
, O
YrbA B
( O
31 O
and O
45 O
kDa O
) O
, O
and O
SpoIVA B
, O
respectively O
. O

We O
determined O
their O
N O
- O
terminal O
amino O
acid O
sequence O
and O
found O
that O
these O
polypeptides O
were O
CotT B
, O
YeeK B
, O
YxeE B
, O
CotF B
, O
YrbA B
( O
31 O
and O
45 O
kDa O
) O
, O
and O
SpoIVA B
, O
respectively O
. O

We O
determined O
their O
N O
- O
terminal O
amino O
acid O
sequence O
and O
found O
that O
these O
polypeptides O
were O
CotT B
, O
YeeK B
, O
YxeE B
, O
CotF B
, O
YrbA B
( O
31 O
and O
45 O
kDa O
) O
, O
and O
SpoIVA B
, O
respectively O
. O

We O
determined O
their O
N O
- O
terminal O
amino O
acid O
sequence O
and O
found O
that O
these O
polypeptides O
were O
CotT B
, O
YeeK B
, O
YxeE B
, O
CotF B
, O
YrbA B
( O
31 O
and O
45 O
kDa O
) O
, O
and O
SpoIVA B
, O
respectively O
. O

Furthermore O
, O
it O
is O
also O
established O
that O
serine O
phosphorylation O
of O
STAT5a B
transactivation O
domain O
, O
via O
the O
MAPK B
pathway O
, O
is O
a O
means O
of O
modifying O
GH B
- O
induced O
transcriptional O
activation O
. O

Furthermore O
, O
it O
is O
also O
established O
that O
serine O
phosphorylation O
of O
STAT5a B
transactivation O
domain O
, O
via O
the O
MAPK B
pathway O
, O
is O
a O
means O
of O
modifying O
GH B
- O
induced O
transcriptional O
activation O
. O

Furthermore O
, O
it O
is O
also O
established O
that O
serine O
phosphorylation O
of O
STAT5a B
transactivation O
domain O
, O
via O
the O
MAPK B
pathway O
, O
is O
a O
means O
of O
modifying O
GH B
- O
induced O
transcriptional O
activation O
. O

Therefore O
, O
in O
VDR B
- O
mediated O
transcriptional O
activation O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
binding O
to O
VDR B
alters O
the O
conformation O
of O
the O
ligand O
binding O
domain O
such O
that O
it O
: O
( O
i O
) O
engages O
in O
strong O
heterodimerization O
with O
RXR B
to O
facilitate O
VDRE O
binding O
, O
( O
ii O
) O
influences O
the O
RXR B
ligand I
binding I
domain I
such O
that O
it O
is O
resistant O
to O
the O
binding O
of O
9 O
- O
cis O
RA O
but O
active O
in O
recruiting O
coactivator O
to O
its O
AF O
- O
2 O
and O
( O
iii O
) O
presents O
the O
AF O
- O
2 O
region O
in O
VDR B
for O
coactivator O
association O
. O

Therefore O
, O
in O
VDR B
- O
mediated O
transcriptional O
activation O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
binding O
to O
VDR B
alters O
the O
conformation O
of O
the O
ligand O
binding O
domain O
such O
that O
it O
: O
( O
i O
) O
engages O
in O
strong O
heterodimerization O
with O
RXR B
to O
facilitate O
VDRE O
binding O
, O
( O
ii O
) O
influences O
the O
RXR B
ligand I
binding I
domain I
such O
that O
it O
is O
resistant O
to O
the O
binding O
of O
9 O
- O
cis O
RA O
but O
active O
in O
recruiting O
coactivator O
to O
its O
AF O
- O
2 O
and O
( O
iii O
) O
presents O
the O
AF O
- O
2 O
region O
in O
VDR B
for O
coactivator O
association O
. O

Therefore O
, O
in O
VDR B
- O
mediated O
transcriptional O
activation O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
binding O
to O
VDR B
alters O
the O
conformation O
of O
the O
ligand O
binding O
domain O
such O
that O
it O
: O
( O
i O
) O
engages O
in O
strong O
heterodimerization O
with O
RXR B
to O
facilitate O
VDRE O
binding O
, O
( O
ii O
) O
influences O
the O
RXR B
ligand I
binding I
domain I
such O
that O
it O
is O
resistant O
to O
the O
binding O
of O
9 O
- O
cis O
RA O
but O
active O
in O
recruiting O
coactivator O
to O
its O
AF O
- O
2 O
and O
( O
iii O
) O
presents O
the O
AF O
- O
2 O
region O
in O
VDR B
for O
coactivator O
association O
. O

Therefore O
, O
in O
VDR B
- O
mediated O
transcriptional O
activation O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
binding O
to O
VDR B
alters O
the O
conformation O
of O
the O
ligand O
binding O
domain O
such O
that O
it O
: O
( O
i O
) O
engages O
in O
strong O
heterodimerization O
with O
RXR B
to O
facilitate O
VDRE O
binding O
, O
( O
ii O
) O
influences O
the O
RXR B
ligand I
binding I
domain I
such O
that O
it O
is O
resistant O
to O
the O
binding O
of O
9 O
- O
cis O
RA O
but O
active O
in O
recruiting O
coactivator O
to O
its O
AF O
- O
2 O
and O
( O
iii O
) O
presents O
the O
AF O
- O
2 O
region O
in O
VDR B
for O
coactivator O
association O
. O

In O
patients O
, O
750 O
mL O
of O
saline O
lowered O
DL O
( O
CO O
) O
( O
- O
8 O
% O
, O
P O
< O
0 O
. O
01 O
versus O
baseline O
) O
, O
D O
( O
M O
) O
( O
- O
10 O
% O
, O
P O
< O
0 O
. O
01 O
versus O
baseline O
) O
, O
aldosterone O
( O
- O
29 O
% O
, O
P O
< O
0 O
. O
01 O
versus O
baseline O
) O
, O
renin B
( O
- O
52 O
% O
, O
P O
< O
0 O
. O
01 O
versus O
baseline O
) O
, O
and O
hematocrit O
( O
- O
6 O
% O
, O
P O
< O
0 O
. O
05 O
versus O
baseline O
) O
and O
increased O
V O
( O
C O
) O
( O
20 O
% O
, O
P O
< O
0 O
. O
01 O
versus O
baseline O
) O
, O
without O
changing O
rap O

We O
have O
previously O
identified O
LIT1 B
, O
a O
paternally O
expressed O
antisense O
RNA O
within O
the O
KvLQT1 B
locus I
through O
a O
positional O
screening O
approach O
using O
human O
monochromosomal O
hybrids O
. O

The O
5 O
' O
ends O
of O
the O
P B
and O
O B
gene I
mRNAs I
are O
separated O
by O
109 O
nucleotide O
pairs O
in O
the O
DNA O
template O
. O

We O
have O
cloned O
the O
cDNA O
for O
the O
SLBP B
from O
humans O
, O
mice O
, O
and O
frogs O
, O
using O
the O
recently O
developed O
yeast O
three O
- O
hybrid O
system O
. O

TGF B
- I
beta1 I
induced O
phosphorylation O
of O
Smad2 B
and O
Smad3 B
in O
Mv1Lu O
mink O
lung O
epithelial O
cells O
. O

TGF B
- I
beta1 I
induced O
phosphorylation O
of O
Smad2 B
and O
Smad3 B
in O
Mv1Lu O
mink O
lung O
epithelial O
cells O
. O

There O
is O
little O
supportive O
evidence O
that O
ACE B
inhibitors O
( O
captopril O
or O
enalapril O
) O
are O
teratogenic O
. O

Previously O
, O
we O
reported O
the O
identification O
of O
a O
23 O
- O
kD O
protein O
that O
interacts O
with O
zyxin B
in O
vitro O
( O
Sadler O
et O
al O
. O
, O
1992 O
) O
. O

In O
gel O
mobility O
shift O
assays O
, O
high O
binding O
activities O
of O
ATPC B
- I
2 I
and O
low O
binding O
activities O
of O
CBF B
were O
observed O
with O
nuclear O
extracts O
from O
tissue O
with O
low O
AtpC B
expression O
levels O
, O
and O
the O
opposite O
was O
observed O
with O
extracts O
from O
tissues O
with O
high O
AtpC B
expression O
levels O
. O

In O
gel O
mobility O
shift O
assays O
, O
high O
binding O
activities O
of O
ATPC B
- I
2 I
and O
low O
binding O
activities O
of O
CBF B
were O
observed O
with O
nuclear O
extracts O
from O
tissue O
with O
low O
AtpC B
expression O
levels O
, O
and O
the O
opposite O
was O
observed O
with O
extracts O
from O
tissues O
with O
high O
AtpC B
expression O
levels O
. O

In O
gel O
mobility O
shift O
assays O
, O
high O
binding O
activities O
of O
ATPC B
- I
2 I
and O
low O
binding O
activities O
of O
CBF B
were O
observed O
with O
nuclear O
extracts O
from O
tissue O
with O
low O
AtpC B
expression O
levels O
, O
and O
the O
opposite O
was O
observed O
with O
extracts O
from O
tissues O
with O
high O
AtpC B
expression O
levels O
. O

Oligomers O
corresponding O
to O
the O
region O
of O
the O
mlc B
- I
1 I
/ I
3 I
enhancer I
, O
which O
encompasses O
this O
conserved O
sequence O
, O
bound O
MEF B
- I
2 I
and O
competed O
for O
its O
binding O
to O
the O
mck B
enhancer O
. O

One O
function O
of O
p53 B
is O
in O
regulating O
cell O
cycle O
check O
- O
point O
control O
after O
DNA O
damage O
. O

Apoptosis O
triggered O
through O
Fas B
and O
F B
/ I
F I
was O
inhibited O
by O
coexpression O
of O
CrmA B
and O
p35 B
, O
but O
not O
Bcl B
- I
xL I
. O

Apoptosis O
triggered O
through O
Fas B
and O
F B
/ I
F I
was O
inhibited O
by O
coexpression O
of O
CrmA B
and O
p35 B
, O
but O
not O
Bcl B
- I
xL I
. O

Apoptosis O
triggered O
through O
Fas B
and O
F B
/ I
F I
was O
inhibited O
by O
coexpression O
of O
CrmA B
and O
p35 B
, O
but O
not O
Bcl B
- I
xL I
. O

The O
product O
of O
one O
gene O
, O
Bv80 B
, O
has O
a O
single O
divergent O
copy O
of O
a O
sequence O
of O
149 O
amino O
acids O
( O
approx O
. O

We O
found O
a O
prevalence O
of O
eating O
disorders O
of O
5 O
. O
9 O
% O
( O
lifetime O
prevalence O
of O
10 O
% O
) O
, O
irrespective O
of O
gender O
and O
type O
of O
diabetes O
; O
4 O
. O
1 O
% O
of O
the O
whole O
sample O
reported O
intentional O
insulin B
undertreatment O
or O
omission O
. O

These O
results O
are O
discussed O
in O
the O
context O
of O
a O
model O
of O
the O
myogenic O
lineage O
that O
is O
based O
on O
the O
expression O
of O
desmin B
. O

We O
constructed O
a O
series O
of O
chimeric O
genes O
containing O
part O
of O
the O
first O
exon O
and O
increasingly O
longer O
5 O
' O
flanking O
sequences O
of O
the O
ODC B
gene I
fused O
to O
either O
bacterial B
chloramphenicol I
acetyltransferase I
( O
CAT B
) O
or O
luciferase B
reporter I
genes I
. O

This O
latter O
complex O
reacts O
with O
an O
antibody O
to O
serum B
response I
factor I
( O
SRF B
) O
and O
exhibits O
the O
same O
binding O
characteristics O
as O
purified O
SRF B
. O

This O
latter O
complex O
reacts O
with O
an O
antibody O
to O
serum B
response I
factor I
( O
SRF B
) O
and O
exhibits O
the O
same O
binding O
characteristics O
as O
purified O
SRF B
. O

Akt B
- O
dependent O
antiapoptotic O
action O
of O
insulin B
is O
sensitive O
to O
farnesyltransferase O
inhibitor O
. O

Akt B
- O
dependent O
antiapoptotic O
action O
of O
insulin B
is O
sensitive O
to O
farnesyltransferase O
inhibitor O
. O

Two O
of O
the O
proteins O
UPRF B
- I
1 I
and O
UPRF B
- I
2 I
( O
which O
is O
apparently O
a O
proteolytic O
degradation O
product O
of O
UPRF B
- I
1 I
) O
bind O
inefficiently O
to O
mutant O
versions O
of O
the O
UPR O
that O
are O
unable O
to O
confer O
responsiveness O
to O
unfolded O
proteins O
to O
the O
( O
CYC1 B
) O
promoter O
. O

Identification O
of O
domains O
mediating O
transcription O
activation O
, O
repression O
, O
and O
inhibition O
in O
the O
paired B
- I
related I
homeobox I
protein I
, O
Prx2 B
( O
S8 B
) O
. O

Identification O
of O
domains O
mediating O
transcription O
activation O
, O
repression O
, O
and O
inhibition O
in O
the O
paired B
- I
related I
homeobox I
protein I
, O
Prx2 B
( O
S8 B
) O
. O

Upstream B
stimulatory I
factor I
USF B
is O
a O
human O
transcriptional O
activation O
factor O
, O
which O
uses O
a O
basic O
/ O
helix O
- O
loop O
- O
helix O
/ O
leucin O
zipper O
( O
b O
/ O
HLH O
/ O
Z O
) O
motif O
to O
homodimerize O
and O
recognize O
specific O
sequences O
in O
the O
promoter O
region O
of O
both O
nuclear O
and O
viral O
genes O
transcribed O
by O
RNA B
polymerase I
II I
. O

43 O
% O
, O
6 O
/ O
14 O
; O
P O
= O
0 O
. O
013 O
) O
, O
whereas O
, O
in O
RCC O
samples O
with O
VHL B
methylation O
or O
mutation O
, O
the O
frequency O
of O
3p14 O
- O
p21 O
LOH O
did O
not O
differ O
from O
that O
of O
sp25 O
- O
p26 O
( O
72 O
% O
, O
18 O
/ O
25 O
vs O
. O

DNA O
sequence O
of O
the O
UL6 B
to O
UL20 B
genes I
of O
infectious O
laryngotracheitis O
virus O
and O
characterization O
of O
the O
UL10 B
gene I
product I
as O
a O
nonglycosylated O
and O
nonessential O
virion O
protein O
. O

Coimmunoprecipitation O
analysis O
suggests O
that O
these O
residues O
likely O
contribute O
to O
the O
multimerization O
function O
required O
for O
homomeric O
complex O
formation O
or O
heteromeric O
complex O
formation O
with O
p50 B
in O
that O
no O
association O
of O
p65 B
delta I
with O
itself O
or O
with O
p50 B
was O
evident O
. O

Coimmunoprecipitation O
analysis O
suggests O
that O
these O
residues O
likely O
contribute O
to O
the O
multimerization O
function O
required O
for O
homomeric O
complex O
formation O
or O
heteromeric O
complex O
formation O
with O
p50 B
in O
that O
no O
association O
of O
p65 B
delta I
with O
itself O
or O
with O
p50 B
was O
evident O
. O

A O
yeast O
mitochondrial O
translation O
initiation O
codon O
mutation O
affecting O
the O
gene O
for O
cytochrome B
oxidase I
subunit I
III I
( O
COX3 B
) O
was O
partially O
suppressed O
by O
a O
spontaneous O
nuclear O
mutation O
. O

These O
results O
demonstrate O
that O
GGTase B
- I
I I
inhibitors O
arrest O
cells O
in O
G0 O
/ O
G1 O
and O
induce O
accumulation O
of O
p21WAF B
in O
a O
p53 B
- O
independent O
manner O
and O
that O
FTase B
inhibitors O
can O
interfere O
with O
cell O
cycle O
events O
by O
a O
mechanism O
that O
involves O
neither O
p21WAF B
nor O
p27KIP B
. O

These O
results O
demonstrate O
that O
GGTase B
- I
I I
inhibitors O
arrest O
cells O
in O
G0 O
/ O
G1 O
and O
induce O
accumulation O
of O
p21WAF B
in O
a O
p53 B
- O
independent O
manner O
and O
that O
FTase B
inhibitors O
can O
interfere O
with O
cell O
cycle O
events O
by O
a O
mechanism O
that O
involves O
neither O
p21WAF B
nor O
p27KIP B
. O

These O
results O
demonstrate O
that O
GGTase B
- I
I I
inhibitors O
arrest O
cells O
in O
G0 O
/ O
G1 O
and O
induce O
accumulation O
of O
p21WAF B
in O
a O
p53 B
- O
independent O
manner O
and O
that O
FTase B
inhibitors O
can O
interfere O
with O
cell O
cycle O
events O
by O
a O
mechanism O
that O
involves O
neither O
p21WAF B
nor O
p27KIP B
. O

These O
results O
demonstrate O
that O
GGTase B
- I
I I
inhibitors O
arrest O
cells O
in O
G0 O
/ O
G1 O
and O
induce O
accumulation O
of O
p21WAF B
in O
a O
p53 B
- O
independent O
manner O
and O
that O
FTase B
inhibitors O
can O
interfere O
with O
cell O
cycle O
events O
by O
a O
mechanism O
that O
involves O
neither O
p21WAF B
nor O
p27KIP B
. O

These O
results O
demonstrate O
that O
GGTase B
- I
I I
inhibitors O
arrest O
cells O
in O
G0 O
/ O
G1 O
and O
induce O
accumulation O
of O
p21WAF B
in O
a O
p53 B
- O
independent O
manner O
and O
that O
FTase B
inhibitors O
can O
interfere O
with O
cell O
cycle O
events O
by O
a O
mechanism O
that O
involves O
neither O
p21WAF B
nor O
p27KIP B
. O

The O
potential O
biological O
significance O
of O
the O
identified O
structural O
motif O
shared O
by O
the O
human B
CCR5 I
, O
CCR3 B
, O
CCR2B B
and O
other O
GPCRs B
is O
discussed O
. O

The O
potential O
biological O
significance O
of O
the O
identified O
structural O
motif O
shared O
by O
the O
human B
CCR5 I
, O
CCR3 B
, O
CCR2B B
and O
other O
GPCRs B
is O
discussed O
. O

The O
potential O
biological O
significance O
of O
the O
identified O
structural O
motif O
shared O
by O
the O
human B
CCR5 I
, O
CCR3 B
, O
CCR2B B
and O
other O
GPCRs B
is O
discussed O
. O

Furthermore O
, O
the O
rapid O
light O
- O
mediated O
increase O
of O
CPRF B
proteins I
was O
insensitive O
to O
transcriptional O
inhibitors O
, O
suggesting O
that O
a O
post O
- O
transcriptional O
mechanism O
controls O
CPRF B
accumulation O
. O

We O
compared O
retrospectively O
the O
efficacy O
of O
granulocyte B
colony I
stimulating I
factor I
( O
G B
- I
CSF I
) O
alone O
with O
chemotherapy O
plus O
G B
- I
CSF I
in O
mobilizing O
CD34 B
- O
positive O
cells O
in O
patients O
with O
malignant O
lymphoma O
. O

We O
now O
show O
that O
purified O
recombinant O
c B
- I
sis I
/ O
PDGF B
can O
induce O
this O
binding O
activity O
which O
we O
have O
termed O
SIF B
, O
for O
sis B
- I
inducible I
factor I
. O

We O
now O
show O
that O
purified O
recombinant O
c B
- I
sis I
/ O
PDGF B
can O
induce O
this O
binding O
activity O
which O
we O
have O
termed O
SIF B
, O
for O
sis B
- I
inducible I
factor I
. O

The O
performances O
of O
two O
tests O
, O
the O
ProstAsure O
index O
and O
the O
percent O
free O
PSA B
test O
, O
were O
evaluated O
in O
detecting O
cancer O
. O

The O
protein O
encoded O
by O
the O
NF2 B
gene I
has O
a O
similarity O
to O
ezrin B
, O
radixin B
and O
moesin B
( O
ERM B
) O
proteins O
that O
link O
membrane O
proteins O
to O
the O
cytoskeleton O
. O

The O
protein O
encoded O
by O
the O
NF2 B
gene I
has O
a O
similarity O
to O
ezrin B
, O
radixin B
and O
moesin B
( O
ERM B
) O
proteins O
that O
link O
membrane O
proteins O
to O
the O
cytoskeleton O
. O

The O
protein O
encoded O
by O
the O
NF2 B
gene I
has O
a O
similarity O
to O
ezrin B
, O
radixin B
and O
moesin B
( O
ERM B
) O
proteins O
that O
link O
membrane O
proteins O
to O
the O
cytoskeleton O
. O

The O
protein O
encoded O
by O
the O
NF2 B
gene I
has O
a O
similarity O
to O
ezrin B
, O
radixin B
and O
moesin B
( O
ERM B
) O
proteins O
that O
link O
membrane O
proteins O
to O
the O
cytoskeleton O
. O

In O
the O
healing O
tendons O
, O
the O
rate O
of O
collagen B
synthesis O
decreased O
and O
the O
rate O
of O
noncollagen O
protein O
synthesis O
remained O
unchanged O
. O

FdsR B
purified O
to O
homogeneity O
after O
overexpression O
of O
fdsR B
in O
E O
. O
coli O
is O
a O
130 O
kDa O
homotetramer O
binding O
to O
the O
fds B
control O
region O
located O
between O
the O
fdsR B
and O
fdsG B
genes I
. O

FdsR B
purified O
to O
homogeneity O
after O
overexpression O
of O
fdsR B
in O
E O
. O
coli O
is O
a O
130 O
kDa O
homotetramer O
binding O
to O
the O
fds B
control O
region O
located O
between O
the O
fdsR B
and O
fdsG B
genes I
. O

FdsR B
purified O
to O
homogeneity O
after O
overexpression O
of O
fdsR B
in O
E O
. O
coli O
is O
a O
130 O
kDa O
homotetramer O
binding O
to O
the O
fds B
control O
region O
located O
between O
the O
fdsR B
and O
fdsG B
genes I
. O

FdsR B
purified O
to O
homogeneity O
after O
overexpression O
of O
fdsR B
in O
E O
. O
coli O
is O
a O
130 O
kDa O
homotetramer O
binding O
to O
the O
fds B
control O
region O
located O
between O
the O
fdsR B
and O
fdsG B
genes I
. O

The O
leader O
peptide O
was O
hypothesized O
to O
inhibit O
ribosome O
release O
at O
the O
tnaC B
stop I
codon I
, O
thereby O
blocking O
Rho B
' O
s O
access O
to O
the O
transcript O
. O

Influence O
of O
huanglian O
used O
in O
combination O
with O
huangqin O
and O
gancao O
on O
the O
erythrocytic O
osmotic O
fragilitas O
of O
experimental O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
deficiency O
in O
rats O
] O
OBJECTIVE O
: O
To O
study O
the O
influence O
of O
common O
combination O
of O
Huanglian O
( O
Coptis O
chinensis O
) O
on O
the O
erythrocytic O
osmotic O
fragilitas O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( O
G6PD B
) O
deficiency O
in O
rats O
. O

This O
sequence O
was O
sufficient O
to O
confer O
p53 B
- O
dependent O
activation O
to O
a O
heterologous O
promoter O
and O
p53 B
was O
capable O
of O
binding O
to O
this O
sequence O
as O
assessed O
by O
gel O
shift O
analysis O
. O

This O
sequence O
was O
sufficient O
to O
confer O
p53 B
- O
dependent O
activation O
to O
a O
heterologous O
promoter O
and O
p53 B
was O
capable O
of O
binding O
to O
this O
sequence O
as O
assessed O
by O
gel O
shift O
analysis O
. O

LCCH1 B
was O
identical O
to O
the O
Rdl B
gene I
, O
a O
known O
GABA B
receptor I
subunit I
gene I
from O
D O
. O
melanogaster O
, O
whereas O
LCCH2 B
and O
LCCH3 B
were O
novel O
D O
. O
melanogaster O
sequences O
that O
exhibited O
structural O
similarity O
to O
other O
members O
of O
the O
ligand B
- I
gated I
chloride I
channel I
gene I
family I
. O

LCCH1 B
was O
identical O
to O
the O
Rdl B
gene I
, O
a O
known O
GABA B
receptor I
subunit I
gene I
from O
D O
. O
melanogaster O
, O
whereas O
LCCH2 B
and O
LCCH3 B
were O
novel O
D O
. O
melanogaster O
sequences O
that O
exhibited O
structural O
similarity O
to O
other O
members O
of O
the O
ligand B
- I
gated I
chloride I
channel I
gene I
family I
. O

LCCH1 B
was O
identical O
to O
the O
Rdl B
gene I
, O
a O
known O
GABA B
receptor I
subunit I
gene I
from O
D O
. O
melanogaster O
, O
whereas O
LCCH2 B
and O
LCCH3 B
were O
novel O
D O
. O
melanogaster O
sequences O
that O
exhibited O
structural O
similarity O
to O
other O
members O
of O
the O
ligand B
- I
gated I
chloride I
channel I
gene I
family I
. O

First O
, O
the O
amino O
- O
terminal O
regulatory O
arm O
of O
the O
GDI B
binds O
to O
the O
switch O
I O
and O
II O
domains O
of O
Cdc42 B
leading O
to O
the O
inhibition O
of O
both O
GDP O
dissociation O
and O
GTP O
hydrolysis O
. O

First O
, O
the O
amino O
- O
terminal O
regulatory O
arm O
of O
the O
GDI B
binds O
to O
the O
switch O
I O
and O
II O
domains O
of O
Cdc42 B
leading O
to O
the O
inhibition O
of O
both O
GDP O
dissociation O
and O
GTP O
hydrolysis O
. O

Analysis O
of O
larger O
cDNA O
clones O
demonstrates O
that O
there O
are O
at O
least O
two O
isoforms O
of O
RIP14 B
that O
differ O
in O
the O
N O
- O
terminal O
( O
A O
and O
B O
) O
and O
hinge O
( O
D O
) O
domains O
. O

In O
addition O
to O
loss O
of O
digit O
identity O
and O
varying O
degrees O
of O
polydactyly O
, O
proximal O
skeletal O
elements O
are O
severely O
shortened O
in O
Xt B
; O
ld B
double O
homozygous O
limbs O
. O

In O
addition O
to O
loss O
of O
digit O
identity O
and O
varying O
degrees O
of O
polydactyly O
, O
proximal O
skeletal O
elements O
are O
severely O
shortened O
in O
Xt B
; O
ld B
double O
homozygous O
limbs O
. O

A O
gene O
with O
a O
high O
degree O
of O
sequence O
identity O
with O
mammalian B
ADP I
- I
ribosylation I
factors I
( O
ARFs B
) O
, O
believed O
to O
be O
important O
in O
vesicular O
transport O
, O
was O
identified O
. O

Mapping O
of O
the O
region O
in O
KAP B
- I
1 I
required O
for O
HP1 B
interaction O
showed O
that O
amino O
acid O
substitutions O
which O
abolish O
HP1 B
binding O
in O
vitro O
reduce O
KAP B
- I
1 I
mediated O
repression O
in O
vivo O
. O

Mapping O
of O
the O
region O
in O
KAP B
- I
1 I
required O
for O
HP1 B
interaction O
showed O
that O
amino O
acid O
substitutions O
which O
abolish O
HP1 B
binding O
in O
vitro O
reduce O
KAP B
- I
1 I
mediated O
repression O
in O
vivo O
. O

The O
specificity O
of O
the O
transcriptional O
activation O
by O
ISGF3 B
is O
mediated O
by O
specific O
elements O
termed O
IFN B
- I
stimulatory I
response I
element I
( O
ISRE B
) O
located O
in O
the O
promoter O
region O
of O
IFN B
- O
inducible O
genes O
. O

The O
specificity O
of O
the O
transcriptional O
activation O
by O
ISGF3 B
is O
mediated O
by O
specific O
elements O
termed O
IFN B
- I
stimulatory I
response I
element I
( O
ISRE B
) O
located O
in O
the O
promoter O
region O
of O
IFN B
- O
inducible O
genes O
. O

The O
specificity O
of O
the O
transcriptional O
activation O
by O
ISGF3 B
is O
mediated O
by O
specific O
elements O
termed O
IFN B
- I
stimulatory I
response I
element I
( O
ISRE B
) O
located O
in O
the O
promoter O
region O
of O
IFN B
- O
inducible O
genes O
. O

To O
this O
end O
we O
generated O
a O
detailed O
physical O
map O
of O
the O
genomic O
region O
spanning O
between O
sequence O
- O
tagged O
site O
markers O
D16S518 B
and O
D16S516 B
. O

To O
this O
end O
we O
generated O
a O
detailed O
physical O
map O
of O
the O
genomic O
region O
spanning O
between O
sequence O
- O
tagged O
site O
markers O
D16S518 B
and O
D16S516 B
. O

Spinophilin B
, O
a O
novel O
protein B
phosphatase I
1 I
binding I
protein I
localized O
to O
dendritic O
spines O
. O

The O
existence O
of O
a O
TFIIIB B
assembly O
pathway O
leading O
to O
the O
faithful O
transcription O
of O
natural O
eukaryotic O
tRNA O
genes O
in O
the O
absence O
of O
TFIIIC B
provides O
novel O
insights O
into O
the O
functional O
flexibility O
of O
the O
eukaryotic O
tRNA O
gene O
transcription O
machinery O
and O
on O
its O
evolution O
from O
an O
ancestral O
RNA B
polymerase I
III I
system O
relying O
on O
upstream O
, O
TATA O
- O
centered O
control O
elements O
. O

The O
existence O
of O
a O
TFIIIB B
assembly O
pathway O
leading O
to O
the O
faithful O
transcription O
of O
natural O
eukaryotic O
tRNA O
genes O
in O
the O
absence O
of O
TFIIIC B
provides O
novel O
insights O
into O
the O
functional O
flexibility O
of O
the O
eukaryotic O
tRNA O
gene O
transcription O
machinery O
and O
on O
its O
evolution O
from O
an O
ancestral O
RNA B
polymerase I
III I
system O
relying O
on O
upstream O
, O
TATA O
- O
centered O
control O
elements O
. O

Ectopic O
Xbra B
can O
induce O
Xegr B
- I
1 I
transcription O
by O
an O
indirect O
mechanism O
that O
appears O
to O
operate O
via O
primary O
activation O
of O
fibroblast B
growth I
factor I
secretion O
. O

3 O
) O
The O
progress O
of O
fibrinolysis O
was O
observed O
by O
serial O
collection O
of O
middle O
ear O
fluid O
in O
the O
same O
side O
ear O
of O
5 O
cases O
out O
of O
17 O
cases O
having O
much O
activity O
for O
fibrin B
degradation O
, O
and O
lowering O
of O
fibrinolytic O
activity O
was O
revealed O
in O
4 O
out O
of O
these O
5 O
cases O
as O
the O
result O
. O

Thus O
G17 B
targets O
the O
c B
- I
fos I
promoter I
CArG I
sequence I
via O
Rho B
A I
- O
dependent O
pathways O
, O
and O
Rho B
A I
appears O
to O
play O
an O
important O
role O
in O
the O
regulation O
of O
the O
trophic O
action O
of O
G17 B
. O

Thus O
G17 B
targets O
the O
c B
- I
fos I
promoter I
CArG I
sequence I
via O
Rho B
A I
- O
dependent O
pathways O
, O
and O
Rho B
A I
appears O
to O
play O
an O
important O
role O
in O
the O
regulation O
of O
the O
trophic O
action O
of O
G17 B
. O

These O
results O
demonstrate O
that O
m2 B
receptors I
couple O
to O
both O
G B
alpha I
i2 I
and O
G B
alpha I
i3 I
in O
vivo O
and O
that O
this O
interaction O
is O
integral O
to O
both O
positive O
and O
negative O
regulatory O
pathways O
leading O
to O
activation O
of O
PLC B
and O
desensitization O
of O
receptor O
signaling O
. O

